Investigating the trigger for human parturition using metabolomic and phosphoproteomic techniques within case-control and cohort studies by Birchenall, Katherine Alice
                          
This electronic thesis or dissertation has been





 Investigating the trigger for human parturition using metabolomic and
phosphoproteomic techniques within case-control and cohort studies
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint
Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible.
1 
 
INVESTIGATING THE TRIGGER FOR HUMAN PARTURITION 
USING METABOLOMIC AND PHOSPHOPROTEOMIC 


















A dissertation submitted to the University of Bristol in accordance with the 
requirements for award of the degree of PhD in the Faculty of Health Sciences 









The mechanism for human labour remains poorly understood, restricted by difficulties in 
human pregnancy experimentation, and this limits our ability to manage complications of 
parturition including spontaneous preterm birth and induction of labour. The studies 
presented in this thesis utilise metabolomic and phosphoproteomic techniques to improve 
our understanding of the pathways involved in the trigger for labour in humans.  
The first study in the thesis compared mass spectrometry metabolomics analysis of maternal 
and cord plasma at the time of delivery, and the results indicate that the trigger for 
spontaneous labour in humans may involve endocannabinoid, sphingolipid and ceramide 
pathways. The second study presented investigates this further, comparing the metabolic 
profiles of maternal, cord artery, and cord vein blood sampled from women during low-risk 
pregnancies, including comparisons of metabolite concentrations between different labour 
onsets and delivery. This study indicates that there are inherent differences in fetal and 
maternal signals between women who spontaneously labour and women who have an 
induction of labour. The third study assessed potential associations between the maternal 
metabolic profile measured in the second trimester with gestational age at delivery within the 
Born in Bradford cohort study (analysis sample n = 7440). This study indicates a metabolic 
profile of dyslipidaemia may be associated with shorter gestational age at delivery, and that 
non-pathological human labour may involve pathways related to inflammation and vascular 
function. The final study used phosphoproteomics analysis of fresh myometrium in vitro, and 
the findings indicate that there may be a myometrial phenotype associated with failed 
induction of labour and failure to progress. 
Taken together, these results provide novel leads to follow in order to progress our quest for 




















I am grateful for the support and guidance that I have received from my supervisors 
Professor Andrés López Bernal, Dr Gavin Welsh, Professor Deborah Lawlor, and Dr 
Carolina Borges. 
A special thank you to the women who participated in the studies. 
























I declare that the work in this dissertation was carried out in accordance with 
the requirements of the University's Regulations and Code of Practice for 
Research Degree Programmes and that it has not been submitted for any other 
academic award. Except where indicated by specific reference in the text, the 
work is the candidate's own work. Work done in collaboration with, or with the 
assistance of, others, is indicated as such. Any views expressed in the 
dissertation are those of the author. 
SIGNED: ..... Katherine Birchenall..................  DATE:...12.03.2020.... 
Students must sign the examination copies but should only print their name in 
the final version that they electronically submit so that no personal signifiers 














DECLARATION OF PUBLICATION ARISING FROM PhD 
 
The results from Chapter 2 of this thesis have been published in a peer-
reviewed journal, and Chapter 2 itself is adapted from the published article 
(Table 2A1 in the Appendices): 
Birchenall, K.A., Welsh, G.I. & López Bernal, A. (2019). Metabolite Changes in 
Maternal and Fetal Plasma Following Spontaneous Labour at Term in 
Humans Using Untargeted Metabolomics Analysis: A Pilot Study. 
International Journal of Environmental Research and Public Health: 16(9), 
1527; doi:10.3390/ijerph16091527. 
We declare that the above article was written by the author of this thesis, 
Katherine Alice Birchenall, with support from the PhD supervisors Professor 
Andrés López Bernal and Dr Gavin Welsh.  
SIGNED:      DATE:  11.03.2020 
Katherine Alice Birchenall 
 
SIGNED:          DATE:     12.03.2020 
Professor Andrés López Bernal 
 
SIGNED:              DATE:   11.03.2020 




ABBREVIATIONS USED IN TEXT 
 
17βHSD 17β hydroxysteroid dehydrogenase  
3β-HSD  3beta-hydroxysteroid dehydrogenase 
95%CI 95 per cent confidence interval 
ACTH Adrenocorticotropic hormone 
ADP-ribose Adenosine 5'-diphosphoribose  
AEA Anandamide 
AHNAK Neuroblast differentiation-associated protein AHNAK 
ALSPAC Avon Longitudinal Study of Parents and Children 
AMP Adenosine 5’-monophosphate 
ANP Atrial natriuretic peptide  
ASAH1 N-acylsphingosine amidohydrolase 1 
ASIC Acid-sensing ion channel  
BASIC Bile acid-sensitive ion channel 
BiB Born in Bradford cohort study 
BLINaC Brain, liver, intestinal Na+ channel  
BMI Body mass index 
CA Cord artery 
Ca2+ Calcium ion 
Ca-CaM-dependent enzyme Calcium ion-calmodulin-dependent enzyme  
CaCl2 Calcium chloride  
cAMP Adenosine 3',5'-cyclic monophosphate  
CB1 Cannabinoid receptor 1 
CB2 Cannabinoid receptor 2 
CDS Central delivery suite 
cGMP Cyclic guanosine monophosphate 
COX-2 Cyclooxygenase-2 
CPMG Car-purcell-meiboom-gill  
CRH Corticotrophin-releasing hormone  
CRMP Collapsin response mediator protein 
CS Caesarean section 
CV Cord vein 
CYP450scc Cytochrome P450  
DAG Directed acyclic graph 
DHEA Dehydroepiandrosterone 
DHEAS Dehydroepiandrosterone-sulphate  
DPYSL3 protein Dihydropyrimidinase-related protein 3 
7 
 
DYRK Dual tyroxine-regulated kinase  
DZ Definitive zone 
EC 
The metabolite quantity identified in cord plasma from 
women who did not labour and delivered via elective 
caesarean section 
ECM Extracellular matrix 
ECS Elective caesarean section 
EDD Estimated date of delivery 
ELISA Enzyme-linked immunosorbent assays  
EM 
The metabolite quantity contained in intervillous plasma 
from women who did not labour and delivered via 
elective caesarean section 
eNOS Endothelial nitric oxide synthase 
ER Endoplasmic reticulum 
ER Oestrogen receptor 
Erα Oestrogen receptor alpha 
ERα Oestrogen receptor alpha 
ERβ Oestrogen receptor beta   
ERβ1 Oestrogen receptor beta 1 
ERΔ7 Oestrogen receptor delta 7 
FAAH Fatty acid amide hydrolase  
FC Fold change 
FDR False discovery rate 
FISH Fluorescent in situ Hybridisation  
FMD Flow mediated dilatation  
FZ Fetal zone 
GC Gas chromatography  
GC-MS Gas chromatography coupled with mass spectrometry  
GDM Gestational diabetes mellitus 
GGCX Gamma-glutamyl carboxylase  
GSK3 Glycogen synthase kinase 3  
GWAS Genome-wide association study 
HBMD Human metabolome database 
HCD Higher-energy collisional dissociation  
HDL High density lipoprotein 
HEK293 cell line Human Embryonic Kidney 293 cells 
HIF1A Hypoxia inducible factor 1 subunit alpha  
hINaC Human intestinal Na+ channel  




High or ultrahigh performance Liquid Chromatography 
coupled to ultraviolet or fluorescence detection  
HSP Heat shock protein  
IDL Intermediate density lipoprotein 
IGF1 Insulin-like growth factor 1 
IL-1 Interleukin-1 
IL-1β Interleukin-1 beta  
IL-4 Interleukin-4 





IOL Induction of labour 
IV Intervillous 
KCL Potassium chloride  
KEGG Kyoto Encyclopedia of Genes and Genomes 
KO Knock-out 
LC Liquid chromatography 
LCA Latent class analysis 
LC-MS 
Liquid chromatography coupled with single-stage mass 
spectrometry  
LC-MS/MS 
Liquid chromatography coupled with tandem mass 
spectrometry  
LDL Low-density lipoprotein 
LDL Low density lipoprotein 
LIF Leukaemia inhibitory factor  
LMP Last menstrual period 
LMW Low-molecular weight 
LMWM Low molecular weight molecules 
LOX Lysyl oxidase  
LOXL2 Lysyl oxidase homolog 2  
Lp(a) Lipoprotein a 
LTQ Lysine tyrosylquinone  
m/z Mass-to-charge ratio 
MAM Mitochondria-associated membrane 
MBRRACE-UK 
Mothers and Babies: Reducing Risk through Audits and 
Confidential Enquiries 
MEF2C Myocyte enhancer factor 2C  
MGP Matrix gla protein  
9 
 
MgS04 Magnesium sulphate  
MHC Myosin heavy chain 
miR MicroRNA 
ml  Millilitre 
MLC Myosin light chain  
mM Millimoles 
MME Membrane metallo-endopeptidase  
MR Mendeilian randomisation 
MS Mass spectrometry 
MYLK Myosin light chain kinase  
MYLP Myosin phosphatase  
MYOCD Myocardin 
Na+ Sodium ion  
NaH2PO4 Monosodium phosphate  
NaHCO3 Sodium bicarbonate 
Nano-LC MS 
Nanoscale-Liquid Chromatography coupled to tandem 
Mass Spectrometry  
NF-kB 
Nuclear Factor kappa-light-chain-enhancer of activated B 
cells  
NHS National health service 
NICE National Institute for Clinical and Health Excellence 
nM  Nano-moles 
NMR Nuclear magnetic resonance  
NO Nitric oxide 
N-PS N-palmitoylserine  
OEA Oleoyl-ethanolamide  
OGTT Oral glucose tolerance test 
OPPTIMUM 
Does progesterone prophylaxis to prevent preterm labour 
improve outcome? Trial 
OR Odds ratio 
Otr Oxytocin receptor 
OXT Oxytocin   
OXT-CON 
Oxytocin-stimulated contraction snap frozen at peak 
phasic contraction 
OXT-REL 
Oxytocin-stimulated phasic contraction snap frozen 20 
seconds following the end of a phasic contraction 
PACS-2 Phosphofurin acidic cluster sorting protein 2  
PAH Pulmonary arterial hypertension  
PDGFR-alpha Platelet-Derived Growth Factor Receptor alpha  







Membrane-associated progesterone receptor component 
1  
PHLDA5 Pleckstrin homology-like domain, family A, member 5  
PKA Protein kinase A  
PLD Phospholipase D 
PPAR- α Peroxisome proliferator-activated receptor-alpha 
PPAR- α interacting complex 
285 
Peroxisomal proliferator-activated receptor A interacting 
complex 285  
PPI Protein-protein interaction 
PR Progesterone receptors  
PRA Progesterone Receptor type A  
PRB Progesterone Receptor type B  
PRC Progesterone receptor c  
PRE No tension applied and considered pre-contraction 
PRISM trial Progesterone in spontaneous miscarriage trial 
PROMISE trial Progesterone in Recurrent Miscarriages trial 
PSMs Peptide spectral matches  




Polyunsaturated fatty acid 
QC Quality control 
RCT Randomised controlled trial 
REL/PRE 
Ratio between (spontaneous contraction, snap frozen 20 
seconds following the end of a phasic contraction) and 
(no tension applied and considered pre-contraction) 
RIPA Radioimmunoprecipitation assay  
ROS Reactive oxygen species 
RR Risk ratio 
RSD Relative standard deviation  
RU486 Mifepristone 
SCOPE Screening for Obstetric and Pregnancy Endpoints  
SD Standard deviation 
SDS Sodium dodecyl sulphate  
SEP Socioeconomic position 
SGTA 
Small glutamine-rich tetratricopeptide repeat-containing 
protein alpha 
SL Spontaneous labour 




Spontaneous contraction snap frozen at peak phasic 
contraction 
SP-REL 
Spontaneous contraction, snap frozen 20 seconds 
following the end of a phasic contraction 
SRF Serum response factor  
TGF Transforming Growth Factor-β 
TGFBI Transforming Growth Factor-Beta-induced Protein ig-h3  
Ti02 Titanium dioxide  
TIMP-1 Tissue inhibitor of metalloproteinase-1  
TMAP N,N,N-trimethyl-alanylproline betaine  
Tmod Tropomodulins  
TMT Tandem mass tag  
TNFα Tumour necrosis factor α  
TPR Tetratricopeptide repeat  
TRPV1 Transient receptor potential vanilloid type 1  
TZ Transitional zone 
UHPLC/MS 
Ultrahigh performance liquid chromatography-tandem 
mass spectrometry  
UK United kingdom 
v/v Vol/vol 
VC 
Metabolite quantity identified in cord plasma from 
women who laboured and delivered vaginally 
VC/EC 
Represents the difference in the means between VC, the 
metabolite quantity identified in cord plasma from 
women who laboured and delivered vaginally, and EC, the 
metabolite quantity identified in cord plasma from 
women who did not labour and delivered via elective 
caesarean section 
VC/EM 
VM/EM represents the difference in the means between 
VM, the metabolite quantity identified in intervillous 
plasma from women who laboured and delivered 
vaginally, and EM, the metabolite quantity contained in 
intervillous plasma from women who did not labour and 
delivered via elective caesarean section 
VD Vaginal delivery 
VLDL Very low density lipoprotein 
VM 
The metabolite quantity identified in intervillous plasma 
from women who laboured and delivered vaginally 
WHO  World health organisation 
βhCG Beta human Chorionic Gonadotropin 




TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION ............................................................................................ 30 
1.1 Rationale for research ...................................................................................................... 30 
1.2 Background ...................................................................................................................... 33 
1.2.1 Human gestation .............................................................................................. 33 
1.2.2 Gestational length definitions .......................................................................... 34 
1.2.3 Mechanisms of parturition ............................................................................... 35 
1.2.4 The epidemiology of preterm birth .................................................................. 36 
1.2.5 Induction of labour ........................................................................................... 37 
1.3 Macro- and micro-structure of the human uterus ........................................................... 38 
1.3.1 The uterus ........................................................................................................ 38 
1.3.2 Myometrial structure and electrophysiology ................................................... 39 
1.3.3 Myocytes and contractility ............................................................................... 40 
1.3.4 The cervix ......................................................................................................... 42 
1.3.5 Placenta ............................................................................................................ 44 
1.4 Control of parturition ....................................................................................................... 50 
1.4.1 Control of parturition in animals ...................................................................... 50 
1.4.2 Rabbit, goat and rodent models ....................................................................... 50 
1.4.3 Sheep models ................................................................................................... 51 
1.4.4 Non-human primate models ............................................................................ 57 
1.4.5 Progesterone and human pregnancy ............................................................... 62 
1.4.6 Feto-placental unit ........................................................................................... 63 
1.4.7 Uterine oestrogen and progesterone receptors............................................... 68 
1.4.8 Corticotrophin-releasing hormone and preterm birth ..................................... 74 
1.4.9 Inflammatory pathways and parturition .......................................................... 75 
1.5 Preterm birth ................................................................................................................... 81 
1.5.1 The cervix and preterm birth............................................................................ 82 
1.5.2 Randomised controlled trials with progesterone for prevention of pregnancy 
loss ............................................................................................................................ 84 
1.5.3 Induction of labour ........................................................................................... 88 
1.6 New approaches to understanding the mechanisms of human parturition: the potential 
of omics data ......................................................................................................................... 89 
1.6.1 The omics techniques ....................................................................................... 90 
1.6.2 Genomics and transcriptomics ......................................................................... 91 
1.6.3 Metabolomics .................................................................................................. 91 
1.6.4 Proteomics ....................................................................................................... 95 
1.7 Summary .......................................................................................................................... 97 
1.8 Thesis aim and objectives ................................................................................................ 99 
CHAPTER 2. INVESTIGATING METABOLITE CHANGES IN MATERNAL AND FETAL PLASMA 
FOLLOWING SPONTANEOUS LABOUR AT TERM IN HUMANS USING UNTARGETED 
METABOLOMICS ............................................................................................................ 101 
2.1 Background .................................................................................................................... 101 
2.2 Disclaimer ...................................................................................................................... 102 
2.3 Study responsibilities ..................................................................................................... 102 
13 
 
2.4 Funding .......................................................................................................................... 103 
2.5 Ethical approval.............................................................................................................. 103 
2.6 Background .................................................................................................................... 103 
2.7 Aims and objectives ....................................................................................................... 105 
2.8 Methodology .................................................................................................................. 106 
2.8.1 Participants .................................................................................................... 106 
2.8.2 Collection of samples ..................................................................................... 108 
2.8.3 Metabolomics analysis ................................................................................... 110 
2.8.4 Statistical analysis .......................................................................................... 111 
2.8.5 Over-representation analysis ......................................................................... 112 
2.9 Results ............................................................................................................................ 114 
2.9.1 Demographics ................................................................................................ 114 
2.9.2 Metabolomics ................................................................................................ 115 
2.9.3 Changes in cord plasma metabolome ............................................................ 115 
2.9.4 Changes in maternal plasma metabolome ..................................................... 119 
2.9.5 Xenobiotics ..................................................................................................... 143 
2.9.6 Lipid super-pathway ....................................................................................... 147 
2.9.7 Nucleotides .................................................................................................... 158 
2.9.8 Amino acids .................................................................................................... 159 
2.9.9 Peptides ......................................................................................................... 160 
2.9.10 Carbohydrate metabolism............................................................................ 161 
2.9.11 Energy super-pathway ................................................................................. 162 
2.9.12 Co-factors and vitamins................................................................................ 163 
2.9.13 Over-representation analysis results ............................................................ 164 
2.10 Discussion .................................................................................................................... 169 
2.10.1 Endocannabinoid-related pathways ............................................................. 172 
2.10.2 Progesterone and pregnenolone.................................................................. 176 
2.10.3 Potential link with lymphocytes ................................................................... 177 
2.10.4 Over-representation analysis ....................................................................... 178 
2.11 Conclusions .................................................................................................................. 180 
2.12 Limitations ................................................................................................................... 182 
CHAPTER 3. SERIAL METABOLOMIC ASSESSMENT OF PREGNANCY AND LABOUR ........... 184 
3.1 Background .................................................................................................................... 184 
3.2 Aims and objectives ....................................................................................................... 186 
3.3 Funding, ethical approval and role of thesis author ....................................................... 187 
3.4 Methodology .................................................................................................................. 188 
3.4.1 Inclusion and exclusion criteria ...................................................................... 188 
3.4.2 Gestational age at spontaneous labour.......................................................... 189 
3.4.3 Recruitment ................................................................................................... 189 
3.4.4 Collecting samples in early labour and at delivery ......................................... 190 
3.4.5 Sample collection and processing .................................................................. 193 
3.4.6 Statistical analysis .......................................................................................... 193 
3.4.7 Over-representation analysis ......................................................................... 196 
3.5 Results ............................................................................................................................ 197 
3.5.1 Recruitment ................................................................................................... 197 
3.5.2 Sample collection ........................................................................................... 198 
3.5.3 Part 1 participants .......................................................................................... 205 
14 
 
3.5.4 Part 2 participants .......................................................................................... 207 
3.5.5 Correlations with gestational age at delivery ................................................. 210 
3.5.6 Summary of differences in maternal metabolites between sampling points 
during pregnancy .................................................................................................... 228 
3.5.7 Summary of differences in metabolites within vascular compartments at 
delivery between different modes of labour onset and delivery ............................ 232 
3.5.8 Endocannabinoids .......................................................................................... 233 
3.5.9 Sphingolipids .................................................................................................. 239 
3.5.10 Sphinganine-1-phosphate and sphinganine ................................................. 241 
3.5.11 Sphingosine and sphingosine-1-phosphate .................................................. 248 
3.5.12 Ceramides .................................................................................................... 249 
3.5.13 Adenosine 3',5'-cyclic monophosphate ........................................................ 253 
3.5.14 Steroids correlated with gestational age at delivery .................................... 253 
3.5.15 Progestin steroids......................................................................................... 258 
3.5.16 17alpha hydroxyprogesterone ..................................................................... 259 
3.5.17 Oestrogen steroids ....................................................................................... 262 
3.5.18 Pregnenolone steroids ................................................................................. 263 
3.5.19 Comparisons between spontaneous labour and induction of labour .......... 263 
3.5.20 Over-representation analysis for correlation analysis .................................. 266 
3.5.21 Over-representation analysis for comparisons of the different vascular 
compartments at delivery ....................................................................................... 272 
3.5.22 Linoleic acid and arachidonate ..................................................................... 289 
3.6 Discussion ...................................................................................................................... 291 
3.6.1 Endocannabinoids .......................................................................................... 292 
3.6.2 Sphingolipids and ceramides .......................................................................... 298 
3.6.3 Progesterone .................................................................................................. 304 
3.6.4 Oestrogens ..................................................................................................... 311 
3.6.5 Differences between the IOL and SL group .................................................... 314 
3.6.6 Correlations with gestational age at delivery ................................................. 316 
3.6.7 Perfluorooctane sulfonate ............................................................................. 321 
3.6.8 Over-representation analysis ......................................................................... 323 
3.7 Conclusions .................................................................................................................... 327 
3.8 Limitations ..................................................................................................................... 328 
CHAPTER 4. MATERNAL METABOLIC PROFILE IN THE SECOND TRIMESTER AND 
GESTATIONAL AGE AT DELIVERY: FINDINGS FROM THE BORN IN BRADFORD COHORT STUDY
 ...................................................................................................................................... 329 
4.1 Background .................................................................................................................... 329 
4.2 Maternal metabolic traits and potential link to gestational age of delivery .................. 330 
4.3 Epidemiology and public health consequences of pre-term and post-term births ........ 332 
4.4 Aim ................................................................................................................................. 333 
4.5 Methodology .................................................................................................................. 334 
4.5.1 Data source .................................................................................................... 334 
4.5.2 Ethics and informed consent .......................................................................... 335 
4.5.3 Data collection ............................................................................................... 335 
4.5.4 Data access ..................................................................................................... 336 
4.5.5 Study eligibility criteria ................................................................................... 337 
4.5.6 Exposure measures: maternal gestational metabolite concentrations .......... 341 
15 
 
4.5.7 Outcome: gestational age at delivery ............................................................. 344 
4.5.8 Data analysis .................................................................................................. 345 
4.5.9 Creation of analysis sample ............................................................................ 354 
4.5.10 Statistical analysis ........................................................................................ 355 
4.6 Results ............................................................................................................................ 358 
4.6.1 Participants’ characteristics ........................................................................... 358 
4.6.2 Association of maternal metabolites with gestational age at delivery ........... 366 
4.6.4 Multivariable logistic regression analysis ....................................................... 375 
4.6.5 Sensitivity analysis .......................................................................................... 376 
4.7 Discussion ...................................................................................................................... 401 
4.7.1 Lipoproteins and triglycerides ........................................................................ 402 
4.7.2 Lipoproteins and pregnancy ........................................................................... 404 
4.7.3 Dyslipidaemia, inflammation and impaired vascular function ....................... 409 
4.7.4 Creatinine ....................................................................................................... 412 
4.7.5 Alpha-1-acid glycoprotein .............................................................................. 413 
4.7.6 Comparison with results of Chapter 3 ............................................................ 413 
4.8 Conclusions .................................................................................................................... 415 
4.9 Limitations of study ........................................................................................................ 416 
CHAPTER 5. INVESTIGATING CHANGES IN PROTEIN PHOSPHORYLATION DURING 
MYOMETRIAL CONTRACTIONS ....................................................................................... 419 
5.1 Background and rationale for study ............................................................................... 419 
5.2 Ethical approval, participant consent and funding ......................................................... 424 
5.3 Role of thesis researcher ................................................................................................ 424 
5.4 Aims ............................................................................................................................... 425 
5.5 Methodology .................................................................................................................. 426 
5.5.1 Myometrial organ bath .................................................................................. 426 
5.5.2 Tissue homogenisation ................................................................................... 430 
5.5.3 Phosphoproteomics ....................................................................................... 431 
5.5.4 Initial analysis ................................................................................................. 433 
5.5.5 Pathway analysis ............................................................................................ 440 
5.6 Part 1 background and results ....................................................................................... 441 
5.6.1 Background .................................................................................................... 441 
5.6.2 Part 1 inclusion criteria .................................................................................. 442 
5.6.3 Part 1 exclusion criteria .................................................................................. 442 
5.6.4 Results ............................................................................................................ 442 
5.7 Part 2 background and results ....................................................................................... 468 
5.7.1 Background .................................................................................................... 468 
5.7.2 Inclusion criteria for the failed IOL group ....................................................... 468 
5.7.3 Inclusion criteria ECS group ............................................................................ 469 
5.7.4 Exclusion criteria ............................................................................................ 469 
5.7.5 Part 2 results .................................................................................................. 469 
5.8 Discussion ...................................................................................................................... 520 
5.8.1 Part 1 discussion total proteins ...................................................................... 521 
5.8.2 Phosphorylation events in Part 1 ................................................................... 531 
5.8.3 Part 2 discussion total proteins ...................................................................... 536 
5.8.4 Phosphorylation events Part 2 ....................................................................... 545 
5.8.5 Comparisons of part 1 and part 2 ................................................................... 549 
16 
 
5.9 Conclusions .................................................................................................................... 550 
5.10 Limitations ................................................................................................................... 550 
CHAPTER 6. DISCUSSION ................................................................................................ 552 
6.1 Summary ........................................................................................................................ 552 
6.2 Linking the findings of the different studies ................................................................... 555 
6.2.1 Association of maternal metabolites during pregnancy with gestational age at 
delivery ................................................................................................................... 557 
6.2.2 Vascular dysfunction ...................................................................................... 558 
6.2.3 Myometrial phenotype associated with failed induction of labour................ 559 
6.3 Study limitations ............................................................................................................ 562 
6.4 Clinical implications........................................................................................................ 563 
6.5 Future studies ................................................................................................................ 564 
APPENDICES................................................................................................................... 567 
APPENDIX 2A1 ...................................................................................................................... 570 
APPENDIX 3A1 ...................................................................................................................... 590 
APPENDIX 3A2 ...................................................................................................................... 593 
APPENDIX 3A3 ...................................................................................................................... 594 
APPENDIX 3A4 ...................................................................................................................... 632 
APPENDIX 3A5 ...................................................................................................................... 647 
APPENDIX 3A6 ...................................................................................................................... 656 
APPENDIX 3A7 ...................................................................................................................... 663 
APPENDIX 4A1 ...................................................................................................................... 671 
APPENDIX 4A2 ...................................................................................................................... 677 
APPENDIX 4A3 ...................................................................................................................... 693 
APPENDIX 4A4 ...................................................................................................................... 703 
APPENDIX 4A5 ...................................................................................................................... 710 
APPENDIX 4A6 ...................................................................................................................... 717 
APPENDIX 4A7 ...................................................................................................................... 724 














LIST OF TABLES 
 
Table 2.1: Characteristics of included human participants .............................................. 117 
Table 2.2: Number of metabolites which significantly increased or decreased at the time of 
delivery.......................................................................................................................... 119 
Table 2.3: Fold-change in cord plasma (VC/EC) for metabolites (xenobiotics excluded) with 
significant p (≤0.05) and q (≤0.10), ordered according to fold-change (greatest to smallest), 
with corresponding sub-pathway and super-pathway .................................................... 121 
Table 2.4: Fold-change in maternal (intervillous) plasma (VM/EM) for metabolites 
(xenobiotics excluded) with significant p (≤0.05) and q (≤0.10), ordered according to fold-
change (greatest to smallest), with corresponding sub-pathway and super-pathway ..... 129 
Table 2.5: Fold-change in cord plasma (VC/EC) for xenobiotics with significant p (≤0.05) and 
q (≤0.10) ........................................................................................................................ 144 
Table 2.6: Fold-change in maternal (intervillous) plasma (VM/EM) for xenobiotics with 
significant p (≤0.05) and q (≤0.10), ................................................................................. 145 
Table 2.7: Fold-change in cord plasma (VC/EC) and maternal (intervillous) plasma (VM/EM) 
for sphingolipids ............................................................................................................ 148 
Table 2.8: Fold-change in cord plasma (VC/EC) and maternal (intervillous) plasma (VM/EM) 
for pregnenolone steroids.............................................................................................. 151 
Table 2.9: Fold-change in cord plasma (VC/EC) and maternal (intervillous) plasma (VM/EM) 
for progestin steroids ..................................................................................................... 152 
Table 2.10: Fold-change in cord plasma (VC/EC) and maternal (intervillous) plasma (VM/EM) 
for endocannabinoid steroids ........................................................................................ 153 
Table 2.11: Fold-change in cord plasma (VC/EC) and maternal (intervillous) plasma (VM/EM) 
for ceramides ................................................................................................................. 154 
Table 2.12: Results of the over-representation enrichment analysis for metabolites with 
significant p (≤0.05) and p (<0.1) for VM/EM.................................................................. 165 
Table 2.13: Results of the over-representation enrichment analysis for metabolites with 
significant p (≤0.05) and p (<0.1) for VC/EC .................................................................... 167 
Table 3.1: Maternal demographics and delivery outcomes for participants of Part 1 
according to mode of delivery. ....................................................................................... 206 
18 
 
Table 3.2: Maternal demographics for included participants for samples taken at 28- and 
34-weeks’ gestation and in latent phase ........................................................................ 210 
Table 3.3: Metabolites which significantly correlate with gestational age at delivery for 
those samples taken at 28 weeks’ gestation .................................................................. 212 
Table 3.4: Metabolites which significantly correlate with gestational age at delivery for 
those samples taken at 34 weeks’ gestation .................................................................. 215 
Table 3.5: Metabolites which significantly correlate with gestational age at delivery for 
those samples taken in latent phase (n=11)/prior start of IOL (n=3) for post-term ......... 220 
Table 3.6: Metabolites which significantly correlate with gestational age at delivery for at 
least two of the sampled time points ............................................................................. 223 
Table 3.7: Table showing significant changes for the endocannabinoids. ....................... 230 
Table 3.8: Significant fold-changes for sphingolipids ...................................................... 243 
Table 3.9: Significant changes for Sphingosines .............................................................. 247 
Table 3.10: Significant changes for ceramide family ....................................................... 250 
Table 3.11: Mean normalised and scaled values for 17alpha-hydroxyprogesterone in each 
of the vascular compartments for each of the modes of labour onset and delivery ........ 254 
Table 3.12: Mean normalised and scaled values for progesterone in each of the vascular 
compartments for each of the modes of labour onset and delivery. .............................. 260 
Table 3.13: Significant changes for progestin and oestrogen steroids (all results shown are 
significant at p≤0.05). .................................................................................................... 261 
Table 3.14: Mean normalised and scaled values for 17alpha-hydroxyprogesterone in each 
of the vascular compartments for each of the modes of labour onset and delivery. ....... 262 
Table 3.15: Results of the over-representation enrichment analysis for metabolites sampled 
at 28 weeks’ gestation which were significantly (p≤0.05) correlated with gestational age at 
spontaneous delivery..................................................................................................... 267 
Table 3.16: Results of the over-representation enrichment analysis for metabolites sampled 
at 34 weeks’ gestation which were significantly (p≤0.05) correlated with gestational age at 
spontaneous delivery..................................................................................................... 268 
Table 3.17: Results of the over-representation enrichment analysis for metabolites in latent 




Table 3.18: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord artery of the IOL group and cord artery of 
the SL group ................................................................................................................... 272 
Table 3.19: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord artery of the ECS group and cord artery of 
the SL group ................................................................................................................... 274 
Table 3.20: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord artery of the ECS group and cord artery of 
the IOL group ................................................................................................................. 276 
Table 3.21: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord vein of the IOL group and cord vein of the 
SL group ......................................................................................................................... 278 
Table 3.22: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord vein of the ECS group and cord vein of the 
SL group ......................................................................................................................... 280 
Table 3.23: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord vein of the ECS group and cord vein of the 
IOL group ....................................................................................................................... 282 
Table 3.24: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the intervillous blood of the IOL group and 
intervillous blood of the SL group .................................................................................. 284 
Table 3.25: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the intervillous blood of the ECS group and 
intervillous blood of the SL group .................................................................................. 286 
Table 3.26: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the intervillous blood of the ECS group and 
intervillous blood of the IOL group ................................................................................. 288 
Table 4.1: Distribution of multi-fetal pregnancies for mothers enrolled in BiB. .............. 340 
Table 4.2: Distribution of pregnancies for mothers enrolled in BiB. ................................ 340 
Table 4.3: Summary of outcome variable (gestational age at delivery) ........................... 360 
Table 4.4: Summary of continuous covariables .............................................................. 361 
Table 4.5: Summary of categorical covariables ............................................................... 362 
20 
 
Table 4.6: Distribution of the characteristics of those in the analysis group according to 
whether delivered preterm, term or post-term .............................................................. 365 
Table 4.7: Metabolites with a significant (adjusted) negative association with gestational 
age at delivery ............................................................................................................... 369 
Table 4.8: Metabolites with a significant (adjusted) positive association with gestational age 
at delivery...................................................................................................................... 374 
Table 4.9: Number of pregnancies within the preterm categories, with mean and range of 
gestational age at delivery (days) within each of these groups. ...................................... 378 
Table 5.1: Accession number and protein description for total proteins where the REL/PRE 
ratio at least halved for all three women, in order of mean REL/PRE. ............................ 444 
Table 5.2: Accession number and protein description for total proteins where the REL/PRE 
ratio at least doubled for all three women, in order of mean REL/PRE. .......................... 452 
Table 5.3: 25 most overrepresented total protein pathways according to Reactome analysis 
(ordered according to p-value size) where REL/PRE at least halved. ............................... 453 
Table 5.4: Ten most overrepresented pathways according to Reactome analysis (ordered 
according to p-value size) where REL/PRE at least doubled. ........................................... 456 
Table 5.5: number of phosphopeptides detected, number of which had a unique master 
protein, and number of related phosphoproteins. ......................................................... 466 
Table 5.6: Phosphorylation events where REL/PRE ratio at least halved for all three women.
 ...................................................................................................................................... 466 
Table 5.7: Phosphorylation events where REL/PRE at least doubled for all three women.
 ...................................................................................................................................... 467 
Table 5.8: Maternal demographics for Part 2. ................................................................ 471 
Table 5.9: Total proteins which significantly at least doubled in the failed IOL group under 
the PRE condition .......................................................................................................... 475 
Table 5.10: Total proteins which significantly at least halved in the failed IOL group under 
the PRE condition .......................................................................................................... 476 
Table 5.11: Total proteins which at least doubled in the failed IOL group and were significant 
at p<0.05 threshold in the SP-REL condition. .................................................................. 478 
Table 5.12: Total proteins which at least halved in the failed IOL group and were significant 
at p<0.05 threshold in the SP-REL condition. .................................................................. 480 
21 
 
Table 5.13: Total proteins which at least doubled in the failed IOL group and were significant 
at p<0.05 threshold in the SP-CON condition. ................................................................ 482 
Table 5.14: Total proteins which at least halved in the failed IOL group and were significant 
at p<0.05 threshold in the SP-CON condition. ................................................................ 484 
Table 5.15: Total proteins which at least doubled in the failed IOL group and were significant 
at p<0.05 threshold in the OXT-REL condition. ............................................................... 486 
Table 5.16: Total proteins which at least halved in the failed IOL group and were significant 
at p<0.05 threshold in the OXT-REL condition. ............................................................... 488 
Table 5.17: Total proteins which at least doubled in the failed IOL group and were significant 
at p<0.05 threshold in the OXT-CON condition. .............................................................. 490 
Table 5.18: Total proteins which at least halved in the failed IOL group and were significant 
at p≤0.05 threshold in the OXT-CON condition. .............................................................. 491 
Table 5.19: Proteins which significantly (p<0.05) at least double in the failed IOL group for 
at least two of the conditions. ....................................................................................... 493 
Table 5.20: Proteins which significantly (p<0.05) at least halved in the failed IOL group for 
at least two of the conditions. ....................................................................................... 495 
Table 5.21: Phosphorylation events which at least doubled in the failed IOL group in the PRE 
condition. ...................................................................................................................... 500 
Table 5.22: Phosphopeptides which at least halved in the failed IOL group in the PRE 
condition. ...................................................................................................................... 501 
Table 5.23: Phosphopeptides which at least doubled in the failed IOL group in the SP-REL 
condition. ...................................................................................................................... 502 
Table 5.24: Phosphopeptides which at least halved in the failed IOL group in the SP-REL 
condition. ...................................................................................................................... 503 
Table 5.25: Phosphopeptides which at least doubled in the failed IOL group in the SP-CON 
condition. ...................................................................................................................... 504 
Table 5.26: Phosphopeptides which at least halved in the failed IOL group in the SP-CON 
condition. ...................................................................................................................... 505 
Table 5.27: Phosphopeptides which at least doubled in the failed IOL group in the OXT-REL 
condition. ...................................................................................................................... 506 
Table 5.28: Phosphopeptides which at least halved in the failed IOL group in the OXT-REL 
condition. ...................................................................................................................... 508 
22 
 
Table 5.29: Phosphopeptides which at least doubled in the failed IOL group in the OXT-CON 
condition. ...................................................................................................................... 511 
Table 5.30: Phosphopeptides which at least halved in the failed IOL group in the OXT-CON 
condition. ...................................................................................................................... 512 
Table 5.31: Phospho-events which at least significantly halve in the failed IOL group under 
more than one condition, with log2-fc for each condition (where p ≤ 0.05). ................... 513 
Table 5.32: Phospho-events which at least double in the failed IOL group under more than 
one condition, with log2-fc for each condition (p-value). ............................................... 514 
 


















LIST OF FIGURES 
Figure 1.1. Illustration of non-pregnant uterine structure (adapted from Aguilar & Mitchell 
(2010)49). ......................................................................................................................... 39 
Figure 1.2: Diagram of blood flow within the human placenta, with separated maternal and 
fetal blood circulations.  Maternal blood flows into the placenta via maternal arteries, pools 
in the intervillous space, and flows out of the placenta via maternal veins. Fetal blood 
circulation through the placenta occurs via fetal venules and arterioles contained within 
chorionic villi that protrude into the intervillous space, allowing selective exchange of 
molecules between the maternal and fetal circulations. Fetal blood flows from the placenta 
to the fetus via the umbilical cord vein and flows from the fetus to the placenta via the 
umbilical cord arteries (usually two), contained within the umbilical cord. Red colour = 
oxygen-rich blood; blue colour = oxygen-depleted blood. ................................................ 48 
Figure 1.3: Diagram of fetal and umbilical cord blood circulation ..................................... 49 
Figure 1.4: Comparison of mean gestational age at delivery between human fetuses with 
anencephaly and no polyhydramnios (n=29) and human fetuses with normally developed 
brain (n=49 996) .............................................................................................................. 56 
Figure 1.5: Diagram of maternal-feto-placental unit with biosynthesis of progesterone and 
oestrogens ....................................................................................................................... 67 
Figure 1.6: Relative abundance of mRNA encoding PRA, PRB, ERα, ERβ, and the PRA/PRB 
ratio in labouring and non-labouring myometrium .......................................................... 72 
Figure 1.7: Illustration showing proposed actions of macrophages at the fetal membranes
 ........................................................................................................................................ 80 
Figure 2.1: Flow diagram for women approached to join the study ................................ 110 
Figure 2.2: Differences in the lipid superpathway between the maternal and cord blood
 ...................................................................................................................................... 158 
Figure 2.3: Differences in the nucleotides super-pathway between the maternal and cord 
blood ............................................................................................................................. 159 
Figure 2.4: Differences in the amino acids super-pathway between the maternal and cord 
blood ............................................................................................................................. 160 
Figure 2.5: Differences in the peptides super-pathway between the maternal and cord blood
 ...................................................................................................................................... 161 
Figure 2.6: Differences in the carbohydrates super-pathway between the maternal and cord 
blood ............................................................................................................................. 162 
24 
 
Figure 2.7: Differences in the energy super-pathway between the maternal and cord blood
 ...................................................................................................................................... 162 
Figure 2.8: Differences in the cofactors and vitamins super-pathway between the maternal 
and cord blood............................................................................................................... 164 
Figure 2.9: overview of the results of the over-representation analysis for VM/EM ....... 166 
Figure 2.10: overview of the results of the over-representation analysis for VC/EC ........ 168 
Figure 2.11: Diagram illustrating proposed hypothesis generate from pilot study .......... 182 
Figure 3.1: Flow diagram showing number of women approached, recruited, and withdrawn 
from the study ............................................................................................................... 201 
Figure 3.2: Samples taken and delivery outcomes for women who spontaneously laboured 
at term .......................................................................................................................... 202 
Figure 3.3: Samples taken and delivery outcomes for women who had induction of labour 
at term or post-term ...................................................................................................... 203 
Figure 3.4: Samples taken and delivery outcomes for women who had an elective caesarean 
section at term. ............................................................................................................. 204 
Figure 3.5: Scatter plots showing correlation between metabolite level and gestational age 
at delivery for perfluorooctanesulfonate (PFOS) ............................................................ 227 
Figure 3.6: Venn diagram illustrating the spread and degree of overlap of metabolites with 
significant differences between paired time points (28 weeks vs 34 weeks = red; 34 weeks 
vs latent phase = yellow; 28 weeks vs latent phase = blue) ............................................ 229 
Figure 3.7: Scatter plot showing correlation between N-palmitoyltaurine level and 
gestational age at delivery at 34 weeks’ gestation, and box-plots showing differences 
between modes of labour onset for latent, intervillous, cord artery and cord vein......... 235 
Figure 3.8: Scatter plots showing correlation between N-stearoyltaurine level and 
gestational age at delivery at 28 weeks’ and 34 weeks’ gestation, and box-plots showing 
differences between modes of labour onset for latent, intervillous, cord artery and cord 
vein ............................................................................................................................... 236 
Figure 3.9: Box plots for scaled metabolite for the three labour onset types within each of 
the labour and delivery samples for oleoyl-ethanolamide, palmitoyl-ethanolamide and 
linoleoyl-ethanolamide .................................................................................................. 237 
Figure 3.10: Scatter plots showing correlation between 5α-androstan-3α, 17α-diol disulfate 
level and gestational age at delivery .............................................................................. 255 
25 
 
Figure 3.11: Correlations between metabolite and gestational age at delivery for 5α-
pregnan-3β, 20α-diol disulfate,  21-hydroxypregnanolone disulfate,  pregnanediol-3-
glucuronide,  dehydroepiandrosterone sulfate and androstenediol (3β, 17β) monosulfate
 ...................................................................................................................................... 256 
Figure 3.12: Correlations between metabolite and gestational age at delivery for 17α-
hydroxypregnanolone glucuronide,  5α-androstan-3α, 17β-diol disulfate, estriol 3-sulfate 
and  estriol 16-glucuronide ............................................................................................ 257 
Figure 3.13: Heat maps comparing scaled normalised values of progesterone, oestriol, 17α-
hydroxyprogesterone, DHEA-S, sphingosine and sphingosine 1-phosphate between the 
spontaneously labouring group, the induction of labour group and the elective caesarean 
section ........................................................................................................................... 266 
Figure 3.14: Overview of the results of the over-representation analysis for metabolites 
sampled at 28 weeks’ gestation which were significantly (p≤0.05) correlated with 
gestational age at spontaneous delivery ........................................................................ 267 
Figure 3.15: Overview of the results of the over-representation analysis for for metabolites 
sampled at 34 weeks’ gestation which were significantly (p≤0.05) correlated with 
gestational age at spontaneous delivery ........................................................................ 269 
Figure 3.16: Overview of the results of the over-representation analysis for for metabolites 
sampled in latent phase which were significantly (p≤0.05) correlated with gestational age 
at spontaneous delivery................................................................................................. 271 
Figure 3.17: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord artery of the IOL group and 
cord artery of the SL group ............................................................................................ 273 
Figure 3.18: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord artery of the ECS group and 
cord artery of the SL group ............................................................................................ 275 
Figure 3.19: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord artery of the ECS group and 
cord artery of the IOL group ........................................................................................... 277 
Figure 3.20: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord vein of the IOL group and cord 
vein of the SL group ....................................................................................................... 279 
Figure 3.21: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord vein of the ECS group and cord 
vein of the SL group ....................................................................................................... 281 
26 
 
Figure 3.22: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord vein of the ECS group and cord 
vein of the IOL group ..................................................................................................... 283 
Figure 3.23: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the intervillous blood of the IOL group 
and intervillous blood of the SL group ............................................................................ 285 
Figure 3.24: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the intervillous blood of the ECS group 
and intervillous blood of the SL group ............................................................................ 287 
Figure 3.25: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the intervillous blood of the ECS group 
and intervillous blood of the IOL group .......................................................................... 289 
Figure 3.26: Heat maps comparing scaled normalised values of arachidonate (20:4n6) and 
linoleate (18:2n6) concentrations in the latent/preoperative, intervillous, cord artery, and 
cord vein samples between the SL, IOL, and ECS groups ................................................. 290 
Figure 4.1: Flow chart for participant inclusion .............................................................. 339 
Figure 4.2: Illustration of processes involved in the Nightingale NMR metabolomics platform
 ...................................................................................................................................... 342 
Figure 4.3: Directed acyclic graph for analysis of the relationship between maternal 
metabolites measured during the second trimester and gestational age at delivery. ..... 349 
Figure 4.4: Flow of participants included in complete cases analysis sample for statistical 
analyses performed. ...................................................................................................... 357 
Figure 4.5: Associations of maternal gestational amino acids and apoplipoproteins 
concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery.......................................................................................................................... 379 
Figure 4.6: Associations of maternal gestational cholesterol metabolites concentrations 
(measured at 26-28 completed weeks’ gestation) with gestational age at delivery ........ 380 
Figure 4.7: Associations of maternal gestational fatty acids (%) metabolites ratios 
(measured at 26-28 completed weeks’ gestation) with gestational age at delivery ........ 381 
Figure 4.8: Associations of maternal gestational fatty acids metabolites concentrations and 
saturation measures (measured at 26-28 completed weeks’ gestation) with gestational age 
at delivery...................................................................................................................... 382 
27 
 
Figure 4.9: Associations of maternal gestational fluid balance and inflammation metabolite 
concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery.......................................................................................................................... 383 
Figure 4.10: Associations of maternal gestational glycerides and phospholipids metabolite 
concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery.......................................................................................................................... 384 
Figure 4.11: Associations of maternal gestational glycolysis and ketone bodies metabolites 
concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery.......................................................................................................................... 385 
Figure 4.12: Associations of maternal gestational lipoprotein particle size (measured at 26-
28 completed weeks’ gestation) with gestational age at delivery ................................... 386 
Figure 4.13: Associations of maternal gestational large high density lipoprotein metabolites 
concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery.......................................................................................................................... 387 
Figure 4.14: Associations of maternal gestational medium high density lipoprotein 
metabolites concentrations (measured at 26-28 completed weeks’ gestation) with 
gestational age at delivery ............................................................................................. 388 
Figure 4.15: Associations of maternal gestational small high density lipoproteins 
metabolites concentrations (measured at 26-28 completed weeks’ gestation) with 
gestational age at delivery ............................................................................................. 389 
Figure 4.16: Associations of maternal gestational very large high density lipoprotein 
metabolites concentrations (measured at 26-28 completed weeks’ gestation) with 
gestational age at delivery ............................................................................................. 390 
Figure 4.17: Associations of maternal gestational low density lipoprotein metabolites 
concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery.......................................................................................................................... 391 
Figure 4.18: Associations of maternal gestational large low density lipoprotein metabolites 
concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery.......................................................................................................................... 392 
Figure 4.19: Associations of maternal gestational medium low density lipoprotein 
metabolites concentrations (measured at 26-28 completed weeks’ gestation) with 
gestational age at delivery ............................................................................................. 393 
Figure 4.20: Associations of maternal gestational small low density lipoproteins metabolites 




Figure 4.21: Associations of maternal gestational large very low density lipoproteins 
metabolite concentrations (measured at 26-28 completed weeks’ gestation) with 
gestational age at delivery ............................................................................................. 395 
Figure 4.22: Associations of maternal gestational medium very low density lipoproteins 
metabolite concentrations (measured at 26-28 completed weeks’ gestation) with 
gestational age at delivery ............................................................................................. 396 
Figure 4.23: Associations of maternal gestational small very low density lipoproteins 
metabolites concentrations (measured at 26-28 completed weeks’ gestation) with 
gestational age at delivery ............................................................................................. 397 
Figure 4.24: Associations of maternal gestational very large very low density lipoproteins 
metabolites concentrations (measured at 26-28 completed weeks’ gestation) with 
gestational age at delivery ............................................................................................. 398 
Figure 4.25: Associations of maternal gestational very small very low density lipoproteins 
metabolites concentrations (measured at 26-28 completed weeks’ gestation) with 
gestational age at delivery ............................................................................................. 399 
Figure 4.26: Associations of maternal gestational chylomicrons and very low density 
lipoproteins metabolites concentrations (measured at 26-28 completed weeks’ gestation) 
with gestational age at delivery ..................................................................................... 400 
Figure 5.1: Myobath-II system with experimental conditions used in each of the four 
chambers used ............................................................................................................... 427 
Figure 5.2: Example of electronic output of myometrial samples connected to force-
transducers using Lab-Trax data acquisition system ....................................................... 429 
Figure 5.3: Flow diagram for methodology for analysis conducted for Part 1.................. 438 
Figure 5.4: Flow diagram for methodology for analysis conducted for Part 2.................. 439 
Figure 5.5: STRING diagram (https://string-db.org/) depicting protein-protein interactions 
between proteins differently expressed between the REL and PRE (REL/PRE) conditions
 ...................................................................................................................................... 460 
Figure 5.6: STRING diagram summarising the total protein data for those proteins which 
either at least doubled or halved in the REL condition compared with PRE (REL/PRE) for 
samples taken from all three women ............................................................................. 461 
Figure 5.7: Proteins which at least halve between the pre-contracting state (PRE) and 
contracting state (SP-REL) highlighted in red within the Coagulation and Complement 
Cascade ......................................................................................................................... 462 
29 
 
Figure 5.8: STRING diagram summarising the proteins for which there were phosphorylation 
events observed in all three samples and which either at least doubled or halved in the REL 
condition compared with PRE (REL/PRE) for samples taken from all three women ........ 463 
Figure 5.9: Volcano plot comparing change in log2-fold change in total protein between 
failed IOL and ECS groups in the pre-contracting condition ............................................ 477 
Figure 5.10: Volcano plot illustrating the log2-fold change in total protein between the 
failed IOL and ECS group in the spontaneously contracting group at peak relaxation ..... 481 
Figure 5.11: Volcano plot of comparing log2-fold change in total protein between the failed 
IOL group and ECS group in the spontaneously contracting group at peak contraction ... 485 
Figure 5.12: Volcano plot of change in total protein between the failed IOL and ECS groups 
in the oxytocin-stimulated group at peak relaxation ...................................................... 489 
Figure 5.13: Volcano plot of change in total protein between the failed IOL and ECS group 
in the oxytocin-stimulated group at peak contraction .................................................... 492 
Figure 5.14: STRING diagram summarising the phosphoproteomic data for proteins for 
which phosphorylation events at least A. double or B. halve, in the failed induction of labour 
group under contracted condition ................................................................................. 516 
Figure 5.15: STRING diagram  summarising the phosphoproteomic data for proteins for 
which phosphorylation events at least double or halve in the failed induction of labour 
group under contracted condition ................................................................................. 517 
Figure 5.16: STRING diagram summarising the phosphoproteomic data for proteins for 
which phosphorylation events at least A. double or B. halve, in the failed induction of labour 
group at peak relaxation ................................................................................................ 518 
Figure 5.17: STRING diagram summarising the phosphoproteomic data for proteins for 
which phosphorylation events at least double or halve in the failed induction of labour 
group at peak relaxation ................................................................................................ 519 
Figure 6.1: Diagram illustrating highlights of findings of the thesis relating to improving 








CHAPTER 1. INTRODUCTION 
 
1.1 Rationale for research 
Parturition is essential for mammalian existence, however despite decades of 
research the mechanism for labour in humans remains poorly understood1-3, 
with negligible advances in safe and effective methods for the inhibition or 
stimulation of uterine contractility in recent years4, 5. This has many implications, 
including limiting our effectiveness at managing preterm birth (PTB) and 
induction of labour (IOL)1, 6, 7. While infection and inflammatory processes have 
been implicated in some episodes of PTB, in many cases no cause is found, and 
it is possible that there is an early triggering of the events of parturition which 
would normally occur at term8, 9. A better understanding of human labour would 
therefore allow development of methods for improved prevention of PTB, as 
well as more effective strategies for IOL.   
There is strong interest in using epidemiological, clinical and molecular markers 
to identify women at risk of complications of pregnancy5, 10, 11, with advances in 
prediction models for complications of pregnancy. These include clinical tests to 
evaluate cervicovaginal fluid, such as: quantitative measurement of fetal 
fibronectin for prediction of preterm labour12; determination of the presence of 
human placental-alpha-microglobulin-1 with the PartoSure test for prediction of 
PTB within 7-14 days13 ; and measurement of phosphorylated insulin-like growth 
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factor binding protein-1 with the Actim Partus bedside test which is also used to 
predict PTB within the next 7 days14. Further potential markers for prediction of 
PTB include 4-hydroxyglutamate (identified from mass spectrometry 
assessment of approximately 900 gestation serum metabolomic markers) as a 
predictor for preeclampsia15, and a predictor model based on four maternal 
serum metabolites (from the same mass spectrometry platform as that for 4-
hydroxyglutamate) for prediction of fetal growth restriction at term16. The latter 
two of these studies involved the use of metabolomics, which is one of a number 
of recent technologies that are enabling new insight into these important clinical 
research questions. Further, a nested case-control study (n=81) within the 
prospective Proteomic Assessment of Preterm Risk (PAPR) study was conducted 
in the United States between 2011 and 2013. Proteomic assessment of maternal 
serum was performed between 17 and 28+6 weeks’ gestation in order to 
develop a mass spectrometry-based serum test for prediction of spontaneous 
preterm labour in asymptomatic pregnant women17. The log ratio of insulin-like 
growth factor-binding protein 4 (IBP4)/Sex Hormone-Binding Protein 4 (SHBG) 
was found to have an odds ratio of 5.04 for spontaneous preterm delivery before 
37 weeks’ gestation, with a sensitivity of 75% and specificity of 74%17. This group 
have since conducted a prospective case-control study (9 cases; 838 non-cases) 
within an independent cohort to show that this ratio is predictive of preterm 
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birth <32 weeks’ gestation, as well as significantly associated with length of stay 
on the neonatal intensive care unit18. The authors of this study also suggest that 
as IBP4 is produced by the placenta and present in increased concentrations in 
women with small for gestational age fetuses, that is may also be a marker for 
placental insufficiency. This is interesting as it supports a potential link with 
placental function and PTB, and therefore raises the possibility that timing of 
gestational age at spontaneous delivery may be related to changing placental 
function towards term. This is a theme which is returned to throughout this 
thesis.  
While such prediction of pathologies of pregnancy are valuable so that women 
who are at risk may be identified early and monitored, these biomarkers do not 
necessarily reflect the causal pathway for the conditions they predict and do not 
always provide answers as to the best way to treat and prevent19-22. It is 
therefore useful to continue research into the mechanistic pathways underlying 
these processes, in parallel with developing prediction models, in order to 
further direct potential development for treatment and prevention of these 
conditions. The overall ethos for the research included in this thesis was to 
improve our understanding of the molecular triggers for spontaneous labour, 
including PTB, by integrating evidence from clinical, laboratory and 
epidemiological studies.  
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1.2 Background  
1.2.1 Human gestation 
The average gestational length for human pregnancy is 40 weeks (280 days) 
following the first day of the last menstrual period (LMP)23, 24. In many settings, 
including in the United Kingdom (UK), an initial estimated date of delivery is 
calculated by adding 280 days to the LMP. This may be adjusted following fetal 
measurements taken at the dating scan, routinely conducted between 11- and 
14-weeks’ gestation, which measures the developing fetus and gives an 
estimated gestational age according to the calculated fetal size25. However, the 
reality is that human gestational length can vary considerably between 
individuals, and the estimated date of delivery (EDD) is rarely precise24, 25. Only 
around 4% of pregnancies deliver at 280 days, and approximately 70% deliver 
within ten days of their predicted EDD24. Gestational length has been studied 
since ancient times, and Aristotle remarked that, unlike other animals which 
have a uniform gestation, humans may have pregnancies of seven to eleven 
months’ gestation26. The reason for this variation is unclear, and while it may be 
due to inherent errors in the EDD calculation, as it is not possible to detect 
precisely when fertilisation occurs, there is also likely variation in the rate of fetal 
maturation and individual differences in the timing of natural delivery. 
Importantly, it is unclear whether there is a single healthy gestational length for 
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humans24. Interestingly, cell-free RNA in maternal blood has been shown to have 
a distinct phenotype at different stages of pregnancy27. A pilot study (n=31) 
indicated that measurement of nine cell-free RNA transcripts within maternal 
blood estimated current gestational age with a similar accuracy to the gold-
standard ultrasound. The same authors also described another pilot study of 38 
women with risk-factors for PTB which showed that seven cell-free RNA 
transcripts could predict preterm birth up to two months in advance. Larger 
studies are required to investigate this further28. 
1.2.2 Gestational length definitions 
A pregnancy is considered to deliver at “term” if the baby is born between 259 
days and 294 days (37 and 42 completed weeks’ gestation)29, 30, “preterm” if 
delivered before 259 days (37 completed weeks) and “post-term” if delivered 
after 294 days (42 completed weeks)29, 31. However, recent discussions among 
experts suggest that the five weeks described as term, i.e., 37 completed weeks 
to 42 completed weeks, may be too long; and that neonatal outcomes for babies 
born within this time frame should not be considered the same, particularly with 
regards to neonatal respiratory morbidity. A further sub-categorisation has been 
suggested, creating the following categories: “early term” (37 completed weeks 
to <39 completed weeks), “full term” (39 completed weeks to <41 completed 
weeks), “late term” (41 completed weeks to <42 completed weeks) and “post-
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term” (42 completed weeks and above)23. However, this suggestion has not 
currently been taken up in the UK. In general, babies who are born outside of 
the “term” boundaries are considered to be at increased risk for perinatal 
complications29, 30. 
1.2.3 Mechanisms of parturition 
Parturition describes the process of birth in mammals. In humans this is a series 
of events, colloquially referred to as labour, which involve rupture of the 
amniotic membranes (which may not occur until immediately before the baby 
is born), cervical softening and dilatation, and activation of the smooth muscle 
of the myometrium to produce contractions that result in delivery of the baby32. 
Although some mechanisms are shared among mammalian species33, the 
triggers for these events in humans remain unclear3, 34.  
Progesterone and oestrogen are key hormones for human reproduction and 
pregnancy, with antagonistic actions on myometrial contraction. During 
pregnancy,  progesterone appears essential for general quiescence of the 
uterine myometrium, and in vitro a decrease in progesterone results in 
increased contractile activity35. In contrast, oestrogen promotes transcription of 
genes which encode proteins that increase myometrial excitability and 
contractility, such as cyclooxygenase-2 (COX-2) and oxytocin receptor (OTr); and 
an increase in oestrogen concentrations can thereby stimulate the myometrium 
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to contract and labour32. In many mammals, parturition seems to be triggered 
by a change in the balance between progesterone and oestrogen so that at the 
time of labour there is a relative decrease in progesterone concentrations, or 
increased sensitivity of tissues to oestrogen compared with progesterone. Much 
research in this area has been conducted in rodents and sheep, although this 
has not been easy to translate to humans, and this will be discussed in the 
coming chapters35. 
1.2.4 The epidemiology of preterm birth 
As described above, PTB is defined by the World Health Organisation (WHO) as 
birth which occurs before 37 completed weeks’ gestation31, 33. PTB is a global 
problem, affecting women within both developed and developing countries, and 
15 million babies are born prior to 37 weeks’ gestation each year36. In 2015, 
more than a million babies died because of complications of PTB, which 
comprised 16% of global deaths in children under five years of age 37. Many more 
of these children have life-long disabilities including cerebral palsy, and visual, 
learning and hearing impairments36, 38. Within the UK, PTB is the largest cause of 
neonatal morbidity and mortality. According to the “Mothers and Babies: 
Reducing Risk through Audits and Confidential Enquiries – UK” (MBRRACE-UK) 
report, 7% (57441 out of 780 114) of UK live births were delivered prior to 37 
weeks gestation in 201539, a statistic which has not substantially changed for 
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over a decade31, 40. The risk for poor neonatal outcome secondary to PTB is 
inversely proportional to the gestational age at delivery, so that those babies 
that are born moderately preterm (between 34 and 37 completed weeks’ 
gestation) have better outcomes than those that are born extremely preterm 
(before 28 weeks’ gestation31). For example, approximately 35% of babies born 
preterm are diagnosed with cerebral palsy, and the risk increases the shorter 
the gestational age at delivery. The incidence of cerebral palsy in those born 
before 28 completed weeks is 111.8 per 1000 neonatal survivors, or 82.25 per 
1000 live births41, compared with an overall prevalence 2-3.5 per 1000 live births 
in the UK42. 
1.2.5 Induction of labour 
Induction or augmentation of labour may be desirable if there are concerns 
about the mother or baby, or because the pregnancy has become very overdue 
(likely to deliver beyond 42 completed weeks’ gestation)43, 44. Current methods 
for IOL can be inefficient, with potentially severe complications for the mother 
and neonate including fetal distress, emergency caesarean section, instrumental 
delivery and postpartum haemorrhage4,43, 44. These complications can result in 
lengthy hospital stays which potentially have a negative impact on the birth 
experience and psychological wellbeing of the women and their families, and 
with financial cost to the National Health Service (NHS)4,43, 44. According to the 
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National Institute for Clinical and Health Excellence (NICE), in 2004 and 2005 one 
in every five UK deliveries was induced; and over a third of these women 
required interventions to deliver their babies, including instrumental delivery or 
caesarean section44. Further, the proportion of pregnancies with IOL in England 
has increased from 20% in 2006-7 to 29% in 2016-17 45, thought to be in part 
due to changing guidelines about which women should be offered IOL at term46-
48.  
1.3 Macro- and micro-structure of the human uterus 
1.3.1 The uterus 
The uterus is the major maternal organ involved in parturition and will be 
described here. The non-pregnant uterus can structurally be considered to 
comprise of three main layers: an inner endometrium, a thick muscular 
myometrium and an outer serosal layer49 (Figure 1.1). The tissues of the uterus 
undergo changes throughout a woman’s life that are largely under the influence 
of oestrogen and progesterone, the main steroid hormones of reproduction and 
pregnancy50-52. The uterus is an essential organ for pregnancy, facilitating 
implantation, placentation and development of the fetus52.  
The endometrium is composed of a basal and a functional layer, the stratum 
basalis and the stratum functionalis, respectively. The basal layer is adjacent to 
the myometrium and is where regeneration of the endometrium occurs. The 
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functional layer is receptive to hormonal influence and changes throughout the 
menstrual cycle, sloughing off with menstruation52. For the majority of 
pregnancy, the myometrium is in a state of relative quiescence and it transitions 
to a contracting state at the time of parturition32. 
 
Figure 1.1. Illustration of non-pregnant uterine structure (adapted from Aguilar & Mitchell 
(2010)49). 
 
1.3.2 Myometrial structure and electrophysiology 
Given that the myometrium is the organ which undergoes coordinated 
contractions to expel the fetus at the time of labour, it is essential to understand 
its role and response to the changing environment during pregnancy, 
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particularly at the time of parturition, in order to answer the overarching 
question of this thesis3. The myometrium is composed of smooth muscle which 
contracts both spontaneously and in response to agonists, the rhythmicity of 
which is related to the generation of slow waves and superimposed action 
potentials 53. Small contractions occur throughout the menstrual cycle as well as 
in pregnancy, and the amplitude, frequency, duration and direction of 
propagation change according to the physiological or pathophysiological 
environment. In non-primates the myometrium is made up of a distinct inner 
circular layer and an outer longitudinal layer, however it is less distinct in 
humans in whom there are intertwined muscular bundles that often surround 
vascular channels49. The contractions which occur in the non-pregnant state 
appear to involve only the junctional or sub-endometrial layer of the 
myometrium (Figure 1.1), producing endometrial waves that are distinct to the 
stronger propulsive contractions of the outer layer during miscarriage and 
parturition. This inner junctional layer has been shown to have an abundance of 
receptors for oestrogen and progesterone which are regulated throughout the 
menstrual cycle49. 
1.3.3 Myocytes and contractility  
Approximately 80-90% of the volume of myocytes is made up of contractile 
machinery including myofilaments and the dense bodies associated with them. 
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The main proteins expressed in myocytes are actin and myosin and, unlike 
skeletal muscle, myocytes contain more actin than myosin. Actin forms thin 
myofilaments of diameter 6-8nm, while myosin forms thick myofilaments of 
diameter 15-18nm. These myofilaments tend to run in parallel along the 
longitudinal axis of the myocytes. Myosin in myocytes is primarily composed of 
myosin II, a hexamer molecule made up of two pairs of myosin light chains (MLC) 
and two heavy chains (MHC). There are three domains to the molecule: a head 
comprised of the globular N-terminal end of MHCs, constituting the actin-
binding region, and an ATP hydrolysis site, termed the “motor domain” as it 
provides the energy for the force of contraction; a tail of thick filaments of the 
C-terminal ends of the MHCs; and a neck domain which creates an angle 
between the head and tail where each of the MLCs are attached via a non-
covalent bond to each of the MHCs49, 54, 55. The head and neck domains make 
cross bridges which interact with the actin filaments during contractile activity. 
There are two main isoforms of the MLCs: one has a molecular mass of 17 
(MLC17), termed the essential light chain, and the other 20 (MLC20), termed the 
regulatory light chain. MLC20 has an important role in regulating muscle 
contraction in uterine smooth muscle. To enable relaxation following 
contraction, the cross-bridge attachment needs to be released, and this involves 
dephosphorylation of MLC20. The dominant MHC in smooth muscle is coded for 
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by a single gene, with splice variants resulting in four distinct isoforms. Different 
genes code for non-muscle MHC which may also be contained within smooth 
muscle. Two isoforms of MLC17 exist due to alternate splicing. In contrast to this, 
two different genes encode the two different MLC20 isoforms, one of which 
associates with smooth muscle MHC, and the other associates with non-muscle 
MHC49, 55, 56. 
The resting membrane potential of the myometrium is determined largely by 
the inward ionic flux of sodium and calcium ions, and the outward ionic flux of 
potassium and chloride ions. As a pregnancy reaches term, the resting 
membrane potential of the myometrial cells becomes gradually more 
depolarised, and in vitro this gradual depolarisation results in an increased 
number of contractions53. The myometrium is autonomous and contracts 
without nervous or hormonal input, and it is unclear whether there are specific 
pacemaker cells or if all cells have inherent pacemaker activity57.  
1.3.4 The cervix 
During normal pregnancy, the cervix remains firm and closed and prevents 
passage of the developing fetus until term50. The uterus is separated from the 
cervix by the squamocolumnar junction, and this is where the squamous 
mucosal epithelium, which covers the outer (ectocervix) and inner (endocervix) 
part of the cervix, meets the columnar epithelium of the uterus. During normal 
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labour, the cervix softens and dilates to facilitate delivery of the baby50. 
Monitoring the rate of cervical dilatation allows clinicians to assess labour 
progress.  
While the cervix is functionally distinct from the uterus, cervical remodelling 
during labour is commonly coordinated with uterine contractions58. The cervix 
is predominately made up of the extracellular matrix (ECM) proteins elastin, 
collagen, and glycosaminoglycans. In addition, 10-15% of cervical tissue is 
comprised of smooth muscle cells. The primary cause of cervical softening is 
believed to be realignment and rearrangement due to mechanical forces of 
elastin, collagen and smooth muscle cells; and the additional rearrangement of 
collagen which occurs as glycosaminoglycans content within the cervix changes 
with time58. Dilatation of the cervix is believed to be in part due to the 
orientation of elastin and a ratcheting effect58. During labour, the cells of the 
cervix are metabolically active, and cervical smooth muscle cells have been 
shown to undergo apoptosis during cervical softening. This has prompted 
suggestions that, as apoptosis is an event that is genetically timed, this could 
explain the differences in gestational length between species 58. Mouse models 
have been used in many studies of the function of the cervix during labour and 




The placenta is the organ via which the fetus and the maternal circulations 
communicate, and it has multiple functions including metabolism, biosynthesis, 
and transport of molecules such as steroids and cholesterol, eliminating waste, 
gas exchange, and prevention of rejection of the pregnancy as a fetal allograft59-
62. The placenta is also a major site of hormone synthesis during pregnancy, 
adapting throughout pregnancy in order to best support the fetus60, and is 
probably involved in the initiation of labour61. Inadequate placentation and 
placental insufficiency can affect fetal growth, development and survival, as well 
as contribute to maternal pathologies such as pre-eclampsia62. Prior to 
implantation, at the blastocyst stage, the outer cells of the embryo are 
separated from the inner cell mass and become the trophoblast, while the inner 
cell mass develops to become the fetus. Trophoblast cells differentiate into the 
cytotrophoblast and the syncytiotrophoblast, and these are the cells which 
invade the maternal endometrium to form the fetal part of the placenta. 
Lacunae form within the synctiotrophoblast, creating the intervillous spaces that 
allows circulation of maternal blood into the placental bed61. The attachment of 
the placenta to the uterine wall is essential for successful pregnancy, and also 
serves to hold the pregnancy within the uterus61.  The cells of the placental 
chorionic villi act as a filter between the fetal and maternal circulations, with no 
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direct contact between the fetal and maternal blood (Figure 1.2). Simple 
diffusion occurs for some low-molecular weight (LMW) and/or non-polar 
molecules such as sodium, gases, urea, water, fatty acids and unconjugated 
steroids. The amount of simple diffusion changes throughout pregnancy as 
diffusion distances decrease with increasing gestation, and diffusion of many of 
these molecules increase as the pregnancy advances. Other molecules depend 
upon active transport60-62. 
The chorion forms a membrane which is continuous with the placental 
trophoblast and which is immediately adjacent to the maternal decidua. The 
amnion is a membrane that surrounds the amniotic cavity, which ultimately 
contains the amniotic fluid and fetus, and lies between the trophoblastic chorion 
and the inner cell mass. Neither the chorion nor the amnion have lymphatics, 
blood vessels or nerves, and together they form the fetal membranes which 
rupture either prior to or during labour61.  
Blood flows between the placenta and the fetus via the umbilical cord which 
originates from the chorion (Figure 1.2 and 1.3)62, 63. The cord typically contains 
two cord arteries and a cord vein, although some have just one cord artery. The 
umbilical vein carries blood from the placenta to the fetus, via the ductus 
venosus, and into the fetal inferior vena cava and right atrium. The blood in the 
umbilical vein contains nutrients and is typically 80% oxygen saturated. The 
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umbilical arteries carry blood away from the fetal descending aorta back to the 
placenta, and the oxygen saturation of the umbilical arteries is around 50% 
(Figure 1.3)63. This indicates that oxygen and nutrients are taken up and 
metabolised by the fetus, while the products of this metabolism are transported 
back to the placenta via the umbilical arteries. In addition, the placenta produces 
some precursor molecules which, as the fetal organs mature, the fetus uses to 
convert to other essential molecules62, 63. In the majority of previous studies 
identified, cord blood samples are not defined as either the cord vein or cord 
artery, and instead are likely mixed or cord vein5, 64-70. However, it is possible to 
sample blood separately from the cord arteries and cord vein at delivery, and 
thereby measure the differing concentrations of different metabolites in the 
blood derived from the fetus (umbilical cord arteries) and the blood derived 
from the placenta (umbilical cord vein), as well as blood from the maternal 
circulation5. Importantly, such measurements could identify pathways and 
interactions between the fetus, placenta and maternal metabolites at the time 
point of delivery that may be important for labour. This triangulation is utilised 
in the studies of this thesis to identify potential pathways that are activated 
between the fetus and the placenta with labour and delivery. 
The placenta produces many of the hormones of human pregnancy, many of 
which are secreted into the maternal circulation, aided by the close proximity of 
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the placental cytotrophoblast and syncytiotrophoblast cells to maternal blood71. 
In contrast, most maternal hormones are prevented from entering the fetal 
compartment by the syncytiotrophoblast cells. This means that the endocrine 
system of the fetal-placental system develops and functions largely in 
independence from the mother71. The syncytiotrophoblast layer is the major 
source of these hormones as it expresses the enzymes required for several72. 
Hormones produced by the placenta include progesterone, oestriol, 
pregnenolone, and beta human chorionic gonadotropin (βhCG). Some of the 
substrates for these hormones are produced by the fetus, and the exchange of 
molecules between the fetus and the placenta as a feto-placental unit is 










Figure 1.2: Diagram of blood flow within the human placenta, with separated maternal and fetal blood circulations.  Maternal blood flows into the placenta 
via maternal arteries, pools in the intervillous space, and flows out of the placenta via maternal veins. Fetal blood circulation through the placenta occurs via 
fetal venules and arterioles contained within chorionic villi that protrude into the intervillous space, allowing selective exchange of molecules between the 
maternal and fetal circulations. Fetal blood flows from the placenta to the fetus via the umbilical cord vein and flows from the fetus to the placenta via the 




Figure 1.3: Diagram of fetal and umbilical cord blood circulation. The umbilical cord vein carries blood rich in oxygen (80% saturation) and other molecules 
from the placenta to the fetus. While some blood flows to the fetal liver, the majority is shunted via the ductus venosus to reach the inferior vena cava directly 
and then flows into the right atrium of the fetal heart. Most of this oxygen-rich blood flows through the foramen ovale, an opening between the two atria 
which usually closes after birth, into the left atrium. From here the blood flows into the fetal left ventricle before being pumped out into the ascending aorta 
and from there to the vessels supplying the heart, brain, and other parts of the body. Returning oxygen-depleted blood (approximately 58% saturation)returns 
to heart via the superior vena cava, via the right atrium into the right ventricle and then into the pulmonary trunk. As the pulmonary vessels have high 
resistance in the fetus, the majority of the blood entering the pulmonary trunk flows through the fetal ductus arteriosus into the descending aorta, and this 
blood then returns to the placenta via the umbilical cord arteries63. Red colour = oxygen-rich blood; blue colour = oxygen-depleted blood. 
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1.4 Control of parturition 
1.4.1 Control of parturition in animals 
One of the challenges of studying human pregnancy is that, in contrast to many 
other conditions that can be studied in animal models, some aspects of 
reproduction are species-specific, and while many mammals share similar DNA 
sequences for many systems, there is far less cross-over for reproductive 
functions3, 7. Such differences are described below and include differences in 
placental structure and function62, the role of the corpus luteum6, 73, functional 
or measurable progesterone withdrawal32, 35, and differences in duration and 
variation in gestational length24, 25. Because this has taken some time to realise, 
and because invasive experimentation on human fetuses is ethically difficult, 
during the last century animal studies were conducted to better understand 
parturition33. While findings from animal models cannot be directly translated 
to elucidate mechanisms of labour in humans, these studies can be used to 
generate hypotheses on the potential function of different hormones involved 
in the human reproductive process and will be discussed here.  
1.4.2 Rabbit, goat, and rodent models 
Experiments in rabbits, goats and rodents have shown that the trigger for labour 
in these mammals is progesterone withdrawal following luteolysis of the corpus 
luteum, which otherwise maintains the pregnancy through progesterone 
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synthesis. Luteolysis is triggered by activation of prostanoid FP receptors in the 
corpus luteum by prostaglandin F2α which is released by the endometrium, 
causing a fall in maternal progesterone which rapidly leads to uterine activation 
and labour73. This mechanism is not directly relevant to human pregnancy and 
labour as the corpus luteum is not required for ongoing pregnancy in humans 
after the first trimester when the placenta takes over progesterone production, 
and therefore luteolysis is not the trigger for labour in humans6. 
1.4.3 Sheep models 
Three important experiments in sheep were conducted in New Zealand by 
Liggins et al. (1968 and 1969)74, 75 which highlighted the potential role of the 
fetus in the trigger for human labour. Although later work has shown that these 
findings are not directly related to humans, as will be discussed below, these 
experiments are worth discussion as they may give some clues as to potential 
interactions in humans. The first experiment involved forming lesions in the 
pituitary gland of lamb fetuses using electrocoagulation. In the first part of this 
experiment, 11 pregnancies had a pituitary lesion of a single fetus pregnancy 
and two had a pituitary lesion in both twins of two twin pregnancies. Of these, 
nine of the pregnancies were abnormally prolonged, and the authors 
subsequently noted that these fetuses had more than 70% of the pituitary gland 
destroyed, whereas the four which delivered at a normal gestation had 60% or 
52 
 
less destroyed. A second group included one singleton fetus with the pituitary 
stalk dissected and one singleton fetus with hypothalamic destruction, and both 
pregnancies continued beyond term and had to be delivered via caesarean 
section without signs of approaching labour. In a third group, three twin 
pregnancies had one unoperated twin and one given a pituitary lesion, and one 
triplet pregnancy had on unoperated fetus and two with pituitary lesions. All of 
these pregnancies delivered at term. And in the final group, four ewes had sham 
operations with no pituitary or hypothalamus destruction, and all four delivered 
at term. The authors concluded that the fetus was essential for timely 
parturition in sheep, and that the mechanism for this involved the pituitary 
gland and probably the hypothalamus76. The second study involved continuous 
administration of adrenocorticotropic hormone (ACTH) directly into the 
peritoneal cavity of singleton fetal lambs, and the finding that this resulted in 
premature spontaneous parturition within four days of this administration. 
Similar results were observed with infusion of cortisol, however infusion of 
oestradiol-17beta did not cause early parturition. Moreover, neither the 
infusion of ACTH nor cortisol directly into pregnant ewes resulted in preterm 
labour. The authors concluded that the pituitary-adrenal system of the fetus was 
vital for parturition in the ewe74. The third study again involved infusion of 
different substances directly into the peritoneal cavities of lamb fetuses. This 
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included infusing six single fetuses with normal saline for 14 days, following 
which pregnancy continued normally; infusing 11 singleton fetuses with 
different concentrations of dexamethasone (a glucocorticoid), and the nine 
fetuses with the higher concentration of dexamethasone delivered prematurely; 
two ewes were infused with dexamethasone while the fetuses were infused 
with normal saline, and neither of these fetuses delivered early; and 
corticosterone (mineralocorticoid) was dissolved in normal saline and infused 
continuously into two further fetuses, again neither of which delivered early; 
and finally, one fetus had deoxycorticosterone (mineralocorticoid) infused  and 
did not deliver early. The authors concluded that glucocorticoids 
(dexamethasone) caused premature delivery when infused directly into the 
lamb fetuses, but premature labour did not occur with direct infusion of the 
mineralocorticoids into the fetus, nor with infusion of glucocorticoid 
(dexamethasone) into the ewe rather than the fetus. The researchers also 
investigated the effect of administering progesterone into the fetus or ewe at 
the same time as infusing dexamethasone into the fetus, and found that 
premature labour was not prevented, which indicated that withdrawal of the 
inhibitory effects of progesterone on the myometrium occurs in these situations 
despite elevated progesterone in the plasma75.  
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Another group conducted an experiment investigating the length of gestation in 
two breeds of sheep with different mean gestational lengths. The researchers 
conducted inter-breed and intra-breed and mixed-breed embryo transfers and 
showed that the breed of the lamb fetus had the greatest impact on gestational 
length rather than the breed of ewe. Finnish Landrace sheep have a mean 
gestation of 144.9 days, and Targhee sheep have a mean gestation of 150.4 days, 
and Finnish Landrace embryos transferred to Targhee sheep had shorter 
gestational lengths, while Targhee embryos transferred to Finnish Landrace 
sheep had longer gestations. Mixed breed pregnancies (one of each breed of 
embryo) had a gestational length between the two. The authors suggested this 
shows an interaction between fetuses in the timing of parturition77.  
Further experiments in sheep have shown that activation of the fetal pituitary-
adrenal axis results in increased fetal cortisol and induction of  P450C17 enzymes 
in the placenta, which in turn promote conversion of C21 steroids to C18 
steroids, resulting in a decrease in maternal progesterone levels, a rise in 
maternal oestradiol levels and increased intrauterine prostaglandin production 
that effects softening of the cervix and myometrial contractility6, 33, 74, 75. As with 
the other mammals described above, the trigger for labour in sheep involves a 
measurable change in the balance between oestrogen and progesterone, with 
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increased oestrogen and decreased progesterone resulting in myometrial 
contractions and labour. 
While these are very elegant experiments, they clearly could not be repeated in 
humans, and therefore to test whether these effects are also present in human 
pregnancies requires other methodologies. Given increased pituitary and 
adrenal function in the sheep results in premature labour, and absent or 
impaired function results in prolonged labour, if this were the same in humans 
then it would be expected that human fetuses without a pituitary gland would 
always deliver post-term. However, a study of 147 singleton human pregnancies 
with anencephaly (where the fetal brain does not develop and therefore the 
fetus does not have a pituitary-adrenal axis) showed this was not the case. While 
those fetuses with anencephaly which developed polyhydramnios tended to 
deliver earlier, likely secondary to increased stretch on the myometrium, those  
without polyhydramnios (n=29) were found to spontaneously labour at a similar 
mean gestation to control singleton pregnancies where the fetus had a normally 
developed brain (Figure 1.2)78. However, the authors did observe increased 
variability in gestational age at delivery in the pregnancies with fetal 
anencephaly and suggested that increased activity of the fetal pituitary-adrenal 
axis towards the end of pregnancy in humans may influence rather than trigger 
the precise timing of spontaneous labour78. While the numbers are relatively 
56 
 
low in this study, which is not surprising given anencephaly is rare and that when 
diagnosed antenatally these pregnancies may be terminated, they do show that 
an absent pituitary and hypothalamus in human fetuses do not always prolong 
gestational length. Therefore it is unlikely that maturity of the fetal pituitary-
adrenal axis is essential for the timing of parturition in humans; however, it may 
be that signals from the fetus are required for precise timing of parturition6, 78 
and these may be involved in the trigger for spontaneous human labour. 
 
 
Figure 1.4: Comparison of mean gestational age at delivery between human fetuses with 
anencephaly and no polyhydramnios (n=29) and human fetuses with normally developed brain 





While many of the measurable endocrine changes associated with parturition in 
these smaller mammals are not found in measurement of maternal blood in 
humans, it remains possible that such changes may occur more locally, for 
example within the intrauterine tissues or the fetus. Such paracrine or autocrine 
systemic changes may not be measureable in the maternal blood, but could 
have important effects on the local tissues that could trigger labour in humans8. 
This thesis aims to investigate whether such local changes are.  
 
1.4.4 Non-human primate models 
Humans are closer in evolutionary terms to non-human primates than to mice 
and sheep. Chimpanzees and humans are both within the primate family 
Hominidae, and the chimpanzee genome shares 98.7% of its sequences with 
humans. As with humans, non-human primates do not have a measurable 
progesterone withdrawal at the time of parturition, and have similar myometrial 
electromyographic activity8, 79. However, despite this, there remain some key 
differences, for example, the average gestational length in the chimpanzee is 
227 days compared with 280 days in humans (although as there are differences 
in the way in which this is measured between humans (first day of last period) 
and chimpanzees (last day of maximal sex skin tumescence), the actual 
difference has been suggested to be around 40 days)80. While studies in non-
human primates have enabled researchers to better understand human 
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parturition, the ethical and logistical demands of non-primate experimentation 
mean that only certain groups have the funding and space to be able to conduct 
such research81, 82. Some findings from non-human primate studies related to 
the aims of this thesis will now be discussed. 
One study investigated gestational length and preterm labour within a 
chimpanzee community at the private Primate Foundation of Arizona, observing 
this community for 30 years.  Of 97 observed pregnancies, the researchers could 
confidently determine gestational length for 93 pregnancies by retrospectively 
reviewing written records. All but one of the chimpanzees born before 208 days 
gestation was either stillborn or died within a couple of days, and the one 
survivor was reported to have a possible incorrectly calculated gestation as 
conception could have occurred one month earlier80. Preterm labour in 
chimpanzees has been defined as births which occur at gestations 2SD or less 
below the average gestational length, and this was found to occur in 16% of 
pregnancies in this study population, which is similar to the rate in humans80, 83.  
As with humans, it is not clear why non-primates go into preterm labour83, and 
intrauterine infection has been investigated as a potential major cause among 
non-primates81, 82. For example, intra-amniotic infusion of Group B streptococci 
in rhesus monkeys results in preterm labour following an increase in uterine 
contractility preceded by an increase in tumour necrosis factor α (TNFα) and 
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interleukin (IL)-1β, TNF-α, IL-6, prostaglandin E2 and prostaglandin F2α84. One 
group sought to determine whether prostaglandin synthesis is blocked by 
indomethacin and thereby prevents stimulation of uterine contractions by IL-1β 
production. The group performed this experiment in 11 pregnant rhesus 
monkeys. Oral indomethacin was administered for five days to six of the rhesus 
monkeys. Human recombinant IL-1β was also infused directly into the amniotic 
cavity on day three of the experiment, and the intrauterine pressures measured 
following this. Five days after the final indomethacin dose, the same study 
protocol was repeated but without administration of indomethacin. A further 
five monkeys received only IL-1β (n=5). In all, the amniotic fluid was periodically 
sampled and prostaglandin E2 and F2α, IL-1β, IL-6, IL-8, TNFα, and IL-1 receptor 
antagonist (all inflammatory cytokines) were measured. The researchers 
determined that indomethacin prevented the increase in uterine activity that 
was seen when IL-1β was infused alone. There were no differences in the levels 
of the inflammatory cytokines between the indomethacin and non-
indomethacin groups, however there was an increase in the two prostaglandins 
in the groups not administered indomethacin. This suggested that, in rhesus 
monkeys at least, indomethacin blocks the development of uterine activity in 




Another study by the same group investigated whether the immunomodulators 
dexamethasone and IL-10 could be used to prevent the uterine contractions 
stimulated by infusion with IL-1β82. Thirteen rhesus monkeys at 135 days 
gestation (where term is 167 days) were administered either: maternal 
dexamethasone (1mg/maternal Kg) every six hours for three days, along with 
intraamniotic infusion of 10µg of human recombinant IL-1β on first day via a 
catheter over two hours (n=4). A second group (n=5) received simultaneous 
maternal intravenous human recombinant IL-10 (25µg/kg) and 200µg human 
recombinant IL-10 into the amniotic fluid every eight hours for three days. Thirty 
minutes after the first infusion of IL-10, human recombinant IL-1β was infused 
into the amniotic fluid at a rate of 5 µg per hour over two hours. A third group 
(n=5) received an intra-amniotic infusion of IL-1β only. The group found that IL-
10 and dexamethasone infusion reduced the uterine activity stimulated by IL-1β 
infusion, as well as concentrations of prostaglandins found in the amniotic fluid. 
Maternal and fetal cortisol, estradiol and dehydroepiandrosterone sulphate 
(DHEA-S) were also reduced in the dexamethasone group, and TNF-α was 
reduced in the IL-10 group. The researchers concluded that dexamethasone and 
IL-10 may be useful in treatment of preterm labour where it is associated with 
infection or inflammation82. However, in the majority of spontaneous preterm 
labour in humans no infective cause is found, and where there may be infection 
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it could be dangerous to prolong a pregnancy where there is infection, both to 
the survival of the mother and the fetus. 
Studies involving non-primates have also informed generation of hypotheses 
regarding evolutionary influences on gestational length, such as the suggestion 
that preterm labour has been evolutionarily preserved as a mechanism to 
protect the mother or fetus from the potential dangers of poor intrauterine or 
maternal conditions80. Such study of the evolution of parturition, with a 
potential survival benefit for earlier parturition, may shed light onto why some 
human pregnancies undergo premature parturition8. One theory is that there is 
a metabolic “crossover” effect towards the end of gestation, where the 
placental provision of nutrients to the fetus becomes inadequate and fails to 
match the growth of the fetus. The fetus then becomes stressed, and this 
metabolic stress increases cortisol levels and arachidonic acid production in the 
placenta, which eventually leads to prostaglandin production and labour. It has 
been suggested that this crossover period may be on average reached at 240 
days gestation in humans, and 228 days in chimpanzees80, 85. 
The apparent similarities between humans and non-human primates do imply 
that they better represent human parturition than mice and sheep. However, as 
mentioned above, there are ethical dilemmas as well as practical considerations 
for such research, requiring large housing areas and professional care for the 
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animals, with the resulting high costs and ethical concerns often prohibitive for 
funding8. The studies in this thesis utilise techniques to investigate metabolic 
changes of pregnancy directly in humans, removing the quandary related to 
experimenting on non-human primates. 
1.4.5 Progesterone and human pregnancy 
Until approximately seven weeks’ gestation, human pregnancy is dependent 
upon progesterone produced by the corpus luteum in response to hCG 
stimulation. After this point the placenta takes over as primary producer of 
progesterone, termed the “luteo-placental shift”35,72. Progesterone is mainly 
derived from maternal cholesterol71, 72, largely derived from low-density 
lipoproteins (LDL)71, the conversion of which occurs in the synctiotrophoblast 
mitochondria. The enzyme cholesterol side-chain cleavage cytochrome P450 
(CYP450scc) is present in the inner membrane of these mitochondria and 
converts maternal cholesterol to pregnenolone, and this is the rate-determining 
step for this process. Pregnenolone is then metabolised into progesterone by 
the enzyme 3beta-hydroxysteroid dehydrogenase (3β-HSD)71, 72. The human 
placenta cannot convert progesterone to 17α-hydroxyprogesterone and 
P450c17 is not expressed in the human placenta, therefore the placenta cannot 
convert progesterone to C19 androgens, and instead placental oestrogens are 
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synthesised from precursors of C19 androgens from the maternal and fetal 
adrenals, as described below71. 
As with other mammals, progesterone is essential for human pregnancy 
continuation. Administration of anti-progestins such as the progesterone 
receptor antagonist mifepristone (RU486) are used to induce abortion of early 
or mid-trimester pregnancies, medical management of delayed miscarriage and, 
previously, promotion of cervical effacement for induction of labour32, 35, 86. In 
humans there is no measurable fall in progesterone at the time of parturition, 
and plasma progesterone and oestrogen levels remain high until the end of third 
stage when the placenta is delivered72, 87. Given that the other mammals 
described above have a measurable progesterone withdrawal, the potential that 
human labour may be associated with a functional withdrawal of progesterone 
is a widely held theory, and researchers have investigated potential forms that 
this may take, some of which will be explored below32, 35.  
1.4.6 Feto-placental unit 
As described above, the findings in sheep indicate a pivotal role for the fetus in 
the timing of labour in sheep, and this has been investigated in humans. Egon 
Diczfalusy (1920-2016) was one of the first to describe the feto-placental unit in 
humans. He observed that the human placenta is deficient in enzymes required 
for production of essential pregnancy steroids, and that these enzymes are 
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instead present in the fetal adrenal glands and liver. The feto-placental unit 
represents interactions between the fetus and the placenta via which precursors 
to steroids are shuttled between the two for generation of essential steroids. 
Specifically, the fetal adrenal provides androgen precursors such as DHEA-S, 
used by the placenta for biosynthesis of oestrogens88-90 (Figure 1.3). Much of the 
investigation into the activity of the human feto-placental unit has been 
performed in vitro, particularly isolated primary human cytotrophoblasts or 
human placental explants, or immortilised trophoblast cell lines, and therefore 
the exact effects in vivo are still unclear72, 91, 92, although there have been further 
advances in recent years with new techniques in gene technology and the omics. 
During fetal development, the human fetal adrenal develops three distinct 
zones: the fetal zone (FZ) and an outer definitive zone (DZ), with a transitional 
zone (TZ) that links the two. During pregnancy, most of the activity of the fetal 
adrenal appears to originate in the FZ, which is unique to humans and higher 
primates, and not present in sheep and rodents93. After birth the FZ rapidly 
disappears and androgen secretion decreases, and it is likely that this is via 
apoptosis94. Because this happens immediately after birth, it is thought that the 
continuation of the FZ during pregnancy is dependent upon placental factors93. 
One study showed that cortisol concentrations in umbilical cord blood sampled 
from pregnancies delivered via elective caesarean section at various gestations 
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were found to decrease in the mid-trimester, followed by a steep rise in the third 
trimester66.  
In pregnancy, the main oestrogen is oestriol rather than the ovarian-cycle 
steroid 17-oestradiol, and oestriol makes up over 90% of urinary oestrogen 
during pregnancy71,91. Importantly, synthesis of oestriol and other oestrogens 
occurs in the placenta, however the placenta does not produce oestrogens 
directly from acetate or cholesterol as it does not have the cytochrome P450 
enzyme CYP17 that is required91. Placental production of oestradiol and 
oestrone (see Figure 1.5) requires dehydroepiandrosterone (DHEA) as a 
precursor, and this is derived from both the maternal adrenal glands95, 96 and the 
fetal adrenal cortex. Sulphatase in the placenta rapidly converts 
dehydroepiandrosterone-sulphate (DHEA-S) to DHEA, which is then converted 
by 3βHSD to androstenedione.  The aromatase enzyme is highly expressed by 
the placenta, and this converts androstenedione to oestrone, following which 
the 17β hydroxysteroid dehydrogenase (17βHSD) enzymes then interconvert 
oestrone and oestradiol61, 71, 72.  
However, as stated, oestriol is the main oestrogen of human pregnancy, and 
only a small proportion of this is produced from conversion of oestrone and 
oestradiol by the placenta. The majority results from DHEA-S produced by the 
fetal adrenals undergoing 16α-hydroxylation to produce 16α-hydroxy-DHEA-S, 
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taking place primarily in the fetal liver as well as the fetal adrenals. 16α-hydroxy-
DHEA-S is then transported to the placenta where a placental sulphatase 
enzyme converts 16α-hydroxy-DHEA-S to 16α-hydroxy-DHEA, which is 
subsequently aromatised to produce oestriol. The transportation of 16-hydroxy 
DHEA as a sulphate conjugate is believed to protect the fetus from the biological 
effects of the steroid, as the sulphinated form is water soluble and inactive. 
Placental oestriol synthesis via this pathway is therefore dependent upon the 
placental sulphatase which is abundant in the placenta, and the high levels of 
oestriol during human pregnancy are dependent upon the activity of the fetal 
pituitary-adrenal axis71, 72. Figure 1.5 summarises these pathways pictorially. 
Given this level of interaction between the fetal/placental/maternal system, and 
given the findings of the importance of the pituitary-adrenal axis in the timing 
of parturition in sheep74, 75, it would not be surprising if part of the trigger for 
human labour originated in the fetus. However, given the findings of no change 
in the median gestational age at delivery in pregnancies affected with 
anencephaly, such a signal may not be essential for eventual delivery but 
required for appropriate timing of labour, and if present too early could result 
in PTB. It is also possible that the fetal signal is not dependent upon the pituitary 
gland, and instead reliant upon another signal from the fetus. There are still 




Figure 1.5: Diagram of maternal-feto-placental unit with biosynthesis of progesterone and oestrogens DHEA=dehydroepiandrosterone; DHEA-
S=dehydroepiandrosterone-sulphate; 3β-HSD=3β-hydroxysteroid dehydrogenase; 17β-HSD=17β-hydroxysteroid dehydrogenase; CRH=corticotrophin-
releasing hormone; ACTH=adrenocorticotropic hormone; 16α-OH-DHEA-S=16α-hydroxy-dehydroepiandrosterone-sulphate71, 72, 95, 96. Colour scheme: 




1.4.7 Uterine oestrogen and progesterone receptors 
A potential mechanism for the functional withdrawal of progesterone at the 
time of human labour is a change in the functional availability of uterine 
progesterone and oestrogen receptors35, 97. Progesterone receptors (PR) belong 
to the nuclear receptor superfamily which act as transcription factors when 
activated by binding of progesterone35. Upon activation, PRs dimerise and are 
transported to the cell nuclei where they bind to specific promotor regions of 
progesterone-responsive genes35. The two predominant isoforms of the nuclear 
PRs are Progesterone Receptor type A (PRA) and Progesterone Receptor type B 
(PRB)35, both of which are formed from the same gene along with a further 
isoform, Progesterone Receptor C (PRC). PRA and PRC are both structurally N-
terminally truncated PRB35, 98, 99. PRA, PRB and PRC isoforms have been shown 
to be expressed in human myometrium. Experimental studies indicate that PRA 
has less activity than PRB, and PRA additionally acts to repress the 
transcriptional activity of PRB through transrepression, thereby blocking 
progesterone activation via PRB100. PRC is predominantly present in the cytosol 
and does not bind to DNA, although it can bind progesterone. It is suggested 
that PRC may also reduce progesterone-PR function by sequestering 
progesterone away from PRB. In addition, PRC has been shown to bind to PRB 




In animal studies, both total PR-knockout and PRA-knockout mice are infertile, 
whereas PRB-knockout mice are fertile and have normal pregnancies, indicating 
that PRA is essential for and can independently affect all the reproductive 
actions of progesterone in the mouse97. These studies indicate that the 
functional activity of progesterone within the myometrium depends not only on 
the level of progesterone and its receptors, but also on the ratio of PRAs, PRBs 
and potentially PRCs32, 35, 98.  
Oestrogen receptors in humans have two main subtypes, ERα and ERβ. These 
are produced from different genes and differ in ligand binding affinity and in 
how they are distributed among different tissues97. ERα appears to be the 
receptor through which the uterotonic actions of oestrogen are driven. Recently 
the spliced ERα receptor variant ERΔ7 has been shown to dominantly suppress 
the uterotonic actions of oestrogen, and this receptor withdraws at term in an 
oestrogen-dependent manner. This mechanism is suggested to be involved in 
the loss of myometrial quiescence at term101, and that changing concentrations 
of oestriol and oestradiol may be responsible for the change in oestrogen 
receptors102.  
Oestriol is an inhibitor of the action of oestradiol at low concentrations but 
becomes an agonist when the ratio of oestriol to oestradiol exceeds 10 to 1.  One 




in spontaneously labouring women at 26 weeks’ gestation and in the last month 
of pregnancy. Oestriol was found to increase, resulting in an increase in the 
oestriol/oestradiol ratio, a decrease in the progesterone/oestriol ratio, and an 
unchanged progesterone/oestradiol ratio. The authors suggested that this 
created an oestrogenic environment for the onset of labour103.  
Investigation of ER and PR receptor immunoactivity and binding has been 
conducted in human labouring and non-labouring myometrium, and ER activity 
was found to be consistently low, with no changes according to labour-status; 
conversely, PR activity was consistently higher than that of ER and its activity 
increased with labour97, 104. However, these experiments did not distinguish 
between the PRA and PRB isoforms. Further experiments showed PRA levels 
within the myometrium specifically increased with labour onset with a 
corresponding decrease in progesterone responsiveness and an overexpression 
of PRA in cell culture experiments using human myometrial cells100, 104. Western 
blot analysis of human myometrium indicated that PRA protein is not present 
before, but is present after, the onset of labour100. It is suggested that the 
increase in PRA at the time of labour could be the mechanism of the functional 
withdrawal of progesterone in humans, and thereby potentially involved in the 




Interestingly, Mesiano et al. (2002)97 showed that PRA, PRB and ERα mRNA 
levels were higher in myometrium taken from 12 women who were in labour 
when compared with myometrium taken from 12 women not in labour, and 
while PRA levels were higher than PRB in both the labouring and non-labouring 
samples, the ratio of PRA/PRB mRNA increased 2-3-fold in the labouring group 
(see Figure 1.4)97. This group went on to investigate whether the responsiveness 
of the myometrium to oestrogen was associated with a change in the ERα gene 
expression between labouring and non-labouring myometrium through 
comparison of levels of ERα mRNA, Oxytocin receptor (OTr) mRNA, and COX-2 
mRNA. Both OTr and COX-2 are contraction-associated genes that are known to 
be activated within the myometrium during labour, with OTr upregulated by 
oestrogen. COX-2 encodes for the form of cyclooxygenase that is inducible and 
is thought to cause an increase in prostaglandin production by gestational 
tissues at the time of parturition. OTr encodes the oxytocin receptor, which is 
essential to enhance the response of myometrium to oxytocin 32. OTr mRNA was 
shown to increase 6-fold during labour, and COX-2 mRNA 115-fold. Both 
correlated positively with ERα mRNA levels in myometrium taken from women 
not in labour (elective caesarean section); and this correlation was not shown in 
myometrium taken from women in labour. The authors suggest this could be 




mRNA expression was found to be low in both labouring and non-labouring 
myometrium, and not affected by labour32. While these findings are in 
concordance with the previously described work which found increased protein 
abundance of PRA with labour, the authors emphasise that the findings do not 
necessarily translate to equivalent changes in receptor function as proteins can 
undergo a variety of modifications following translation such as 
phosphorylation97.  
 
Figure 1.6: Relative abundance of mRNA encoding PRA, PRB, ERα, ERβ, and the PRA/PRB ratio in 
labouring and non-labouring myometrium. * = p≤0.05 (Figure extracted from Mesiano et al. 
(2002)97) 
A potential aetiology for the mechanism of a functional withdrawal of 
progesterone at term is that an increased expression of PRA results in decreased 
myometrial responsiveness to progesterone and an increase in ERα expression. 




increased oestrogen responsiveness results in an increase in the production of 
contractile proteins leading to increased myometrial contractility and labour 32, 
35. However, other researchers argue against this. For example, Condon et al. 
(2006)98 investigated myometrial protein levels rather than mRNA, and found 
that while PRB protein was present in the nuclei of lower uterine segment and 
fundal myometrium in both labour and non-labour, levels only increased in the 
fundus with labour, not in the lower segment98. Further, that PRA protein was 
found neither in the nuclei nor cytoplasm of myometrium taken from labouring 
and non-labouring women. While this contrasts with findings of previous studies, 
the authors suggest these previous studies used experimental techniques which 
would have incorrectly identified PRC as PRA98. This study counters the 
hypothesis that functional progesterone withdrawal is secondary to PR isoform 
expression, as the inhibitory PRA protein was not found in any of the myometrial 
samples, although PRC could play a role35, 98. It is noted that in all of these studies 
there are inconsistencies and that this is in part due to the variability of 
performing experiments on human cell lines and tissues in vitro35. 
Of note, if functional progesterone withdrawal does not occur at the 
myometrium, then it is possible that it occurs within the decidua or fetal tissues 
including the amnion and chorion35. For example, one group investigated the 




and decidua sampled at the time of caesarean section at term from women who 
had laboured (n=7) and those who had not (n=7). Nuclear expression of the 
nuclear progesterone receptor mRNA was quantified using reverse transcriptase 
polymerase chain reaction, and localisation determined via 
immunohistochemistry. It was determined that nuclear PR mRNA was highest in 
the chorio-decidua, but that this did not change with labour, and that these 
mRNA were very low in the amnion samples. Further, immunohistochemistry 
indicated that the PRs were only present in the decidual cell nuclei, which 
suggests that the decidua is a more likely target of progesterone actions in 
pregnancy105.    
1.4.8 Corticotrophin-releasing hormone and preterm birth 
Maternal corticotrophin-releasing hormone (CRH) has been shown to be 
associated with the timing of parturition, with increased levels in the maternal 
plasma occurring as pregnancy progresses. CRH is found to be high in women 
who have a preterm delivery in some situations, but notably not if the preterm 
delivery is associated with infection. In addition, towards the end of pregnancy, 
levels of the CRH binding protein have been shown to reduce, thereby increasing 
the bioactivity of circulating CRH. CRH production is stimulated by 
glucocorticoids by the placenta; and CRH results in corticotrophin production by 




nitric oxide inhibit CRH production by the placenta. It is suggested that the 
increased levels of placental CRH during pregnancy results in increased 
production by the maternal adrenal glands of cortisol and DHEA-S, the latter of 
which is a substrate for the synthesis of oestrogen7.  
1.4.9 Inflammatory pathways and parturition 
Another potential trigger for parturition involves inflammatory pathways106, 
with a change in the balance between inflammatory and non-inflammatory 
responses50. Previous studies have shown that the transcriptome of labour is 
associated with inflammatory pathways, including those for cytokines32. One 
group used computer programming techniques to integrate three datasets of 
gene expression in labouring compared with non-labouring myometrium. The 
researchers showed that labour at term was associated with differential 
expression of cytokines and of genes regulating pathways related to cell 
differentiation, proliferation and apoptosis32. This was in contrast to the 
pathways of muscle relaxation and cyclic AMP signalling that they found were 
enriched in non-labour (elective caesarean section)32, 56, 107.  
However, it has been questioned whether inflammation is a cause or a result of 
labour. For example, one group performed myometrial studies to test the 
activation of two pro-inflammatory pathways, the nuclear factor kappa-light-




Activator Protein 1 (AP-1) pathway, at different points of pregnancy. They found 
that the NF-kB declined towards term but was increased in early and established 
labour. Further, that while flow cytometry indicated that neutrophil numbers 
increased with labour, immunohistochemistry showed that these were located 
within the blood vessels rather than within the myometrium itself108. This 
suggests that inflammation may be a result of labour rather than the trigger, and 
may also be seen in work which compares not in labour myometrium sampled 
from caesarean section at term with in labour myometrium sampled at 
caesarean section, as if frozen at the time of sampling3, the inflammatory effects 
of the labour immediately preceding the caesarean are likely to bias the results. 
This is supported by a study which investigated leucocyte infiltration in 
myometrial and decidual samples from 648 women at the time of caesarean 
section, including in women with signs or symptoms of infection. Two-hundred 
and fifty-three women had elective caesarean section with no preceding labour 
or rupture of membranes; 48 had a caesarean section in labour with in-tact 
membranes; and 347 had a caesarean section following rupture of membranes. 
Eighty-nine of the pregnancies were delivered preterm (less than 37 weeks’ 
gestation). Overall, inflammation was detected in 240 (42.9%) of 559 decidual 
samples, and 155 (24.0%) of 646 of the myometrial samples. The three main 




of leucocytes were being in labour, chorioamnionitis and endometritis. Fifty-
three women were diagnosed with chorioamnionitis and 58 with endometritis.  
Chorioamnionitis and endometritis were both associated with increased 
presence of myometrial infilatration of leucocytes for both preterm (odds ratio 
5.1 (p = 0.02) and 12.8 (p = 0.007), respectively) and term (odds ratio 3.8 (p = 
0.0001) and 2.6 (p = 0.002), respectively). The researchers found that in both the 
preterm and the term group, for those without clinical signs of infection, the 
findings of a moderate infiltrate of leucocytes was associated with the onset of 
labour. In women who were delivered at term, the odds ratio for having a 
moderate to marked myometrial inflammation was 3.2 (p = 0.05) in women who 
were 3-5 cm dilated, and 3.8 (p = 0.02) in women who were 6-10 cm dilated. In 
women who delivered at term the odds ratio for myometrial inflammatory 
infiltrate was 7.8 (p = 0.002). There was no association found between 
myometrial infiltration and the prediction of development of post-operative 
endometritis109. 
Regarding the myometrial work in this thesis where myometrium is compared 
between those with elective caesarean section and emergency (in labour) 
caesarean section, the potential of inflammatory reactions from the labour were 
attempted to be removed by allowing the myometrium to equilibrate in buffer 




1.4.9.1 Nuclear Factor kappa-light-chain-enhancer of activated B cells 
The NF-kB signalling pathway is rooted in activation of NF-kB by pro-
inflammatory cytokines including TNFα and IL-1, resulting in expression of genes 
that code for inflammatory factors such as chemokines, cytokines, and adhesion 
molecules110. NF-kB has been associated with inflammatory conditions such as 
rheumatoid arthritis, asthma and multiple sclerosis110. One group observed that 
NF-kB was activated in samples of fundal myometrium sampled from women in 
labour but was not activated in fundal myometrium sampled from women not 
in labour. In myometrium taken from the lower segment, NF-kB was neither 
activated in labour nor when not in labour. The authors also determined that 
activation of the NF-kB pathway via stimulation with IL-1β in hTERT myometrial 
cells (which do not express PRA or PRC) in culture resulted in an increase in PRB 
expression98. The authors suggest that their findings indicate that changes in the 
expression of different PR isoforms with labour may be due to stimulation of 
inflammatory response pathways within the uterus. 
1.4.9.2 Amniotic fluid and surfactant 
Increased presence of inflammatory factors such as interleukins within the 
amniotic fluid and infiltration of the myometrium by macrophages and 
neutrophils are associated with labour in humans106. Interestingly, such 




women who deliver at term. While it is feasible that a proportion of PTB results 
from infection leading to an inflammatory response, the majority of PTB and 
term deliveries are not known to be associated with infection and other 
aetiologies for activation of these inflammatory pathways have been sought106.  
An early suggestion was that maturation of the fetal lung and increased 
production of surfactant would result in surfactant being present in the amniotic 
fluid as term approached, and that this could trigger a type of inflammatory 
response106, 111. One group found that fetal pulmonary surfactant isolated from 
amniotic fluid stimulated the release of prostaglandin E from incubated discs of 
human amnion; and that arachidonic acid made up 2% of the surfactant lecithin 
fatty acids111. The researchers suggested that phospholipids from surfactant that 
is secreted into the amniotic fluid from the matured fetal lung are a source of 
the arachidonic precursor for prostaglandin synthesis by the amnion106, 111. 
However, if this were the case it would not necessarily explain all preterm labour 
as the fetal lungs are not matured until later in the third trimester112. 
1.4.9.3 Macrophages 
Tissue macrophages and other inflammatory cells within the decidua may also 
play a role in such an inflammatory pathway for the initiation of labour. The 
decidua is in contact with both the myometrium and the amnion/chorion, and 




increased quantities of prostaglandin F2α6, 113. It has also been shown that tissue 
macrophages can produce pro-inflammatory cytokines such as TNF-α and IL-1, 
and therefore some argue that this could be the mechanism responsible for PTB 
that is associated with infection, as presented pictorially in Figure 1.56. 
 
Figure 1.7: Illustration showing proposed actions of macrophages at the fetal membranes . 
Macrophages synthesise prostaglandin and thromboxane and proposed to be involved in onset of 
preterm labour associated with infection. The release of prostaglandins and inflammatory markers 
likely cause contractions in neighbouring myometrium. PG = prostaglandin; Tx = thromboxane; PLC, 
PLA2=phospholipases; R=receptors. Adapted from López Bernal (2007)2. 
1.4.9.4 Lipid profile and preterm birth 
Epidemiological studies indicate that women who experience PTB are at 
increased risk for developing cardiovascular disease in later life114-116. It has also 
been shown that risk factors for PTB are similar to those for cardiovascular 
disease, such as smoking, dyslipidaemia and previous PTB115. One group 




significantly associated with placental vascular pathology including atherosis, 
thrombosis and infarcts of villi115, 117. A systematic review investigating a 
potential association between maternal lipids and PTB found that the results 
from nine cohort studies and five case-control studies were heterogenous, but 
that there was a possible increased risk of spontaneous PTB in women who had 
high triglyceride levels, but no association between low or high density 
lipoprotein cholesterol and PTB. In addition, elevated homocysteine levels were 
also associated with PTB in the second trimester. The authors concluded that 
the potential association between triglycerides and homocysteine and PTB 
warranted further investigation115. This is important as it is possible that 
modification of some of these factors could reduce the risk for PTB in some 
women. Chapter 4 of this thesis involves analysis of NMR metabolomics and 
gestational age at delivery, including analysis of maternal triglyceride and 
lipoprotein concentrations. 
 
1.5 Preterm birth 
While this thesis is focused mainly on improving our understanding of 
spontaneous labour at term, it is also hypothesised that this would improve our 
understanding of some causes of PTB. Much previous research has been 
conducted on PTB as it is this condition which has such high morbidity and 




from research into PTB in order to determine if there may be some factors 
identified in the diagnosis of PTB that can inform the investigation and 
experimentation into term labour. For example, there have been many large 
randomised controlled trials into progesterone administered to the mother 
(described below) with no reduction in PTB rate. The studies which will be 
outlined in this thesis indicate that this may be because maternal administration 
of progesterone does not prevent changes in fetal signals that trigger labour. 
1.5.1 The cervix and preterm birth 
Spontaneous PTB is a heterogenous condition, and for approximately 50% of 
cases there is no obvious cause. In some cases premature cervical dilatation has 
been noted prior to the onset of any symptoms such as uterine contractions31, 
50, 118. Researchers have investigated potential pathways involving cervical 
dilatation as a trigger for spontaneous labour. Where once it was presumed that 
preterm remodelling and dilatation of the cervix followed the same pattern as 
that of the cervix at term, studies, including those on mice, indicate that there 
are independent pathways in PTB that seem to involve an acceleration of the 
cervical events at term, and another in response to infection50. For example, PTB 
in the mouse can be induced through administration of the progesterone 
receptor antagonist Mifepristone, effectively resulting in a decrease in 




term. In contrast, the premature cervical ripening and dilatation in an infection 
mouse model, induced through administration of LPS into the mouse uterine 
horn, results in a proinflammatory response with an influx of neutrophils to the 
cervix and an increased expression of COX-250, 119. Further, genetically 
engineered mice without the C5a complement receptor do not respond to 
either mifepristone or LPS with PTB, suggesting that the complement system is 
involved in both the preterm and term physiology of these mice models50. 
Gonzalez et al. (2009)119 performed microarray analysis of cervical tissue taken 
from the following mouse models: induced PTB following administration of 
mifepristone; induced PTB following administration of LPS (inflammatory 
model); and term labour in the mouse. This identified distinct gene pathways 
between the three mouse models, where there was increased expression of 
genes associated with inflammation and immunity in the cervix of the LPS-
induced labour but not with term labour119. Cytokine expression was also 
reported to increase postnatally, but not at the time of term labour. The authors 
suggest that this could indicate that activation of immune pathways are 
sufficient for cervical ripening but are not essential; and that the molecular 
mechanisms within the cervix associated with PTB and term labour are distinct, 
according to the aetiology and timing of the labour; with corresponding 




strength50, 119. While these experiments are not ethical in humans, women with 
conditions such as Ehlers-Danlos and Marfan syndrome, where there is a genetic 
defect in collagen or elastin synthesis, have increased incidence of premature 
rupture of membranes and/or cervical insufficiency120. It has been suggested 
that polymorphisms or failure to activate certain genes associated with 
connective tissue metabolism and synthesis may predispose individuals to 
preterm or post-term deliveries, respectively50. 
1.5.2 Randomised controlled trials with progesterone for prevention of 
pregnancy loss 
The high burden of complications of labour such as PTB on society described 
above has motivated researchers to investigate potential treatments for 
prevention and treatment of pregnancy loss, including miscarriage and PTB. If 
such treatments were found to be effective, they could cast light on the pathway 
for spontaneous labour in humans. For this reason, such studies will be explored 
here.  
Because of the quiescent effect of progesterone on the myometrium, and in part 
because of the effect of progesterone withdrawal in other mammals in 
triggering labour, progesterone has long been administered to women 
considered at risk of miscarriage or preterm labour. However, the efficacy of this 




effectiveness of progesterone on preventing miscarriage in women with 
recurrent (defined variably as two-or-more or three-or-more miscarriages) 
miscarriage included thirteen Randomised Controlled Trials (RCT). Nine of these 
RCTs compared progesterone to placebo and four compared progesterone with 
standard care. Data from eleven of these trials were used for analysis (n=2359 
women), considered to be of low risk for bias according to the Cochrane 
standards. The meta-analysis indicated that there was a reduction in the number 
of women having miscarriages in the progesterone treatment group (Risk Ratio 
(RR) 0.69, 95% confidence interval (95%CI) 0.51 to 0.92), and a more 
pronounced effect was observed for women with three previous miscarriages 
compared with two previous. The authors concluded that for women with 
unexplained recurrent miscarriages, progesterone supplementation is likely to 
reduce the rate of miscarriage in subsequent pregnancies, however the trials 
included were small and therefore larger trials were recommended. 121  
Larger RCTs have since been published, with varying results. The PROMISE 
(Progesterone in Recurrent Miscarriages) trial was a multicentre, double-blind, 
placebo-controlled, randomised trial comparing women with a history of 
recurrent miscarriage (defined as three or more consecutive or non-consecutive 
losses in the first trimester) treated with twice-daily vaginal suppositories 




matched placebo (n=432). Treatment commenced soon after a positive 
pregnancy test. The authors found no difference between the rate of live births 
between the treatment and placebo arm (RR 1.04, 95%CI 0.94 to 1.15), and the 
authors concluded that progesterone therapy in the first trimester of pregnancy 
does not improve live birth rate among women with unexplained recurrent 
miscarriage122. The PRISM (Progesterone in spontaneous miscarriage) trial was 
a multi-centre, randomised, double-blind, placebo-controlled trial compared 
active treatment with progesterone to placebo in comparing women who 
presented before 12 completed weeks’ gestation with bleeding. Women were 
again randomised to the same treatment (n=2079) and matched placebo 
(n=2074) groups as for the PROMISE trial. The primary outcome was live birth 
rate, and the authors found no strong evidence of a clinically relevant difference 
in live birth rates between the two groups (Relative Rate 1.03, 95%CI 1.00 to 
1.07)123. However, in a subsequent publication using data from the PRISM trial a 
sub-group analysis, that was not prespecified, has been reported. It suggested 
that for women with bleeding in early pregnancy and who have a history of three 
or more previous miscarriages (n=137 treatment vs n=148 placebo), there was 
a possible benefit to treatment (RR for live birth 1.28, 95%CI 1.08 to 1.51)124, 
with a difference in live birth rate of 72% in the treatment arm and 52% in the 




presenting with bleeding in the first trimester may benefit from progesterone 
treatment following discussion with the women regarding the uncertainty of the 
evidence. However, as some of these findings were post-hoc subgroups, these 
findings should be considered exploratory and the findings would need to be 
replicated. 
OPPTIMUM (Does progesterone prophylaxis to prevent preterm labour improve 
outcome?) was a multicentre, randomised, double-blind placebo-controlled trial 
comparing treatment with 200mg daily of Progesterone vaginal pessary (n=618) 
or a matched placebo (n=610), administered between 22-24 completed weeks 
to 34 completed weeks of gestation to women who were at risk of preterm birth 
(previous spontaneous birth at less than 34 weeks gestation, or a cervical length 
less than 25mm, or a positive fetal fibronectin test with other positive history). 
The primary outcomes were fetal death or birth before 34 weeks gestation, a 
composite of brain injury, death or bronchopulmonary dysplasia in the neonatal 
period, and a standardised cognitive score measured in the child at 2 years of 
age. Progesterone did not change the rate of these outcomes when compared 
with placebo. The odds ratio (OR) for preterm birth was 0.86, with a 95%CI of 
0.61 to 1.22. The authors recommended that OPPTIMUM should encourage 




review their practise in order to identify women who may benefit. Further, that 
alternative strategies are required to prevent preterm birth125. 
These large, well-designed, multi-centre RCTs into the effect of treatment with 
progesterone on pregnancy loss seem to indicate that there is either none or 
very limited benefit in treatment of PTB or recurrent miscarriage with 
progesterone pessaries. Although there may be some improved outcomes for 
women with at least three previous miscarriages and bleeding in early 
pregnancy, this finding would require replication in a larger pre-defined study. 
This indicates that exogenous progesterone administered via the mother is not 
likely to prevent pregnancy loss in most women at risk of preterm birth or 
recurrent miscarriage. Further research is required to better understand the 
mechanism of labour so that other potential treatments can be designed, and 
studies in this thesis are designed to investigate whether there may be more 
local changes in progesterone and oestrogen, including possible communication 
between the fetus and placenta.  
1.5.3 Induction of labour 
With regards to induction of labour, the prostaglandin F2α was found to increase 
in the utero-ovarian vein of sheep at the time of labour; and accordingly labour 
in ewes can be induced with administration of F2α in later gestation, although 




through inhibition of 3β-hydroxysteroid dehydrogenase also induced labour and 
delivery in sheep33. In humans, maternal oestrogen levels are high throughout 
pregnancy, and despite this the myometrium remains in relative quiescence 
until term. An hypothesis for this apparent insensitivity of the myometrium to 
oestrogen during human pregnancy is suppression of the oestrogen receptor 
ERα by progesterone32, and administration of the progesterone antagonist 
RU486 to Rhesus monkeys induces both labour and the expression of ERα by the 
myometrium32. Induction of labour with current methods are unsuccessful 
approximately 33% of the time126, and it is likely that an improved understanding 
of the mechanisms of spontaneous labour would allow better targeting of drugs 
to improve the efficiency of IOL. In addition, a better understanding of pathways 
associated with failed IOL would help to inform research into what is required 
for successful IOL. 
1.6 New approaches to understanding the mechanisms of human parturition: the 
potential of omics data 
As described, treatment options for prevention of pregnancy loss, including PTB, 
and IOL’ remain limited; and for prevention of pregnancy loss in particular, few 
options have proven efficacy. A large part of this problem is that we do not fully 
understand the mechanism for labour in humans. Advances in this area of 




happens in humans; and experimental techniques such as myometrial cell 
culture do not always replicate what occurs to the uterus and myometrium 
during human pregnancy and labour in vivo127. Over the past decades many 
advances have been made in our understanding of reproduction and pregnancy. 
Recently, new techniques have been developed that may allow us to further 
elaborate and gain a better understanding of these biological pathways, 
capitalising on high-dimensional omics data and large-scale cohort studies, as 
will be discussed here. 
1.6.1 The omics techniques 
The omics techniques include genomics, transcriptomics, proteomics, and 
metabolomics. These technologies and their uses are rapidly developing and 
allow a fine-grained snapshot of a person’s molecular profile. These techniques 
can be used as a systematic approach to generate and validate hypotheses 
which can be tested in future studies128, including understanding of normal 
physiological as well as disease processes and biomarker discovery128. Excitingly, 
because omics studies allow investigation of global metabolites and proteins in 
a relatively non-invasive manner, including in human pregnancy, they provide a 
methodology by which human labour can potentially be investigated more 
directly and systematically. Possible pitfalls in analysis of omics studies include 




observational studies in humans it is also important to collect, and include in the 
analysis, background data in order to control for confounding factors128. This 
thesis presents studies involving metabolomics and proteomics and these will 
be discussed here. Genomics and transcriptomics will also be described briefly. 
1.6.2 Genomics and transcriptomics 
Genomics is the study of the genome, the total DNA contained within a cell or 
organism. The human genome is comprised of 3.2 billion bases with 
approximately 30 000 – 40 000 genes, although only half appear to code for 
proteins129. DNA microarrays are used to compare and contrast the expression 
of thousands of genes between individuals simultaneously130. The transcriptome 
is the set of all RNA molecules generated from genes in the genome of a cell or 
collection of cells. DNA microarrays are used to compare and contrast the 
expression levels of each gene, with expression of a gene measured in terms of 
the number of mRNA molecules for that gene128. While this can be used to 
analyse gene activity within disease, mRNA abundance does not always reflect 
protein abundance and this has to be taken into account when interpreting 
results128.  
1.6.3 Metabolomics 
The study of complex but interrelated biochemical pathways has been facilitated 




changes in multiple metabolites in small samples of bodily fluids or tissues131. 
Metabolites are intermediate and final products of metabolism which include 
lipids, carbohydrates, peptides, nucleotides, hormones, and signalling 
molecules131-133. Importantly, the metabolome is the final product of the 
transcriptome and proteome, and therefore is likely to be the most analogous 
to the phenotype of a system128, 131, although the metabolome is also affected 
by environmental input such as medications and diet131-133.  
Generally, the process of metabolomics involves two stages. The first stage 
includes experimental analytical techniques to quantify concentrations of 
multiple metabolites within a sample of interest, most commonly utilising mass 
spectrometry (MS) or nuclear magnetic resonance (NMR). The second stage is 
data processing using advanced computational programmes131, 134. Liquid 
chromatography (LC) or gas chromatography (GC) coupled to MS results in 
excellent separation of molecules within a sample according to their mass-to-
charge ratio. Different MS platforms include: LC coupled with single-stage MS 
(LC-MS) or tandem MS (LC-MS/MS); GC coupled to MS (GC-MS); and high or 
ultrahigh performance LC coupled to ultraviolet or fluorescence detection 
(HPLC/UPLC)135. LC-MS, GC-MS and NMR are the most commonly used 
metabolomics analytical techniques, and 80% of published metabolomics 




disadvantages to each of the different platforms, and decisions regarding this 
are often based on the study and sample type, as well as the cost and availability 
of a platform 135.  
The benefits of MS platforms over NMR platforms have been reported to be a 
potential for increased sensitivity, and that MS allows detection of a greater 
number of metabolites134 including molecules with nanomolar (nm) 
concentrations. This potentially allows for closer analysis of physiological 
pathways. MS platforms can be more selective and considered a better method 
for targeted analysis whereas NMR has often been used for nonselective 
analysis although improving techniques, such as with the Nightingale Platform 
(used by Born in Bradford), are reducing this difference136. In contrast, NMR is 
typically more reproducible than MS, and because of the problem of peak 
overlaps between multiple metabolites NMR achieves faster throughput. With 
NMR, all the metabolites that are at a level that is detectable can be measured 
at one time, whereas different ionisation methods are required to increase the 
number of metabolites measured with MS. Further, NMR involves minimal 
sample preparation, whereas MS requires more including chromatography; and 
NMR is quantitative as metabolite concentrations are proportional to the signal 




NMR can usually measure up to 200 metabolites in one measurement, whereas 
with MS techniques several hundred can be detected and quantified135. 
In addition, NMR is particularly good for large scale metabolomics studies as it 
is highly automatable and reproducible135, and advances in these technologies 
have relatively recently allowed extensive metabolomic profiling within large 
cohort studies136. This has propelled us into a potential for discovering and 
uncovering pathways and biomarkers which previously have been hidden, and 
this could include the trigger for human labour. In order to get the most 
comprehensive results it is often recommended to use multiple platforms135.  
As blood samples, including serum and plasma, are useful and practical samples 
to measure during pregnancy, it is useful that this is where much of the acute 
changes in the metabolome are likely to be found136. Previous studies have 
included use of metabolomics to investigate pregnancy related changes in 
maternal and cord blood, fetal membranes, cervico-vaginal secretions, urine 
and amniotic fluid; with the potential of identifying metabolic profiles or 
biomarkers associated with different outcomes, such as PTB137, 138, missed 
miscarriage139, diagnosis of exposure to chorioamnionitis in the neonate140, and 
the effect of maternal diet on amniotic fluid composition137, 138, 141. Some of 
these will be discussed further within the upcoming chapters of this thesis. Prior 




which specifically used metabolomics and phosphoproteomics to investigate 
potential associations with gestational age at delivery and the trigger for human 
labour5. 
1.6.4 Proteomics 
As described above, the functional content of genes may be best analysed from 
the proteome142, 143. However, the investigation of protein function within 
eukaryotic cells is complicated by post-translational modifications such as 
phosphorylation, methylation, lipid attachment and glycosilation142, as it is not 
always known how these modifications may affect protein function. Proteomic 
analysis generally involves the following steps: protein separation and isolation; 
techniques to determine structural characteristics of these proteins; and use of 
databases to identify the individual proteins143. Prior to the development of 
techniques for global proteomic analysis, proteins were most typically isolated 
using chromatography-based techniques such as affinity chromatography, size 
exclusion chromatography and ion-exchange chromatography. Enzyme-linked 
immunosorbent assays (ELISA) and western blotting techniques were used for 
analysis of selected proteins. Further, for separation of complex proteins, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and two-




detailed quantification of proteins present, however only a limited number of 
proteins are detected with each experiment.  
Development of MS techniques in the proteomics process allows measuring 
proteomes with high coverage in one experiment143, 144. Site-specific enzymatic 
proteases, for example trypsin, are used to digest proteins to peptides and these 
are fragmented within the mass spectrometer. The resulting spectra are used to 
identify the corresponding peptide sequence from databases144. Protein 
expression proteomics investigates the expression of different proteins in 
samples which differ by a variable, for example disease or non-disease, and such 
studies can help to identify proteins associated with a certain disease143. As such, 
proteomics can provide an insight into the dynamic relationship between genes 
and the cell environment, and such studies have been used to identify disease 
biomarkers for clinical use128.  
Phosphoproteomics allows analysis of total proteins and phosphorylation of 
proteins within tissues, and has recently been used in experimentation of the 
myometrium in humans145. Using phosphoproteomics, one group detected 22 
phosphopeptides where the relative ratio either doubled or halved between 
spontaneous or oxytocin-driven phasic contractions in vitro. The largest changes 
were seen with phosphorylation of myosin light chain kinase on serine 1760, 




activity. The authors found that phosphoproteomics analysis of myometrium in 
this setting presents a novel platform for assessment changes in proteins during 
spontaneous and oxytocin-induced contractions145. The specific 
phosphoproteomics methodology used in this thesis are described in more 
detail in Chapter 5. 
1.7 Summary 
Complications of PTB and IOL can cause long term disabilities and  increased 
psychological stress and worry to women and their families, as well as increased 
financial cost to the National Health Service (NHS)4, 36,43, 44. While advances have 
been made in prediction models for PTB, there are still limited treatment 
options available. Currently management of preterm labour involves trying to 
reduce contractions for up to 24 hours in order to administer steroids and 
magnesium sulphate for maturation of the fetal lungs and stabilisation of the 
fetal neurological membranes for neuroprotection, respectively. There are no 
current treatments available that stop or prevent PTB once preterm labour has 
commenced31, 146. There are still large gaps in understanding of the mechanisms 
for labour in humans which include the timing of gestational length, and 
whether this relates to an interaction between the maternal/placental/fetal 
circulations, potentially driven by the fetus. Given maternal progesterone 




very possible that the mechanisms involved in the trigger of labour are locally 
driven, and involve local signals between the fetus, placenta, decidua and 
myometrium.  
As discussed, while the mechanisms of labour in mammals such as sheep and 
rodents are relatively well understood, the elucidated mechanisms do not seem 
to be directly replicated in humans; and in vitro models do not always 
adequately reflect what happens in vivo to the uterus during pregnancy and 
labour. Moreover, while it is hypothesised that there may be a functional 
withdrawal of progesterone in humans that results in myometrial contractions 
and labour, exogenous administration of progesterone to women does not 
appear to prevent preterm birth or miscarriage in the majority of scenarios.  
The recent advances in omics technologies bring with them potential to be able 
to analyse direct cellular pathways that are occurring during pregnancy, labour 
and at delivery, and without causing risk to the mother or baby. The overarching 
aim of this thesis is to use these technologies to better understand human 






1.8 Thesis aim and objectives 
Aim 1: To further knowledge and understanding of the mechanisms and trigger 
of human parturition using omics technologies.  
Objective 1.1: To further our understanding of the signals between the mother, 
placenta and fetus at the time of term labour by elucidating the metabolome of 
maternal blood, the cord vein, and cord artery, respectively, at the time of 
delivery. 
Objective 1.2: To determine if there are differences in these signals between 
spontaneous labour, induction of labour and no labour (caesarean section). Any 
differences would indicate further areas to investigate with regards to the 
process of spontaneous labour at term.  
Aim 2: To investigate whether the maternal metabolome during pregnancy is 
associated with gestational length of pregnancy. 
Objective 2.1: Investigate maternal metabolome at different time points during 
pregnancy and determine if there is an association with gestational age at 
spontaneous labour. 
Objective 2.2: Investigate an association between maternal metabolites 
sampled during pregnancy and gestational age at delivery for women included 




Aim 3: Given the myometrium generates the contractions of labour and 
expulsion of the fetus, the third aim of the thesis is to investigate what signals 
are necessary within the myometrium for successful labour. 
Objective 3.1: to investigate the phosphoproteome changes with myometrial 
contraction and relaxation. 
Objective 3.2: To investigate whether there are differences in the 
phosphoproteome between myometrium sampled from women where the 
cervix has previously dilated to 10 cm  (full dilatation) with myometrium 
sampled from women who have an emergency caesarean section for failure to 
progress.  
The next four chapters of this thesis present studies undertaken by Katherine 
Birchenall (thesis author) to answer the above aim and objectives: Chapter 2 and 
Chapter 3 present two clinical studies which utilised MS metabolomics to 
investigate human pregnancy; Chapter 4 presents a study that used NMR 
metabolomics data from the Born in Bradford cohort study; and Chapter 5 
presents a study which investigated phosphoproteomics in human myometrium. 
There is no separate methodology chapter, and instead each of the studies in 
Chapters 2-5 are presented independently, all containing sections on 
background, methodology, results, discussion and conclusions. Finally, Chapter 




CHAPTER 2. INVESTIGATING METABOLITE CHANGES IN 
MATERNAL AND FETAL PLASMA FOLLOWING 




This pilot study was designed to investigate the effect of labour on the human 
metabolome in pregnancies delivered at term. It was hypothesised that a better 
understanding of any differences in the human metabolome within cord and 
maternal blood at term between those who laboured and delivered vaginally 
(VD) and those who did not labour and delivered via elective caesarean section 
(CS) would help identify potential target pathways for metabolites involved in 
the spontaneous initiation of labour. This study was also intended to 
demonstrate the potential of mass spectrometry (MS) metabolomics analysis of 
maternal plasma in human pregnancy, which had not been extensively 
performed previously.  
The results of this study demonstrate that even with a relatively small sample 
size, significant and robust changes can be identified providing new insights into 







The findings from the study presented in this chapter have been published in a 
peer-reviewed journal5, the reference for which is: 
Birchenall, K.A., Welsh, G.I. & Lopez Bernal, A. (2019). Metabolite Changes in 
Maternal and Fetal Plasma Following Spontaneous Labour at Term in 
Humans Using Untargeted Metabolomics Analysis: A Pilot Study. 
International Journal of Environmental Research and Public Health: 16(9), 
1527; doi:10.3390/ijerph16091527. 
This thesis chapter is adapted from that publication, which was written in full by 
the thesis author (Katherine Birchenall) with support from supervisors Professor 
Andrés López Bernal and Dr Gavin Welsh (co-authors). The full paper is attached 
in the Appendices (2A1).  
2.3 Study responsibilities 
The thesis author (Katherine Birchenall) designed this study, wrote the protocol, 
recruited all participants, collected, and processed all samples, and analysed the 
results. The MS metabolomics described, along with some initial statistical 
analysis, was performed by Metabolon, Inc., with support from Dr Gregg 
Michelotti at Metabolon, Inc.. This will be described further below. All reference 







This part of the PhD was funded by the Mother and Baby Trust, an Above and 
Beyond charity [grant number G109481-101]. 
2.5 Ethical approval 
The study was conducted in accordance with the Declaration of Helsinki, and 
ethical approval for the study was gained from the National Research Ethics 
Service Committee-South West, Bristol (reference number: E5431). 
2.6 Background 
Our understanding of the mechanisms of human parturition remains incomplete 
and consequently management options for complications of pregnancy such as 
preterm birth (PTB), and common interventions such as induction of labour 
(IOL)2, 36, remain clinically unsatisfactory4. 
A better understanding of human labour at term (defined as 37–42 weeks’ 
gestation) would allow development of methods for improved prediction and 
prevention of PTB, as well as more effective strategies for IOL29, 30, 47. The 
aetiology of PTB is heterogeneous and frequently pathological, however it may 
result in stimulation of the same triggers for parturition as spontaneous labour 
at term2, 147. The proportion of pregnancies with IOL in England has increased 
from 20.3% in 2006–2017 to 29.4% in 2016–201730, 45-48. IOL can be inefficient, 




lengthy hospital stays at high cost to the National Health Service and a negative 
impact on the birth experience4, 43, 44. There is a need to identify the metabolic 
changes underlying the physiological onset of spontaneous human labour and 
to develop new clinically useful predictive markers and better drug targets. 
Metabolomics allows the investigation of a wide range of metabolites across the 
main biochemical pathways148. The advantage of studying the metabolome or 
metabolic profile of a system is that it reveals the current activity rather than a 
prediction of what may happen, as is the case with genomic studies132, 133, 149. 
The most commonly used metabolomic techniques are mass spectrometry (MS) 
and nuclear magnetic resonance (NMR), paired with data processing using 
advanced computational programmes134, 149. NMR can measure a broad range 
of metabolites however it is less sensitive than MS. Gas chromatography (GC) or 
liquid chromatography (LC) coupled to MS provides excellent separation of 
molecules within a sample according to their mass-to-charge ratio and analysis 
at a wide range of concentrations. As MS is more sensitive, it can be utilised to 
measure more metabolites, but it has a longer analysis time than NMR134. 
Metabolomics has been used to investigate pregnancy related changes in 
maternal and cord blood, fetal membranes, cervico-vaginal secretions, urine 
and amniotic fluid; with the potential of identifying metabolic profiles or 




miscarriage139, diagnosis of exposure to chorioamnionitis in the neonate140, and 
the effect of maternal diet on amniotic fluid composition137, 138, 141. However, 
studies focusing on parturition are scarce. 
This chapter presents novel MS metabolomics data from a pilot study designed 
to investigate the effect of parturition on plasma metabolites in the fetal and 
maternal circulation at the time of delivery. The findings demonstrate that even 
with a relatively small sample size significant and robust changes can be 
identified providing new insights into the metabolic responses of the maternal-
feto-placental unit in spontaneous labour. 
2.7 Aims and objectives 
The aim of this study was to investigate differences in the cord and maternal 
plasma metabolic profiles between women who spontaneously labour and 
deliver vaginally and those who deliver via elective caesarean section and do not 
labour.  
The specific objectives were: 
1. Determine feasibility of recruiting women to this type of study. 
2. To identify potential pathways using MS metabolomics in a small cohort 
of women (numbers limited by time and available funds), and assess the 








Women with low-risk pregnancies were recruited at term who planned either a 
spontaneous labour and vaginal delivery (VD) or an elective caesarean section 
(CS) for reasons not related to maternal or fetal disease, for example breech 
presentation. It was intended to recruit ten women to each group. The target 
number of ten was chosen as this was a pilot study and it was not known how 
useful the MS metabolomics technology would be in this setting. Such a study 
design had not previously been published (according to a literature search by 
the researcher) and therefore ten per group was deemed a reasonable target 
following discussion with the researcher and supervisors. 
The inclusion criteria were as follows:  
• women with uncomplicated singleton term pregnancies.  
• age 18-40 years.  
• no significant past medical history.  
The exclusion criteria were as follows:  




• age under 18 years or over 41 years. 
• taking medications likely to affect metabolomics. 
• Diabetes. 
• pre-eclampsia. 
• other metabolic conditions.  
• raised temperature. 
• signs of fetal distress during labour.  
The following demographic information was collected:  
• ethnicity. 
• age. 
• Body Mass Index (BMI). 
• smoking status. 
• time last eaten. 
• time of delivery. 
• duration of delivery. 




• Apgar scores of the baby at delivery. 
• cord gases if taken.  
Forty women were approached at St Michael’s Hospital, Bristol, between 
October 2016 and January 2017. The women were asked if they may be 
interested in taking part in the study and given an information leaflet (Appendix 
3A1) and the study explained by the researcher. For those women who were 
happy to consent to the study, the researcher returned, and the women signed 
the consent form (Appendix 3A2) (Figure 2.1). Thirty-eight women gave 
informed, written consent to take part in the study. 17 women were excluded 
for the following reasons: one had their labour induced, one had increased 
maternal age, two developed pyrexia during their labour, one developed a 
pyrexia and pre-eclampsia during their labour, two had an emergency CS, and 
ten delivered when the researcher was not present in the hospital. Twelve 
women delivered via elective CS and ten of these were included in the study (as 
ten was the intended number to include in each group), and nine women 
delivered via spontaneous VD and were included in the study.  
2.8.2 Collection of samples 
Cord blood and maternal (intervillous) blood samples were obtained within 30 
minutes of delivery of the baby and placenta. Delayed cord clamping is routinely 




deliveries, and this occurred for all the deliveries in this study. Intervillous 
samples were collected through making a cut in the placenta using a scalpel and 
extracting blood using a 10 ml syringe, as described previously150. This method 
of maternal blood sampling was used to limit the intrusion of the study on the 
important bonding time for the family at delivery, negating the need to 
physically take blood from the mother immediately following delivery and 
meant that the researcher did not have to enter the delivery room at all during 
this significant time. The midwives brought the placenta to the researcher (who 
was standing just outside the door of the delivery room) immediately. The 
researcher collected the mixed cord sample from both the cord vein and cord 
artery using a sterile 21 Gauge needle and syringe, transferred into a Vacutainer 
tube containing EDTA, then centrifuged at 1000 x g for ten minutes. Two 
hundred microlitres of the clear upper plasma layer was transferred into chilled 
propylene tubes and immediately stored at -80 degrees Celsius prior to 
transportation. All samples were frozen within an hour of delivery.  
Samples were collected between October 2016 and February 2017, and were 
transported to Metabolon, Inc. in April 2017. Samples were labelled with a 
unique study identifier, with no patient identifying information. All patient 
identifying information and matching study identifier were kept on an encrypted 




kept in a study file, locked in a filing cabinet, in a specified locked research office 
within St Michael’s Hospital. The Human Tissue Act was adhered to at all times. 
 
Figure 2.1: Flow diagram for women approached to join the study 
 
2.8.3 Metabolomics analysis 
The samples were transported on dry ice to Metabolon, Inc., (North Carolina, 




tandem mass spectrometry (UHPLC/MS)151-153. All samples were analysed 
together to reduce risk of batch bias. This included the measurement of 826 
known metabolites for each sample, grouped into 108 sub-pathways and the 
following eight super-pathways: Lipid, Amino Acid, Peptide, Energy, Nucleotide, 
Cofactors and Vitamins, and Xenobiotics. Briefly, plasma samples were 
subjected to methanol extraction then split into aliquots for analysis by 
UHPLC/MS in the positive (involving two methods, one optimized for hydrophilic, 
and the other hydrophobic compounds), negative or polar ion mode. 
Metabolites were identified by automated comparison of ion features to a 
reference library of chemical standard, followed by visual inspection for quality 
control154. For quality assurance and quality control (QC), pooled QC plasma 
replicates, as well as several internal standards, were assessed to determine 
instrument variability, with representative relative standard deviation (RSD) = 
3% for internal standards and 7% for endogenous biochemicals.   
2.8.4 Statistical analysis 
The two experimental groups were labelled VC/EC and VM/EM. VC/EC 
represents the difference in the means between VC, the metabolite quantity 
identified in cord plasma from women who laboured and delivered vaginally, 
and EC, the metabolite quantity identified in cord plasma from women who did 




means between VM, the metabolite quantity identified in intervillous plasma 
from women who laboured and delivered vaginally, and EM, the metabolite 
quantity contained in intervillous plasma from women who did not labour and 
delivered via elective CS. Welch’s two-sample t-test was used to identify 
metabolites for which the means were significantly different between VC and 
EC or VM and EM. Analysis was performed on log-transformed data, considered 
significant if p≤0.05. A q-value was also calculated to control for false discovery 
rate and account for the multiple comparisons which occur in metabolomic-
based studies. Metabolon, Inc., estimate that ten metabolites will be shown to 
be significant by chance for every 200 compounds analysed, and a q-value of 
<0.10 gives high confidence that a significant difference is not due to chance. 
The statistical analysis plan was designed by the researcher, and Metabolon, Inc. 
performed the initial statistical analysis in ArrayStudio and R, as part of their 
collaboration in the project.  
2.8.5 Over-representation analysis 
Overrepresentation analysis (ORA) software has been utilised to enhance and 
guide analysis of transcriptomics and proteomic analysis (discussed further in 
Chapter 5), and similar software has been developed for metabolomics analyses.  
Previous work has been conducted to compare the effectiveness of different 




MetaboAnalyst, REACTOME, MetExplore, and KEGGREST. ORA analyses were 
found to be consistent regardless of the analytic approach used155. For the 
metabolomics analysis in this thesis,  MetaboAnalyst (version 4.0) was selected 
as it is specifically designed for use with metabolomics and has been used 
successfully by other researchers156, 157. The MetaboAnalyst software is based 
on the statistical package R and maps common compound names to a range of 
database identifiers, including KEGG, Human Metabolome Database (HMDB), 
METLIN, and PubChem158. There are some limitations to ORA analysis, including 
that there is the potential for some bias towards those diseases and pathways 
which have previously been investigated, as only a small proportion of the 
metabolome is currently elucidated. On the other hand, examining and 
explaining results according to biological knowledge from the literature can also 
be biased according to the prior background knowledge or interest of the 
researcher157. Therefore, for this thesis, both ORA enrichment pathway analysis 
and investigation of individual metabolite changes will be performed to aid 
understanding of the results observed. In addition, such standardised pathway 
analysis can help to compare outcomes of the different studies included in this 
thesis. 
For the MS analysis in this thesis, HMDB identifiers were put inputted into the 




analysis performed. The pathway enrichment analysis selected implemented 
the hypergeometric test to evaluate whether a specific metabolite group is 
represented more than would be expected by chance within the given 
compound list. Raw one-tailed p values are calculated, as well as a p-value 
calculated following adjustment for multiple testing using the Holm method157, 
158. For the present chapter, MetaboloAnalyst was used for those metabolites 
which had a significant p-value (≤0.05) for VM/EM and VC/EC.  
2.9 Results 
2.9.1 Demographics 
Table 2.1 presents the characteristics of the labouring and non-labouring groups. 
All nine women in the vaginal delivery group had confirmed labours of 
spontaneous onset. All women were of white ethnicity and there were no 
significant differences in age, parity, or Apgar scores at birth between the two 
groups. None of the women had experienced medical complications during the 
pregnancy, nor had there been concern for any of the fetuses. The mean BMI at 
booking was 21.6 in the VD group and 25.6 in the elective CS group (p=0.02), 
due to an outlier in the elective CS group with BMI 38.3. Further analysis was 
performed and confirmed her inclusion did not affect the spread of results. The 
median gestation at delivery was 40 weeks in the VD group and 39 weeks and 2 




are routinely booked between 39 and 40 weeks’ gestation whereas spontaneous 
deliveries may occur up to three weeks later. 
2.9.2 Metabolomics 
All the results refer to ten women in the elective CS group and nine women in 
the VD group. It was not possible to obtain intervillous blood from one placenta, 
reducing the VM samples to eight. The numbers of metabolites with significant 
(p≤0.05) differences between VM and EM, and VC and EC, in the eight super-
pathways are presented in Table 2.2. Of the 108 metabolite sub-pathways 
measured, 83 contained metabolites with statistically significant VC/EC and/or 
VM/EM differences. For the following analysis, xenobiotic metabolites will be 
considered separately. 
2.9.3 Changes in cord plasma metabolome 
Table 2.3 shows the changes in cord plasma (VC/EC) of specific metabolites 
within the sub-pathways ordered according to the magnitude of fold-change. Of 
these, 120 metabolites significantly increased in the cord plasma of women who 
laboured, 102 of which also had a significant q value (<0.10), indicating these 
differences are unlikely to have occurred due to chance. These comprised 58 
lipid metabolites, 14 amino acid metabolites, nine carbohydrate metabolites, 
eight nucleotide metabolites, six energy metabolites, three cofactors and 




molecules. The metabolite with the largest VC/EC fold-change was heme, which 
had an average 14.30-fold increase in the cord plasma (p=0.024) taken from 
women who laboured.  
39 metabolites significantly decreased in the cord plasma of women who 
laboured (VC/EC), and 27 of these had a significant q value: eleven amino acids, 








Table 2.1: Characteristics of included human participants 
Demographic VD Elective CS p value 
 
(n = 9) (n = 10) (at ≤0.05) 
Age (years)  32.4 (24-39)a 34.6 (30-40) a NS 
BMI at pregnancy booking 21.6 (19.9-23.1) a 25.56 (21.7-38.3) a 0.02 
Ethnicity 
   




                    Never 8 4 
 
                    Ex 0 5 
 
                    Current 1 (4/day) 1 (10/day) 
 
Maternal past medical history    
 Eczema: 1 
ICSI pregnancy (own sperm/egg): 1 
Previous postnatal depression: 1 
Well controlled asthma: 1 
MTHFR gene 1: 1 
NA 
Gravida 1.2 (0-2) a 2.4 (0-5) a NS 
Parity 0.6 (0-2) a 1.7 (0-7) a NS 




Indication for elective CS 
   
Breech NA 3 NA 
Previous CS NA 3 NA 
Maternal request NA 1 NA 
Previous 3rd degree vaginal tear NA 1 NA 
Previous traumatic delivery NA 1 NA 
Tocophobia NA 1 NA 
Duration of labour in minutes 312 minutes (70 - 650) a NA NA 
Gestation at delivery (weeks+days) 40 (38+1-41+6) a 39+2 (38+4-40+3) a 0.04 
Apgar scores at 1, 5 and 10 minutes: 
  
NS 
                    8,9,10 1 0 
 
                    9,10,10 8 10 
 
Management of third stage: 
  
NS 
       Syntometrine or Carbetocin 8 10 
 
                     Physiological 1 0 
 
Interval between delivery and freezing of 
sample (minutes) 
50 (36-60) a 30.7 (24-45) a 0.02 
a Mean (range); VD = Vaginal Delivery; CS = Caesarean Section; BMI = Body Mass Index; NS = not significant; NA = non-applicable; ICSI = 





Table 2.2: Number of metabolites which significantly increased or decreased at the time of 
delivery between women who spontaneously laboured and delivered vaginally and women 
who did not labour and delivered via elective caesarean section in the maternal 
(intervillous) plasma (VM/EM) and cord plasma (VC/EC) for each of the super pathways. 







↑ ↓ Total (%) ↑ ↓ Total (%) 
Lipid 405 13
9 
14 153 (37.8) 73 12 85 (21.0) 
Amino Acid 177 9 15 24 (13.6) 15 14 29 (16.4) 
Xenobiotics 108 18 3 21 (19.4) 16 5 21 (19.4) 
Carbohydrate 29 7 0 7 (24.1) 9 0 9 (31.0) 
Cofactors and 
Vitamins 
31 3 4 7 (22.6) 3 5 8 (25.8) 
Energy 11 3 0 3 (27.3) 6 0 6 (54.6) 
Nucleotide 38 2 2 4 (10.5) 9 3 12 (31.6) 
Peptide 24 0 1 1 (4.2) 3 5 8 (33.3) 
Partially 
characterised 
3 2 0  2 0  
VM = Maternal (intervillous) plasma from women who laboured and delivered vaginally (n=8); EM = 
maternal plasma from women who did not labour and delivered via caesarean section (n=10); VC = 
cord plasma from women who laboured and delivered vaginally (n=9); EC= cord plasma from women 
who did not labour and delivered via elective caesarean section (n=10); ↑ = Number of metabolites 
significantly elevated; ↓ = Number of metabolites significantly decreased. 
 
2.9.4 Changes in maternal plasma metabolome 
Table 2.4 shows the corresponding changes in maternal plasma metabolites 
(VM/EM). Overall, 165 metabolites statistically significantly increased in 
labouring women, all of which had a significant q value. These included: nine 
amino acids, seven carbohydrates, three cofactors and vitamins, three energy 




molecules. The metabolite with the greatest significant-fold increase in 
maternal plasma of women who laboured was the partially characterised 
molecule glucuronide of C10H18O2 (8), with an average 10.85-fold increase in 
VM plasma. The dicarboxylate fatty acids maleate and adipate (C6-DC) increased 
10.42-fold and 8.06-fold, respectively. 
36 metabolites were significantly decreased in the maternal plasma of women 
who laboured when compared with women who did not labour (VM/EM), with 
a corresponding significant q value, comprising fifteen amino acids, four 
cofactors and vitamins, fourteen lipids, two nucleotides and one peptide. 
Among these were steroid sulphates, including 3-dehydrocholate (p=0.002), 
16a-hydroxy DHEA 3-sulfate (0=0.007) and andro steroid monosulfate 




Table 2.3: Fold-change in cord plasma (VC/EC) for metabolites (xenobiotics excluded) with significant p (≤0.05) and q (≤0.10), ordered 
according to fold-change (greatest to smallest), with corresponding sub-pathway and super-pathway. 
Metabolite Sub-Pathway Super-Pathway Fold-






Heme Hemoglobin and Porphyrin Metabolism Cofactors and Vitamins 14.30 0.0239 0.0918 
Fibrinopeptide A, Phosphono-Ser Fibrinogen Cleavage Peptide Peptide 11.71 0.0144 0.0689 
Glucuronide Of C10H18O2 Partially Characterized Molecules Partially Characterised 
Molecules 
9.98 0.0159 0.0734 
Spermidine Polyamine Metabolism Amino Acid 7.26 0.0172 0.0764 
Adenosine 5'-Diphosphoribose (Adp-Ribose) Nicotinate and Nicotinamide Metabolism Cofactors and Vitamins 7.25 0.0180 0.0784 
Glycerol 3-Phosphate Glycerolipid Metabolism Lipid 7.13 0.0064 0.0435 
Glucuronide Of C10H18O2 Partially Characterized Molecules Partially Characterised 
Molecules 
7.07 0.0214 0.0887 
Inosine Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide 6.01 0.0016 0.0194 
Cysteine-Glutathione Disulfide Glutathione Metabolism Amino Acid 5.13 0.0035 0.0312 
Cortisol Corticosteroids Lipid 3.57 0.0000 0.0015 
Adenosine 3',5'-Cyclic Monophosphate (Camp) Purine Metabolism, Adenine containing Nucleotide 3.53 0.0009 0.0141 
Maltose Glycogen Metabolism Carbohydrate 3.39 0.0254 0.0925 
Trans-Urocanate Histidine Metabolism Amino Acid 3.23 0.0012 0.0148 




Cortisone 21-Sulfate Corticosteroids Lipid 3.02 0.0001 0.0051 
Hypoxanthine Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide 2.96 0.0001 0.0049 
Androstenediol (3Alpha, 17Alpha) Monosulfate Androgenic Steroids Lipid 2.80 0.0110 0.0583 
3-Phosphoglycerate Glycolysis, Gluconeogenesis and Pyruvate 
Metabolism 
Carbohydrate 2.77 0.0233 0.0918 
5Alpha-Androstan-3Alpha,17Beta-Diol 
Monosulfate 
Androgenic Steroids Lipid 2.63 0.0141 0.0677 
N-Formylphenylalanine Tyrosine Metabolism Amino Acid 2.56 0.0056 0.0403 
Xanthine Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide 2.55 0.0000 0.0008 
Palmitoleate (16:1N7) Long Chain Monounsaturated Fatty Acid Lipid 2.52 0.0190 0.0805 
1,2-Dipalmitoyl-Gpe (16:0/16:0) Phosphatidylethanolamine (PE) Lipid 2.51 0.0269 0.0955 
Margaroylcarnitine (C17) Fatty Acid Metabolism (Acyl Carnitine, 
Long Chain Saturated) 
Lipid 2.47 0.0105 0.0579 
Eicosenoylcarnitine (C20:1) Fatty Acid Metabolism (Acyl Carnitine, 
Monounsaturated) 
Lipid 2.43 0.0045 0.0362 
5-Dodecenoate (12:1N7) Medium Chain Fatty Acid Lipid 2.41 0.0018 0.0209 
3-Hydroxylaurate Fatty Acid, Monohydroxy Lipid 2.40 0.0000 0.0020 
S-Adenosylhomocysteine (Sah) Methionine, Cysteine, SAM and Taurine 
Metabolism 
Amino Acid 2.34 0.0223 0.0898 




Galactonate Fructose, Mannose and Galactose 
Metabolism 
Carbohydrate 2.31 0.0185 0.0796 
Androsterone Sulfate Androgenic Steroids Lipid 2.27 0.0007 0.0128 
Cysteinylglycine Glutathione Metabolism Amino Acid 2.21 0.0123 0.0625 
Lactate Glycolysis, Gluconeogenesis and Pyruvate 
Metabolism 
Carbohydrate 2.13 0.0000 0.0018 
Alpha-Ketoglutarate TCA Cycle Energy 2.13 0.0011 0.0148 
Adenosine 5'-Monophosphate (Amp) Purine Metabolism, Adenine containing Nucleotide 2.12 0.0246 0.0918 
Hexadecadienoate (16:2N6) Long Chain Polyunsaturated Fatty Acid (n3 
and n6) 
Lipid 2.09 0.0004 0.0094 
Stearoylcarnitine (C18) Fatty Acid Metabolism (Acyl Carnitine, 
Long Chain Saturated) 
Lipid 2.08 0.0256 0.0925 
Myristoleate (14:1N5) Long Chain Monounsaturated Fatty Acid Lipid 2.03 0.0165 0.0745 
3-Hydroxydecanoate Fatty Acid, Monohydroxy Lipid 2.01 0.0002 0.0066 
Glycerophosphoinositol Phospholipid Metabolism Lipid 1.98 0.0134 0.0653 
(16 Or 17)-Methylstearate (A19:0 Or I19:0) Fatty Acid, Branched Lipid 1.96 0.0041 0.0353 
Fructose Fructose, Mannose and Galactose 
Metabolism 
Carbohydrate 1.96 0.0186 0.0796 
Palmitoleoylcarnitine (C16:1) Fatty Acid Metabolism (Acyl Carnitine, 
Monounsaturated) 
Lipid 1.95 0.0009 0.0141 
1-Palmitoyl-2-Oleoyl-Gpe (16:0/18:1) Phosphatidylethanolamine (PE) Lipid 1.93 0.0095 0.0554 
Oleoylcarnitine (C18:1) Fatty Acid Metabolism (Acyl Carnitine, 
Monounsaturated) 




Laurate (12:0) Medium Chain Fatty Acid Lipid 1.90 0.0010 0.0146 
Acetylcarnitine (C2) Fatty Acid Metabolism (Acyl Carnitine, 
Short Chain) 
Lipid 1.89 0.0004 0.0094 
10-Heptadecenoate (17:1N7) Long Chain Monounsaturated Fatty Acid Lipid 1.89 0.0026 0.0282 
Pantothenate Pantothenate and CoA Metabolism Cofactors and Vitamins 1.89 0.0241 0.0918 
N-Acetylglucosamine/N-Acetylgalactosamine Aminosugar Metabolism Carbohydrate 1.88 0.0033 0.0304 
Malate TCA Cycle Energy 1.86 0.0012 0.0148 
Ribulonate/Xylulonate Pentose Metabolism Carbohydrate 1.85 0.0009 0.0141 
Cortisone Corticosteroids Lipid 1.85 0.0010 0.0145 
Dihomo-Linoleoylcarnitine (C20:2) Fatty Acid Metabolism (Acyl Carnitine, 
Polyunsaturated) 
Lipid 1.84 0.0059 0.0413 
Oleate/Vaccenate (18:1) Long Chain Monounsaturated Fatty Acid Lipid 1.84 0.0067 0.0438 
Linolenate [Alpha Or Gamma; (18:3N3 Or 6)] Long Chain Polyunsaturated Fatty Acid (n3 
and n6) 
Lipid 1.83 0.0067 0.0438 
Xanthosine Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide 1.82 0.0005 0.0104 
10-Nonadecenoate (19:1N9) Long Chain Monounsaturated Fatty Acid Lipid 1.81 0.0012 0.0151 
Linoleate (18:2N6) Long Chain Polyunsaturated Fatty Acid (n3 
and n6) 
Lipid 1.81 0.0032 0.0301 
Laurylcarnitine (C12) Fatty Acid Metabolism (Acyl Carnitine, 
Medium Chain) 
Lipid 1.80 0.0084 0.0518 




Succinate TCA Cycle Energy 1.78 0.0098 0.0565 
2-Hydroxyglutarate Fatty Acid, Dicarboxylate Lipid 1.76 0.0024 0.0275 
Myristate (14:0) Long Chain Saturated Fatty Acid Lipid 1.75 0.0071 0.0450 
Oestrone 3-Sulfate Estrogenic Steroids Lipid 1.74 0.0132 0.0651 
Myristoleoylcarnitine (C14:1) Fatty Acid Metabolism (Acyl Carnitine, 
Monounsaturated) 
Lipid 1.72 0.0077 0.0483 
Palmitoylcarnitine (C16) Fatty Acid Metabolism (Acyl Carnitine, 
Long Chain Saturated) 
Lipid 1.72 0.0115 0.0597 
Eicosenoate (20:1) Long Chain Monounsaturated Fatty Acid Lipid 1.69 0.0030 0.0298 
Glycerol Glycerolipid Metabolism Lipid 1.68 0.0000 0.0003 
N-Acetyltaurine Methionine, Cysteine, SAM and Taurine 
Metabolism 
Amino Acid 1.68 0.0016 0.0194 
Caprylate (8:0) Medium Chain Fatty Acid Lipid 1.67 0.0160 0.0734 
Dihomo-Linoleate (20:2N6) Long Chain Polyunsaturated Fatty Acid (n3 
and n6) 
Lipid 1.65 0.0045 0.0362 
Linoleoylcarnitine (C18:2) Fatty Acid Metabolism (Acyl Carnitine, 
Polyunsaturated) 
Lipid 1.64 0.0003 0.0087 
(14 Or 15)-Methylpalmitate (A17:0 Or I17:0) Fatty Acid, Branched Lipid 1.64 0.0029 0.0298 
Uracil Pyrimidine Metabolism, Uracil containing Nucleotide 1.64 0.0109 0.0583 
Myristoylcarnitine (C14) Fatty Acid Metabolism (Acyl Carnitine, 
Long Chain Saturated) 
Lipid 1.63 0.0010 0.0146 
Pyruvate Glycolysis, Gluconeogenesis and Pyruvate 
Metabolism 




(S)-3-Hydroxybutyrylcarnitine Fatty Acid Metabolism (Acyl Carnitine, 
Hydroxy) 
Lipid 1.61 0.0236 0.0918 
Glutamate, Gamma-Methyl Ester Glutamate Metabolism Amino Acid 1.59 0.0287 0.0988 
Decanoylcarnitine (C10) Fatty Acid Metabolism (Acyl Carnitine, 
Medium Chain) 
Lipid 1.58 0.0131 0.0651 
5-Dodecenoylcarnitine (C12:1) Fatty Acid Metabolism (Acyl Carnitine, 
Monounsaturated) 
Lipid 1.57 0.0245 0.0918 
Arachidonoylcarnitine (C20:4) Fatty Acid Metabolism (Acyl Carnitine, 
Polyunsaturated) 
Lipid 1.55 0.0006 0.0105 
Palmitate (16:0) Long Chain Saturated Fatty Acid Lipid 1.54 0.0065 0.0435 
Isocitric Lactone TCA Cycle Energy 1.54 0.0221 0.0898 
Margarate (17:0) Long Chain Saturated Fatty Acid Lipid 1.53 0.0049 0.0373 
5,6-Dihydrouracil Pyrimidine Metabolism, Uracil containing Nucleotide 1.53 0.0094 0.0554 
(12 Or 13)-Methylmyristate (A15:0 Or I15:0) Fatty Acid, Branched Lipid 1.53 0.0100 0.0570 
1-Stearoyl-2-Oleoyl-Gpi (18:0/18:1) Phosphatidylinositol (PI) Lipid 1.51 0.0264 0.0943 
Phenyllactate (Pla) Phenylalanine Metabolism Amino Acid 1.50 0.0054 0.0392 
Vanillactate Tyrosine Metabolism Amino Acid 1.49 0.0005 0.0099 
Imidazole Lactate Histidine Metabolism Amino Acid 1.47 0.0256 0.0925 
Stearoyl-Arachidonoyl-Glycerol (18:0/20:4) Diacylglycerol Lipid 1.44 0.0161 0.0734 
Docosadienoate (22:2N6) Long Chain Polyunsaturated Fatty Acid (n3 
and n6) 
Lipid 1.43 0.0053 0.0391 




Creatine Creatinine Metabolism  Amino Acid 1.41 0.0029 0.0298 
Fumarate TCA Cycle Energy 1.41 0.0043 0.0358 
2-Hydroxy-3-Methylvalerate Leucine, Isoleucine and Valine Metabolism Amino Acid 1.41 0.0130 0.0650 
Stearate (18:0) Long Chain Saturated Fatty Acid Lipid 1.31 0.0068 0.0440 
Glucose Glycolysis, Gluconeogenesis and Pyruvate 
Metabolism 
Carbohydrate 1.31 0.0105 0.0579 
Oleoyl Ethanolamide Endocannabinoid Lipid 1.31 0.0226 0.0904 
Pentadecanoate (15:0) Long Chain Saturated Fatty Acid Lipid 1.30 0.0043 0.0358 
5-Oxoproline Glutathione Metabolism Amino Acid 1.18 0.0035 0.0312 
Serine Glycerine, Serine and Threonine 
Metabolism 
Amino Acid 0.85 0.0113 0.0591 
Tryptophan Tryptophan Metabolism Amino Acid 0.83 0.0243 0.0918 
Arginine Urea cycle, Arginine and Proline 
Metabolism 
Amino Acid 0.82 0.0103 0.0579 
Histidine Histidine Metabolism Amino Acid 0.80 0.0047 0.0368 
Citrulline Urea cycle, Arginine and Proline 
Metabolism 
Amino Acid 0.80 0.0213 0.0887 
Gamma-Glutamylleucine Gamma-glutamyl Amino Acid Peptide 0.80 0.0257 0.0925 
N1-Methylinosine Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide 0.79 0.0275 0.0967 
Indole-3-Carboxylic acid Tryptophan Metabolism Amino Acid 0.74 0.0086 0.0526 




Gamma-Glutamyl-Alpha-Lysine Gamma-glutamyl Amino Acid Peptide 0.72 0.0180 0.0784 
Picolinate Tryptophan Metabolism Amino Acid 0.69 0.0047 0.0368 
2'-Deoxyuridine Pyrimidine Metabolism, Uracil containing Nucleotide 0.69 0.0251 0.0925 
1-Methylnicotinamide Nicotinate and Nicotinamide Metabolism Cofactors and Vitamins 0.68 0.0239 0.0918 
5-Methyluridine (Ribothymidine) Pyrimidine Metabolism, Uracil containing Nucleotide 0.66 0.0037 0.0324 
Xanthurenate Tryptophan Metabolism Amino Acid 0.66 0.0152 0.0719 
N-Acetyltyrosine Tyrosine Metabolism Amino Acid 0.62 0.0053 0.0391 
N1-Methyl-4-Pyridone-3-Carboxamide Nicotinate and Nicotinamide Metabolism Cofactors and Vitamins 0.60 0.0286 0.0988 
N1-Methyl-2-Pyridone-5-Carboxamide Nicotinate and Nicotinamide Metabolism Cofactors and Vitamins 0.56 0.0110 0.0583 
1-Stearoyl-Gpi (18:0) Lysophospholipid Lipid 0.54 0.0170 0.0759 
Isoleucylglycine Dipeptide Peptide 0.51 0.0003 0.0081 
N-Acetylkynurenine Tryptophan Metabolism Amino Acid 0.51 0.0119 0.0611 
N-Acetyl-2-Aminooctanoate Fatty Acid, Amino Lipid 0.47 0.0110 0.0583 
Cholate Primary Bile Acid Metabolism Lipid 0.44 0.0221 0.0898 
Valylglycine Dipeptide Peptide 0.38 0.0003 0.0081 
3-Dehydrocholate Secondary Bile Acid Metabolism Lipid 0.29 0.0001 0.0065 
Palmitoylcholine Fatty Acid Metabolism (Acyl Choline) Lipid 0.18 0.0093 0.0554 





Table 2.4: Fold-change in maternal (intervillous) plasma (VM/EM) for metabolites (xenobiotics excluded) with significant p (≤0.05) and q 
(≤0.10), ordered according to fold-change (greatest to smallest), with corresponding sub-pathway and super-pathway. 
Metabolite Sub-Pathway Super-Pathway Fold-
change             
(VM/EM) 
p-value q-value 
Glucuronide Of C10H18O2 Partially Characterized Molecules Partially Characterized Molecules 10.85 0.0113 0.053 
Maleate Fatty Acid, Dicarboxylate Lipid 10.42 0.0359 0.0857 
Adipate (C6-Dc) Fatty Acid, Dicarboxylate Lipid 8.06 0.0178 0.0625 
N-Acetylaspartate (Naa) Alanine and Aspartate Metabolism Amino Acid 7.14 0.0007 0.0113 
Caproate (6:0) Medium Chain Fatty Acid Lipid 6.71 0.012 0.0539 
Glucuronide Of C10H18O2 Partially Characterized Molecules Partially Characterized Molecules 6.44 0.0267 0.0759 
Corticosterone Corticosteroids Lipid 5.41 0.0001 0.0076 
Cortisol Corticosteroids Lipid 5.02 0.0003 0.0079 
1-Oleoylglycerol (18:1) Monoacylglycerol Lipid 4.49 0.0069 0.0417 
Arachidoylcarnitine (C20) Fatty Acid Metabolism (Acyl Carnitine) Lipid 4.24 0.0128 0.0559 
Androsterone Sulfate Androgenic Steroids Lipid 3.99 0.0042 0.0325 
Epiandrosterone Sulfate Androgenic Steroids Lipid 3.7 0.0132 0.0565 
Androstenediol (3Alpha, 17Alpha) 
Monosulfate 
Androgenic Steroids Lipid 3.45 0.0089 0.0476 




12-Hete Eicosanoid Lipid 3.21 0.0053 0.0357 
5Alpha-Androstan-3Beta,17Beta-
Diol Disulfate 
Androgenic Steroids Lipid 3.09 0.0347 0.0839 
Oleoyl-Linoleoyl-Glycerol 
(18:1/18:2) 
Diacylglycerol Lipid 2.93 0.0407 0.0919 
9,10-Dihome Fatty Acid, Dihydroxy Lipid 2.9 0.0091 0.0476 
Lactosyl-N-Nervonoyl-Sphingosine 
(D18:1/24:1) 
Ceramides Lipid 2.83 0.0024 0.0261 
1-Stearoyl-2-Oleoyl-Gpe (18:0/18:1) Phosphatidylethanolamine (PE) Lipid 2.81 0.0211 0.0693 
Androsterone Glucuronide Androgenic Steroids Lipid 2.74 0.0138 0.0565 
1-Linoleoyl-Gpi (18:2) Lysophospholipid Lipid 2.72 0.0005 0.0109 
Palmitoleoyl-Linoleoyl-Glycerol 
(16:1/18:2) 
Diacylglycerol Lipid 2.7 0.0358 0.0857 
3-Methyladipate Fatty Acid, Dicarboxylate Lipid 2.68 0.0295 0.078 
Eicosenoylcarnitine (C20:1) Fatty Acid Metabolism (Acyl Carnitine) Lipid 2.58 0.0003 0.0079 
Erucate (22:1N9) Long Chain Fatty Acid Lipid 2.58 0.001 0.0144 
P-Cresol-Glucuronide Tyrosine Metabolism Amino Acid 2.57 0.0461 0.0942 
Palmitoyl-Linoleoyl-Glycerol 
(16:0/18:2) 
Diacylglycerol Lipid 2.57 0.0265 0.0759 
Oleoyl-Linoleoyl-Glycerol 
(18:1/18:2) 




2-Hydroxybehenate Fatty Acid, Monohydroxy Lipid 2.49 0.0304 0.0792 
Oleoyl-Oleoyl-Glycerol (18:1/18:1) Diacylglycerol Lipid 2.47 0.0449 0.0934 
Pristanate Fatty Acid, Branched Lipid 2.45 0.0439 0.0934 
Xanthosine Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide 2.4 0.0171 0.0615 
Oleoyl-Oleoyl-Glycerol (18:1/18:1) Diacylglycerol Lipid 2.38 0.0066 0.0414 
Maltose Glycogen Metabolism Carbohydrate 2.36 0.0178 0.0625 
Lignoceroylcarnitine (C24) Fatty Acid Metabolism (Acyl Carnitine) Lipid 2.35 0.0044 0.0338 
Ribulonate/Xylulonate Pentose Metabolism Carbohydrate 2.34 0.0003 0.0079 
5Alpha-Pregnan-3Beta,20Alpha-Diol 
Monosulfate (1) 
Progestin Steroids Lipid 2.31 0.0049 0.0353 
12,13-Dihome Fatty Acid, Dihydroxy Lipid 2.31 0.043 0.0934 
Fructose Fructose, Mannose and Galactose 
Metabolism 
Carbohydrate 2.28 0.0326 0.0809 
Diacylglycerol (16:1/18:2, 
16:0/18:3) 
Diacylglycerol Lipid 2.26 0.0094 0.0477 
Ximenoylcarnitine (C26:1) Fatty Acid Metabolism (Acyl Carnitine) Lipid 2.25 0.0025 0.0261 
5Alpha-Pregnan-3Beta,20Alpha-Diol 
Monosulfate (2) 
Progestin Steroids Lipid 2.25 0.0039 0.0318 




Diacylglycerol (12:0/18:1, 14:0/16:1, 
16:0/14:1) 
Diacylglycerol Lipid 2.21 0.0424 0.0934 
Campesterol Sterol Lipid 2.18 0.0113 0.053 
1-Palmitoyl-2-Oleoyl-Gpe 
(16:0/18:1) 
Phosphatidylethanolamine (PE) Lipid 2.18 0.0225 0.0728 
Dihomo-Linoleoylcarnitine (C20:2) Fatty Acid Metabolism (Acyl Carnitine) Lipid 2.17 0.0307 0.0792 
Laurate (12:0) Medium Chain Fatty Acid Lipid 2.16 0.0001 0.0065 
5Alpha-Pregnan-3Beta,20Beta-Diol 
Monosulfate (1) 
Progestin Steroids Lipid 2.13 0.0053 0.0357 
Palmitoyl-Oleoyl-Glycerol 
(16:0/18:1) 
Diacylglycerol Lipid 2.12 0.0168 0.0614 
13-Hode + 9-Hode Fatty Acid, Monohydroxy Lipid 2.11 0.0146 0.057 
5,6-Dihydrouracil Pyrimidine Metabolism, Uracil 
containing 
Nucleotide 2.06 0.0278 0.076 
Alpha-Ketoglutarate TCA Cycle Energy 2.05 0.0106 0.0517 
3Beta-Hydroxy-5-Cholestenoate Sterol Lipid 2.03 0.0147 0.057 
1-Stearoyl-2-Docosahexaenoyl-Gpe 
(18:0/22:6) 
Phosphatidylethanolamine (PE) Lipid 2.03 0.0363 0.0858 
Behenate (22:0) Long Chain Fatty Acid Lipid 2 0.003 0.0271 
Diacylglycerol (14:0/18:1, 
16:0/16:1) 




Pyruvate Glycolysis, Gluconeogenesis, and 
Pyruvate Metabolism 
Carbohydrate 1.98 0.0002 0.0079 
1-Palmitoleoyl-2-Linolenoyl-Gpc 
(16:1/18:3) 
Phosphatidylcholine (PC) Lipid 1.98 0.0323 0.0809 
Lactate Glycolysis, Gluconeogenesis, and 
Pyruvate Metabolism 
Carbohydrate 1.96 0 0.0015 
Myristoyl-Linoleoyl-Glycerol 
(14:0/18:2) 
Diacylglycerol Lipid 1.96 0.0138 0.0565 
Lactosyl-N-Palmitoyl-Sphingosine 
(D18:1/16:0) 
Ceramides Lipid 1.93 0.0013 0.0177 
10-Nonadecenoate (19:1N9) Long Chain Fatty Acid Lipid 1.92 0.0051 0.0357 
Glycerol Glycerolipid Metabolism Lipid 1.91 0.0002 0.0079 
Ceramide (D18:1/17:0, D17:1/18:0) Ceramides Lipid 1.88 0.0443 0.0934 
Cystine Methionine, Cysteine, SAM and Taurine 
Metabolism 
Amino Acid 1.87 0.0054 0.0357 
10-Heptadecenoate (17:1N7) Long Chain Fatty Acid Lipid 1.87 0.0027 0.0265 
Decanoylcarnitine (C10) Fatty Acid Metabolism (Acyl Carnitine) Lipid 1.86 0.0006 0.0113 
Lactosyl-N-Behenoyl-Sphingosine 
(D18:1/22:0) 
Sphingolipid Metabolism Lipid 1.86 0.0311 0.0797 
2,3-Dihydroxy-2-Methylbutyrate Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid 1.84 0.0211 0.0693 






Phosphatidylethanolamine (PE) Lipid 1.83 0.0332 0.0811 
Nervonate (24:1N9) Long Chain Fatty Acid Lipid 1.81 0.0015 0.0195 
Margarate (17:0) Long Chain Fatty Acid Lipid 1.81 0.0026 0.0261 
Linolenate [Alpha Or Gamma; 
(18:3N3 Or 6)] 
Polyunsaturated Fatty Acid (n3 and n6) Lipid 1.8 0.0145 0.057 
Tricosanoyl Sphingomyelin 
(D18:1/23:0) 
Sphingolipid Metabolism Lipid 1.8 0.0241 0.074 
Laurylcarnitine (C12) Fatty Acid Metabolism (Acyl Carnitine) Lipid 1.78 0.0009 0.0144 
Dihomo-Linoleate (20:2N6) Polyunsaturated Fatty Acid (n3 and n6) Lipid 1.78 0.0048 0.0353 
Palmitoleate (16:1N7) Long Chain Fatty Acid Lipid 1.78 0.0084 0.0461 
N-Stearoyl-Sphingosine 
(D18:1/18:0) 
Ceramides Lipid 1.78 0.009 0.0476 
1-Palmitoleoyl-2-Linoleoyl-Gpc 
(16:1/18:2) 
Phosphatidylcholine (PC) Lipid 1.78 0.0116 0.0532 
Caprylate (8:0) Medium Chain Fatty Acid Lipid 1.78 0.0236 0.0734 
5-Dodecenoate (12:1N7) Medium Chain Fatty Acid Lipid 1.78 0.0244 0.0745 
Hexadecadienoate (16:2N6) Polyunsaturated Fatty Acid (n3 and n6) Lipid 1.78 0.0321 0.0809 
1-Stearoyl-Gpi (18:0) Lysophospholipid Lipid 1.76 0.0031 0.0273 
Cholesterol Sterol Lipid 1.76 0.0049 0.0353 




Docosapentaenoate (N3 Dpa; 
22:5N3) 
Polyunsaturated Fatty Acid (n3 and n6) Lipid 1.74 0.0026 0.0261 
Sphingomyelin (D18:2/23:0, 
D18:1/23:1, D17:1/24:1) 
Sphingolipid Metabolism Lipid 1.74 0.0056 0.0362 
1-Palmitoyl-Gpi (16:0) Lysophospholipid Lipid 1.74 0.0166 0.061 
Caprate (10:0) Medium Chain Fatty Acid Lipid 1.74 0.0389 0.09 
N-Stearoyl-Sphingadienine 
(D18:2/18:0) 
Ceramides Lipid 1.73 0.0087 0.0471 
Nonadecanoate (19:0) Long Chain Fatty Acid Lipid 1.71 0.001 0.0148 
Sphingomyelin (D18:1/21:0, 
D17:1/22:0, D16:1/23:0) 
Sphingolipid Metabolism Lipid 1.71 0.0162 0.0601 
17-Methylstearate (I19:0) Fatty Acid, Branched Lipid 1.7 0.0003 0.0079 
Oleate/Vaccenate (18:1) Long Chain Fatty Acid Lipid 1.7 0.0041 0.0325 
15-Methylpalmitate (I17:0) Fatty Acid, Branched Lipid 1.7 0.005 0.0356 
Oleoylcarnitine (C18:1) Fatty Acid Metabolism (Acyl Carnitine) Lipid 1.7 0.0068 0.0416 
Glycosyl-N-Behenoyl-
Sphingadienine (D18:2/22:0) 
Ceramides Lipid 1.69 0.0449 0.0934 
13-Methylmyristate (I15:0) Fatty Acid, Branched Lipid 1.67 0.0076 0.0435 
Linoleate (18:2N6) Polyunsaturated Fatty Acid (n3 and n6) Lipid 1.67 0.0104 0.0513 
Carotene Diol Vitamin A Metabolism Cofactors and Vitamins 1.66 0.027 0.076 




Arachidate (20:0) Long Chain Fatty Acid Lipid 1.66 0.0037 0.0318 
Myristate (14:0) Long Chain Fatty Acid Lipid 1.65 0.0141 0.0565 
1-(1-Enyl-Palmitoyl)-2-Linoleoyl-Gpc 
(P-16:0/18:2) 
Plasmalogen Lipid 1.65 0.014 0.0565 
1-Stearoyl-2-Arachidonoyl-Gpe 
(18:0/20:4) 
Phosphatidylethanolamine (PE) Lipid 1.65 0.0207 0.0693 
Pregnanediol-3-Glucuronide Progestin Steroids Lipid 1.65 0.045 0.0934 
Imidazole Lactate Histidine Metabolism Amino Acid 1.64 0.0115 0.0532 
1-Myristoyl-2-Arachidonoyl-Gpc 
(14:0/20:4) 
Phosphatidylcholine (PC) Lipid 1.64 0.0201 0.0685 
Oleoyl-Arachidonoyl-Glycerol 
(18:1/20:4) 
Diacylglycerol Lipid 1.64 0.0283 0.076 
Carotene Diol Vitamin A Metabolism Cofactors and Vitamins 1.63 0.0266 0.0759 
3-Hydroxylaurate Fatty Acid, Monohydroxy Lipid 1.63 0.0274 0.076 
Ceramide (D18:1/20:0, D16:1/22:0, 
D20:1/18:0) 
Ceramides Lipid 1.61 0.033 0.0811 
N-Behenoyl-Sphingadienine 
(D18:2/22:0) 
Sphingolipid Metabolism Lipid 1.61 0.0435 0.0934 
Glycosyl Ceramide (D18:1/20:0, 
D16:1/22:0) 
Ceramides Lipid 1.61 0.0457 0.0942 
1-Palmitoyl-2-Arachidonoyl-Gpe 
(16:0/20:4) 






Sphingolipid Metabolism Lipid 1.56 0.0007 0.0113 
Sphingomyelin (D18:1/19:0, 
D19:1/18:0) 
Sphingolipid Metabolism Lipid 1.56 0.0006 0.0113 
Octanoylcarnitine (C8) Fatty Acid Metabolism (Acyl Carnitine) Lipid 1.56 0.0281 0.076 
Glycosyl-N-Stearoyl-Sphingosine 
(D18:1/18:0) 
Ceramides Lipid 1.55 0.0464 0.0942 
Pentadecanoate (15:0) Long Chain Fatty Acid Lipid 1.54 0.0029 0.027 
Ceramide (D18:2/24:1, D18:1/24:2) Ceramides Lipid 1.53 0.0397 0.091 
5Alpha-Pregnan-3Beta-Ol,20-One 
Sulfate 
Progestin Steroids Lipid 1.52 0.0405 0.0919 
Sphingomyelin (D17:2/16:0, 
D18:2/15:0) 
Sphingolipid Metabolism Lipid 1.51 0.0254 0.075 
Glycosyl-N-Palmitoyl-Sphingosine 
(D18:1/16:0) 
Ceramides Lipid 1.51 0.0305 0.0792 
N-Palmitoyl-Sphinganine 
(D18:0/16:0) 
Sphingolipid Metabolism Lipid 1.51 0.0447 0.0934 
2-Hydroxynervonate Fatty Acid, Monohydroxy Lipid 1.5 0.0111 0.0529 
Ceramide (D16:1/24:1, D18:1/22:1) Ceramides Lipid 1.5 0.0429 0.0934 
Beta-Hydroxyisovalerate Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid 1.49 0.0252 0.075 






Phosphatidylcholine (PC) Lipid 1.46 0.0287 0.0766 
4-Hydroxy-2-Oxoglutaric Acid Fatty Acid, Dicarboxylate Lipid 1.46 0.0325 0.0809 
Stearate (18:0) Long Chain Fatty Acid Lipid 1.45 0.0022 0.0259 
Palmitate (16:0) Long Chain Fatty Acid Lipid 1.45 0.0084 0.0461 
Cis-4-Decenoylcarnitine (C10:1) Fatty Acid Metabolism (Acyl Carnitine) Lipid 1.45 0.0161 0.0601 
3-Hydroxy-2-Ethylpropionate Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid 1.44 0.0003 0.0079 
Glucose Glycolysis, Gluconeogenesis, and 
Pyruvate Metabolism 
Carbohydrate 1.44 0.0025 0.0261 
Alpha-Tocopherol Tocopherol Metabolism Cofactors and Vitamins 1.41 0.0219 0.0714 
Sphingomyelin (D18:2/14:0, 
D18:1/14:1) 
Sphingolipid Metabolism Lipid 1.41 0.014 0.0565 
1-Palmitoyl-2-Gamma-Linolenoyl-
Gpc (16:0/18:3N6) 
Phosphatidylcholine (PC) Lipid 1.41 0.0204 0.0688 
1-Linoleoyl-2-Arachidonoyl-Gpc 
(18:2/20:4N6) 
Phosphatidylcholine (PC) Lipid 1.39 0.0363 0.0858 
Thyroxine Tyrosine Metabolism Amino Acid 1.38 0.015 0.0572 
1-Stearoyl-2-Arachidonoyl-Gpi 
(18:0/20:4) 
Phosphatidylinositol (PI) Lipid 1.37 0.043 0.0934 
Sphingomyelin (D18:2/18:1) Sphingolipid Metabolism Lipid 1.36 0.002 0.024 






Sphingolipid Metabolism Lipid 1.34 0.0134 0.0565 
Behenoyl Sphingomyelin 
(D18:1/22:0) 
Sphingolipid Metabolism Lipid 1.33 0.0237 0.0734 
1-Stearoyl-2-Linoleoyl-Gpc 
(18:0/18:2) 
Phosphatidylcholine (PC) Lipid 1.33 0.0325 0.0809 
Lignoceroyl Sphingomyelin 
(D18:1/24:0) 
Sphingolipid Metabolism Lipid 1.32 0.017 0.0615 
Sphingomyelin (D18:2/23:1) Sphingolipid Metabolism Lipid 1.3 0.0039 0.0318 
1-Palmitoyl-2-Oleoyl-Gpc 
(16:0/18:1) 
Phosphatidylcholine (PC) Lipid 1.28 0.0013 0.0177 
Sphingomyelin (D18:1/24:1, 
D18:2/24:0) 
Sphingolipid Metabolism Lipid 1.28 0.0028 0.027 
Sphingomyelin (D18:1/14:0, 
D16:1/16:0) 
Sphingolipid Metabolism Lipid 1.27 0.0124 0.0547 
Sphingomyelin (D18:1/17:0, 
D17:1/18:0, D19:1/16:0) 
Sphingolipid Metabolism Lipid 1.24 0.004 0.0318 
1-Oleoyl-2-Docosahexaenoyl-Gpc 
(18:1/22:6) 
Phosphatidylcholine (PC) Lipid 1.24 0.0066 0.0414 
Palmitoyl Sphingomyelin 
(D18:1/16:0) 
Sphingolipid Metabolism Lipid 1.23 0.0138 0.0565 
3-Methyl-2-Oxobutyrate Leucine, Isoleucine and Valine 
Metabolism 






Sphingolipid Metabolism Lipid 1.21 0.0331 0.0811 
Citrate TCA Cycle Energy 1.2 0.0249 0.0749 
Sphingomyelin (D18:1/20:0, 
D16:1/22:0) 
Sphingolipid Metabolism Lipid 1.2 0.0254 0.075 
Palmitoyl Ethanolamide Endocannabinoid Lipid 1.19 0.0093 0.0477 
Sphingomyelin (D18:2/24:1, 
D18:1/24:2) 
Sphingolipid Metabolism Lipid 1.14 0.0073 0.0424 
1-Palmitoyl-2-Palmitoleoyl-Gpc 
(16:0/16:1) 
Phosphatidylcholine (PC) Lipid 1.14 0.04 0.0912 
Arginine Urea cycle; Arginine and Proline 
Metabolism 
Amino Acid 0.8 0.0444 0.0934 
Trans-4-Hydroxyproline Urea cycle; Arginine and Proline 
Metabolism 
Amino Acid 0.77 0.0289 0.0768 
Histidine Histidine Metabolism Amino Acid 0.76 0.0156 0.0587 
Serine Glycine, Serine and Threonine 
Metabolism 
Amino Acid 0.75 0.0201 0.0685 
Citrulline Urea cycle; Arginine and Proline 
Metabolism 
Amino Acid 0.73 0.0081 0.0457 
Threonine Glycine, Serine and Threonine 
Metabolism 
Amino Acid 0.72 0.0275 0.076 
Ornithine Urea cycle; Arginine and Proline 
Metabolism 




Tryptophan Tryptophan Metabolism Amino Acid 0.69 0.0493 0.0997 
Indole-3-Carboxylic Acid Tryptophan Metabolism Amino Acid 0.66 0.0078 0.0445 
Tetradecanedioate (C14-Dc) Fatty Acid, Dicarboxylate Lipid 0.66 0.0281 0.076 
Lysine Lysine Metabolism Amino Acid 0.64 0.0053 0.0357 
S-1-Pyrroline-5-Carboxylate Glutamate Metabolism Amino Acid 0.63 0.0393 0.0905 
Picolinate Tryptophan Metabolism Amino Acid 0.61 0.0135 0.0565 
Hexadecenedioate (C16:1-Dc) Fatty Acid, Dicarboxylate Lipid 0.61 0.0098 0.0491 
Gamma-Glutamyl-Alpha-Lysine Gamma-glutamyl Amino Acid Peptide 0.59 0.0039 0.0318 
Indolebutyrate Tryptophan Metabolism Amino Acid 0.58 0.0444 0.0934 
5-Methyluridine (Ribothymidine) Pyrimidine Metabolism, Uracil 
containing 
Nucleotide 0.58 0.0005 0.0104 
Bilirubin (Z,Z) Hemoglobin and Porphyrin Metabolism Cofactors and Vitamins 0.57 0.015 0.0572 
N-Palmitoylserine Endocannabinoid Lipid 0.56 0.0419 0.0934 
Homoarginine Urea cycle; Arginine and Proline 
Metabolism 
Amino Acid 0.51 0.021 0.0693 
Phosphoethanolamine Phospholipid Metabolism Lipid 0.5 0.0255 0.075 
Glycohyocholate Secondary Bile Acid Metabolism Lipid 0.5 0.0443 0.0934 
Bilirubin (E,Z Or Z,E) Hemoglobin and Porphyrin Metabolism Cofactors and Vitamins 0.46 0.0261 0.0759 






Androgenic Steroids Lipid 0.37 0.0422 0.0934 
Pyridoxal Vitamin B6 Metabolism Cofactors and Vitamins 0.34 0.0453 0.0937 
Adenosine Purine Metabolism, Adenine containing Nucleotide 0.33 0.0228 0.0731 
Oestriol 3-Sulfate Estrogenic Steroids Lipid 0.32 0.0189 0.0657 
17Alpha-Hydroxypregnenolone 3-
Sulfate 
Pregnenolone Steroids Lipid 0.31 0.0266 0.0759 
Androstenediol (3Beta,17Beta) 
Disulfate (1) 
Androgenic Steroids Lipid 0.31 0.0464 0.0942 
N-Acetylkynurenine Tryptophan Metabolism Amino Acid 0.3 0.0145 0.057 
21-Hydroxypregnenolone 
Monosulfate 
Pregnenolone Steroids Lipid 0.3 0.0278 0.076 
N-Acetyl-2-Aminooctanoate Fatty Acid, Amino Lipid 0.27 0.0031 0.0273 
Andro Steroid Monosulfate 
C19H28O6S 
Androgenic Steroids Lipid 0.26 0.0174 0.0619 
16A-Hydroxy Dhea 3-Sulfate Androgenic Steroids Lipid 0.22 0.0071 0.042 





Metronidazole is given to all non-allergic women having elective caesarean 
sections at St Michael’s Hospital, and in this case all ten women included who 
had an elective caesarean section were administered it at the time of knife-to-
skin, while none of the women included who laboured and went on to have a 
vaginal delivery received it, and this was reflected in the results.  There were 
significant increases in both maternal and cord plasma of the following 
analgesics: 4-acetamidophenol, 3-(N-acetyl-L-cystein-S-yl) acetaminophen, 4-
acetaminophen sulfate, 4-acetamidophenylglucuronide, 2-
hydroxyacetaminophen sulfate, 2-methoxyacetaminophen sulfate, 2-
methoxyacetaminophen glucuronide, 3-(cystein-S-yl) acetaminophen and 
ibuprofen. There was a large increase of triethanolamine in cord and maternal 
blood from women who were delivered vaginally. Ranitidine was significantly 
decreased in cord plasma of labouring vs non-labouring women, but there were 
no changes in maternal plasma. Ranitidine is given to all women who have an 
elective caesarean section to take the night before and then the morning of the 
operation. For women in labour ranitidine is given if they have an epidural when 
they are in active labour. This may explain the difference observed in these 




Table 2.5: Fold-change in cord plasma (VC/EC) for xenobiotics with significant p (≤0.05) and q (≤0.10), ordered according to fold-change (greatest 
to smallest), with corresponding sub-pathway and super-pathway (of note, the fold-change for Metronidazole is recorded as 0 as there was 0 quantity 
recorded in the VC group, however the p-value is the smallest). 
Metabolite Sub-Pathway Super-Pathway Fold-change             (VC/EC) p-value q-value 
Triethanolamine Chemical Xenobiotics 39.65 0.0028 0.0298 
4-Acetamidophenol Drug - Analgesics, Anesthetics Xenobiotics 16.03 0.0000 0.0031 
4-Acetaminophen Sulfate Drug - Analgesics, Anesthetics Xenobiotics 7.73 0.0004 0.0093 
4-Acetamidophenylglucuronide Drug - Analgesics, Anesthetics Xenobiotics 5.60 0.0003 0.0093 
2-Hydroxyacetaminophen Sulfate Drug - Analgesics, Anesthetics Xenobiotics 5.60 0.0005 0.0100 
2-Methoxyacetaminophen Sulfate Drug - Analgesics, Anesthetics Xenobiotics 5.09 0.0002 0.0081 
2-Methoxyacetaminophen Glucuronide Drug - Analgesics, Anesthetics Xenobiotics 4.13 0.0004 0.0093 
3-(Cystein-S-Yl) Acetaminophen Drug - Analgesics, Anesthetics Xenobiotics 3.99 0.0005 0.0099 
3-(N-Acetyl-L-Cystein-S-Yl) Acetaminophen Drug - Analgesics, Anesthetics Xenobiotics 3.71 0.0087 0.0526 
Ibuprofen Drug - Analgesics, Anesthetics Xenobiotics 2.71 0.0011 0.0146 
Benzoate Benzoate Metabolism Xenobiotics 2.26 0.0158 0.0734 
Ranitidine Drug - Gastrointestinal Xenobiotics 0.54 0.0059 0.0413 
Acesulfame Food Component/Plant Xenobiotics 0.31 0.0061 0.0424 
Saccharin Food Component/Plant Xenobiotics 0.04 0.0000 0.0000 





Table 2.6: Fold-change in maternal (intervillous) plasma (VM/EM) for xenobiotics with significant p (≤0.05) and q (≤0.10),  ordered according to 
fold-change (greatest to smallest) (of note, the fold-change for Metronidazole is recorded as 0 as there was 0 quantity recorded in the VC group, however 
the p-value is the smallest). 
Metabolite Sub-Pathway Super-Pathway Fold-change (VM/EM) p-value q-value 
Triethanolamine Chemical Xenobiotics 19.54 0.0121 0.0539 
4-Acetamidophenol Drug - Analgesics, Anesthetics Xenobiotics 18.20 0.0000 0.0039 
3-(Cystein-S-Yl) Acetaminophen Drug - Analgesics, Anesthetics Xenobiotics 10.15 0.0007 0.0113 
4-Acetaminophen Sulfate Drug - Analgesics, Anesthetics Xenobiotics 10.09 0.0002 0.0079 
2-Methoxyacetaminophen Sulfate Drug - Analgesics, Anesthetics Xenobiotics 9.91 0.0001 0.0066 
4-Acetamidophenylglucuronide Drug - Analgesics, Anesthetics Xenobiotics 8.84 0.0002 0.0078 
3-(N-Acetyl-L-Cystein-S-Yl) Acetaminophen Drug - Analgesics, Anesthetics Xenobiotics 8.27 0.0070 0.0417 
2-Hydroxyacetaminophen Sulfate Drug - Analgesics, Anesthetics Xenobiotics 8.06 0.0003 0.0079 
2-Methoxyacetaminophen Glucuronide Drug - Analgesics, Anesthetics Xenobiotics 7.39 0.0001 0.0070 
4-Hydroxybenzoate Benzoate Metabolism Xenobiotics 6.14 0.0107 0.0517 
Morphine-6-Glucuronide Drug - Analgesics, Anesthetics Xenobiotics 3.91 0.0370 0.0870 
Morphine-3-Glucuronide Drug - Analgesics, Anesthetics Xenobiotics 3.05 0.0380 0.0885 
Ibuprofen Drug - Analgesics, Anesthetics Xenobiotics 2.90 0.0004 0.0082 
Benzoate Benzoate Metabolism Xenobiotics 2.78 0.0444 0.0934 




Phytanate Food Component/Plant Xenobiotics 2.51 0.0025 0.0261 
3-Methylxanthine Xanthine Metabolism Xenobiotics 2.19 0.0233 0.0734 
7-Methylxanthine Xanthine Metabolism Xenobiotics 1.78 0.0247 0.0748 
Umbelliferone Sulfate Food Component/Plant Xenobiotics 0.32 0.0376 0.0878 
Saccharin Food Component/Plant Xenobiotics 0.14 0.0007 0.0113 




2.9.6 Lipid super-pathway 
The lipid super-pathway contained the most differences between labouring and 
non-labouring women (Figure 2.2 and Table 2.2). Most of these changes were 
significant increases in maternal plasma (VM/EM). 405 metabolites were 
identified in this super-pathway: 34.3% (139/405) of the metabolites 
significantly increased and 3.5% (14/405) significantly decreased in the maternal 
plasma of women who laboured when compared to non-labour; 
correspondingly, 18.0% (73/405) of the metabolites significantly increased in the 
cord plasma of women who laboured, and 3.0% (12/405) significantly decreased. 
Of note, 22 sphingolipids (Table 2.7) significantly increased in maternal plasma 
of labouring women with only one corresponding increase found in cord plasma; 
whereas the sub-pathway with the most significant changes seen in the cord 
plasma within the lipid super-pathway were fatty acid metabolism (acyl 
carnitine), long chain fatty acids and polyunsaturated fatty acids (Figure 2.2). 
There were significant increases in the medium and long chain fatty acids in both 
cord and maternal plasma and there were selective changes in the maternal and 
fetal circulation for acyl carnitines, acyl cholines, and eicosanoids (12-HETE and 






Table 2.7: Fold-change in cord plasma (VC/EC) and maternal (intervillous) plasma (VM/EM) for sphingolipids, with corresponding p and q values 
(significant when p≤0.05 and q≤0.10). 
Sphingolipid Fold-change             
(VC/EC) 
p-value q-value Fold-change             
(VM/EM) 
p-value q-value 
Sphinganine 1.54 NS 0.3393 1.28 NS 0.362 
Sphinganine-1-Phosphate 1.28 NS 0.2858 1.53 NS 0.197 
N-Palmitoyl-Sphinganine (D18:0/16:0) 1.42 NS 0.1602 1.51 0.045 0.093 
N-Palmitoyl-Sphingadienine (D18:2/16:0) 1.21 NS 0.494 1.28 NS 0.213 
N-Behenoyl-Sphingadienine (D18:2/22:0) 1.06 NS 0.5461 1.61 0.044 0.093 
Myristoyl Dihydrosphingomyelin (D18:0/14:0) 1.17 NS 0.216 1.02 NS 0.498 
Palmitoyl Dihydrosphingomyelin (D18:0/16:0) 1.04 NS 0.4674 0.98 NS 0.452 
Behenoyl Dihydrosphingomyelin (D18:0/22:0) 1.06 NS 0.5635 0.9 NS 0.261 
Palmitoyl Sphingomyelin (D18:1/16:0) 1.06 NS 0.2737 1.23 0.014 0.057 
Stearoyl Sphingomyelin (D18:1/18:0) 0.9 NS 0.3165 1.02 NS 0.466 
Behenoyl Sphingomyelin (D18:1/22:0) 0.94 NS 0.4308 1.33 0.024 0.073 
Tricosanoyl Sphingomyelin (D18:1/23:0) 1.05 NS 0.5663 1.8 0.024 0.074 
Lignoceroyl Sphingomyelin (D18:1/24:0) 1.06 NS 0.5133 1.32 0.017 0.062 
Sphingomyelin (D18:1/14:0, D16:1/16:0) 1.05 NS 0.4497 1.27 0.012 0.055 
Sphingomyelin (D18:2/14:0, D18:1/14:1) 1.08 NS 0.4942 1.41 0.014 0.057 




Sphingomyelin (D18:2/16:0, D18:1/16:1) 1.03 NS 0.5712 1.09 NS 0.118 
Sphingomyelin (D18:1/17:0, D17:1/18:0, D19:1/16:0) 1.09 NS 0.3643 1.24 0.004 0.032 
Sphingomyelin (D18:1/18:1, D18:2/18:0) 0.98 NS 0.5218 0.88 NS 0.335 
Sphingomyelin (D18:1/20:0, D16:1/22:0) 0.92 NS 0.3642 1.2 0.025 0.075 
Sphingomyelin (D18:1/20:1, D18:2/20:0) 0.93 NS 0.4066 0.91 NS 0.388 
Sphingomyelin (D18:1/21:0, D17:1/22:0, D16:1/23:0) 1.14 NS 0.4942 1.71 0.016 0.06 
Sphingomyelin (D18:1/22:1, D18:2/22:0, D16:1/24:1) 1 NS 0.5663 1.09 NS 0.351 
Sphingomyelin (D18:2/23:0, D18:1/23:1, D17:1/24:1) 1.28 NS 0.1998 1.74 0.006 0.036 
Sphingomyelin (D18:1/24:1, D18:2/24:0) 1.06 NS 0.4865 1.28 0.003 0.027 
Sphingomyelin (D18:2/24:1, D18:1/24:2) 1 NS 0.579 1.14 0.007 0.042 
Sphingosine 1.83 NS 0.1642 0.98 NS 0.539 
Sphingosine 1-Phosphate 1.27 NS 0.1783 1.38 NS 0.109 
Sphingomyelin (D18:2/23:1) 1.12 NS 0.3657 1.3 0.004 0.032 
Sphingomyelin (D18:2/21:0, D16:2/23:0) 1.23 NS 0.2532 1.56 0.001 0.011 
Sphingomyelin (D18:1/20:2, D18:2/20:1, D16:1/22:2) 1.06 NS 0.5133 1.18 NS 0.208 
Sphingomyelin (D18:2/24:2) 0.89 NS 0.2953 0.94 NS 0.468 
Sphingomyelin (D18:1/25:0, D19:0/24:1, D20:1/23:0, D19:1/24:0) 1.64 0.046 0.1299 1.14 NS 0.314 
Sphingomyelin (D18:1/22:2, D18:2/22:1, D16:1/24:2) 0.92 NS 0.3643 1.21 0.033 0.081 
Sphingomyelin (D18:0/20:0, D16:0/22:0) 1.16 NS 0.5509 0.92 NS 0.309 




Sphingomyelin (D17:2/16:0, D18:2/15:0) 1.09 NS 0.4276 1.51 0.025 0.075 
Sphingomyelin (D18:2/18:1) 1.07 NS 0.4308 1.36 0.002 0.024 
Sphingomyelin (D18:1/19:0, D19:1/18:0) 1.09 NS 0.4352 1.56 0.001 0.011 
N-Palmitoyl-Heptadecasphingosine (D17:1/16:0) 1.15 NS 0.4012 1.54 NS 0.188 
N-Stearoyl-Sphinganine (D18:0/18:0) 1.12 NS 0.5295 1.16 NS 0.49 
Sphingadienine 1.35 NS 0.5274 0.58 NS 0.264 















Table 2.8: Fold-change in cord plasma (VC/EC) and maternal (intervillous) plasma (VM/EM) for pregnenolone steroids, with corresponding p and 
q values (significant when p≤0.05 and q≤0.10). 
Pregnenolone Steroids Fold-change (VC/EC) p-value q-value Fold-change             (VM/EM) p-value q-value 
Pregnenolone Sulfate 1.10 NS 0.5121 0.39 0.055 0.108 
17alpha-Hydroxypregnenolone 3-Sulfate 1.23 NS 0.5178 0.31 0.027 0.076 
17alpha-Hydroxypregnanolone Glucuronide 0.85 NS 0.2681 0.9 NS 0.435 
21-Hydroxypregnenolone Monosulfate  0.78 NS 0.2146 0.3 0.028 0.076 
21-Hydroxypregnenolone Disulfate 0.94 NS 0.5039 0.44 NS 0.15 
21-Hydroxypregnanolone Disulfate 1.12 NS 0.4033 1 NS 0.417 
Pregnen-Diol Disulfate C21H34O8S2 1.37 NS 0.5635 1.01 NS 0.47 












Table 2.9: Fold-change in cord plasma (VC/EC) and maternal (intervillous) plasma (VM/EM) for progestin steroids, with corresponding p and q values 
(significant when p≤0.05 and q≤0.10) 
Progestin Steroids Fold-change             
(VC/EC) 
p-value q-value Fold-change             
(VM/EM) 
p-value q-value 
Progesterone 1.42 NS 0.1545 1.38 NS 0.532 
5alpha-Pregnan-3beta-Ol,20-One Sulfate 1.11 NS 0.4856 1.52 0.041 0.092 
5alpha-Pregnan-3beta,20beta-Diol Monosulfate 1.34 NS 0.3011 2.13 0.005 0.036 
5alpha-Pregnan-3beta,20alpha-Diol Monosulfate 1 1.36 NS 0.2510 2.31 0.005 0.035 
5alpha-Pregnan-3beta,20alpha-Diol Monosulfate 2 1.52 NS 0.3514 2.25 0.004 0.032 
5alpha-Pregnan-3beta,20alpha-Diol Disulfate 1.12 NS 0.3907 1.34 NS 0.309 
5alpha-pregnan-diol disulfate 1.05 NS 0.4194 1.69 NS 0.3101 
5alpha-Pregnan-3alpha,20beta-Diol Disulfate  1.43 NS 0.1853 0.86 NS 0.314 
Pregnanediol-3-Glucuronide 0.95 NS 0.5413 1.65 0.045 0.093 








Table 2.10: Fold-change in cord plasma (VC/EC) and maternal (intervillous) plasma (VM/EM) for endocannabinoid steroids, with corresponding 
p and q values (significant when p≤0.05 and q≤0.10). 
Endocannabinoid Steroids Fold-change (VC/EC) p-value q-value Fold-change             
(VM/EM) 
p-value q-value 
Palmitoyl Ethanolamide (PEA) 1.19 0.0357 0.1158 1.19 0.009 0.048 
N-Palmitoylserine 0.93 NS 0.4460 0.56 0.042 0.093 
Oleoyl Ethanolamide (OEA) 1.31 0.0226 0.0904 1.39 NS 0.209 
Arachidonoyl Ethanolamide (AEA/Andamide) 1.48 0.0296 0.1015 1.25 NS 0.277 
Linoleoyl Ethanolamide 1.34 0.0707 0.1642 1.32 NS 0.226 
N-Stearoyltaurine 0.96 NS 0.5605 1.22 NS 0.413 
N-Palmitoyltaurine 0.97 NS 0.5321 0.81 NS 0.255 
N-Linoleoyltaurine 0.98 NS 0.5461 0.83 NS 0.196 










Table 2.11: Fold-change in cord plasma (VC/EC) and maternal (intervillous) plasma (VM/EM) for ceramides, with corresponding p and q values 
(significant when p≤0.05 and q≤0.10).
Ceramide Fold-change 
(VC/EC) 
p-value q-value Fold-change 
(VM/EM) 
p-value q-value 
N-Palmitoyl-Sphingosine (D18:1/16:0) 1.38 NS 0.1455 1.49 NS 0.135 
N-Stearoyl-Sphingosine (D18:1/18:0) 1.27 NS 0.351 1.78 0.009 0.048 
N-Stearoyl-Sphingadienine (D18:2/18:0) 1.49 NS 0.1491 1.73 0.009 0.047 
Ceramide (D16:1/24:1, D18:1/22:1) 1.26 NS 0.3228 1.5 0.043 0.093 
Ceramide (D18:1/14:0, D16:1/16:0) 1.28 NS 0.3303 1.53 NS 0.119 
Ceramide (D18:1/17:0, D17:1/18:0) 1.79 NS 0.195 1.88 0.044 0.093 
Ceramide (D18:1/20:0, D16:1/22:0, D20:1/18:0) 1.05 NS 0.5688 1.61 0.033 0.081 
Ceramide (D18:2/24:1, D18:1/24:2) 1.34 NS 0.2513 1.53 0.04 0.091 
Glycosyl-N-Palmitoyl-Sphingosine (D18:1/16:0) 1.35 NS 0.1674 1.51 0.031 0.079 
Glycosyl-N-Stearoyl-Sphingosine (D18:1/18:0) 1.21 NS 0.4308 1.55 0.046 0.094 
Glycosyl-N-Behenoyl-Sphingadienine (D18:2/22:0) 1.38 NS 0.4688 1.69 0.045 0.093 
Glycosyl-N-(2-Hydroxynervonoyl)-Sphingosine (D18:1/24:1(2OH)) 0.57 NS 0.5276 1.99 NS 0.121 
Lactosyl-N-Palmitoyl-Sphingosine (D18:1/16:0) 1.73 NS 0.1461 1.93 0.001 0.018 
Lactosyl-N-Nervonoyl-Sphingosine (D18:1/24:1) 2.99 NS 0.1762 2.83 0.002 0.026 
Glycosyl Ceramide (D18:1/20:0, D16:1/22:0) 1.22 NS 0.5114 1.61 0.046 0.094 
Glycosyl Ceramide (D18:1/23:1, D17:1/24:1) 1.67 NS 0.3228 1.36 NS 0.324 
Glycosyl Ceramide (D18:2/24:1, D18:1/24:2) 1.33 NS 0.3755 1.5 NS 0.112 
Of the steroid metabolites, cholesterol was significantly increased in the maternal plasma of women who laboured (VM/EM) 
(Table 2.4) but did not change in the cord plasma (VC/EC). 17α-hydroxypregnenolone 3-sulfate and 21-




with no corresponding changes seen in the cord plasma (Table 2.8). There were 
significant increases in 5α-pregnan-3β-ol,20-one sulfate, 5α-pregnan-3β,20β-
diol monosulfate, 5α-pregnan-3β,20α-diol monosulfate, 5α-pregnan-3β,20α-
diol monosulfate and pregnanediol-3-glucuronide in maternal plasma, which 






Of the steroid metabolites, cholesterol was significantly increased in the 
maternal plasma of women who laboured (VM/EM) (Table 2.4) but did not 
change in the cord plasma (VC/EC). 17α-hydroxypregnenolone 3-sulfate and 21-
hydroxypregnenolone monosulfate were significantly decreased in the maternal 
plasma of women who laboured (VM/EM), with no corresponding changes seen 
in the cord plasma (Table 2.8). There were significant increases in 5α-pregnan-
3β-ol,20-one sulfate, 5α-pregnan-3β,20β-diol monosulfate, 5α-pregnan-
3β,20α-diol monosulfate, 5α-pregnan-3β,20α-diol monosulfate and 
pregnanediol-3-glucuronide in maternal plasma, which were not seen in the 
cord (Table 2.9).  
Of the endocannabinoid metabolites, three were significantly increased in the 
cord plasma of women who laboured when compared with those who did not 
(VC/EC); and one significantly increased, and one significantly decreased in the 
maternal plasma of women who laboured (VM/EM) (Table 2.10). Twelve of 
seventeen ceramide metabolites significantly increased in the maternal plasma 
(VM/EM), however there were no such significant differences seen in the cord 
plasma samples (VC/EC) (Table 2.11).  
Corticosterone significantly increased in maternal plasma (VM/EM) and in cord 
plasma (VC/EC) (5.41 and 3.09-fold, respectively) of women who laboured, and 






were also significant increases in cortisone and cortisone 21-sulfate in cord 
plasma but not in maternal plasma (Tables 2.3 and 2.4).  
Androstenediol (3β,17β) disulfate and andro steroid monosulfate C19H28O4S 
significantly decreased in maternal plasma of women who laboured (VM/EM). 
16a-hydroxy DHEA 3-sulfate significantly decreased in both the cord and 
maternal plasma. Androsterone glucuronide, epiandrosterone sulfate, 5α-
androstan-3β and 17β-diol disulfate significantly increased in the maternal 
plasma, and androsterone sulfate and androstenediol (3α, 17α) monosulfate 
significantly increased in both maternal and cord plasma (Tables 2.3 and 3.4).  
Of the oestrogenic steroids, oestrone 3-sulfate significantly increased in the cord 
plasma with no change in the maternal plasma, while oestriol 3-sulfate 
significantly decreased in the maternal plasma with no change in the cord 







Figure 2.2: Differences in the lipid superpathway between the maternal and cord blood. Comparison 
of number of metabolites with significant changes between maternal (intervillous) plasma taken from 
women who laboured and maternal (intervillous) plasma taken from women who did not labour 
(VM/EM) compared with cord plasma taken from women who laboured and cord plasma taken from 
women who did not labour (VC/EC) for each of the sub-pathways within the Lipids super-pathways. 
2.9.7 Nucleotides 
The most significant changes seen within the nucleotide super-pathway were 
within VC/EC (Figure 2.3), including significant increases in inosine, 
hypoxanthine, and xanthine, and a significant decrease in N1-methylinosine. 5-






maternal plasma (VM/EM), while 5,6-dihydrouracil and xanthosine significantly 
increased (Tables 2.3 and 2.4).  
 
Figure 2.3: Differences in the nucleotides super-pathway between the maternal and cord blood. 
Comparison of number of metabolites with significant changes between maternal (intervillous) 
plasma taken from women who laboured and maternal (intervillous) plasma taken from women who 
did not labour (VM/EM) compared with cord plasma taken from women who laboured and cord 
plasma taken from women who did not labour (VC/EC) for each of the sub-pathways within the 
Nucleotides super-pathway. 
 
2.9.8 Amino acids 
Unlike the other super-pathways, most of the significant changes within the 
amino-acid super-pathway were decreases in VC/EC and VM/EM (Figure 2.4). 
Serine, histidine, tryptophan, N-acetylkynurenine, picolinate, indole-3-
carboxylic acid, citrulline and arginine significantly decreased in both VC/EC and 
VM/EM. Carnosine, N-acetyltyrosine and xanthurenate significantly decreased 
in VC/EC only, while S-1-pyrroline-5-carboxylate, indolebutyrate, ornithine, 
homoarginine, threonine, lysine and trans-4-hydroxyproline decreased in 
VM/EM only. By contrast, N-acetylaspartate increased 7.14-fold in VM/EM only, 








Figure 2.4: Differences in the amino acids super-pathway between the maternal and cord blood. 
Comparison of number of metabolites with significant changes between maternal (intervillous) 
plasma taken from women who laboured and maternal (intervillous) plasma taken from women who 
did not labour (VM/EM) compared with cord plasma taken from women who laboured and cord 




24 metabolites were measured in this super-pathway (Figure 2.5 and Table 2.2). 
Two of the four fibrinogen cleavage peptide metabolites measured were 
significantly increased in cord plasma of women who laboured compared with 
non-labour: fibrinopeptide A des-ala increased 12.12-fold and fibrinopeptide A 
phosphono-ser increased 11.34-fold. There were no corresponding changes in 







Figure 2.5: Differences in the peptides super-pathway between the maternal and cord blood. 
Comparison of number of metabolites with significant changes between maternal (intervillous) 
plasma taken from women who laboured and maternal (intervillous) plasma taken from women who 
did not labour (VM/EM) compared with cord plasma taken from women who laboured and cord 
plasma taken from women who did not labour (VC/EC) for each of the sub-pathways within the 
Peptides super-pathway.  
 
2.9.10 Carbohydrate metabolism 
29 metabolites were measured in this super-pathway (Figure 2.6 and Table 2.2), 
and of these glucose, maltose, fructose, ribulonate/xylulonate, pyruvate and 
lactate were significantly increased in both the cord and maternal plasma taken 
from women who laboured compared with non-labour. 3-phosphoglycerate was 








Figure 2.6: Differences in the carbohydrates super-pathway between the maternal and cord blood. 
Comparison of number of metabolites with significant changes between maternal (intervillous) 
plasma taken from women who laboured and maternal (intervillous) plasma taken from women who 
did not labour (VM/EM) compared with cord plasma taken from women who laboured and cord 
plasma taken from women who did not labour (VC/EC) for each of the sub-pathways within the 
Carbohydrates super-pathway. 
 
2.9.11 Energy super-pathway 
11 metabolites were measured in this super-pathway (Table 2.2). Six 
metabolites of the TCA cycle were significantly increased in cord plasma of 
labouring women, but only three increased in maternal plasma (Figure 2.7, 
Tables 2.3 and 2.4). There were no significant changes in oxidative 
phosphorylation. 
 
Figure 2.7: Differences in the energy super-pathway between the maternal and cord blood. 
Comparison of number of metabolites with significant changes between maternal (intervillous) 
plasma taken from women who laboured and maternal (intervillous) plasma taken from women who 
did not labour (VM/EM) compared with cord plasma taken from women who laboured and cord 







2.9.12 Co-factors and vitamins 
31 metabolites were measured in this super-pathway (Figure 2.8 and Table 2.2). 
Of these, 1-methylnicotinamide, N1-methyl-2-pyridone-5-carboxamide and N1-
methyl-4-pyridone-3-carboxamide from nicotinate and nicotinamide 
metabolism were significantly decreased in the cord plasma taken from women 
who laboured (VC/EC), and adenosine 5'-diphosphoribose (ADP-ribose) 
significantly increased (Table 2.2). There were no such changes in the maternal 
plasma.  
Heme significantly increased 14.3-fold in cord plasma (VC/EC), with no change 
seen in the maternal plasma, and two metabolites of vitamin A metabolism and 
one metabolite of vitamin B6 metabolism were significantly increased with 
labour in maternal plasma (VM/EM), with no corresponding changes in the cord 









Figure 2.8: Differences in the cofactors and vitamins super-pathway between the maternal and cord 
blood. Comparison of number of metabolites with significant changes between maternal (intervillous) 
plasma taken from women who laboured and maternal (intervillous) plasma taken from women who 
did not labour (VM/EM) compared with cord plasma taken from women who laboured and cord 
plasma taken from women who did not labour (VC/EC) for each of the sub-pathways within the 
Cofactors and Vitamins super-pathway.  
 
2.9.13 Over-representation analysis results 
Table 2.12 and Figure 2.9 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for those metabolites which 
were significant at p<0.05. Beta oxidation of very long chain fatty acids, glucose-
alanine cycle, and fatty acid biosynthesis were the most over-represented 
pathways, with more than the expected number of hits, although the over-









Table 2.12: Results of the over-representation enrichment analysis for metabolites with 
significant p (≤0.05) and p (<0.1) for VM/EM,  where total is the total number of metabolites in 
the original pathway, expected is the number of metabolites that would be expected by chance, hit is 
the number of metabolites observed in the current study, raw p is the original p value calculated from 
the pathway analysis, and Holm p is the p value adjusted for multiple testing using the Holm-
Bonferroni method. 
Metabolite pathway Total Expected Hits Raw p Holm p 
Beta Oxidation of Very Long Chain Fatty Acids 17 2.32 4 0.193 1 
Glucose-Alanine Cycle 13 1.78 3 0.258 1 
Fatty Acid Biosynthesis 35 4.79 6 0.342 1 
Methylhistidine Metabolism 4 0.547 1 0.445 1 
Alpha Linolenic Acid and Linoleic Acid 
Metabolism 
19 2.6 3 0.493 1 
Phosphatidylethanolamine Biosynthesis 12 1.64 2 0.504 1 
Urea Cycle 29 3.96 4 0.576 1 
Transfer of Acetyl Groups into Mitochondria 22 3.01 3 0.597 1 
Ammonia Recycling 32 4.38 4 0.658 1 
Biotin Metabolism 8 1.09 1 0.693 1 
Alanine Metabolism 17 2.32 2 0.699 1 
Oxidation of Branched Chain Fatty Acids 26 3.55 3 0.713 1 
Phytanic Acid Peroxisomal Oxidation 26 3.55 3 0.713 1 
Aspartate Metabolism 35 4.79 4 0.728 1 
Gluconeogenesis 35 4.79 4 0.728 1 
Homocysteine Degradation 9 1.23 1 0.735 1 
Lactose Degradation 9 1.23 1 0.735 1 
Mitochondrial Beta-Oxidation of Short Chain 
Saturated Fatty Acids 
27 3.69 3 0.738 1 
Malate-Aspartate Shuttle 10 1.37 1 0.772 1 

















Figure 2.9: overview of the results of the over-representation analysis for VM/EM, with the 
metabolite pathways on the y-axis, and the enrichment ratio (calculated by number of metabolites in 
the pathway identified by this study divided by the number of metabolites expected to be identified 










Table 2.13 and Figure 2.10 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for those metabolites which 
were significant at p≤0.05 for VC/EC. These show that for VC/EC, methylhistidine 
metabolism, the urea cycle and beta oxidation of very long chain fatty acids were 
the most over-represented, although again the over-representation did not 
reach statistical significance.  
Table 2.13: Results of the over-representation enrichment analysis for metabolites with 
significant p (≤0.05) and p (<0.1) for VC/EC, where total is the total number of metabolites in the 
pathway according to the MetaboAnalyst database, expected is the number of metabolites that would 
be expected by chance, hit is the number of metabolites observed in the current study, raw p is the 
original p value calculated from the pathway analysis, and Holm p is the p value adjusted for multiple 
testing using the Holm-Bonferroni method. 
Metabolite pathways Total Expected Hits Raw p Holm p 
Methylhistidine Metabolism 4 0.434 2 0.0604 1 
Urea Cycle 29 3.14 6 0.0842 1 
Beta Oxidation of Very Long Chain 
Fatty Acids 
17 1.84 4 0.103 1 
Arginine and Proline Metabolism 53 5.75 9 0.109 1 
Ammonia Recycling 32 3.47 6 0.123 1 
Citric Acid Cycle 32 3.47 6 0.123 1 
Mitochondrial Electron Transport 
Chain 
19 2.06 4 0.141 1 
Beta-Alanine Metabolism 34 3.69 6 0.153 1 
Glucose-Alanine Cycle 13 1.41 3 0.159 1 
Warburg Effect 58 6.29 9 0.166 1 
Nicotinate and Nicotinamide 
Metabolism 
37 4.01 6 0.204 1 
Alanine Metabolism 17 1.84 3 0.277 1 
Glycerolipid Metabolism 25 2.71 4 0.283 1 
Glycine and Serine Metabolism 59 6.4 8 0.303 1 
Aspartate Metabolism 35 3.79 5 0.327 1 
Gluconeogenesis 35 3.79 5 0.327 1 
Fatty Acid Biosynthesis 35 3.79 5 0.327 1 
Purine Metabolism 74 8.02 9 0.41 1 
Carnitine Synthesis 22 2.38 3 0.433 1 
Transfer of Acetyl Groups into 
Mitochondria 







Figure 2.10: overview of the results of the over-representation analysis for VC/EC, with the 
metabolite pathways on the y-axis, and the enrichment ratio (calculated by number of metabolites in 
the pathway identified by this study divided by the number of metabolites expected to be identified 









This study is unique in its comparison of the metabolomic profile of cord and 
maternal plasma at the time of delivery between women who have laboured 
and delivered vaginally and women who have not laboured and delivered via 
elective caesarean section. The clear-cut differences in metabolite levels 
between the two groups confirm the strong impact that active labour has on 
both the mother and neonate. A proportion of these changes may be due to the 
stress of labour itself, but it seems plausible that within there are clues as to 
which pathways trigger spontaneous parturition in women. In addition, the 
observed changes in xenobiotics such as metronidazole were as expected, 
supporting the robustness of metabolomic methodology in this setting. While it 
cannot be ruled out that the intervillous blood samples had some degree of fetal 
blood contamination, the very distinct metabolic profiles that were obtained in 
cord and intervillous plasma confirms the fetal and maternal circulations were 
sampled separately150, thereby confirming the reliability of this non-invasive 
method for experimental sampling of maternal blood after delivery. These 
maternal and fetal differences are maintained, at least in part, by placental 








It could be argued that the stress of labour resembles strenuous exercise, and it 
would be useful to look to studies which investigate metabolic changes due to 
exercise to see if they match any of the changes observed here. Medium- and 
long-chain acetylcarnitines increase up to 9-fold following intense exercise in 
men 159. A major source of acetylcarnitine is acetyl Co-A, formed from pyruvate 
oxidation, and this increase following exercise is likely due to a switch to 
increased fatty acid oxidation in skeletal muscle instead of glycolysis during 
exercise160, 161. The significant increases in acylcarnitine fatty acid metabolism 
observed in the present study within both the cord and maternal plasma of 
labouring women (VC/EC and VM/EM) (Tables 2.3 and 2.4) could in part be 
explained by fatty acid oxidation for energy used by the woman and neonate 
during labour and delivery. However, while the source of this may be from 
working skeletal muscle in the labouring mother, this explanation is less likely in 
the fetus/neonate who is not thought to be using their skeletal muscles during 
labour and delivery. The increased levels of stress metabolites observed in 
labour, including cortisol, are likely to be generating fatty acid mobilisation162. 
The increase in sphingomyelins observed in labouring maternal plasma and the 
increase in acylcarnitine fatty acid metabolism in both the cord and maternal 






metabolism at the time of labour following the relative decrease of these 
metabolites in pregnancy163. 
Labour and vaginal delivery would be expected to affect metabolites of fetal and 
maternal adrenal origin, particularly glucocorticoids, as part of the physiological 
stress response151, 164. In support of this theory, cortisol and its major 
metabolites cortisone, cortisone 21-sulfate and corticosterone were 
significantly increased in the cord plasma of women who spontaneously 
laboured and delivered vaginally (VC) when compared with those who did not 
labour (EC). Similarly, cortisol and corticosterone were significantly increased in 
the maternal plasma taken from women who laboured and delivered vaginally 
(VM) when compared with those who did not labour (EM) (Tables 2.3 and 2.4). 
This data confirms that there is activation of the fetal and maternal adrenal 
cortex during labour and vaginal delivery, and while this may be part of the 
mechanism initiating spontaneous labour, further studies are needed to 
investigate this hypothesis. 
Recent studies also suggest that the effect of the intrapartum fetal environment 
may alter epigenetics, potentially having life-long effects165-167. Epigenetics are 
heritable changes in gene expression which are independent of the underlying 
DNA sequence. It is suggested that environment factors can alter epigenetics, 






subsequent life events, including health165-168. For example, it has been reported 
that there is an increased risk for type 1 diabetes167, atopy169 and obesity168, 170 
in children and young adults born via elective caesarean section when compared 
with those born via vaginal delivery. However, more recently a large cohort 
study has disputed the claim regarding obesity171. While this area of research 
remains controversial, the results from the present study illustrate how different 
the intrapartum fetal environments are between elective caesarean section and 
spontaneous vaginal delivery. 
Within cord plasma (VC/EC), heme was the metabolite with the greatest fold-
change (Table 2.2). Heme is a complex of iron with protoporphyrin IX, present 
in haemoglobin and myoglobin. Its levels in the plasma can increase rapidly 
following haemolysis or tissue injury152. It is possible that the increased heme 
present in the cord taken from women who laboured in this study is a marker of 
the increased trauma and tissue damage which a neonate experiences during 
vaginal delivery when compared with delivery via caesarean section. 
2.10.1 Endocannabinoid-related pathways 
Endocannabinoids are formed from membrane phospholipids and are described 
as non-classical neurotransmitters153. The two characterised cannabinoid 
receptors are CB1 and CB2. CB1 is present in areas of the brain (where activation 






including the uterus. CB2 is largely limited to cells and organs of the immune 
system172. AEA is one of the most well described endocannabinoids and is a 
bioactive lipid which binds to CB1 and CB2. Fatty acid amide hydrolase (FAAH) is 
the primary enzyme which breaks down AEA172. Interestingly, cannabis 
stimulates the endocannabinoid system, and its use has been associated with 
pregnancy complications such as preterm birth, placental abruption, fetal 
growth restriction and spontaneous miscarriage5, 173.  
Endocannabinoids are considered potential biomarkers for reproductive events, 
with both predictive and diagnostic uses153. For example, previous studies show 
that maternal plasma AEA declines throughout pregnancy before a sharp 
increase at the time of labour173, and AEA has been found to be 3.7-fold higher 
in women labouring at term than in non-labouring women at term. One group 
measured the AEA levels in plasma in women who went through induction of 
labour (IOL), comparing AEA in blood taken before IOL and again when the 
women were in active labour. The researchers found a 1.5-fold increase in mean 
plasma AEA levels, with a negative correlation between “the percentage change 
in plasma AEA level and the induction-to-delivery interval”174. Another group 
found that AEA levels in the placenta were significantly higher than in fetal 
membranes. Further, that AEA concentrations were significantly higher in the 






consistent finding, suggesting either transport across the placenta or placental 
production of AEA173. It is known that the uterus can produce its own AEA172, 
and myometrial studies show that AEA exerts a concentration-dependent 
relaxation effect on human myometrial contraction in vitro175. Elevated plasma 
AEA in early pregnancy (<8 weeks) has been shown to be predictive of 
miscarriage, and lower peripheral lymphocyte expression of FAAH was found in 
women who miscarried compared with those whose pregnancy continued173, 176. 
The CB1-knock out mouse has elevated corticotrophin-releasing hormone (CRH) 
and spontaneous preterm labour174. It has been previously suggested that 
increased AEA could lead to an increase in prostaglandins, as FAAH converts AEA 
to ethanolamine and arachidonic acid, which is necessary for the production of 
prostaglandins, and that this could be the link between elevated AEA and 
labour5, 174.  
Ceramide is a ubiquitous sphingolipid second messenger and an important 
signal effector molecule, and is mainly produced de novo in the endoplasmic 
reticulum but can be produced within minutes from the breakdown of 
sphingolipids, for example in lysosomes, in the cellular response to apoptosis 
and stress177. It has been reported that the increase in oxidative stress resulting 
from maternal pre-eclampsia (PET) increases de novo production of ceramides 






ceramides. The authors suggested that this may cause the increased trophoblast 
cell autophagy that is observed in women with PET177. CB1 activation has been 
shown to induce sphingomyelin hydrolysis and acute production of ceramide 
within minutes in primary astrocytes and C6 glioma cells, and it is also thought 
that CB2 activation leads to de novo sustained ceramide production172. In 
tumour cells, CB1 activation leading to ceramide production has been shown to 
lead to apoptosis172, and TNF-α appears to be involved in the link between CB1 
and CB2 activation and ceramide production172,177,5, 178, whereby inflammatory 
events may stimulate the onset of labour. 
In this study, AEA, OEA, and PEA were significantly increased in the cord plasma 
taken from the women who laboured (VC/EC) (Table 2.10). PEA was significantly 
increased in the corresponding maternal plasma (VM/EM), while N-oleoylserine 
significantly decreased in maternal plasma173, 174. Interestingly, there are  reports 
of increased ceramide levels and expression of serine palmitoyl transferase, the 
rate-limiting enzyme for ceramide synthesis de novo, in the placentas of women 
who laboured compared with those who delivered by elective CS179. The data 
presented here support the view that the 
endocannabinoid/ceramide/sphingolipid pathway has the potential to stimulate 






2.10.2 Progesterone and pregnenolone 
Parturition has long been associated with changes in progesterone and 
pregnenolone metabolism in many species180, 181, and as discussed in the 
introduction, many researchers believe that the functional progesterone 
withdrawal is involved in the initiation of labour in humans174. Although there 
were no significant differences in progesterone levels in the cord (VC/EC) or 
maternal (VM/EM) plasma found in the present study, there was a significant 
increase in metabolites of the progestin sub-pathway in the maternal plasma of 
labouring women (VM/EM). It has previously been reported that there is a 
strong positive correlation of 3β and 16α hydroxyl-steroids with gestational 
age182, reflecting maturation of the fetal adrenal zone and potential involvement 
of these metabolites in the preparation for labour.  
Further, the data from this pilot study uncovers a rich and complex pattern of 
steroid metabolites in spontaneous labour and vaginal delivery reflected in both 
maternal and fetal circulations (Table 2.8 and 2.9). Of interest is the relative 
increase in VC/EC of pregnenolone and hydroxypregnenolone sulphates which 
are mirrored by changes in the opposite direction in the maternal circulation 
(Table 2.8). Moreover, progesterone and pregnandiol metabolites increased in 
both the maternal and fetal circulations (Table 2.9). These changes indicate 






cholesterol through the P450scc and 3-β-hydroxysteroid dehydrogenase 
pathway during labour. Phillips et al. (2014)183 have previously demonstrated 
changes in cholesterol-transporting lipoproteins in the maternal circulation in 
women in spontaneous labour183, confirming the need for high cholesterol 
turnover during parturition. The results of the present study show for the first 
time a comprehensive picture of C21 metabolites in the maternal and fetal 
circulations in relation to labour and vaginal delivery that can be used to guide 
future studies investigating steroid changes at parturition. 
2.10.3 Potential link with lymphocytes 
Reviewing the literature and the results from this pilot study has led to the 
development of the hypothesis that activation of the endocannabinoid system 
may be involved in the trigger of parturition in humans, and that this activation 
may be driven by lymphocytes and progesterone. In early pregnancy, decreased 
levels of FAAH in peripheral lymphocytes is associated with miscarriage184. It has 
been suggested that peripheral lymphocytes could therefore be involved in 
control of pregnancies through the regulation of AEA in the uterus176, which 
could in turn regulate lymphocyte-dependent cytokines184. Progesterone is 
known to upregulate lymphocyte FAAH activity via the transcription factor 
Ikaros, resulting in increased breakdown and decreased levels of AEA153,176,184. 






an increase in AEA. Progesterone has also been shown to favour t-cells 
producing th2 cytokines (IL-4 and IL-10), thus inhibiting th1 cytokines (IL-12 and 
INF-γ) and therefore allowing successful pregnancy. Progesterone, via IL-4, has 
also been shown to stimulate the release of Leukaemia inhibitory factor (LIF) 
from t-lymphocytes, and low LIF production has been found in women with 
recurrent miscarriages. Further, macrophages express both CB1 and CB2, and 
can produce AEA and 2-AG, as well as producing LIF (pro-inflammatory), and 
therefore may also be involved184. One group found that stimulating human 
lymphocytes with progesterone enhanced FAAH activity in a dose-response. The 
researchers also found that AEA reduced LIF release from leucocytes, but that 
PEA did not affect the amount released. The suggestion is that reduced LIF leads 
to miscarriage in early pregnancy184. Endocannabinoids have been found to 
increase IL-4, IL-6, and IL-10 production; and to inhibit the release from 
lymphocytes of TNFα and INFγ5, 153.  As functional progesterone withdrawal has 
been linked to the onset of labour174, it could be that this is the mechanism 
behind the increase in AEA observed in previous studies immediately prior to 
labour5. 
2.10.4 Over-representation analysis 
Although the ORA indicated that none of the metabolite pathways were 






relevant. The pathways with the greatest enrichment ratio for VM/EM included 
fatty acid biosynthesis pathways and methylhistidine metabolism; and for 
VC/EC, methylhistidine metabolism, urea cycle, and beta oxidation of very long 
chain fatty acids were the most over-represented pathways. 
Methylhistidine is positively associated with a high protein diet185, and the 
urinary excretion of 3-methylhistidine has been found to be increased in later 
pregnancy, suggesting that the protein that is held in the maternal muscles in 
early pregnancy is later catabolised, providing a source of amino acids, 
potentially for fetal protein synthesis186. One group found that 3-
methylhistidine, creatinine, acetyl groups and acetate were independent 
predictors of pre-eclampsia in serum taken from 143 women between 26 and 
41 weeks of gestation, 17 of whom developed pre-eclampsia; by contrast 3-
methylhistidine was negatively associated with development of pre-
eclampsia187. In Chapter 3 of this thesis, maternal serum 3-methylhistidine is 
shown to increase throughout pregnancy, being highest in latent phase 
(Appendix 3A3) and 1-methylhistidine was lower in the cord artery of those who 
were induced than the cord artery of those who spontaneously laboured (0.76-
fold change, p=0.029) (Appendix 3A4). It is possible that methylhistidine 
metabolism may be associated with vascular changes of pre-eclampsia and in 






increase observed throughout pregnancy may reflect increasing catabolism of 
muscle for provision of amino acids, and the increase observed in labouring 
women may be a result of increased muscle activation with labour. The over-
representation of fatty acid metabolism may also represent increased 
breakdown of fatty acids. 
2.11 Conclusions 
This pilot study demonstrates that there are a wide range of metabolic changes 
at the time of delivery between women who laboured spontaneously and 
women who did not labour. The data will be useful to investigate the 
biochemical pathways involved in the physiological mechanism of labour in 
normal term pregnancy and provide a pattern against which pathological 
changes in preterm labour can be compared. These results indicate an interplay 
between metabolites in the maternal and fetal circulations which point to the 
involvement of the endocannabinoid, sphingolipid, ceramide and steroid 
systems in the mechanism of active labour. Figure 2.9 illustrates this hypothesis, 
including the suggested link with fatty acid amide hydrolase (FAAH). FAAH is the 
primary enzyme which breaks down the endocannabinoids anandamide (AEA)172, 
oleoyl-ethanolamide (OEA) and palmitoyl-ethanolamide (PEA)188. AEA is the 
most studied endocannabinoid, and elevated plasma AEA in early pregnancy (<8 






peripheral lymphocyte expression of FAAH was found in women who miscarried 
compared with those in whom pregnancy was ongoing173, 176. It has been 
previously suggested that higher concentrations of AEA could lead to an increase 
in prostaglandins as FAAH converts AEA to ethanolamine and arachidonic acid. 
Arachidonic acid is necessary for the production of prostaglandins, and 
therefore this could be a link between elevated AEA and labour174. Stimulating 
human lymphocytes in cell culture with progesterone enhanced FAAH activity in 
a dose-response184, and therefore if there was a functional withdrawal of 
progesterone that also reduced the sensitivity of lymphocytes to progesterone, 
this could in turn reduce FAAH activity and therefore result in increased AEA 
concentrations immediately prior to labour5. Further studies are now warranted, 
where serial maternal samples are taken throughout pregnancy to determine 
when these changes take place, especially focusing on the weeks and days 







Figure 2.11: Diagram illustrating proposed hypothesis generate from pilot study (FAAH = fatty acid 
amide hydrolase).  
 
2.12 Limitations 
A potential limitation to this study is the relatively low number of participants in 
each group. However, clear and significant changes in metabolite levels were 
identified within this pilot group with relatively little noise, demonstrating the 
reliability of this approach. The platform used is very robust with 26.9% 
(222/826) of metabolites significantly changing in maternal plasma and 21.1% 
(174/826) in cord plasma with labour. The method is unlikely to show false 






skin for all women in the elective CS group, but none of the women in the VD 
group received it; reassuringly, all the maternal and cord plasma of the non-
labour group contained metronidazole and none of the labouring group 
contained it (Tables 2.5 and 2.6). Another limitation is the fact that the study is 
cross sectional, rather than serial, so it is difficult to know whether the changes 
observed with labour are part of the mechanism of the initiation of labour or a 
consequence of the stress and metabolic demands of several hours of active 
labour. Nevertheless, this data shows that metabolomic techniques are a 
powerful and reliable approach to identify biochemical changes associated with 
labour.  
The results of this study informed the design of the study presented in the next 













CHAPTER 3. SERIAL METABOLOMIC ASSESSMENT OF 
PREGNANCY AND LABOUR 
 
3.1 Background 
This chapter follows on from Chapter 2 where the metabolomic profile of cord 
and maternal blood at the time of delivery was compared between women who 
laboured spontaneously and women who did not labour. The hypothesis 
generated from these results was that the trigger for labour in humans results 
from an interplay between metabolites in the maternal and fetal circulations, 
with involvement of endocannabinoid, sphingolipid, ceramide and steroid 
pathways in the mechanism of active labour5. This serial metabolomics study 
was designed to test and expand this hypothesis in order to better understand 
any interaction with the suspected functional progesterone withdrawal that is 
hypothesised to be involved in the onset of spontaneous labour in humans.  
As the previous study design was cross sectional, with all samples taken at the 
time of delivery, it was not possible to definitively conclude that the changes 
seen were secondary to the physiological stress of labour itself, or as a result of 
the spontaneous onset of labour. This follow-on study was therefore designed 
to serially assess the maternal metabolome at different points during low-risk 






The present study had two parts: Part 1 was designed to investigate whether 
there were differences in the metabolomic profile between the intervillous 
blood (maternal), cord artery (fetal) blood and cord vein (placental) blood, and 
whether these were affected by the mode of labour onset and delivery; and 
whether this could give further insight to the fetal/maternal interaction at 
labour. Given that the cord vein carries blood from the placenta, the cord artery 
carries blood from the fetus, and the intervillous blood is predominantly 
maternal, characterising the metabolome of these separate compartments 
following different onsets of labour and delivery was hoped to further identify 
the interactions between the maternal and fetal systems, and whether the 
trigger for labour may originate in the fetus or mother. Part 2 involved taking 
serial blood samples from women with low-risk pregnancies at 28 weeks’ 
gestation, 34 weeks’ gestation, and latent phase of spontaneous labour. 28- and 
34-weeks’ gestation were chosen as these are times when women routinely 
have blood tests with midwives, and therefore would not require the women to 
attend extra visits or have extra blood tests. This was considered particularly 
important given this study was exploratory. The metabolome of these samples 
would be analysed to determine whether there were associations between 






3.2 Aims and objectives 
Aim 1 (Part 1 of study): To determine if there are differences in the metabolomic 
profile of the intervillous (maternal) blood, cord artery (fetal), and cord vein 
(placental) at the time of delivery (in Chapter 2 cord blood was not separated 
into arterial and venous). 
Aim 2 (Part 1 of study): Determine if any differences in Aim 1 are affected by the 
mode of labour onset and delivery. The different modes of labour onset and 
delivery assessed were spontaneous labour (SL), induction of labour (IOL) 
followed by vaginal delivery, and elective caesarean section (ECS).  
Objective 1.1: To answer aims 1 and 2, samples were taken from four women 
who spontaneously laboured at term (37 to 42 completed weeks’ gestation) and 
delivered vaginally, four women who had an IOL at term and delivered vaginally, 
and four women who had an ECS at term. As this was an exploratory study, four 
participants per group were selected, with the intention of informing power 
calculations for follow-on studies if indicated by the results. The samples taken 
for each woman were a sample in latent phase for the SL group (early labour, 
before 4 cm  cervical dilatation30), or a sample at the start of the induction 
process for the IOL group, or at the pre-operative clinic (day before ECS) for the 
ECS group. Further samples were taken from the placenta: intervillous (IV) (as 






metabolomic profile of these different samples were compared between the 
different modes of labour, and to answer aim 2, the metabolomic profile of each 
of the different vascular compartments were compared between the mode of 
labour onset and delivery groups.   
Aim 3 (Part 2 of study): To determine whether there is an association between 
the maternal metabolomic profile at 28 weeks’ gestation, 34 weeks’ gestation, 
or in latent phase, and gestational age at the onset of spontaneous labour. 
Objective 3.1: Maternal blood was sampled at 28 weeks’ gestation, 34 weeks’ 
gestation, and in latent phase in women with low-risk pregnancies who went on 
to spontaneously labour. Samples were sent to Metabolon, Inc., for global MS 
metabolomics analysis.  
3.3 Funding, ethical approval and role of thesis author 
Funding for this study (£19 940) was granted by the Above and Beyond charity 
in July 2018. Ethical approval was granted by from the National Research Ethics 
Service Committee-South West, Bristol (reference number: E5431). 
The thesis author (Katherine Birchenall) came up with the idea for the study, 
designed the study protocol, wrote the grant for funding, recruited all women, 






metabolomics and initial statistical analysis were performed by Metabolon, Inc., 
as described further below. 
3.4 Methodology 
3.4.1 Inclusion and exclusion criteria 
The inclusion criteria were:  
• Low-risk singleton pregnancy 
• BMI 18-30 
• Age 20-40 years 
The exclusion criteria were:  
• BMI under 18 or over 30 
• Age under 20 or over 40 years 
• Multiple pregnancy 
• Taking medications likely to alter metabolomics 
• Development of chorioamnionitis or other infection 
• Development of maternal or fetal complications such as diabetes or pre-
eclampsia 
ECSs were for non-maternal or fetal disease, such as breech, previous caesarean 






IOL were also for non-maternal or fetal disease indications, to include post-term 
and perceived reduced fetal movements. 
3.4.2 Gestational age at spontaneous labour 
To answer aim 3, it was important to know the gestational age when the 
included women spontaneously laboured. Women who had iatrogenic labour, 
for example IOL or ECS were therefore excluded. However, women who had IOL 
for post-term (recommended by NICE to be offered around 40 weeks’ and 12 
days gestation to reduce the risk of stillbirth that increases after 42 weeks’ 
gestation) were included as this would be the latest that women would be 
expected to labour in England under current protocols29. 
3.4.3 Recruitment  
In order to recruit women with low-risk pregnancies to the study to answer the 
first aim, the thesis author attended two community health centres and met 
with the community midwives to discuss the study and intentions, and confirm 
the feasibility of the study design. During booking appointments (in first 
trimester of pregnancy), the community midwives gave eligible women the 
study information leaflet (3A1, Appendix) and asked if they would be interested 
in speaking with the researcher (thesis author) about the study. If they were, the 
researcher would then meet the women after their booking appointment, 






information leaflet. Women who were still interested in the study agreed to be 
met at the dating scan (performed between 11-14 weeks’ gestation). At the 
dating scan, if the women were still happy to take part, the consent form (3A2, 
Appendix) was signed, and any further questions answered. Each woman was 
allocated a study code at the time of recruitment. 
The women were subsequently met at their routine appointments with the 
community midwives at 28 weeks’ gestation and 34 weeks’ gestation. At these 
appointments, the researcher took an extra blood draw for the study at the 
same time as the routine Full Blood Count that women are offered at these 
gestations.  
3.4.4 Collecting samples in early labour and at delivery 
3.4.4.1 Spontaneously labouring group 
Stickers were placed on the maternity notes with the study name, the 
researcher and the researcher’s contact number. Posters were also placed on 
Central Delivery Suite and the Midwifery-Led Unit so that the sole researcher 
(Katherine Birchenall) was alerted when the women attended hospital in early 
labour (latent phase). A further blood sample was then drawn in latent phase. 
At delivery, the researcher would be outside the delivery room and the midwife 
would double-clamp the cord (following routine delayed cord clamping that is 






mother and baby5) and then bring the placenta outside the room to the 
researcher as soon as the cord was cut (there are always two midwives in the 
rooms at the time of delivery so this did not take care away from the women). 
For all women, one sample was taken from the cord vein (CV), one from the cord 
artery (CA) and one intervillous (IV sample), within 30 minutes of delivery.  
3.4.4.2 Induction of labour group 
At St Michael’s Hospital, Bristol, the IOL protocol involves women attending the 
IOL suite on the antenatal ward and remaining in hospital for the duration of the 
induction process. Dinoprostone is a prostaglandin PGE2 analogue126. 10 mg of 
dinoprostone within a pessary (slow-release, trade name Propess) is inserted 
into the woman’s vagina, close to the cervix. It is removed after 24 hours, or 
earlier if the woman starts labouring before the 24-hour period. A cervical 
assessment then occurs, and a Bishop’s Score calculated, as per protocol at St 
Michael’s Hospital. If the woman’s cervix has dilated sufficiently to allow 
artificial rupture of the membranes, then the woman is transferred to the 
central delivery suite (CDS) for this. If not, then a further 0.5 – 1 mg of 
dinoprostone within a gel (faster-release, trade name Prostin) is again inserted 
into the vagina close to the cervix. A further cervical assessment is performed 
after 6 hours, and if the cervix remains closed, a further 0.5 mg Prostin is 






possible. For the purpose of this study, as the aim was to compare with latent 
phase, the blood sample to match with the latent phase sample of the 
spontaneously labouring women was taken when the women had been 
transferred to CDS for their ARM. By this point the women in this study had a 
cervical dilatation that would be defined as latent stage (1-4 cm dilated)29. The 
researcher stayed outside the room and the placenta was brought to her 
following delivery of the baby as for the SL group. 
3.4.4.3 Elective caesarean section group 
Regarding ECSs, the initial intention was to recruit these women at the booking 
appointments and that some of these women would require ECS. If not enough 
women were recruited by this method, it was intended that women would be 
recruited from the pre-operative clinic on the day prior to their ECS. For all 
women with ECS, a peripheral blood sample was taken from the woman at the 
time of the pre-operative clinic (at the same time as other routine blood tests), 
and this was to match the blood test taken in latent phase for the SL group. 
During ECS, again following delayed clamping of the cord for approximately one 
minute, the surgeon double-clamped the cord and the placenta was brought 
immediately to the researcher who was in a room adjacent to the theatre. Again, 
for all women one sample was taken from the CV, one from the CA and one IV 






3.4.5 Sample collection and processing 
As described, peripheral blood samples were taken from low-risk women at 28 
weeks’ gestation and 34 weeks’ gestation, in latent phase of spontaneous 
labour/early IOL/pre-operative clinic for the ECS group, and IV blood and CA and 
CV immediately following delivery. All samples were collected into EDTA tubes 
and processed following Metabolon, Inc., standard operating procedures as with 
Chapter 25. 
As Metabolon, Inc., recommends that all samples are processed within an hour, 
a motorised scooter was purchased so that the researcher could transport the 
samples from the community centres to the laboratory within the time frame. 
In addition, this scooter helped with being able to attend deliveries at all times 
of the day and night. As with the study in Chapter 2, plasma samples were stored 
at -80 degrees Celsius until analysis. The metabolites in maternal and fetal blood 
were measured with the Metabolon, Inc., MS metabolomics platforms 
(http://www.metabolon.com/), as described in Chapter 2.   
3.4.6 Statistical analysis 
While the statistical analysis plan was designed by the researcher, Metabolon, 
Inc. performed the initial statistical analysis as part of their collaboration in the 
project. As with Chapter 2, metabolites were normalised to sample volume then 






was then rescaled to set the median to be equal to 1, giving a scaled value for 
each metabolite. Missing values were imputed with the minimum value.  
To answer aims 1 and 2, samples from four women who spontaneously laboured 
(SL group), four women who were induced (IOL group), and four women who 
had an ECS (ECS group) were taken at the following time points: latent phase of 
SL/day before ECS/day of commencement of IOL; and at delivery (collected 
within 30 minutes of delivery of placenta) from the CV, CA and IV (maternal) 
blood. The following statistical analyses were performed in ArrayStudio and R 
statistical packages for part 1 of the study: 
a. A one-way analysis of variance (ANOVA) test to compare potential 
differences in mean  values of the recorded participant demographic 
variables and delivery outcomes between the SVD, IOL and ECS groups. 
b. Welch’s t-test to compare the mean amount of each metabolite 
measured within the latent phase/day of IOL/pre-operative samples 
between the SL, IOL and ECS groups, respectively. 
c. Welch’s t-test to compare the mean amount of each metabolite 
measured within the CA samples between the SL, IOL and ECS groups 
d. Welch’s t-test to compare the mean amount of each metabolite 






e. Welch’s t-test to compare the mean amount of each metabolite 
measured within the IV blood between the SL, IOL and ECS group.  
f. Paired t-test to compare the mean amount of each metabolite 
measured between each of the different samples (latent/CV/CA/IV) 
within the same mode of delivery groups.  
To answer aim 3, samples taken at 28 weeks’, 34 weeks’ and in latent phase of 
labour had MS metabolomics analysis performed and the gestational age at 
spontaneous delivery (in days) were also known. The following statistical 
analyses were performed in ArrayStudio and R statistical packages: 
a. Spearman’s rank correlation to individually assess whether there were 
associations between: 
i. Metabolomic profile at 28 weeks and gestational age at 
spontaneous labour. 
ii. Metabolomic profile at 34 weeks and gestational age at 
spontaneous labour. 
iii. Metabolomic profile in latent phase and gestational age at 
spontaneous labour. 
b. Paired t-test to determine changes between metabolites at each time 






To account for multiple testing, a q-value was calculated by Metabolon, Inc., 
based on the understanding that when 200 compounds are analysed, 
approximately ten compounds would reach a significance of p ≤0.05 by chance. 
As described in Chapter 2 (section 2.8.4), a q-value <0.1 indicates high 
confidence in a result.   
3.4.7 Over-representation analysis 
As discussed in Chapter 2, given the large amount of data produced by ‘omics 
studies, ORA is a useful tool for interpretation of results155, 157, 158, 189. 
MetaboAnalyst software (www.metaboanalyst.ca) has been developed using 
the statistical programme R, specifically for analysis of metabolomics studies, 
and was used for analysis of the metabolomics data generated by this study. 
MetaboloAnalyst (version 4.0) is a free web-based tool that maps common 
compound names to a range of database identifiers, including KEGG, HMDB, 
METLIN, and PubChem158.  
For the MS metabolomics analysis in this thesis, HMDB identifiers were inputted 
into the MetaboAnalyst programme online (www.metaboanalyst.ca) and 
enrichment analysis performed. The pathway enrichment analysis selected 
implements the hypergeometric test to evaluate whether a specific metabolite 
group is represented more than would be expected by chance within the given 






calculated following adjustment for multiple testing using the Holm method157, 
158. For this chapter, those metabolites which had a significant p-value (≤0.05) 
were entered into the MetaboAnalyst software for each of the experimental 
comparisons (a full list of these comparisons are presented in Appendices 3A3 




61 women with low-risk pregnancies were approached by the researcher at 
booking appointments with the community midwives and of these: five declined, 
one had a first-trimester miscarriage, thirteen booked at a different hospital, 
one booked a home birth, nine were excluded for maternal conditions, and one 
moved out of the area. 31 women agreed to meet at their dating scan (11-14 
weeks’ gestation) and signed the consent form. Two women required referral to 
the fetal medicine unit for fetal concerns and were therefore excluded, and one 
woman developed pregnancy-induced hypertension and was therefore 
excluded. Rolling recruitment continued throughout the study in order to ensure 
that enough women were recruited, and once the intended number of women 






study as no further samples were required (Figure 3.1). The first woman was 
approached in August 2018 and the final woman recruited in August 2019. 
3.5.2 Sample collection 
24 women had plasma samples taken at 28 weeks’ gestation; and one woman 
declined having a sample taken at this time point as she had her routine bloods 
taken early and did not want extra tests (Figure 3.1). One woman spontaneously 
delivered at 34 weeks’ gestation and her delivery was missed, therefore no 
sample was taken at 34 weeks’ gestation. Thus 24 women had samples taken at 
34 weeks’ gestation. Of these women, one woman had a spontaneously preterm 
labour at 35 weeks and 3 days and delivered out of area, twelve women 
spontaneously laboured at term, nine had labour induced at term or post-term, 
and two booked for an ECS at term (Figure 3.1).  
Of the women who went into spontaneous labour at term, eleven had a sample 
taken in the latent phase of labour. One woman was missed as she 
spontaneously laboured with a baby in breech position and therefore had an 
emergency caesarean section (Figure 3.2). Of the eleven women for whom a 
latent phase sample was taken: four had a normal vaginal delivery, two had a 
ventouse or kiwi delivery, one had a forceps delivery and four had an emergency 
caesarean section in labour. CV, CA and IV samples were taken within thirty 






Of the nine women who had an IOL (Figure 3.3): three were induced for post-
term, one for obstetric cholestasis, one for maternal request for family reasons, 
one for suspected reduced fetal growth velocity, one for pregnancy-induced 
hypertension, and two for reduced fetal movements. Seven of these women had 
blood taken at the initial stage of induction (insertion of pessary; before artificial 
rupture of membranes); two were missed: one had an emergency caesarean 
section for suspected fetal distress following IOL for reduced fetal movements, 
and one had a normal vaginal delivery following IOL for reduced fetal 
movements. Of those women for whom a blood sample was taken at the time 
of induction: two had a normal vaginal delivery, three had a forceps assisted 
vaginal delivery, one had a ventouse assisted vaginal delivery, and one woman 
had an emergency caesarean section in labour. Excepting the woman who had 
the emergency caesarean section, CA, CV and IV samples were taken within 
thirty minutes of delivery of the placenta for all. Other than the women who 
were induced for post-dates, all women who were induced were excluded from 
Part 2 of the study as they did not spontaneously labour, and therefore the 
samples taken from them at 28 weeks and 34 weeks’ gestation were not 
processed. Samples at the start of IOL and at delivery collected from four of the 






indications for IOL at term for the four women who were included were: reduced 
fetal movements at term, post-term, and maternal request for family reasons. 
Two of the women recruited at booking planned an ECS (Figure 3.4). As four 
women with ECS were required for Part 1, two women with low-risk pregnancies 
booked to have an ECS at term were recruited from the ECS pre-operative clinic. 
All four of these women had a sample taken the day before their ECS at the same 
time as their routine pre-operative blood tests, and CA, CV and IV blood samples 
were taken within thirty minutes of delivery of the placenta. 
Overall, 89 samples were sent to Metabolon, Inc., for global metabolomic 
analysis. The samples from the placenta and cord were taken immediately 
following delivery of the placenta, and all samples were processed within 60 









Figure 3.1: Flow diagram showing number of women approached, recruited, and withdrawn from the study, as well as number of women who had 28 



























3.5.3 Part 1 participants 
Part 1 compared the metabolomic profile of latent/start of induction/pre-
operative samples, CA, CV and IV samples from four women who spontaneous 
laboured (Figure 3.2), four women who had IOL (Figure 3.3), and four women 
who had an ECS (Figure 3.4).  
Table 3.1 presents the demographic profile, pregnancy course and delivery 
outcomes for these women. Using a one-way ANOVA analysis, there were no 
statistical differences between the three groups regarding age at recruitment, 
booking BMI, Gravida, parity, estimated blood loss at delivery and birthweight. 
However, there was a significant difference between gestational age at delivery 
(p=0.03). In this study, the women who delivered spontaneously laboured after 
term, whereas two of those who were induced were induced before 40 











Table 3.1: Maternal demographics and delivery outcomes for participants of Part 1 













Age at recruitment 
(years) 
31.5a 31.75 a 34.5 a 0.421 
 
(24-36) (29-34) (34-35) 
 
BMI 23.925 a 24.125 a 25.325 a 0.855  
(23.1-25.4) (19.4-29.2) (22.5-28.7) 
 
Past medical history ALL NIL ALL NIL 3 NIL 
 




Gravida 1.5b 1.5 2 b 0.79  
(1-3) (1-4) (2-3) 
 
Parity 0 b 0 1 b 0.3  
(0-1) (0-2) ALL 1 
 
Alcohol during pregnancy ALL NO ALL NO ALL NO 
 
     
Ethnicity ALL WE ALL WE ALL WE 
 
     
Smoking during 
pregnancy 
ALL NO ALL NO 1 3/day 
3 NO 
 
     
Indication for El CS NA NA 2 PREV CS 
 
   
1 MAT REQ 
 
   
1 PREV 3RD 
 






1 MAT REQ 
  
Gestational age at 
delivery 
287.5 b 276 b 274.5 b 0.035 
 
(287-290) (269-292) (272-278) 
 
Mode of delivery 3 NVD 2 NVD 4 EL CS 
 
 















Estimated blood loss 512.5 a 350 a 600 a 0.51  
(250-1100) (100-800) (500-700) 
 
Analgesia 3 ENT 2 EPI 4 sp 
 
 



















     















Baby Apgar score 8,9,10-9,10,10 7,10,10-9,10,10 ALL 9,10,10 
 
     
Birthweight 3.80925 a 3.39 a 3.4275 a 0.416  
(3.515-4.18) (2.36-4.164) (3.202-3.588) 
 
Baby sex 3 F 3 F 3 F 
 
 
1 M 1 M 1 M 
 
Collection to freezing 
interval 
    
aMean ;   bMedian;   BMI=Body Mass Index; EBL=Estimated Blood Loss; NA=Not Applicable; WE=White European; 
PREV CS=Previous Caesarean Section; MAT REQ=Maternal Request; PREV 3rd=Previous Third Degree Perineal 
Tear; PT=Post-Term; RFM=Reduced Fetal Movements; NVD=Normal Vaginal Delivery; VEN=Ventouse or Kiwi 
Assisted Vaginal Delivery; FORC=Forceps Assisted Vaginal Delivery; El CS=Elective Caesaran Section; ENT=Entonox; 
LA=Local Anaesthetic; EPI=Epidural; SP=Spinal Regional Anaesthetic; SYM=Syntometrine (Oxytocin+Ergometrine); 
CAR=Carbetocin;  F=Female; M=Male 
3.5.4 Part 2 participants 
The aim of Part 2 was to investigate whether there is an association between 
the metabolomic profile of maternal blood at 28 completed weeks’, 34 
completed weeks’ gestation, or latent phase, and gestational age at 
spontaneous labour and delivery. All women who remained low-risk and who 
spontaneously laboured and who had blood samples taken at these time points 
were included in Part 2. In addition, women who were induced for post-term 
were included if they had otherwise remained low risk; as described above, this 
was because these women would be medically recommended not to continue 






stillbirth after this date. Therefore, it would be expected that no woman would 
be recommended to await spontaneous delivery after 42 weeks’ gestation, and 
it was considered appropriate to include these women and to mark their 
gestational age at delivery as the gestational age at delivery (40 weeks’ + 12-14 
days). Therefore, all samples collected at 28 weeks’ gestation and 34 weeks’ 
gestation were included in Part 2, and samples taken in latent phase for the 12 
women who spontaneously laboured at term and the samples taken at the time 
of induction for two women who were induced at post-term for not having 
laboured by these dates.  
Table 3.2 presents the maternal demographics for the participants at each 
sample point. Samples from sixteen women were included for those taken at 28 
weeks’ and 34 weeks’ gestation, and samples for fourteen women were 
included for those taken in the latent phase. Unsurprisingly, as most of the 
women had samples taken at each time point, there were no significant 
differences in the participant demographics between three different time points. 
15 of the women included in the 28 weeks’ group were included in the 34 weeks’ 
group (one woman who was included at 28 weeks’ gestation did not have 
further samples taken as she spontaneously delivered at 34 weeks’ gestation; 
and one woman did not have a sample taken at 28 weeks’ gestation as she had 






gestation and in latent phase). Two women had samples taken at 28 weeks’ 
gestation and 34 weeks’ gestation but not in latent phase simply because the 
researcher was not called into the hospital for their deliveries and they were 
missed. 
At all three time points, the average age at recruitment was 31 years (range 24-
40) for all groups, the average BMI was 24 (range 20-29.2), the median parity 
was 0 (range 0-1), none of the women drank alcohol during pregnancy, 15 
women were non-smokers and one woman smoked up to five cigarettes a day. 
15 of the women who were included in the 28 weeks’ and 34 weeks’ gestation 
samples were white European and one woman was white European/Chinese; 
and 13 of the women included in the latent phase samples were white European 
and one white European/Chinese. Thirteen of the women included at 28 weeks’ 
and 34 weeks’ gestation spontaneously laboured and three were induced for 
post-term. For the latent phase samples this reduced to 11 women who 
spontaneously laboured and 3 women who were induced for post-term. The 
average gestational age at delivery was 287 days for all three groups (range 240 
to 295 for 28 weeks’ gestation samples; 252 to 295 at 34 weeks’ gestation 







Table 3.2: Maternal demographics for included participants for samples taken at 28- and 
















Age at Recruitment (years) 31.6a 31.3 a 31.4 a 0.975  
(24-40) (24-40) (24-40) 
 
BMI 24.5 a 24.8 a 24.6 a 0.959  
(20-28.8) (20-29.2) (20-29.2) 
 
PMH Nil NIL NIL 
 
     
Gravida 2b 2 b 1.5 b 0.95  
(1-4) (1-4) (1-4) 
 
Parity 0 b 0 b 0 b 0.878  
(0-1) (0-2) (0-2) 
 
Alcohol during pregnancy 16 NIL 16 NIL 14 NIL 
 
     
Ethnicity 15 WE 15 WE 13 WE 
 
 
1 WE/Chinese 1 WE/Chinese 1 WE/Chinese 
 
Smoking during pregnancy 1 5/day 1 5/day 1 5/day 
 
 
15 NIL 15 NIL 13 NIL 
 
Type of labour onset 13 SP 13 SP 11 SP 
 
 
3 IOL PT 3 IOL PT 3 IOL PT 
 
Gestational age at delivery 287 b 287 b 287 b 0.192  
(240-295) (252-295) (280-295) 
 
     
Maternal complications NIL NIL NIL 
 
     
Apgar scores 7,8,9-9,10,10 7,10,10-9,10,10 7,10,10-9,10,10 
 
     
Birthweight 3.620 a 3.707 a 3.734 a 0.679  
(2.44-4.18) (3.196-4.18) (3.196-4.18) 
 







Sample collection to freezing 
time  
    
 
3.5.5 Correlations with gestational age at delivery 
63 of the 1032 metabolites measured at 28 weeks’ gestation were significantly 
(p≤0.05) correlated with gestational age at delivery (49 negative association; 14 






metabolites measured at 34 weeks’ gestation were significantly (p≤0.05) 
correlated with gestational age at delivery (75 negative association; 9 positive 
association), and two of these had q<0.1 (Table 3.4); and 53 of the 1032 
metabolites measured in latent phase (n=11) or at the beginning of IOL for post-
term (n=3) were significantly (p≤0.05) correlated with gestational age at delivery 
(50 negative association; 3 positive association), and one of these had a q<0.1 
(Table 3.5). 
Seven metabolites were significantly correlated with gestational age at all three 
time points; a further 15 were significantly correlated with gestational age at 28 
weeks’ gestation and 34 weeks’ gestation, but not in latent phase; a further four 
significantly correlated with gestational age at 28 weeks’ gestation and latent 
phase but not at 34 weeks’ gestation; and a further ten metabolites were 
significantly correlated with gestational age at 34 weeks’ gestation and in latent 
phase, but not at 28 weeks’ gestation (Table 3.6). The seven metabolites 
significantly correlated at all time points were: octadecanedioylcarnitine (C18-
DC), octadecenedioylcarnitine (C18:1-DC), 5alpha-androstan-3alpha,17alpha-
diol disulfate, glycochenodeoxycholate glucuronide (1), tauroursodeoxycholic 
acid sulfate (1), N4-acetylcytidine and perfluorooctanesulfonate (PFOS) (Table 
3.6 and Figure 3.5). At all-time points, all of these were negatively correlated 






Table 3.3: Metabolites which significantly correlate with gestational age at delivery for those samples taken at 28 weeks’ gestation, ordered 
according to p-value (considered significant if p≤0.05.  




5alpha-pregnan-3beta,20alpha-diol disulfate Progestin Steroids Lipid -0.8149 0.0001 0.0806 
Glucuronide of piperine metabolite 
C17H21NO3 (4) 
Food Component/Plant Xenobiotics 0.7971 0.0002 0.0806 
Indolin-2-one Food Component/Plant Xenobiotics -0.7839 0.0003 0.0806 
Octadecenedioylcarnitine (C18:1-DC) Fatty Acid Metabolism (Acyl 
Carnitine, Dicarboxylate) 
Lipid -0.7465 0.0009 0.1657 
Beta-cryptoxanthin Vitamin A Metabolism Cofactors and 
Vitamins 
0.7287 0.0014 0.2026 
5alpha-pregnan-3beta,20alpha-diol 
monosulfate (1) 
Progestin Steroids Lipid -0.7004 0.0025 0.3107 
3-hydroxyhexanoylcarnitine (1) Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid -0.6883 0.0032 0.3388 
Tauro-beta-muricholate Primary Bile Acid Metabolism Lipid -0.6751 0.0041 0.3388 
Octadecanedioylcarnitine (C18-DC) Fatty Acid Metabolism (Acyl 
Carnitine, Dicarboxylate) 
Lipid -0.6682 0.0047 0.3388 
2-naphthol sulfate Chemical Xenobiotics -0.6603 0.0054 0.3388 
Deoxycholic acid glucuronide Secondary Bile Acid Metabolism Lipid -0.6499 0.0064 0.3388 
Pelargonate (9:0) Medium Chain Fatty Acid Lipid -0.6484 0.0066 0.3388 
Glyco-beta-muricholate Primary Bile Acid Metabolism Lipid -0.6484 0.0066 0.3388 
6-hydroxyindole sulfate Chemical Xenobiotics -0.6409 0.0075 0.3388 
Perfluorooctanesulfonate (PFOS) Chemical Xenobiotics -0.6394 0.0076 0.3388 
(2 or 3)-decenoate (10:1n7 or n8) Medium Chain Fatty Acid Lipid -0.6380 0.0078 0.3388 
Taurodeoxycholate Secondary Bile Acid Metabolism Lipid -0.6365 0.0080 0.3388 






(2-butoxyethoxy) acetic acid Chemical Xenobiotics 0.6276 0.0092 0.3392 
Androstenediol (3beta,17beta) monosulfate (1) Androgenic Steroids Lipid 0.6275 0.0093 0.3392 
Indolepropionate Tryptophan Metabolism Amino acid 0.6171 0.0109 0.3392 
Tauroursodeoxycholic acid sulfate (1) Secondary Bile Acid Metabolism Lipid -0.6147 0.0113 0.3392 
N-acetylglucosamine/N-acetylgalactosamine Aminosugar Metabolism Carbohydrate -0.6142 0.0114 0.3392 
Glycochenodeoxycholate glucuronide (1) Primary Bile Acid Metabolism Lipid -0.6112 0.0119 0.3392 




0.6112 0.0119 0.3392 
Glucuronide of piperine metabolite 
C17H21NO3 (5) 
Food Component/Plant Xenobiotics 0.6101 0.0121 0.3392 
21-hydroxypregnanolone disulfate Pregnenolone Steroids Lipid -0.6082 0.0124 0.3392 
Dodecanedioate (C12-DC) Fatty Acid, Dicarboxylate Lipid -0.6038 0.0133 0.3392 
Taurodeoxycholic acid 3-sulfate Secondary Bile Acid Metabolism Lipid -0.6038 0.0133 0.3392 
Dodecadienoate (12:2) Fatty Acid, Dicarboxylate Lipid -0.5978 0.0145 0.3573 
Dehydroepiandrosterone sulfate (DHEA-S) Androgenic Steroids Lipid 0.5933 0.0154 0.3644 
Gamma-glutamylhistidine Gamma-glutamyl Amino Acid Peptide -0.5919 0.0157 0.3644 
3-hydroxyoleoylcarnitine Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid -0.5802 0.0185 0.4148 
Chenodeoxycholic acid sulfate (1) Primary Bile Acid Metabolism Lipid -0.5773 0.0192 0.4167 
1-linoleoylglycerol (18:2) Monoacylglycerol Lipid -0.5755 0.0197 0.4167 
17alpha-hydroxypregnenolone 3-sulfate Pregnenolone Steroids Lipid 0.5695 0.0213 0.4384 
8-methoxykynurenate Tryptophan Metabolism Amino acid -0.5665 0.0222 0.4440 
Aconitate [cis or trans] TCA Cycle Energy -0.5577 0.0248 0.4840 
Gamma-glutamylmethionine Gamma-glutamyl Amino Acid Peptide -0.5532 0.0262 0.4954 
Gamma-CEHC Tocopherol Metabolism Cofactors and 
Vitamins 
-0.5517 0.0267 0.4954 
3-indoxyl sulfate Tryptophan Metabolism Amino acid -0.5487 0.0277 0.5014 
Phenol sulfate Tyrosine Metabolism Amino acid -0.5458 0.0288 0.5077 
Glycodeoxycholate 3-sulfate Secondary Bile Acid Metabolism Lipid -0.5428 0.0298 0.5142 










0.5339 0.0332 0.5275 
4-hydroxyphenylacetylglutamine Acetylated Peptides Peptide -0.5309 0.0343 0.5275 
Laurylcarnitine (C12) Fatty Acid Metabolism (Acyl 
Carnitine, Medium Chain) 
Lipid -0.5309 0.0344 0.5275 
3-formylindole Food Component/Plant Xenobiotics 0.5309 0.0344 0.5275 
N-stearoyltaurine Endocannabinoid Lipid -0.5283 0.0354 0.5275 
N-acetylalanine Alanine and Aspartate 
Metabolism 
Amino acid -0.5279 0.0356 0.5275 
10-undecenoate (11:1n1) Medium Chain Fatty Acid Lipid -0.5220 0.0381 0.5422 
5alpha-androstan-3alpha,17alpha-diol 
disulfate 
Androgenic Steroids Lipid -0.5190 0.0394 0.5422 
N6-succinyladenosine Purine Metabolism, Adenine 
containing 
Nucleotide -0.5170 0.0403 0.5422 
Trans-3,4-methyleneheptanoate Food Component/Plant Xenobiotics -0.5161 0.0407 0.5422 
Pregnanediol-3-glucuronide Progestin Steroids Lipid -0.5130 0.0421 0.5422 
9-hydroxystearate Fatty Acid, Monohydroxy Lipid 0.5119 0.0426 0.5422 
Mead acid (20:3n9) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid -0.5086 0.0443 0.5422 





-0.5086 0.0443 0.5422 
N-acetylcitrulline Urea cycle; Arginine and Proline 
Metabolism 
Amino acid 0.5084 0.0444 0.5422 
3-hydroxyadipate Fatty Acid, Dicarboxylate Lipid -0.5079 0.0446 0.5422 
Hydroquinone sulfate Drug - Topical Agents Xenobiotics -0.5079 0.0446 0.5422 
N4-acetylcytidine Pyrimidine Metabolism, Cytidine 
containing 
Nucleotide -0.5041 0.0465 0.5557 
Myristoleoylcarnitine (C14:1) Fatty Acid Metabolism (Acyl 
Carnitine, Monounsaturated) 







Table 3.4: Metabolites which significantly correlate with gestational age at delivery for those samples taken at 34 weeks’ gestation, ordered 
according to p-value (considered significant if p≤0.05).  
Metabolite Sub pathway Super pathway Spearman 
Correlation 
p-value q-value 
Hydroxy-N6,N6,N6-trimethyllysine Lysine Metabolism Amino acid -0.8111 0.0001 0.0797 
N6-methyladenosine Purine Metabolism, Adenine 
containing 
Nucleotide -0.8066 0.0002 0.0797 
Tauroursodeoxycholic acid sulfate (1) Secondary Bile Acid Metabolism Lipid -0.7584 0.0007 0.1694 
Hydroxyasparagine Alanine and Aspartate 
Metabolism 
Amino acid -0.7486 0.0008 0.1694 
Octadecanedioylcarnitine (C18-DC) Fatty Acid Metabolism (Acyl 
Carnitine, Dicarboxylate) 
Lipid -0.7501 0.0008 0.1694 
Gamma-glutamylthreonine Gamma-glutamyl Amino Acid Peptide -0.7396 0.0011 0.1756 
5alpha-androstan-3alpha,17alpha-diol 
disulfate 
Androgenic Steroids Lipid -0.7277 0.0014 0.1861 
Dehydroepiandrosterone sulfate (DHEA-S) Androgenic Steroids Lipid 0.7248 0.0015 0.1861 
Androstenediol (3beta,17beta) monosulfate 
(1) 
Androgenic Steroids Lipid 0.7099 0.0021 0.2192 
5-(galactosylhydroxy)-L-lysine Lysine Metabolism Amino acid -0.7069 0.0022 0.2192 
N-acetylglucosamine/N-acetylgalactosamine Aminosugar Metabolism Carbohydrate -0.6965 0.0027 0.2467 
C-glycosyltryptophan Tryptophan Metabolism Amino acid -0.6875 0.0032 0.2698 
Flavin adenine dinucleotide (FAD) Riboflavin Metabolism Cofactors and Vitamins -0.6831 0.0035 0.2714 
N-acetylglucosaminylasparagine Aminosugar Metabolism Carbohydrate -0.6771 0.0040 0.2819 
Suberoylcarnitine (C8-DC) Fatty Acid Metabolism (Acyl 
Carnitine, Dicarboxylate) 
Lipid -0.6682 0.0047 0.3101 
Oestriol 16-glucuronide Estrogenic Steroids Lipid -0.6578 0.0056 0.3378 
Perfluorooctanesulfonate (PFOS) Chemical Xenobiotics -0.6563 0.0058 0.3378 
N-stearoyl-sphingosine (d18:1/18:0) Ceramides Lipid -0.6459 0.0069 0.3809 
Pro-hydroxy-pro Urea cycle; Arginine and Proline 
Metabolism 






Ribonate Pentose Metabolism Carbohydrate -0.6355 0.0082 0.4068 
3-hydroxy-2-ethylpropionate Leucine, Isoleucine and Valine 
Metabolism 
Amino acid -0.6280 0.0092 0.4164 
Nicotinamide adenine dinucleotide (NAD+) Nicotinate and Nicotinamide 
Metabolism 
Cofactors and Vitamins -0.6280 0.0092 0.4164 
Sulfate Chemical Xenobiotics -0.6250 0.0096 0.4173 
1-linoleoyl-GPA (18:2) Lysophospholipid Lipid -0.6146 0.0113 0.4186 
Gamma-glutamylglutamate Gamma-glutamyl Amino Acid Peptide -0.6117 0.0118 0.4186 
1-stearoyl-2-oleoyl-GPC (18:0/18:1) Phosphatidylcholine (PC) Lipid -0.6102 0.0121 0.4186 
Deoxycholic acid glucuronide Secondary Bile Acid Metabolism Lipid -0.6102 0.0121 0.4186 
Pseudouridine Pyrimidine Metabolism, Uracil 
containing 
Nucleotide -0.6102 0.0121 0.4186 
N4-acetylcytidine Pyrimidine Metabolism, Cytidine 
containing 
Nucleotide -0.6057 0.0129 0.4186 
Succinoyltaurine Methionine, Cysteine, SAM and 
Taurine Metabolism 
Amino acid -0.6043 0.0132 0.4186 
N-palmitoyltaurine Endocannabinoid Lipid -0.6009 0.0138 0.4186 
Pregnenediol sulfate (C21H34O5S) Pregnenolone Steroids Lipid 0.5997 0.0141 0.4186 
5alpha-pregnan-3beta,20alpha-diol disulfate Progestin Steroids Lipid -0.5983 0.0144 0.4186 
(N(1) + N(8))-acetylspermidine Polyamine Metabolism Amino acid -0.5953 0.0150 0.4186 
Phytanate Food Component/Plant Xenobiotics -0.5953 0.0150 0.4186 
3-(3-amino-3-carboxypropyl) uridine Pyrimidine Metabolism, Uracil 
containing 
Nucleotide -0.5927 0.0155 0.4186 
5alpha-androstan-3beta,17alpha-diol disulfate Androgenic Steroids Lipid -0.5923 0.0156 0.4186 
Nonadecanoate (19:0) Long Chain Saturated Fatty Acid Lipid -0.5908 0.0160 0.4186 
Dimethylguanidino valeric acid (DMGV) Urea cycle; Arginine and Proline 
Metabolism 
Amino acid -0.5849 0.0173 0.4430 
5alpha-androstan-3alpha,17beta-diol disulfate Androgenic Steroids Lipid -0.5823 0.0179 0.4445 






Hypoxanthine Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
Nucleotide -0.5789 0.0188 0.4445 
5,6-dihydrouridine Pyrimidine Metabolism, Uracil 
containing 
Nucleotide -0.5774 0.0192 0.4445 
N,N,N-trimethyl-alanylproline betaine (TMAP) Urea cycle; Arginine and Proline 
Metabolism 
Amino acid -0.5715 0.0207 0.4641 
4-hydroxyglutamate Glutamate Metabolism Amino acid -0.5655 0.0224 0.4641 
3-hydroxyhexanoylcarnitine (1) Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid -0.5655 0.0224 0.4641 
Oestriol 3-sulfate Estrogenic Steroids Lipid -0.5655 0.0224 0.4641 
1-stearoyl-GPG (18:0) Lysophospholipid Lipid -0.5645 0.0227 0.4641 
Cis-urocanate Histidine Metabolism Amino acid -0.5637 0.0230 0.4641 
1-palmitoyl-GPA (16:0) Lysophospholipid Lipid -0.5615 0.0236 0.4641 
Sphingomyelin (d18:2/24:1, d18:1/24:2) Sphingomyelins Lipid 0.5596 0.0242 0.4641 
Pregnanediol-3-glucuronide Progestin Steroids Lipid -0.5581 0.0247 0.4641 
Beta-cryptoxanthin Vitamin A Metabolism Cofactors and Vitamins 0.5581 0.0247 0.4641 
21-hydroxypregnanolone disulfate Pregnenolone Steroids Lipid -0.5548 0.0257 0.4655 
3-formylindole Food Component/Plant Xenobiotics 0.5536 0.0261 0.4655 
Octadecenedioylcarnitine (C18:1-DC) Fatty Acid Metabolism (Acyl 
Carnitine, Dicarboxylate) 
Lipid -0.5506 0.0271 0.4655 
Glycochenodeoxycholate glucuronide (1) Primary Bile Acid Metabolism Lipid -0.5506 0.0271 0.4655 
2-naphthol sulfate Chemical Xenobiotics -0.5506 0.0271 0.4655 
N,N,N-trimethyl-5-aminovalerate Lysine Metabolism Amino acid -0.5462 0.0286 0.4835 
Stearate (18:0) Long Chain Saturated Fatty Acid Lipid -0.5432 0.0297 0.4930 
1,5-anhydroglucitol (1,5-AG) Glycolysis, Gluconeogenesis, and 
Pyruvate Metabolism 
Carbohydrate -0.5417 0.0302 0.4937 
S-adenosylhomocysteine (SAH) Methionine, Cysteine, SAM and 
Taurine Metabolism 
Amino acid -0.5395 0.0310 0.4955 








Androgenic Steroids Lipid -0.5358 0.0324 0.5053 
Succinylcarnitine (C4-DC) TCA Cycle Energy -0.5328 0.0336 0.5137 
N-stearoyltaurine Endocannabinoid Lipid -0.5318 0.0340 0.5137 
Deoxycholic acid 12-sulfate Secondary Bile Acid Metabolism Lipid -0.5280 0.0355 0.5290 
(R)-3-hydroxybutyrylcarnitine Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid -0.5253 0.0366 0.5373 
N-palmitoylglycine Fatty Acid Metabolism (Acyl 
Glycine) 
Lipid -0.5209 0.0386 0.5493 
Sphingomyelin (d18:1/22:1, d18:2/22:0, 
d16:1/24:1) 
Sphingomyelins Lipid 0.5209 0.0386 0.5493 
Arachidate (20:0) Long Chain Saturated Fatty Acid Lipid -0.5194 0.0392 0.5502 
N-acetylhistidine Histidine Metabolism Amino acid -0.5149 0.0412 0.5502 
Gamma-glutamylphenylalanine Gamma-glutamyl Amino Acid Peptide -0.5149 0.0412 0.5502 
17alpha-hydroxypregnanolone glucuronide Pregnenolone Steroids Lipid -0.5149 0.0412 0.5502 
Adipoylcarnitine (C6-DC) Fatty Acid Metabolism (Acyl 
Carnitine, Dicarboxylate) 
Lipid -0.5134 0.0419 0.5502 
Urate Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
Nucleotide -0.5134 0.0419 0.5502 
Hexadecanedioate (C16-DC) Fatty Acid, Dicarboxylate Lipid -0.5090 0.0441 0.5561 
Stearoylcarnitine (C18) Fatty Acid Metabolism (Acyl 
Carnitine, Long Chain Saturated) 
Lipid -0.5090 0.0441 0.5561 
Linoleoyl-linoleoyl-glycerol (18:2/18:2) [2] Diacylglycerol Lipid 0.5090 0.0441 0.5561 
Hyocholate Secondary Bile Acid Metabolism Lipid -0.5049 0.0461 0.5696 
3-aminoisobutyrate Pyrimidine Metabolism, Thymine 
containing 
Nucleotide 0.5045 0.0463 0.5696 
N1-methyladenosine Purine Metabolism, Adenine 
containing 
Nucleotide -0.5030 0.0470 0.5718 
Tiglylcarnitine (C5:1-DC) Leucine, Isoleucine and Valine 
Metabolism 






Pantothenate Pantothenate and CoA 
Metabolism 






















Table 3.5: Metabolites which significantly correlate with gestational age at delivery for those samples taken in latent phase (n=11)/prior start 
of IOL (n=3) for post-term, ordered according to p-value (considered significant if p≤0.05).  
Metabolite Sub pathway Super pathway Correlation p-value q-value 
N-acetylmethionine Methionine, Cysteine, SAM and 
Taurine Metabolism 
Amino acid -0.8860 0.0000 0.0249 
N-formylmethionine Methionine, Cysteine, SAM and 
Taurine Metabolism 
Amino acid -0.7697 0.0013 0.5114 
Glycochenodeoxycholate glucuronide (1) Primary Bile Acid Metabolism Lipid -0.7563 0.0017 0.5114 
N-acetylserine Glycine, Serine and Threonine 
Metabolism 
Amino acid -0.7496 0.0020 0.5114 
5-(galactosylhydroxy)-L-lysine Lysine Metabolism Amino acid -0.7294 0.0031 0.5736 
Hydroxyasparagine Alanine and Aspartate 
Metabolism 
Amino acid -0.7227 0.0035 0.5736 
Cis-4-decenoylcarnitine (C10:1) Fatty Acid Metabolism (Acyl 
Carnitine, Monounsaturated) 
Lipid -0.7160 0.0040 0.5736 
2,3-dihydroxy-5-methylthio-4-pentenoate 
(DMTPA) 
Methionine, Cysteine, SAM and 
Taurine Metabolism 
Amino acid -0.6936 0.0059 0.7075 
5alpha-androstan-3alpha,17alpha-diol disulfate Androgenic Steroids Lipid -0.6847 0.0069 0.7075 
Octadecenedioylcarnitine (C18:1-DC) Fatty Acid Metabolism (Acyl 
Carnitine, Dicarboxylate) 
Lipid -0.6780 0.0077 0.7075 
Oestriol 16-glucuronide Estrogenic Steroids Lipid -0.6780 0.0077 0.7075 
Arabitol/xylitol Pentose Metabolism Carbohydrate -0.6623 0.0099 0.8299 
N-acetylhistidine Histidine Metabolism Amino acid -0.6533 0.0113 0.8414 
N-acetylalanine Alanine and Aspartate 
Metabolism 
Amino acid -0.6511 0.0117 0.8414 
Perfluorooctanesulfonate (PFOS) Chemical Xenobiotics -0.6422 0.0133 0.8415 
Oestriol 3-sulfate Estrogenic Steroids Lipid -0.6354 0.0146 0.8415 
Hexanoylcarnitine (C6) Fatty Acid Metabolism (Acyl 
Carnitine, Medium Chain) 
Lipid -0.6332 0.0151 0.8415 






Tetradecanedioate (C14-DC) Fatty Acid, Dicarboxylate Lipid -0.6198 0.0181 0.8415 
N,N,N-trimethyl-alanylproline betaine (TMAP) Urea cycle; Arginine and Proline 
Metabolism 
Amino acid -0.6153 0.0192 0.8415 
1-palmitoyl-GPE (16:0) Lysophospholipid Lipid 0.6086 0.0209 0.8415 
5-hydroxymethyl-2-furoylcarnitine Food Component/Plant Xenobiotics -0.6030 0.0225 0.8415 
17alpha-hydroxypregnanolone glucuronide Pregnenolone Steroids Lipid -0.5996 0.0234 0.8415 
Gamma-carboxyglutamate Glutamate Metabolism Amino acid -0.5974 0.0241 0.8415 
Cortisol 21-sulfate Corticosteroids Lipid -0.5966 0.0243 0.8415 
Hydroquinone sulfate Drug - Topical Agents Xenobiotics -0.5911 0.0260 0.8415 
1-oleoyl-GPE (18:1) Lysophospholipid Lipid 0.5885 0.0268 0.8415 
Octadecanedioylcarnitine (C18-DC) Fatty Acid Metabolism (Acyl 
Carnitine, Dicarboxylate) 
Lipid -0.5862 0.0276 0.8415 
N6-carbamoylthreonyladenosine Purine Metabolism, Adenine 
containing 
Nucleotide -0.5862 0.0276 0.8415 
Octadecanedioate (C18-DC) Fatty Acid, Dicarboxylate Lipid -0.5795 0.0299 0.8415 
Chiro-inositol Inositol Metabolism Lipid 0.5776 0.0305 0.8415 
Linoleoyl-linoleoyl-glycerol (18:2/18:2) [2] Diacylglycerol Lipid -0.5773 0.0306 0.8415 
O-sulfo-L-tyrosine Chemical Xenobiotics -0.5773 0.0306 0.8415 
5alpha-androstan-3alpha,17beta-diol disulfate Androgenic Steroids Lipid -0.5723 0.0325 0.8415 
3-indoxyl sulfate Tryptophan Metabolism Amino acid -0.5706 0.0331 0.8415 
Decanoylcarnitine (C10) Fatty Acid Metabolism (Acyl 
Carnitine, Medium Chain) 
Lipid -0.5638 0.0357 0.8415 
N-acetyl-cadaverine Lysine Metabolism Amino acid -0.5616 0.0366 0.8415 
Phenylacetylglutamine Acetylated Peptides Peptide -0.5616 0.0366 0.8415 
Suberate (C8-DC) Fatty Acid, Dicarboxylate Lipid -0.5616 0.0366 0.8415 
Tauroursodeoxycholic acid sulfate (1) Secondary Bile Acid Metabolism Lipid -0.5580 0.0381 0.8415 
Octanoylcarnitine (C8) Fatty Acid Metabolism (Acyl 
Carnitine, Medium Chain) 
Lipid -0.5571 0.0385 0.8415 
4-ethylcatechol sulfate Benzoate Metabolism Xenobiotics -0.5571 0.0385 0.8415 






N-acetylputrescine Polyamine Metabolism Amino acid -0.5527 0.0404 0.8415 
Pimeloylcarnitine/3-methyladipoylcarnitine (C7-
DC) 
Fatty Acid Metabolism (Acyl 
Carnitine, Dicarboxylate) 
Lipid -0.5527 0.0404 0.8415 
N4-acetylcytidine Pyrimidine Metabolism, Cytidine 
containing 
Nucleotide -0.5504 0.0414 0.8415 
Pro-hydroxy-pro Urea cycle; Arginine and Proline 
Metabolism 
Amino acid -0.5482 0.0424 0.8415 
Indoleacetylglutamine Tryptophan Metabolism Amino acid -0.5424 0.0451 0.8415 
5-hydroxyindoleacetate Tryptophan Metabolism Amino acid -0.5417 0.0454 0.8415 
N-acetyl-beta-alanine Pyrimidine Metabolism, Uracil 
containing 
Nucleotide -0.5415 0.0455 0.8415 
5alpha-pregnan-3beta,20alpha-diol 
monosulfate (1) 
Progestin Steroids Lipid -0.5370 0.0477 0.8415 
4-acetamidobutanoate Polyamine Metabolism Amino acid -0.5348 0.0488 0.8415 
Linoleoyl-docosahexaenoyl-glycerol (18:2/22:6) 
[2] 













Table 3.6: Metabolites which significantly correlate with gestational age at delivery for at least two of the sampled time points (p≤0.05). 




































Lipid -0.5190 0.0394 -0.7277 0.0014 -0.6847 0.0069 
Glycochenodeoxycholate 
glucuronide (1) 
Primary Bile Acid 
Metabolism 










Nucleotide -0.5041 0.0465 -0.6057 0.0129 -0.5504 0.0414 
Perfluorooctanesulphonate 
(PFOS) 


















Lipid -0.6883 0.0032 -0.5655 0.0224 
  





























Lipid 0.6275 0.0093 0.7099 0.0021 
  
Glyco-beta-muricholate Primary Bile Acid 
Metabolism 
Lipid -0.6484 0.0066 -0.5387 0.0313 
  
Deoxycholic acid glucuronide Secondary Bile 
Acid Metabolism 
Lipid -0.6499 0.0064 -0.6102 0.0121 
  








Xenobiotics 0.5309 0.0344 0.5536 0.0261 
  
2-naphthol sulfate Chemical Xenobiotics -0.6603 0.0054 -0.5506 0.0271 
  
N-acetylalanine Alanine and 
Aspartate 
Metabolism 








3-indoxyl sulfate Tryptophan 
Metabolism 








Lipid -0.7004 0.0025 
  
-0.5370 0.0477 
Hydroquinone sulfate Drug - Topical 
Agents 
Xenobiotics -0.5079 0.0446 
  
-0.5911 0.0260 
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Figure 3.5: Scatter plots showing correlation between metabolite level and gestational age at delivery for perfluorooctanesulfonate (PFOS), the chemical 
for which the correlation was significant at each of the sample time points with Spearman correlations of: A. -0.639 (p=0.008) at 28 weeks’ gestation (n=16); 
B. -0.656 (p=0.006) at 34 weeks’ gestation (n=16); C. -0.6488 (p=0.0133) in latent phase (n=14). Scaled PFOS for each sample determined following 











3.5.6 Summary of differences in maternal metabolites between sampling points 
during pregnancy 
Using paired t-tests, between 28 and 34 weeks’ gestation, 159 metabolites 
significantly increased (p≤0.05; 117 of which q<0.1), and 40 metabolites 
significantly decreased (p≤0.05; 28 of which q<0.1). Between 28 weeks’ 
gestation and latent phase 364 metabolites significantly increased (p≤0.05; all 
of which q<0.1) and 54 metabolites significantly decreased (p≤0.05; all of which 
q<0.1). Between 34 weeks’ gestation and latent phase 306 metabolites 
significantly increased (p≤0.05; all of which q<0.1) and 50 significantly decreased 
(p≤0.05; all of which q<0.1) (Table 3A3, Appendices). Figure 3.6 is a Venn 
diagram designed to illustrate the overlap of the of metabolites with significant 
differences between paired time points (28 weeks vs 34 weeks; 34 weeks vs 
latent phase; 28 weeks vs latent phase). This shows that differences between 
metabolites at the paired time points 28 weeks vs 34 weeks is not simply a 
subset of 28 weeks vs latent phase, which likewise is not a subset of 34 weeks 
vs latent phase. This indicates that there are specific changes in certain 
metabolites which occur at certain gestations of pregnancy, and these could be 








Figure 3.6: Venn diagram illustrating the spread and degree of overlap of metabolites with 
significant differences between paired time points (28 weeks vs 34 weeks = red; 34 weeks vs latent 





























Oleoyl ethanolamide 1.41 1.33 
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0.31 0.19 0.16 0.19 0.44 
   
N-oleoylserine 
           
N-palmitoylserine 0.69 




   
Significant fold-changes for endocannabinoids (all results shown are significant at p≤0.05); paired t-tests for differences in the mean value between: latent 
phase samples and samples taken at 28 weeks’ gestation (L/28); latent phase samples and samples taken at 34 weeks’ gestation (L/34);  cord vein samples 
and cord artery samples of the elective caesarean section group (CVCS/CACS); cord vein samples and intervillous samples of the spontaneously labouring 
group (CVS/IVS); cord vein samples and intervillous samples of the elective caesarean section group (CVCS/IVCS); cord artery and intervillous samples of the 
induction of labour group (CAIOL/IVIOL); cord artery and intervillous samples of the elective caesarean section group (CACS/IVCS); and Welch’s t-test for 
differences in the mean value between: samples taken in the pre-operative clinic for the elective caesarean group and samples taken in the latent phase of 
the spontaneously labouring group (LCS/L); cord artery samples of the induction of labour group and cord artery of the spontaneously labouring group 
(CAIOL/CAS); cord artery of the elective caesarean section group and cord artery of the spontaneously labouring group (CACS/CAS); and cord vein of the 
induction of labour group and cord vein of the spontaneously labouring group (CVIOL/CVS). Comparison of metabolites associated with different modes of 
delivery: (all groups n=4): CVCS= cord vein for elective caesarean section group; CACS = cord artery sample for elective caesarean section group; CVS= cord 
vein sample for spontaneous labour group; IVS = intervillous (maternal) blood for spontaneous labour group; IVCS = intervillous blood sample for elective 
caesarean section group; CAIOL = cord artery sample for induction of labour group; IVIOL = intervillous blood sample for induction of labour group; LCS = term 






for the induction of labour group. Colour code: purple = increase; yellow = decrease. Comparison of metabolites associated with gestational age at delivery 
at different time points sampled: Latent=samples taken in latent phase spontaneous labour or start of IOL for post-dates (n=14); 28 = samples taken at 28 








3.5.7 Summary of differences in metabolites within vascular compartments at 
delivery between different modes of labour onset and delivery 
Regarding the CA, Welch’s two-sample t-tests indicated that: 104/1032 (10%) of 
the measured metabolites  were significantly (p≤0.05) different between the CA 
of the IOL group and the CA of the SL group, and 16 of these had a q-value <0.1; 
232/1032 (22.4%) were significantly (p≤0.05) different between the CA of the 
ECS group and the CA of the SL group, and 230 of these also had a q-value <0.1; 
and 82/1032 (7.9%) metabolites were significantly (p≤0.05) different between 
the CA of the ECS group and CA of the IOL group, and 35 of these also had a q-
value <0.1 (Appendix 3A4). 
Regarding the CV, Welch’s two-sample t-tests indicated that: 113/1032 (10.9%) 
of the metabolites were significantly (p≤0.05) different between the CV of the 
IOL group and the CV of the SL group, and 10 had a p<0.1; 130/1032 (12.6%) 
were significantly (p≤0.05) different between the CV of the ECS group and the 
CV of the SL group, and 21 of these had a q-value <0.1 (Appendix 3A5); and 
60/1032 (5.8%) of the metabolites were significantly (p ≤0.05) different between 
the CV of the IOL group and the CV of the ECS group, and 2 of these had a q-
value <0.1 (Appendix 3A5).  
Regarding the IV blood, Welch’s two-sample t-tests indicated that: 30/1032 






blood of the IOL group and the IV blood of the SL group, and none had a 
significant q value; 111/1032 (10.8%) were significantly (p ≤0.05) different 
between the IV blood of the ECS group and the IV blood of the SL group, and 10 
of these had a q-value <0.1; and 50/1032 (4.9%) were significantly (p ≤0.05) 
different between the IV blood of the IOL group and the IV blood of the ECS 
group, and none of these had a q-value <0.1 (Appendix 3A7). 
3.5.8 Endocannabinoids 
N-palmitoyltaurine was significantly negatively correlated with gestational age 
at delivery (Figure 3.7) at 34 weeks’ gestation. N-palmitoyltaurine was also 
significantly reduced in the CA of people with ECS when compared with the CA 
of women who spontaneously laboured (0.63-fold change (-FC), p=0.0032). 
Whereas the other endocannabinoids measured increased with gestation and 
were decreased in the CV and CA compared with the concentrations in the IV 
blood, N-palmitoylserine significantly decreased between 28 weeks’ gestation 
and latent phase (0.69-FC, p=0.0110), and significantly increased in the CV (5.40-
fold change, p=0.0197) and the CA (4.76-FC, p=0.0172)  compared with the IV 
blood of the ECS group. It was also significantly increased in the pre-operative 
sample from the ECS group compared with the latent phase of spontaneous 






N-stearoyltaurine was negatively correlated with gestational age at delivery in 
samples taken at 28 weeks’ and 34 weeks’ gestation (Figure 3.8), it was also 
significantly reduced in the CA of the IOL group compared with CA of the SL 
group, and also significantly reduced in the CA of the ECS group compared with 
the SL group. Again, this would fit with increased levels being associated with 
earlier gestational age at delivery in spontaneous labour at term compared with 
no labour, and therefore it may be involved in the trigger for human labour. It 
was significantly higher in the CV of the IOL group when compared with the SL 
group (1.56-fold change, p=0.0305), it was also increased in the CV of the ECS 
group compared with the SL group, but this did not reach significance (1.51-fold 
change, p=0.0625).  
The endocannabinoids oleoyl-ethanolamide (OEA), palmitoyl-ethanolamide 
(PEA) and linoleoyl-ethanolamide all significantly increased between 28 weeks’ 
gestation and latent phase, and between 34 weeks’ gestation and latent phase. 
OEA increased 1.41-fold (p=0.005) in the latent phase compared with 28 weeks’ 
gestation, and 1.33-fold-change (p=0.0057) between 34 weeks’ gestation and 
latent phase. Further, N-oleoyltaurine and N-stearoyltaurine were both 
significantly increased in latent phase compared with levels at 28 weeks’ 
gestation, and N-palmitoylserine significantly decreased between 28 weeks’ 







Figure 3.7: Scatter plot showing correlation between N-palmitoyltaurine level and gestational age 
at delivery at 34 weeks’ gestation, and box-plots showing differences between modes of labour 
onset for latent, intervillous, cord artery and cord vein: A. scatter plot showing correlation between 
metabolite level and gestational age at delivery for N-palmitoyltaurine at 34 weeks’ gestation with 
Spearman correlation -0.601 (p=0.014) (n=16). B. Box plots for N-palmitoyltaurine for the three modes 
of labour onset showing median value level (horizontal line within plot) and mean (cross within plot), 
and interquartile range for each of the different sample points (L=latent/pre-op, intervillous, CA=cord 
artery, CV=cord vein) for each of the different modes of labour and delivery (S=spontaneous, 
IOL=induction of labour, CS=elective caesarean section) (each group n=4). ** indicates p≤0.01. Scaled 
N-palmitoyltaurine for each sample determined following normalisation by sample volume, log-







Figure 3.8: Scatter plots showing correlation between N-stearoyltaurine level and gestational age at 
delivery at 28 weeks’ and 34 weeks’ gestation, and box-plots showing differences between modes 
of labour onset for latent, intervillous, cord artery and cord vein. A and B: scatter plots showing 
correlation between N-stearoyltaurine level and gestational age at delivery at A. 28 weeks’ gestation, 
with Spearman correlation -0.528 (p=0.035) (n=16); and B. 34 weeks’ gestation, with Spearman 
correlation -0.532 (p=0.034) (n=16). C. Box plots for N-stearoyltaurine for the three modes of labour 
onset types within each of the labour and delivery samples showing median value level (horizontal 
line within plot) and mean (cross within plot), and interquartile range for each of the different sample 
points (L=latent/pre-op, intervillous, CA=cord artery, CV=cord vein) for each of the different modes of 
labour and delivery (S=spontaneous, IOL=induction of labour, CS=elective caesarean section) (each 
group n=14). * indicates p≤0.05. Scaled N-stearoyltaurine for each sample determined following 
normalisation by sample volume, log-transformation, then rescaling to set the median N-







Figure 3.9: Box plots for scaled metabolite for the three labour onset types within each of the labour 
and delivery samples for oleoyl-ethanolamide, palmitoyl-ethanolamide and linoleoyl-ethanolamide. 
Box plots for scaled metabolite for the three labour onset types within each of the labour and delivery 
samples showing median value level (horizontal line within plot) and mean (cross within plot), and 
interquartile range for each of the different sample points (L=latent/pre-op, intervillous, CA=cord 
artery, CV=cord vein) for each of the different modes of labour and delivery (S=spontaneous, 
IOL=induction of labour, CS=elective caesarean section) (each group n=4). *** indicates p≤0.001; * 
indicates p≤0.05. A. oleoyl-ethanolamide (OEA); B. palmitoyl-ethanolamide (PEA); C. linoleoyl-
ethanolamide (LEA). Scaled metabolite for each sample determined following normalisation by sample 






PEA was significantly increased in latent phase when compared with both 28 
weeks’ gestation (1.52-fold change, p=0.0007) and 34 weeks’ gestation (1.42-
fold change, p=0.002). Levels in the CV were significantly lower than in the IV 
blood in the SL group (0.68-FC, p=0.023) (see Figure 3.9) and ECS group (0.72-FC, 
p=0.0179), and significantly reduced in the CA compared with the IV blood in the 
ECS group (0.69-FC, p=0.0132). PEA was significantly reduced in the pre-
operative samples for the ECS than in the latent phase of the group in 
spontaneous labour (0.56-FC, p=0.0008). PEA was also reduced in the CA of the 
ECS group when compared with the SL group, although this did not reach 
significance (0.71-fold change, p=0.0584). 
LEA more than doubled between 28 weeks’ gestation and latent phase (2.06-FC, 
p=0.0002) and between 34 weeks’ gestation and latent phase (2.01-FC, 
p=0.0035). It was significantly lower in the CV than the IV blood in the SL group 
(0.31-FC, p=0.017), and significantly lower in the CV of the ECS group than the 
IV blood (0.19-fold change, p=0.007). It was significantly reduced in the CA of 
women in the ECS group compared with the IV blood (0.19-FC, p=0.007). As with 
PEA, LEA was also significantly reduced in the maternal blood samples taken at 







Of note, in contrast to the samples analysed in Chapter 2, Anandamide (AEA), 
one of the main endocannabinoids researched, was not detected in this study. 
Metabolon, Inc., were asked to investigate, and revisited the spectrometry 
results and confirmed that there was no quantifiable signal for AEA in any of the 
samples of this study. It was highlighted that as a non-targeted platform, MS 
metabolomics is not optimised for the detection of specific compounds. 
Metabolon, Inc., also looked historically at their database and found that AEA 
was detected in only approximately 15% of the studies they have conducted in 
human blood, and concluded that it is likely a labile metabolite that is present 
in the blood at levels which is close to the detection levels. The samples were 
treated in exactly the same way for both studies before transfer to the United 
States and therefore there is no other obvious explanation for this difference.  
3.5.9 Sphingolipids 
Twenty-eight sphingomyelins (the major member of the sphingolipid family) 
were measured in this study. In Part 2, the concentration of three of the 
sphingomyelins in the samples taken at 34 weeks’ gestation were significantly 
correlated with gestational age at delivery. Stearoyl sphingomyelin (d18:1/18:0) 
was negatively correlated, while sphingomyelin (d18:1/22:1, d18:2/22:0, 






correlated (-0.5789, p=0.0188 and 0.5596, p=0.0242, q=0.4641, respectively) 
(Table 3.8). 
Nineteen of the 28 sphingomyelins measured were significantly lower (range of-
FC 0.17-0.73) in the CV than the IV blood of the SL group, and the same 
significant changes were observed for 16 of these in the ECS group. 
Concentrations of eight sphingomyelins were significantly lower in the CA than 
the IV blood in the SL group, and 19 were significantly lower in the CA of ECS 
group (Table 3.8). In contrast, two sphingomyelins were significantly higher in 
the CV when compared with the IV blood in all three modes of labour (Table 3.8).  
Most of the sphingomyelins were found in higher concentrations in the IV, CA 
and CV of the SL than the ECS groups, but the majority of these were not 
significantly different at the p≤0.05 level. Concentrations of palmitoyl 
sphingomyelin (d18:1/16:0), behenoyl sphingomyelin (d18:1/22:0), and 
sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0) were significantly lower in 
the CA of the ECS group compared with the SL group (0.87-FC, 0.73-FC, and 0.72-
FC, respectively). Further concentrations of sphingomyelin (d18:1/20:1, 
d18:2/20:0) was significantly lower in the IV of the ECS group than the SL group 
(0.68-fold-change). There were no significant differences in sphingomyelin 






3.5.10 Sphinganine-1-phosphate and sphinganine 
Of the metabolites of sphingolipid synthesis, most changes were seen in 
concentrations of sphinganine-1-phosphate and sphinganine (Table 3.8). 
Although both sphinganine and sphinganine-1-phosphate increased in the 
maternal plasma during pregnancy, these metabolites showed differing 
concentration ratios in the cord and IV blood at delivery. Whereas in the ECS 
group sphinganine was reduced 0.10-fold (p=0.0013) in the CV compared with 
the IV, and the CA had 0.17-fold (p=0.0001) the amount present in the IV 
samples, sphinganine-1-phosphate levels were 2.85-fold (p= 0.0032) greater in 
the CV than IV samples, and 2.21-fold (p= 0.0191) greater in the CA than the IV 
blood. In addition, sphinganine-1-phosphate was slightly but significantly 
increased in the CV compared with the CA (1.29-fold change, p=0.0097) in the 
ECS group. Similar differences were observed in the SL group where sphinganine 
concentration was 0.22-fold less (p=0.0008) in the CA compared with the IV 
samples, while sphinganine-1-phosphate was 6.92-fold (p=0.0007) greater in 
the CA than the IV sample; and sphinganine-1-phosphate was  8.06-fold (p= 
0.0232) greater in the CV than IV sample.  
Regarding differences between modes of labour and delivery, concentrations of 
sphinganine-1-phosphate were significantly lower in the CA of the IOL group 






than in the CA of the SL group. Sphinganine was significantly lower in the CV of 
both the IOL group (0.19-FC, p=0.0218) and the ECS group (0.12-FC, p=0.0142) 
than in the SL group. These results indicate that sphinganine and sphinganine-
1-phosphate are differentially expressed by the mother and fetus and between 
modes of labour and delivery.  
In addition, a third lipid involved in sphingolipid metabolism, sphingadienine, 
decreased during pregnancy between 28 weeks’ and latent phase (0.70-fold 
change, p=0.0048), and between 34 weeks’ gestation and latent phase (0.58-






Table 3.8: Significant fold-changes for sphingolipids (all results shown are significant at p≤0.05); paired t-tests for differences in the mean value 
between: cord vein and cord artery of the spontaneously labouring group (CVS/CAS); cord vein and cord artery of the induction of labour group 
(CVIOL/CAIOL); cord vein and cord artery of the elective caesarean section group (CVCS/CACS); cord vein and intervillous blood of the 
spontaneously labouring group (CVS/IVS); cord vein and intervillous samples of the elective caesarean section group (CVCS/IVCS); cord artery 
and intervillous samples of the spontaneously labouring group (CAS/IVS); cord artery and intervillous blood of the elective caesarean section 
group (CACS/IVCS); and Welch’s t-test for differences in the mean value between: pre-operative sample of the elective caesarean section group 
and the latent phase sample of the spontaneously labouring group (LCS/L); cord artery of the induction of labour group and the cord artery of 
the spontaneously labouring group (CAIOL/CAS); cord artery of the elective caesarean section group and the cord artery of the spontaneously 
labouring group (CSCS/CAS); cord vein of the induction of labour group and the cord vein of the spontaneously labouring group (CVIOL/CVS); 
cord vein of the elective caesarean section group and the cord vein of the spontaneously labouring group (CVCS/CVS); intervillous sample of the 
elective caesarean section group and the intervillous blood of the spontaneously labouring sample (IVCS/IVS); and the intervillous sample of the 
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All groups n=4: CVCS= cord vein for elective caesarean section group; CACS = cord artery sample for elective caesarean section group; CVS= cord vein 
sample for spontaneous labour group; IVS = intervillous (maternal) blood for spontaneous labour group; IVCS = intervillous blood sample for elective 
caesarean section group; CAIOL = cord artery sample for induction of labour group; IVIOL = intervillous blood sample for induction of labour group; LCS = 
term not in labour sample taken day prior to elective caesarean section; L = samples taken in latent phase for spontaneous labour group; CVIOL = cord vein 













Table 3.9: Significant changes for Sphingosines (all results shown are significant at p≤0.05): paired t-tests for cord vein and cord artery of the 
elective caesarean section group (CVCS/CACS); cord vein and intervillous samples of the elective caesarean section group (CVCS/IVCS); cord vein 
and intervillous samples of the elective caesarean section group (CVCS/IVCS); cord artery and intervillous samples of the spontaneously labouring 
group (CAS/IVS);  cord artery and intervillous blood of the elective caesarean section group (CACS/IVCS); Welch’s t-test for cord artery of the 
elective caesarean section group and the cord artery of the spontaneously labouring group (CACS/CAS); cord artery of the spontaneously 
labouring group and the cord artery of the induction of labour group (CACS/CAIOL); cord vein of the induction of labour group and the cord vein 
of the spontaneously labouring group (CVIOL/CVS); cord vein of elective caesarean section group and cord vein of spontaneously labouring group 
(CVCS/CVS); and intervillous sample of the elective caesarean section group and intervillous blood of the spontaneously labouring group 
(IVCS/IVS). 




















Sphingosine Sphingosines Lipid 
  
0.17 0.27 0.20 0.49 0.42 0.28 0.22 
 
Sphingosine 1-phosphate Sphingosines Lipid 1.49 3.69 2.78 4.38 
 
0.43 0.61 




         
0.50 
All groups n=4: CVCS= cord vein for elective caesarean section group; CACS = cord artery sample for elective caesarean section group; CVS= cord vein 
sample for spontaneous labour group; IVS = intervillous (maternal) blood for spontaneous labour group; CVCS = cord vein sample for elective caesarean 
section group; IVCS = intervillous blood sample for elective caesarean section group; CAS = cord artery sample for spontaneous labour group; CAIOL = cord 
artery sample for induction of labour group; IVIOL = intervillous blood sample for induction of labour group; LCS = term not in labour sample taken day prior 






3.5.11 Sphingosine and sphingosine-1-phosphate 
Concentrations of sphingosine did not change during pregnancy. However, 
concentrations were different at the time of labour between the different 
compartments and the different modes of labour onset and delivery. 
Concentrations of sphingosine were significantly lower in the CV (0.17-FC, 
p=0.003) and CA (0.20-FC, p=0.002) than in the IV samples in the ECS group. It 
was also lower in the CA than the IV samples (0.27-FC, p=0.007) in the SL group. 
There were also differences according to type of labour onset: concentrations 
of sphingosine were significantly lower in the CA of the ECS group than the CA 
of the SL group (0.49-FC, p=0.016), and lower in the CV in the ECS group than 
the CV in the SL group (0.22-FC, p=0.034). Further, concentration of sphingosine 
in the CA of the ECS group was also significantly lower than that in the CA of the 
IOL group (0.42-FC, p=0.017). And the CV of the IOL group had significantly lower 
sphingosine concentration than the CV of the SL group (0.28-FC, p=0.049) (Table 
3.9).  
Differences in sphingosine 1-phosphate between vascular compartments were 
generally in the opposite direction to those for sphingosine. Levels of 
sphingosine 1-phosphate were 1.49-fold greater in the CV than CA of the ECS 
group (p=0.004), and 2.78-fold greater in the CV than IV (p=0.010). In the SL 






IV (p=0.016), and 4.38-fold higher in the CA than IV (p=0.011). Differences 
between the different modes of labour onset and delivery were in the same 
direction as for sphingosine: levels in the CA of the ECS group were significantly 
lower than both the CA in the SL group (0.43-FC, p=0.001) and IOL group (0.61-
FC, p=0.043) (Table 3.9). 
3.5.12 Ceramides 
Overall, the ceramide metabolites tended to increase slightly with gestation 
throughout pregnancy (Table 3.10). N-stearoyl-sphingosine (d18:1/18:0) was 
negatively correlated with gestational age at spontaneous labour (-0.6459, 
p=0.007), and this was the only ceramide that was associated with gestational 
age at delivery. Just over half of the measured ceramides were lower in the CV 
and CA than the IV blood, potentially indicating that the source of these is likely 
maternal (Table 3.10). There were few differences between the concentrations 
of ceramide metabolites in the different vascular compartments and the mode 
of labour onset and delivery, other than a significantly greater level in the CV of 
women who spontaneously laboured compared with the CV of those who were 
induced of the Hexosylceramides (HCER) glycosyl-N-stearoyl-sphingosine 
(d18:1/18:0), glycosyl-N-behenoyl-sphingadienine (d18:2/22:0) and glycosyl 
ceramide (d18:1/20:0, d16:1/22:0), which had fold changes of 1.54 (p=0.005), 






Table 3.10: Significant changes for ceramide family (including ceramides, dihydroceramides, hexosylceramides, lactosylceramides and ceramide 
PE); all results shown are significant at p≤0.05. Paired t-tests for differences in the mean value between: latent phase samples and 28 week’s 
gestation samples of the spontaneously labouring group (L/28); latent phase samples and 34 week’s gestation samples of the spontaneously 
labouring group (L/34);  cord vein and cord artery of the spontaneously labouring group (CVS/CAS); cord vein and intervillous blood of the 
spontaneously labouring group (CVS/IVS); ); cord artery and intervillous blood of the elective caesarean section group (CACS/IVCS); cord artery 
and intervillous blood of the induction of labour group (CAIOL/IVIOL); cord artery and intervillous samples of the elective caesarean section 
group (CACS/MCS); and Welch’s t-test for differences in the mean value between:  pre-operative sample of the elective caesarean section group 
and the latent phase sample of the spontaneously labouring group (LCS/L); cord artery of the induction of labour group and the cord artery of 
the spontaneously labouring group (CAIOL/CAS); cord artery of the elective caesarean section group and the cord artery of the spontaneously 
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1.08 
    
0.75 
 
All groups n=4: CVCS= cord vein for elective caesarean section group; CACS = cord artery sample for elective caesarean section group; CVS= cord vein 
sample for spontaneous labour group; IVS = intervillous (maternal) blood for spontaneous labour group; IVCS = intervillous blood sample for elective 






term not in labour sample taken day prior to elective caesarean section; L = samples taken in latent phase for spontaneous labour group; CVIOL = cord vein 






3.5.13 Adenosine 3',5'-cyclic monophosphate 
Adenosine 3',5'-cyclic monophosphate (cAMP) was significantly reduced in the 
CV of both the IOL (0.22-FC, p=0.0336) and the ECS (0.11-FC, p=0.0091) groups 
when compared with the SL group, and also between the ECS pre-operative 
samples when compared with the latent phase of SL (0.69-FC, p=0.0302). cAMP 
was also lower in the CA than CV in the IOL (0.56-fc, p=0.0497) and ECS group 
(0.36-fc, p=0.0397). There was an opposite effect in the SL group with a 2.56-
fold increased concentration in the CA than the CV in the SL group, however this 
was not significant (p=0.081). Further, the concentration in the IV sample was 
significantly higher than that in the CV sample for the IOl group (0.47-FC, 
p=0.0284) and ECS group (0.11-FC, p=0.006), whereas there was no change in 
the SL group (CVS/MS = 1.21-FC, p=0.831). 
3.5.14 Steroids correlated with gestational age at delivery 
Regarding those steroid metabolites which were significantly correlated with 
gestational age at delivery at more than one time point: 5alpha-androstan-
3alpha,17alpha-diol disulfate was correlated at all time points (Figure 3.10); 21-
hydroxypregnanolone disulfate, 5alpha-pregnan-3beta,20alpha-diol disulfate, 
pregnanediol-3-glucuronide, dehydroepiandrosterone sulfate (DHEA-S) and 
androstenediol (3beta,17beta) monosulfate (1) were correlated with gestational 






(Table 3.11 and Figure 3.11); 5alpha-pregnan-3beta,20alpha-diol monosulfate 
(1) was correlated with gestational at delivery at 28 weeks’ gestation and in 
latent phase (Figure 3.12); and 17alpha-hydroxypregnanolone glucuronide, 
5alpha-androstan-3alpha,17beta-diol disulfate, oestriol 3-sulfate and oestriol 
16-glucuronide were significantly correlated at 38 weeks’ gestation and in latent 
phase (Figure 3.12). All of these were negatively correlated with gestational age 
at delivery except for DHEA-S and androstenediol (3beta, 17 beta) monosulfate 
(1) which were positively correlated.  
Table 3.11: Mean normalised and scaled values for 17alpha-hydroxyprogesterone in each 
of the vascular compartments for each of the modes of labour onset and delivery (n = 4 for 
each group). 95%CI = 95% confidence interval. 
Dehydroepiandrosterone sulfate Mean normalised and scaled value 
(95%CI) 




























Figure 3.10: Scatter plots showing correlation between 5α-androstan-3α, 17α-diol disulfate level and gestational age at delivery at: A. 28 weeks’ gestation, 
with Spearman correlation -0.519 (p=0.039) (n=16); B. 34 weeks’ gestation, with Spearman correlation -0.728 (p=0.001) (n=16); C. Latent phase with Spearman 
correlation -0.685 (p=0.007) (n=14). Scaled 5α-androstan-3α, 17α-diol disulfate for each sample determined following normalisation by sample volume, log-







Figure 3.11: Correlations between metabolite and gestational age at delivery for 5α-pregnan-3β, 
20α-diol disulfate,  21-hydroxypregnanolone disulfate,  pregnanediol-3-glucuronide,  
dehydroepiandrosterone sulfate and androstenediol (3β, 17β) monosulfate. Scatter plots showing 
correlation between scaled metabolite and gestational age at delivery at 28 weeks’ and 34 weeks’  
gestation, for: A. 5α-pregnan-3β, 20α-diol disulfate at (i) 28 and (ii) 34 weeks’ gestation; B. 21-
hydroxypregnanolone disulfate at (i) 28 and (ii) 34 weeks’ gestation; C. pregnanediol-3-glucuronide at 
(i) 28 and (ii) 34 weeks’ gestation; D. dehydroepiandrosterone sulfate (DHEA-S) at (i) 28 and (ii) 34 
weeks’ gestation; and E. androstenediol (3β, 17β) monosulfate (1) at (i) 28 and (ii) 34 weeks’ gestation. 
Spearman correlation with p-value are shown for each comparison. Scaled metabolite for each sample 
determined following normalisation by sample volume, log-transformation, then rescaling to set the 







Figure 3.12: Correlations between metabolite and gestational age at delivery for 17α-
hydroxypregnanolone glucuronide,  5α-androstan-3α, 17β-diol disulfate, estriol 3-sulfate and  
estriol 16-glucuronide. Scatter plots showing correlation between scaled metabolite and gestational 
age at delivery at 34 weeks’ gestation and latent phase, for: A. 17α-hydroxypregnanolone glucuronide 
at (i) 34 weeks’ gestation and (ii) latent phase; B. 5α-androstan-3α, 17β-diol disulfate at (i) 28 weeks’ 
gestation and (ii) latent phase; C. estriol 3-sulfate at (i) 28 weeks’ gestation and (ii) latent phase; D. 
estriol 16-glucuronide at (i) 28 weeks’ gestation and (ii) latent phase. Spearman correlation with p-
value are shown for each comparison. Scaled metabolite for each sample determined following 
normalisation by sample volume, log-transformation, then rescaling to set the median for all samples 






3.5.15 Progestin steroids 
Progesterone was significantly lower in the CV than CA in the SL group (0.29-FC, 
p=0.008), but conversely was significantly higher in the CV than CA of the IOL 
group (2.20-fold change, p=0.021). The concentration of progesterone was also 
twice as high in the CV sample than the CA sample in the ECS group, however 
this was not significant. In all three groups, the progesterone concentration in 
the CV was significantly lower than that of the IV sample (SL: 0.12-fold change, 
p=0.005; IOL: 0.51-FC, p=0.046; ECS: 0.36-fold change, p=0.015), and likewise 
the concentration in the CA was significantly lower than in the IV samples (SL: 
0.39-fold change, p=0.005; IOL: 0.23-FC, p=0.005; ECS: 0.17-fold change, 
p=0.010) (Table 3.12 and 3.13).  
Importantly there were changes between the labouring groups. Progesterone 
concentration was significantly lower in the CA of the ECS group compared with 
the SL group (0.26-FC, p=0.008), and was also lower in the CA of the ECS group 
compared with the IOL group (0.45-FC, p=0.073), but this was not significant. 
Progesterone was significantly higher in the CV of the IOL group compared with 
both the CV of the ECS group (2.28-FC, p=0.043) and SL group (4.27-fold, 






3.5.16 17alpha hydroxyprogesterone 
17alpha hydroxyprogesterone increased between 28 weeks’ gestation and 34 
weeks’ gestation (1.27-FC, p=0.013) and again between 28 weeks’ gestation and 
latent phase (1.67-FC, p=0.001) in the women who spontaneously laboured, but 
there was no correlation with gestational age at spontaneous delivery. As with 
progesterone, in the SL group, 17α-hydroxyprogesterone was significantly 
greater in the CA than the CV at delivery (0.39-FC, p=0.020). And, again as with 
progesterone, this was reversed in the IOL and ECS group, where the 
concentration of 17α-hydroxyprogesterone was greater in the CV than the CA at 
delivery (CVIOL/CAIOL: 1.90-FC, p=0.007; CVCS/CACS: 1.76-FC, p=0.003). Also, 
as with progesterone, in all modes of labour and delivery, the concentration of 
17α-hydroxyprogesterone in the IV samples was consistently higher than in the 
CA and CV (Table 3.10). The concentration of 17α- hydroxyprogesterone in the 
CA of the SL group was significantly higher than in the CA of the ECS group (0.34-
FC, p=0.021), and non-significantly higher than the CA of the IOL group (0.47-FC, 
p=0.433); whereas the concentration of 17α-hydroxyprogesterone in the CV of 
the IOL group was significantly higher than in the CV of the SL group (3.50-FC, 
p=0.036). The CV of the ECS group had a greater concentration of 17α-






and the CV of the IOL group had a greater 17α- hydroxyprogesterone 
concentration than the CV of the ECS group (Table 3.12 and 3.13).  
Table 3.12: Mean normalised and scaled values for progesterone in each of the vascular 
compartments for each of the modes of labour onset and delivery. The values for the 
metabolites were normalised and scaled by Metabolon, Inc., so that levels of different metabolites 
could be compared more directly (n=4 for each group). 95%CI = 95% confidence interval. 
Progesterone Mean normalised and scaled values 
(95%CI) 


























Table 3.13: Significant changes for progestin and oestrogen steroids (all results shown are significant at p≤0.05).  
 















Mode labour onset (paired t-test)        





CV/M 0.12 0.22 
 
0.13 
   
 
CA/M 0.39 0.56 
     
IOL CV/CA 2.20 1.90 
     
 
CV/M 0.51 0.82 
 
0.77 
   
 
CA/M 0.23 0.43 
     
ECS CV/CA  1.76 
     
 





CA/M 0.17 0.26 0.19 0.10 0.72 5.46 
 
Vascular compartment  (Welch's t-test)   
     
Cord artery ECS/SL 0.26 0.34 0.42 0.18 
   
 
CS/IOL  0.47 0.35 
    
Cord vein IOL/SL 4.27 3.50 
 
6.45 
   
 
CS/SL   0.34 
    
 
IOL/CS 2.28 2.29 2.22 
    
Intervillous CS/SL   
    
0.21 
GA association (Spearman 
correlation) 
  
     
 









Latent=samples taken in latent phase spontaneous labour or start of IOL for post-dates (n=14); 34 weeks = samples taken at 34 weeks’ gestation (n=16); SL 
= spontaneous labour group (n=4); CS = elective caesarean section group (n=4); IOL = induction of labour group (n=4); CV = cord vein sample; CA = cord 




3.5.17 Oestrogen steroids 
Oestriol did not change significantly during pregnancy but was 6.45-fold greater 
in the CV of the IOL group than the CV of the SL group (p=0.0352) (Table 3.10). 
However, oestriol 16-glucuronide and oestriol 3-sulfate were both correlated 
with gestational age at delivery in the samples taken at 34 weeks’ gestation and 
in latent phase (Table 3.14). In addition, oestriol 16-glucuronide was reduced in 
the CA (0.72-FC, p=0.043) and CV (0.74-FC, p=0.029) of the ECS group compared 
with the IV blood. Oestriol 3-sulfate was the only oestrogenic steroid to be 
greater in the CA (5.46-fc, p=0.005) and CV (5.32-fc, p=0.006) than the IV blood 
in the ECS group. Oestriol-3-glucuronide was significantly less in the IV blood of 
the ECS group than the IV blood of the SL group (0.21-FC, p=0.038) (Table 3.13 
and 3.14). 
Table 3.14: Mean normalised and scaled values for 17alpha-hydroxyprogesterone in each 
of the vascular compartments for each of the modes of labour onset and delivery. The values 
for the metabolites were normalised and scaled by Metabolon, Inc., so that levels of different 
metabolites could be compared more directly. (n=4 for each group). 95%CI = 95% confidence interval. 
Oestriol Normalised and scaled value 
(95%CI) 
























Oestrone 3-sulfate was significantly lower in the CV (0.18-FC, p=0.007) and CA 
(0.19-FC, p=0.010) than IV blood of the ECS group. There were also differences 
in metabolite levels between different modes of labour and delivery. Oestrone 
3-sulfate was significantly lower in the CA of the ECS group than the CA of both 
the spontaneously labouring (0.37-FC, p=0.030) and IOL groups (0.35-FC, 
p=0.013). Further, it was significantly lower in the CV of the ECS group compared 
with the CV of the SL group (0.34-fC, p=0.013), and significantly higher in the CV 
of the IOL group than the ECS group (2.22-FC, p=0.024) (Table 3.13).  
3.5.18 Pregnenolone steroids  
Levels of two of the pregnenolone steroids differed in the latent/pre-operative 
samples between the three modes of labour: 21-hydroxypregnenolone 
monosulfate (1) was significantly reduced in both the latent phase of the IOL 
group (0.30-FC, p=0.006) and the ECS group (0.45-FC, p=0.032) compared with 
the SL group. 21-hydroxypregnenolone monosulfate (2) was also reduced in the 
latent phase of the IOL group compared with that of the SL group (0.42-FC, 
p=0.026); it was also reduced in the ECS group, but this was not significant. 
3.5.19 Comparisons between spontaneous labour and induction of labour 
10.1% (104/1032) of the metabolites measured were significantly (p≤0.05) 
different between the CA of the SL and IOL groups (Table 3A4, Appendices), and 




3A5, Appendices). This is in comparison with only 3.1% (32/1032) significantly 
different between the latent phase samples (Table 3A6, Appendices), and 2.9% 
(30/1032) significantly different in the IV samples (Table 3A7, Appendices). The 
greatest difference in all four groups was higher mean concentrations of 
Ranitidine in the IOL group. This is likely because two of the women in the IOL 
group had an epidural, and women with epidurals were routinely offered 
Ranitidine every six hours at St Michael’s Hospital to reduce the risk of aspiration 
in case of the need for a general anaesthetic.  
Of those metabolites that were significantly different between the cord arteries, 
88 were higher, and 16 lower, in the CA of the SL group compared with the IOL 
group. Those metabolites which were significantly lower by at least half in the 
CA of the IOL group compared with the SL group included 1-stearoyl-GPS (18:0) 
(0.1-FC, p=0.002), inosine 5’-monohosphate (0.18-FC, p=0.002), 1-stearoyl-2-
oleoyl-GPS (18:0/19:1) (0.21-FC, p=0.002), androsterone sulphate (0.35-FC, p-
0.013) and sphinganine-1-phosphate (0.49-FC, p=0.013). Five fibrinogen peptide 
metabolites were increased in the CA of the IOL group compared with the SL 
group: Fibrinopeptide B (142.41-FC, p=0.00), Fibrinopeptide B (1-13) (101.32-FC, 
p = 0.001), Fibrinopeptide A (76.31-FC, p=0.0003) as well as adenosine 5’-




Of those metabolites that were significantly different between the CV samples, 
42 were higher, and 71 lower, in the SL group compared with the IOL group. 
Those with the greatest fold-change in the CV included oestriol, which was 6.45-
fold higher in the CV of the IOL group compared with the SL group (p = 0.035), 
and progesterone, which was 4.27-fold higher in the CV of the IOL group 
compared with the ECS group (p = 0.043). Of note, oestriol was 0.52-FC lower in 
the CA of the IOL group compared with the SL group, but this was not significant 
(p=0.29), and progesterone was 0.57-fold lower in the CA of the IOL group 
compared with the SL group, however again this did not reach significance. 
Although not significant, oestriol was 4.63-fold higher in the CV of the ECS group 
(non-significant) than the CV of the SL group, and 0.35-fold lower in the CV of 
the ECS group than the CV of the IOL group (non-significant) (see Figure 13).  
Further, 17alpha-hydroxyprogesterone was 3.50-fold higher in the CV of the IOL 
group compared with the SL group (p=0.036) and arachidonate (20:4n6) was 
2.46-fold higher (p=0.005). Those that were significantly lower in the CV of the 
IOL group compared with the SL group included the corticosteroids 
corticosterone and cortisol (0.48-FC, p=0.022 and 0.41-FC, p=0.028, 
respectively), sphingosine (0.28-FC, p=0.049), sphinganine (0.19-FC, p=0.022), 
adenosine 3’,5’-cyclic monophosphate (cAMP) (0.22-FC, p=0.034), and cytidine 





Figure 3.13: Heat maps comparing scaled normalised values of progesterone, oestriol, 17α-
hydroxyprogesterone, DHEA-S, sphingosine and sphingosine 1-phosphate between the 
spontaneously labouring group, the induction of labour group and the elective caesarean section 
group for: A. the latent phase and intervillous (IV) samples; and B. the cord vein (CV) and cord artery 
(CA) samples. N=4 in each group. Heat map coloured according to scale from blue (lowest) to white 
(middle) to red (highest). SL = spontaneously labouring; IOL = induction of labour; ECS = elective 
caesarean section.  
 
3.5.20 Over-representation analysis for correlation analysis 
Table 3.15 and Figure 3.14 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 63 metabolites which 
were significantly associated (p≤0.05) at 28 weeks’ gestation with gestational 
age at spontaneous delivery. Glycerol phosphate shuttle, riboflavin metabolism 
and glycerolipid metabolism pathways were the most over-represented, 




Table 3.15: Results of the over-representation enrichment analysis for metabolites sampled 
at 28 weeks’ gestation which were significantly (p≤0.05) correlated with gestational age at 
spontaneous delivery, where total is the total number of metabolites in the pathway according to 
the MetaboAnalyst database, expected is the number of metabolites that would be expected by 
chance, hit is the number of metabolites observed in the current study, raw p is the original p value 
calculated from the pathway analysis, and Holm p is the p value adjusted for multiple testing using the 
Holm-Bonferroni method.  
Metabolite pathway Total Expected Hits Raw p Holm p 
Glycerol Phosphate Shuttle 11 0.269 1 0.239 1 
Riboflavin Metabolism 20 0.488 1 0.393 1 
Glycerolipid Metabolism 25 0.61 1 0.465 1 
Androgen and Estrogen Metabolism 33 0.806 1 0.563 1 
Bile Acid Biosynthesis 65 1.59 1 0.81 1 
 
 
Figure 3.14: Overview of the results of the over-representation analysis for metabolites 
sampled at 28 weeks’ gestation which were significantly (p≤0.05) correlated with 
gestational age at spontaneous delivery, with the metabolite pathways on the y-axis, and the 
enrichment ratio (calculated by number of metabolites in the pathway identified by this study divided 
by the number of metabolites expected to be identified by chance in that pathway); the colour of the 




Table 3.16 and Figure 3.15 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 84 metabolites which 
were significantly associated (p≤0.05) at 34 weeks’ gestation with gestational 
age at spontaneous delivery. Mitochondrial beta-oxidation of long-chain fatty 
acids, betaine metabolism and Glycerol Phosphate Shuttle were the most over-
represented pathways, although none were significantly over-represented. 
Table 3.16: Results of the over-representation enrichment analysis for metabolites sampled 
at 34 weeks’ gestation which were significantly (p≤0.05) correlated with gestational age at 
spontaneous delivery, where total is the total number of metabolites in the pathway according to 
the MetaboAnalyst database, expected is the number of metabolites that would be expected by 
chance, hit is the number of metabolites observed in the current study, raw p is the original p value 
calculated from the pathway analysis, and Holm p is the p value adjusted for multiple testing using the 
Holm-Bonferroni method.  
Metabolite pathway Total Expected Hits Raw p Holm 
p 
Mitochondrial Beta-Oxidation of Long Chain 
Saturated Fatty Acids 
28 1.2 4 0.0286 1 
Betaine Metabolism 21 0.902 3 0.0573 1 
Glycerol Phosphate Shuttle 11 0.473 2 0.0776 1 
Estrone Metabolism 24 1.03 3 0.0798 1 
Plasmalogen Synthesis 26 1.12 3 0.0966 1 
Methylhistidine Metabolism 4 0.172 1 0.161 1 
Androgen and Estrogen Metabolism 33 1.42 3 0.165 1 
Beta-Alanine Metabolism 34 1.46 3 0.176 1 
Butyrate Metabolism 19 0.816 2 0.195 1 
Mitochondrial Electron Transport Chain 19 0.816 2 0.195 1 
Nicotinate and Nicotinamide Metabolism 37 1.59 3 0.209 1 
Threonine and 2-Oxobutanoate Degradation 20 0.859 2 0.211 1 
Carnitine Synthesis 22 0.945 2 0.243 1 
Sphingolipid Metabolism 40 1.72 3 0.244 1 
Caffeine Metabolism 24 1.03 2 0.276 1 
Methionine Metabolism 43 1.85 3 0.28 1 
Histidine Metabolism 43 1.85 3 0.28 1 
Glycerolipid Metabolism 25 1.07 2 0.292 1 
Phytanic Acid Peroxisomal Oxidation 26 1.12 2 0.308 1 
Mitochondrial Beta-Oxidation of Short Chain 
Saturated Fatty Acids 






Figure 3.15: Overview of the results of the over-representation analysis for for metabolites 
sampled at 34 weeks’ gestation which were significantly (p≤0.05) correlated with 
gestational age at spontaneous delivery, with the metabolite pathways on the y-axis, and the 
enrichment ratio (calculated by number of metabolites in the pathway identified by this study divided 
by the number of metabolites expected to be identified by chance in that pathway); the colour of the 






Table 3.17 and Figure 3.16 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 53 metabolites which 
were significantly associated (p≤0.05) in latent phase with gestational age at 
spontaneous delivery. Phenylacetate metabolism, glycerol phosphate shuttle 
and riboflavin metabolism were the most over-represented pathways, although 
none were significantly over-represented. 
Table 3.17: Results of the over-representation enrichment analysis for metabolites in latent 
phase which were significantly (p≤0.05) correlated with gestational age at spontaneous 
delivery, where total is the total number of metabolites in the pathway according to the 
MetaboAnalyst database, expected is the number of metabolites that would be expected by chance, 
hit is the number of metabolites observed in the current study, raw p is the original p value calculated 
from the pathway analysis, and Holm p is the p value adjusted for multiple testing using the Holm-
Bonferroni method.  
Metabolite pathway Total Expected Hits Raw p Holm 
p 
Phenylacetate Metabolism 9 0.237 1 0.215 1 
Glycerol Phosphate Shuttle 11 0.29 1 0.256 1 
Riboflavin Metabolism 20 0.527 1 0.417 1 
Estrone Metabolism 24 0.633 1 0.477 1 
Glycerolipid Metabolism 25 0.659 1 0.491 1 
Mitochondrial Beta-Oxidation of Short Chain 
Saturated Fatty Acids 
27 0.712 1 0.519 1 
Phospholipid Biosynthesis 29 0.765 1 0.544 1 






Figure 3.16: Overview of the results of the over-representation analysis for for metabolites 
sampled in latent phase which were significantly (p≤0.05) correlated with gestational age 
at spontaneous delivery, with the metabolite pathways on the y-axis, and the enrichment ratio 
(calculated by number of metabolites in the pathway identified by this study divided by the number 
of metabolites expected to be identified by chance in that pathway); the colour of the bar represents 







3.5.21 Over-representation analysis for comparisons of the different vascular 
compartments at delivery 
3.5.21.1 Over-representation analysis for cord artery comparisons 
Table 3.18 and Figure 3.17 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 104 metabolites which 
were significantly different (p≤0.05) between the CA of the IOL and SL groups.  
Table 3.18: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord artery of the IOL group and cord artery of 
the SL group, where total is the total number of metabolites in the pathway according to the 
MetaboAnalyst database, expected is the number of metabolites that would be expected by 
chance, hit is the number of metabolites observed in the current study, raw p is the original 
p value calculated from the pathway analysis, and Holm p is the p value adjusted for multiple 
testing using the Holm-Bonferroni method. 
Metabolite pathways Total Expected Hits Raw p Holm p 
Alpha Linolenic Acid and Linoleic Acid 
Metabolism 
19 1.43 6 0.00183 0.18 
Aspartate Metabolism 35 2.63 7 0.0125 1 
Fatty Acid Biosynthesis 35 2.63 6 0.0415 1 
Beta Oxidation of Very Long Chain Fatty Acids 17 1.28 3 0.13 1 
Butyrate Metabolism 19 1.43 3 0.166 1 
Glutathione Metabolism 21 1.58 3 0.205 1 
Vitamin K Metabolism 14 1.05 2 0.284 1 
Mitochondrial Beta-Oxidation of Short Chain 
Saturated Fatty Acids 
27 2.03 3 0.332 1 
Mitochondrial Beta-Oxidation of Medium Chain 
Saturated Fatty Acids 
27 2.03 3 0.332 1 
Arginine and Proline Metabolism 53 3.99 5 0.368 1 
Alanine Metabolism 17 1.28 2 0.37 1 
Propanoate Metabolism 42 3.16 4 0.39 1 
Methionine Metabolism 43 3.23 4 0.408 1 
Histidine Metabolism 43 3.23 4 0.408 1 
Ammonia Recycling 32 2.41 3 0.437 1 
Riboflavin Metabolism 20 1.5 2 0.452 1 
Glycine and Serine Metabolism 59 4.44 5 0.461 1 
Biotin Metabolism 8 0.602 1 0.466 1 
Thiamine Metabolism 9 0.677 1 0.507 1 






Figure 3.17: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord artery of the IOL group and 
cord artery of the SL group, with the metabolite pathways on the y-axis, and the enrichment ratio 
(calculated by number of metabolites in the pathway identified by this study divided by the number 
of metabolites expected to be identified by chance in that pathway); the colour of the bar represents 
the unadjusted p value, as shown by the key. 
 
Table 3.19 and Figure 3.18 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 232 metabolites which 






Table 3.19: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord artery of the ECS group and cord artery of 
the SL group , where total is the total number of metabolites in the pathway according to the 
MetaboAnalyst database, expected is the number of metabolites that would be expected by chance, 
hit is the number of metabolites observed in the current study, raw p is the original p value calculated 
from the pathway analysis, and Holm p is the p value adjusted for multiple testing using the Holm-
Bonferroni method.  
Metabolite pathways Total Expected Hits Raw p Holm p 
Alpha Linolenic Acid and Linoleic Acid 
Metabolism 
19 2.78 9 0.000615 0.0602 
Beta Oxidation of Very Long Chain Fatty Acids 17 2.49 5 0.0893 1 
Fatty Acid Biosynthesis 35 5.13 8 0.126 1 
Glucose-Alanine Cycle 13 1.9 3 0.294 1 
Glutathione Metabolism 21 3.08 4 0.371 1 
Transfer of Acetyl Groups into Mitochondria 22 3.22 4 0.406 1 
Pyruvaldehyde Degradation 10 1.46 2 0.443 1 
Galactose Metabolism 38 5.57 6 0.491 1 
Citric Acid Cycle 32 4.69 5 0.515 1 
Mitochondrial Electron Transport Chain 19 2.78 3 0.543 1 
Taurine and Hypotaurine Metabolism 12 1.76 2 0.544 1 
Androgen and Estrogen Metabolism 33 4.83 5 0.544 1 
Thyroid hormone synthesis 13 1.9 2 0.589 1 
Aspartate Metabolism 35 5.13 5 0.6 1 
Steroidogenesis 43 6.3 6 0.621 1 
Urea Cycle 29 4.25 4 0.635 1 
Sulfate/Sulfite Metabolism 22 3.22 3 0.647 1 
Caffeine Metabolism 24 3.52 3 0.707 1 
Estrone Metabolism 24 3.52 3 0.707 1 







Figure 3.18: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord artery of the ECS group and 
cord artery of the SL group, with the metabolite pathways on the y-axis, and the enrichment ratio 
(calculated by number of metabolites in the pathway identified by this study divided by the number 
of metabolites expected to be identified by chance in that pathway); the colour of the bar represents 
the unadjusted p value, as shown by the key. 
 
Table 3.20 and Figure 3.19 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 82 metabolites which 




Table 3.20: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord artery of the ECS group and cord artery of 
the IOL group, where total is the total number of metabolites in the pathway according to the 
MetaboAnalyst database, expected is the number of metabolites that would be expected by chance, 
hit is the number of metabolites observed in the current study, raw p is the original p value calculated 
from the pathway analysis, and Holm p is the p value adjusted for multiple testing using the Holm-
Bonferroni method.  
Metabolite pathways Total Expected Hits Raw p Holm p 
Citric Acid Cycle 32 1.62 5 0.0197 1 
Warburg Effect 58 2.95 6 0.0675 1 
Transfer of Acetyl Groups into Mitochondria 22 1.12 3 0.0962 1 
Glucose-Alanine Cycle 13 0.66 2 0.138 1 
Urea Cycle 29 1.47 3 0.179 1 
Alanine Metabolism 17 0.863 2 0.212 1 
Mitochondrial Electron Transport Chain 19 0.965 2 0.251 1 
Glutathione Metabolism 21 1.07 2 0.289 1 
Steroidogenesis 43 2.18 3 0.375 1 
Pyruvaldehyde Degradation 10 0.508 1 0.408 1 
Pyruvate Metabolism 48 2.44 3 0.445 1 
Glutamate Metabolism 49 2.49 3 0.459 1 
Taurine and Hypotaurine Metabolism 12 0.609 1 0.467 1 
Starch and Sucrose Metabolism 31 1.57 2 0.474 1 
Ketone Body Metabolism 13 0.66 1 0.494 1 
Amino Sugar Metabolism 33 1.68 2 0.508 1 
Androgen and Estrogen Metabolism 33 1.68 2 0.508 1 
Beta-Alanine Metabolism 34 1.73 2 0.524 1 
Purine Metabolism 74 3.76 4 0.528 1 






Figure 3.19: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord artery of the ECS group and 
cord artery of the IOL group, with the metabolite pathways on the y-axis, and the enrichment ratio 
(calculated by number of metabolites in the pathway identified by this study divided by the number 
of metabolites expected to be identified by chance in that pathway); the colour of the bar represents 
the unadjusted p value, as shown by the key. 
 
3.5.21.2 Over-representation analysis for cord vein comparisons 
Table 3.21 and Figure 3.20 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 113 metabolites which 




Table 3.21: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord vein of the IOL group and cord vein of the 
SL group, where total is the total number of metabolites in the pathway according to the 
MetaboAnalyst database, expected is the number of metabolites that would be expected by 
chance, hit is the number of metabolites observed in the current study, raw p is the original 
p value calculated from the pathway analysis, and Holm p is the p value adjusted for multiple 
testing using the Holm-Bonferroni method. 
Metabolite pathways Total Expected Hits Raw p Holm p 
Alpha Linolenic Acid and Linoleic Acid 
Metabolism 
19 1.48 11 1.53x10-8 1.50x10-6 
Beta Oxidation of Very Long Chain Fatty 
Acids 
17 1.33 3 0.141 1 
Glutathione Metabolism 21 1.64 3 0.222 1 
Steroidogenesis 43 3.36 5 0.24 1 
Methylhistidine Metabolism 4 0.312 1 0.278 1 
Fatty Acid Biosynthesis 35 2.73 4 0.29 1 
Phosphatidylcholine Biosynthesis 14 1.09 2 0.3 1 
Galactose Metabolism 38 2.97 4 0.345 1 
Mitochondrial Beta-Oxidation of Short 
Chain Saturated Fatty Acids 
27 2.11 3 0.354 1 
Methionine Metabolism 43 3.36 4 0.437 1 
Fructose and Mannose Degradation 32 2.5 3 0.463 1 
Carnitine Synthesis 22 1.72 2 0.524 1 
Malate-Aspartate Shuttle 10 0.781 1 0.558 1 
Nicotinate and Nicotinamide Metabolism 37 2.89 3 0.564 1 
Estrone Metabolism 24 1.88 2 0.572 1 
Cardiolipin Biosynthesis 11 0.859 1 0.593 1 
Phosphatidylethanolamine Biosynthesis 12 0.938 1 0.625 1 
Glucose-Alanine Cycle 13 1.02 1 0.655 1 
Starch and Sucrose Metabolism 31 2.42 2 0.713 1 






Figure 3.20: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord vein of the IOL group and cord 
vein of the SL group, with the metabolite pathways on the y-axis, and the enrichment ratio 
(calculated by number of metabolites in the pathway identified by this study divided by the number 
of metabolites expected to be identified by chance in that pathway); the colour of the bar represents 
the unadjusted p value, as shown by the key. 
 
Table 3.22 and Figure 3.21 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 130 metabolites which 




Table 3.22: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord vein of the ECS group and cord vein of the 
SL group, where total is the total number of metabolites in the pathway according to the 
MetaboAnalyst database, expected is the number of metabolites that would be expected by chance, 
hit is the number of metabolites observed in the current study, raw p is the original p value calculated 
from the pathway analysis, and Holm p is the p value adjusted for multiple testing using the Holm-
Bonferroni method.   
Metabolite pathways Total Expected Hits Raw p Holm p 
Alpha Linolenic Acid and Linoleic Acid Metabolism 19 1.65 4 0.0752 1 
Beta Oxidation of Very Long Chain Fatty Acids 17 1.48 3 0.178 1 
Mitochondrial Beta-Oxidation of Short Chain 
Saturated Fatty Acids 
27 2.35 3 0.421 1 
Phosphatidylinositol Phosphate Metabolism 17 1.48 2 0.443 1 
Butyrate Metabolism 19 1.65 2 0.503 1 
Methionine Metabolism 43 3.74 4 0.524 1 
Glutathione Metabolism 21 1.83 2 0.558 1 
Pyruvaldehyde Degradation 10 0.869 1 0.599 1 
Fatty Acid Biosynthesis 35 3.04 3 0.6 1 
Caffeine Metabolism 24 2.09 2 0.633 1 
D-Arginine and D-Ornithine Metabolism 11 0.956 1 0.634 1 
Glycerol Phosphate Shuttle 11 0.956 1 0.634 1 
Cardiolipin Biosynthesis 11 0.956 1 0.634 1 
Purine Metabolism 74 6.43 6 0.638 1 
Nicotinate and Nicotinamide Metabolism 37 3.22 3 0.639 1 
Glycerolipid Metabolism 25 2.17 2 0.655 1 
Galactose Metabolism 38 3.3 3 0.658 1 
Taurine and Hypotaurine Metabolism 12 1.04 1 0.666 1 
Phosphatidylethanolamine Biosynthesis 12 1.04 1 0.666 1 






Figure 3.21: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord vein of the ECS group and cord 
vein of the SL group, with the metabolite pathways on the y-axis, and the enrichment ratio 
(calculated by number of metabolites in the pathway identified by this study divided by the number 
of metabolites expected to be identified by chance in that pathway); the colour of the bar represents 





Table 3.23 and Figure 3.22 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 60 metabolites which 
were significantly different (p≤0.05) between the CV of the ECS and IOL groups.  
Table 3.23: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the cord vein of the ECS group and cord vein of the 
IOL group, where total is the total number of metabolites in the pathway according to the 
MetaboAnalyst database, expected is the number of metabolites that would be expected by chance, 
hit is the number of metabolites observed in the current study, raw p is the original p value calculated 
from the pathway analysis, and Holm p is the p value adjusted for multiple testing using the Holm-
Bonferroni method.   
Metabolite pathways Total Expected Hits Raw p Holm p 
Steroidogenesis 43 1.55 5 0.0165 1 
Glucose-Alanine Cycle 13 0.47 2 0.0772 1 
Beta-Alanine Metabolism 34 1.23 3 0.121 1 
Methylhistidine Metabolism 4 0.145 1 0.137 1 
Galactose Metabolism 38 1.37 3 0.154 1 
Glutathione Metabolism 21 0.759 2 0.174 1 
Transfer of Acetyl Groups into Mitochondria 22 0.795 2 0.187 1 
Homocysteine Degradation 9 0.325 1 0.283 1 
Lactose Degradation 9 0.325 1 0.283 1 
Androgen and Estrogen Metabolism 33 1.19 2 0.337 1 
Warburg Effect 58 2.1 3 0.35 1 
Taurine and Hypotaurine Metabolism 12 0.434 1 0.359 1 
Gluconeogenesis 35 1.26 2 0.364 1 
Histidine Metabolism 43 1.55 2 0.467 1 
Alanine Metabolism 17 0.614 1 0.468 1 
Lactose Synthesis 20 0.723 1 0.524 1 
Glutamate Metabolism 49 1.77 2 0.538 1 
Pantothenate and CoA Biosynthesis 21 0.759 1 0.542 1 
Sulfate/Sulfite Metabolism 22 0.795 1 0.559 1 





Figure 3.22: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the cord vein of the ECS group and cord 
vein of the IOL group, with the metabolite pathways on the y-axis, and the enrichment ratio 
(calculated by number of metabolites in the pathway identified by this study divided by the number 
of metabolites expected to be identified by chance in that pathway); the colour of the bar represents 





3.5.21.3 Over-representation analysis for intervillous blood comparisons 
Table 3.24 and Figure 3.23 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 30 metabolites which 
were significantly different (p≤0.05) between the IV blood of the IOL and SL 
groups.  
Table 3.24: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the intervillous blood of the IOL group and 
intervillous blood of the SL group, where total is the total number of metabolites in the 
pathway according to the MetaboAnalyst database, expected is the number of metabolites 
that would be expected by chance, hit is the number of metabolites observed in the current 
study, raw p is the original p value calculated from the pathway analysis, and Holm p is the p 
value adjusted for multiple testing using the Holm-Bonferroni method. 
Metabolite pathway Total Expected Hits Raw p Holm p 
Tryptophan Metabolism 60 0.996 2 0.262 1 
Caffeine Metabolism 24 0.398 1 0.334 1 
Glycerolipid Metabolism 25 0.415 1 0.345 1 
Phospholipid Biosynthesis 29 0.481 1 0.389 1 
Nicotinate and Nicotinamide Metabolism 37 0.614 1 0.468 1 
Retinol Metabolism 37 0.614 1 0.468 1 
Galactose Metabolism 38 0.631 1 0.477 1 






Figure 3.23: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the intervillous blood of the IOL group 
and intervillous blood of the SL group, with the metabolite pathways on the y-axis, and the 
enrichment ratio (calculated by number of metabolites in the pathway identified by this study divided 
by the number of metabolites expected to be identified by chance in that pathway); the colour of the 
bar represents the unadjusted p value, as shown by the key. 
 
Table 3.25 and Figure 3.24 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 111 metabolites which 







Table 3.25: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the intervillous blood of the ECS group and 
intervillous blood of the SL group, where total is the total number of metabolites in the pathway 
according to the MetaboAnalyst database, expected is the number of metabolites that would be 
expected by chance, hit is the number of metabolites observed in the current study, raw p is the 
original p value calculated from the pathway analysis, and Holm p is the p value adjusted for multiple 
testing using the Holm-Bonferroni method.   
 
Total Expected Hits Raw p Holm p 
Glucose-Alanine Cycle 13 0.686 3 0.0272 1 
Homocysteine Degradation 9 0.475 2 0.0775 1 
Transfer of Acetyl Groups into Mitochondria 22 1.16 3 0.105 1 
Alanine Metabolism 17 0.896 2 0.225 1 
Gluconeogenesis 35 1.85 3 0.279 1 
Glutathione Metabolism 21 1.11 2 0.305 1 
Warburg Effect 58 3.06 4 0.366 1 
Glycine and Serine Metabolism 59 3.11 4 0.379 1 
Glycolysis 25 1.32 2 0.384 1 
Lactose Degradation 9 0.475 1 0.387 1 
Cysteine Metabolism 26 1.37 2 0.403 1 
Pyruvaldehyde Degradation 10 0.527 1 0.42 1 
Selenoamino Acid Metabolism 28 1.48 2 0.441 1 
Urea Cycle 29 1.53 2 0.459 1 
Taurine and Hypotaurine Metabolism 12 0.633 1 0.48 1 
Glutamate Metabolism 49 2.58 3 0.485 1 
Citric Acid Cycle 32 1.69 2 0.512 1 
Galactose Metabolism 38 2 2 0.607 1 
Pyrimidine Metabolism 59 3.11 3 0.615 1 






Figure 3.24: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the intervillous blood of the ECS group 
and intervillous blood of the SL group, with the metabolite pathways on the y-axis, and the 
enrichment ratio (calculated by number of metabolites in the pathway identified by this study divided 
by the number of metabolites expected to be identified by chance in that pathway); the colour of the 
bar represents the unadjusted p value, as shown by the key. 
 
Table 3.26 and Figure 3.25 show the results of the ORA enrichment analysis 
performed using the MetaboloAnalyst software for the 50 metabolites which 




Table 3.26: Results of the over-representation enrichment analysis for metabolites 
significantly different (p≤0.05) between the intervillous blood of the ECS group and 
intervillous blood of the IOL group, where total is the total number of metabolites in the pathway 
according to the MetaboAnalyst database, expected is the number of metabolites that would be 
expected by chance, hit is the number of metabolites observed in the current study, raw p is the 
original p value calculated from the pathway analysis, and Holm p is the p value adjusted for multiple 
testing using the Holm-Bonferroni method.   
Metabolite pathways Total Expected Hits Raw p Holm p 
Urea Cycle 29 1.08 3 0.0886 1 
Glutamate Metabolism 49 1.82 4 0.103 1 
Arginine and Proline Metabolism 53 1.97 4 0.128 1 
Homocysteine Degradation 9 0.334 1 0.289 1 
Malate-Aspartate Shuttle 10 0.371 1 0.316 1 
Pyruvaldehyde Degradation 10 0.371 1 0.316 1 
Ammonia Recycling 32 1.19 2 0.335 1 
Amino Sugar Metabolism 33 1.22 2 0.349 1 
Aspartate Metabolism 35 1.3 2 0.376 1 
Gluconeogenesis 35 1.3 2 0.376 1 
Glucose-Alanine Cycle 13 0.482 1 0.39 1 
Alanine Metabolism 17 0.631 1 0.477 1 
Spermidine and Spermine Biosynthesis 18 0.668 1 0.497 1 
Alpha Linolenic Acid and Linoleic Acid 
Metabolism 
19 0.705 1 0.516 1 
Threonine and 2-Oxobutanoate Degradation 20 0.742 1 0.534 1 
Pyruvate Metabolism 48 1.78 2 0.541 1 
Transfer of Acetyl Groups into Mitochondria 22 0.816 1 0.569 1 
Glycolysis 25 0.928 1 0.616 1 
Cysteine Metabolism 26 0.965 1 0.631 1 






Figure 3.25: Overview of the results of the over-representation enrichment analysis for 
metabolites significantly different (p≤0.05) between the intervillous blood of the ECS group 
and intervillous blood of the IOL group, with the metabolite pathways on the y-axis, and the 
enrichment ratio (calculated by number of metabolites in the pathway identified by this study divided 
by the number of metabolites expected to be identified by chance in that pathway); the colour of the 
bar represents the unadjusted p value, as shown by the key. 
 
3.5.22 Linoleic acid and arachidonate 
Therefore, the ORA performed identified only one pathway as being significantly 




and linoleic acid metabolism pathway, which was significantly over-represented 
in those metabolites significantly different between the CV of the IOL group and 
CV of the SL group (Table 3.21). Likewise, the raw-p indicated that this pathway 
was also over-represented between the CA of the ECS and CA of the SL group, 
and between the CA of the IOL group and the CA of the SL group, although these 
did not reach significance when adjusted for multiple testing. Linoleate is the 
conjugate base of linoleic acid. Figure 3.26 is a heat map illustrating the different 
concentrations of linoleate (18:2n6) found in the CA, CV and IV samples of the 
SL, IOL and ECS groups.  Figure 3.26 also presents those concentrations for the 
metabolite arachidonate (20:4n6), which was significantly 2.46-fold lower in the 
CV of the SL group than the CV of the IOL group, and 2.42-fold greater in the CV 
of the elective CS group than the CV of the SL group, although this was not 
significant. 
       
 Arachidonate (20:4n6) Linoleate (18:2n6) 
Sample SL IOL ECS SL IOL ECS 
Latent/preoperative 1.2 1.5 0.8 2.2 2 1 
Intervillous 6.6 4.4 6.6 2.3 2.3 2.4 
Cord Vein 0.6 1.6 1.6 0.2 1 0.5 
Cord Artery 1.8 1.1 0.8 1.1 0.4 0.2 
       
Figure 3.26: Heat maps comparing scaled normalised values of arachidonate (20:4n6) and 
linoleate (18:2n6) concentrations in the latent/preoperative, intervillous, cord artery, and 
cord vein samples between the SL, IOL, and ECS groups: n=4 in each group; heat map coloured 
according to scale from blue (lowest) to white (middle) to red (highest); SL = spontaneously labouring; 





In this timely and original study, several important groups of metabolites were 
found to be correlated with gestational age at delivery; and there were also 
relationships between the different vascular compartments at delivery, and 
between different modes of labour and delivery. Given that relatively few 
detailed clinical studies of this type have been performed in humans, this global 
analysis of metabolites at the multiple time-points sampled provide valuable 
information and insights into the trigger for labour in humans. These can be 
taken forward into future clinical studies. It is acknowledged that the sample 
sizes in this metabolomic study are small, especially compared with the numbers 
of women in the Born in Bradford cohort of Chapter 4. In particular, increased 
confidence in the correlations calculated for the samples taken at 28 weeks’ 
gestation would be gained from inclusion of more women who delivered before 
34 weeks’ gestation. However, given the limitations of cost and resources for 
recruitment of women, this study is important as a hypothesis-free global 
assessment of metabolites during pregnancy, at delivery, and between the 
different modes of labour; taking advantage of the increased number of 
metabolites measured with the MS metabolomics platform compared with NMR 
metabolomics. For example, the separate sampling of the CA and CV of the SL, 




and oestriol of the IOL group are closer to the ECS concentrations than the SL 
group, despite the physical event of labour. This could point to inherent 
differences between spontaneous and induced labour. In summary, this study 
has successfully built upon the study presented in Chapter 2 and has identified 
metabolites that can be taken forward in further studies, providing a rationale 
for the design of clinical protocols in future research. The major findings will now 
be discussed. Results from part 1 and part 2 will be discussed together for groups 
of metabolites to gain a fuller understanding as to the findings for individual and 
groups of metabolites both during pregnancy and at delivery. 
3.6.1 Endocannabinoids 
The previous study presented in Chapter 2 found that the endocannabinoids 
OEA, PEA, LEA and AEA significantly increased with labour in cord blood, and 
that PEA significantly increased and N-palmitoylserine decreased in the IV blood 
of labouring women. The subsequent hypothesis generated was that the trigger 
for human labour may involve an increase in endocannabinoid concentrations 
that stimulates production of ceramides and sphingolipids, which in turn 
stimulates production of prostaglandins and labour. It was suggested that these 
endocannabinoids may originate in the fetal circulation and associated with a 
decrease in lymphocyte production of the enzyme that catabolises 




part designed to test this hypothesis, and the findings related to these 
metabolites will be discussed first.  
3.6.1.1 N-palmitoyltaurine and N-stearoyltaurine 
While concentrations of most of the endocannabinoids measured tended to rise 
during pregnancy, N-stearoyltaurine and N-palmitoyltaurine were negatively 
correlated with gestational age at delivery. N-palmitoyltaurine was also 
significantly higher in the CA of the SL group when compared with ECS group. N-
stearoyltaurine was significantly higher in the CA of the SL group than both the 
IOL and ECS groups. For both metabolites, these findings would fit with the 
hypothesis of increased endocannabinoid levels being associated with earlier 
gestational age at spontaneous labour, and increased levels produced by the 
fetus at delivery following spontaneous labour at term compared with no labour 
(ECS) or induced labour. As with other metabolites that will be discussed in this 
section, it is interesting that there are differences in metabolite levels in the CA 
between the SL and IOL group, given that both groups underwent the 
physiological stress of labour. These changes could point towards the inherent 
changes that occur with the trigger for spontaneous labour, and in particular 
fetal-derived metabolites. 
N-palmitoyltaurine and N-stearoyltaurine are N-acyl taurines. N-acyl taurines 




enzyme FAAH190. At present relatively little is known about the physiological role 
of these molecules in human physiology. Members of the N-acyl taurine family 
have been shown to activate transient receptor potential vanilloid type 1 
(TRPV1), which is a non-selective ligand-gated cation channel. Activation of 
TRPV1 by N-acyl taurines results in calcium ion influx and membrane 
depolarisation and secretion of insulin191, 192. In pancreatic β-cell lines in vitro 
such activation stimulates insulin secretion192, and accumulation of N-
palmitoyltaurine was found to be associated with dysfunction of islet of 
Langerhans cells193. AEA has also been found to be an agonist at TRPV1 in Human 
Embryonic Kidney 293 cells (HEK293 cell line) and Xenopus oocytes in vitro194, 195, 
although this effect was not replicated in the human myometrial smooth cell-
line ULTR in vitro 196. While it is relatively early days in the investigation of the 
N-acyl taurines in human pregnancy, both metabolites may be involved in the 
pathway for spontaneous labour, and may be produced by the fetus, and 
warrant further investigation in a larger study. This could include investigation 
of a potential role in calcium ion regulation with contraction, including with 
myometrial organ baths.  
3.6.1.2 Anandamide 
While AEA was detected in the samples of Chapter 2, AEA was not detected in 




samples were processed in the same manner as previously. AEA is broken down 
by FAAH into arachidonate and ethanolamine197 which results in AEA having a 
short half-life. Of note, arachidonate was significantly increased between 28 
weeks’ gestation and latent phase and was also significantly lower in the 
maternal blood taken in pre-operative clinic for the ECS group compared with 
the samples taken in latent phase for the SL group. Arachidonate was also 
significantly higher in the CV than CA of women who had IOL, and significantly 
lower in the CV and CA than IV samples in all three modes of labour onset. 
Arachidonate was significantly higher in the CV of the IOL group than the SL 
group. While this certainly does not prove that AEA is involved, it is possible that 
these changes in arachidonate were in part a result of rapid AEA breakdown by 
FAAH.  
3.6.1.3 OEA, PEA and LEA 
OEA was significantly increased in the cord blood of labouring women compared 
with no-labour in the pilot study. In the present study, OEA concentrations 
increased significantly between 28- and 34-weeks’ gestation, pregnancy, but 
there was no correlation found between OEA levels and gestational age at 
spontaneous labour. There were no differences in the levels of OEA between the 
three labour types, which suggests that it is not directly involved in the pathway 




in the maternal circulation (IV) than in the fetal/placental circulation (CV and CA). 
Thus, OEA increases generally in pregnancy, but it is unlikely to be directly 
involved in the trigger for human labour. 
In Chapter 2, PEA was significantly increased in the IV and cord blood with labour 
compared with no labour. In the current study, PEA had a similar patter to OEA, 
and was significantly increased in latent phase when compared with both 28 
weeks’ gestation and 34 weeks’ gestation. Levels in the IV were consistently 
higher than that of the CV samples for all three labour onset groups, although 
only significant with SL and ECS. However, unlike OEA, PEA was significantly 
higher in the latent phase samples of the SL group when compared with the pre-
operative samples for the ECS group, and it was also higher in the CA of the SL 
group compared with the ECS group, although this was not significant. 
Accordingly, PEA is potentially involved in the trigger for human labour. The 
higher concentrations measured in the IV samples compared with CV for all 
three groups indicate that any increase originates in the mother rather than the 
placenta as had been suggested by the pilot study. The differences with the 
findings of the pilot study may be because the cord blood was not separated 
into venous and arterial.  
OEA and PEA are fatty acid ethanolamides, classified as endocannabinoids by 




peroxisome proliferator-activated receptor-α (PPAR- α) nuclear receptor. OEA 
does not bind to the cannabinoid receptors, and it has been shown that many 
of the physiological responses of OEA, such as lipolysis and anti-inflammatory 
effects are mediated via PPAR-α198, 199. PEA has similar anti-inflammatory actions 
via activation of PPAR-α199-201.  Cells such as macrophages express phospholipase 
D (PLD) which promotes the release of OEA and PEA from N-acyl-
phosphatidylethanolamine, a cell membrane phospholipid202. PPARs are a 
nuclear receptor family with α, β and γ isoforms, and ligand activation promotes 
target gene transcription. These heterodimerise with retinoid X receptor and 
bind to sequences in the DNA called PPAR response elements. Transactivation 
of PPARs is believed to be modulated by recruitment of regulator proteins which 
bind to a further site on the PPAR molecules. PPARs transcribe genes related to 
metabolism, inflammation and cell differentiation, and PPARα has been 
investigated in inflammatory pathways and fatty acid catabolism regulation 200. 
Of note, peroxisomal proliferator-activated receptor A interacting complex 285 
(PPAR-α interacting complex 285) at least halved between the pre-contraction 
and relaxed contracting state of myometrium (REL/PRE) in the upcoming 
Chapter 5, PPAR-α interacting complex 285 functions as a coactivator of PPAR-
α203.  Given the finding of increased PEA in the spontaneous labour latent phase 




complex 285 in the proteomics study, PEA may be involved in the spontaneous 
onset of labour but is likely to have a different impact to AEA. 
In Chapter 2, concentrations of LEA, another endocannabinoid, were similar 
between the IV and cord blood. In this study LEA was found to be in higher 
concentrations as pregnancy progressed; and was higher in the latent phase 
samples of the SL group than the pre-operative samples of the ECS group. 
Therefore, as with PEA, it is possible that LEA is associated with the trigger for 
labour and this warrants further investigation. 
3.6.2 Sphingolipids and ceramides 
In the present study, a number of sphingomyelins were significantly lower in the 
CA and CV than the IV samples in both the SL and ECS group. This indicates that 
higher concentrations of sphingomyelins are found in the maternal circulation 
rather than the fetal or placental circulations, and this fits with the original 
hypothesis where an increase in endocannabinoids, potentially derived from the 
fetus, resulted in increased sphingolipids and ceramides in the maternal blood.  
Sphingolipids are a lipid family of molecules which are made up of a long-chain 
aminediol base N-linked to a fatty acid via an amide bond. The most common 
base is sphingosine, which is a bioactive lipid in-its-own right. Family members 
of the sphingolipid group include ceramides, sphingomyelins, cerebrosides and 




both structural and lipid mediator roles, and sphingomyelin is the most common 
in the outer plasma membrane layer of eukaryotic cells204. Ceramides are both 
precursors and breakdown products of sphingomyelins, and are important for 
metabolic signalling204. Sphingolipid metabolites have been shown to be 
involved in both mitogenic and apoptotic processes, and ceramides play a role 
in the regulation of apoptosis stimulated by TNFα and Fas ligand, as well as 
ionising radiation205. Ceramides are also known to regulate the content of 
diacylglycerol and platelet activating factor204.  
As discussed in Chapter 2, ceramides can be produced either de novo from the 
endoplasmic reticulum or via the breakdown of sphingolipids and are present in 
lysosomes. Lysosomal ceramide concentrations are dynamically balanced 
between ceramide generation via hydrolysis of sphingomyelin through 
sphingomyelinases, and their breakdown catalysed by ceramidases such as N-
acylsphingosine amidohydrolase 1 (ASAH1) producing sphingosine and fatty 
acyl-CoA177, 206.  Sphingosine can then be further phosphorylated by sphingosine 
kinase to produce sphingosine 1-phosphate206, and sphingosine 1-phosphate 
can be broken down by pyridoxal phosphate-dependent lyase on the 
endoplasmic reticulum (ER)205. 
In the present study, only one form of ceramide was detected, ceramide 




all of which were significantly increased in the IV blood of the women who 
delivered vaginally. In the present study, ceramide (d18:1/14:0, d16:1/16:0) was 
significantly higher in the IV blood than in the CV or CA samples with all modes 
of labour onset. However, there were no significant changes between modes of 
labour onset in concentrations of this ceramide. This may be because there is no 
effect, or it may be that the study size did not give the study statistical power to 
detect these differences, as the non-significant fold change between 
concentrations of ceramide (d18:1/14:0, d16:1/16:0) in the CA of the IOL group 
and the SL group, and the CA of the ECS group and the SL group were both 0.66 
(non-significant). 
Other ceramides that were detected included N-palmitoyl (d18:1/16:0) and N-
stearoyl (d18:1/18:0). Again, there were no significant changes detected 
between the mode of labour onset groups, however the concentration of both 
in the CV of the SL group were approximately double that of the CV of the IOL 
and the ECS group. Therefore, in a larger study these ceramides may be found 
to be significantly changed with spontaneous labour. In a previous study, 
concentrations of N-palmitoyl (d18:1/16:0) and N-stearoyl (d18:1/18:0) were 
higher in the placenta of women who had pre-eclampsia when compared with 




stearoyl was also increased in the maternal plasma of the group with pre-
eclampsia207. These ceramides warrant further study.  
3.6.2.1 Sphingosine and sphingosine 1-phosphate 
Ceramide and sphingosine 1-phosphate play essential but often opposing roles 
in cellular signalling and metabolism. Whereas ceramide is involved in apoptosis 
and stress-related responses, sphingosine 1-phosphate stimulates proliferation, 
cell survival and tissue regeneration. Consequently, the balance between the 
two is vital for cell fate decisions206, and altered ceramide concentrations have 
been implicated in pathologies such as cardiovascular diseases208 and 
Alzheimer’s disease209. Moreover, mitogenesis has been shown to be regulated 
by sphingosine 1-phosphate in cell lines in vitro such as airway smooth muscle. 
In cell culture of arterial and smooth muscle cells, mitogenic stimuli produce a 
rapid transient increase in sphingosine 1-phosphate, which is more usually 
present in low levels205.  
An important downstream effect of sphingosine 1-phosphate is Ca2+ regulation, 
thought to involve Ca2+ stores within the endoplasmic reticulum through a 
pathway independent of inositol triphosphate. In smooth muscle cells, Ca2+ 
mobilised via sphingosine 1-phosphate activation promotes an increase in cyclic 
adenosine monophosphate (cAMP) and protein kinase A (PKA) activation (a 




and changed cell motility. PKC activates sphingosine kinase which increases 
levels of sphingosine 1-phosphate 205. Drugs which increase cAMP temporarily 
suppress myometrial contractions, but this effect wears off after approximately 
24-48 hours210. 
In the present study, both sphingosine and sphingosine 1-phosphate 
concentrations were greater in the CA of the SL and the IOL groups than the ECS 
group. This suggests that these metabolites are elevated with labour and may 
be derived from the fetus, particularly as no such differences were detected in 
maternal blood samples during pregnancy or in latent phase. Sphingosine 
concentration was greater in the CV of the SL group than of both the IOL and 
ECS group which could indicate that the placenta produces more sphingosine 
with spontaneous labour than with induction of labour. In addition, sphingosine 
was lower in the CA than the IV samples in the SL group and the ECS group; while 
sphingosine 1-phophate was higher in the CA than the IV in the SL group and the 
ECS group, and higher in the CV than the IV in the SL group.  
As discussed, sphingosine 1-phosphate can mobilise Ca2+ stores211, and this has 
been observed to increase cAMP205. In the present study, the higher 
concentrations of sphingosine and sphingosine 1-phosphate observed with 
labour matched with corresponding increases in cAMP with labour, and cAMP 




operative sample of the ECS group. cAMP was also significantly higher in the CV 
of the SL group than both the IOL and ECS group. Moreover, cAMP levels were 
lower in the CV than CA of the IOL and ECS group, whereas the reverse was true 
for the SL group where concentrations were nearly 3-fold higher in the CV than 
CA. Further, the concentration of cAMP was more than double in the IV 
compared with the CV concentrations for the IOL and ECS group, with no change 
in the SL group.  
In summary, these findings could be a reflection of increased placental 
production of cAMP with spontaneous labour, potentially as a result of 
increased phosphorylation of sphingosine to sphingosine 1-phosphate by the 
fetus (as sphingosine was significantly lower in both the CA and CV than the IV 
in the SL group), that is not observed with induction of labour and no labour. 
Given sphingosine, sphingosine 1-phosphate and cAMP can affect Ca2+ 
homeostasis and actin assembly, and given the importance of Ca2+ in the 
contraction of myocytes, it is possible that these observed changes represent 
signals from the fetus with spontaneous labour that stimulate myometrial 
smooth muscle contractions. However, this is making a lot of assumptions, and 
further studies would be needed to investigate this, especially the balance 





Bringing this altogether and relating to the hypothesis generated in Chapter 2, 
these results support the findings that changes in endocannabinoids and 
sphingolipids appear to be associated with spontaneous labour in humans, 
including N-stearoyltaurine and N-palmitoyltaurine having a negative 
correlation with gestational age at delivery, and PEA found in higher 
concentrations in latent phase of the spontaneous labour group than the ECS 
group. However, with the cord blood now split into cord artery and cord vein 
(compared with mixed cord blood in Chapter 2), the hypothesis generated from 
Chapter 2 that the differences in endocannabinoid production comes from the 
fetus are not supported. Instead, these changes seem to be more obvious in the 
maternal blood, although it is still possible that uterine lymphocytes are involved 
in these changes and warrant further investigation. 
3.6.3 Progesterone  
There were no significant differences in progestin or oestrogen steroids in latent 
phase/pre-operative samples between the three groups, which fits with the 
previous findings that there is no obvious measurable progesterone withdrawal 
in the maternal blood at the time of labour. Further, for all modes of labour 
onset and delivery there was consistently higher progesterone in the IV samples 
compared with the cord blood samples, which is consistent with previous 




there were differences between the concentrations in the CA and CV of the 
different modes of labour onset which could give further clues as to the 
spontaneous onset of labour in humans, and these will be discussed now. 
For the IOL group and the ECS group there was more than double the 
concentration of progesterone in the CV than the CA, as would be expected 
given the high production of progesterone from the placenta. In contrast, this 
was found to be reversed in the SL group, with the CV having 0.29-fold the 
concentration of progesterone as the CA. Further, the CV of the IOL group had 
4.27-fold higher mean concentration of progesterone than the SL group, and the 
CV of the ECS group had nearly double the mean concentration of the SL group. 
It is not clear what this means, but the lower progesterone in the CV of the SL 
group than the IOL group could represent a decrease in progesterone 
production by the placenta associated with spontaneous labour. Further, the 
progesterone in the CA of the SL group was more than double that of the IOL 
and ECS groups, therefore there could be a switch in the progesterone 
production so that the fetus increased production and the placenta decreased 
production. This warrants more investigation in larger studies. 
Previous experimental studies have shown that the action of progesterone on 
the myometrium include relaxation, inhibition of gap junction formation and 




investigate progesterone levels of 67 women delivered with elective or 
emergency caesarean section. Blood samples were taken from the CA, CV and a 
peripheral maternal blood sample. The researchers found maternal 
progesterone levels at delivery were similar whether or not the woman was in 
labour, and the only differences in the CV progesterone level was a decrease in 
women with an emergency CS for fetal distress, regardless of whether the CS 
was elective or emergency (in labour)70. Another group found that serum 
progesterone concentration in the CV was significantly higher in babies born by 
emergency CS and spontaneous vaginal delivery than ECS and concluded that 
the fetus produces higher levels of progesterone due to stress in these situations. 
There were no differences in the maternal serum progesterone levels between 
the three groups investigated213.  In the present study, the concentration of 
progesterone was higher in the CV of the IOL group than the CV of both the 
spontaneously labouring and the ECS group, and the concentration in the CV of 
the ECS group was non-significantly greater than in the CV of the SL group. This 
does not fit with the previous studies as the IOL group and SL group had similar 
vaginal deliveries, and the ECS deliveries would be presumed to be under the 
least stress. While it could be argued that the IOL group had a more stressful 
labour given three of the women had oxytocin infusion to promote contractions 




given all of the fetuses were delivered vaginally. The ECS group also had higher 
progesterone in the CV than the SL group, and this group would have been 
considered to have the least stress. These observed differences may be because 
in the present study progesterone was detected on a MS metabolomics platform 
rather than by radioimmunoassay (which potentially opens to cross-reaction by 
other interfering steroids). 
A further study examined differences in progesterone concentrations between 
the CV and CA in women who delivered via ECS, and found that the CV 
concentration was consistently higher than in the CA69. This is the same finding 
as in this present study, with both the ECS and IOL group having higher 
progesterone concentrations in the CV than CA, and only the SL group having a 
higher concentration in the CA than CV. The authors found no correlation with 
progesterone levels in the retroplacental blood, and concluded that 
progesterone is secreted by the placenta, independent of the mother and 
fetus69.  
In summary, the shift in the balance in progesterone ratio of the CA and CV 
between the SL group and the IOL and ECS groups could potentially represent a 
reduction in progesterone production by the placenta with spontaneous labour, 
which could be perceived as a progesterone withdrawal by the myometrium. 





17α-hydroxyprogesterone is a progesten steroid that is related to progesterone 
and is a weaker agonist than progesterone at the progesterone receptor. It is 
produced primarily by the adrenal glands, including the fetal adrenal glands, and 
also by the ovary and corpus luteum during pregnancy. It is converted from 
progesterone by the enzyme 17α-hydroxylase; and 21-hydroxylase enzyme, also 
known as CYP21A2, subsequently metabolises it to 11-deoxycortisol, which is 
then converted to cortisol. Although not directly related to the present thesis, it 
is worth noting that 21-hydroxylase deficiency is the most common congenital 
adrenal hyperplasia, in which 17 α-hydroxyprogesterone levels are elevated, 
and which results in elevated ACTH levels leading to adrenal hyperplasia and an 
increase in androgenic hormones which can cause virilisation in females214, 215.  
A previous study investigating maternal 17α-hydroxyprogesterone 
concentrations in peripheral blood observed an initial rise in early pregnancy, 
thought to indicate production of progesterone by the corpus luteum. Levels of 
17α-hydroxyprogesterone then returned to baseline as the placenta takes over 
progesterone production, indicating that the placenta has reduced 17α-
hydroxylase activity. Levels of 17α-hydroxyprogesterone were then found to 
increase again at approximately 32 weeks’ gestation, thought to be derived from 




preterm, preterm and term infants, and found that 17α-hydroxyprogesterone 
was reduced in the very preterm and preterm babies compared with term, and 
showed that the concentrations strongly correlated with gestational age at 
delivery. The authors acknowledge that this may have been secondary to 
maternal steroid administration prior to delivery of the preterm babies, as is 
routinely administered to stimulate lung maturation. 17α-hydroxyprogesterone 
levels were later found to have risen in the preterm neonates on day 3 of life 64.  
Interestingly, in the present study the differences in mean concentrations for 
progesterone discussed above were similar for 17α-hydroxyprogesterone 
concentrations, which were higher in the CV than CA for both the IOL and ECS 
group, but lower in the CV than CA for the SL group. Accordingly, the 
concentration of 17α-hydroxyprogesterone in the CA of the SL group was higher 
than that for the ECS group, and also the concentration in the CA of the IOL 
group was higher than that in the ECS group. Conversely, the concentration in 
the CV was far greater in the IOL group than the CV of the SL group, and higher 
in the CV of the ECS group than the SL group. This could indicate a major change 
in production at the time of spontaneous labour that is not replicated with 
current induction of labour methods.  
As discussed in Chapter 1, progesterone has been administered to women with 




now suggest that progesterone pessaries per vagina may be beneficial in women 
with three previous miscarriages and who have bleeding in early pregnancy123, 
however this treatment does not appear to reduce the risk in other situations122-
125. Weekly intramuscular injection of 17α hydroxyprogesterone caproate, a 
synthetic progestogen (the caproate molecule is not made in humans), has also 
been administered to women in an attempt to reduce the risk of preterm birth, 
and the efficacy of this is debated212,217. A randomised controlled trial (RCT) 
involving women who had a history of preterm birth showed that weekly 
injections with 17α-hydroxyprogesterone caproate (a synthetic progestogen) or 
placebo, found that treatment reduced the rate of preterm births compared 
with placebo212. In a study designed to investigate why 17α-
hydroxyprogesterone may have this effect, direct application of 17α-
hydroxyprogesterone caproate to human myometrium in an organ bath did not 
cause myometrial relaxation. The authors suggested that any relaxation effect 
17α-hydroxyprogesterone caproate may have on the myometrium could be 
through altered gene expression218. Another study investigating the effect of 
progesterone and 17α-hydroxyprogesterone caproate on human myometrium 
in organ bath found that while progesterone did have a relaxing effect, 17α-
hydroxyprogesterone caproate did not, and in fact at higher doses was 




administration219. In a further study, researchers investigating the effect of 17α-
hydroxyprogesterone caproate on term not in labour myometrium found that it 
did not stimulate Cox-2 or TNFα production220. There are also reports that 
administration of 17α-hydroxyprogeterone caproate may confer embryo or 
fetal toxicity, particularly in early pregnancy221, and others warn that the 
addition of the caproate means that this drug should not be assumed to be the 
same as 17α hydroxyprogesterone or progesterone, as some have done217. 
Therefore, it is unclear what the effect, if any, the difference in 17α-
hydroxyprogesterone CA/CV ratio between the SL group and the IOL and ECS 
group may have. It could have an effect similar to progesterone, or it may be 
that it is related to changes in cortisol production. While progesterone levels are 
similar in the mother regardless of mode of labour onset or delivery, there is a 
change in the ratio of progesterone and 17α-hydroxyprogesterone produced by 
the fetus (CA) and placenta (CV) that could be involved in the trigger for labour.  
3.6.4 Oestrogens 
There are four oestrogens present in human pregnancy: oestriol, oestradiol, 
oestrone and oestetrol, with oestriol and oestradiol dominating. All four of these 
oestrogens have been shown to increase during pregnancy. Oestriol is formed 
via DHEA-S, which is produced by the fetal adrenal gland upon stimulation of 




contrast, oestradiol is produced from conversion of DHEA-S produced from 
DHEA-S from both the maternal and fetal adrenal glands102. There are two forms 
of the oestrogen receptor (ER), namely ERα and ERβ. ERα appears to be the 
receptor through which the uterotonic actions of oestrogen are driven. Recently 
the spliced ERα receptor variant ERΔ7 has been shown to dominantly suppress 
the uterotonic actions of oestrogen, and this receptor withdraws at term in an 
oestrogen-dependent manner. This mechanism is suggested to be involved in 
the loss of myometrial quiescence at term101, and that changing concentrations 
of oestriol and oestradiol may be responsible for the change in oestrogen 
receptors102.  
Oestriol is an inhibitor of the action of oestradiol at low concentrations but 
becomes an agonist when the ratio of oestriol to oestradiol exceeds 10 to 1.  One 
group investigated changes in the ratios of progesterone, oestriol and oestradiol 
in spontaneously labouring women at 26 weeks’ gestation and in the last month 
of pregnancy. Oestriol was found to increase, resulting in an increase in the 
oestriol/oestradiol ratio, a decrease in the progesterone/oestriol ratio, and an 
unchanged progesterone/oestradiol ratio. The authors suggested that this 
created an oestrogenic environment for the onset of labour103.  
In the present study, mean concentrations of maternal oestriol did not 




important differences in the ratio of oestrogen to progesterone between the 
different types of labouring groups, and in the different vascular compartments. 
This could therefore indicate different sites of production that may be related 
to the spontaneous onset of labour. For example, oestriol was 0.18-fold lower 
in the CA of the ECS group than the SL group, which would fit with the previously 
described increase in oestriol with spontaneous labour102. Oestriol 
concentrations followed a similar pattern to that of progesterone and were 
higher in the CA than the CV in the SL group, but higher in the CV than the CA 
for both the IOL and ECS groups. The mean concentration of oestriol in the CA 
of the SL group was higher than the mean concentration in both the ECS and IOL 
group, and the mean concentration of oestriol in the CV of the IOl group was 
over 6-fold greater than the CV of the SL group, and the concentration in the CV 
of the ECS group was over 4-fold greater than the CV of the SL.  Concentrations 
in the IV and latent phase samples were similar between the groups. Therefore, 
this could reflect an increase in oestriol production by the fetus and reduction 
in oestriol by the placenta with spontaneous labour that does not occur with no 
labour, but importantly also does not occur with induction of labour. Although 
this needs to be tested in future studies, these changes are potentially important 
and could indicate that the change in progesterone and oestriol balance with 




Oestradiol was not detected in this study, although 17beta-oestradiol did not 
change between the different modes of labour onset.  
3.6.5 Differences between the IOL and SL group 
It is worth highlighting here the potential importance of the findings from this 
study of differences in the ratio of concentrations of some of the discussed 
metabolites in the CA and CV between the different modes of labour onset, and 
specifically differences between the IOL and SL groups. One of the potential 
criticisms of the study described in Chapter 2 is that the differences in 
metabolites between the labouring and non-labouring groups may just be 
because of the physiological stress of labour itself. However, the results from 
this study show that despite the apparently similar preceding events of 
physiological labour and vaginal delivery of the IOL and SL groups, metabolite 
levels in the CV and CA were different between these two groups. For example, 
the heatmap of Figure 3.13 A. shows that in the latent phase, progesterone, 
oestriol, 17α-hydroxyprogesterone, DHEA-S, sphingosine and sphingosine 1-
phosphate were similar in the latent and IV samples between the SL, IOL, and 
ECS groups. However, Figure 1.13 B. is the heat map for the same metabolites 
in the CV and CA samples, which shows that the levels are similar for the IOL and 
ECS group, but that the SL group is different. These differences may have been 




entity, as with the study presented in Chapter 2, rather than separately sampling 
the CA and CV as in this study. 
A previous study investigated the effect of IOL with Dinoprostone (prostaglandin 
PGE2 analogue as used in this study for induction of labour; trade name is 
Propess) on maternal serum progesterone, oestradiol and oestriol levels, 
measured with immunoassays in: women who responded to IOL and women 
who did not, women who spontaneously laboured, and women who had an ECS. 
Blood samples were taken at two time points: start of labour or on admission 
for ECS, and just before delivery. Oestrogen levels were found to be unchanged 
in all groups. Progesterone levels did not change during spontaneous labour but 
decreased from admission to delivery in those who had a successful IOL but not 
those who did not222. 
These results and the results from the present study support a hypothesis that 
there may be an inherent difference in the signals from the fetus with 
spontaneous labour compared with induction of labour, despite the intervening 
event of labour itself. And that with regards to these steroids in the present 
study, the concentrations in the CV and CA of the IOL group are more like the 
ECS group than the SL group. It could be interpreted that fetal production of 
oestriol and progesterone are associated with spontaneous labour but not with 




In summary, these findings indicate that IOL labour is different to spontaneous 
labour and may be due to spontaneous labour resulting from signals from the 
fetus. Moreover, it could be that because IOL is exogenously imposed upon the 
mother that the signals that would originate in the fetus with spontaneous 
labour either do not occur or occur much later. This could in part explain why 
those with IOL are more likely to have complications such as failure to progress, 
and an improved understanding of these differences could lead to better 
targeted management of induction of labour43.  
3.6.6 Correlations with gestational age at delivery 
Although this study was not designed to identify metabolites to predict 
spontaneous labour, there is value in identifying those metabolites that 
corelated with gestational age at delivery as these may point to the pathways 
involved in spontaneous labour. Those metabolites for which mean maternal 
concentrations were significantly correlated with gestational age at delivery will 
be discussed here. 
3.6.6.1 Octadecanedioylcarnitine (C18-DC) and octadecenedioylcarnitine (C18:1-
DC) 
There is no information in the literature regarding the two metabolites 
octadecanedioylcarnitine (C18-DC) and octadecenedioylcarnitine (C18:1-DC), 




metabolites have been detected in mouse faeces using MS metabolomics with 
Metabolon, Inc., following investigation of effect of bacteriophages on a human 
model of gut bacteria and metabolome223. Therefore, it is unclear at present 
what these metabolites represent other than a potential involvement with fatty 
acid metabolism. 
3.6.6.2 Pregnanediol-3-glucuronide 
Pregnanediol-3-glucuronide is a major metabolite of progesterone, and is 
excreted in the urine224. One group found that urinary measurement of 
pregnanediol-3-glucuronide was lower in ectopic pregnancies compared with 
ongoing intrauterine pregnancies, and suggested it could be used to predict 
ectopic pregnancies225. In the present study, increased serum pregnanediol-3-
glucuronide was correlated with earlier gestational age at delivery at 28 weeks’ 
gestation and 34 weeks’ gestation. This could correspond to increased levels of 
progesterone, or increased levels of progesterone metabolism. It is interesting 
that mean concentrations of this metabolite were higher CA of the SL and IOL 
groups than the ECS group, as it could suggest that there is increased 
metabolism of progesterone within the fetus during labour.  
3.6.6.3 17alpha-hydroxypregnanolone glucuronide 
17alpha-hydroxypregnanolone glucuronide was significantly negatively 




phase. It was also significantly lower in the IV blood of the SL group when 
compared with the ECS group, which would not necessarily be expected given 
the correlation results. Moreover, it was significantly lower in the CV than CA in 
the SL group, which could indicate that its source is fetal. The opposite was 
found for the ECS group, where concentration of 17alpha-hydroxypregnanolone 
glucuronide in the IV blood was almost double that in both the CV and CA , which 
could be a result of the ECS group having higher maternal levels than the SL 
group.  
3.6.6.4 N,N,N-trimethyl-alanylproline betaine 
N,N,N-trimethyl-alanylproline betaine (TMAP) was significantly negatively 
correlated with gestational age at delivery at 34 weeks’ gestation and in latent 
phase, and was lower in the latent phase of the SL and IOL groups when 
compared with the pre-operative sample for the ECS group. TMAP was also 
significantly higher in the CV of the SL group compared with the ECS group. 
Thereby higher mean concentrations of TMAP was associated with earlier 
gestational age at delivery, and maternal levels were higher at term in women 
in latent phase than in women at term but not labouring. There is relatively little 
known about TMAP, however in a study involving untargeted metabolomics, 




undergoing dialysis226. It is possible that this metabolite is involved in vascular 
function, and it would warrant further investigation.  
3.6.6.5 DHEA-S 
In Part 2, DHEA-S levels were positively correlated with gestational age at 
delivery at all time points, although only significantly in latent phase. This could 
indicate that decreased levels are associated with an earlier gestational age at 
spontaneous labour. In addition, mean concentrations of DHEA-S were 
significantly decreased at 34 weeks’ gestation compared with 28 weeks’, and 
between latent phase and 28 weeks’ gestation. It was also significantly increased 
in the CA of placenta taken from women who had an ECS compared with the 
levels in the maternal blood and was doubled in the CV of women compared 
with maternal blood in this group, although not significant. This was not the case 
for other deliveries. 
This suggests that higher levels of DHEA-S in the maternal blood may be 
associated with later gestational age at delivery. It is not clear why the DHEA-S 
in the non-labouring women may be so much higher in the CA and CV than in 
the maternal blood, and that this difference isn’t present in the labouring group, 
other than to say that in non-labouring fetuses the levels are significantly 




As mentioned in the introduction74-76, in sheep the fetal hypothalamic-pituitary-
adrenal (HPA) axis maturation is involved in the trigger for parturition, where 
increased fetal cortisol results in increased maternal oestrogen and resultant 
decreased progesterone and labour. In non-human primates, parturition 
without progesterone withdrawal is preceded by an increase in fetal DHEA-S. 
DHEA-S is a precursor to oestriol during pregnancy65. Oh et al. (2006)65 measured 
cord cortisol and DHEA-S levels in utero and at preterm, term, labouring and 
non-labouring foetuses/neonates and found that changes in fetal cord cortisol 
levels did not change until 36 weeks’ gestation, after which the levels increased 
towards term, and that active labour was significantly associated with an 
increase in cord cortisol. DHEA-S was found to decrease until  36 weeks’ 
gestation, after which point it also increased.  
In addition, 16alpha-hydroxy DHEA-3-sulfate, which was found to be reduced in 
the cord and IV blood of the labouring group compared with the non-labouring 
group in Chapter 2, had changes in the opposite direction to DHEA-S in the 
present study. This metabolite significantly increased between 28 weeks’ 
gestation and 34 weeks’ gestation, and again between 34 weeks’ gestation and 
latent phase, although there was no correlation between maternal 




spontaneous delivery. In summary, DHEA-S is an important adrenal product and 
may reflect fetal adrenal gland maturation towards term.  
3.6.7 Perfluorooctane sulfonate 
Interestingly, perfluorooctane sulfonate (PFOS) was negatively correlated with 
gestational age at each time point. PFOS is a perfluorinated chemical that has 
been used in industry including hydraulic fluids in the aviation industry, and 
previously for coating for textiles, carpets and leather. It was banned in the 
European Union under the 2006/122/EC directive which came into force in 2008. 
Public Health England reported in 2009 that the general public are only exposed 
to trace levels of PFOS, but because of the potential risk to both humans and the 
environment it has been banned in the EU. Public Health England reported that 
PFOS does not appear to be mutagenic or a cancer risk at the levels the general 
public are exposed to227. The half-life of PFOS in human serum is approximately 
five years228. Perfluorooctanoate (PFOA) is another perfluorinated chemical227 
that was detected in the maternal and cord serum, but was not correlated with 
gestational age at delivery in this study. A population study in an area of the 
United States that is highly exposed to PFOA showed no association between 
serum PFOS (5262 pregnancies) levels or PFOA (1845 pregnancies) and self-
reported miscarriage or preterm delivery in the five years prior to the sample 




eclampsia; and low birth weight was weakly associated with PFOS; and birth 
defects weakly associated with PFOA229. The issue with this study is that all 
outcomes were self-reported and therefore there may be inaccuracies. In 
addition, as all were from the high-exposure area, it may be that there was not 
enough comparison with people with low or normal levels.  
There have been some reports that PFOS may affect oestrogen haemostasis in 
pregnancy230. Moreover, in cell culture of porcine ovarian theca and granulosa 
cells, PFOS was found to inhibit the steroids released by these cells in response 
to luteinising hormone and follicle stimulating hormone, respectively231. 
Progesterone and androstenedione secretion by theca cells in response to 
luteinising hormone was reduced in these cells231. The authors concluded that 
PFOS appears to act as an endocrine disruptor in ovarian cells231. Similar 
conclusions were drawn from a study in H295R cell culture (an angiotensin-II 
responsive steroid producing adrenocortical cell line), where exposure to PFOS 
increased supernatant oestradiol concentrations and decreased supernatant 
testosterone. Exposure to PFOS of zebra fish embryos resulted in an increased 
gene expression of esr1 (for ERα) and a decrease in expression of esr2b (ERβ1)232.  
The present study was performed in Bristol, UK in 2018/2019. In a sub-study of 
457 mother-son pairs within the Avon Longitudinal Study of Parents and 




detected in all maternal pregnancy samples taken at around 30 weeks’ gestation, 
and an inverse association between PFOS and birth weight, crown to heel length 
and head circumference was observed233. And in a similar study with ALSPAC of 
447 mother-daughter pairs, an association was found between higher levels of 
PFOS at birth and lower birth weight, but with greater weight at 20 months of 
age234.  
In further analysis performed by the thesis author but not included in this thesis, 
1000 women (from the Born in Bradford cohort study, described in Chapter 4) 
had MS metabolomics analysis performed on fasting blood samples collected 
during the second trimester. Unadjusted linear regression analysis showed that 
a 1 standard deviation increase in maternal blood mean PFOS concentration was 
associated with a 0.514 day reduction in mean gestational age at delivery (95% 
confidence interval: -1.014 to -0.015 p=0.044).  
Thus, multiple lines of evidence from different studies in this thesis support an 
inverse association of PFOS with gestational age at delivery. This effect is still 
present despite production of PFOS being effectively banned by the EU over a 
decade ago and warrants further study. 
3.6.8 Over-representation analysis  
The over-representation analysis indicated that the alpha linolenic acid and 




those metabolites which were significantly different between the CV of the IOL 
group and the CV of the SL group. Linoleate is the conjugate base of linoleic acid, 
and in this study linoleate was significantly higher in the latent phase samples of 
the SL group than the pre-operative samples of the ECS group. Further, linoleate 
was significantly higher in the CV than CA of the SL group, whereas for both the 
IOL and ECS groups it was significantly higher in the CV than the CA. Further, 
linoleate was significantly higher in the CA of the SL group than the CA of both 
the IOL and ECS groups, with no significant difference between the CA of the IOL 
and ECS groups.  
Linoleic acid is a polyunsaturated fatty acid (PUFA) and has become the most 
common n-6 PUFA in the human diet over recent decades. Interestingly, 
following elongation and desaturation, it can produce arachidonic acid235. 
Arachidonic acid, as has been discussed previously, is a precursor to 
prostaglandins as well as other eicosanoid mediators such as leukotrienes and 
thromboxanes, which are associated with inflammatory processes235. One group 
investigated the effect of a high linoleic acid maternal diet in mice on the heart 
function of offspring, and specifically whether such a diet was associated with 
changes in circulating fatty acids and cardiac function. The researchers found 
that a high linoleic acid diet: decreased the circulating total- and HDL-cholesterol 




decreased total plasma n-3 PUFA; and did affect overall cardiac function of the 
offspring235. In addition, in Chapter 4 of this thesis, an increase in 18:2 linoleic 
acid was associated with a shorter gestational length, although an increase in 
the ratio of 18:2 linoleic acid to total fatty acids was associated with a longer 
gestational length (Figures 4.7 and 4.8). When taken in the context of the 
previously conducted study, the former observation supports the hypothesis 
that there is an association between maternal dyslipidaemia and a shorter 
gestational age at spontaneous labour, which will be discussed in more detail in 
Chapter 4. Further, in a previous study involving the Born in Bradford cohort, 
linoleic acid was negatively associated with pre-eclampsia236. 
In addition, previous research has shown that linoleic acid intake is important 
for production of anandamide (AEA), as the production of AEA is dependent 
upon the metabolic derivatives of arachidonic acid in phospholipids. In a mouse 
study, the effect of a diet in which linoleic acid made up 1% of the energy intake 
was compared to the effect of a diet in which linoleic acid made up 8% of the 
energy intake. The 8% version was found to increase the tissue concentration of 
arachidonic acid, with an associated increase in AEA and diet-induced obesity237. 
Arachidonic acid is part of the arachidonate cascade, and arachidonate is formed 
following removal of a proton from the arachidonic acid carboxyl group238. In 




IOL and ECS groups, and conversely higher in the CA of the SL group than the CA 
of the IOL and ECS groups. In addition, arachidonate increased between 28-
weeks’ gestation and in latent phase and was significantly lower in the pre-
operative samples of the ECS group when compared with the samples from the 
latent phase in the SL group.   
In summary, both arachidonate and linoleate were higher in the CA than CV in 
the SL group, but lower in the CA than CV in both the IOL and elective CS groups. 
This again shows differing ratios of metabolite concentrations between the CA 
and CV, and that this ratio for the IOL group is more alike the ECS group than the 
SL group, despite the intervening labour. In addition, both metabolites were 
higher in the latent phase of the SL and IOL group than the pre-operative sample 
of the ECS group, with similar levels in the intervillous blood. Therefore, this 
supports the idea suggested in section 3.6.1.2 that it may be that the elevated 
arachidonate is a result of the metabolism of AEA by FAAH in the CA, resulting 
in increased arachidonate, and that endocannabinoid activation, potentially 
from the fetus (CA in the SL group) may be involved in the trigger for human 
labour.  
Regarding further findings of the ORA, although not significant, over-
represented pathways for metabolites significantly correlated with gestational 




group and both the IOL and ECS groups in the CA and CV, included beta-
oxidation of very long chain fatty acids, and fatty acid biosynthesis. This suggests 
that mobilisation of fatty acids is important for spontaneous labour and 
corresponds to the findings presented in Chapter 4 (discussed further in section 
4.7.6). 
3.7 Conclusions  
This study has highlighted metabolites that correlate with gestational age at 
delivery and warrant further investigation. Importantly, by analysing the cord 
artery and cord vein separately, and between different modes of labour onset, 
the results of this study indicate that there are differences in the ratio of 
metabolites in the cord vein and cord artery between women who 
spontaneously labour and women who have induced labour or elective 
caesarean section. This includes progesterone and oestriol and potentially 
endocannabinoid metabolism. This is interesting because it shows that despite 
the apparently similar physiological events of labour that women who 
spontaneously labour and women who have induced labour go through, there 
are persistent differences in the cord artery and cord vein. 
It is possible that these results represent changes in the production of certain 
metabolites by the fetus, which may coincide with maturation of the fetal 




progesterone and oestrogen with spontaneous labour. These differences may 
also in part account for induced labour having higher risk for adverse pregnancy 
outcomes, including emergency caesarean section and instrumental delivery, 
because without the signals from the fetus the myometrium may not contract 
as efficiently. These findings warrant further investigation. 
3.8 Limitations 
Limitations for this study include that the numbers are relatively small, and 
larger studies are required to confirm the hypotheses discussed. In addition, 
most of the blood tests were taken in a non-fasted state and this may have 
affected results. However, despite this, the strengths of this study include that 
because the numbers are small, detailed information was known about the 
women and the pregnancies, and samples were taken at multiple time points. 
In addition, despite the small numbers, the relatively tight 95% confidence 
intervals suggest that this is a useful method for comparing levels of metabolites 
in pregnancy, and that metabolite levels are consistent between the groups 
studied. There is also the potential to use bioinformatic pipelines to extract 






CHAPTER 4. MATERNAL METABOLIC PROFILE IN THE 
SECOND TRIMESTER AND GESTATIONAL AGE AT DELIVERY: 
FINDINGS FROM THE BORN IN BRADFORD COHORT STUDY  
 
4.1 Background 
While smaller clinical cohort studies, such as those of the previous three 
chapters of this thesis, can be designed to investigate specific pathways at 
specific time points during pregnancy, the size of these studies can limit 
statistical power and generalisation of results to other settings. On the other 
hand, epidemiological studies which incorporate data from large population-
based cohorts can maximise statistical power and provide information that can 
potentially be more relevant to wider populations. Triangulation is a 
methodology which advocates approaching a question from multiple angles 
using different methodologies with contrasting biases, rather than depending 
upon a single method20. If these different methodologies give consistent results, 
this improves confidence in the validity of the results. In the previous chapters 
of this thesis, findings from studies using mass spectrometry (MS) metabolomic 
profile analysis of repeat sampling at different time points in pregnancy, 
including during labour and immediately following birth, have been presented. 
This chapter complements those by using an epidemiological approach to 
address the over-riding aim of this thesis that is improving understanding of the 




this study explores the association between a gestational Nuclear Magnetic 
Resonance (NMR) serum determined metabolomics profile and gestational 
length in a prospective birth cohort. Data from the Born in Bradford (BiB) cohort 
has been analysed, in which fasting serum samples were collected as part of an 
oral glucose tolerance test (OGTT) for gestational diabetes at 26-28 weeks of 
gestation. BiB is a large multi-ethnic cohort, and 7440 women (see methodology 
section and Figure 4.1 for those pregnancies excluded) were included in the 
analyses presented in this chapter.  
4.2 Maternal metabolic traits and potential link to gestational age of delivery 
Previous studies have investigated maternal and cord metabolomic profiles and 
potential association with conditions such as preterm birth and small for 
gestational age. One group performed a retrospective case-control study 
comparing plasma sampled from women who delivered preterm (between 22 
weeks and 36 weeks gestation) (n=57) or at term (between 38 and 41 weeks) 
(n=25), as well as women with threatened preterm labour who went on to 
deliver at term (n=49). Plasma samples were taken within 7 days of delivery for 
the preterm group, and during labour in the threated preterm and term delivery 
groups. Blood was centrifuged and plasma stored at -80 degrees Celsius until 
metabolomics analysis using liquid chromatography quadrupole time of flight 




were most differentiated between the three groups, and the authors concluded 
that there were differences in the metabolome between women who delivered 
preterm and those who delivered at term. However, potential issues with this 
study design include that the samples were taken at different time points of 
labour, including up to seven days after delivery in the preterm group. These 
factors mean that any differences between the metabolomic profiles of the 
three groups are not necessarily related to gestational age at delivery239. 
Therefore, while these results are potentially interesting, and point towards 
differences in fatty acids, these findings require further testing. Another group 
performed a nested case-control study using LC-MS metabolomics to investigate 
the potential for obtaining biomarkers for prediction of spontaneous preterm 
birth in asymptomatic women at 15 and/or 20 weeks’ gestation. 50 infants were 
delivered before 37 weeks’ gestation, and 55 delivered after 41 weeks’ gestation. 
Samples were collected during antenatal clinics and blood processed within 3 
hours of collection and stored at -80degrees Celsius. Participants were enrolled 
in the Screening for Obstetric and Pregnancy Endpoints (SCOPE) study, based in 
Cork, Ireland. The authors found no significant differences between the two 
groups when using standard t-tests, even with an FDR cut-off of 0.1, which the 
authors put down to heterogeneity in the disease group. Instead, the authors 




developed a biomarker panel for future investigation which included bile acids, 
prostaglandins, vitamin D and fatty acids240. Issues with this study include the up 
to three hours between sample taking and processing, during which time fast-
acting metabolites may metabolise, and the highlighted heterogeneity in the 
participants. Further studies include a group which analysed maternal blood, 
cord artery and cord vein blood at the time of delivery for women delivering 
babies preterm (cases n=7) or term (n=8). These findings suggested enhanced β-
oxidation of short- and medium-chain fatty acids in the preterm group67. 
Another group performed metabolomic analysis of newborn blood sampled for 
metabolic screening, and created a model that explained 52.8% of the variation 
in gestational age at delivery, that included 37 metabolite measurements241. 
There remains a gap in the literature regarding the pathways for spontaneous 
labour in humans, and the use of metabolomics in this area does not appear to 
have been utilised to its full potential as yet, particularly in larger cohort studies 
as with the BiB cohort. 
4.3 Epidemiology and public health consequences of pre-term and post-term 
births  
Approximately 7% of pregnancies deliver preterm (<37 completed weeks’ 
gestation)39. Preterm birth is responsible for 16% of global deaths in children 




preterm are later diagnosed with cerebral palsy41. In contrast, current 
management options for pregnancies which are clinically recommended to be 
artificially shortened by inducing labour are frequently inefficient, with an 
increased risk for complications of labour including fetal distress, instrumental 
delivery, emergency caesarean section and post-partum haemorrhage 4, 43. 
Induction rates in the UK are currently increasing, from 20% in 2006-7 to 29% in 
2016-17 45, and therefore there is need for improved management options.     
While recently published metabolomics studies have pointed towards useful 
biomarkers for prediction of pathologies of pregnancy such as small for 
gestational age, gestational diabetes, and preterm labour 15, 16, such biomarkers 
may not reflect the relevant causal pathways21, 22. Therefore, in order to better 
understand the causal pathways, and to identify better targets for drug 
development, studies which investigate association and potential causal 
pathways are required, and hence the work presented in this thesis. This chapter 
will specifically investigate potential associations of maternal metabolites in the 
second trimester and gestational age at delivery in order to provide direction for 
future research in studies investigating causation.  
4.4 Aim 
The aim for this chapter was to assess potential associations between the 




participating in the BiB study and gestational age at delivery (continuous 
variable, preterm and post-term birth).  
4.5 Methodology 
4.5.1 Data source 
The BiB cohort was set up in 2007 to investigate the effect of socioeconomic, 
behavioural, genetic and nutritional factors, on childhood development and 
health within a deprived multi-ethnic population 242. Recruitment took place 
between March 2007 and November 2011. At the time of recruitment, Bradford 
was the sixth largest city in the UK, with high levels of deprivation, and the 
maternity unit had 6000 deliveries per year. Because of their background, many 
women in Bradford are considered at high risk for development of gestational 
diabetes. Therefore, all women in Bradford, except those with known diabetes, 
are offered a second trimester fasting oral glucose tolerance test (OGTT) 
between 26- and 28-weeks’ gestation. Women who had their pregnancies 
booked in Bradford were invited to participate in the BiB cohort at the time of 
their OGTT and over 80% consented242. Overall, 12 453 women with 13 776 
pregnancies were recruited to the study; and 12 331 pregnancies (89% of total 
pregnancies) completed the OGTT and had stored fasting samples which were 




4.5.2 Ethics and informed consent 
All participants gave written informed consent. Ethical approval for the BiB data 
collection was provided by Bradford Research Ethics Committee (Ref 
07/H1302/112). 
4.5.3 Data collection 
Most women were recruited at the time of their OGTT as described above, 
however for 17%242 of the pregnancies included in the BiB cohort (2334/13776 
pregnancies), women were offered an OGTT but did not attend the appointment. 
These women were subsequently recruited at hospital visits attended later in 
pregnancy, or during the hospital stay for birth. For those women who 
consented to participate in BiB at the time of the OGTT, an extra 20ml of fasting 
blood sample was taken at the same time as the fasting OGTT blood sample 
draw for future analysis. Trained phlebotomists drew the blood samples in 
serum separating blood collecting tubes which were then transferred 
immediately to the laboratories at the Bradford Royal Infirmary. The samples 
were centrifuged at 1000 x g for ten minutes at room temperature. Automated 
pipettes were used to aliquot 1ml of serum into 1.5 microtubes vials. Care was 
taken throughout to track and confidentially label each sample with the relevant 
mother and pregnancy unique identifiers, and the serum samples were stored 




a half hours of the sample being obtained. There were no freeze-thaw cycles for 
the samples on which subsequent NMR metabolomics analysis was 
performed236. In summary, 12 453 women across 13 776 pregnancies were 
recruited into the BiB cohort, and there were OGTT results for 12 331 
pregnancies (11 231 women), and NMR data for 11 479 pregnancies (10 574 
women).  
At recruitment, women had their weight and height measured, and a baseline 
questionnaire was completed via interview. Over 50% of the obstetric 
population in Bradford are of South Asian origin, the majority of which are of 
Pakistani origin and specifically from the city of Mirpur (Kashmir region). 
Interviews were therefore undertaken in English, Urdu or Mirpuri. Mirpuri is not 
a written language hence the verbal interview was essential. Further details 
regarding labour, delivery, and baby outcomes were obtained from electronic 
and paper hospital records.  
4.5.4 Data access 
The custodians of BiB are committed to making study data widely available to 
international researchers, and many documents are freely available online 
(https://borninbradford.nhs.uk/about-us/). Full details of how to apply to access 
existing data for analyses are available from 




use the BiB data to undertake the study presented here, alongside an application 
to undertake analyses by having access to the relevant data files for this study 
using the BiB data files held in Bristol, was submitted via this pathway and access 
was granted on 18th June 2018. 
4.5.5 Study eligibility criteria 
Women with singleton pregnancies recruited into the BiB cohort were eligible 
for inclusion in the study presented in this chapter. Only one pregnancy per 
woman was included.  
Multi-fetal pregnancies were excluded as it is plausible that carrying two or 
more fetuses would alter maternal gestational metabolite concentrations more 
so than with single-fetal pregnancies, and most multi-fetal pregnancies are 
iatrogenically delivered preterm. Only one pregnancy was included per mother 
to avoid including multiple observations from the same mother in the analysis, 
important as the statistical methods used assume independence of observations 
between participants. The first pregnancy recruited into the cohort for each 
woman was included, and parity was controlled for in the analysis. 
Figure 4.1 shows the flow of BiB participants from all pregnancies recruited, to 
the eligible dataset (all singleton pregnancies and only one pregnancy per 
mother), and the final analysis dataset. Of the 13776 pregnancies recruited into 




excluded as triplet pregnancies (Figure 4.1 and Table 4.1). A further 1306 were 
removed in order to include only one pregnancy per mother (this would have 
been 1323 pregnancies if the multi-fetal pregnancies had not already been 
removed as 17 of the women with multi-fetal pregnancies also had one other 
pregnancy included in the BiB cohort) (Figure 4.1 and Table 4.2). The eligible 
sample included 12 308 (89% of total recruited sample) mothers with one 
singleton pregnancy. Women with pregnancies who had any data missing 
among the eligibility variables, exposure variables, outcome variable or co-
variables were then removed (n=4868), leaving 7440 women with one singleton 





Figure 4.1: Flow chart for participant inclusion: Total sample = all women and pregnancies recruited 
to BiB; Eligible sample = multi-fetal pregnancies excluded and only one pregnancy per mother 










Table 4.1: Distribution of multi-fetal pregnancies for mothers enrolled in BiB. 







Table 4.2: Distribution of pregnancies for mothers enrolled in BiB. 
Number of pregnancies 
(PregnancyID) per mother 
(MotherID) recorded in 
BiB 
Number of pregnancies 
in  total dataset 
Number of 





1 11 168 12 308 7440 
2 2494 0 0 
3 114 0 0 













4.5.6 Exposure measures: maternal gestational metabolite concentrations  
The exposures for this study were the NMR serum metabolites measured in 
fasted serum samples taken from women at 26 to 28 weeks’ gestation. Up to 
157 metabolic traits were measured using NMR at the University of Bristol 
Bioresource Laboratories and NMR metabolite facilities. Measurements were 
then quantified by Nightingale Health (Nightingale Health©(Helsinki, Finland)). 
The Nightingale Health NMR metabolomics platform involves the use of three 
molecular windows for metabolite quantification, with two applied to native 
serum and one applied to lipid extract from the serum using minimal 
preparation. For metabolite quantification, two spectra (LIPO and LMWM) were 
obtained from the two native serum samples, and one (LIPID window) from the 
lipid extract. A Bruker AVANCE III spectrometer was used to measure the NMR 
spectra, operated at 500 or 600 MHz. The native serum samples were measured 
at 37 degrees Celsius, and the lipid extract at 22 degrees Celsius. The LIPO 
window provides a standard human serum spectrum, with lipid molecules 
within lipid particles causing broad overlapping resonances. Recording of the 
LIPO data was achieved through use of eight  transients gained using  NOESY-
presat pulse sequence with water peak suppression and a 10-millisecond mixing 





Figure 4.2: Illustration of processes involved in the Nightingale NMR metabolomics platform used to produce the metabolomics data analysed in this 




using the LMWM window and recorded via a relaxation-filtered pulse sequence 
which allowed enhanced detection of the smaller solutes through suppression 
of broad signals from macromolecules and lipids. A Car-Purcell-Meiboom-Gill 
(CPMG) pulse sequence with fixed echo delay of 403 microseconds and a 78 
milliseconds T2 filter applied with 24 transients was used. Finally, a standard 1D 
spectrum using 32 transients was used to acquire the LIPID window243, 244 (See 
Figure 4.2). 
Automated NMR spectra analysis was performed to obtain metabolite molar 
concentrations. To account for the difficulties of overlapping spectral data, a 
ridge regression was applied for each metabolite. Calibration of lipoprotein lipid 
data quantification models involved high-performance LC methods, followed by 
cross-validation against lipid data acquired from non-NMR analysis. 
Quantification of LMW molecules and molecules from serum lipid extract 
(quantified as mmol per litre) was based on regression modelling and calibrated 
against metabolite measures that were manually applied. Iterative line-shape 
with PERCH NMR (PERCH solutions ltd, Kupio, Finland) software was used for 
calibration data quantification. Due to variation in the lipid extraction protocol 
it is not possible to directly establish absolute quantification for the lipid extract 




cholesterol that was quantified from the LIPO spectrum results of the native 
serum 243, 244. 
4.5.7 Outcome: gestational age at delivery 
As described previously, preterm birth is birth which occurs prior to 259 days 
gestation (37 completed weeks), and post-term is defined as pregnancy which 
exceeds 294 days (more than 42 completed weeks). Term pregnancy is defined 
as 259 days to 294 days inclusive (37-42 completed weeks’ gestation)29. The 
World Health Organisation (https://www.who.int/news-room/fact-
sheets/detail/preterm-birth) further classifies preterm birth as extremely 
preterm (less than 196 days’ or 28 completed weeks’ gestation), very preterm 
(196 days or more but less than 224 days’ gestation, or 28 to <32 weeks’ 
gestation), and moderate to late preterm (224 days or more but less than 259 
days’ gestation, or 32 to <37 weeks’ gestation)29. These definitions were used 
for analysis in this study.  
The primary outcome for this study was gestational age at delivery, and the 
gestational age at delivery for each of the pregnancies was obtained from 
electronic and paper medical records. Gestational age (outcome) was analysed 
in the following ways:  




2. Preterm birth defined as less than 259 days (<37 completed weeks 
gestation) compared to term birth, defined as 259 days to 294 days, 
inclusive (37 to 42 completed weeks’ gestation); 
3. Post-term birth, defined as more than 294 days (over 42 completed weeks’ 
gestation) compared to term birth; 
4. Extremely preterm defined as less than 196 days (<28 completed weeks’) 
compared to term birth;  
5. Very preterm, defined as 196 days to less than 224 days (≥28 completed 
weeks’ to <32 completed weeks) compared to term birth; 
6. moderate to late preterm, defined as 224 days to less than 259 days (32 
weeks to less than 37 weeks’ gestation) compared to term birth. 
Analyses with the outcomes described in 3, 4, and 5 above were considered 
exploratory as statistical power would be relatively limited for those outcomes. 
4.5.8 Data analysis 
4.5.8.1 Directed Acyclic Graphs  
When the aim of an analysis using observational data is to understand causal 
relations, as in the present study, a major concern is the potential that the 
results obtained may be biased because of residual confounding. Confounding 
occurs when one or more characteristics influence both the exposure of interest 




age at delivery). Causal effect estimates from multivariable adjusted analyses in 
observational data assume that all confounders have been thought of, 
accurately measured and appropriately adjusted for. For the present study, the 
intention was to take a systematic approach in deciding what may confound the 
analyses.  
Directed Acyclic Graphs (DAGs) are a type of causal diagram that have been 
increasingly used to improve study design and data analysis for causal inference. 
DAGs represent expert knowledge and a priori assumptions about the causal 
structure underlying the data, and can be used to guide data analysis. 
Understanding DAG theory can aid identification of what needs to be adjusted 
for and what should not be adjusted for. This can be useful if potential 
confounders are identified and not all are measured in the dataset. If 
relationships between confounders are correctly presented in the DAG 
(assuming all confounders are measured with minimal or no error), the DAG can 
be used to identify whether all relevant confounders are included in a proposed 
regression model19, 245. For the present study, a priori knowledge was used to 
identify potential confounders and a DAG was created to represent known or 
plausible relationships between these confounders, the study exposure and 




Within a DAG, nodes represent variables and are connected by unidirectional 
arrows pointing in the direction that a causal relationship is known or plausible. 
Paths between several nodes must be acyclic, i.e. no path can return to a node 
from whence it originated246,19. DAGs are completely dependent upon expert 
knowledge on the underlying causal structure, and could therefore  be 
developed on the basis of wrong assumptions about the data given our 
incomplete knowledge of the relationships between many human 
characteristics19.  
For this study, potential confounders (or covariables) were identified following 
a review of relevant literature, clinical knowledge, and through discussion with 
the supervisors of this PhD. The Dagitty web interface (www.dagitty.net) was 
used to draw a DAG with the assumed underlying causal assumptions for this 
study, and to determine which variables should be adjusted for in the analysis19. 
Figure 4.3 shows the final DAG used for this study. Initial iterations of the DAG 
also included medications that participants were recorded as taking during 
pregnancy. However, after investigation of the data and further discussion it was 
decided that the recorded medications were unlikely to influence gestational 
age at delivery and were therefore not adjusted for in the models used. 
Conversely, parity was not included in the first iteration of the DAG, however 




both metabolite levels and gestational age at delivery236, 247, 248 and was adjusted 
for.  All variables in the DAG were included in the subsequent analyses as 
covariates. For each of these covariables, the reason for identifying it as a 
potential confounder and the method by which the relevant data was collected 











Figure 4.3: Directed acyclic graph for analysis of the relationship between maternal metabolites measured during the second trimester and 




4.5.8.2 Assessment of confounders 
Maternal age has previously been shown to affect both gestational age at 
delivery249 and pregnancy metabolic profile236. Women reported their date of 
birth at the time of the baseline interview, and with the date of the interview 
this was used to calculate maternal age and recorded as the mother’s age in 
years at the time of the baseline questionnaire.  
Maternal body mass index (BMI) has been associated with an altered pregnancy 
metabolomic profile236, 250 and gestational age at delivery251. At the time of the 
baseline interview, women were weighed and had their height measured 
unshod and in light clothing, following a protocol that all assessors were trained 
to follow. As the women at baseline questionnaire were 26-28 weeks’ gestation, 
the fetus, amniotic fluid and physiological changes of pregnancy would influence 
their weight. Therefore, early pregnancy BMI was calculated using weight 
measurement extracted from that measured at the booking antenatal clinic 
generally attended in the first trimester. Therefore the maternal BMI used in this 
study was calculated as: (booking weight in kilograms)/(height measured at time 
of recruitment in metres)2. 
Maternal ethnicity may also influence both maternal metabolic profile236 and 




reported data and linked data from General Practitioners, and ethnicity was 
categorised as White European, South Asian or Other.  
Socioeconomic position (SEP) has been associated with pregnancy metabolic 
profile236 as well as gestational age at delivery253, 254,255. Within the BiB cohort, 
information regarding different components of SEP was collected at the time of 
recruitment to BiB and recorded in the mother and father baseline 
questionnaires. Two potential methods for assessing SEP are: to use one or more 
individual assessment points, such as education and information regarding index 
of multiple deprivation; or to combine multiple factors of SEP into one score255. 
Latent class analysis (LCA) is an example of the latter, and is a statistical method 
for classifying individuals into groups on the basis of conditional probabilities 
that incorporate multiple factors related to SEP. This means that individuals 
within each group will have similar responses to categorical variables255. LCA has 
previously been successfully applied to the BiB data, for which the following SEP 
factors were included in the analysis: employment status of the mother and 
father; education of the mother and father; subjective poverty; receiving means 
tested benefits; being up to date with bills; housing tenure; able to afford a 
holiday for at least a week at least once a year; to have food and drink with 
family and friends at least once a month; to afford two pairs of all-weather 




furniture; replace or repair major electrical goods; a hobby or leisure activity; 
keep home warm; to spend money on themselves255. Following this analysis, the 
following five latent classes were derived: Least socioeconomically deprived and 
most educated, employed not materially deprived, employed no access to 
money, benefits and not materially deprived, and most economically deprived. 
For the present study, the derived variables from the LCA described above were 
used to adjust comprehensively for  SEP 255.  
Alcohol intake during pregnancy has previously been found to be associated 
with preterm labour, although the evidence is not strong 256, and has been 
shown to alter the metabolic profile of non-pregnant individuals257. Data for 
alcohol intake during pregnancy and in the three months before pregnancy was 
also recorded in the maternal baseline questionnaire and was dependent upon 
the women remembering and reporting that they had consumed alcohol. This 
was categorised into yes/no/can’t remember.  
Cigarette smoking could also plausibly influence maternal metabolites and 
gestational age at delivery258-260. Whether or not a woman smoked cigarettes 
during pregnancy was derived from the questions in the maternal baseline 
questionnaire, categorised as yes or no to smoking during pregnancy.  
The type of onset of labour would also influence the gestational age at delivery, 




shortened gestations, and it is plausible that the type of onset of labour may 
have had an influence on the maternal metabolite level. Information on labour 
onset was extracted from electronic records, and categorised as spontaneous, 
induction or elective caesarean section (no labour).  
Parity has been associated with differences in gestational age at delivery 247, 248 
and pregnancy metabolomic profiles 236. Data regarding parity was derived from 
the hospital paper  notes or electronic records, and was recorded as an integer 
value. 
Pre-existing diabetes (type 1 and type 2) and gestational diabetes (GDM) have 
been associated with altered metabolome261,236, 262 and preterm birth263,264. Pre-
existing diabetes data was obtained from electronic records and paper notes 
and categorised as yes or no to diabetes prior to pregnancy. Data regarding GDM 
was obtained from the OGTT results. GDM was categorised as being diagnosed, 
not diagnosed or not documented. 
Pre-existing hypertension is associated with altered metabolome265, as is 
pregnancy induced hypertension and pre-eclampsia236, 266, and both have been 
associated with preterm birth267-269. Data regarding pre-existing hypertension 
was obtained from electronic and paper medical records, categorised as no or 




abstracted from the maternal paper records, categorised as normotensive, 
gestational hypertension, or pre-eclampsia.  
A previous study found concentrations of total cholesterol, LDL cholesterol, and 
apolipoprotein B-100 were raised in the plasma of women with intrahepatic 
cholestasis of pregnancy (also-known-as obstetric cholestasis) when compared 
with controls 270. Obstetric cholestasis is also associated with earlier delivery of 
pregnancy, although this may be iatrogenic271. Prevalence of OC varies 
worldwide, and in the UK affects 0.7% of pregnancies in multi-ethnic populations, 
but 1.2-1.5% of women of Pakistani-Asian background, and 5% in women of 
Araucanian-Indian origin 272. Obstetric cholestasis was not documented in the 
BiB study, so it was not possible to control for this in the analysis. 
4.5.9 Creation of analysis sample 
In this study, complete case analyses were used in order to deal with the issue 
of missing data. Complete case analyses involve performing all regression 
models on the same sub-sample, which includes only those participants with no 
missing data for exposure, outcome or identified covariables (confounders). In 
general, complete case analysis is expected to be unbiased if missingness is not 
related to the outcome in the main analysis model conditioned on exposure, and 
that all covariables are included in the main analyses273. For the present study, 




complete data on serum NMR, gestational age and all confounders (see Figures 
4.1 and 4.4 for numbers for each of the different main analyses). As this method 
requires the same sample set to be included in both the unadjusted and 
confounder adjusted models, any differences between these estimates would 
likely be due to confounding.   
4.5.10 Statistical analysis 
The metabolic traits assessed in the second trimester of pregnancy were 
transformed to standard deviation (SD) units. Table 4A1 (Appendix) shows each 
metabolite measured with units and standard deviation for the analysis sample. 
SD units were used to allow for comparisons across the association of individual 
metabolites and gestational age at delivery.   
Figure 4.4 summarises the statistical analyses performed. Linear regression was 
used to estimate the association between each of the maternal metabolites and 
gestational age at delivery where gestational age was measured as a continuum 
in days. In order to further analyse whether there may be differences in 
maternal metabolites between different extremes of gestational age at delivery, 
logistic regression was performed to compare metabolite concentrations of 
those pregnancies which delivered preterm (<259 days, n=392) with those that 
were born at term (259-294 days gestation, n=6994); and similarly to compare 




(>294 days, n=54) with those that were delivered at term. Following discussion 
with supervisors, it was intended that all models would be presented with no 
adjustment and with adjustment for the minimal sufficient set of confounders 
as described above. Further sensitivity analysis was then performed to 
determine if there were differences between the categories of preterm birth, 
where those which were born extremely preterm (<196 days, n=12), very 
preterm (≥196 to <224 days, n=51), or moderate to late preterm (≥224 <259 
days, n=329) were separately compared with those born at term.  
In order to account for multiple testing, a p-value threshold calculation was 
conducted according to previous work using this NMR data250. Principal 
component analyses were conducted on z-scored NMR data, including data 
from the BiB cohort, to estimate the number of independent dimensions in the 
data and it was determined that the first 17 principal components explained 95% 
of the variance in the metabolic measures. Therefore, for the present study a 













4.6.1 Participants’ characteristics 
Figure 4.1, and Tables 4.3-4.5 and 4A2 (Appendix) show the differences in 
pregnancy numbers and missing data between the total recruited pregnancies 
(n=13776), the eligible sample (n=12308) and the analysis sample (n=7440). 
Specifically, Table 4.3 shows the median, minimum and maximum gestational 
age values in days, and the number of missing values for the total recruited 
pregnancies, the eligible pregnancies and the analysis sample pregnancies; 
Table 4.4 shows the median, maximum, minimum and missing values for the 
continuous co-variables maternal age and maternal BMI among all recruited 
pregnancies, all eligible pregnancies, and within the analysis sample; and Table 
4.5 shows the total number for each category and total missing values for each 
of the remaining covariables other than obstetric cholestasis, again among the 
total recruited sample, eligible pregnancies sample and analysis sample.   
7440 pregnancies (60.5% of eligible) had no missing data for NMR, gestational 
age or the confounder variables, and comprised the analysis sample. Despite the 
difference in number of pregnancies, the three samples had very similar 
distributions of exposures (Table 4A2, Appendix), outcome (Table 4.3) and 
measured confounders (Table 4.4). The one exception was pre-existing maternal 




only four in the analysis group. This is likely due to the NMR sample being taken 
at the time of the OGTT, and those with pre-existing diabetes would presumably 
be less likely to attend for this test. 
Table 4.6 shows the distribution of co-variables for the 7440 pregnancies 
included in this study according to whether the pregnancies delivered preterm, 
term or post-term. 94% (6994/7440) of the pregnancies were delivered at term, 
while 5% (392/7440) delivered preterm, and 1% (54/7440) delivered post-term. 
The median gestational age at delivery in the preterm group was 247 days (range 
176-258 days), 280 days in the term group (range 259-294 days), and 296 days 
in the post-term group (range 195-313 days).  
There were no substantial differences in median maternal age at enrolment, 
maternal BMI or parity across the three categories of gestational age at delivery. 
The distribution of ethnicity was similar among women who delivered preterm  
and term, however post-term delivery seemed more common in white 
European women. The proportion reporting cigarette smoking in pregnancy 
were slightly higher in those delivering pre-term than at term or post-term. 
There were no substantial differences in the distribution across the 
socioeconomic quintiles for pregnancies delivering preterm and term, however 
a higher proportion of women who delivered post-term were in the two least 




the highest proportion of preterm birth (6.1%), and those in the 3rd quintile had 
the lowest proportion (4.7%). 
Regarding labour onset, there was a higher proportion of spontaneous labour in 
the term group, and the post-term group had the lowest proportion of 
spontaneous labour and the highest proportion of induced labour, which is in 
keeping with national guidelines regarding induction of labour for post-term 
pregnancies. The caesarean section rate was highest in the pre-term group and 
was considerably lower than the national average, reported by NHS Digital as 
20-25% for the years 2016-1745, in both the term and post-term groups.  
 
Table 4.3: Summary of outcome variable (gestational age at delivery) for: all pregnancies 
recruited to BiB; all eligible pregnancies (women with singleton pregnancies and only one pregnancy 






All eligible pregnancies 
(singleton pregnancies and 
one pregnancy per mother)  
Analysis sample 
(all eligible with no 
missing data)  
Median 279 279 279 
Minimum 174 174 176 
Maximum 313 313 313 
Missing 415 395 0 




Table 4.4: Summary of continuous covariables for: all pregnancies recruited to BiB (12453 women across 13776 pregnancies); all eligible pregnancies 
(women with singleton pregnancies and only one pregnancy per mother) n=12308; Analysis sample (all eligible pregnancies with no missing data) n= 7440. 
Variable All recruited pregnancies 
n=13776  
(12453 mothers) 
All eligible pregnancies 
(singleton pregnancies and 
one pregnancy per mother) 
n=12308 
Analysis sample (all eligible with 
no missing data for variables or 
NMR) 
n=7440 
Mother age in years at baseline questionnaire 
   
Number of observations recorded 11395 10247 7440 
Median 27 27 27 
Minimum 14 14 15 
Maximum 49 49 49 
Missing 2381 2061 0 
Total 13776 12308 7440 
Body Mass Index 
   
Number of observations recorded 10495 9445 7440 
Median 25.0 25.0 25.0 
Minimum 12.9 12.9 14.7 
Maximum 57 57.0 57.0 
Missing 3281 2863 0 
Total 13776 12308 7440 







Table 4.5: Summary of categorical covariables for: all pregnancies with questionnaire data; all pregnancies with NMR metabolomics data; all eligible 
pregnancies with NMR metabolomics data (singleton pregnancies and one pregnancy per mother, randomly selected); and all eligible pregnancies with NMR 
metabolomics data and gestational age at delivery recorded. 
 
All recruited pregnancies 
n=13776 pregnancies 
(12453 mothers) 
All eligible pregnancies 
(singleton pregnancies and 
one pregnancy per mother) 
n=12308 
Analysis sample (all eligible 
with no missing data for 
variables or NMR) 
n=7440 
Variable Number (%) Number (%) Number (%) 
Ethnicity: 
      
White European 5,474 (39.7) 4975 (40.4) 3341 (44.9) 
South Asian 6,982 (50.7) 6110 (49.6) 3640 (48.9) 
Other 910 (6.6) 833 (6.8) 459 (6.2) 
Missing 410 (3) 390 (3.2) 0  




      
Least socioeconomically deprived and most educated 2231 (16.2) 2027 (16.5) 1468 (19.7) 
Employed not materially deprived 2248 (16.3) 2100 (17.1) 1594 (21.4) 
Employed no access to money 1721 (12.5) 1538 (12.5) 1118 (15.0) 
Benefits and not materially deprived 3325 (24.1) 2910 (23.6) 2110 (28.4) 
Most economically deprived 1800 (13.1) 1605 (13.0) 1150 (15.5) 







































































































Alcohol during pregnancy or three months prior:       
Yes 3480 (25.3) 3237 (26.3) 2440 (32.8) 
No 7882 (57.2) 6981 (56.7) 4993 (67.1) 
Don't remember 7 (0.05) 7 (0.06) 7 (0.1) 






Cigarette smoking during pregnancy: 
      
Yes 1870 (13.6) 1724 (14) 1312 (17.6) 
No 9504 (70.0) 8504 (69.1) 6128 (82.4) 









      
Yes 70 (0.5) 61 (0.5) 4 (0.1) 
No 12705 (92.2) 11353 (92.2) 7436 (99.9) 







Gestational Diabetes Mellitus:  
      
Yes 884 (6.4) 775 (6.3) 568 (7.6) 
No 10037 (72.9) 9004 (73.2) 6872 (92.4) 








      
Yes 116 (0.8) 108 (0.9) 70 (0.9) 











Hypertensive disorders of pregnancy: 
      
Normotensive 9840 (71.4) 8778 (71.3) 6678 (89.8) 
PIH 776 (5.6) 716 (5.8) 564 (7.6) 
PET 279 (2.0) 264 (2.1) 198 (2.6) 
Missing  2881 (20.9) 2550 (20.72) 0  
Total 13776  12308  7440  
Type of labour onset: 
      
Spontaneous  9,234 (67) 8264 (67.1) 5190 (69.8) 
Caesarean section (no labour) 1,413 (10.3) 1193 (9.7) 670 (9.0) 
Induction of labour 2,702 (19.6) 2448 (19.9) 1580 (21.2) 












Table 4.6: Distribution of the characteristics of those in the analysis group according to 
whether delivered preterm, term or post-term (n=7440). Of note there are no missing values for 
these co-variables within this complete analysis sample. 
Demographic variable 
Preterm 
(< 259 days) 
Term  
























Maternal BMI (kg/m2): 









































































Maternal smoking during pregnancy: 

























Maternal socioeconomic status: 
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Number 
Percentage 
         Caesarean section (no labour) 
Number 
Percentage 
         Induction of labour 
Number 
































4.6.2 Association of maternal metabolites with gestational age at delivery 
Table 4A1 (Appendix) lists the total metabolites measured, along with the units, 
mean values and SD for the total analysis sample. Estimates for the variation in 
gestational age at delivery per SD-unit increase in maternal metabolites with 
associated 95% confidence intervals can be found in Figures 4.5-4.26 and Tables 
4A2-7 (Appendix). In each Figure, panel A displays the difference in gestational 
days per 1 SD change in metabolite, both unadjusted and adjusted for the 
available confounders; panel B shows the odds ratios for preterm birth 
compared to term, and post-term  birth compared to term, again unadjusted 
and adjusted; and panel C presents the odds ratios for extremely preterm, very 
preterm, and moderate to late preterm compared to term. For the latter 
sensitivity analysis, only the unadjusted model was possible due to the limited 




and unadjusted models for the linear and logistic regressions. Numerous 
maternal metabolic traits were associated with gestational age at delivery. The 
description of results will focus on estimates for the adjusted models, although 
unadjusted estimates are also presented in the Figures for comparison. 
4.6.2.1 Multivariable linear regression analysis  
Figures 4.5-4.26A show the results for the adjusted and unadjusted linear 
regressions of gestational age at delivery as a continuous variable on the 157 
metabolites measured. For the majority of metabolites, a greater metabolite 
concentration was associated with a lower mean gestational age at delivery. 
After taking account of multiple testing (see above), there was statistical 
evidence for a positive association between three of the metabolites (Table 4.7) 
and a negative association between 76 of the metabolites (Table 4.8) with mean 
gestational age at delivery.  
Triglycerides in medium HDL (Figure 4.14A), glycerol (Figure 4.11A) and 
glycoprotein acetyls (a1-acid glycoprotein) (Figure 4.9A) were the metabolites 
associated with the largest change in gestational age, with nearly a day decrease 
in gestational age at delivery per SD-unit increase in metabolite. Triglycerides 
and VLDLs were also highly represented in the metabolic traits significantly 
associated with gestational age at delivery (Table 4.7). Higher VLDL particle size 




VLDLs) were associated with lower mean gestational age at delivery. Higher 
concentration of triglycerides across lipoproteins (ie VLDL, LDL and HDL) was 
also related to lower mean gestational age at delivery. Higher particle and lipids 
concentration in small HDL particles were also related to lower gestational age 
at delivery. 
Figure 4.5A shows that 1SD-increases in alanine, apolipoprotein B, 
phenylalanine and leucine concentrations were associated with shorter mean 
gestational age at delivery by approximately half a day. Figure 4.10A shows that 
a 1SD increase in the majority of glycerides and phospholipids (Figure 4.10A) 
concentrations were associated with a decrease in mean gestational age at 
delivery by half to one day. Similar associations were observed for creatinine, 
glycoprotein acetyls (mainly a1-acid glycoprotein) (Figure 4.9), fatty acids (Figure 





Table 4.7: Metabolites with a significant (adjusted) negative association with gestational age at delivery (p<0.0029). 









Triglycerides in medium HDL Lipoprotein subclasses 
HDL 
mmol/l -0.914 0.013 -1.200 -0.628 3.818E-10 7440 
Glycerol Glycolysis related 
metabolites 
mmol/l -0.858 0.016 -1.150 -0.566 8.685E-09 7421 
Glycoprotein acetyls (a1-acid glycoprotein) Fluid balance and 
inflammation 
mmol/l -0.857 0.198 -1.148 -0.566 8.381E-09 7436 
Phospholipids in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.825 0.044 -1.107 -0.544 9.412E-09 7440 
Free cholesterol in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.783 0.031 -1.063 -0.503 4.266E-08 7440 
Serum total triglycerides Glycerides and 
phospholipids 
mmol/l -0.770 0.580 -1.049 -0.490 7.125E-08 7435 
Triglycerides in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.767 0.097 -1.048 -0.487 8.633E-08 7440 
Triglycerides in VLDL Glycerides and 
phospholipids 
mmol/l -0.758 0.460 -1.038 -0.478 1.133E-07 7435 
Triglycerides in very small VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.756 0.042 -1.037 -0.476 1.282E-07 7440 
Concentration of small VLDL particles Lipoprotein subclasses 
VLDL 
mol/l -0.751 0.000 -1.030 -0.472 1.400E-07 7440 
Phospholipids in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.749 0.037 -1.027 -0.470 1.471E-07 7440 
Triglycerides in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.745 0.117 -1.024 -0.466 1.739E-07 7440 
Free cholesterol in medium VLDL Lipoprotein subclasses 
VLDL 




Total lipids in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.744 0.215 -1.023 -0.465 1.770E-07 7440 
Triglycerides in small LDL Lipoprotein subclasses 
LDL 
mmol/l -0.743 0.013 -1.021 -0.465 1.639E-07 7440 
Free cholesterol in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.741 0.023 -1.020 -0.463 1.885E-07 7440 
Concentration of large VLDL particles Lipoprotein subclasses 
VLDL 
mol/l -0.737 0.000 -1.016 -0.458 2.299E-07 7440 
Phospholipids in medium VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.737 0.058 -1.016 -0.458 2.228E-07 7440 
Total lipids in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.735 0.199 -1.014 -0.456 2.444E-07 7440 
Triglycerides in medium VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.731 0.163 -1.010 -0.452 2.977E-07 7440 
Concentration of medium VLDL particles Lipoprotein subclasses 
VLDL 
mol/l -0.722 0.000 -1.001 -0.444 3.826E-07 7440 
Triglycerides in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.721 0.035 -1.000 -0.443 3.862E-07 7440 
Total lipids in medium VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.721 0.298 -0.999 -0.442 3.988E-07 7440 
Phospholipids in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.717 0.009 -0.994 -0.440 4.053E-07 7440 
Concentration of very large VLDL particles Lipoprotein subclasses 
VLDL 
mol/l -0.710 0.000 -0.988 -0.432 5.616E-07 7440 
Triglycerides in small HDL Lipoprotein subclasses 
HDL 
mmol/l -0.705 0.016 -0.991 -0.420 1.300E-06 7440 
Total lipids in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.705 0.055 -0.983 -0.428 6.487E-07 7440 
Total cholesterol in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.692 0.046 -0.970 -0.415 1.050E-06 7440 












mmol/l -0.681 0.002 -0.958 -0.405 1.408E-06 7440 
Free cholesterol in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.674 0.005 -0.950 -0.398 1.740E-06 7440 
Total cholesterol in medium VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.666 0.080 -0.943 -0.390 2.382E-06 7440 
Concentration of small HDL particles Lipoprotein subclasses 
HDL 
mol/l -0.666 0.000 -0.945 -0.387 2.983E-06 7440 
Monounsaturated fatty acids; 16:1, 18:1 Fatty acids and saturation 
measures 
mmol/l -0.652 0.997 -0.936 -0.368 6.845E-06 7386 
Total lipids in small HDL Lipoprotein subclasses 
HDL 
mmol/l -0.646 0.142 -0.925 -0.368 5.418E-06 7440 
Cholesterol esters in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.636 0.022 -0.913 -0.359 6.795E-06 7440 
Total cholesterol in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.633 0.011 -0.909 -0.357 6.879E-06 7440 
Triglycerides in LDL Glycerides and 
phospholipids 
mmol/l -0.632 0.070 -0.909 -0.355 7.901E-06 7435 
Triglycerides in cms & extremely large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.629 0.012 -0.904 -0.354 7.483E-06 7440 
Total lipids in cms & extremely large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.629 0.018 -0.904 -0.354 7.457E-06 7440 




mol/l -0.628 0.000 -0.903 -0.353 7.641E-06 7440 
Triglycerides in LDL Lipoprotein subclasses 
LDL 
mmol/l -0.622 0.042 -0.899 -0.344 1.139E-05 7440 
Triglycerides in medium LDL Lipoprotein subclasses 
LDL 
mmol/l -0.612 0.020 -0.889 -0.336 1.447E-05 7440 
Triglycerides in HDL Glycerides and 
phospholipids 
mmol/l -0.601 0.042 -0.879 -0.323 2.276E-05 7435 




Cholesterol esters in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.596 0.006 -0.872 -0.321 2.236E-05 7440 
Total cholesterol in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.594 0.082 -0.869 -0.319 2.332E-05 7440 
Monounsaturated fatty acids to total fatty 
acids 
Fatty acids (%) % -0.586 2.415 -0.902 -0.270 2.791E-04 7386 




mmol/l -0.583 0.004 -0.857 -0.309 3.117E-05 7440 
Triglycerides in large LDL Lipoprotein subclasses 
LDL 
mmol/l -0.579 0.039 -0.856 -0.303 4.031E-05 7440 
Cholesterol esters in medium VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.577 0.043 -0.852 -0.302 3.869E-05 7440 
Creatinine Fluid balance and 
inflammation 
mmol/l -0.575 0.006 -0.853 -0.296 5.314E-05 7431 
Phenylalanine Aromatic amino acids mmol/l -0.569 0.011 -0.861 -0.278 1.283E-04 7436 
Leucine Branched--chain amino 
acids 
mmol/l -0.569 0.010 -0.851 -0.286 8.260E-05 7433 
Total phosphoglycerides Glycerides and 
phospholipids 
mmol/l -0.555 0.399 -0.831 -0.280 7.897E-05 7409 
Total fatty acids Fatty acids and saturation 
measures 
mmol/l -0.542 2.779 -0.817 -0.268 1.088E-04 7386 
Apolipoprotein B Apolipoproteins g/l -0.536 0.228 -0.810 -0.263 1.223E-04 7435 
Saturated fatty acids Fatty acids and saturation 
measures 
mmol/l -0.536 1.044 -0.811 -0.262 1.305E-04 7386 
Phosphatidylcholine and other cholines Glycerides and 
phospholipids 
mmol/l -0.531 0.459 -0.806 -0.256 1.525E-04 7407 
Mean diameter for VLDL particles Lipoprotein particle size nm -0.525 1.009 -0.804 -0.245 2.374E-04 7435 
Ratio of triglycerides to phosphoglycerides Glycerides and 
phospholipids 
#N/A -0.524 0.160 -0.807 -0.241 2.849E-04 7409 
Free cholesterol in small HDL Lipoprotein subclasses 
HDL 




Total cholesterol in small HDL Lipoprotein subclasses 
HDL 
mmol/l -0.516 0.067 -0.790 -0.242 2.243E-04 7440 
Total cholines Glycerides and 
phospholipids 
mmol/l -0.500 0.485 -0.775 -0.225 3.606E-04 7407 
Cholesterol esters in chylomicrons & 
extremely large VLDL 
Lipoprotein subclasses 
VLDL 
mmol/l -0.493 0.002 -0.766 -0.220 3.945E-04 7440 
Alanine Amino acids mmol/l -0.485 0.048 -0.758 -0.213 4.849E-04 7408 
Concentration of very small VLDL particles Lipoprotein subclasses 
VLDL 
mol/l -0.477 0.000 -0.751 -0.203 6.396E-04 7440 
Remnant cholesterol (non-HDL, non-LDL) Cholesterol mmol/l -0.477 0.467 -0.750 -0.204 6.211E-04 7435 
Phospholipids in small HDL Lipoprotein subclasses 
HDL 
mmol/l -0.475 0.094 -0.752 -0.198 7.814E-04 7440 
Cholesterol esters in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.465 0.054 -0.738 -0.192 8.468E-04 7440 
Phospholipids in medium HDL Lipoprotein subclasses 
HDL 
mmol/l -0.451 0.087 -0.726 -0.176 1.295E-03 7440 
Phospholipids in small LDL Lipoprotein subclasses 
LDL 
mmol/l -0.447 0.034 -0.721 -0.173 1.380E-03 7440 
Total lipids in very small VLDL Lipoprotein subclasses 
VLDL 
mmol/l -0.442 0.161 -0.716 -0.169 1.522E-03 7440 
Cholesterol esters in small HDL Lipoprotein subclasses 
HDL 
mmol/l -0.437 0.059 -0.710 -0.165 1.676E-03 7440 
Apolipoprotein B:apolipoprotein A-I Apolipoproteins #N/A -0.434 0.121 -0.708 -0.159 1.945E-03 7435 
Phospholipids in medium LDL Lipoprotein subclasses 
LDL 







Table 4.8: Metabolites with a significant (adjusted) positive association with gestational age at delivery (p<0.0029). 
Metabolite Group Units Change in GA per SD-










Polyunsaturated Fatty Acids to 
total Fatty Acids 
Fatty acids (%) % 0.548 2.386 0.254 0.842 2.60E-04 7386 
Omega-6 Fatty Acids to total Fatty 
Acids 
Fatty acids (%) % 0.520 2.205 0.224 0.816 5.67E-04 7386 






4.6.4 Multivariable logistic regression analysis 
The adjusted and unadjusted results of the two separate multivariable logistic 
regressions of metabolite concentration in pregnancies delivered preterm and 
post-term compared with term are presented in Panel B of Figures 4.5-4.26. The 
results of the logistic regression comparing post-term with term indicate that 
there is no strong evidence that any of the 157 metabolites tested is associated 
with post-term delivery (Panel B Figures 4.5-4.26 and Table 4A4). 
For the analysis comparing preterm with term, the results are similar to those 
for the linear regressions with gestational age as a continuous variable. An 
increase of 1SD in mean diameter of HDL particles was associated with reduced 
odds for delivering preterm (Figure 4.12B, 4.13B and 4.16B) while an increase of 
1SD in mean diameter of VLDL particles was associated with higher odds for 
delivering preterm (Figures 4.12B, 4.15B, 4.17B, 4.20B). VLDL concentrations 
were particularly associated with higher odds for delivering preterm (Figures 
4.21-4.26B).  
The volcano plot 4A8 (Appendix) presents the logOR values derived from the 
logistic regression outputs of both post-term (red dots) and preterm (blue dots) 
with term for the 157 metabolite conditions measured, plotted against -log10(p-
value). This plot illustrates that for the post-term analyses, p-values were high 




preterm. This would be expected as the number of cases was low in comparison 
to preterm.  
4.6.5 Sensitivity analysis 
A sensitivity analysis was performed where those pregnancies which delivered 
preterm were further categorised into extremely, very, and moderate to late 
preterm. Metabolite concentrations of those pregnancies which delivered 
extremely preterm, those which delivered very preterm, and those which 
delivered moderate to late preterm, were compared with those which delivered 
at term. Table 4.9 shows the number of pregnancies included in these three 
categories of preterm birth and the mean gestational age at delivery. As 
previously discussed, because of the limited number of cases this analysis is 
considered exploratory and only unadjusted results are presented in Panel C of 
Figures 4.5-4.26.  
Although unadjusted, the results indicate that there may be a dose-response 
association between concentrations of many of the metabolites and degree of 
prematurity at delivery. This includes concentrations of glycoprotein acetyls (a1-
acid glycoprotein), creatinine (Figure 4.9C), phenylalanine, leucine (Figure 4.5C), 
polyunsaturated fatty acids to total fatty acids ratio, monounsaturated fatty 
acids to total fatty acids (Figure 4.7C), and estimated degree of unsaturation 




particles was associated with decreased odds for more extreme preterm, while 
increased diameter of VLDL particles was associated with increased odds (Figure 
4.12C). In addition, increased concentration of very large HDL was associated 
with decreased odds for extremely and very preterm birth (Figure 4.16C), while 
increasing concentrations of VLDLs was associated with increased odds for 




Table 4.9: Number of pregnancies within the preterm categories, with mean and range of gestational age at delivery (days) within each of 
these groups. 
Preterm category Number of pregnancies Mean gestational age at 
delivery (days) 
Range of gestational age at 
delivery (days) 
Extremely preterm (<28 weeks gestation) 12 187.8 176-195 
Very preterm (28 to 31+6 weeks’ gestation) 51 210.9 196-223 





Figure 4.5: Associations of maternal gestational amino acids and apoplipoproteins concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: Panel A 
shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher amino acid and apolipoprotein concentrations, with their 95% confidence 
intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 days, or 37-42 
completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher amino acid and apolipoprotein concentration, with 95%CI [adjusted preterm results are 
light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C shows of unadjusted 
odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared to term, and moderate 
to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher amino acid and apolipoprotein concentration, with 95%CI [extremely preterm are black, very 
preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late preterm. Solid circles indicate 





Figure 4.6: Associations of maternal gestational cholesterol metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: Panel A shows 
results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher cholesterol concentrations, with their 95% confidence intervals (n=7440). Panel B 
shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 days, or 37-42 completed weeks) and 
post-term (>294 days or >42 completed weeks) compared to term per 1SD higher cholesterol concentration, with 95%CI [adjusted preterm results are light blue, unadjusted preterm are purple, 
adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C shows of unadjusted odds ratios of extremely preterm (<196 
days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared to term, and moderate to late preterm (224 days to <259 
days, or 32 weeks to <37 weeks) compared to term per 1SD higher cholesterol concentration, with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are 
light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late preterm. Solid circles indicate significant at the p=0.0029 threshold, open circles 





Figure 4.7: Associations of maternal gestational fatty acids (%) metabolites ratios (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: Panel A shows results of 
adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher fatty acids (%) ratios concentrations, with their 95% confidence intervals (n=7440). Panel B 
shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 days, or 37-42 completed weeks) and 
post-term (>294 days or >42 completed weeks) compared to term per 1SD higher fatty acids (%) ratios concentration, with 95%CI [adjusted preterm results are light blue, unadjusted preterm 
are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C shows of unadjusted odds ratios of extremely 
preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared to term, and moderate to late preterm (224 
days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher fatty acids (%) ratios concentration, with 95%CI [extremely preterm are black, very preterm are red, and 
moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late preterm. Solid circles indicate significant at the p=0.0029 





Figure 4.8: Associations of maternal gestational fatty acids metabolites concentrations and saturation measures (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher fatty acids and saturation measures concentrations, with their 
95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 
294 days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher fatty acids and saturation measures concentration, with 95%CI 
[adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. 
Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed w eeks) 
compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher fatty acids and saturation measures concentration, with 
95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate 





Figure 4.9: Associations of maternal gestational fluid balance and inflammation metabolite concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: 
Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher fluid balance and inflammation markers concentrations, with their 95% 
confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 
days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher fluid balance and inflammation markers concentration, with 95%CI 
[adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. 
Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) 
compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher fluid balance and inflammation markers concentration, 
with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for 





Figure 4.10: Associations of maternal gestational glycerides and phospholipids metabolite concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: 
Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher glycerides and phospholipids concentrations, with their 95% confidence 
intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 days, or 37-42 
completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher glycerides and phospholipids concentration, with 95%CI [adjusted preterm results are 
light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C shows of unadjusted 
odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared to term, and moderate 
to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher glycerides and phospholipids concentration, with 95%CI [extremely preterm are black, very 
preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late preterm. Solid circles indicate 





Figure 4.11: Associations of maternal gestational glycolysis and ketone bodies metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: 
Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher glycolysis intermediates and ketone bodies concentrations, with their 
95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 
days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher glycolysis intermediates and ketone bodies concentration, with 95%CI 
[adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. 
Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) 
compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher glycolysis intermediates and ketone bodies concentration, 
with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for 






Figure 4.12: Associations of maternal gestational lipoprotein particle size (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: Panel A shows results of adjusted 
(black) and unadjusted (red) difference in mean gestational age in days per 1SD higher lipoprotein particle size , with their 95% confidence intervals (n=7440). Panel B shows results of adjusted 
and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 days, or 37-42 completed weeks) and post-term (>294 days or >42 
completed weeks) compared to term per 1SD higher lipoprotein particle size, with 95%CI [adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and 
unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) 
compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) 
compared to term per 1SD higher lipoprotein particle size , with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely 





Figure 4.13: Associations of maternal gestational large high density lipoprotein metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: 
Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher large high density lipoprotein traits concentrations, with their 95% 
confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 days, 
or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher large high density lipoprotein traits concentration, with 95%CI [adjusted preterm 
results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C shows of 
unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared to term, 
and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher large high density lipoprotein traits concentration, with 95%CI [extremely 
preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late preterm. 





Figure 4.14: Associations of maternal gestational medium high density lipoprotein metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher medium high density lipoprotein traits concentration, with their 
95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 
days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher medium high density lipoprotein traits concentration, with 95%CI [adjusted 
preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C 
shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared 
to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher medium high density lipoprotein traits concentration, with 95%CI 
[extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late 





Figure 4.15: Associations of maternal gestational small high density lipoproteins metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher small high density lipoprotein traits concentrations, with their 
95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 
days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher small high density lipoprotein traits concentration, with 95%CI [adjusted 
preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C 
shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared 
to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher small  high density lipoprotein traits concentration, with 95%CI 
[extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late 





Figure 4.16: Associations of maternal gestational very large high density lipoprotein metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher very large high density lipoprotein traits concentrations, with 
their 95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days 
to 294 days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher very large high density lipoprotein traits concentration, with 95%CI 
[adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. 
Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) 
compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher very large high density lipoprotein traits concentration, 
with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for 





Figure 4.17: Associations of maternal gestational low density lipoprotein metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: Panel 
A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher low density lipoprotein traits concentrations, with their 95% confidence intervals 
(n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 days, or 37-42 completed 
weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher low density lipoprotein traits concentration, with 95%CI [adjusted preterm results are light blue, 
unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C shows of unadjusted odds ratios 
of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared to term, and moderate to late 
preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher low density lipoprotein traits concentration, with 95%CI [extremely preterm are black, very preterm 
are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late preterm. Solid circles indicate significant at 





Figure 4.18: Associations of maternal gestational large low density lipoprotein metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: 
Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher large low density lipoprotein traits concentrations, with their 95% 
confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 days, 
or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher large low density lipoprotein traits concentration, with 95%CI [adjusted preterm 
results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C shows of 
unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared to term, 
and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher large low density lipoprotein traits concentration, with 95%CI [extremely 
preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late preterm. 





Figure 4.19: Associations of maternal gestational medium low density lipoprotein metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher medium low density lipoprotein traits concentrations, with their 
95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 
days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher medium low density lipoprotein traits concentration, with 95%CI [adjusted 
preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C 
shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared 
to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher medium low density lipoprotein traits concentration, with 95%CI 
[extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late 





Figure 4.20: Associations of maternal gestational small low density lipoproteins metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at delivery: 
Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher small low density lipoprotein traits concentrations, with their 95% 
confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days to 294 days, 
or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher small low density lipoprotein traits concentration, with 95%CI [adjusted preterm 
results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. Panel C shows of 
unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) compared to term, 
and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher small low density lipoprotein traits concentration, with 95%CI [extremely 
preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for moderate to late preterm. 





Figure 4.21: Associations of maternal gestational large very low density lipoproteins metabolite concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher large very low density lipoprotein traits concentrations, with 
their 95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days 
to 294 days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher large very low density lipoprotein traits concentration, with 95%CI 
[adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. 
Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) 
compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher large very low density lipoprotein traits concentration, 
with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for 





Figure 4.22: Associations of maternal gestational medium very low density lipoproteins metabolite concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher medium very low density lipoprotein traits concentrations, with 
their 95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days 
to 294 days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher medium very low density lipoprotein traits concentration, with 
95%CI [adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-
term. Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) 
compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher medium very low density lipoprotein traits concentration, 
with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for 





Figure 4.23: Associations of maternal gestational small very low density lipoproteins metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age at 
delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher small very low density lipoprotein traits concentrations, with 
their 95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 days 
to 294 days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher small very low density lipoprotein traits concentration, with 95%CI 
[adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for post-term. 
Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed weeks) 
compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher small very low density lipoprotein traits concentration, 
with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 329 for 





Figure 4.24: Associations of maternal gestational very large very low density lipoproteins metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age 
at delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher very large very low density lipoprotein traits concentrations, 
with their 95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 
days to 294 days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher very large very low density lipoprotein traits concentration, 
with 95%CI [adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for 
post-term. Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed 
weeks) compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher very large very low density lipoprotein traits 
concentration, with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 





Figure 4.25: Associations of maternal gestational very small very low density lipoproteins metabolites concentrations (measured at 26-28 completed weeks’ gestation) with gestational age 
at delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher very small very low density lipoprotein traits concentrations, 
with their 95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to term (reference; 259 
days to 294 days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher very small very low density lipoprotein traits concentration, 
with 95%CI [adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for preterm, 6994 for term, and 54 for 
post-term. Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to <224 days, or 28 to <32 completed 
weeks) compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher very small very low density lipoprotein traits 
concentration, with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm results, 51 for very preterm results, and 





Figure 4.26: Associations of maternal gestational chylomicrons and very low density lipoproteins metabolites concentrations (measured at 26-28 completed weeks’ gestation) with 
gestational age at delivery: Panel A shows results of adjusted (black) and unadjusted (red) difference in mean gestational age in days per 1SD higher chylomicrons & very low density lipoprotein 
traits concentrations, with their 95% confidence intervals (n=7440). Panel B shows results of adjusted and unadjusted odds ratios of  preterm (<259 days or <37 completed weeks) compared to 
term (reference; 259 days to 294 days, or 37-42 completed weeks) and post-term (>294 days or >42 completed weeks) compared to term per 1SD higher chylomicrons & very low density 
lipoprotein traits concentration, with 95%CI [adjusted preterm results are light blue, unadjusted preterm are purple, adjusted postterm are black and unadjusted posterm are red] N = 392 for 
preterm, 6994 for term, and 54 for post-term. Panel C shows of unadjusted odds ratios of extremely preterm (<196 days, or <28 completed weeks) compared to term, very preterm (196 days to 
<224 days, or 28 to <32 completed weeks) compared to term, and moderate to late preterm (224 days to <259 days, or 32 weeks to <37 weeks) compared to term per 1SD higher chylomicrons 
& very low density lipoprotein traits concentration, with 95%CI [extremely preterm are black, very preterm are red, and moderate to late preterm are light blue]. N = 12 for extremely preterm 





The results from this chapter show that there are associations between 
concentrations of numerous maternal circulating metabolites measured in the 
second trimester and gestational age at delivery. While it is not possible to say 
that any of the associations described here are causal, they do provide clues as 
to what may initiate spontaneous labour in humans and therefore indicate 
which metabolites should be prioritised in further investigations. These findings 
consistently point to triglycerides and numerous lipoprotein-related traits being 
associated with reduced gestational age at delivery, specifically VLDLs and HDL 
lipids, particle concentration and mean diameter, as well as other non-
lipoprotein-related metabolites including glycoprotein acetyls (a1-acid 
glycoprotein), glycerol, creatinine, and amino acids such as phenylalanine, 
alanine and leucine. Although it could be argued that the observed differences 
in gestational age of not more than one day with a 1SD increase in concentration 
of metabolites is not clinically significant when taken in isolation, the persistent 
associations presented are useful in beginning to answer the aims of this study. 
Identification and investigation of these associations provide further evidence 
to putative factors involved in spontaneous parturition in humans.  
It is interesting that for some of the metabolites measured increases in 




compared with term, whereas there were no alterations in the odds of 
delivering post-term compared with term. This may be partly a result of low 
statistical power since few observations were characterised as post-term, 
however it should be emphasised that effect estimates were typically centred 
around the null value, and, therefore, it is likely that those who delivered at term 
had a similar metabolomic profile to those that delivered post-term. The 
sensitivity analysis involving splitting of the preterm group into extremely, very, 
and moderate and late preterm, while unadjusted and underpowered, indicates 
that there could be a dose-response association between these metabolites and 
the degree of prematurity. 
4.7.1 Lipoproteins and triglycerides 
Triglycerides and cholesterol are both insoluble in water and transported in the 
plasma within lipoproteins274. Triglycerides are comprised of three fatty acid 
molecules attached to a glycerol spine and are hydrolysed by lipases in the gut 
to form fatty acids and monoglycerides. Monoglycerides are re-esterified within 
enterocytes and incorporated into lipoproteins and chylomicrons275. 
Lipoproteins are complex particles containing a central core of triglycerides and 
cholesterol esters surrounded by phospholipids, free cholesterol, and 
apolipoproteins. There are seven classes of plasma lipoproteins, categorised 




intermediate density lipoprotein (IDL), low density lipoprotein (LDL), high 
density lipoprotein (HDL), chylomicron, chylomicron remnants, and Lipoprotein 
a (lp(a)). Chylomicrons are the largest and least dense lipoproteins, while HDL 
are the smallest and most dense274, 276. Chylomicron remnants, Lp(a), VLDL, IDL 
and LDL are reported to be pro-atherogenic, while HDL is reported to be anti-
atherogenic; and increased plasma concentrations of cholesterol and 
lipoprotein are implicated in the formation of atherosclerosis and cardiac 
disease274, 276. While the effects of cardiac disease may not be initially seen to be 
directly relevant to answering the aims of this thesis, vascular impairment plays 
a role in pathological conditions of pregnancy, such as pre-eclampsia, 
intrauterine growth restriction and preterm birth277, and therefore it is plausible 
that such interactions are important for gestational age at delivery. 
Under normal conditions, hepatic triglyceride is released by the liver into the 
circulation via VLDL particles275, and triglycerides are subsequently removed 
from VLDL by muscle and adipose tissues, resulting in the formation of IDLs 
which are enriched in cholesterol. LDLs are derived from both IDL and VLDL and 
hold most of circulating cholesterol. There is an association between 
concentrations of the smallest and most dense LDL particles and increased 




2 diabetes, obesity, metabolic syndrome and inflammatory and infectious 
states274, 276.  
Conversely, HDLs are important for reverse cholesterol transport, moving 
cholesterol from the peripheral tissues, including away from the walls of vessels, 
back to the liver for excretion, and thereby providing an anti-atherogenic 
effect278,279. HDL is a lipoprotein complex that is protein and cholesterol ester-
rich, with reported inverse associations between HDL concentration and risk for 
cardiovascular disease278. HDL is anti-inflammatory, anti-apoptotic, anti-oxidant 
and anti-thrombotic274. As an anti-oxidant, HDL reduces the oxidative stress 
from oxidised LDL, and its role in promoting anticoagulation involves 
enhancement of the activity of protein S and protein C, and through inhibition 
of TNFα, neutrophil activation, adhesion and infiltration278; both of which could 
be important in pregnancy maintenance and gestational length. In the non-
pregnant state, high plasma triglyceride concentrations result in HDL and LDL 
taking on more triglyceride from VLDL in exchange for cholesteryl esters. 
Hepatic lipase then catalyses the triglyceride-rich HDL, resulting in smaller HDL 
particles and thereby reducing the concentration of plasma HDL278,277.  
4.7.2 Lipoproteins and pregnancy 
There are known changes in maternal lipoprotein metabolism during pregnancy, 




pregnancy, there is heightened maternal insulin sensitivity and adipose tissue is 
stored, presumably in preparation for the increased demand by the fetus in later 
pregnancy and as a substrate for steroid hormone synthesis by the placenta277-
279. Insulin sensitivity then decreases, with a shift towards insulin-resistance, as 
pregnancy progresses towards and into the third trimester280, alongside a 
hypercoagulable, hyperlipidaemic, and increased inflammatory state277-280. It 
therefore appears that a certain balance is required here for ongoing pregnancy, 
and an imbalance, as suggested by the results of this study, this may lower the 
threshold for spontaneous labour.  
VLDL holds most plasma triglycerides in both pregnant and non-pregnant 
women, and larger VLDLs contain more triglyceride. VLDL concentrations 
increase during normal pregnancy, likely secondary to the increased insulin 
resistance promoting release of fatty acids through lipolysis and increasing 
glucose availability for the fetus278, 279, and increased VLDL particle size has been 
linked with recurrent preterm delivery279. In the non-pregnant state, HDL 
concentrations decrease when there is increased insulin resistance and 
increased triglycerides, for example in people who are obese or have type 2 
diabetes279. Conversely, during pregnancy HDL concentrations increase across 
the first and second trimester278 despite increasing triglyceride levels. It is 




weeks counters the oxidative stress resulting from establishment of the 
placental circulation (also around 10 weeks) with invasion of the trophoblast and 
release of the maternal spiral arteries278. The increased production of HDL 
during pregnancy, potentially driven by oestradiol, could be an adaptive and 
protective response to increased insulin resistance and increased triglyceride 
plasma concentrations during pregnancy, which could otherwise result in severe 
endothelial dysfunction and long-term damage278. During the third trimester 
HDL concentrations decrease279.  
In women who are obese, pregnancy is associated with both increased 
concentrations of triglycerides and VLDL, and decreased concentrations of HDL, 
when compared with pregnant women who are not obese. Previous researchers 
have concluded that this indicates there is not an adequate increase in HDL 
production by women who are obese, increasing the risk for endothelial 
dysfunction278 and obesity-related conditions such as pre-eclampsia, preterm 
birth (spontaneous and iatrogenic), and stillbirth278, 281. Further, small LDL 
particle concentrations are increased in women who are obese and women with 
pre-eclampsia, both of which are associated with preterm birth277.  
In a retrospective cohort including 2.9 million pregnant women in the USA, 9162 
women had dyslipidaemia, where there is increased LDL and VLDL with 




birth, even after adjustment for BMI, maternal age at delivery, ethnicity, 
hypertension, and education282. Another group modelled genetic risk scores for 
total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides in order to 
estimate genetic predisposition to dyslipidaemia in 164 women with pre-
eclampsia and 110 controls, replicated in a US and European population. These 
genetic risk scores were not associated with the risk for pre-eclampsia283, which 
is interesting as it suggests that simply having a genetic risk for dyslipidaemia 
does not in itself increase the risk for pre-eclampsia, although the null results 
may also be due to a lack of power. A further recent study, which used the same 
BiB NMR data investigated in this present study, used age-adjusted analysis to 
determine that within the BiB cohort gestational diabetes was positively 
associated with VLDL, VLDL cholesterol, phospholipids, most glycerides, and all 
metabolites related to glycolysis; and negatively associated with HDL and LDL, 
glutamine and fatty acid ratios. Pre-eclampsia had a positive association with 
VLDL lipoproteins, phospholipids, glycerides, metabolites of glycolysis, 
creatinine, and fatty acids; and was negatively associated with fatty acid ratios, 
linoleic, DHA, omega-3 and -6, SFA and PUFA. However, with adjustment for BMI 
the lipid associations, but not the amino acid associations, moved towards the 




insulin resistance and obesity. In the present study these factors were adjusted 
for, and the association between a change in gestational age persisted. 
In the present study, an increase in the mean diameter of HDL particles by 1SD 
was associated with an increased mean gestational age at delivery of half a day, 
and a 1SD increase in total cholesterol, cholesterol esters, and free cholesterol 
in large and very large HDLs was also associated with an increase in gestational 
age at delivery. This contrasts with the effect of a 1SD increase in the total 
cholesterol, cholesterol esters and free cholesterol in medium and small HDLs, 
which were associated with a reduction in gestational age at delivery, although 
the mean change was less than half a day. Moreover, an increase in triglycerides 
within any size of lipoprotein was consistently associated with a reduction in 
gestational length, albeit by a half to one day. Given that these results are 
controlled for pre-eclampsia, hypertension, pre-existing diabetes and 
gestational diabetes, this indicates that changes in the lipid profile may be 
important in the timing of spontaneous labour in humans, even in the absence 
of obvious pathology. While this may indicate that there is an underlying 
undetected insulin-resistance, it could also reflect that the trigger for normal 
labour in humans involves a mechanism related to vascular health, possibly at 
the maternal/placental interface. This could mean that for women with pre-




are triggered earlier, including vascular pathology of the placenta that have 
previously been shown to be associated with PTB117. However, this is speculative, 
and further investigation would be required to investigate this hypothesis 
further. 
4.7.3 Dyslipidaemia, inflammation and impaired vascular function 
A potential link between dyslipidaemia and spontaneous labour could involve 
inflammation, as a shift towards an inflammatory environment may itself trigger 
labour. Elevated triglyceride concentrations in pregnancy are reportedly 
associated with smaller and more dense LDLs that are both pro-inflammatory 
and pro-atherogenic39,278,277, 279. Obesity in pregnancy was found to be 
associated with increased triglycerides and lower HDL lipoprotein 
concentrations and no change in LDL concentration, when compared with non-
obese controls. Obesity was also associated with increased inflammatory 
markers such as Interleukin-6 and CRP, and endothelial-independent and 
endothelial-dependent vasodilatory responses were reduced in pregnant 
women who were obese when compared with lean 284.  
One group investigated the effect of lipoprotein particle concentration and size, 
measured in pregnant women at 9 weeks gestation, on whether the pregnancies 
were delivered preterm. Lipoproteins were measured on an NMR metabolomics 




concentrations as well as increased systemic inflammation. The decreased VLDL 
particle concentration measurement was observed to be secondary to fewer 
small VLDL particles, which the authors suggested could reflect an impaired lipid 
response277. In the present study, associations between VLDL concentration and 
gestational age at delivery were reduced for all sizes of VLDL. While these 
associations were between half and one day decrease in mean gestational age 
per 1 SD increase in metabolite concentration for most sizes of VLDL, the 
associations with very small VLDL were less than half a day, and half of these 
were non-significant. 
In the non-pregnant state, the observed dyslipidaemia and increased 
inflammatory changes of pregnancy described would be associated with 
impaired vascular function, production of reactive oxygen species (ROS), and 
potential vascular endothelial damage. However, during normal pregnancy 
vascular function is instead found to improve, with a positive association 
reported between triglyceride concentrations and flow-mediated dilatation of 
vessels during pregnancy278. HDL regulates endothelial nitric oxide (NO) 
synthase (eNOS) expression, and thereby promotes vasodilatation of blood 
vessels278, 285. Outside of pregnancy, dysfunction in NO production alongside 
endothelial dysfunction occurs prior to atherosclerosis, and during pregnancy 




previous studies indicate that vascular dysfunction is a major factor in disorders 
of pregnancy such as preterm birth and stillbirth277-279. 
Within the prospective cohort Cardiovascular Risk in Young Finns study, 119 
women (57 pregnant women matched with 62 controls) were assessed for lipid 
profile and brachial flow mediated dilatation (FMD), which is a measure of 
endothelial-dependent vasodilation. Brachial FMD is increased in normal 
pregnancy secondary to increased NO bioactivity. The authors found that serum 
LDL-cholesterol, HDL-cholesterol, triglycerides and total cholesterol were 
significantly increased during pregnancy when compared with non-pregnant 
controls, and that brachial FMD also increased, particularly at advanced 
gestation. There was a direct correlation between serum total cholesterol, 
triglycerides and FMD in the pregnant women, whereas there was a negative 
correlation in the non-pregnant women. The authors concluded that in healthy 
pregnant women increased gestational age was associated with improved 
endothelium dependent vasodilatation, despite the changing lipid profile285.  
In the present study, higher levels of HDL-related metabolites were associated 
with an increased gestational age at delivery and reduced odds of delivering 
preterm compared with term; whereas an increase in mean diameter for VLDL, 
which is associated with increased triglyceride concentrations, was associated 




While this fits with the previously described obesogenic pregnancy profile 
related with lipid dysfunction, the present study shows a persistent association 
even when controlled for maternal BMI, pre-eclampsia, and diabetes. On the 
background of the previous findings, and the other chapters in this thesis, this 
could potentially align with the idea that if HDL protects endothelial function, 
increased HDL levels could result in improved placentation and improved 
chances of the pregnancy continuing to term. Or, put another way, that those 
women with lower HDL levels in an otherwise healthy pregnancy have a lower 
threshold at which there may be vascular changes which may affect the placenta 
and lead to earlier labour. This could be related to inflammation. The 
inflammatory response that has been seen in preterm birth may therefore not 
always be related to pathogens but rather a low-grade inflammation driven by 
metabolic factors which may increase the threshold towards the point that 
triggers parturition. This would otherwise be later in people who don’t have this 
high level of triglycerides already.  
4.7.4 Creatinine 
An increase in plasma creatinine was associated with a reduction in gestational 
age at delivery and increased the odds of delivering preterm in a dose-response 
manner. This could potentially fit with the dyslipidaemia picture, as increased 




dysfunction may have impaired renal function, resulting in increased creatinine 
concentrations. Again, this is despite having controlled for pre-eclampsia, BMI 
and mode of labour onset. However, this would need further investigation in 
future studies. 
4.7.5 Alpha-1-acid glycoprotein 
Following a search of the literature, there does not seem to be much research 
conducted into alpha-1-acid glycoprotein, an acute phase protein,  and 
gestational age at delivery or preterm birth. In neonates, alpha-1-acid 
glycoprotein concentrations is higher in the cord blood of babies born vaginally 
than those born by elective caesarean section, with a correlation between 
gestational age at delivery and alpha-1-acid glycoprotein concentration. The 
researchers concluded that levels of alpha-1-acid glycoprotein are influenced by 
gestational age at delivery and mode of delivery286 . Taken with the results of 
the present study, this could indicate that if levels of alpha-1-acid glycoprotein 
reflect a pro-inflammatory state, that this could be linked to earlier gestational 
age at delivery.  
4.7.6 Comparison with results of Chapter 3 
In Chapter 3, MS metabolomics were conducted on maternal plasma sampled 
at 28 weeks’ gestation, 34 weeks’ gestation, and in latent phase, and analysis 




spontaneous labour. In BiB, metabolites were measured using NMR, which 
primarily detects abundant metabolites such as lipids. Studies in Chapters 3 and 
4 have included different metabolites and analytical approaches. Therefore, 
while the results of the two studies cannot be directly compared, inferences can 
be made based on the overall patterns found in each of these studies, and it is 
interesting to see if the findings from both techniques support each other.  
The over-representation analysis of the Chapter 3 correlation data can be 
viewed in section 3.5.19, and showed that: at 28 weeks’ gestation, metabolites 
which were significantly correlated with gestational age at delivery were most 
over-represented in the glycerol phosphate shuttle, riboflavin metabolism, and 
glycerolipid metabolism pathways; and at 34 weeks, the most over-represented 
pathways were mitochondrial beta-oxidation of long chain saturated fatty acids, 
betaine metabolism, and glycerol phosphate shuttle pathways. The fact that 
several of the more over-represented pathways in Chapter 3 are related to lipid 
metabolism is consistent with results of this chapter, where many of the 
metabolites associated with gestational age at delivery were lipid-related. 
There was also overlap between the two studies for amino acids, fluid balance 
and inflammation, and glyceride and phospholipids metabolite groups. None of 
the metabolites that associated with gestational age at delivery in the BiB cohort 




however the direction of the non-significant correlations did match those of this 
Chapter. This lack of significance is likely a consequence of the smaller number 
of samples included in Chapter 3, as well as the MS metabolomics measuring 
different metabolites of the same compound. For example, N-acetylalanine, a 
metabolite of alanine, was significantly negatively correlated with gestational 
age at delivery when measured at 28 weeks and in latent phase in Chapter 3. 
This would match with the finding from the BiB cohort that increased alanine is 
associated with a lower gestational age at delivery. In summary, the analysis 
shows support between the results of the two chapters, although the 
differences in metabolomics technique and sample size means that they are not 
directly comparable.  
4.8 Conclusions 
While dyslipidaemia and vascular dysfunction may not seem to be immediately 
relevant to the aim of the present study, namely improving our understanding 
of the spontaneous trigger for labour in humans, the results in this chapter and 
the preceding chapters of this thesis begin to paint a picture that suggests that 
all pathologies of pregnancy may be interlinked, and that the link could be 
vascular physiopathology. Vascular dysfunction is associated with pre-eclampsia 
and preterm birth, and some of the changes found in myometrial tissue in this 




labour could be linked to a physiological vascular dysfunction, potentially at the 
placental/fetal interface, that usually occurs when the pregnancy reaches term. 
In the pathological setting this change occurs earlier, associated with shorter 
gestational length, pre-eclampsia and preterm labour.  
In summary, the findings presented here support the hypothesis that the trigger 
for labour, particularly preterm spontaneous labour, could be associated with 
an inflammatory environment associated with dyslipidaemia and vascular 
dysfunction. Further, these results suggest potentially modifiable risk factors 
that could be prioritised for further investigation as fruitful targets to prevent 
preterm labour. Subsequently, the next steps will involve replicating results and 
using other approaches to strengthen causal inference on the relation of these 
maternal risk factors with gestational age at delivery. 
4.9 Limitations of study 
Limitations of this study include that given the NMR platform primarily measures 
lipids, the metabolites measured are all linked to each other and therefore the 
consistent findings of an association with gestational age may be because many 
of these metabolic measures are highly correlated. Currently BiB samples are 
being processed using MS metabolomics and therefore it will be interesting to 
repeat this study using the MS data, which represents more metabolic pathways. 




hypothesised key confounders, the results could still be biased by residual 
confounding due to unmeasured or inaccurately measured confounders.  
A further important source of potential bias is the risk that incomplete data is 
not missing at random, which could mean that the selection of participants 
based on non-missing data (i.e. complete case analysis) in this study could 
introduce bias in the effect estimates. However, the similarity in the distribution 
of the key characteristics of the participants between the eligible and analysis 
samples is reassuring in this respect.  
The BiB cohort represents a multi-ethnic group of differing parity. Although the 
results of this study were adjusted for ethnicity, it is possible that they would 
not be replicated in a population of very different ethnicity or cultural 
backgrounds. However, in two recent studies which investigated prediction 
models for pre-eclampsia15 and fetal growth restriction at term15, modelling 
using pregnancy metabolomics data among the Pregnancy Outcome Prediction 
(POP) study was replicated using the metabolomics data of the BiB cohort. This 
is despite differences in ethnicity and parity of the participants of the two 
cohorts: the POP study was conducted in Cambridge, UK, and by design 
recruited only nulliparous women, over 95% of whom were white. This 
validation for two different pregnancy outcomes across the two different 




compared between different cohorts and indicates that the results presented in 





























CHAPTER 5. INVESTIGATING CHANGES IN PROTEIN 
PHOSPHORYLATION DURING MYOMETRIAL CONTRACTIONS 
 
5.1 Background and rationale for study 
Up to this point, the studies included in this thesis have investigated associations 
between maternal and cord blood metabolites and human labour. The two 
studies presented in this chapter move on to investigate the potential role of 
the myometrium in the process of parturition in humans. This is important as it 
is the myometrium of the uterus which coordinates contractions for expulsion 
and delivery of the baby and placenta, and therefore the metabolomic changes 
that have been shown to be associated with labour so far may affect myometrial 
function.  
As discussed in Chapter 1, in vitro human myometrium intrinsically undergoes 
phasic contractions as a result of spontaneous cell membrane depolarisation. 
Slowly depolarising action potentials instigate sudden rapid entry of calcium 
ions (Ca2+) into the myometrial cells upon opening of voltage-gated Ca2+ 
channels. These phasic contractions are driven by the reversible and opposing 
actions of myosin light chain kinase (MYLK) and myosin phosphatase (MYLP), 
coordination of which generates the force of myometrial contractions54, 145, 287.   
MYLK is a Ca2+-calmodulin (Ca-CaM)-dependent enzyme that reversibly 




changes in intracellular Ca2+ concentration. While MYLK activity is driven by Ca2+ 
concentration, regulatory phosphorylation of MYLP can occur that is not 
dependent of Ca2+ concentration287.  Myometrial agonists such as oxytocin (OXT) 
exert their effects through binding to G protein-coupled receptors which 
increase the Ca2+ influx into the myocytes via the Gq/Phospholipase C 
pathway287, 288. Phosphorylation events of myometrial contractility have 
previously been investigated, including previous work by Hudson et al. (2017), 
which showed that a reversible phosphorylation of a regulatory subunit of MYLP 
(at Threonine 853) can occur during phasic myometrial contractions, and that 
this plays a role in the Ca2+-sensitivity induced by oxytocin. Inhibition of MYLP 
would increase oxytocin-induced Ca2+-sensitivity287. 
Failure to progress in labour, also described as arrest of descent or labour 
dystocia, is diagnosed clinically if a woman’s cervix does not dilate at the 
expected rate of at least 2 cm  every four hours for first labours. In subsequent 
labours this classification stands, and in addition failure to progress may be 
diagnosed if there is a slowing of the rate of dilatation30. Clinically, failure to 
progress is often explained as being secondary to cephalopelvic disproportion, 
where the fetus is deemed too large for the maternal pelvis, or because of 
malposition of the fetus289. However, this is not always the case, and it is 




functionality of the myometrium. If this hypothesis were true and the areas of 
these differences were elucidated, this could progress the quest for an improved 
understanding of the trigger for spontaneous labour in humans. It would also 
provide targets for drug development for IOL. 
Previous researchers have performed genomic analysis of the myometrium of 
women who were diagnosed with failure to progress. For example, one group 
performed genomic analysis to compare myometrium taken from women who 
were at term and not in labour (elective caesarean section (ECS)) with women 
who had an emergency caesarean section for failure to progress. The 
researchers identified four hundred genes that were differentially expressed 
between these two groups. Following signalling pathway impact analysis, 
significant pathways were identified that were associated with failure to 
progress, including those involved in regulation of the actin cytoskeleton, 
cytokine-cytokine receptor interaction, complement and coagulation cascade, 
and focal adhesion. The authors also found increased protein expression of 
Interleukin-6, a pro-inflammatory cytokine, in the myometrium of women with 
failure to progress in labour. This group snap froze and processed the 
myometrial samples immediately following delivery, and therefore the results 
of this study may in part reflect the recent physiological stress of labour 




identified differences in the gene expression between those who had an ECS (no 
labour) and those who had an emergency caesarean section (labour). This 
included  pathways involved in responses to hypoxia, inflammation, apoptosis, 
stress, muscle contraction and chemokine signalling289. These findings indicate 
that there may be inherent differences in the myometrium of women who are 
diagnosed with failure to progress.  
While genomic studies are very useful in determining which genes are being 
transcribed, they do not always reflect the proteins produced and the action of 
these proteins291, 292. Global phosphoproteomics allows investigation of the total 
proteome and phosphoproteome of cells and tissues, facilitating assessment of 
both the proteins present within a target tissue at a set time point and protein 
phosphorylation events. Post-translational phosphorylation of proteins is 
important as such modifications can alter protein function293.  
In the present study, global phosphoproteomics was used to investigate the 
phosphoproteome of myometrium sampled from women who had an ECS at 
term (not in labour) and the phosphoproteome of myometrium sampled from 
women who had an emergency caesarean section following failed induction of 
labour (IOL). Any differences between these two groups could reflect a 
myometrial phenotype that may be associated with failure to progress, and 




pathway of spontaneous labour in humans. In addition, as discussed above, 
previous studies investigating the genomics of failed IOL have snap frozen 
myometrial samples at the time of delivery. It is therefore possible that any 
differences observed could be a direct result of the stress of labour experienced 
by the failed IOL group but not by the elective caesarean section group. In order 
to control for this, the experimental design for the present study included an 
equilibration period for all samples, intended to allow a wash-out of those 
proteins and phosphorylations which may have occurred as a direct result of the 
stress of the preceding labour in the failed IOL group. Following this equilibration 
period, samples from both groups were then subjected to the same 
experimental environments to better represent the inherent responses of the 
myometrium.  
There were two parts to this study: Part 1 was continuation of work by Hudson 
et al. (2017) to investigate phoshophoproteomic differences between 
contracting myometrium and non-contracting myometrium sampled from 
women at ECS; and Part 2 investigated phosphoproteomic differences between 
myometrium sampled from women who had a failed IOL due to failure to 




5.2 Ethical approval, participant consent and funding 
Ethical approval for this study was granted by the North Somerset and South 
Bristol Research Ethics Committee, and funding was from the David Telling 
Charitable Trust (reference number 354). All women gave written informed 
consent.  
5.3 Role of thesis researcher 
Whereas for the other chapters, the author of this thesis (Katherine Birchenall) 
designed and performed all aspects of the studies, including recruitment, 
sample collection and statistical analysis. While this was the same for Part 2 of 
this chapter, this was not the case for Part 1. 
For Part 1 of this study, the recruitment, experimentation and 
phosphoproteomic analysis had been performed prior to the start of this PhD, 
and the thesis author’s role was in analysis of the data. For Part 2 of this chapter, 
the thesis author recruited and performed the experiments during the time of 
the PhD, processed the samples ready for phosphoproteomics, and analysed the 







The aims of this chapter were: 
1.  To elucidate potential cellular pathways involved in the contraction and 
relaxation of the myometrium, and to investigate potential regulatory 
factors to guide future research. 
2. To investigate whether myometrial phosphorylation patterns are 
different between women who have an elective caesarean section having 
previously laboured and reached full cervical dilatation in a previous 
pregnancy, and those who have an emergency caesarean section 
following failed induction of labour. Any differences may demonstrate 
essential signalling pathways or changes in myometrial protein 
phosphorylation that are required for effective coordination of 
myometrial contractions and timely vaginal delivery of the fetus. 
If there are differences in phosphorylation patterns between the 
myometrium of women who have a failed induction of labour and women 
who have laboured to full dilatation, it would indicate that the proteins 
affected are functionally necessary for successful myometrial contractility. 
Such information could be used for development of better methods for 




involved in labour, with adequate myometrial contractions an important end 
point.  
5.5 Methodology 
5.5.1 Myometrial organ bath 
Myometrial samples were taken at the time of caesarean section following 
delivery of the baby and placenta. An approximately 1 cm  by 1 cm  by 1 cm  strip 
of myometrium was sampled from the upper border of the lower uterine 
incision. This sample was obtained by the operating surgeon, and the tissue was 
then immediately washed in ice-cold isotonic saline and transported to the 
laboratory for immediate processing. With minimal handling of the 
myometrium, and while keeping the samples submerged in isotonic saline, the 
samples were cut into five strips of approximately 5 mm by 20 mm dimensions 
with a scalpel287. 
A four-chamber Myobath-II system (World Precision Instruments (WPI), 
Stevenage, UK) was used for the myometrial contractility experiments. Four of 
the cut myometrial strips were mounted using s-shaped hooks, and one was 
individually fixed under tension in each of the four 10ml chambers of the 
Myobath-II system (see Figure 5.1). A fifth strip was connected to the upper s-




the same solution exposures while not under tension and therefore did not 
contract287.  
The strips were equilibrated in oxygenated Krebs solution at 37 degrees Celsius 
for 45 minutes, with a buffer change every fifteen minutes (three changes). The 
composition of the Krebs solution used was: 1.25 mM Magnesium Sulphate 
(MgS04), 4.7 mM Potassium Chloride (KCL), 1.25 mM Calcium Chloride (CaCl2), 
2.5 mM Monosodium Phosphate (NaH2PO4), 130 mM Sodium Chloride (NaCl),  
 
Figure 5.1: Myobath-II system with experimental conditions used in each of the four 
chambers used (World Precision Instruments) 
 
25 mM Sodium Bicarbonate (NaHCO3), 11.1 nM glucose and 10 mM Hepes at pH 
7.6. This buffer solution had been optimised by Hudson et al. (2017)145, and was 




directly comparable. The s-hooks attached at either end of the four myometrial 
strips were connected to force transducers, and this electronic data was 
collected using Lab-Trax data acquisition system which transformed the applied 
force from the myometrial strips into a proportional voltage (WPI, Stevenage, 
UK). Figure 5.2 shows an example output287. 
Through monitoring of the force transducer output on a monitor, the resting 
tension for each of the myometrial strips was set to 2g (as per Hudson et al. 
(2017)145 methodology) through adjustment of the height of the upper s-hook 
(WPI, Stevenage, UK)287. The force transducer output was then monitored for 
each of the baths until spontaneous contractions were observed (occurring in 
most cases after approximately 60 minutes). According to the experiment 
conducted, the myometrial strips were either allowed to continue to contract 
spontaneously or the agonist oxytocin (OXT) (Merck, Darmstadt, Germany) was 
added directly to the bath287. For those experiments involving OXT, the strips 
were directly exposed to 10 nM OXT and contractions were observed until 






Figure 5.2: Example of electronic output of myometrial samples connected to force-
transducers using Lab-Trax data acquisition system (World Precision Instruments) (figure 
adapted from Hudson & López-Bernal, 2012). Samples: SP-REL = spontaneous contractions 
with sample snap frozen at maximum relaxation; SP-CON = spontaneous contractions with 
sample snap frozen at maximum contraction; OXT-REL = oxytocin-enhanced contractions 
with sample snap frozen at maximum relaxation; and OXT-CON = oxytocin-enhanced 
contractions with sample snap frozen at maximum contraction. 
 
Approximately 40 minutes after OXT was or was not added, the strips from all 
four baths were snap frozen and put into liquid nitrogen in quick succession. The 
snap freezing was performed by dipping two flat spatulas in liquid nitrogen and 
then holding the strips between the two spatulas. Each strip took approximately 
5 seconds to raise from the organ bath, snap freeze, and place in liquid nitrogen. 




1. PRE: no tension applied and considered pre-contraction. 
2. SP-REL: spontaneous contraction (no OXT) snap frozen 20 seconds following 
the end of a phasic contraction. 
3. SP-CON: spontaneous contraction (no OXT) snap frozen at peak phasic 
contraction.  
4. OXT-REL: oxytocin-stimulated phasic contraction (with OXT) snap frozen 20 
seconds following the end of a phasic contraction. 
5. OXT-CON: oxytocin-stimulated contraction (with OXT) snap frozen at peak 
phasic contraction.  
These tissues were then stored at -80 degrees Celsius until protein extraction 
was performed.  
5.5.2 Tissue homogenisation  
In preparation for proteomic analysis, the individual myometrial strips were 
homogenised in radioimmunoprecipitation assay (RIPA) buffer at approximately 
100mg of wet tissue per millilitre of buffer, using a Polytron homogeniser, 
keeping everything on ice. The RIPA buffer used is made up of 150 mM NaCl, 50 
mM Tris of pH 8.0, 1%NP-40 (a detergent to break down the cell membranes, 
including the nuclear membrane), 0.1% sodium dodecyl sulphate (SDS), 0.5% 




Limited, Burgess Hill, UK). The lysates were cleared through centrifugation for 
ten minutes at 16 000 g at 4 degrees Celsius. The BCA assay kit (Perbio Science 
UK, Cramlington, UK) was used to determine the protein concentrations. The 
protein concentrations were adjusted to 2mg per millilitre, and 100µg of protein 
was then used for the phosphoproteomic analysis145.  
5.5.3 Phosphoproteomics 
Mass Spectrometry (MS) phosphoproteomic analysis was performed by Dr Kate 
Heesom’s group in the University of Bristol Proteomics Facility, School of 
Medical Sciences (https://www.bristol.ac.uk/life-
sciences/research/facilities/proteomics/). For the tandem mass tag (TMT) and 
phospho-peptide enrichment, 100µg of each sample was digested with 2.5 µg 
Trypsin at 37 degrees Celsius overnight, then labelled differentially with TMT 
four-plex reagents (according to the protocol suggested by the manufacturer, 
Thermo Fisher Scientific, Loughborough, UK). Each sample had a different 
isobaric tag. The labelled samples were pooled, allowed to evaporate to dryness, 
resuspended in buffer made up of 57% acetonitrile vol/vol (v/v), 26% lactic acid 
v/v, and 0.4% TFA v/v, and then underwent titanium dioxide (Ti02)-based 
phosphopeptides enrichment, again according to the manufacturer’s 




For the Nanoscale-Liquid Chromatography coupled to tandem Mass 
Spectrometry (Nano-LC MS), the enriched phosphopeptides were fractionated 
with a Dionex Ultimate 3000 nanoHPLC system (Thermo Scientific), in line with 
an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific). 
Peptides were diluted in 1% formic acid v/v and then transferred to an Acclaim 
PepMap C18 reverse phase analytical column (Dionex). A wash was then 
performed with 0.5% v/v acetonitrile in 0.1% v/v formic acid, following which 
the peptides were resolved on a 75um x 250 mm Acclaim PepMap C18 reverse 
phase analytical column (Dionex) with a flow rate of 300 µl per minute, across a 
150 minute organic gradient of seven gradient segments of different percentage 
concentration of solvent B (aqueous 80% acetonitrile in 0.1% formic acid): 1 
minute of 1-6% solvent B, 58 minutes of 6-15% solvent B, 58 minutes of 15-32% 
solvent B, 3 minutes of 32-40% solvent B, 1 minute of 40-90% solvent B, then 
held at 90% solvent B for 6 minutes, then finally reduced to 1% solvent B for 1 
minute294.  
Following this step, ionisation of the peptides occurred using nanoelectrospray 
ionisation at 2.0 kV at a temperature of 250 degrees Celsius, with use of an 
emitter made of stainless steel and with an internal diameter of 30 µm (Thermo 
Scientific). An LTQ-Orbitrap Velos mass spectrometer, controlled by Xcalibur 2.1 




This was operated in data-dependent acquisition mode. In the mass range m/z 
300 to 1800, the Orbitrap was set to analyse at 60 000 resolution (at m/z 400), 
with subsequent selection of the top ten multiply charged ions within each duty 
cycle for MS/MS fragmentation using higher-energy collisional dissociation 
(HCD) with activation time of 0.1 millisecond, at a resolution of 7500, and 
normalised collision energy within the Orbitrap. Charge state filtering, where 
unassigned precursor ions were not selected for fragmentation, and dynamic 
exclusion were used294.  
5.5.4 Initial analysis 
Proteome Discoverer software v2.1 (Thermo Scientific) was used to process and 
quantify the raw data files. A SEQUEST algorithm search was performed against 
the UniProt Human database (https://www.uniprot.org/) as well as a Common 
Contaminants database295, 296. Through this, it was noted whether the peptides 
matched with proteins from the human database or the contaminants database. 
Any peptides that were found exclusively in the contaminants database were 
excluded. For the total proteomics, the results were filtered using a 5% false 
discovery rate (FDR) cut-off and were then normalised on the total peptide 
amount for each sample. The results were then adjusted according to the pool 
samples so that results could be compared across the three different runs. When 




unique. They were not unique if the phospho-peptide sequence matched to 
more than one master protein, and where it was not possible to determine 
which was the source master protein, these phosphopeptides were removed 
from the analysis (Figures 5.3 and 5.4).  
The 5% FDR cut off was performed by Dr Heesom’s laboratory as part of the 
proteomics processing. This involved searching each spectra generated by the 
MS process against a species protein database and also against the same 
database but for which all of the protein sequences are reversed (named a 
reverse decoy database). A score is given to each match of a spectra according 
to how closely the spectra match the that predicted for the given peptide 
sequence, so that a higher score indicates a better match. It would be expected 
that there would only be low scores for the decoy database as they were not 
real protein sequences. The distribution of these scores is then analysed for both 
databases, and a cut-off calculated where there is only a 5% chance that a 
peptide would match to the decoy database instead of the “real” database. All 
peptides below this cut off were then considered low-confidence peptides and 
excluded from the analysis.  
For Part 1 of this study, the TMT tags allowed the abundance of individual 
peptides in each sample to be reported and the data were presented as the 




identify potential proteins and phosphorylations which changed between the 
non-contracting and the contracting state in term not in labour myometrium. 
The programme R was primarily used to analyse the data. The total protein and 
phosphoprotein datasets were merged according to accession number, and the 
phosphoprotein REL/PRE ratios were normalised according to the REL/PRE 
ratios for the total proteins. The mean normalised REL/PRE value was then 
calculated for each of the measured phosphoproteins. Those total proteins and 
phosphoproteins which either doubled or halved in the myometrium from all 
three women were identified and put through String (String-db.org), Kyoto 
Encyclopedia of Genes and Genomes (KEGG) (https://www.genome.jp/kegg/) 
and Reactome (https://reactome.org/) online software (described further 
below). This method was used rather than simply using the mean, as a consistent 
finding in all three samples was considered to be more clinically useful (Figure 
5.3).  
Part 2 aimed to compare the total protein and the phosphoproteome of 
myometrium taken from women who had an emergency caesarean section for 
failed IOL at term with the myometrium taken from women who had an ECS at 
term for each experimental condition (PRE, SP-REL, SP-CON, OXT-REL and OXT-
CON). It was possible to perform more sophisticated statistical analysis for the 




of the PhD). For this part of the study, all Peptide Spectral Matches (PSMs) of 
phosphopeptides with identical peptide sequences and predicted 
phosphorylation sites were summed to give a single abundance value for each 
unique phosphopeptide. These phosphopeptide abundance values were then 
normalised by the same normalisation factor as was applied to the total protein 
values. This meant that any change applied to the total protein was also applied 
to the phosphopeptides. These values were then scaled by the pool sample for 
each run in the same way as performed for the total proteins, so that 
abundances could be compared accurately across the experiments. At this point 
there were two key values: total protein abundance (normalised to total peptide 
for each protein and scaled according to the pool values for each protein) and 
phosphoprotein abundance (again, normalised to the total peptides and scaled 
according to the pool values). All the values for total protein abundance and 
phosphoprotein abundance for each of the samples (including all conditions) 
were log2-transformed as this achieved a distribution that was closer to normal 
to increase the power of the analysis. The next normalisation step was to 
subtract the log2 protein abundance from the log2 phosphoprotein abundance 
to give a phosphopeptides abundance relative to the total protein, i.e. a relative 
phosphopeptides abundance, allowing better comparison of real change in the 




changes in total protein abundance. For each of the conditions (PRE, SP-REL, SP-
CON, OXT-REL and OXT-CON) the mean log2 phosphopeptide abundance was 
calculated for the failed IOL group and the elective caesarean section group, the 
log2-fold change calculated and Welch’s t-test performed. For the purpose of the 
analysis in this thesis, changes were considered significant if p≤0.05, and 
phosphorylation events which were significantly different between the failed 
induction of labour and the elective group were highlighted if the 
















5.5.5 Pathway analysis 
The above methodology gave an overall summary of the proteins and 
phosphorylation events which occurred in the different conditions tested. 
Online software is available which aid identification of potential protein 
interactions within selected samples and perform analysis to determine if a 
specific set of proteins are over-represented among known pathways. Accession 
codes for all those proteins which either at least doubled or halved between 
compared conditions in Part 1 and Part 2 of this study were entered into the 
bioinformatic software programmes including String, Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway database, and Reactome. String and 
Reactome allow performance of an “overrepresentation analysis”, where those 
pathways which are enriched, or overrepresented, in the results of the study 
more than that which would be expected with chance are identified. For 
Reactome, a p-value is calculated comparing the proteins in the study sample 
with those that would be expected if randomly selected, as well as a false 
discovery rate (FDR), calculated using the Benjamini-Hochberg approach297. 
String analyses the list of proteins and calculates a p-value for Protein-Protein 
Interaction (PPI), which is a measure of whether the group of proteins has 





5.6 Part 1 background and results 
5.6.1 Background 
As explained above, Part 1 of this study continued analysis of data produced by 
Hudson et al. (2017)145. The aim of this study was to conduct a global analysis of 
the changes in the myometrial phosphoproteome during spontaneous and OXT-
induced contractions, and to potentially determine novel phosphorylation sites 
involved in contractility145. The initial analysis identified 22 phosphopeptides 
which either doubled or halved during spontaneous and/or OXT-augmented 
contractions. The largest change was seen in the phosphorylation of MYLK at 
serine 1760, which is within a site associated with decreased calmodulin binding 
and subsequent decreased kinase activity. This phosphorylation increased 
9.83+/-3.27-fold (p<0.05) during spontaneous contraction (SP-CON) and 
18.56+/-8.18-fold (p<0.01) during OXT-augmented contraction (OXT-CON), 
when compared with SP-REL145. The total protein changes from this study had 








5.6.2 Part 1 inclusion criteria 
• Women undergoing an ECS at term for indications not relating to 
maternal or fetal disease, including fetal malposition, maternal request or 
previous caesarean section. 
5.6.3 Part 1 exclusion criteria 
• Emergency caesarean section 
• Known maternal disease 
• Maternal infection 
5.6.4 Results 
5.6.4.1 Part 1 participants’ characteristics 
The three women included all had an ECS between 37 and 41 completed weeks 
gestation. The women otherwise had low-risk pregnancies with no maternal or 
fetal concerns. Indications for ECS were: fetal malposition, previous caesarean 
section and maternal request.  
5.6.4.2 Part 1 phosphoproteomics results 
There were REL/PRE ratio data for 9174 proteins, and REL/PRE ratio information 





5.6.4.3 Part 1 total proteins 
Using the analysis method illustrated in Figure 5.3, 178 proteins at least halved 
between the pre-contracting phase (PRE) and the contraction phase (SP-REL) 
conditions (Table 5.1), and five at least doubled (Table 5.2). All those proteins 
which either at least doubled or halved in the spontaneously contracting phase 
compared with the pre-contracting phase (REL/PRE) in all three samples were 
entered into bioinformatic software programmes including Reactome, String, 
and KEGG, as described above297.  
Table 5.3 shows the 25 pathways which the Reactome software highlighted as 
being the most overrepresented. The entities found represent the number of 
entities found in the Part 1 dataset that are present in the named pathway, 
divided by the total number of known entities in that particular pathway. The 
entities p-value is the statistical test for over-representation, as described, and 
the entities FDR corrects the p-value test for multiple testing. The reactions 
found represent the number of pathways identified in the overall pathway for 
which there is at least one entity from the study dataset found. The reactions 
ratio is the ratio of reactions in the specific pathway which contain entities from 
the study dataset, divided by the total number of reactions within the Reactome 




Table 5.1: Accession number and protein description for total proteins where the REL/PRE ratio at least halved for all three women, in order 
of mean REL/PRE. 








Acid-sensing ion channel 5  ASIC5 Q9NY37 0.171 0.054 0.299 0.174675 
Putative heat shock protein HSP 90-beta 4  HSP90AB4P Q58FF6 0.194 0.066 0.277 0.179087 
COL8A2 protein (Fragment)  COL8A2 Q4VAP9 0.160 0.101 0.312 0.190707 
T-cell lymphoma invasion and metastasis 1 variant 
(Fragment)  
 Q59GK8 0.185 0.082 0.308 0.191501 
Alternative protein SV2A  SV2A L8E840 0.195 0.094 0.288 0.192258 
Protein CXorf40B (Fragment)  CXorf40B S4R3G8 0.134 0.194 0.250 0.192549 
Heavy chain of factor I (Fragment)   Q6LAM1 0.195 0.136 0.266 0.198744 
Leucine-rich repeat transmembrane neuronal 
protein 3  
LRRTM3 Q86VH5 0.190 0.075 0.343 0.202634 
Complement C2  C2 P06681 0.169 0.166 0.276 0.203823 
MHC class I antigen (Fragment)  HLA-C J9PWW9 0.193 0.097 0.322 0.204 
Alpha-2-HS-glycoprotein  AHSG P02765 0.186 0.119 0.308 0.204276 
Isocitrate dehydrogenase [NAD] subunit alpha, 
mitochondrial (Fragment)  
IDH3A H0YLI6 0.199 0.106 0.313 0.206203 
ETS domain-containing protein Elk-3 (Fragment)  ELK3 F8VZQ0 0.199 0.104 0.328 0.210359 
Uncharacterized protein   B4E1Z4 0.192 0.160 0.294 0.215487 




Afamin  AFM P43652 0.189 0.131 0.328 0.216285 
Lymphocyte cytosolic protein 2 (Fragment)  LCP2 E5RKA2 0.211 0.101 0.350 0.220541 
Ig kappa chain V-III region GOL OS=Homo sapiens 
PE=1 SV=1 - [KV307_HUMAN] 
 P04206 0.226 0.152 0.287 0.221674 
cDNA FLJ53950, highly similar to Angiotensinogen   B4E1B3 0.183 0.153 0.337 0.224544 
Serotransferrin (Fragment)  TF C9JVG0 0.219 0.116 0.345 0.226664 
Gasdermin-B  GSDML B2CM73 0.172 0.115 0.402 0.229643 
V4-1 protein (Fragment)  V4-1 Q5NV68 0.286 0.000 0.405 0.230223 
Nuclear pore complex protein Nup98-Nup96 
(Fragment)  
NUP98 H0YDF4 0.247 0.174 0.281 0.233823 
Complement factor I light chain  CFI G3XAM2 0.187 0.174 0.343 0.234673 
cDNA FLJ50624   B7Z5L2 0.277 0.119 0.313 0.236541 
MRDS1 protein (Fragment)  MRDS1 Q8IZS4 0.251 0.096 0.366 0.237525 
Transferrin variant (Fragment)   Q53H26 0.261 0.107 0.350 0.239237 
Alpha-1-antichymotrypsin  SERPINA3 P01011 0.237 0.130 0.357 0.241487 
Alpha-1-acid glycoprotein 2  ORM2 P19652 0.236 0.119 0.369 0.241575 
Ceruloplasmin (Fragment)   Q1L857 0.236 0.130 0.363 0.242832 
Myosin-reactive immunoglobulin light chain variable 
region (Fragment)  
 Q9UL83 0.309 0.153 0.270 0.243847 
cDNA, FLJ94361, highly similar to Homo sapiens 
serine (or cysteine) proteinase inhibitor, clade 




A(alpha-1 antiproteinase, antitrypsin), member 6 
(SERPINA6), mRNA  
Sex hormone-binding globulin  SHBG I3L145 0.211 0.180 0.348 0.246362 
Alpha-1-antitrypsin  SERPINA1 P01009 0.222 0.142 0.377 0.246759 
Thyroxine-binding globulin  SERPINA7 P05543 0.220 0.162 0.361 0.247522 
Serum albumin  ALB P02768 0.227 0.130 0.386 0.247628 
Myosin-reactive immunoglobulin heavy chain 
variable region (Fragment) OS=Homo sapiens PE=2 
SV=1 - [Q9UL88_HUMAN] 
 Q9UL88 0.306 0.137 0.311 0.251172 
N-deacetylase/N-sulfotransferase (Heparan 
glucosaminyl) 1 variant (Fragment)  
 Q59GK2 0.253 0.200 0.305 0.252713 
cDNA FLJ46572 fis, clone THYMU3041573   Q6ZR80 0.251 0.224 0.300 0.258675 
cDNA FLJ53075, highly similar to Kininogen-1   B4DPP8 0.184 0.149 0.445 0.25953 
Antithrombin-III  SERPINC1 P01008 0.189 0.196 0.404 0.262913 
Peroxisomal proliferator-activated receptor A 
interacting complex 285  
PRIC285 A7E2C9 0.259 0.146 0.399 0.267948 
HSPC254 (Fragment)   Q9P0C7 0.240 0.187 0.379 0.268763 
Hemopexin  HPX P02790 0.232 0.180 0.398 0.269767 
Apolipoprotein A-I  APOA1 P02647 0.277 0.186 0.364 0.275777 
Torsin family 3, member A, isoform CRA_b  TOR3A A0A024R943 0.269 0.160 0.403 0.277476 
Vitamin D-binding protein  GC P02774 0.264 0.190 0.379 0.277481 




IGL@ protein  IGL@ Q6PIK1 0.287 0.198 0.349 0.278325 
Ig kappa chain V-I region DEE   P01597 0.311 0.201 0.323 0.278384 
C-reactive protein(1-205)  CRP Q5VVP7 0.264 0.193 0.381 0.279079 
Transthyretin  TTR P02766 0.283 0.168 0.388 0.27967 
Ig heavy chain V-III region TUR   P01779 0.243 0.212 0.385 0.279983 
tRNA (guanine-N(7)-)-methyltransferase non-
catalytic subunit WDR4  
WDR4 P57081 0.237 0.159 0.450 0.282096 
V3-4 protein (Fragment)  V3-4 Q5NV62 0.339 0.212 0.297 0.282735 
Haptoglobin  HP P00738 0.241 0.325 0.290 0.285602 
Rheumatoid factor RF-ET6 (Fragment)   A2J1N5 0.463 0.106 0.294 0.287805 
IgG H chain OS=Homo sapiens PE=2 SV=1 - 
[S6BGE0_HUMAN] 
 S6BGE0 0.287 0.174 0.409 0.289817 
Putative upstream-binding factor 1-like protein 6  UBTFL6 P0CB48 0.266 0.197 0.410 0.291095 
Claudin-10  CLDN10 P78369 0.267 0.188 0.421 0.291845 
60S ribosomal protein L10-like  RPL10L Q96L21 0.263 0.185 0.429 0.292394 
Ig heavy chain variable region (Fragment)   A0A068LKQ0 0.293 0.200 0.391 0.294428 
cDNA, FLJ93914, highly similar to Homo sapiens 
histidine-rich glycoprotein (HRG), mRNA  
 B2R8I2 0.215 0.264 0.407 0.295174 
Ig kappa chain V-III region POM   P01624 0.364 0.105 0.420 0.296392 
Ig kappa chain V-I region Roy   P01608 0.312 0.176 0.416 0.301331 




Zinc finger MYM-type protein 3  ZMYM3 A6NHN7 0.266 0.153 0.494 0.303994 
Putative uncharacterized protein DKFZp686G11190  DKFZp686G11190 Q6MZQ6 0.277 0.159 0.484 0.306337 
IgG L chain   S6BAR0 0.294 0.202 0.424 0.306421 
Myosin-reactive immunoglobulin heavy chain 
variable region (Fragment)  
 Q9UL89 0.309 0.194 0.417 0.306845 
NK1 transcription factor-related protein 2  NKX1-2 Q9UD57 0.311 0.204 0.417 0.310642 
ATP synthase protein 8  ATP8 Q6RM58 0.275 0.304 0.362 0.313637 
V1-22 protein (Fragment)  V1-22 Q5NV88 0.296 0.272 0.373 0.313656 
Alpha-2-antiplasmin  SERPINF2 P08697 0.219 0.242 0.481 0.314162 
Ig lambda chain V-II region BUR   P01708 0.303 0.199 0.441 0.314365 
Myosin-reactive immunoglobulin light chain variable 
region (Fragment)  
 Q9UL70 0.357 0.257 0.330 0.314583 
Ig gamma-2 chain C region  IGHG2 P01859 0.331 0.206 0.419 0.318381 
Ig heavy chain variable region (Fragment)   A0A068LKQ5 0.330 0.218 0.414 0.320759 
Immunoglobulin heavy chain variant (Fragment)   Q9NPP6 0.365 0.210 0.391 0.322146 
Apolipoprotein A-II (Fragment)  APOA2 V9GYG9 0.275 0.303 0.406 0.328051 
Heparin cofactor 2  SERPIND1 P05546 0.251 0.328 0.407 0.328895 
Putative uncharacterized protein DKFZp686K18196 
(Fragment)  
DKFZp686K18196 Q6N092 0.302 0.236 0.451 0.329612 
Ig kappa chain V-I region Wes   P01611 0.333 0.207 0.457 0.33268 




cDNA FLJ14473 fis, clone MAMMA1001080, highly 
similar to Homo sapiens SNC73 protein (SNC73) 
mRNA  
 Q96K68 0.331 0.225 0.445 0.333596 
Coagulation factor XII-Mie   Q8IZZ5 0.286 0.320 0.398 0.334685 
Protein IGKV2D-24 (Fragment)  IGKV2D-24 A0A075B6R9 0.322 0.248 0.436 0.335101 
Kininogen 1, isoform CRA_b  KNG1 B4E1C2 0.241 0.354 0.414 0.336223 
Complement component C6  C6 P13671 0.341 0.217 0.458 0.338469 
Putative uncharacterized protein DKFZp686K04218 
(Fragment)  
DKFZp686K04218 Q7Z379 0.367 0.198 0.453 0.339185 
Complement C3  C3 P01024 0.313 0.267 0.439 0.339726 
Haptoglobin-related protein  HPR P00739 0.345 0.330 0.348 0.3411 
Myosin-reactive immunoglobulin light chain variable 
region (Fragment)  
 Q9UL78 0.331 0.292 0.404 0.342398 
Bone marrow proteoglycan  PRG2 P13727 0.246 0.297 0.499 0.347319 
cDNA FLJ51742, highly similar to Inter-alpha-trypsin 
inhibitor heavy chain H4  
 B7Z544 0.380 0.319 0.345 0.347931 
DF protein  DF Q6FHW3 0.271 0.440 0.334 0.348498 
Alpha-2-macroglobulin  A2M P01023 0.342 0.292 0.417 0.350212 
Epididymis luminal protein 180 (Fragment)  HEL180 B6EDE2 0.401 0.196 0.455 0.350831 
Ig kappa chain V-IV region STH (Fragment)   P83593 0.318 0.244 0.490 0.350888 
Complement factor H-related protein 2  CFHR2 V9GYE7 0.343 0.306 0.406 0.351515 




Rearranged VH4-34 V gene segment (Fragment)  VH4-34 Q7Z3Y6 0.343 0.243 0.477 0.354457 
cDNA FLJ54981, highly similar to Asparaginyl-tRNA 
synthetase, cytoplasmic (EC 6.1.1.22)  
 B4DF91 0.343 0.259 0.469 0.357127 
Protein IGKV3-11  IGKV3-11 A0A087WZW8 0.385 0.204 0.484 0.357979 
Complement component C8 alpha chain  C8A P07357 0.391 0.317 0.369 0.358861 
Cryocrystalglobulin CC1 heavy chain variable region 
(Fragment)  
 B1N7B6 0.327 0.288 0.462 0.358917 
Anti-H1N1 influenza HA kappa chain variable region 
(Fragment)  
 G3GAU4 0.311 0.284 0.484 0.359899 
IgG H chain   S6BGD4 0.406 0.185 0.493 0.361408 
Ig lambda-7 chain C region (Fragment)  IGLC7 A0A075B6L1 0.336 0.359 0.389 0.361505 
Uncharacterized protein   Q7Z2U7 0.383 0.208 0.495 0.36181 
cDNA FLJ78071, highly similar to Human MHC class 
III complement component C6 mRNA  
 A8K8Z4 0.422 0.248 0.421 0.363487 
Ig kappa chain V-I region BAN   P04430 0.377 0.260 0.455 0.364185 
Zinc-alpha-2-glycoprotein  AZGP1 P25311 0.350 0.260 0.491 0.367259 
Immunoglobulin J chain  IGJ P01591 0.387 0.327 0.395 0.369822 
Complement C4A3 (Fragment)  C4A V9H0D6 0.466 0.470 0.176 0.370672 
Complement component 9, isoform CRA_a  C9 A0A024R035 0.387 0.273 0.457 0.372345 
Tetranectin  CLEC3B P05452 0.355 0.380 0.395 0.37671 
Ig kappa chain V-I region Lay   P01605 0.377 0.294 0.461 0.377028 




Ig mu chain C region  IGHM A0A087WYJ9 0.334 0.383 0.421 0.37923 
Ig kappa chain C region  IGKC A0A087WYL9 0.362 0.373 0.405 0.379857 
cDNA, FLJ95492, highly similar to Homo sapiens 
myosin regulatory light chain interacting 
protein(MIR), mRNA  
 B2RBG2 0.346 0.304 0.500 0.383065 
Protein AMBP  AMBP P02760 0.419 0.309 0.448 0.391841 
Apolipoprotein L1 (Fragment)  APOL1 U5LKR8 0.315 0.416 0.453 0.394813 
Molybdenum cofactor synthesis-step 1 protein B 
splice type I (Fragment)  
MOCS1 Q9NP26 0.466 0.315 0.412 0.397583 
cDNA, FLJ79457, highly similar to Insulin-like growth 
factor-binding proteincomplex acid labile chain  
 B0AZL7 0.299 0.439 0.458 0.398735 
Carboxypeptidase N catalytic chain  CPN1 P15169 0.369 0.345 0.484 0.399288 
Probable Xaa-Pro aminopeptidase 3  XPNPEP3 Q9NQH7 0.409 0.346 0.451 0.401726 
Transcription factor AP-2-epsilon  TFAP2E Q6VUC0 0.414 0.342 0.463 0.406294 
Ig kappa chain V-I region EU   P01598 0.468 0.265 0.487 0.406536 
CD5 antigen-like  CD5L O43866 0.397 0.401 0.432 0.410149 
Ig gamma-3 chain C region  IGHG3 A0A087WXL8 0.453 0.314 0.482 0.416541 
Phosphatidylinositol 3,4,5-trisphosphate 5-
phosphatase 1  
INPP5D Q92835 0.405 0.354 0.493 0.417309 
Single chain Fv (Fragment)   Q9HCC1 0.378 0.428 0.465 0.423404 
Calcium/calmodulin-dependent protein kinase type 
1B  




cDNA FLJ78207, highly similar to Human 
complement protein component C7 mRNA  
 A8K2T4 0.374 0.492 0.443 0.436489 
Glutamate [NMDA] receptor subunit epsilon 2 
variant (Fragment)  
 Q59HA9 0.489 0.407 0.470 0.455341 
Carboxypeptidase B2  CPB2 A0A087WSY5 0.496 0.491 0.483 0.490011 
 
 
Table 5.2: Accession number and protein description for total proteins where the REL/PRE ratio at least doubled for all three women, in order 
of mean REL/PRE. 
Protein description Gene Accession REL/PRE for 565 REL/PRE for 592 REL/PRE for 604 Mean REL/PRE 
Mitogen-activated protein kinase 11  MAP3K11 E9PID4 3.521 4.269 3.022 3.604 
Tristetraprolin (Fragment)  ZFP36 M0QZ04 4.009 3.966 2.334 3.437 
Transcription factor jun-B  JUNB P17275 4.744 5.589 2.397 4.243 
C-C motif chemokine 2  CCL2 P13500 4.295 6.108 2.159 4.187 










Table 5.3: 25 most overrepresented total protein pathways according to Reactome analysis (ordered according to p-value size) where REL/PRE 
at least halved. 
Pathway Name Entities found p-value for entities 
found 
FDR for entities found Reactions found Reactions ratio 
Scavenging of heme 
from plasma 
20/99 1.11x10-16 6.66x10-15 12/12 9.61x10-4 
Regulation of 
complement cascade 
23/135 1.11x10-16 6.66x10-15 35/42 0.003 
Complement cascade 24/146 1.11x10-16 6.66x10-15 57/71 0.006 
Binding and uptake of 
ligands by scavenger 
receptors 
20/129 2.22x10-16 9.99x10-15 17/33 0.003 
Initial triggering of 
complement 




15/95 1.03x10-12 3.09x10-11 2/2 1.60x10-4 
Creation of C4 and C2 
activators 
15/103 3.20x10-12 3.09x10-11 2/2 1.60x10-4 
FCGR activation 14/101 3.32x10-11 7.31x10-10 6/6 4.8x10-4 
CD22 mediated BCR 
regulation 




Role of phospholipids in 
phagocytosis 
14/114 1.59x10-10 2.85x10-9 5/12 9.61x10-4 
FCERI mediated Ca+2 
mobilisation 
14/117 2.21x10-10 3.54x10-9 5/11 8.81x10-4 
FCERI mediated MAPK 
activation 
14/119 2.75x10-10 4.12x10-9 9/20 0.002 
Role of LAT2/NTAL/LAB 
on calcium mobilisation 
13/102 4.73x10-10 6.62x10-9 2/7 5.61x10-4 
Haemostasis 31/723 5.42x10-10 7.04x10-9 24/327 0.026 
Antigen activates B cell 
receptor (BCR) leading 
to generation of second 
messengers 
12/95 2.5x10-9 3x10-8 10/25 0.002 
Regulation of actin 
dynamics for phagocytic 
cup formation 




14/175 3.44x10-8 3.44x10-7 17/42 0.003 
Cell surface interactions 
at the vascular wall 
16/246 5.87x10-8 5.87x10-7 3/64 0.005 
FCERI mediated NF-kB 
activation 




Fc epsilon receptor 
(FCERI) signaling 
14/218 4.82x10-7 4.32x10-6 22/63 0.005 
Platelet degranulation 11/128 5.40x10-7 4.32x10-6 3/11 8.81x10-4 
Response to elevated 
platelet cytosolic Ca2+ 
11/133 7.82x10-7 6.26x10-6 3/14 0.001 
Signaling by the B Cell 
Receptor (BCR) 
12/176 1.79x10-6 1.25x10-5 13/43 0.003 
Innate Immune System 33/1186 3.81x10-6 2.67x10-5 108/696 0.056 
Post-translational 
protein phosphorylation 











Table 5.4: Ten most overrepresented pathways according to Reactome analysis (ordered according to p-value size) where REL/PRE at least 
doubled. 
Pathway Name Entities found p-value for entities 
found 




3/111 9.22x10-6 7.37x10-4 3/46 0.004 
Cytokine Signalling in 
Immune system 
4/954 2.3x10-4 0.009 5/699 0.056 
Signaling by Interleukins 3/456 6.1x10-4 0.016 4/490 0.039 
Transcriptional 
activation of cycle 
inhibitor p21 
1/4 0.002 0.028 1/5 4x10-4 
Transcriptional 
activation of p53 
responsive genes 
1/4 0.002 0.028 1/5 4x10-4 
TFAP2 (AP-2) family 
regulates transcription 
of cell cycle factors 
1/5 0.002 0.028 1/5 4x10-4 
RUNX3 regulates 
CDKNIA transcription 
1/7 0.003 0.032 2/6 4.8x10-4 
TP53 Regulates 
transcription of genes 
involved in G1 cell cycle 
arrest 





targets in the cytosol 
1/14 0.006 0.032 1/9 7.21x10-4 
FOXO-mediated 
transcription of cell 
cycle genes 







Figures 5.5A, 5.5B, and 5.6 show STRING diagrams (https://string-db.org/) 
summarising the total protein changes for those proteins which either doubled 
(Figure 5.5A), halved (Figure 5.5B) or either halved or doubled (Figure 5.6) in the 
REL compared to PRE ratio. There were significantly more protein-protein 
interactions (PPI) than would be randomly expected (p<1.0x10-16), and the 
diagrams indicate the potential interactions which may be occurring in vivo 
when in the contracting state. Analysis of the total proteins which at least halved 
in the spontaneously contracting state (REL/PRE) indicated changes of proteins 
involved in the complement and coagulation, with 11 of 74 proteins halving in 
the REL group compared with the PRE (Figure 5.7). These 11 proteins were: 
coagulation factor XI, antithrombin III, heparin cofactor II, α1-antitripsin, 
α2=antiplasmin, complement factor I, complement component 2, complement 
component 3, complement component 6 and complement component 8 
subunit α.  
For those proteins that at least doubled in all three samples, Reactome analysis 
indicated that the most overrepresented pathway was Interleukin-4 and 
Interleukin-13 signalling, followed by cytokine signalling in the immune system. 
Table 5.4 shows the 10 pathways which Reactome highlighted as being the most 
overrepresented according to the Reactome statistical analysis as described 




(REL/PRE ratio = 0.175)  and Putative Heat Shock protein beta4 (REL/PRE ratio = 







Figure 5.5: STRING diagram (https://string-db.org/) depicting protein-protein interactions between proteins differently expressed between 
the REL and PRE (REL/PRE) conditions. Proteins shown in A. have 2-fold higher expression in REL than in PRE. Proteins shown in B. have 2-fold higher 





Figure 5.6: STRING diagram summarising the total protein data for those proteins which either at least doubled or halved in the REL 
condition compared with PRE (REL/PRE) for samples taken from all three women(https://string-db.org/) . Both groups have significantly more 





Figure 5.7: Proteins which at least halve between the pre-contracting state (PRE) and contracting state (SP-REL) highlighted in red within the 
Coagulation and Complement Cascade (produced using KEGG software, false discovery rate of p=4.21e-23. F11 = Coagulation Factor XI (Gene name (GN) 
= F11); AT3 = Antithrombin III (GN=SERPINC1); HCII = Heparin cofactor II (SERPIND1); A1AT = Alpha-1-antitrypsin (SERPINA1); α2AP = alpha-2-antiplasmin 
(GN=SERPINF2); A2M = Alpha-2-macroglobulin (GN=A2M); FI = Complement factor I (GN=CF1); C3 = Complement component 3 (GN = C3); C2 = Complement 








Figure 5.8: STRING diagram summarising the proteins for which there were phosphorylation events observed in all three samples and which 
either at least doubled or halved in the REL condition compared with PRE (REL/PRE) for samples taken from all three women (https://string-




5.6.4.4 Part 1 phosphopeptides 
There were many phosphorylation events observed. Table 5.5 shows the 
number of phosphopeptides measured for each woman and the number that 
mapped to one (i.e. unique) master protein according to the sequence. Two 
phosphopeptides at least halved between the pre-contracting condition and 
spontaneously contracting state (REL/PRE) in all three samples (Table 5.6), and 
three doubled (Table 5.7). Specifically, phosphorylation of neuroblast 
differentiation-associated protein AHNAK (AHNAK) at Serine 5552, and 
phosphorylation of 182 kDa tankyrase-1-binding protein at Serine 1297 were at 
least halved in the SP-REL condition compared with PRE; and phosphorylation of 
Filamin-A at Serine 968, phosphorylation of Leiomodin-1 at Serine 555, and 
phosphorylation of DYSL3 protein at  Serine 518, Serine 522 and Threonine 514, 
all doubled in the REL condition compared with PRE. Of note, none of these 
phosphorylation sites were found to be significantly different between the failed 
IOL group and ELSCS group in part 2, although other phosphorylation events 
were significantly different on some of these same proteins.  
Figure 5.8 is a STRING diagram (https://string-db.org/) summarising the proteins 
for which there were phosphorylation events observed in all three samples 
which either at least doubled or halved in the REL condition compared with PRE 




more protein-protein interaction (PPI) than expected (p<1.0-16), indicating the 
potential interactions that may occur in vivo, and particularly highlighting a 




Table 5.5: number of phosphopeptides detected, number of which had a unique master protein, and number of related phosphoproteins. 
Sample label Number phosphopeptides detected Number with unique master protein, and 
therefore used in analysis 
Number of related phosphoproteins 
565  56 299 3 172 1232 
592 101 873 5 291 1 488 
604 56 932 4997 1 648 
 
 
Table 5.6: Phosphorylation events where REL/PRE ratio at least halved for all three women. 








AHNAK Q09666 gPAFNmAsPESDFGINLk Serine 5552 0.201 0.175 
0.276 
0.456 








Table 5.7: Phosphorylation events where REL/PRE at least doubled for all three women. 
Protein description Gene Accession Sequence Site 565 592 604 
Filamin-A FLNA P21333 sPFSVAVSPsLDLSk Serine 968 3.114 2.094 2.097 





















5.7 Part 2 background and results 
5.7.1 Background 
The rationale behind this part of the study was to determine if there are inherent 
differences between the proteomic profile of the myometrium of women who 
fail to progress following IOL and are delivered via emergency caesarean section 
and women who have an elective caesarean section. A better understanding of 
this could result in better selection of women for recommendation for induction 
of labour, potentially an improved or tailored forms of induction, and also it 
could indicate which myometrial processes and pathways are important for 
labour and vaginal delivery. The majority of the experimental stages for Part 2 
were performed during this PhD by the thesis author, including recruitment, 
processing of myometrial samples, and Myobath II experiments. However, three 
of the six Myobath II experiments were performed with support from Dr Hudson. 
All protein extraction for phosphoproteomics and all analysis of data was 
performed solely by the thesis author, with support from Dr Heesom’s group.  
5.7.2 Inclusion criteria for the failed IOL group 
• Induction of labour for non-fetal/maternal concerns 
• Non-smoker 
• No maternal infection 




5.7.3 Inclusion criteria ECS group 
• Elective caesarean section for non-fetal/maternal concerns 
• Non-smoker 
• Term pregnancy (>37 weeks’ gestation) 
5.7.4 Exclusion criteria 
• Pre-term pregnancy 
• Maternal infection 
• Maternal or fetal disease 
5.7.5 Part 2 results  
5.7.5.1 Participants’ characteristics 
There were three women in each group. Table 5.8 shows the participant 
demographics for Part 2, with three women in each group. Of note, all the 
women in the induction of labour group were induced for post-term, all were in 
their first pregnancy and all have subsequently had another pregnancy for which 
they had an ECS. All the ECS group had previously had one pregnancy and all 
three had laboured to fully dilated: two had a normal vaginal delivery and one 
had a trial of forceps but converted to caesarean section as malposition of baby 
and fetal bradycardia. This is important as shows that the myometrium in the 
ECS group had all previously laboured to full dilatation and did not have failure 




and previous third-degree perineal tear. The gestational age at delivery was 
different between the two groups, and this is likely because ECS are routinely 
conducted between 39 and 40 completed weeks’ gestation, whereas all of the 
failed IOL group were induced for post-dates, which is routinely offered from 40 
weeks and 12 days gestation at St Michael’s Hospital. The IOL procedure for all 
three women in the IOL group was with vaginal prostaglandins followed by 
artificial rupture of membranes and intravenous infusion of oxytocin, as per 
local protocols. All three women had an emergency caesarean section in labour: 
one women failed to progress beyond 3 cm dilatation and there was fetal 
distress; one failed to progress beyond 6 cm ; and the other failed to progress 

















ECS group p-value 
Age at Recruitment 
(years) 




BMI 24.6 a 26.2a NS  
(20-32.7) (20-29.2) 
 
PMH Nil NIL NA     
Gravida 1b 3 b NS  
(1-3) (2-4) 
 





Alcohol during pregnancy NIL NIL NA     
Ethnicity ALL WE ALL WE NA 
Smoking during pregnancy NIL 2 NIL NS   
1 3/day 
 
Indication for induction Post-term NA NA 




Uterotonic given at 
delivery 
3 Carbetocin 3 Carbetocin NA 
Gestational age at 
delivery 




Maternal complications NIL NIL NA 
Birthweight 3.7 a 3.4 a NS  
(2.44-4.18) (3.3-3.6) 
 
Baby sex  3 M  1 F 
2 M 
NA 
aMean ;   bMedian;   BMI=Body Mass Index; PMH=Past Medical History; CS=Caesarean Section; 
WE=White European; PP = Placenta Praevia; MR=Maternal Request; PTDT=Previous Third 
Degree Tear; F=Female; M=Male 
 
5.7.5.2 Part 2 total proteins 
The phosphoproteomics results are presented below. Unfortunately, three 




women one of the conditions did not have a sample. One woman had no sample 
for PRE, one no sample for SP-CON and one no sample for OXT-CON. 
In the pre-contracting (PRE) group: the mean concentration of 68 proteins at 
least doubled in the failed IOL group (n=3) compared with the ECS group (n=3), 
and 13 of these were significant (p≤0.05) (Table 5.9); and the mean 
concentration of 76 of the total proteins at least halved in the failed IOL group, 
and 19 of these were significant (p≤0.05) (Table 5.10). Figure 5.9 presents these 
results in a volcano plot.  
In the spontaneously contracting peak relaxation (SP-REL) group: the mean 
concentration of 89 proteins at least doubled in the failed IOL group (n=3) 
compared with the ECS group (n=3), and 33 of these were significant at the 
p<0.05 threshold (see Table 5.11); the mean concentration of 84 proteins at 
least halved in the failed IOL group, and 23 of these were significant (see Table 
5.12). Figure 5.10 presents these results in a volcano plot.  
In the spontaneously contracting peak contraction (SP-CON) group: the mean 
concentration of 100 proteins at least doubled in the failed IOL group (n=3) 
compared with the ECS group (n=2), and 29 of these were significant (see Table 
5.13); while the mean concentration of 57 at least halved in the failed IOL group, 
and 16 of these were significant (see Table 5.14). Figure 5.11 presents these 




In the OXT-stimulated contracting sample taken at maximal relaxation (OXT-REL) 
group: the mean concentration of 122 proteins at least doubled in the failed IOL 
group (n=3) compared with the ECS group (n=3), and 35 of these were significant 
(see Table 5.15); the mean concentration of 124 proteins at least halved in the 
failed IOL group, and 14 of these were significant (see Table 5.16). Figure 5.12 
presents these results in a volcano plot.  
In the OXT-stimulated contracting sample taken at maximum contraction (OXT-
CON) group: the mean concentration of 84 proteins at least doubled in the failed 
IOL group (n=3) compared with the ECS group (n=2), and 18 of these were 
significant (see Table 5.17); and the mean concentration of 170 proteins at least 
halved in the failed IOL group, and 20 of these were significant (see Table 5.18). 
Figure 5.13 presents these results in a volcano plot. 
The most significant (where p≤0.05) increases in total protein in the failed IOL 
group were seen in the relaxed state, with or without OXT stimulation (SP-REL 
and OXT-REL). Table 5.19 shows the total proteins for which the mean 
concentration at least doubled in the failed IOL group in one or more conditions. 
Matrix Gla protein and Lysl oxidase homolog 2  significantly at least doubled in 
all five conditions; Transforming growth factor-beta-induced protein ig-h3, TNC 
variant protein and Prostacyclin synthase significantly at least doubled in all five 




significantly at least doubled for the failed IOL group in all five conditions other 
than OXT-CON. 
The most significant (p≤0.05) decreases in mean concentration of total protein 
were observed for the failed IOL group in the OXT-stimulated conditions, both 
relaxed (OXT-REL) and contracted (OXT-CON), however not all were significant 
(14/124 and 20/170, respectively). If it is surmised that the myometrium in the 
failed IOL group did not result in adequate coordination of contractions to cause 
effective cervical dilatation, these results could be interpreted as the 
myometrium taken from this group was less responsive to stimulation by OXT 
than the myometrium from the elective CS group. Therefore, these proteins may 
be important for the pathway involved in effective myometrial function in 
induced labour and potentially spontaneous labour. Table 5.20 lists the total 
proteins for which the mean concentration at least halved in the failed IOL group 
in at least two of the five conditions. Membrane metallo-endopeptidase and 
Atrial natriuretic peptide-converting enzyme were significantly at least halved in 
the failed IOL group in all conditions other than OXT-REL; Nuclear receptor 
subfamily 2, isoform CRA_a was significantly at least halved in the failed IOL 
group in all conditions other than OXT-CON; and Peptidyl-prolyl cis-trans 
isomerase-like 3 was significantly at least halved in the failed IOL group in all 




Activating signal co-integrator 1 complex subunit 2, Endosialin, and Epididymis 
secretory protein Li 45 all significantly at least halved in the failed IOL group in 
three out of five of the conditions compared with the ECS group. MHC class I 
antigen, CDC42 effector protein (Rho GTPas binding) 4 isoform CRA_a, 
Selenium-binding protein 1, Scavenger receptor class A member 5 and Tubulin 
polymerization-promoting protein family member 3 were all significantly at 
least halved in two of the conditions.  
 
Table 5.9: Total proteins which significantly at least doubled in the failed IOL group under 
the PRE condition (significant at p ≤ 0.05). 
Protein Log2-FC p-value 
Keratin, type I cytoskeletal 10  1.030 0.021 
Protein S100-A9  1.047 0.019 
Immunoglobulin heavy variable 3-35 (non-functional) 
(Fragment)  
1.081 0.027 
Quinone oxidoreductase  1.090 0.040 
GCT-A3 light chain variable region (Fragment)  1.151 0.036 
MHC class I antigen  1.190 0.048 
Uncharacterized protein  1.212 0.007 
Polypeptide N-acetylgalactosaminyltransferase  1.322 0.021 
Connective tissue growth factor  1.338 0.011 
Lysyl oxidase homolog 2  1.422 0.006 
Phospholipid transfer protein, isoform CRA_c  1.926 0.004 
Prostaglandin G/H synthase 1  2.522 0.019 





Table 5.10: Total proteins which significantly at least halved in the failed IOL group under 
the PRE condition (significant at p ≤ 0.05). 
Protein Description Log2-fold 
change 
p-value 
Membrane metallo-endopeptidase  -2.010 0.018 
EF hand domain family, member D1 variant (Fragment)  -1.915 0.014 
Atrial natriuretic peptide-converting enzyme  -1.555 0.028 
Calcitonin receptor-like, isoform CRA_a  -1.432 0.022 
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5  -1.300 0.013 
Epididymis secretory protein Li 45  -1.293 0.029 
Gamma-glutamyltransferase 5  -1.278 0.045 
Aminopeptidase  -1.265 0.042 
Nuclear receptor subfamily 2, group F, member 2, isoform CRA_a  -1.207 0.015 
Guanine nucleotide-binding protein subunit gamma  -1.202 0.041 
cDNA FLJ55809  -1.124 0.012 
Activating signal cointegrator 1 complex subunit 2  -1.091 0.022 
MHC class I antigen (Fragment)  -1.090 0.027 
MHC Class I antigen (Fragment)  -1.080 0.040 
Acyl-CoA synthetase short-chain family member 3, mitochondrial  -1.075 0.002 
Choline/ethanolamine kinase  -1.032 0.018 
Protein ABHD11  -1.029 0.041 
Podocalyxin  -1.017 0.015 











Figure 5.9: Volcano plot comparing change in log2-fold change in total protein between 
failed IOL and ECS groups in the pre-contracting condition. Volcano plot illustrating the 
mean log2-fold change in total protein between the failed IOL group (n=3) and the ECS group 
(n=3) (IOL/elcs) (x-axis) plotted against the –log10(p-value) (y-axis) in the pre-contracting 
condition. Horizontal dashed red line indicates p=0.05, above which differences between 
the failed IOL group and ECS group are significant; two vertical red dashed lines indicate 
halving and doubling between the failed IOL and ECS groups. Dot colour scheme: Black = 
non-significant and neither halved nor doubles; grey = either halved or doubled but not 
significant; orange = significant difference but neither halved nor doubles; red = significant 




Table 5.11: Total proteins which at least doubled in the failed IOL group and were significant at p<0.05 threshold in the SP-REL condition. 
Protein Log2-FC p-value 
Follistatin-related protein 1  1.007 0.002 
Tropomyosin alpha-4 chain (Fragment)  1.044 0.002 
Chromosome 1 open reading frame 24, isoform CRA_a  1.085 0.004 
Lactadherin  1.130 0.029 
Solute carrier family 25 member 4 isoform 1 (Fragment)  1.147 0.048 
Myosin-reactive immunoglobulin heavy chain variable  region(Fragment)  1.182 0.028 
Collagen alpha-1(XII) chain  1.183 0.039 
Insulin-like growth factor-binding protein 7  1.209 0.016 
Fibulin-1 1.245 0.016 
Inter-alpha (Globulin) inhibitor H2, isoform CRA_a  1.269 0.002 
Fibulin-1  1.273 0.008 
Ubiquitin-like protein ISG15 1.303 0.017 
Prostacyclin synthase (Fragment)  1.316 0.027 
Inter-alpha-trypsin inhibitor heavy chain H1  1.347 0.017 
Phospholipid transfer protein, isoform CRA_c  1.350 0.037 
Interferon-induced protein with tetratricopeptide repeats 1  1.351 0.018 
OX-2 membrane glycoprotein  1.419 0.017 




Lysyl oxidase homolog 2  1.676 0.003 
cDNA FLJ90373 fis, clone NT2RP2004606, highly similar to Metalloproteinase inhibitor 1  1.760 0.028 
Polypeptide N-acetylgalactosaminyltransferase  1.862 0.035 
Uncharacterized protein DKFZp686F13142  1.910 0.005 
Connective tissue growth factor  1.931 0.027 
Calmodulin regulator protein PCP4  2.009 0.039 
Pentraxin-related protein PTX3  2.082 0.007 
Matrix Gla protein  2.509 0.025 
Thrombospondin 1, isoform CRA_a  2.556 0.023 
TNC variant protein (Fragment)  2.559 0.007 
Transforming growth factor-beta-induced protein ig-h3  2.636 0.012 
Serpin peptidase inhibitor, clade E (Nexin, plasminogen activator inhibitor type 1), member 1, isoform CRA_b  3.002 0.003 
Serpin peptidase inhibitor, clade E (Nexin, plasminogen activator inhibitor type 1), member 2, isoform CRA_b  3.029 0.003 
cDNA FLJ78437, highly similar to Homo sapiens cartilage oligomeric matrix protein (COMP), mRNA  3.080 0.039 








Table 5.12: Total proteins which at least halved in the failed IOL group and were significant 
at p<0.05 threshold in the SP-REL condition. 
Protein description Log2-FC p-value 
Membrane metallo-endopeptidase -2.205 0.034 
Tubulin polymerization-promoting protein family member 3  -1.926 0.018 
MHC class I antigen  -1.834 0.016 
HCG1773630  -1.811 0.040 
Fatty acid-binding protein, epidermal  -1.717 0.019 
Aldehyde oxidase  -1.663 0.024 
Endosialin  -1.648 0.008 
Selenium-binding protein 1  -1.562 0.002 
Myomegalin  -1.560 0.043 
Scavenger receptor class A member 5  -1.507 0.027 
ASPA protein (Fragment)  -1.389 0.037 
Peptidyl-prolyl cis-trans isomerase-like 3  -1.382 0.024 
Nuclear receptor subfamily 2, group F, member 2, isoform CRA_a  -1.375 0.019 
Insulin-like growth factor-binding protein 5  -1.214 0.023 
Epididymis secretory protein Li 45  -1.147 0.013 
cDNA, FLJ95861, highly similar to Homo sapiens Meis1, myeloid ecotropic 
viral integration site 1homolog (mouse) (MEIS1), mRNA  
-1.144 0.004 
Pleckstrin homology domain-containing family A member 5  -1.127 0.036 
3-hydroxybutyrate dehydrogenase, type 2, isoform CRA_b  -1.114 0.003 
StAR-related lipid transfer protein 5  -1.042 0.008 
Cadherin 11, type 2, OB-cadherin (Osteoblast)  -1.033 0.003 
Parathymosin  -1.022 0.038 
Atrial natriuretic peptide-converting enzyme  -1.010 0.025 
cDNA, FLJ92910, highly similar to Homo sapiens programmed cell death 4 











Figure 5.10: Volcano plot illustrating the log2-fold change in total protein between the 
failed IOL and ECS group in the spontaneously contracting group at peak relaxation. Volcano 
plot illustrating the mean log2-fold change in total protein between the failed IOL group 
(n=3) and the ECS group (n=3) (IOL/elcs) (x-axis) plotted against the –log10(p-value) (y-axis) 
in the spontaneously contracting group snap frozen at peak relaxation. Horizontal dashed 
red line indicates p=0.05, above which differences between the failed IOL group and ECS 
group are significant; two vertical red dashed lines indicate halving and doubling between 
the failed IOL and ECS groups. Dot colour scheme: Black = non-significant and neither halved 
nor doubles; grey = either halved or doubled but not significant; orange = significant 








Table 5.13: Total proteins which at least doubled in the failed IOL group and were significant 





Actin alpha cardiac muscle 1 (Fragment)  1.003 0.034 
Rho GTPase-activating protein 45  1.031 0.032 
Inter-alpha (Globulin) inhibitor H2, isoform CRA_a  1.039 0.048 
Lambda-chain (AA -20 to 215)  1.064 0.046 
Solute carrier family 25 member 4 isoform 1 (Fragment)  1.092 0.037 
NADH:ubiquinone oxidoreductase MLRQ subunit homolog, isoform CRA_a  1.136 0.008 
Prostacyclin synthase (Fragment)  1.176 0.015 
Protein S100-A12  1.188 0.025 
Latent-transforming growth factor beta-binding protein 2  1.189 0.041 
Connective tissue growth factor  1.238 0.020 
Lysozyme C  1.279 0.012 
Collagen alpha-1(XII) chain  1.298 0.034 
[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, 
mitochondrial  
1.299 0.023 
Protein S100-A8  1.370 0.006 
Myosin-reactive immunoglobulin light chain variable region (Fragment)  1.378 0.011 
ASPN protein  1.401 0.036 
Polypeptide N-acetylgalactosaminyltransferase  1.490 0.007 
Lysyl oxidase homolog 2  1.554 0.020 
Serpin peptidase inhibitor, clade E (Nexin, plasminogen activator inhibitor type 
1), member 2, isoform CRA_b  
1.568 0.022 
Protein S100-A9  1.613 0.011 
Calmodulin regulator protein PCP4  1.622 0.028 
Serpin peptidase inhibitor, clade E (Nexin, plasminogen activator inhibitor type 
1), member 1, isoform CRA_b  
1.730 0.021 
Myosin-reactive immunoglobulin heavy chain variable region (Fragment)  1.780 0.008 
Thrombospondin 1, isoform CRA_a  1.870 0.024 
Biglycan (Fragment)  2.075 0.034 




Transforming growth factor-beta-induced protein ig-h3  2.199 0.024 
Matrix Gla protein  2.350 0.026 






Table 5.14: Total proteins which at least halved in the failed IOL group and were significant 
at p<0.05 threshold in the SP-CON condition. 
Protein description Log2-FC p-value 
MHC class I antigen (Fragment)  -2.576 0.049 
Membrane metallo-endopeptidase  -2.080 0.035 
MHC class I antigen  -2.078 0.006 
Ephrin-B1  -1.838 0.022 
Peptidyl-prolyl cis-trans isomerase-like 3  -1.609 0.012 
Four and a half LIM domains protein 5  -1.564 0.018 
Epididymis luminal protein 57  -1.554 0.038 
Epididymis secretory protein Li 45  -1.467 0.003 
NAD(P)H dehydrogenase [quinone] 1  -1.360 0.045 
Scavenger receptor class A member 5  -1.298 0.027 
Fatty acid-binding protein, epidermal  -1.285 0.047 
Aldehyde oxidase  -1.212 0.013 
Selenium-binding protein 1  -1.109 0.020 
Atrial natriuretic peptide-converting enzyme  -1.090 0.007 
SAM and SH3 domain-containing protein 1  -1.088 0.028 


















Figure 5.11: Volcano plot of comparing log2-fold change in total protein between the failed 
IOL group and ECS group in the spontaneously contracting group at peak contraction. 
Volcano plot illustrating the mean log2-fold change in total protein between the failed IOL 
group (n=3) and the ECS group (n=2) (IOL/elcs) (x-axis) plotted against the –log10(p-value) 
(y-axis) in the spontaneously contracting group snap frozen at peak contraction. Horizontal 
dashed red line indicates p=0.05, above which differences between the failed IOL group and 
ECS group are significant; two vertical red dashed lines indicate halving and doubling 
between the failed IOL and ECS groups. Dot colour scheme: Black = non-significant and 
neither halved nor doubles; grey = either halved or doubled but not significant; orange = 
significant difference but neither halved nor doubles; red = significant difference and either 






Table 5.15: Total proteins which at least doubled in the failed IOL group and were significant 
at p<0.05 threshold in the OXT-REL condition. 
Protein Log2-FC p-
value 
Monocarboxylate transporter 2  1.002 0.006 
Follistatin-related protein 1 1.044 0.034 
Nuclear envelope protein okuribin  1.057 0.034 
Tropomyosin alpha-4 chain (Fragment)  1.091 0.017 
Thrombospondin-3  1.116 0.024 
Probable phospholipid-transporting ATPase IIA 1.122 0.026 
Secreted protein, acidic, cysteine-rich (Osteonectin), isoform CRA_a  1.132 0.024 
cDNA FLJ46731 fis, clone TRACH3019621, highly similar to UDP-N-
acetylglucosamine--dolichyl-phosphate N- 
acetylglucosaminephosphotransferase (EC 2.7.8.15)  
1.140 0.040 
Anaphase-promoting complex subunit 5  1.149 0.043 
Microfibril-associated glycoprotein 4 1.166 0.016 
Fibroleukin  1.171 0.013 
Protein CYR61  1.184 0.049 
OX-2 membrane glycoprotein  1.186 0.030 
Cysteine-rich motor neuron 1 protein  1.214 0.003 
Chromosome 1 open reading frame 24, isoform CRA_a  1.307 0.037 
Neurofilament light polypeptide isoform 2 (Fragment)  1.329 0.033 
Prostacyclin synthase (Fragment)  1.368 0.002 
Alcohol dehydrogenase 1B  1.389 0.033 
Filamin-A (Fragment)  1.414 0.024 
Inter-alpha-trypsin inhibitor heavy chain H1  1.420 0.019 
Inter-alpha (Globulin) inhibitor H2, isoform CRA_a 1.425 0.011 
Lysyl oxidase homolog 2  1.435 0.034 
Polypeptide N-acetylgalactosaminyltransferase  1.440 0.003 
cDNA FLJ90373 fis, clone NT2RP2004606, highly similar to 
Metalloproteinase inhibitor 1  
1.851 0.003 
Diphosphoinositol polyphosphate phosphohydrolase 3-alpha  2.005 0.038 




TNC variant protein (Fragment)  2.091 0.021 
Pentraxin-related protein PTX3  2.112 0.019 
Transforming growth factor-beta-induced protein ig-h3  2.148 0.042 
Cytochrome b5 type B (Fragment) 2.211 0.010 
Serpin peptidase inhibitor, clade E (Nexin, plasminogen activator inhibitor 
type 1), member 1, isoform CRA_b  
2.577 0.013 
Matrix Gla protein  2.739 0.016 
Thrombospondin-1  2.752 0.034 
Thrombospondin-4  3.192 0.018 
cDNA FLJ78437, highly similar to Homo sapiens cartilage oligomeric matrix 





Table 5.16: Total proteins which at least halved in the failed IOL group and were significant 
at p<0.05 threshold in the OXT-REL condition. 
Protein description Log2-FC p-value 
MHC class I antigen (Fragment)  -5.499 0.013 
Platelet membrane glycoprotein Ib beta  -1.823 0.018 
Peptidyl-prolyl cis-trans isomerase-like 3  -1.707 0.011 
SEC14-like 2 (S. cerevisiae), isoform CRA_b  -1.616 0.022 
Fatty acid-binding protein, epidermal  -1.467 0.038 
CDC42 effector protein (Rho GTPase binding) 4, isoform CRA_a  -1.451 0.021 
Tubulin polymerization-promoting protein family member 3  -1.397 0.024 
Endosialin  -1.295 0.000 
Nuclear receptor subfamily 2, group F, member 2, isoform CRA_a -1.214 0.004 
Cytosolic 5'-nucleotidase 3A -1.189 0.008 
6-phosphogluconate dehydrogenase, decarboxylating  -1.187 0.003 
Activating signal cointegrator 1 complex subunit 2  -1.108 0.026 
cGMP-dependent 3',5'-cyclic phosphodiesterase -1.093 0.041 
cDNA, FLJ92910, highly similar to Homo sapiens programmed cell death 4 




















Figure 5.12: Volcano plot of change in total protein between the failed IOL and ECS groups 
in the oxytocin-stimulated group at peak relaxation. Volcano plot illustrating the mean log2-fold 
change in total protein between the failed IOL group (n=3) and the ECS group (n=3) (IOL/elcs) (x-axis) 
plotted against the –log10(p-value) (y-axis) in the oxytocin-stimulated group snap frozen at peak 
relaxation. Horizontal dashed red line indicates p=0.05, above which differences between the failed 
IOL group and ECS group are significant; two vertical red dashed lines indicate halving and doubling 
between the failed IOL and ECS groups. Dot colour scheme: Black = non-significant and neither halved 
nor doubles; grey = either halved or doubled but not significant; orange = significant difference but 






Table 5.17: Total proteins which at least doubled in the failed IOL group and were significant 
at p<0.05 threshold in the OXT-CON condition. 
Protein Log2-FC p-value 
ATP synthase protein 8  1.067 0.023 
Fibulin-1  1.075 0.016 
Aldehyde dehydrogenase X, mitochondrial  1.089 0.032 
Metallothionein-2  1.111 0.034 
Keratin 16  1.192 0.025 
Zinc transporter 7  1.199 0.039 
HBV PreS1-transactivated protein 1  1.253 0.024 
Lysyl oxidase homolog 2  1.282 0.045 
Thrombospondin-3  1.297 0.019 
Prostacyclin synthase (Fragment)  1.358 0.039 
Septin 6 isoform E  1.389 0.029 
Cyclin-dependent kinase 2-associated protein  1.520 0.002 
Protein unc-13 homolog B  1.695 0.013 
Pentraxin-related protein PTX3  1.770 0.020 
Matrix Gla protein  2.119 0.027 
TNC variant protein (Fragment)  2.348 0.025 
Transforming growth factor-beta-induced protein ig-h3  2.526 0.034 




Table 5.18: Total proteins which at least halved in the failed IOL group and were significant 
at p≤0.05 threshold in the OXT-CON condition. 
Protein description Log2-FC p-value 
MHC class I antigen  -3.402 0.039 
MHC class I antigen  -2.311 0.026 
Membrane metallo-endopeptidase  -2.056 0.047 
cDNA FLJ55606, highly similar to Alpha-2-HS-glycoprotein -1.614 0.025 
Pregnancy-specific beta-1-glycoprotein 1 -1.564 0.025 
Peptidyl-prolyl cis-trans isomerase-like 3  -1.454 0.009 
Transferrin variant (Fragment)  -1.399 0.003 
Aldehyde oxidase  -1.338 0.015 
Serum albumin  -1.308 0.043 
F-box/WD repeat-containing protein 5 -1.285 0.048 
Atrial natriuretic peptide-converting enzyme  -1.231 0.024 
CDC42 effector protein (Rho GTPase binding) 4, isoform CRA_a  -1.194 0.016 
Beta-2-microglobulin  -1.182 0.042 
Endosialin -1.177 0.003 
Alpha-1-antitrypsin  -1.159 0.043 
Pirin  -1.138 0.002 
Acid sphingomyelinase-like phosphodiesterase 3a  -1.138 0.016 
cDNA FLJ53691, highly similar to Serotransferrin  -1.128 0.035 
Testicular secretory protein Li 41 -1.050 0.044 





Figure 5.13: Volcano plot of change in total protein between the failed IOL and ECS group 
in the oxytocin-stimulated group at peak contraction. Volcano plot illustrating the mean 
log2-fold change in total protein between the failed IOL group (n=3) and the ECS group (n=2) 
(IOL/elcs) (x-axis) plotted against the –log10(p-value) (y-axis) in the oxytocin-stimulated group 
snap frozen at peak contraction. Horizontal dashed red line indicates p=0.05, above which 
differences between the failed IOL group and ECS group are significant; two vertical red 
dashed lines indicate halving and doubling between the failed IOL and ECS groups. Dot colour 
scheme: Black = non-significant and neither halved nor doubles; grey = either halved or 
doubled but not significant; orange = significant difference but neither halved nor doubles; 






Table 5.19: Proteins which significantly (p<0.05) at least double in the failed IOL group for at least two of the conditions. 









Matrix Gla protein  MGP  P08493 ✓ ✓ ✓ ✓ ✓ 
Lysyl oxidase homolog 2  LOXL2 Q9Y4K0 ✓ ✓ ✓ ✓ ✓ 
Polypeptide N-acetylgalactosaminyltransferase   B3KNV8 ✓ ✓ ✓  ✓ 
Transforming growth factor-beta-induced protein ig-h3  TGFBI  Q15582 ✓ ✓ ✓ ✓  
TNC variant protein (Fragment)  
TNC variant 
protein  Q4LE33 
✓ ✓ ✓ ✓ 
 
Prostacyclin synthase (Fragment)  PGIS Q6LEN0 ✓ ✓ ✓ ✓  
Serpin peptidase inhibitor, clade E (Nexin, plasminogen 
activator inhibitor type 1), member 1, isoform CRA_b  SERPINE1 A0A024QYT5 
✓ ✓ ✓ 
  
Thrombospondin 1, isoform CRA_a  THBS1 A0A024R9Q1 ✓ ✓ ✓   
Inter-alpha (Globulin) inhibitor H2, isoform CRA_a  ITIH2  D3DRR6 ✓ ✓ ✓   
Pentraxin-related protein PTX3 PTX3 P26022 ✓ ✓  ✓  
Thrombospondin-4  THBS4  P35443 ✓ ✓ ✓   
Connective tissue growth factor  CTGF  Q5M8T4 ✓  ✓  ✓ 
Serpin peptidase inhibitor, clade E (Nexin, plasminogen 





Chromosome 1 open reading frame 24, isoform CRA_a C1orf24  A0A024R978 ✓ ✓    
Solute carrier family 25 member 4 isoform 1 (Fragment)  SLC25A4 A0A0S2Z3H3 ✓  ✓   
cDNA FLJ78437, highly similar to Homo sapiens cartilage 
oligomeric matrix protein (COMP), mRNA   A8K3I0 
✓ ✓ 
   
cDNA FLJ90373 fis, clone NT2RP2004606, highly similar to 
Metalloproteinase inhibitor 1   B3KQF4 
✓ ✓ 
   
Phospholipid transfer protein, isoform CRA_c  PLTP  B3KUE5 ✓    ✓ 
Fibulin-1 OS=Homo sapiens   B4DUV1 ✓   ✓  
Tropomyosin alpha-4 chain (Fragment)  TPM4  K7ELP0 ✓ ✓    
Protein S100-A9  S100A9  P06702   ✓  ✓ 




OX-2 membrane glycoprotein  CD200  P41217 ✓ ✓    
Calmodulin regulator protein PCP4  PCP4  P48539 ✓  ✓   
Thrombospondin-3  THBS3 P49746  ✓  ✓  
Follistatin-related protein 1  FSTL1  Q12841 ✓ ✓    
Collagen alpha-1(XII) chain  COL12A1 Q99715 ✓  ✓   
Myosin-reactive immunoglobulin heavy chain variable 

















Table 5.20: Proteins which significantly (p<0.05) at least halved in the failed IOL group for at least two of the conditions. 









Membrane metallo-endopeptidase MME B7ZKY6 ✓ 
 
✓ ✓ ✓ 
Nuclear receptor subfamily 2, group F, member 2, isoform 
CRA_a 
NR2F2 F1D8R0 ✓ ✓ ✓ 
 
✓ 
Peptidyl-prolyl cis-trans isomerase-like 3  PPIL3 Q9H2H8 ✓ ✓ ✓ ✓ 
 
Atrial natriuretic peptide-converting enzyme  CORIN Q9Y5Q5 ✓ 
 
✓ ✓ ✓ 
Fatty acid-binding protein, epidermal   FABP5 Q01469 ✓ ✓ ✓ 
  






















CDC42 effector protein (Rho GTPase binding) 4, isoform 







cDNA, FLJ92910, highly similar to Homo sapiens 
programmed cell death 4 (neoplastic transformation 
inhibitor) (PDCD4), transcript variant 1, mRNA  
 
B2R6E2 ✓ ✓ 
   








Tubulin polymerization-promoting protein family 
member 3  
TPPP3 Q9BW30 ✓ ✓ 
   
Total  
  






5.7.5.3 Study 2 phosphoproteomics 
In the pre-contracting (PRE) group: 8 phosphopeptides at least doubled in the 
failed IOL group (n=3) compared with the ECS group (n=2) (see Table 5.21), none 
of which were significant; and 7 phosphopeptides at least halved in the failed 
IOL group compared with the ECS group (see Table 5.22), and one of these was 
significant. 
In the SP-REL group: 4 phosphopeptides at least doubled in the failed IOL group 
(n=3) compared with the ECS group (n=3) (see Table 5.23), and one was 
significant; and 4 phosphopeptides at least halved in the failed IOL group (see 
Table 5.24), none of which were significant. 
In the SP-CON group: 3 phosphopeptides at least doubled in the failed IOL group 
(n=3) compared with the ECS group (n=2) (see Table 5.25), none of which were 
significant; and 7 at least halved in the IOL group (see Table 5.26), 1 of which 
was significant. 
In the OXT-REL group: 18 phosphopeptides at least doubled in the failed IOL 
group (n=3) compared with the ECS group (n=3) (see Table 5.27), 4 of which 
were significant; and 22 phosphopeptides at least halved in the failed IOL group 




In the OXT-CON group: 9 phosphopeptides at least doubled in the IOL group 
(n=3) compared with the ECS group (n=2) (see Table 5.29), 2 of which were 
significant; and 8 at least halved in the IOL group (see Table 5.30), 2 of which 
were significant. 
Of the phosphopeptides which at least significantly halved or doubled in the 
failed IOL group compared with the ECS group, only one was shared between 
two conditions: Neuroblast differentiation-associated protein AHNAK (AHNAK) 
significantly at least halved in both the PRE and OXT-REL conditions. This 
phosphopeptide also halved in the SP-CON condition, but this was not significant. 
As well as investigating the phosphorylation events which were significantly 
different between the failed IOL group and the ECS group, the phosphorylation 
events which were replicated across more than one condition were also 
investigated, even if not significant, as it may be that if the study had increased 
power these may be significant, and the fact that these changes were seen in 
multiple conditions may indicate inherent differences in the myometrium of the 
failed IOL group. Of all the phosphorylation-events, Table 5.31 shows those 
which at least halved in the failed IOL group under more than one condition, 
although not all were significant at the p≤0.05 level. This shows that 
phosphorylation of Serine 176 on Integrin, alpha 5 (Fibronectin receptor, alpha 




(0.329)) and PRE (-1.698 (0.115)) conditions when compared with the same 
conditions for the ECS group; phosphorylation of Serine 759 cDNA FLI77630, 
highly similar to Homo sapiens BPY2 interacting protein 1, mRNA more than 
halved in both SP-CON and PRE in the failed IOL group; phosphorylation of Serine 
151 of cDNA FLI59374, highly similar to Homo sapiens caldesmon 1, transcript 
variant 2, mRNA at least halved in the failed IOL group in the SP-REL, OXT-REL 
and PRE conditions; Serine 194 phosphorylation of transforming growth factor 
beta-1-induced transcript 1 protein was halved in the failed IOL group under SP-
CON (p<0.05) and OXT-CON; Serine 210 phosphorylation of Neuroblast 
differentiation-associated protein AHNAK more than halved in the failed IOL 
group in SP-CON and PRE conditions; Serine 65 phosphorylation of Transcription 
elongation factor A protein-like 3 was at least halved in the failed IOL group 
under SP-CON and OXT-CON conditions; and phosphorylation jointly of Serine 
1620 and 1621 of 182 kDa tankyrase-1-binding protein was at least halved under 
OXT-REL and OXT-CON conditions. 
Table 5.32 shows those phosphorylation events which at least doubled in the 
failed IOL group under more than one condition, but again not all significant at 
the p≤0.05 level. Phosphorylation of Serine 478 of cDNA FLJ53399, highly similar 
to Monocarboxylate transporter 1 at least doubled in the failed IOL group under 




Filamin-A at least doubled in the failed IOL group under SP-REL (p≤0.05), OXT-
REL and OXT-CON conditions; phosphorylation of Serine 65 of Transcription 
elongation factor A protein-like 3 more than doubled in the failed IOL group 
under OXT-REL (p≤0.05) and PRE conditions; and Serine 384 of Protein Lunapark 





Table 5.21: Phosphorylation events which at least doubled in the failed IOL group in the PRE condition. 
Protein Gene Accessio
n 
Sequence detected Site log 2 fc  p 
value 
Cortactin, isoform CRA_c 
OS=Homo sapiens  
CTTN Q14247 [K].TQTPPVSPAPQPTEER.[L] Threonine 
401 
1.617 0.084 
Protein lunapark  
 
LNP Q9C0E8 [K].ASDSEEPEEK.[Q] Serine 384 1.631 0.096 
Transcription elongation factor A 
protein-like 3  
TCEAL3 Q969E4 
 
[K].REDEGEPGDEGQLEDEGSQEK.[Q] Serine 65 1.115 0.104 




[K].EISDDEAEEEK.[G] Serine 226 1.090 0.397 
cDNA FLJ53399, highly similar to 
Monocarboxylate transporter 1  
 B4E106 
 
[K].DTEGGPKEEESPV.[-] Serine 478 2.181 0.425 
Mutant desmin   A5Z217 
 
[R].TFGGAPGFPLGSPLSSPVFPR.[A] Serine 28  
Serine 32 
1.388 0.543 
Mutant desmin   A5Z217 
 
[R].TSGGAGGLGSLR.[A] Ambiguous 1.025 0.545 
Mutant desmin   A5Z217 
 





Table 5.22: Phosphopeptides which at least halved in the failed IOL group in the PRE condition. 




Integrin, alpha 5 (Fibronectin 
receptor, alpha polypeptide), 
isoform CRA_b  
ITGA5 A0A024RB01 
 
[R].LLESSLSSSEGEEPVEYK.[S] Serine 176 -1.698 0.115 
SAM and SH3 domain-containing 
protein 1 (Fragment) 
SASH1 O94885 
 
[R].EQSDDETEESVK.[F] Serine 248 -1.456 0.209 
Neuroblast differentiation-
associated protein AHNAK  
AHNAK Q09666 
 
[R].LPSGSGAASPTGSAVDIR.[A] Serine 210 -1.425 0.034 
cDNA FLJ59374, highly similar to 
Homo sapiens caldesmon 1 (CALD1), 
transcript variant 2, mRNA  
CALD1 B4DPW5 
 
[K].RGSIGENQIKDEK.[I] Serine 151 -1.205 0.087 
Eukaryotic translation initiation 




[K].NKPGPNIESGNEDDDASFK.[I] Serine 214 -1.186 0.232 
cDNA FLJ77630, highly similar to 
Homo sapiens BPY2 interacting 
protein 1, mRNA  
 A8K940 
 
[K].AVPMAPAPASPGSSNDSSAR.[S] Serine 759 -1.174 0.174 
Nuclear ubiquitous casein and 
cyclin-dependent kinase substrate 1 
OS=Homo sapiens  
NUCKS1 Q9H1E3 
 





Table 5.23: Phosphopeptides which at least doubled in the failed IOL group in the SP-REL condition. 








Filamin-A  FLNA P21333 
 
[K].IPEISIQDMTAQVTSPSGK.[T] Serine 2180 1.550 0.034 
Vacuolar protein sorting-





[K].GSDSDSEGDNPEK.[K] Serine 97 1.032 0.071 
Filamin-A  FLNA P21333 
 
[K].FNEEHIPDSPFVVPVASPSGDAR.[R] Serine 2327 1.600 0.117 
cDNA FLJ53399, highly similar 
to Monocarboxylate 
transporter 1  
 B4E106 
 








Table 5.24: Phosphopeptides which at least halved in the failed IOL group in the SP-REL condition. 
Protein Descriptions Gene 
Nam
e 
Accession Annotated Sequence Site LOG2 
FC 
p value 











Testicular secretory protein Li 7   A0A140VK0
7 
 





cDNA FLJ59374, highly similar to Homo 
sapiens caldesmon 1 (CALD1), transcript 
variant 2, mRNA  
 B4DPW5 
 





Integrin, alpha 5 (Fibronectin receptor, alpha 


















Table 5.25: Phosphopeptides which at least doubled in the failed IOL group in the SP-CON condition. 








28 kDa heat- and acid-stable phosphoprotein  PDAP1 Q13442 
 
[K].KSLDSDESEDEEDDYQQK.[R] Serine 60 
Serine 63  
1.199 2.89E-
01 






[K].EGEEPTVYSDEEEPK.[D] Serine 181  1.491 3.36E-
01 
cDNA FLJ53399, highly similar to Monocarboxylate 
transporter 1  
 B4E106 
 




















Table 5.26: Phosphopeptides which at least halved in the failed IOL group in the SP-CON condition. 
Protein Descriptions Gene 
Name 

















[R].MEMINVSGYVAQEK.[L] Ambiguous -1.473 0.150 
Plectin  PLEC Q15149 
 







[R].LPSGSGAASPTGSAVDIR.[A] Serine 210 -1.095 0.131 
Transforming growth 
factor beta-1-induced 
transcript 1 protein  
TGFB1I1 O43294 
 
[R].VQNHLPASGPTQPPVVSSTNEGSPSPPEPTGK.[G] Serine 194 -1.039 0.010 
Transcription 






[R].EDEGEPGDEGQLEDEGSQEK.[Q] Serine 65 -1.038 0.078 
cDNA FLJ77630, highly 
similar to Homo sapiens 
BPY2 interacting protein 
1, mRNA  
 A8K940 
 







Table 5.27: Phosphopeptides which at least doubled in the failed IOL group in the OXT-REL condition. 




Protein phosphatase 1 regulatory 
subunit 12B  
sm-M20 E1CKY7 
 
[R].LESGGSNPTTSDSYGDR.[A] Serine 43 1.049 0.001 
Synaptopodin 2  SYNPO2 B9EG60 
 
[R].GTGAGGDSGPEEDYLSLGAEACNFMQSSSAK.[Q] Serine 729 1.405 0.029 
SH3 and PX domain-containing 
protein 2A  
SH3PXD2A Q5TCZ1 
 
[K].EAEEGPTGASESQDSPR.[K] Serine 547 1.016 0.031 
Transcription elongation factor A 
protein-like 3  
TCEAL3 Q969E4 [K].REDEGEPGDEGQLEDEGSQEK.[Q] Serine 65 1.205 0.036 





Alpha B crystallin  CRYAB C3VMY8 
 
[R].APSWFDTGLSEMR.[L] Serine 59 1.207 0.087 
Talin-1  TLN1 A0A1S5UZ07 
 
[R].GSQAQPDSPSAQLALIAASQSFLQPGGK.[M] Ambiguous 1.018 0.100 
Membrane-associated 
progesterone receptor 
component 1  
PGRMC1 O00264 
 
[R].GDQPAASGDSDDDEPPPLPR.[L] Serine 57 1.080 0.117 





Synaptopodin 2  SYNPO2 B9EG60 
 
[R].APPPVAYNPIHSPSYPLAALK.[S] Serine 930 1.181 0.146 
Eukaryotic translation initiation 
factor 5B  
EIF5B A0A087WUT6 [K].WDGSEEDEDNSK.[K] Serine 164 2.041 0.160 
Filamin-A  FLNA P21333 [K].IPEISIQDMTAQVTSPSGK.[T] Serine 2180 1.013 0.175 
Neuroblast differentiation-
associated protein AHNAK  
AHNAK Q09666 
 
[R].DDGVFVQEVTQNSPAAR.[T] Serine 41 1.492 0.214 
Microtubule-associated protein 
1B, isoform CRA_b  
MAP1B A0A024RAM4 
 
[K].GEAEQSEEEADEEDKAEDAR.[E] Serine 1016 1.041 0.230 
WD repeat-containing protein 44  WDR44 Q5JSH3 
 
[K].EYVSNDAAQSDDEEKLQSQPTDTDGGR.[L] Serine 403 1.211 0.254 
cDNA FLJ53399, highly similar to 
Monocarboxylate transporter 1  
 B4E106 
 
[K].DTEGGPKEEESPV.[-] Serine 478 1.670 0.279 
Lon protease homolog, 
mitochondrial OS=Homo sapiens 
GN=LONP1 PE=3 SV=1 
LONP1 E5KMI6 
 
[R].MEMINVSGYVAQEK.[L] Serine 659 1.053 0.281 
Filamin-A  FLNA P21333 
 










Gene Name Accession Annotated Sequence Phosphosites LOG2 FC p-value 
Smoothelin  
 





AHNAK Q09666 [R].LPSGSGAASPTGSAVDIR.[A] Ambiguous -1.002 0.04 
Alpha-adducin  ADD1 P35611 [R].KQKGSEENLDEAR.[E] Serine 586 -1.255 0.043 
Serine/threonine-
protein kinase 10  
STK10 O94804 
 
[K].QVAEQGGDLSPAANR.[S] Serine 438 -1.016 0.046 
Plectin PLEC Q15149 [K].GYYSPYSVSGSGSTAGSR.[T] Serine 4626 -1.076 0.059 
Palladin  PALLD Q8WX93 [R].DSGDENEPIQER.[F] Serine 1121 -1.228 0.06 






like protein 1  
PLCL1 Q15111 [K].KLPSDPDVLEGEVTDEDEEAEMSR.[R] Threonine 556 -1.529 0.073 
Epididymis luminal 
protein 113  
HEL113 V9HWE1 [R].QVQSLTCEVDALK.[G] Serine 325 -1.526 0.113 
CDC42 binding 
protein kinase beta 
(DMPK-like), 
isoform CRA_a  




highly similar to 






protein 1, mRNA  
Melanoma antigen 
family D, 2, 
isoform CRA_a  
MAGED2 A0A024R9Y7 [K].HLDGEEDGSSDQSQASGTTGGR.[R] Serine 191 
Serine 194 
-1.099 0.171 




1-binding protein  






 B7Z2A4 [K].VVQEYIDAFSDYANFK.[-] Y 809 -1.368 0.221 










MACF1 H3BQK9 [R].EVEEELATSGGQSPTGEQIPQFQQR.[Q] Serine 5733 -1.679 0.26 
cDNA FLJ59374, 




variant 2, mRNA  
 B4DPW5 [K].RGSIGENQIK.[D] Serine 151 -1.664 0.289 
cDNA FLJ55039, 
moderately similar 











to Sorbin and SH3 
domain-containing 
protein 1  
 B7Z9B7 [R].ASGSFAPISQTPPSFSPPPPLVPPAPEDLR.[R] Serine 440 -1.145 0.451 
Nexilin (F actin 
binding protein), 
isoform CRA_b  
















Table 5.29: Phosphopeptides which at least doubled in the failed IOL group in the OXT-CON condition. 
Protein description Gene 
Name 




Myosin light chain kinase, smooth muscle  MYLK Q15746 [K].DEVEVSDDDEK.[E] Serine 1438 3.393 0.008 
Myosin light chain kinase, smooth muscle  MYLK Q15746 [K].DEVEVSDDDEKEPEVDYR.
[T] 
Serine 1438 2.005 0.019 
Filamin-A  FLNA P21333 [K].IPEISIQDMTAQVTSPSGK.
[T] 
Serine 2180 1.567 0.067 
Protein lunapark  LNP Q9C0E8 [K].ASDSEEPEEK.[Q] Serine 384 1.911 0.114 
Heat shock protein HSP 90-alpha  HSP90AA1 P07900 [R].DKEVSDDEAEEK.[E] Serine 231 1.138 0.117 
Calnexin  CANX P27824 [K].QKSDAEEDGGTVSQEEED
R.[K] 
Serine 564 1.017 0.117 
Epididymis luminal protein 113  HEL113 V9HWE1 [R].SSVPGVR.[L] Serine 73 1.461 0.123 
Small glutamine-rich tetratricopeptide 
repeat-containing protein alpha  
SGTA O43765 [R].TPSASNDDQQE.[-] Serine 305 1.253 0.527 









Table 5.30: Phosphopeptides which at least halved in the failed IOL group in the OXT-CON condition. 
Protein description Gene 
Name 
Accession Annotated sequence Phosphosites Log2-fc p value 
WWC family member 3  WWC3 T2C6S4 [R].SDSDSSTLPR.[K] Serine 1052 -1.473 0.030 
Epididymis luminal protein 
114  
HEL114 V9HWK2 [R].DPSASPGDAGEQAIR.[Q] Serine 288 -1.109 0.049 
182 kDa tankyrase-1-binding 
protein 




factor A protein-like 3  
TCEAL3 Q969E4 [R].EDEGEPGDEGQLEDEGSQEK.[Q] Serine 65 -1.063 0.103 
Rho guanine nucleotide 
exchange factor 12  
ARHGEF12 Q9NZN5 [R].TDCSSGDASRPSSDNADSPK.[S] Serine 309 -1.080 0.116 
Transforming growth factor 
beta-1-induced transcript 1 
protein 
TGFB1I1 O43294 [R].VQNHLPASGPTQPPVVSSTNEGSPS 
PPEPTGK.[G] 
Serine 194 -1.354 0.154 
Myosin light chain kinase, 
smooth muscle  




cDNA FLJ56912, highly 
similar to Fibulin-2  




Table 5.31: Phospho-events which at least significantly halve in the failed IOL group under more than one condition, with log2-fc for each 
condition (where p ≤ 0.05).
 Protein name Gene name Accession Site REL-SP REL-OT CON-SP CON-OT PRE 
Integrin, alpha 5 (Fibronectin receptor, 
alpha polypeptide), isoform CRA_b  
ITGA5 A0A024RB01 Serine 176 -1.139 
(0.329) 
   
-1.698 
(0.115) 
cDNA FLJ77630, highly similar to Homo 
sapiens BPY2 interacting protein 1, mRNA  
 







cDNA FLJ77630, highly similar to Homo 






   
Phosphatidate cytidylyltransferase  
 






cDNA FLJ59374, highly similar to Homo 
sapiens caldesmon 1 (CALD1), transcript 
variant 2, mRNA  







Transforming growth factor beta-1-induced 
transcript 1 protein  








protein AHNAK  








protein AHNAK  




   











   
Transcription elongation factor A protein-
like 3 





















Table 5.32: Phospho-events which at least double in the failed IOL group under more than one condition, with log2-fc for each condition (p-
value). 
Protein name Gene 
name 
Accession Site REL-SP REL-OT CON-SP CON-OT PRE 
cDNA FLJ53399, highly similar to 
Monocarboxylate transporter 1  
 

















Filamin-A  FLNA P21333 Serine 2327 1.6 
(0.117) 
    




   
Transcription elongation factor A protein-
like 3  







Protein lunapark  LNP Q9C0E8 Serine 384 








Figure 5.14A and 5.14B shows STRING diagrams (https://string-db.org/) 
summarising the phosphoproteomic data for proteins for which 
phosphorylation events at least A. double or B. halve, in the failed IOL group 
under the two contracted conditions (SP-CON and OXT-CON). Both groups have 
significantly more protein-protein interaction (PPI) than expected (p<1.0-16). 
Figure 5.15 shows a STRING diagram summarising the phosphoproteomic data 
for proteins for which phosphorylation events at least doubled or halved in the 
failed IOL group under the two contracted conditions (SP-CON and OXT-CON). 
This group has significantly more protein-protein interaction (PPI) than expected 
(p<1.0-16) and this suggests that these proteins may interact in vivo, and in this 
case may be associated with a failed IOL profile. Figure 5.16 shows a String 
diagram summarising the phosphoproteomic data for proteins for which 
phosphorylation events at least A. double or B. halve, in the failed induction of 
labour group under the peak relaxation conditions (SP-REL and OXT-REL). Both 
groups have significantly more protein-protein interaction (PPI) than expected 
(p<1.0-16). Figure 5.17 shows String diagrams summarising the 
phosphoproteomic data for proteins for which phosphorylation events at least 
doubled or halved in the failed IOL group under the peak relaxation conditions 
(SP-REL and OXT-REL). This group has significantly more protein-protein 





Figure 5.14: STRING diagram summarising the phosphoproteomic data for proteins for which phosphorylation events at least A. double or B. halve, in 
the failed induction of labour group under contracted condition (SP-CON and OXT-CON) (https://string-db.org/). Both groups have significantly more 







Figure 5.15: STRING diagram  summarising the phosphoproteomic data for proteins for which phosphorylation events at least double or halve in the failed 
induction of labour group under contracted condition (SP-CON and OXT-CON) (https://string-db.org/). This group has significantly more protein-protein 






Figure 5.16: STRING diagram summarising the phosphoproteomic data for proteins for which phosphorylation events at least A. double or B. halve, in 
the failed induction of labour group at peak relaxation (SP-REL and OXT-REL) (https://string-db.org/). Both groups have significantly more protein-protein 






Figure 5.17: STRING diagram summarising the phosphoproteomic data for proteins for which phosphorylation events at least double or halve in the 
failed induction of labour group at peak relaxation (SP-REL and OXT-REL) (https://string-db.org/). This group has significantly more protein-protein 





This chapters presents novel data on protein distribution and phosphorylation 
in fresh human myometrium. The findings from Part 1 indicates that there are 
differences in the phosphoproteome between the pre-contracting (PRE) and 
contracting state (SP-REL) of human myometrial tissue; and findings from Part 2 
suggests that myometrial proteins and phosphorylation events are differentially 
expressed in women with failed IOL compared with women having an elective 
caesarean section. This could reflect differential myometrial phenotypes. These 
findings have the potential to improve our understanding of the pathways 
involved in spontaneous labour in humans, and have produced a wealth of data 
from which future studies can be launched.  
As discussed in the introduction and throughout the previous chapters, 
suggested hypotheses for the trigger of human parturition include a change in 
balance from a dominantly progesterone environment to one dominated by 
oestrogen, as well as activation of inflammatory pathways.  Progesterone and 
oestrogen appear to have antagonistic effects on the myometrium, and previous 
studies have shown that oestrogen promotes transcription of genes such as 
COX-2 and the OXT receptor (OTr), which stimulate myometrial activity, while 
progesterone stimulates those which result in decreased myometrial activity35. 




in expression of progesterone and oestrogen receptors on uterine myocyte cell 
surfaces at the time of labour97, 100,32. 
5.8.1 Part 1 discussion total proteins 
5.8.1.1 Complement and coagulation pathways 
Overall, in Part 1, 178 proteins at least halved and five at least doubled for all 
three samples under the SP-REL condition compared with the PRE condition 
(REL/PRE). By uploading the list of these proteins to the String software 
programme online, the complement and coagulation pathways were identified 
as having multiple proteins involved. The resultant KEGG diagram from this 
search (Figure 5.6) illustrates these pathways and indicates that 11 of the 74 
identified proteins in the pathway at least halved between REL and PRE.  
This includes CRP, a marker of inflammation and known to be synthesised by 
smooth muscle cells298, which was lower in the SP-REL condition compared with 
the PRE. This could be interpreted as evidence that with contractions comes a 
paradoxical decrease in inflammatory markers, and on initial review this is 
surprising as it may be expected that complement and inflammatory markers 
would increase when the myometrium is contracting. Another explanation for 
this change, and the finding that complement proteins decreased, is that these 
proteins may be catabolised. Sharp et al. (2016)3 took myometrial samples at 




who were not labouring. Samples were snap frozen and stored at -80 degrees 
Celsius. Transcription analysis of these samples showed an increase in 
expression of genes coding for inflammatory markers with active labour along 
with a decrease in genes involved with muscle-specific pathways3. One 
explanation for the difference in the results of the Sharp et al. (2016) study and 
the present study is that the previous researchers measured RNA rather than 
protein. Another potential explanation is that the previous researchers 
processed and snap-froze the myometrium immediately following sample 
collection. Given the labouring myometrium would likely have been under a high 
action and potentially inflammatory response when compared with the 
myometrium from the not-in-labour women, this could have artificially 
heightened the inflammatory response observed in the myometrium from the 
emergency caesarean section group. In contrast, for the present study, the 
myometrium was taken from women at elective caesarean section, and strips 
were allowed to equilibrate in the Myobath-II prior to further experimentation, 
and that was the same for all of the samples. The latter experimental model may 
provide a better representation of the difference in proteins between the pre-
contracting and contracting state. However, a further potential explanation is 
that the PRE condition is not a good representation of pre-contraction, and 




thereby artificially increasing the inflammatory response. Nevertheless, in both 
of these studies the complement and inflammatory pathways appear to be 
important in contraction, and certainly warrant further investigation. 
In further support of an involvement of these pathways with labour, another 
research group integrated three myometrial transcriptome datasets and found 
that there were 126 genes which were associated with labour in all three 
datasets. These included interleukins and cytokines, as well as those related to 
apoptosis and cell proliferation32. These findings support the present 
phosphoproteomics findings, which themselves are arguably closer to the 
functionality of the myometrium than the genomic profile.  
5.8.1.2 Thrombin 
Within the coagulation pathway (Figure 5.7), it is interesting that antithrombin 
III and heparin cofactor II were found to at least halve in the contracting state 
(SP-REL) compared with the pre-contracting state (PRE) in all three samples. In 
the coagulation pathway these proteins act to inhibit thrombin production. If 
antithrombin III and heparin cofactor II are metabolised or have reduced 
production in the contracting state of myometrium, it would follow that this may 
result in a subsequent increase in thrombin levels that are associated with 
myometrial contraction. Previous studies have shown that bleeding activates 




can be associated with preterm labour and an “irritated uterus”300, 301. Thrombin 
is a protease that interacts with the G protein-coupled membrane protease-
activated receptor family302. Activation of this receptor by thrombin in rats 
stimulates myometrial contractions via activation of the phosphatidyl-inositol 
signalling pathway and subsequent influx of calcium ions into the cytosol both 
in vitro303 and in vivo302. These contractions are of a similar strength to those 
induced by oxytocin303,302. Further, in cultured endometrial stromal cells, 
thrombin stimulates matrix metalloproteinase-1 production, and the source of 
thrombin is thought to be decidual cells which is suggested to lead to matrix 
degradation. Studies of human preterm birth show that levels of thrombin-
antithrombin complexes are raised in maternal plasma and in amniotic fluid, and 
increased thrombin-antithrombin plasma complexes have been associated with 
subsequent premature rupture of membranes. Thrombin was shown to be 
increased in the amniotic membranes of women who delivered preterm 
compared with term delivery304. In primary amnion mesenchymal cells, 
thrombin has been shown to upregulate MMP mRNA as well as PGE2 mRNA304. 
A previously suggested mechanism for rupture of membranes involving 
thrombin is that the mechanical structure of the amnion is dependent upon 
interstitial collagens, and degradation of these collagens by MMPs has been 




study that lower levels of proteins which inhibit thrombin were associated with 
the contracting state would fit with this theory, as the potential subsequent 
increase in thrombin levels could promote contractions in the contracting state. 
Previous evidence suggests that thrombin is a potential trigger for spontaneous 
labour and may particularly be involved with preterm birth. This could 
potentially be stimulated by changes in the myometrial or amniotic membrane 
vasculature which causes release of thrombin and warrants further 
investigation. 
5.8.1.3 Acid-sensing ion channel 5 
The greatest overall mean decreases in protein in the contracting state (SP-REL) 
were in acid-sensing ion channel (ASIC) 5 and Putative Heat Shock protein β4. 
ASICs (ASIC 1-5) are a family of degenerin/epithelial sodium ion (Na+) channel 
receptors which are expressed in the nervous system. ASICs have primarily been 
researched in their role in fear behaviour and pain sensation, and their 
contribution to neurodegeneration following a stroke305. However, ASIC 5 
appears to have a different role to the other ASIC channels306, with only 30% 
similarity with the other ASIC proteins307. ASICs 1-4 are activated by protons 
when extracellular pH becomes more acidic, and participate in pathological 
processes involving hypoxia such as pain, malignancy and apoptosis308. When a 




a neurone, conformational change occurs to allow passage of Na+ into the cell 
which results in membrane depolarisation and activation of voltage-gated Ca2+-
channels. The resulting influx of Ca2+ depolarises the neuron causing an 
excitatory response309. In contrast, ASIC 5 does not respond to low pH307 and its 
physiological function in humans remains poorly understood310. ASIC 5 has been 
named the brain, liver, intestinal Na+ channel (BLINaC), bile acid-sensitive ion 
channel (BASIC), and human intestinal Na+ channel (hINaC). ASIC 5 mRNA is 
highly expressed in the liver and brain, and in the liver is activated by bile 
acids307, 310, and has also been found in the intestinal tract, lung, kidney and 
testes310. Recent electrophysiological studies of the function of human ASIC 5 in 
HEK293 cells using the patch clamp technique revealed that extracellular Ca2+ 
blocks the receptor and renders the channels inactive at rest; and the channels 
are activated by bile acids310.  
Although there appear to be no previous published studies which describe ASIC 
5 in the myometrium,  this is potentially an important protein for normal 
functioning of the human myometrium given the finding in the present study of 
lower levels in the relaxed contracting state compared to pre-contracting. Of 
note, obstetric cholestasis is a condition of pregnancy for which the pathology 
is not well understood and which is associated with increased maternal plasma 




be directly involved in activating labour, it would be expected that women with 
obstetric cholestasis were highly likely to deliver preterm as the bile acids may 
activate the receptor. However, although there is evidence of a slight increase 
in preterm birth rate for pregnancies affected by obstetric cholestasis, a sizeable 
proportion of these are iatrogenic, and there does not appear to be a large 
increase in risk of preterm birth272, 311. Given these findings, ASIC channel 
receptors require further investigation in relation to myometrial contraction, 
human labour, including potential association with some of the poor obstetric 
outcomes associated with obstetric cholestasis.  
5.8.1.4 Heat Shock Proteins 
The protein with the second biggest difference between the SP-REL group and 
the PRE group in Part 1 was Putative Heat Shock Protein (HSP) 90-β4. In addition, 
other HSPs were found differentially phosphorylated in Part 2, including the 
phosphorylation of HSP 90-β at Serine 226 which non-significantly more than 
doubled in all three samples in the failed IOL group under the PRE condition, and 
phosphorylation of HSP-90α at Serine 231 which more than doubled in the failed 
IOL group under OXT-CON conditions. 
HSPs have been previously been studied at different stages of pregnancy. One 
group found a 69% reduction in sHSP αB-crystallin in labouring human 




frozen at the time of sampling) and changes in the phosphorylation of HSP27 
with labour. Further investigation have shown these proteins to be associated 
with remodelling of actin at the time of labour, and that HSP27 moved from the 
perinuclear region to the actin cytoskeleton with labour312. In the ewe, HSP 90 
and HSP 70 were increased in both the myometrium and endometrium during 
labour when compared with pre-labour. Further, treating ewe myometrium 
with oestrogen stimulated a similar increase in HSP-90 and -70 mRNA, while 
treatment with progesterone suppressed this response313. Moreover, it has 
been suggested that oestrogen and progesterone may regulate HSPs, and HSP 
90 and 70 have been shown to bind to progesterone receptors (PR), rendering 
the PR inactive, and dissociation of HSP from the PR results in reactivation of the 
PR.  In addition, oestrogen has been shown to stimulate expression of HSP 90α 
in cell culture of endometrial cells, and progesterone depresses expression314. 
Therefore it has been suggested that in humans increased HSP 70 and HSP 90 
may stimulate oestrogen receptor (ER) function and inhibit PR function, thereby 
causing an effective progesterone withdrawal and triggering myometrial 
contraction and labour313. 
Moreover, small glutamine-rich tetratricopeptide repeat-containing protein 
alpha (SGTA) binds to HSP 70 and 90315, and in Part 2 of the present study 




high in the failed IOL group when contracting under stimulation with oxytocin 
(OXT-CON) than in the ECS group under the same conditions (Table 5.28). In 
addition, the receptors of steroid hormones require assembly of the co-
chaperones HSP 70 and HSP 90 in order to form a functional conformation. 
Other co-chaperones are also required to support this role and a feature of many 
of these proteins is the tetratricopeptide repeat (TPR) that is highly conserved 
and allows interaction with the c-domain of HSP 90 and HSP 70. SGTA down-
regulates expression of androgen receptors through localisation of the 
receptors in the cytoplasm and reducing the amount reaching the nucleus. In 
vitro, PR requires HSPs 40, 70 and 90, p23 and Hop in order to fold properly and 
bind to progesterone. SGTA also down-regulates expression of PR, and SGTA 
knockdown in cell culture results in increased expression of PR, whereas 
overexpression of SGTA decreases the activity of PR. This effect does not occur 
with the ER316. One group found that phosphorylation of SGTA at Serine 305 was 
essential for stabilisation of Platelet-Derived Growth Factor Receptor alpha 
(PDGFR-α) in cancer cells dependent on PDGFR-α for survival317.  
In Part 1 of the present study, HSPβ total protein levels were twice as high in the 
PRE samples as the REL samples, which would indicate a decrease of HSPβ in the 
contracting phase compared with the pre-contracting phase. This doesn’t 




progesterone withdrawal and contraction, as suggested by the studies discussed 
above, however these previous studies compared labouring myometrium 
immediately snap-frozen at the time of elective caesarean section with non-
labouring myometrium, and therefore it is possible that the findings may be 
confounded by the immediate preceding physiological stress that the 
myometrium had been subjected to. The differential phosphorylations seen in 
the failed IOL group under OXT-CON and PRE conditions in Part 2 of the present 
study may alter the usual binding activity of HSP-90 to the PRs, thereby affecting 
contractility. The observed doubling in phosphorylation of small glutamine-rich 
tetratricopeptide repeat-containing protein alpha at Serine 305 in the failed IOL 
group is interesting; phosphorylation at this site may make it more or less likely 
to bind with PR, thereby affecting the myometrial response to oxytocin during 
induction of labour. However, there may be another explanation, for example 
the increase in HSP and phosphorylation of SGTA may instead be a response to 
increased PR activity and an attempt to decrease this activity, or it may be that 
there is stabilisation of another cell surface receptor that we do not yet know of 
that may contribute to failed IOL. It is also possible that because the 
myometrium has already laboured that there is a prolonged effect from this, 




5.8.2 Phosphorylation events in Part 1 
In study 1, phosphorylation of AHNAK at Serine 5552, and of 182 kDa tankyrase-
1-binding protein at Serine 1297 were at least halved in all three samples in the 
SP-REL condition compared with PRE; and phosphorylation of Filamin-A at 
Serine 968, of Leiomodin-1 at Serine 555, and of DYSL3 protein at Serine 518, 
Serine 522 and Threonine 514, all doubled in the REL condition compared with 
PRE. None of these phosphorylation sites were found to be significantly different 
between the failed IOL group and ECS group in Part 2, although phosphorylation 
events on other sites of the same proteins were significantly different.  
5.8.2.1 Leiomodin-1 
Leiomodin-1 has previously been found within smooth muscle, including the 
uterus. Leiomodin-1 is a member of the tropomodulins (Tmod) family, which are 
proteins involved in actin-capping, and which work with tropomyosin to prevent 
depolymerisation at the pointed end of actin filaments. It is thought that 
Leiomodin-1 may also cap actin, but this is yet to be proven. Leiomodin-1 has 
also been shown to bind to tropomyosin in its N-terminal318. However, the N-
terminal does not seem to be the site phosphorylated in the present study 
(including those phosphorylations which  only occurred within one sample).  
Leiomodin-1 is under transcriptional control of myocardin (MYOCD) and is 




in pulmonary arterial hypertension (PAH), a condition where there is excessive 
proliferation of smooth muscle cells resulting in remodelling and occlusion of 
vessels, there were reduced levels of LMOD1 and MEF2C mRNA in smooth 
muscle cells derived from people with PAH when compared to a control group. 
This was also associated with an increase in microRNA (miR)-214319.  
The phenotype of smooth muscle cells is dictated by the set of genes expressed, 
and it is thought that differential gene expression allows smooth muscle cells to 
adapt to the organ in which they are involved. Dysfunction in the expression of 
these genes have been observed in pathologies such as cancer, atherosclerosis, 
obstructive bladder and reproductive disease. SMC (smooth muscle cell)-
restricted genes is a term used for those genes specific for SMC 
differentiation320, and it has previously been reported that a large proportion of 
SMC-restricted genes are under the control of the transcription factor Serum 
Response Factor (SRF)320. MYOCD is a known co-factor of SRF, and Myocyte 
Enhancer Factor 2C (MEF2C) contributes an additional regulatory influence. 
Interaction of MEF2C-MYOCD is believed to upregulate genes to coordinate a 
contractile SMC phenotype319, and LMOD-1 is believed to be an important gene 
for this phenotype319, 320.  
In Part 1 of the present study, phosphorylation of LMOD-1 at serine 555 was at 




be important in promoting the effect on myometrial contractile activity of 
LMOD-1. If this phosphorylation is impaired, contractility may not be so 
effective. A search of Phosphosite and Uniprot indicates that research into this 
phosphorylation site has not been performed in myocytes, making it a novel 
target for future research. 
5.8.2.2 Dihydropyrimidinase-related protein 3 
Further consistent phosphorylation changes observed in all three samples 
between PRE and REL were three phosphorylations on the Dihydropyrimidinase-
related protein 3 (DPYSL3 protein). DPYSL3, also known as Collapsin response 
mediator protein (CRMP)-4, is a hydrolase belonging to the DHOase family 
(www.phosphosite.org).  Uniprot (www.uniprot.org) describes this protein as 
being essential for class 3 semaphorins signalling and the resultant cytoskeleton 
remodelling. This protein is involved with actin crosslink formation, and also part 
of a cellular response to cytokine stimulus (www.phosphosite.org). Further, in a 
previous study, mRNA from DPYSL3 was found to more than double in pregnant 
myometrium when compared with non-pregnant myometrium321. The DPYSL3 
gene has also been found to be upregulated in “ripe” (Bishops score of 5 or 
more) when compared with “unripe” cervical samples in women at term but not 




Glycogen Synthase Kinase 3 (GSK3) is an unusual protein kinase as it requires a 
prior priming phosphorylation of the protein at another site before it will act. 
GSK3 is known to cause the phosphorylation of CRMP-4, but only once it has 
already been primed through phosphorylation of S-522 by another kinase. 
CRMP-2 is in the same family as CRMP-4 and is better studied; and the same 
phosphorylation sites in CRMP-2 are present in CRMP-4, including S-518, T-514, 
and T-509, as well as the priming site of S-522. In neuroblastoma cells in culture, 
cyclin-dependent kinase 5 and dual tyroxine-regulated kinase (DYRK)-2 were 
able to phosphorylate CRMP-4 at S522, and thereby prime CRMP4 for 
phosphorylation by GSK3 at the subsequent sites. This group also determined 
that stimulation of neuroblastoma cells with IGF1 (Insulin-like growth factor 1) 
decreased CRM4 phosphorylation, likely through inhibition of GSK3 activity323.    
In Part 1 of the present study, the phosphorylation events which were at least 
doubled in all three samples were T-514, S-518 and S-522;  therefore, this could 
reflect an increase in CDK5 or DYRK2 and/or GSK3 activity. 
5.8.2.3 Filamin-A 
Serine 968 of Filamin-A had an average 2.435-fold increase in phosphorylation 
in the contracting state (SP-REL) compared with pre-contracting (PRE). Filamin-
A is a ubiquitous protein of the cytoskeleton involved in linkage of actin 




the embryo. Phosphorylation of Serine 968 has previously been identified with 
Mass Spectrometry phosphoproteomics but has not previously been further 
investigated.  
In summary, the phosphorylation events which at least doubled in the 
contracting state (REL) compared with pre-contracting (PRE) in Part 1 of this 
study involve proteins that interact with actin, and the effect of phosphorylation 
at these sites on the function of these proteins warrant further investigation. It 
is possible that these changes are simply the result of increased contractile 
activity, however they may also represent a part of the pathway for the trigger 
for labour in humans.  
5.8.2.4 Neuroblast differentiation-associated protein AHNAK 
Phosphorylation of neuroblast differentiation-associated protein AHNAK 
(AHNAK) at Serine 5552 halved under the SP-REL condition compared with the 
PRE condition in Part 1 of the present study; and phosphorylation of AHNAK at 
Serine 210 was significantly reduced in the failed IOL group under the PRE 
condition.  This is a recognised phosphorylation site of AHNAK although its 
action has not been investigated (phosphosite.org). In a previous study, gene 
expression of AHNAK was found to be lower in labouring samples than non-
labouring myometrial samples that were processed and snap-frozen at the time 




labour rather than being related to the trigger for labour3. AHNAK has also been 
investigated in cardiac smooth muscle, and binds to the L-type Ca2+-channel, 
conferring a link between Ca2+-channels and the actin cytoskeleton145, 324.  
AHNAK is therefore another protein which warrants investigation in its role in 
myometrial contraction and the trigger for labour, including the effect of its 
phosphorylation at Serine 5552 and Serine 210. 
5.8.2.5 182 tankyrase-1-binding protein 
Phosphorylation of 182 kDa tankyrase-1-binding protein halved under the REL 
condition compared with under the PRE condition in Part 1, and was seen to be 
doubled in the OXT-REL and OXT-CON conditions of the failed IOL group in study 
2. If the SP-REL/PRE condition can be considered to show the difference 
between resting state and contracting state, and as these phosphorylation 
events halve in the contracting state but in the contracting state of the oxytocin 
stimulated conditions of the failed IOL group these phosphorylation events 
more than double, this suggests that this protein is of potential functional 
interest. 
5.8.3 Part 2 discussion total proteins  
The number of significant differences in the proteome and phosphoproteome 
between the myometrium taken from women with failed IOL and myometrium 




failed IOL and failure to progress may be associated with a specific phenotype 
that confers myometrial dysfunction, thereby providing clues as to proteins 
required for spontaneous labour in humans. All of the myometrial samples in 
this study were allowed to equilibrate in buffer solution in the Myobath-II prior 
to being treated under the same conditions in the organ bath. Theoretically this 
could mean that the comparisons between the two maternal sample groups are 
more reliably attributed to inherent differences in the myometrium rather than 
potentially confounded by the immediately preceding stress of labour 
experienced by the failed IOL group, as could have been the case had the 
myometrium been processed immediately following collection. 
5.8.3.1 Matrix Gla Protein 
The mean concentration of Matrix Gla Protein (MGP) was at least doubled in the 
failed IOL group, under all of the experimental conditions (PRE, SP-REL, SP-CON, 
OXT-REL, OXT-CON). MGP is an inhibitor of vascular smooth muscle calcification 
that is dependent upon vitamin-K, and is present in vascular smooth muscle and 
bone325. There appears to be limited prior knowledge of the action of MGP in 
the myometrium in the published literature, however a published abstract by 
Stetson et al. (2018) 326 described a study whereby MGP myometrial expression 
was measured using immunohistochemistry and RNAseq with qRT-PCR 




women at term and not in labour; women in preterm labour; and women who 
were preterm and not in labour. Maternal MGP samples were also analysed 
using ELISA. Further, MGP was assessed within pregnant and non-pregnant 
myometrial cell lines. The group found that pregnant myometrial cells in culture 
had a higher expression of MGP than the non-pregnant cell lines; that maternal 
serum MGP levels were unaffected by labour at term; and that there were 
significantly higher levels of MGP gene expression in the not-in-labour 
myometrial samples than both those labouring at term and those labouring 
preterm. Further, that immunohistochemistry showed a co-localisation of MGP 
with smooth-muscle actin monofilaments326. In a further study327 investigating 
MGP and sperm maturation, MGP and γ-glutamyl carboxylase (GGCX) were 
found to be present in vesicles that allowed intercellular communication, and 
that this was dependent upon a low-Ca2+ environment: in a high Ca2+ 
concentration environment MGP is unable to bind to proteins327. In Part 2 of the 
present study, MGP was more than twice as high in the failed IOL group, 
matching the higher levels associated with no labour when compared with 
labour in the Stetson et al. (2018) study. Therefore it is possible that elevated 
MGP is associated with a non-labouring myometrium phenotype, and perhaps 




through impaired intercellular communication associated with increased 
extracellular Ca2+. 
5.8.3.2 Lysyl oxidase homolog 2 and transforming growth factor-beta-induced 
protein ig-h3 
Lysyl oxidase homolog 2 (LOXL2) was found to at least double in all five 
conditions in the failed IOL group when compared with the ECS group. LOXL2 is 
a member of the lysine tyrosylquinone (LTQ)-dependent lysyl oxidase (LOX) 
family, which are copper-dependent amine oxidases328. As with other members 
of the LOX family, LOXL2 is thought to promote stiffening of the extracellular 
matrix (ECM) through its catalysing of cross-linking of the ECM proteins, 
including elastin and collagen. This in turn leads to changes in the cellular 
mechano-transduction. The LOX family have been particularly investigated as 
they are thought to play a role in breast cancer, and have been implicated in 
cancer cell migration, via activation of FAK/Src signalling pathways as a result of 
the hydrogen peroxide produced following ECM substrate oxidation328. LOXL2 is 
found in many human tissues, with greatest expression in the reproductive 
organs, including uterus, placenta and prostate. LOXL2 has been implicated in 
many cancers, and has been found to be upregulated in cancer cells and 
tissues328. Hypoxia induces the expression of LOXL2, and it is a transcriptional 




LOXL2 has also been associated with the upregulation of matrix 
metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1), 
thereby promoting extracellular matrix (ECM) degradation which has been 
implicated in promotion of dissemination of metastases in breast cancer. 
Inhibitors of LOXL2 have been developed and these result in a reduction in 
tumour and fibrotic microenvironment formation in mice328. 
LOXL2 concentrations are also increased by Transforming Growth Factor (TGF)-
β, which is known to be a promoter of accumulation of collagen and fibrotic 
disease of different tissues, including the lung and heart329. Interestingly, 
Transforming Growth Factor-Beta-induced Protein ig-h3 (TGFBI or βig-H3) also 
significantly at least doubled in the failed IOL group when compared with the 
ECS group in all conditions excepting PRE. βig-H3 is an extracellular matrix 
protein that is induced by TGF-β330, and secreted from smooth muscle cells, 
fibroblasts, and chondrocytes330, 331. It is known to be involved in both 
physiological and pathological processes such as adhesion and migration, 
inflammation and morphogenesis. It enables linkage of different ECM proteins, 
and can bind to collagen types I, II and IV and proteoglycans. βig-H3 is present 
in the kidneys and urine of people with diabetes, and has been suggested as a 
marker of nephropathy severity330. Further, βig-H3 was found in the urine of 




both normal pregnancies and pregnancy induced hypertension, indicating that 
TGF-β may be involved in the renal pathology caused by pre-eclampsia332.  βig-
H3 is thought to be a tumour suppressor, as unlike LOXL2, it is reduced in breast, 
prostate and lung cancer cells. However, very high levels of βig-H3 are also 
associated with worsened cancer prognosis and metastases in some cases, 
including in the deposition of ECM involved in the invasive growth of melanoma 
cells. Interestingly, peritoneal cells in culture were found to abundantly secrete 
βig-H3 which promoted motility and adhesion to the peritoneal cells of ovarian 
cancer cells; and therefore are implicated in ovarian cancer metastasis to the 
peritoneum, although βig-H3 was downregulated in ovarian cancer cells330, 333. 
In mice, βig-H3 was found to peak at day 4, when trophoblastic invasion occurs 
334. In Part 2, both βig-H3 and LOXL2 significantly at least doubled in the failed 
IOL group compared with the ECS group, and on the background of the previous 
findings this could be a result of increased TGF-β. This in turn could potentially 
have two implications in its association with failed IOL, in that it could indicate 
that there is increased stiffness of the myometrium rendering the myometrium 
less able to coordinate contractions in such a way as to allow labour; or it may 
be that as a similar profile is observed with pre-eclampsia, that the observed 
failure to progress in labour may be secondary to impaired vascularity of the 




phosphorylation of Serine 194 of TGFBI halved in the SP-CON condition in the 
failed IOL group.  
5.8.3.3 Atrial natriuretic peptide-converting enzyme 
Atrial natriuretic peptide (ANP)-converting enzyme total protein levels 
significantly at least halved between the failed IOL group compared with the 
elective caesarean section group in all conditions other than OXT-REL.  Yan et al. 
(1999)335  identified Corin, a predicted type II transmembrane protein, in the 
human heart335. Yan et al. (2000)336 later determined that Corin was the sought-
after ANP-converting enzyme336. In the murine heart, ANP-converting enzyme 
mRNA is present from embryo day 9.5 (E9.5). Using Fluorescent in situ 
Hybridisation (FISH), ANP-converting enzyme mRNA was also found in the 
uterus of pregnant mice, and this was in highest concentrations in decidual cells 
near to the embryo implantation site335.  A further study illustrated that ANP 
receptors are functionally active in myometrium of pregnant women, as 
treatment of human myometrial membrane with ANP increased production of 
cyclic guanosine monophosphate (cGMP)337. 
Atrial Natriureteric Peptide (ANP) is well studied in cardiac tissues and is a 
hormone which reduces blood pressure through excretion of sodium ions and 
thereby reduces blood volume. ANP is converted into its active form from the 




results in increased blood pressure338. As ANP-converting enzyme is a 
transmembrane protein, it is expected to have its action at the site where it is 
found. Cui et al. (2012)338 created an ANP-converting enzyme Knock-out (KO) 
mouse which had a cardiac promoter able to convert pro-ANP to ANP in the 
heart but not in the uterus, and normal blood pressure was maintained in the 
non-pregnant mouse. However, in the pregnant ANP-converting enzyme-KO 
mouse, blood pressure increased during pregnancy and only returned to normal 
post-partum. In the ANP-converting enzyme-KO mice, spiral artery remodelling 
and trophoblast invasion were impaired. Further, uterine ANP-converting 
enzyme mRNA levels were lower in women with pre-eclampsia than those from 
normal pregnancies. This suggests that ANP-converting enzyme is important for 
physiological changes at the feto-maternal interface, and specifically in this case 
with pre-eclampsia 338. 
Further, Cootauco et al. (2008)339 performed a myometrial organ bath study and 
observed that in myometrium primed with oxytocin, adding increasing 
concentrations of ANP reduced the frequency of myometrial contractions. 
Myometrial cell culture taken from myometrium of women at elective 
caesarean section showed an increasing ANP concentration within these cells 
with increased gestational age. The concentration of ANP decreased when the 




were treated with Nifedipine (a tocolytic agent). The authors concluded that 
ANP causes myometrial relaxation in a dose-dependent manner339. In another 
study, Soloff et al. (2011)340 immortalised myometrial cells prepared from 
women in late gestation and treated the cells with increasing doses of 
progesterone, followed by Affymetrix GeneChip analysis. The authors found that 
the expression of ANP-converting enzyme was upregulated nearly 8-fold 
following treatment with progesterone340.  
In summary, it seems that ANP causes myometrial relaxation, and increased ANP 
levels reduce the frequency of myometrial contractions in oxytocin-treated 
human myometrium 339, and that ANP-converting enzyme is required to activate 
ANP. In Part 2 of the present study, levels of ANP-converting enzyme in the failed 
IOL labour group was found to be at least half that measured in the ECS group 
in all conditions other than OXT-CON, which would theoretically result in a 
reduction of ANP production and, theoretically, increased frequency of 
myometrial contractions. Or, as reduced ANP and ANP-converting enzyme is 
associated with hypertension and impaired trophoblast invasion and spiral 
artery remodelling, this reduced ANP-converting enzyme in the failed IOL group 
could indicate that impaired response to IOL is associated with impaired spiral 




5.8.3.4 Membrane metallo-endopeptidase 
Membrane metallo-endopeptidase (MME) was also found to significantly at 
least halve in the failed IOL group compared with the ECS group, in all groups 
other than OXT-REL (as with ANP). In the heart, MME is known to break down 
ANP341. This warrants further investigation given the previously discussed 
findings in the literature. 
5.8.3.5 Pleckstrin homology-like domain, family A, member 5 
Pleckstrin homology-like domain, family A, member 5 (PHLDA5) total protein 
significantly doubled in the failed IOL group compared with the ECS group under 
SP-REL conditions. And phosphorylation of this protein non-significantly halved 
under both contracting conditions. Another member of this family, PHLDA2, has 
been associated with birthweight and growth restriction, and in cell culture of 
primary trophoblast cells overexpression of PHLDA2 inhibited proliferation and 
induced apoptosis342, and therefore also warrants further investigation in future 
studies. 
5.8.4 Phosphorylation events Part 2 
The most significant phosphorylation events in the failed IOL group when 
compared with the ECS group are summarised in the String diagram presented 
in Figure 5.14A, which shows those proteins for which phosphorylation events 




Membrane-associated progesterone receptor component 1 (PGRMC1), calnexin, 
Heat shock protein HSP 90-β, and Small glutamine-rich tetratricopeptide repeat-
containing protein alpha; the second linking Vimentim, Filamin A and Myosin 
Light Chain Kinase. These have significantly more interactions than that which 
would be expected if proteins were randomly selected, with a PPI of <1.0e-16. 
These differences suggest that phosphorylation changes in these proteins may 
interfere with normal myometrial function. Figure 5.14B shows proteins for 
which the phosphorylation events halved in the contracted states, and Figure 
5.15 shows proteins for which phosphorylation events both halved and doubled 
in the contracted state. 
5.8.4.1 Myosin light chain kinase 
Two phosphorylation events occurred for myosin light chain kinase (MYLK), both 
in the OXT-CON group: phosphorylation of MYLK at serine 1438 more than 
doubled in the failed IOL group under OXT-CON. Under the same condition, 
phosphorylation of MYLK at Serine 1776 halved in the failed IOL group .Using 
data from the same experiments as Part 1 of the present study, Hudson et al. 
(2017)145 found that phosphorylation of serine 1760 increased during 
spontaneous contraction (SP-CON) and oxytocin driven contractions (OXT-CON), 
which was verified with Western blotting145. This site was not differentially 




recognised as a phosphorylation site by software such as Uniprot and 
Phosphosite, little else is known about it other than it is close to the calmodulin-
binding region at 1711-1774 residues (www.uniprot.com and 
www.phosphosite.com). Serine 1438 is recognised as a phosphorylation site, but 
again little is known about its functional significance. This is the phosphorylation 
site that significantly increased the most in the failed IOL group when compared 
with the ECS group, and seems to increase only in response to oxytocin 
stimulated contraction in the present study. Given that IOL usually involves 
infusion of oxytocin to stimulate contractions, if there is a phosphorylation of 
MYLK at this site which somehow impedes normal function of the kinase, it could 
be an area to target in future studies. Future work is therefore required to 
investigate the functional effects, if any, of these phosphorylation events. 
5.8.4.2 Membrane-associated progesterone receptor component 1 
Membrane-associated progesterone receptor component 1 (PGRMC1) is a 
member of the membrane-associated progesterone receptor family. PGRMC1 
levels have been found to be reduced in term myometrium, either in labour or 
not in labour, when compared to preterm myometrium; and treatment of 
myometrial strips with an antibody to PGRMC1 suppressed the ability of 
progesterone to induce relaxation in myometrial strips343. Wang et al. (2016)344 




from women at term not in labour and those having an emergency caesarean 
section and found that there was significantly decreased PGRMC1 mRNA and 
protein in the myometrium taken from the women who were at term not in 
labour. The authors suggested that this could be a pathway for functional 
withdrawal of progesterone in women at term 344. In Part 2 of the present study, 
phosphorylation of PGRMC1 at Serine 181 doubled in the failed IOL group when 
compared with the ECS group under the SP-CON condition and at Serine 57 
under the OXT-REL condition. Although not significant, this doubling could 
indicate an increase of the activity of this receptor in the failed IOL group which 
may render the myometrium less likely to contract and more likely to remain 
under the influence of progesterone and in the quiescent state; this could 
contribute to the failure to progress. However this is speculative and would 
require further study. 
5.8.4.3 Calnexin 
Calnexin is a nexin on the endoplasmic reticulum which interacts with Ca2+ 
pumps on the endoplasmic reticulum that are mainly found at the mitochondria-
associated membrane (MAM). In addition, calnexin is also found in varying 
concentrations on the cell membrane. Under normal conditions, approximately 
80% of calnexin is found in the endoplasmic reticulum, again with the majority 




a cytosolic sorting protein which is involved in normal distribution of calnexin 
throughout the cell. In cell culture, if PACS-2 is knocked down, the proportion of 
calnexin at the cell surface increases. Interestingly, phosphorylation of calnexin 
at both Serine 554 and 564 decrease the binding ability of PACS-2 to calnexin, 
and serine 554/564 Asp phosphomimic mutation results in a similar 
redistribution of Calnexin as with PACS-2 knock down, so that more calnexin is 
found at the cell surface345. This site had increased phosphorylation in the failed 
IOL group under OXT-CON conditions, and therefore may have resulted in 
increased calnexin at the myocyte cell surface. As calnexin can also act as a 
chaperone protein, it is possible that this could have had some effect on the cell 
interactions and contractility. 
5.8.5 Comparisons of part 1 and part 2 
As both part 1 and part 2 investigated PRE and SP-REL conditions, the results can 
be compared to determine the consistency of the conclusions. Reassuringly, 
proteins for which the REL/PRE ratio at least halved in all three samples for part 
1 were also found to halve for the elective caesarean section group of part 2, 
including complement component C8 alpha chain, cryocrystalglobulin CC1 
heavy chain variable region, and cDNA FLJ55673, highly similar to Complement 
factor B. Other proteins followed the same direction of change but did not 





This study provides a wealth of novel proteomic and phosphoproteomic data 
identifying proteins and phosphorylation events which can be targeted in future 
research into the molecular mechanism of labour. Some results confirm findings 
in the literature, but most are novel findings which warrant further investigation. 
Importantly, these results support the hypothesis that there is a myometrial 
phenotype associated with failed IOL and failure to progress in labour that is 
potentially associated with dysfunctional myometrium. Particularly interesting 
pathways include those involving actin, thrombin, vascular formation and cell 
adhesion.  
5.10 Limitations 
Many of the potential conclusions discussed are speculative and would require 
further investigation. The conclusions may also be limited by there only being 
three women in each of the groups. Moreover, the apparent change in 
myometrial phenotype in Part 2 may be the consequence of the difficult 
induction of labour rather than the underlying physiopathological cause of the 
failure to progress. More research is needed at a functional level, combining 
myometrial contractility measurements and molecular studies. The strength of 




approaches are a potentially powerful resource to understand the complex 



























CHAPTER 6. DISCUSSION  
 
6.1 Summary 
The overarching aim of my thesis was to further knowledge of the mechanism 
of human parturition. The four studies described in this thesis have utilised 
‘omics technologies in both clinical case-control and cohort settings to improve 
our understanding of the trigger for labour in humans. This includes 
identification of metabolites, proteins and myometrial protein phosphorylation 
sites that are linked to different modes of labour onset and delivery, as well as 
gestational age at delivery.  The techniques used allow measurement of 
metabolite changes between labour and non-labour within the uterine 
environment immediately following delivery.  
Chapters 2 and 3 showed the efficacy, reliability and consistency of the 
Metabolon, Inc., Mass Spectrometry metabolomics platform in this setting, 
despite there only being ten women included in each group. For example, in 
Chapter 2, all the women who had an elective caesarean section were 
administered the antibiotic Metronidazole, whereas it was not administered to 
any in the vaginal delivery group and this was directly reflected in the results 
(see section 2.9.5).  
The results indicate that spontaneous labour involves signals generated by the 




ratios of steroid metabolites between the cord artery and cord vein. On the 
other hand, there were fewer differences in the intervillous and maternal blood 
with labour, which fits with previous research. This is important because it 
suggests that the difficulties experienced with the current management of 
preterm labour and induction of labour is because medications given 
systemically to the mother do not address underlying issues in the fetal 
circulation.  These results provide important novel leads to investigate for future 
research. 
The fetus is enclosed within the myometrium and membranes, with its 
circulation separated from the maternal circulation by the placenta. It is well 
established that there are no obvious changes in the maternal circulating levels 
of progesterone and oestrogens with labour; and it remains difficult to elucidate 
the triggering pathways involved with labour by studying only the maternal 
circulation. The results presented in this thesis suggest that the trigger for labour 
relates to changes in metabolite production by the fetus; with increased 
progesterone and oestriol produced by the fetus compared to that produced by 
the placenta. And that this is associated with reduced progesterone produced 
by the placenta, potentially in a negative feedback mechanism.  
The reason for the increased expression of progesterone by the fetus may well 




activation, of the enzyme 3beta hydroxysteroid dehydrogenase. This enzyme 
catalyses conversion of pregnenolone to progesterone; 17alpha hydroxy 
pregnenolone to 17 alpha-hydroxy progesterone; and DHEA to 
androstenedione. This provides androgen substrates for aromatisation to 
oestrone and oestradiol (from the second trimester high placental aromatase 
activity converts increasing amounts of androgen to oestrogen346). The results 
of this thesis show that 17alpha hydroxyprogesterone follows a similar pattern 
to progesterone in terms of CA/CV ratios and supports the concept of fetal 
adrenal maturation. A previous study investigated activation of the fetal adrenal 
gland with regards to fetal virilisation. Differentiation to male or female sex 
occurs during the first trimester, as a result of male hormones secreted by the 
fetal testis. Overexposure of a female (46 XX) fetus to androgens results in 
virilised genitalia. This happens if there is a deficiency of cytochrome p450 21-
hydroxylase, as with congenital adrenal hyperplasia, resulting in reduced fetal 
cortisol production, resulting in a reduction in negative feedback on ACTH 
production normally instigated by cortisol. The excess ACTH leads to excessive 
androgen production are produced346. 
The results in chapter 2 showed an increase in cortisol in the cord of the 
labouring group (VC/EC), however it could not be excluded that this was 




Subsequently, in chapter 3, while the concentration of cortisol in the cord vein 
was higher in the labouring groups than the non-labouring groups, the amount 
in the CV of the IOL group was significantly lower than that in the CV of the SL 
group (0.41-FC, p=0.028), despite both groups going through the contractions of 
labour and vaginal delivery. This suggests that spontaneous labour is associated 
with increased activation of adrenal enzymes, for example 3βHSD.   
 
6.2 Linking the findings of the different studies 
Although the studies in this thesis approached the overarching question of the 
thesis from different angles, there are general agreements between them. 
Chapter 2 resulted in the generation of a hypothesis for the potential pathway 
for labour, which was  largely supported by the results from Chapter 3, 
suggesting that the pathway for labour involves elevated endocannabinoids in 
the cord would result in increased production of sphingolipids and ceramides, 
which could in turn stimulate prostaglandin production, resulting in labour. 
Moreover, this pathway may involve uterine lymphocytes. Progesterone has 
been shown to decrease FAAH activity in human lymphocytes in vitro, and FAAH 
breaks down endocannabinoids including AEA, PEA and OEA184, 188, 190, 197, 347-349. 
A reduction in progesterone concentration or sensitivity immediately prior to 
labour could result in an increase in endocannabinoid, sphingolipid, ceramide 




One of the most important findings of this thesis is a difference in certain 
metabolites between the cord artery and cord vein with different modes of 
labour onset and delivery. These results clearly show that the metabolic profiles 
of these two compartments are distinct, providing valuable insight into 
metabolites differentially produced by the fetus and placenta with spontaneous 
labour. The differences in the metabolome of these compartments are 
particularly consequential between spontaneous and induced labour given both 
groups had undergone the prolonged stress of labour. For example, with regards 
to the mean concentrations of oestriol and progesterone in cord artery and cord 
vein, the induction group was more alike the elective caesarean section group 
than the spontaneously labouring group. Further, eleven per cent of the 
measured metabolites were significantly different between the cord vein of the 
spontaneously labouring and induction of labour groups, and 10.1% different in 
the cord artery. This was compared with just 3.1% difference between the 
maternal latent phase samples, and 2.9% difference in the intervillous maternal 
samples.  
These differences in progesterone and oestriol may represent a type of local 
progesterone withdrawal: less progesterone produced by the placenta with 
spontaneous labour could be perceived by myometrial cells as a form of 




maternal blood. In addition, this could in part explain why progesterone 
administered to the mother does not prevent preterm labour and preterm 
birth125. In many previous studies where cord blood was sampled as a whole and 
not defined as arterial or venous, as was done in chapter 2, such differences 
would have been missed. It would be worthwhile to replicate these findings in 
larger studies.  
In addition, the results from Chapter 3 also indicate that there may be a link 
between spontaneous labour and a pathway involving the balance between 
ceramide, sphingosine and sphingosine 1-phosphate, and the resultant effect on 
cAMP, calcium homeostasis and actin disassembly. Alterations in this balance 
may influence myometrial contractility, and may be involved in spontaneous 
labour, potentially linking with the changes observed in endocannabinoid 
concentrations and the onset of spontaneous labour. 
6.2.1 Association of maternal metabolites during pregnancy with gestational age 
at delivery 
The maternal metabolome during pregnancy has been systematically 
investigated in the studies included in this thesis, particularly in Chapters 3 and 
4, and numerous metabolites are shown to be associated with gestational age 
at delivery, and with preterm birth. The ORA analysis indicates that pathways 




spontaneous labour involve fatty acid metabolism. This includes a potential 
association with dyslipidaemia and earlier gestational age at delivery. However, 
as with the other findings, further investigation using other approaches, such as 
Mendelian Randomisation, are essential to determine whether any of the 
differences in metabolites observed in these studies may be part of a causal 
pathway.  
6.2.2 Vascular dysfunction 
There were also indicators of changes in vascular function potentially being 
involved with the trigger for spontaneous labour, this included findings from 
Chapters 4 and 5. Specifically, that the trigger for labour, particularly preterm 
spontaneous labour, could be associated with dyslipidaemia, inflammation, and 
potentially vascular dysfunction. Further, these results suggest potentially 
modifiable risk factors that could be prioritised for further investigation as 
fruitful targets to prevent preterm labour. Subsequently, the next steps will 
involve replicating results and using other approaches to strengthen causal 
inference on the relation of these maternal risk factors with gestational age at 
delivery. Vascular dysfunction has also been associated with other pathologies 
of pregnancy such as pre-eclampsia and gestational diabetes; it is likely that all  
these pathologies are linked, and it may be that spontaneous labour occurs at a 




threshold is crossed labour occurs. In women where there is already some 
vascular dysfunction, such as in women with pre-existing dyslipidaemia, 
diabetes or hypertension, it may be that it takes less for the threshold to be 
reached and these women are more likely to have preterm birth. It is important 
that in Chapter 4 the association between dyslipidaemia and shorter mean 
gestational age at delivery persisted even after adjustment for the identified 
potential confounders. 
6.2.3 Myometrial phenotype associated with failed induction of labour 
The number of significant differences in the proteome and phosphoproteome 
between the myometrium of women with failed IOL and myometrium of women 
at elective caesarean section support an hypothesis that failed IOL and failure to 
progress may be associated with a specific myometrial phenotype that confers 
myometrial dysfunction, thereby providing clues as to proteins required for 
spontaneous labour in humans.   
The proteins and phosphorylation events identified include those that are 
involved in calcium homeostasis, actin and cytoskeleton function, and vascular 
function. Some results confirm findings in the literature, but most are novel 
findings which warrant further investigation. Evaluating the functional effects of 
these findings are vital next steps. This study provides a wealth of novel 




phosphorylation events which can be targeted in future research into the 









6.3 Study limitations 
A potential limitation of my thesis is the small sample sizes for the clinical studies. 
However, while future work will involve larger studies to confirm the results of 
this thesis, it was an important finding that the metabolomic profiles observed 
in Chapters 2 and 3 were consistent between the groups, with relative tight 95% 
confidence intervals. This suggests that the differences observed in this thesis 
may be due to the differences in mode of labour onset, delivery, and gestational 
age at delivery that these studies were designed to investigate.  
In the BiB study, residual confounding and missing data may have introduced 
bias in the results. However, to the extent that these have been explored in the 
analysis models used, there is no indication that the missing data represents a 
major source of bias. For example, the comparison of outcomes between the 
total recruited pregnancies (n=13 776), the eligible sample (n=12 308), and the 
analysis sample (n=7 440) (the latter of which had no missing data), showed no 
significant differences in outcomes and results between the three groups (see 
section 4.6.1). 
A further limitation regarding the myometrial studies is that the Myobath II is 
not a perfect representation of what occurs in vivo. It is obviously difficult to 




tissue would seem to be more reliable than cell culture techniques; nevertheless, 
there remains the potential for misrepresentation in organ bath experiments. 
6.4 Clinical implications 
The observed differences in cord artery and cord vein metabolites between 
spontaneous and induced labour may help explain why exogenous progesterone 
does not prevent pregnancy loss or PTB, and provide novel targets for drug 
development. However, given the limited sample size of the current studies, 
replication of these findings in follow-on studies is needed. 
The ineffectiveness and inefficiencies of the current management of both PTB 
and IOL may in part be due to spontaneous labour involving specific signals from 
the fetus that act locally on the fetal membranes, cervix and myometrium. The 
current management options for PTB prevention and IOL include maternal 
administration of progesterone and oxytocin, respectively, and the reason these 
options are relatively ineffective and inefficient could be due to such methods 
not altering or matching the fetal signals of spontaneous labour. 
Novel drugs targeting mechanisms directly implicated in human labour may 
allow us to induce labour in a way that better reproduces spontaneous labour 
and increase the likelihood of normal vaginal delivery. Further, if there is a 
specific myometrial phenotype associated with failed induction of labour there 




the myometrial contractions are stimulated. Both approaches could reduce the 
increased risk for adverse pregnancy outcomes that are currently associated 
with induction of labour30.  
The findings from Chapter 4 suggest that a general pattern of dyslipidaemia may 
be associated with shorter gestational age at delivery. As such dyslipidaemia has 
been investigated and treated for reduction of cardiovascular disease, it may be 
that specific drugs can be developed to target these pathways, or lifestyle 
changes recommended to women who are at higher risk, in order to reduce the 
risk for preterm birth. 
6.5 Future studies 
The studies included in this thesis have generated several hypotheses on the 
potential key molecular mechanisms involved in the trigger for human labour. 
These hypotheses can be followed up in subsequent studies which may inform 
the development of drugs for better treatment and prevention of preterm birth, 
and to better induce labour when indicated. To this end, future studies to 
continue the research presented in this thesis could include: 
1. A large study to investigate metabolomic differences between the cord 
artery and cord vein with different types of labour onset. Numbers 
needed for appropriate power for this study would be guided by Chapters 




2. Large cohort study to further investigate metabolome changes at 
different gestations of pregnancy. Particularly investigating potential 
differences and similarities between women according to age, past 
medical history, BMI, dyslipidaemia, and other demographic features, and 
the effect this may have on gestational age at delivery. 
3. The findings from Chapter 4  show that certain metabolites are associated 
with gestational age at delivery, and the next step will be to determine if 
these are likely to reflect a causal relationship. Mendelian randomisation 
(MR) is a method that uses genetic variants to investigate the effect of 
modifiable causes on diseases350-352. MR can be used to further investigate 
possible causal links between metabolites and gestational age at delivery. 
This would involve two steps. First, one needs to identify common genetic 
variants that are associated with elevations in certain blood metabolites, 
which are available from metabolomics genome-wide association studies 
(GWAS). Second, an MR study would test whether people with such 
genetic variants have a higher incidence of PTB than those who do not 
have these genetic variants. Importantly, MR studies are more robust to 
the common limitations of epidemiological studies, such as reverse 
causation (i.e. genetic variants are determined from conception) and 




outcome confounders). However, it must be noted that MR in this model 
would assume that the genetic variant influences PTB only by affecting 
metabolite levels, and that MR assumes long-term exposure to altered 
metabolite levels. Therefore, if labour is influenced by transient 
metabolite changes, MR in this setting may not be informative. However, 
it may also be that certain genetic variants confer increased susceptibility 
to changes in metabolites that results in having a lower threshold at which 
labour occurs.  
4. Study to test the hypothesis that immune cells within the uterus are 
involved in the trigger for spontaneous human labour, including the 
involvement of FAAH within lymphocytes and the control of 
endocannabinoids. This will involve characterising the lymphocyte 
populations in cord arterial, cord vein and maternal blood, and 
determining whether there are differences in these populations between 
women who labour and women who do not labour at the time of delivery. 
5. Further Myobath II studies to confirm the phosphoproteomic findings of 
Chapter 5, including use of specific phosphoantibodies to validate the 
phosphorylation changes. Experiments would be designed with cellular 
biochemistry experts to investigate of the functional effects of the 
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Abstract: The mechanism of human labour remains poorly understood, limiting our ability to manage 
complications of parturition such as preterm labour and induction of labour. In this study we have 
investigated the effect of labour on plasma metabolites immediately following delivery, comparing 
cord and maternal plasma taken from women who laboured spontaneously and delivered vaginally 
with women who were delivered via elective caesarean section and did not labour. Samples were 
analysed using ultra high-performance liquid chromatography-tandem mass spectrometry. Welch’s 
two-sample t-test was used to identify any significant differences. Of 826 metabolites measured, 
26.9% (222/826) were significantly altered in maternal plasma and 21.1% (174/826) in cord plasma. 
Labour involves changes in many maternal organs and poses acute metabolic demands in the uterus 
and in the fetus and these are reflected in our results. While a proportion of these differences are 
likely to be secondary to the physiological demands of labour itself, these results present a 
comprehensive picture of the metabolome in the maternal and fetal circulations at the time of 
delivery and can be used to guide future studies. We discuss potential causal pathways for labour 
including endocannabinoids, ceramides, sphingolipids and steroids. Further work is necessary to 
confirm the specific pathways involved in the spontaneous onset of labour. 
Keywords: human parturition; endocannabinoid; steroids; energy metabolism 
 
1. Introduction 
Our understanding of the mechanisms of human parturition remains incomplete and consequently 
management options for complications of pregnancy such as preterm labour (PTL), and common 




A better understanding of human labour at term (defined as 37–42 weeks’ gestation) would allow 
development of methods for improved prediction and prevention of PTL, as well as more effective 
strategies for IOL [4–6]. The aetiology of PTL is heterogeneous and frequently pathological, however 
it may result in stimulation of the same triggers for parturition as spontaneous labour at term [1,7]. 
The proportion of pregnancies with IOL in England has increased from 20.3% in 2006–2017 to 29.4% 
in 2016–2017 [4,6,8–10]. IOL can be inefficient, with potentially severe complications for the mother 
and neonate, including lengthy hospital stays at high cost to the National Health Service and a 
negative impact on the birth experience [3,11,12]. The use of clinical and molecular markers to 
identify women at risk of complications of pregnancy remains challenging due to their poor 
predictive value [13,14]. 
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There is a need to identify the metabolic changes underlying the physiological onset of spontaneous 
human labour and to develop new clinically useful predictive markers and better drug targets. 
Metabolomics allows the investigation of a wide range of metabolites across the main biochemical 
pathways [15]. The advantage of studying the metabolome or metabolic profile of a system is that it 
reveals the current activity rather than a prediction of what may happen, as is the case with genomic 
studies [16–18]. The most commonly used metabolomic techniques are mass spectrometry (MS) and 
nuclear magnetic resonance (NMR), paired with data processing using advanced computational 
programmes [18,19]. NMR can measure a broad range of metabolites however it is less sensitive 
than MS. Gas chromatography (GC) or liquid chromatography (LC) coupled to MS provides excellent 
separation of molecules within a sample according to their mass-to-charge ratio and analysis at a 
wide range of concentrations. As MS is more sensitive, it can be utilised to measure more 
metabolites, but it has a longer analysis time than NMR [19]. Metabolomics has been used to 
investigate pregnancy related changes in maternal and cord blood, fetal membranes, cervico-vaginal 
secretions, urine and amniotic fluid; with the potential of identifying metabolic profiles or 
biomarkers associated with different outcomes, such as PTL [20,21], missed miscarriage [22], 
diagnosis of exposure to chorioamnionitis in the neonate [23], and the effect of maternal diet on 
amniotic fluid composition [20,21,24]. However, to our knowledge there are no previous studies 
focusing on parturition. 
Here we present novel MS data from a pilot study designed to investigate the effect of parturition on 
plasma metabolites in the fetal and maternal circulation at the time of delivery and demonstrate 
that even with a relatively small sample size significant and robust changes can be identified 
providing new insights into the metabolic responses of the maternal-feto-placental unit in 
spontaneous labour. 
2. Materials and Methods 
2.1. Participants 
Nine women with a vaginal delivery (VD) following active labour of spontaneous onset and ten 
women who had an elective caesarean section (CS) for reasons not related to maternal or fetal 
disease gave informed, written consent for inclusion before they participated in the study. The study 
was conducted in accordance with the Declaration of Helsinki, and ethical approval for the study was 
gained from the National Research Ethics Service Committee-South West, Bristol (reference number: 
E5431). The inclusion criteria were: women with uncomplicated singleton term pregnancies; age 18–




under 18 years or over 41 years of age; taking medications likely to affect metabolomics; diabetes; 
pre-eclampsia; other metabolic conditions; raised temperature or signs of fetal distress during 
labour. The following demographic information was collected: ethnicity, age, BMI, smoking status, 
time last eaten, time of delivery, duration of delivery, drugs given during hospital stay, Apgar scores 
of the baby, and cord gases if taken. 
2.2. Collection of Samples 
Cord blood and maternal (intervillous) blood samples were obtained within 30 minutes of delivery of 
the baby and placenta, as described in detail previously [25], following delayed cord clamping which 
is routinely carried out at St Michael’s Hospital for both VD and elective CS provided there are no 
contraindications. Samples were collected using a sterile 21 Gauge needle and syringe, transferred 
into Vacutainer tubes containing EDTA, then centrifuged at 1000× g for ten minutes. 200 µL of the 
clear upper plasma layer was transferred into chilled propylene tubes and stored at −80 ◦C. 
2.3. Metabolomic Analysis 
The samples were transported on dry ice to Metabolon, Inc. (Morrisville, NC, USA) for ultrahigh 
performance liquid chromatography-tandem mass spectrometry (UHPLC/MS) [26–28]. All samples 
were analysed together in order to reduce risk of batch bias. This included the measurement of 826 
known metabolites for each sample, grouped into 108 sub-pathways and the following eight super-
pathways: Lipid, Amino Acid, Peptide, Energy, Nucleotide, Cofactors and Vitamins, and Xenobiotics. 
Briefly, plasma samples were subjected to methanol extraction then split into aliquots for analysis by 
UHPLC/MS in the positive (involving two methods, one optimized for hydrophilic, and the other 
hydrophobic compounds), negative or polar ion mode. Metabolites were identified by automated 
comparison of ion features to a reference library of chemical standard, followed by visual inspection 
for quality control [29]. Multiple water blanks were included on each plate of experimental samples 
to identify any compounds resulting from storage or handling. Compounds which were detected at a 
level at least triple that found in the water blanks and which were confirmed to be present relative 
to a chemical reference standard were included in the final analysis. For quality assurance and 
quality control (QC), pooled QC plasma replicates, as well as several internal standards, were 
assessed to determine instrument variability, with representative relative standard deviation (RSD) = 
3% for internal standards and 7% for endogenous biochemicals. 
2.4. Statistical Analysis 
The two experimental groups were labelled VC/EC and VM/EM. VC/EC represents the difference in 
the means between VC, the metabolite quantity identified in cord plasma from women who 
laboured and delivered vaginally, and EC, the metabolite quantity identified in cord plasma from 
women who did not labour and delivered via elective CS. VM/EM represents the difference in the 
means between VM, the metabolite quantity identified in intervillous plasma from women who 
laboured and delivered vaginally, and EM, the metabolite quantity contained in intervillous plasma 
from women who did not labour and delivered via elective CS. Welch’s two-sample t-test was used 
to identify metabolites for which the means were significantly different between VC and EC or VM 
and EM. Analysis was performed on log-transformed data, considered significant if p ≤ 0.05. A q-
value was also calculated to control for false discovery rate and account for the multiple 
comparisons which occur in metabolomic-based studies, where a q-value of <0.10 gives high 







Table 1 presents the characteristics of the labouring and non-labouring groups. All nine women in 
the vaginal delivery group had confirmed labours of spontaneous onset. All women were of white 
ethnicity and there were no significant differences in age, parity, employment status, Apgar scores at 
birth, birthweight or gender of fetus. None of the women had experienced medical complications 
during the pregnancy, nor had there been concern for any of the fetuses. The mean BMI at booking 
was 21.6 in the VD group and 25.6 in the elective CS group (p = 0.02), due to an outlier in the elective 
CS group with BMI 38.3. Further analysis was performed and confirmed her inclusion did not affect 
the spread of results. The median gestation at delivery was 40 weeks in the VD group and 39 weeks 
and 2 days in the elective CS group (p = 0.04), an expected difference as planned CSs are routinely 
booked between 39 and 40 weeks’ gestation whereas spontaneous deliveries may occur up to three 
weeks later. 
Table 1. Characteristics of included human participants. 
Demographic 
VD n = 9 Elective CS n = 10 p Value 
(at ≤ 
0.05) 
Age (years) 32.4 (24–39) a 34.6 (30–40) a NS 
BMI at pregnancy booking 21.6 (19.9–23.1) a 25.56 (21.7–38.3) a 0.02 
Ethnicity White British: 9 
White British: 9 
White Romanian: 1 
NS 
Smoking history:   NS 
Never 8 4  
Ex 0 5  
Current 1 (4/day) 1 (10/day)  









(MTHFR gene 1): 1 
NA 




 Home maker 1 2 
Gravida 1.2 (0–2) a 2.4 (0–5) a NS 
Parity 0.6 (0–2) a 1.7 (0–7) a NS 
Significant pregnancy 
complications 




Indication for elective CS NA 
Breech: 3 










Duration of labour in minutes 312 min (70–
650) a 
NA NA 







Apgar scores at 1, 5 and 10 
min: 
  NS 
8,9,10 1 0  
9,10,10 8 10  
Management of third stage:   NS 
Syntometrine or Carbetocin 8 10  
Physiological 1 0  
Interval between delivery 
and freezing of sample 
(minutes) 
38 (36–60) b 28.5 (24–45) b 0.02 
Gender of fetus:   NS 
Female 5 4  
Male 4 6  
Apgar scores at 1, 5 and 10 
min: 
  NS 
8,9,10 1 0  
9,10,10 8 10  
Birth weight (Kilograms): 3.4 (3.2–3.9) a 3.6 (3.1–4.1) a NS 
a Mean (range); b Median (range); VD = Vaginal Delivery; CS = Caesarean Section; BMI = Body Mass 
Index; NS = not significant; NA = non-applicable; ICSI = intracytoplasmic sperm injection. 
3.2. Metabolomics 
All the results refer to ten women in the elective CS group and nine women in the VD group. It was 
not possible to obtain intervillous blood from one placenta, reducing the VM samples to eight. The 
numbers of metabolites with significant (p ≤ 0.05) differences between VM and EM, and VC and EC, 
in the eight super-pathways are presented in Table 2. Of the 108 metabolite sub-pathways 
measured, 83 contained metabolites with significant VC/EC and/or VM/EM differences. For the 
following analysis, xenobiotic metabolites will be considered separately. 
Table 2. Number of metabolites which significantly increased or decreased at the time of delivery 




labour and delivered via elective caesarean section in the maternal (intervillous) plasma (VM/EM) 









↑ ↓ Total (%) ↑ ↓ Total 
(%) 
Lipid 405 139 14 153 (37.8) 73 12 85 
(21.0) 
Amino Acid 177 9 15 24 (13.6) 15 14 29 
(16.4) 
Xenobiotics 108 18 3 21 (19.4) 16 5 21 
(19.4) 




31 3 4 7 (22.6) 3 5 
8 
(25.8) 
Energy 11 3 0 3 (27.3) 6 0 6 
(54.6) 
Nucleotide 38 2 2 4 (10.5) 9 3 12 
(31.6) 




3 2 0  2 0  
VM = Maternal (intervillous) plasma from women who laboured and delivered vaginally (n = 8); EM = 
maternal plasma from women who did not labour and delivered via caesarean section (n = 10); VC = 
cord plasma from women who laboured and delivered vaginally (n = 9); EC= cord plasma from 
women who did not labour and delivered via elective caesarean section (n = 10); ↑ = Number of 
metabolites significantly elevated; ↓ = Number of metabolites significantly decreased. 
3.3. Changes in Cord Plasma Metabolome 
Table S1 shows the changes in cord plasma (VC/EC) of specific metabolites within the sub-pathways 
ordered according to the magnitude of fold-change. 120 metabolites significantly increased in the 
cord plasma of women who laboured, 102 of which also had a significant q value (<0.10), indicating a 
high likelihood that the significant change was not due to chance. These comprised 58 lipid 
metabolites, 14 amino acid metabolites, nine carbohydrate metabolites, eight nucleotide 
metabolites, six energy metabolites, three cofactors and vitamins metabolites, two peptide 
metabolites and two partially characterised molecules. The metabolite with the largest VC/EC fold-
change was heme, which had an average 14.30-fold increase in the cord plasma (p = 0.024) taken 
from women who laboured. 
Thirty-nine metabolites significantly decreased in the cord plasma of women who laboured 
(VC/EC), and 27 of these had a significant q value: eleven amino acids, six lipids, four peptides, three 
cofactors and vitamins and three nucleotides. 
3.4. Changes in Maternal Plasma Metabolome 
Table S2 shows the corresponding changes in maternal plasma metabolites (VM/EM). Overall, 165 




included: nine amino acids, seven carbohydrates, three cofactors and vitamins, three energy 
metabolites, 139 lipids, two nucleotides, and two partially characterised molecules. The metabolite 
with the greatest significant-fold increase in maternal plasma of women who laboured was the 
partially characterised molecule glucuronide of C10H18O2 (8), with an average 10.85-fold increase in 
VM plasma. The dicarboxylate fatty acids maleate and adipate (C6-DC) increased 10.42-fold and 
8.06-fold, respectively. 
Thirty-six metabolites were significantly decreased in the maternal plasma of women who laboured 
when compared with women who did not labour (VM/EM), with a corresponding significant q value, 
comprising fifteen amino acids, four cofactors and vitamins, fourteen lipids, two nucleotides and one 
peptide. Among these were steroid sulphates, including 3-dehydrocholate (p = 0.002), 16α-hydroxy 
DHEA 3-sulfate (p = 0.007) and androsteroid monosulfate C19H28O4S (p = 0.017), with 0.13, 0.22 
and 
0.26 fold-changes, respectively. 
3.5. Xenobiotics 
The findings within the xenobiotic metabolites were as expected, reflecting the drugs known to be 
administered to the women. For example, metronidazole was given to all ten women who were 
delivered via elective CS but not to any of the women who delivered vaginally, and this was reflected 
in the results (Tables S3 and S4). 
3.6. Lipid Super-Pathway 
The lipid super-pathway contained the most differences between labouring and non-labouring 
women (Figure 1g and Table 2). Most of these changes were significant increases in maternal plasma 
(VM/EM). 405 metabolites were identified in this super-pathway: 34.3% (139/405) of the 
metabolites significantly increased and 3.5% (14/405) significantly decreased in the maternal plasma 
of women who laboured when compared to non-labour; correspondingly, 18.0% (73/405) of the 
metabolites significantly increased in the cord plasma of women who laboured, and 3.0% (12/405) 
significantly decreased. Of note, 22 sphingolipids (Table S5) significantly increased in maternal 
plasma of labouring women with only one corresponding increase found in cord plasma; whereas 
the sub-pathway with the most significant changes seen in the cord plasma within the lipid super-
pathway were fatty acid metabolism (acyl carnitine), long chain fatty acids and polyunsaturated fatty 
acids (Figure 1g). There were significant increases in the medium and long chain fatty acids in both 
cord and maternal plasma and there were selective changes in the maternal and fetal circulation for 
acyl carnitines, acyl cholines, and eicosanoids (12-HETE and 23-HHTrE) (Tables S1 and S2). 
Of the steroid metabolites, cholesterol was significantly increased in the maternal plasma of women 
who laboured (VM/EM) (Table S2) but did not change in the cord plasma (VC/EC). 17α-
hydroxypregnenolone 3-sulfate and 21-hydroxypregnenolone monosulfate were significantly 
decreased in the maternal plasma of women who laboured (VM/EM), with no corresponding 
changes seen in the cord plasma (Table S6). Conversely, progesterone significantly increased in the 
cord plasma (VC/EC), with no change seen in maternal plasma (VM/EM). There were significant 
increases in 5α-pregnan-3β-ol,20-one sulfate, 5α-pregnan-3β,20β-diol monosulfate, 5α-pregnan-
3β,20α-diol monosulfate, 5α-pregnan-3β,20α-diol monosulfate and pregnanediol-3-glucuronide in 
maternal plasma, which were not seen in the cord (Table S7). 
Of the endocannabinoid metabolites, three were significantly increased in the cord plasma of 




increased, and one significantly decreased in the maternal plasma of women who laboured (VM/EM) 
(Table S8). Twelve of seventeen ceramide metabolites significantly increased in the maternal plasma 
(VM/EM), however there were no such significant differences seen in the cord plasma samples 
(VC/EC) (Table S9). Corticosterone significantly increased in maternal plasma (VM/EM) and in cord 
plasma (VC/EC) (5.41 and 3.09-fold, respectively) of women who laboured, and the corresponding 
increases for cortisol were 5.02-fold and 3.57-fold. There were also significant increases in cortisone 
and cortisone 21-sulfate in cord plasma but not in maternal plasma (Tables S1 and S2). 
Androstenediol (3β,17β) disulfate and androsteroid monosulfate C19H28O4S significantly decreased 
in maternal plasma of women who laboured (VM/EM). 16a-hydroxy DHEA 3-sulfate significantly 
decreased in both the cord and maternal plasma. Androsterone glucuronide, epiandrosterone 
sulfate, 5α-androstan-3β and 17β-diol disulfate significantly increased in the maternal plasma, and 
androsterone sulfate and androstenediol (3α, 17α) monosulfate significantly increased in both 





Figure 1. Comparative histograms showing the number of metabolites with significant changes 
between maternal (intervillous) plasma taken from women who laboured and maternal plasma 
(intervillous) taken from women who did not labour (VM/EM) compared with cord plasma taken 
from women who laboured and cord plasma taken from women who did not labour (VC/EC) for each 
if the sub-pathways within the following super-pathways: (a) Amino Acids; (b) Cofactors and 
Vitamins; (c) Carbohydrates; (d) Nucleotides; (e) Peptides; (f) Energy; (g) Lipids. 
Of the oestrogenic steroids, estrone 3-sulfate significantly increased in the cord plasma with no 




with no change in the cord (Tables S1 and S2). 
3.7. Nucleotides 
The majority of the significant changes seen within the nucleotide super-pathway were within 
VC/EC (Figure 1d), including significant increases in inosine, hypoxanthine, and xanthine, and a 
significant decrease in N1-methylinosine. 5-methyluridine (ribothymidine) significantly decreased in 
both cord (VC/EC) and maternal plasma (VM/EM), while 5,6-dihydrouracil and xanthosine 
significantly increased (Tables S1 and S2). 
3.8. Amino Acids 
Unlike the other super-pathways, most of the significant changes within the amino-acid super-
pathway were decreases in VC/EC and VM/EM (Figure 1a). Serine, histidine, tryptophan, N-
acetylkynurenine, picolinate, indole-3-carboxylic acid, citrulline and arginine significantly decreased 
in both VC/EC and VM/EM. 
Carnosine, N-acetyltyrosine and xanthurenate significantly decreased in VC/EC only, while S-1-
pyrroline-5-carboxylate, indolebutyrate, ornithine, homoarginine, threonine, lysine and trans-4-
hydroxyproline decreased in VM/EM only. By contrast, N-acetylaspartate increased 7.14-fold in 
VM/EM only, and cysteine-glutathione disulfide increased 5.21-fold in VC/EC (Tables S1 and S2). 
3.9. Peptides 
Twenty metabolites were measured in this super-pathway (Figure 1e and Table 2). Two of the four 
fibrinogen cleavage peptide metabolites measured were significantly increased in cord plasma of 
women who laboured compared with non-labour: fibrinopeptide A des-ala increased 12.12-fold and 
fibrinopeptide A phosphono-ser increased 11.34-fold. There were no corresponding changes in 
maternal plasma. 
3.10. Carbohydrate Metabolism 
Twenty nine metabolites were measured in this super-pathway (Figure 1c and Table 2), and of these 
glucose, maltose, fructose, ribulonate/xylulonate, pyruvate and lactate were significantly increased 
in both the cord and maternal plasma taken from women who laboured compared with non-labour. 
3-phosphoglycerate was significantly increased in cord plasma. 
3.11. Energy Super-Pathway 
Eleven metabolites were measured in this super-pathway (Table 2). Six metabolites of the TCA cycle 
were significantly increased in cord plasma of labouring women, but only three increased in 
maternal plasma (Tables S1 and S2). There were no significant changes in oxidative phosphorylation. 
3.12. Co-Factors and Vitamins 
 Thirty-one metabolites were measured in this super-pathway
 (Figure 1b and 
Table 2). Of these, 1-methylnicotinamide, N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-
pyridone-3-carbox-amide from nicotinate and nicotinamide metabolism were significantly decreased 
in the cord plasma taken from women who laboured (VC/EC), and adenosine 5’-diphosphoribose 




Heme significantly increased 14.3-fold in cord plasma (VC/EC), with no change seen in the maternal 
plasma, and two metabolites of vitamin A metabolism and one metabolite of vitamin B6 metabolism 
were significantly increased with labour in maternal plasma (VM/EM), with no corresponding 
changes 
in the cord (Tables S1 and S2). 
4. Discussion 
To our knowledge, this study is unique in its comparison of the metabolomic profile of cord and 
maternal plasma at the time of delivery between women who have laboured and delivered vaginally 
and women who have not laboured and delivered via elective caesarean section. The clear-cut 
differences in metabolite levels between the two groups confirm the strong impact that active 
labour has on both mother and neonate. A proportion of these changes may be due to the stress of 
labour itself, but we believe that within these metabolites there are clues as to which pathways 
trigger spontaneous parturition in women. In addition, the observed changes in xenobiotics such as 
metronidazole were as expected, supporting the robustness of metabolomic methodology in this 
setting. While it cannot be ruled out that the intervillous blood samples had some degree of fetal 
blood contamination, the very distinct metabolic profiles that we obtained in cord and intervillous 
plasma confirms the fetal and maternal circulations were sampled separately [25], thereby 
confirming the reliability of this non-invasive method for experimental sampling of maternal blood 
after delivery. 
It could be argued that the stress of labour resembles strenuous exercise, and it would be useful to 
look to studies which investigate metabolic changes due to exercise to see if they match any of the 
changes observed here. Medium- and long-chain acetylcarnitines increase up to 9-fold following 
intense exercise in men [30]. A major source of acetylcarnitine is acetyl Co-A, formed from pyruvate 
oxidation, and this increase following exercise is likely due to a switch to increased fatty acid 
oxidation in skeletal muscle instead of glycolysis during exercise [31,32]. The significant increases in 
acylcarnitine fatty acid metabolism observed in both the cord and maternal plasma of labouring 
women (VC/EC and VM/EM) (Tables S1 and S2) could in part be explained by fatty acid oxidation for 
energy used by the woman and neonate during labour and delivery. However, while the source of 
this may be from working skeletal muscle in the labouring mother, this explanation is less likely in 
the fetus/neonate who is not thought to be using their skeletal muscles during labour and delivery. 
The increased levels of stress metabolites observed in labour, including cortisol, are likely to be 
generating fatty acid mobilisation [33]. The increase in sphingomyelins observed in labouring 
maternal plasma and the increase in acylcarnitine fatty acid metabolism in both the cord and 
maternal plasma of labouring women could indicate a considerable shift in intermediary metabolism 
at the time of labour following the relative decrease of these metabolites in pregnancy [34]. 
Labour and vaginal delivery would be expected to affect metabolites of fetal and maternal adrenal 
origin, particularly glucocorticoids, as part of the physiological stress response [35,36]. In support of 
this theory, we found cortisol and its major metabolites cortisone, cortisone 21-sulfate and 
corticosterone were significantly increased in the cord plasma of women who spontaneously 
laboured and delivered vaginally (VC) when compared with those who did not labour (EC). Similarly, 
cortisol and corticosterone were significantly increased in the maternal plasma taken from women 
who laboured and delivered vaginally (VM) when compared with those who did not labour (EM) 
(Tables S1 and S2). Our data confirm that there is activation of the fetal and maternal adrenal cortex 
during labour and vaginal delivery, and while this may be part of the mechanism initiating 




Within cord plasma (VC/EC), heme was the metabolite with the greatest fold-change (Table S1). 
Heme is a complex of iron with protoporphyrin IX, present in haemoglobin and myoglobin. Its levels 
in the plasma can increase rapidly following haemolysis or tissue injury [37]. It is possible that the 
increased heme present in the cord taken from women who laboured is a marker of the increased 
trauma and tissue damage which a neonate experiences during vaginal delivery when compared 
with delivery via caesarean section. 
4.1. Endocannabinoids, Ceramides and Sphingolipids 
Endocannabinoids have been investigated as biomarkers for reproductive events, with both 
predictive and diagnostic uses [38]. Formed from membrane phospholipids, endocannabinoids are 
described as non-classical neurotransmitters [38]. Of the two characterised cannabinoid receptors, 
CB1 is present in areas of the brain, peripheral nerve terminals and extraneural sites including the 
uterus, whereas CB2 is largely limited to cells and organs of the immune system [39]. N-
arachidonoylethanolamine (anandamide or AEA) binds to CB1 and CB2 and is broken down by the 
enzyme Fatty Acid Amide Hydrolase (FAAH) [39]. Cannabis exogenously acts on the endocannabinoid 
system, and its use has been associated with pregnancy complications such as preterm birth, 
placental abruption, fetal growth restriction and spontaneous miscarriage [40]. Elevated plasma AEA 
in early pregnancy (<8 weeks) and lower peripheral lymphocyte expression of FAAH has been 
associated with miscarriage [40,41], and the CB1-knock out mouse has elevated corticotrophin-
releasing hormone (CRH) and spontaneous preterm labour [42]. The uterus can produce its own AEA 
[39], and myometrial studies show a concentration-dependent relaxation effect of AEA on human 
myometrial contraction in vitro [43]. Of note, FAAH converts AEA to ethanolamine and releases 
arachidonic acid for prostaglandin synthesis, providing a potential link between elevated AEA and 
labour [42]. Ceramide is a ubiquitous sphingolipid second messenger released rapidly in response to 
apoptosis and stress [44]. CB1 activation induces sphingomyelin hydrolysis and acute production of 
ceramide, while CB2 activation leads to de novo sustained ceramide production [39]. The pro-
inflammatory cytokine TNFα is involved in CB1 and CB2 activation and ceramide production 
[39,44,45], whereby inflammatory events may stimulate the onset of labour. 
In this study, AEA, oleoyl ethanolamide (OEA), and palmitoyl ethanolamide (PEA) were significantly 
increased in the cord plasma taken from the women who laboured (VC/EC) (Table S8). PEA was 
significantly increased in the corresponding maternal plasma (VM/EM), while N-oleoylserine 
significantly decreased in maternal plasma. Interestingly, while in previous studies maternal plasma 
AEA has been shown to decline throughout pregnancy until a sharp increase at the time of 
spontaneous or induced labour [40,42], we found no difference in the maternal plasma (VM/EM) 
immediately following delivery between women who laboured and women who did not; however 
there was a significant increase in endocannabinoids, including AEA, in the cord plasma of women 
who laboured (VC/EC). It is possible that any increase in AEA is localised to the placenta during 
labour, and it has previously been shown that AEA concentrations are significantly higher in the 
umbilical vein than the umbilical arteries, which suggests either production by or transportation 
across the placenta [40]. In addition, we found 71% (12/17) of the measured ceramides increased 
significantly in the maternal plasma (VM/EM) (Table S9), while none increased in the cord plasma 
(VC/EC). Correspondingly, 40% (22/55) of measured sphingolipids were increased in the maternal 
plasma (VM/EM) while only 2% (1/55) significantly changed in the cord plasma (VC/EC). This finding 
supports previous reports of increased ceramide levels and expression of serine palmitoyl 
transferase, the rate-limiting enzyme for ceramide synthesis de novo, in the placentas of women 
who laboured compared with those who delivered by elective CS. This group also reported an 




mechanisms in labour [46]. Our data support the view that the 
endocannabinoid/ceramide/sphingolipid pathway has the potential to stimulate labour [40,42,46]. 
4.2. Prostaglandins 
Prostaglandins are involved in the early preparation for parturition including cervical ripening 
(prostaglandin E2) and stimulation of contractility (prostaglandin F2α), as well as rupture of 
membranes. Increases in prostaglandins, prostacyclin and their metabolites during advancing labour 
have been demonstrated in maternal plasma, amnion and amniotic fluid [47–49]. Prostacyclin and 
thromboxane metabolites increase in maternal urine in threatened preterm labour [50], and the 
prostacyclin metabolite 6-ketoprostaglandin F1α increases in maternal urine both during vaginal 
delivery and elective CS [51]. 
In our study, the eicosanoid 12-HETE was significantly increased in the maternal plasma of women 
who laboured and delivered vaginally (VM/EM) (Table S2), however no prostaglandins were 
detected. This may be due to the concentrations of prostaglandins in plasma being too low to detect 
using this metabolomic platform, or because the samples were collected following placental 
separation with a potentially rapid turnover resulting in these eicosanoid metabolites being excreted 
into the urine prior to sample collection. 
4.3. Progesterone and Pregnenolone 
Functional progesterone withdrawal has been linked to the onset of labour [42]. Although there 
were no significant differences in progesterone levels in the cord (VC/EC) or maternal (VM/EM) 
plasma in our study, there was a significant increase in metabolites of the progestin sub-pathway in 
the maternal plasma of labouring women (VM/EM). There is a strong positive correlation of 3β- and 
16α-hydroxysteroids with gestational age [52]. This reflects maturation of the fetal adrenal zone and 
potential involvement of these metabolites in the preparation for labour. 
Parturition has long been associated with changes in progesterone and pregnenolone metabolism in 
many species [53,54]. Our findings have uncovered a rich and complex pattern of steroid 
metabolites in spontaneous labour and vaginal delivery reflected in both maternal and fetal 
circulations (Tables S6 and S7). Of interest is the relative increase in VC/EC of pregnenolone and 
hydroxypregnenolone sulfates which are mirrored by changes in the opposite direction in the 
maternal circulation (Table S6). Moreover, progesterone and pregnandiol metabolites increased in 
both the maternal and fetal circulations (Table S7). These changes indicate increased turnover of C21 
compounds, which are the first steroids derived from cholesterol through the P450scc and 3β-
hydroxysteroid dehydrogenase pathway during labour. We have previously demonstrated changes 
in cholesterol-transporting lipoproteins in the maternal circulation in women in spontaneous labour 
[55], confirming the need for high cholesterol turnover during parturition. Our results present, for 
the first time, a comprehensive picture of C21 metabolites in the maternal and fetal circulations in 
relation to labour and vaginal delivery that can be used to guide future studies investigating steroid 
changes at parturition. 
4.4. Estrogen 
Estrogen synthesis in pregnancy results from the integration of maternal, placental and fetal tissues 
[56]. Placental Corticotrophin Releasing Hormone (CRH) stimulates the fetal adrenals to produce 
DHEA-sulfate (DHEA-S), which is 16-hydroxylated in the fetal liver and converted to estriol and 
estrone in the placenta [57,58]. In our study, 16a-hydroxy DHEA 3-sulfate significantly decreased in 




in the maternal plasma (VM/EM) and estrone 3-sulfate significantly increased in the cord plasma 
(VC/EC) of women who laboured (Tables S1 and S2). This provides an interesting insight into the 
effect of labour on the metabolism of estrogens. It is likely that these changes are related to 
substrate availability, including DHEA and its sulfated derivatives, as well as local changes in enzyme 
activity involving sulfatases, sulfotransferases, hydroxylases and aromatases, and their redox 
cofactors including NADH and NADPH in the uterus, placenta, adrenals, liver and other organs. The 
regulatory effect of hormones and growth factors such as CRH [58,59] and epidermal growth factor 
[60] on each pathway will be modulated by acute changes in cofactor availability during the process 
of labour which places strong energy and redox demands on the uterus. Previously reported 
increases in the estriol/estradiol ratio in maternal plasma occur gradually over several weeks before 
labour onset [59]. Our findings of a decrease in 16a-hydroxy DHEA 3-sulfate in the cord and maternal 
plasma and a decrease in estriol 3-sulfate in the maternal plasma of women who laboured may 
indicate a sudden decrease in production of DHEA-S by the fetal adrenals at the time of or during 
spontaneous labour. This adds further depth to our knowledge of the complex steroid pathways 
involved in the spontaneous onset of human labour. In addition, changes in estrogenic metabolites 
in the maternal and fetal circulations may not necessarily reflect local tissue changes, such as within 
the myometrium, which may also have a functional effect on uterine contractility [61]. While there 
are many practical advantages in sampling the peripheral circulation, and our study provides clear 
cut overall differences in steroid metabolites between labouring and non-labouring women, the 
limitation of metabolomic studies using peripheral blood is that the dilution effect and the 
contribution of many organs to steroid metabolism may obscure local changes in individual tissues. 
Further work is necessary to understand these mechanisms, combining peripheral plasma 
metabolomics with measurements of enzyme activity in specific tissues. A potential limitation to this 
study is the relatively low number of participants in each group. However, clear and significant 
changes in metabolite levels were identified within this pilot group with relatively little noise, 
demonstrating the reliability of this approach. The platform used is very robust 
with 26.9% (222/826) of metabolites significantly changing in maternal plasma and 21.1% (174/826) 
in cord plasma with labour. The method is unlikely to show false positive results: for example 
metronidazole was given at the time of knife-to-skin for all women in the elective CS group, but 
none of the women in the VD group received it; reassuringly, all the maternal and cord plasma of the 
non-labour group contained metronidazole and none of the labouring group contained it (Tables S3 
and S4). Another limitation is the fact that the study is cross sectional, rather than serial, so it is 
difficult to know whether the changes observed with labour are part of the mechanism of the 
initiation of labour or a consequence of the stress and metabolic demands of several hours of active 
labour. Nevertheless, our data show that metabolomic techniques are a powerful approach to 
identify biochemical changes associated with labour. 
5. Conclusions 
In this pilot study we have demonstrated a wide range of metabolic changes at the time of delivery 
between women who laboured spontaneously and women who did not labour. The data will be 
useful to investigate the biochemical pathways involved in the physiological mechanism of labour in 
normal term pregnancy and provide a pattern against which pathological changes in preterm labour 
can be compared. Our results demonstrate an interplay between metabolites in the maternal and 
fetal circulations which point to the involvement of the endocannabinoid, sphingolipid, ceramide 
and steroid systems in the mechanism of active labour. Further studies are now warranted, where 
serial maternal samples are taken throughout pregnancy to determine when these changes take 
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APPENDIX 3A1: Copy of patient information leaflet used for the study outlined in 







Division of Obstetrics and Gynaecology  
St. Michael’s Hospital 
Southwell Street 
Bristol BS2 8EG 
 
Telephone: 0117 34 25341 
e-mail: a.lopezbernal@bristol.ac.uk 
 




Patient Information Sheet: Investigating Human Labour 
 
You are being invited to contribute samples for a research study. Before you decide whether you 
wish to contribute, it is important for you to understand why the research is being done, and what it 
will involve.  
• Part 1 tells you the purpose of this study and what will happen to you if you take part.  
• Part 2 gives you more detailed information about the conduct of the study. 
 
Please read the following information carefully and ask us if there is anything that is unclear, or on 




What is the purpose of the study?  
The aim of the project is to identify certain substances in the womb that may trigger labour, in order 
that we can identify and eventually prevent women from going into premature labour or facilitate 
induction of labour when indicated. 
 
Why have I been chosen?  
The samples you give us will help us understand how labour begins, with the long-term aim of being 
able to predict and prevent premature labour or to facilitate induction of labour in late pregnancy. 
 
Do I have to take part?  
No, you are under no obligation to contribute samples to this study. It is up to you whether you 
decide to take part. If you do decide to take part, you are free to withdraw your consent at any time. 
Your delivery will be unaffected whether or not you decide to take part. If you withdraw your 
consent after samples have been taken, they will be disposed of under strict Trust guidelines which 
govern the disposal of such samples with the provision that it will not affect your treatment. 
 




We would like to take a small sample from your placenta, once your baby has been delivered. The 
samples will be about the size of a peanut. We would also like to take blood samples from the cord 
and a matching sample from you if possible. As the placenta will already be delivered, this process 
will involve no pain or potential harm to either yourself or your baby. This tissue would normally be 
disposed of after delivery.  
If you happen to require a Caesarean section, we would also like to take a small sample of tissue, 
again about the size of a peanut, from your womb during the operation. Taking the sample would 
have no effect on your operation, or subsequent recovery. 
 
What are the possible disadvantages and risks of taking part?  
Very rarely taking tissue from the womb will cause a little extra bleeding but there are no long 
term effects from this. Taking placental and cord blood samples has no known risks. 
 
What are the possible benefits of taking part? 
The procedure will be of no direct benefit to you or your baby. However, the samples you give us 
will help us understand how labour begins, with the long-term aim of being able to predict and 
prevent preterm labour. 
 
What if there is a problem?  
Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed. 
 
Contact Details:  
If you would like to contact a member of our team, if you have any concerns or would like any 
further information, you can do so by contacting Dr Kate Birchenall  
 
This completes Part 1 of the Information Sheet.  
If the information in Part 1 has interested you and you are considering participation, 





If you have a concern about any aspect of this study, you should ask to speak with the researchers 
who will do their best to answer your questions. If you remain unhappy and wish to complain 
formally, you can do this through the NHS Complaints Procedure. Details can be obtained from the 
hospital. 
 
Will my taking part in this study be kept confidential?  
If you do decide to contribute to the study, the researchers and clinicians will record some details of 
your delivery (for example the gestational age at delivery and mode of delivery). These details will be 
collected from your maternity records and are essential to the project, enabling us to distinguish 
between term and preterm samples, in labour and not in labour samples, for example. Only the 
researchers involved with the study will have access to this information. Our procedures for handling, 
processing, storage and destruction of the data are compliant with the Data Protection Act 1998. The 
data and samples will be given a laboratory number and will be anonymised. The samples, including 
DNA, may be retained after the study is completed to contribute to further studies on preterm labour, 
or disposed of under strict Trust and Human Tissue Authority guidelines. The laboratory information 
gained from the samples will have no effect on any subsequent treatment you may have. 
 
What will happen to any samples I give?  
The samples will be analysed in the University of Bristol, but some extracts may be analysed in 
other centres through existing collaborators with specific methods to investigate the mechanism 





What will happen to the results of the research study?  
You will not be notified of the results of the study. The results will be published in medical journals 
and presented at national and international scientific meetings and medical conferences. You will 
not be identified in any report/publication. 
 
Who is organising and funding the research?  
Professor López Bernal is leading the research and it is funded by Bristol Research Charities 
(David Telling Trust; Mother and Baby Trust) 
 
Who has reviewed the study?  
This study was given a favourable ethical opinion by the NRES Committee South West – Central 
Bristol. 
 
Thank you for taking the time to read this information sheet. You may keep this 
information sheet and if you are happy to be involved in the study you will also be 
given a copy of the signed consent form. 
 
























APPENDIX 3A2: Copy of patient consent form used for studies presented in 









Division of Obstetrics and Gynaecology  
St. Michael’s Hospital 
Southwell Street 
Bristol BS2 8EG 
 
Telephone: 0117 34 25341 
e-mail: a.lopezbernal@bristol.ac.uk 
 
Patient Consent Form: Investigating Human Labour 
 
Head of Research Project: Professor A. López Bernal 
Consultant, Lead for Day Assessment Unit:   
Researcher, Dr Kate Birchenall  




Patient Identifier ____________________________________  
 
 
1. I confirm that I have read the Patient information sheet Version 10 dated 23 September 2016 for the 
above study. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my medical care or legal rights being affected. If I withdraw my consent 
after the samples have been taken, they will be disposed of under UHB Trust / HTA guidelines.  
 
 
3. I give permission for my medical records to be looked at and the information taken from them to be 
analysed in strict confidence by responsible people from the research team.  
 
4. I agree to take part in the above study.  
 
5. I agree to allow any remaining samples after completion of this study to be retained in an 
anonymised form for similar studies with ethical approval. 
 
 
______________________ ______________ _______________________ 
Name of Patient (BLOCK CAPITALS) Date Signature 
___________________ _______________ _______________________ 
 
Name of person taking consent   
(if different from researcher) Date Signature 
_________________________ _______________ _______________________ 
Researcher Date Signature 
 




APPENDIX 3A3: Table presenting metabolites for which the fold-change is significant (p≤0.05) between: 28 and 34 weeks’ 
gestation samples (34/28); 28 weeks’ gestation and latent stage samples (Latent/28 weeks); 34 weeks’ gestation and latent 
stage (Latent/34). Corresponding p-values and q-values are shown. 

















Drug - Analgesics, 
Anesthetics 
Xenobiotics 22.26 0.0065 0.0437 325.10 0.0003 0.0012 14.60 0.0024 0.0066 
4-acetaminophen sulfate Drug - Analgesics, 
Anesthetics 
Xenobiotics 14.51 0.0116 0.0654 480.17 0.0003 0.0014 33.08 0.0029 0.0074 
2-hydroxyacetaminophen 
sulfate 
Drug - Analgesics, 
Anesthetics 
Xenobiotics 9.27 0.0473 0.1447 188.77 0.0002 0.0010 20.36 0.0020 0.0060 
2-isopropylmalate Food 
Component/Plant 





Lipid 3.03 0.0003 0.0049 3.52 0.0001 0.0008       
2,3-dihydroxyisovalerate Food 
Component/Plant 





Lipid 2.87 0.0255 0.1018             
5-hydroxyindoleacetate Tryptophan 
Metabolism 





Lipid 2.27 0.0242 0.1006 2.36 0.0009 0.0028 1.04 0.0083 0.0147 
4-hydroxyglutamate Glutamate 
Metabolism 
Amino Acid 2.22 0.0001 0.0033 3.09 0.0000 0.0002 1.39 0.0109 0.0177 
taurohyocholate Secondary Bile 
Acid Metabolism 
Lipid 2.06 0.0269 0.1035 3.74 0.0210 0.0263       
testosterone sulfate Androgenic 
Steroids 
Lipid 2.00 0.0002 0.0034 7.11 0.0000 0.0004 3.56 0.0001 0.0011 
glycohyocholate Secondary Bile 
Acid Metabolism 









Lipid 1.73 0.0105 0.0604             
oleoyl-oleoyl-glycerol 
(18:1/18:1) [2] 
Diacylglycerol Lipid 1.72 0.0013 0.0121 2.28 0.0003 0.0012       
glycochenodeoxycholate 3-
sulfate 
Primary Bile Acid 
Metabolism 
Lipid 1.72 0.0096 0.0580 2.03 0.0043 0.0078       





Lipid 1.71 0.0127 0.0673 5.18 0.0022 0.0049 3.04 0.0017 0.0054 
phenylalanylhydroxyproline Dipeptide Peptide 1.70 0.0007 0.0086 1.68 0.0208 0.0261       
glycocholate Primary Bile Acid 
Metabolism 
Lipid 1.69 0.0469 0.1441 3.52 0.0413 0.0448       
1,3-dimethylurate Xanthine 
Metabolism 
Xenobiotics 1.68 0.0132 0.0680 1.94 0.0014 0.0036       
5alpha-pregnan-
3beta,20alpha-diol disulfate 
Progestin Steroids Lipid 1.64 0.0000 0.0012 1.66 0.0002 0.0008       
estriol 3-sulfate Estrogenic 
Steroids 























Amino Acid 1.55 0.0036 0.0285 1.81 0.0107 0.0160       
pregnanolone/allopregnanolo
ne sulfate 
Progestin Steroids Lipid 1.54 0.0002 0.0035 1.87 0.0001 0.0006       
estriol 16-glucuronide Estrogenic 
Steroids 






Progestin Steroids Lipid 1.53 0.0006 0.0073 1.97 0.0000 0.0004       
indole-3-carboxylate Tryptophan 
Metabolism 
Amino Acid 1.53 0.0117 0.0654             
progesterone Progestin Steroids Lipid 1.51 0.0002 0.0034 1.82 0.0000 0.0001 1.21 0.0014 0.0051 




Progestin Steroids Lipid 1.43 0.0000 0.0020 1.41 0.0023 0.0050       









Amino Acid 1.42 0.0034 0.0275 1.60 0.0028 0.0059       




Amino Acid 1.41 0.0000 0.0004 1.53 0.0004 0.0016       
sphinganine Sphingolipid 
Synthesis 
Lipid 1.41 0.0230 0.0980 1.38 0.0264 0.0314       













Lipid 1.40 0.0071 0.0472             
N-stearoyl-sphinganine 
(d18:0/18:0) 
Dihydroceramides Lipid 1.39 0.0284 0.1072 1.53 0.0375 0.0415       
17beta-estradiol Estrogenic 
Steroids 
Lipid 1.38 0.0000 0.0003 1.83 0.0002 0.0009 1.33 0.0105 0.0173 
glutamate Glutamate 
Metabolism 








2-hydroxyoctanoate Fatty Acid, 
Monohydroxy 
Lipid 1.37 0.0345 0.1205             
pelargonate (9:0) Medium Chain 
Fatty Acid 
Lipid 1.36 0.0002 0.0040 1.28 0.0034 0.0068       
N1,N12-diacetylspermine Polyamine 
Metabolism 
Amino Acid 1.35 0.0002 0.0040       0.66 0.0000 0.0001 
estriol-3-glucuronide Estrogenic 
Steroids 










Nucleotide 1.33 0.0157 0.0763 1.34 0.0134 0.0190       
estrone 3-sulfate Estrogenic 
Steroids 
Lipid 1.33 0.0393 0.1291 1.84 0.0053 0.0092       
isocaproate (i6:0) Fatty Acid, 
Branched 




Nucleotide 1.32 0.0180 0.0834 1.25 0.0261 0.0313       
indolin-2-one Food 
Component/Plant 
Xenobiotics 1.32 0.0387 0.1279             
N-acetyl-isoputreanine Polyamine 
Metabolism 
Amino Acid 1.31 0.0000 0.0004 1.39 0.0000 0.0003       




Lipid 1.31 0.0005 0.0066 2.11 0.0000 0.0005 1.61 0.0295 0.0336 








1.31 0.0144 0.0722 1.55 0.0275 0.0324       













Peptide 1.31 0.0416 0.1330 1.73 0.0001 0.0007 1.32 0.0291 0.0334 
cortisone Corticosteroids Lipid 1.30 0.0000 0.0003 1.54 0.0000 0.0001 1.19 0.0411 0.0422 










Lipid 1.29 0.0000 0.0003 1.68 0.0000 0.0000 1.30 0.0000 0.0001 
oleoyl-linoleoyl-glycerol 
(18:1/18:2) [2] 
Diacylglycerol Lipid 1.29 0.0041 0.0322 1.43 0.0056 0.0095       
20a-dihydroprogesterone Progestin Steroids Lipid 1.28 0.0001 0.0031 1.94 0.0000 0.0002 1.52 0.0014 0.0051 
ribitol Pentose 
Metabolism 
Carbohydrate 1.28 0.0012 0.0120 1.37 0.0001 0.0007       




Lipid 1.28 0.0116 0.0654 4.63 0.0000 0.0001 3.60 0.0001 0.0014 
hexadecasphingosine (d16:1) Sphingosines Lipid 1.28 0.0328 0.1166       0.74 0.0075 0.0140 





Lipid 1.25 0.0001 0.0031 1.55 0.0000 0.0005 1.24 0.0008 0.0039 
oleoyl-arachidonoyl-glycerol 
(18:1/20:4) [2] 
Diacylglycerol Lipid 1.25 0.0327 0.1166 1.71 0.0021 0.0049 1.37 0.0243 0.0294 
4-acetamidobutanoate Polyamine 
Metabolism 









Progestin Steroids Lipid 1.24 0.0002 0.0034 1.63 0.0000 0.0001 1.32 0.0016 0.0053 
3-hydroxybutyroylglycine Fatty Acid 
Metabolism (Acyl 
Glycine) 








Lipid 1.24 0.0253 0.1018 1.14 0.0023 0.0052       









Lipid 1.23 0.0000 0.0003 1.55 0.0000 0.0002 1.26 0.0007 0.0036 
erythritol Food 
Component/Plant 
Xenobiotics 1.23 0.0245 0.1011 1.49 0.0005 0.0019 1.21 0.0127 0.0193 





1.22 0.0001 0.0031             





Nucleotide 1.21 0.0054 0.0376             
dodecadienoate (12:2) Fatty Acid, 
Dicarboxylate 





Nucleotide 1.21 0.0298 0.1091 1.63 0.0045 0.0082 1.35 0.0050 0.0112 
sphingosine 1-phosphate Sphingosines Lipid 1.21 0.0351 0.1206 1.36 0.0160 0.0215       
androstenediol 
(3beta,17beta) disulfate (2) 
Androgenic 
Steroids 
Lipid 1.20 0.0012 0.0120 1.84 0.0013 0.0034 1.54 0.0012 0.0049 




1.20 0.0298 0.1091 1.36 0.0005 0.0018 1.14 0.0247 0.0297 
beta-citrylglutamate Glutamate 
Metabolism 














Nucleotide 1.19 0.0004 0.0053 1.29 0.0095 0.0145       
N-acetylneuraminate Aminosugar 
Metabolism 
Carbohydrate 1.19 0.0077 0.0498             
trans-2-hexenoylglycine Fatty Acid 
Metabolism (Acyl 
Glycine) 






Lipid 1.18 0.0001 0.0031 1.24 0.0005 0.0018       
hydroxyasparagine Alanine and 
Aspartate 
Metabolism 
Amino Acid 1.18 0.0004 0.0062 1.31 0.0009 0.0027 1.12 0.0407 0.0418 
(N(1) + N(8))-acetylspermidine Polyamine 
Metabolism 





Lipid 1.18 0.0010 0.0109 1.18 0.0304 0.0351       
N-acetylputrescine Polyamine 
Metabolism 
Amino Acid 1.18 0.0012 0.0120 1.35 0.0254 0.0307       
cortolone glucuronide (1) Corticosteroids Lipid 1.18 0.0104 0.0604 1.70 0.0003 0.0012 1.45 0.0008 0.0039 
5-(galactosylhydroxy)-L-lysine Lysine 
Metabolism 
Amino Acid 1.17 0.0012 0.0120 1.44 0.0000 0.0003 1.24 0.0002 0.0018 
16a-hydroxy DHEA 3-sulfate Androgenic 
Steroids 
Lipid 1.17 0.0236 0.0994 1.66 0.0001 0.0006 1.42 0.0001 0.0010 




Amino Acid 1.17 0.0443 0.1390 1.56 0.0000 0.0005 1.33 0.0016 0.0053 
N-acetylhistidine Histidine 
Metabolism 









O-sulfo-L-tyrosine Chemical Xenobiotics 1.16 0.0086 0.0528 1.34 0.0001 0.0005 1.16 0.0003 0.0025 
dimethylglycine Glycine, Serine 
and Threonine 
Metabolism 
Amino Acid 1.15 0.0002 0.0040 1.24 0.0197 0.0252       
C-glycosyltryptophan Tryptophan 
Metabolism 
Amino Acid 1.15 0.0008 0.0093 1.13 0.0384 0.0420       
erythronate Aminosugar 
Metabolism 
Carbohydrate 1.15 0.0008 0.0093 1.39 0.0000 0.0001 1.21 0.0000 0.0002 
3-methoxytyrosine Tyrosine 
Metabolism 





Lipid 1.15 0.0213 0.0925 1.25 0.0012 0.0034 1.09 0.0331 0.0363 
alpha-ketoglutaramate Glutamate 
Metabolism 






Nucleotide 1.15 0.0365 0.1232             
tetradecadienoate (14:2) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 















Nucleotide 1.14 0.0045 0.0339 1.46 0.0000 0.0002 1.28 0.0000 0.0002 
2S,3R-dihydroxybutyrate Fatty Acid, 
Dihydroxy 


















































Carbohydrate 1.12 0.0005 0.0067 1.24 0.0000 0.0000 1.11 0.0024 0.0066 
N-acetylglutamine Glutamate 
Metabolism 
Amino Acid 1.12 0.0155 0.0761 1.43 0.0005 0.0018 1.27 0.0038 0.0090 
N-palmitoyl-sphinganine 
(d18:0/16:0) 



















2-hydroxynervonate Fatty Acid, 
Monohydroxy 
Lipid 1.11 0.0353 0.1206 1.47 0.0001 0.0005 1.32 0.0001 0.0010 
choline Phospholipid 
Metabolism 
Lipid 1.10 0.0026 0.0223             









Lipid 1.10 0.0223 0.0955 1.15 0.0414 0.0449       
gamma-carboxyglutamate Glutamate 
Metabolism 
Amino Acid 1.10 0.0310 0.1130 1.24 0.0002 0.0011 1.13 0.0123 0.0191 
7-alpha-hydroxy-3-oxo-4-
cholestenoate (7-Hoca) 
Sterol Lipid 1.09 0.0000 0.0012 1.28 0.0001 0.0005 1.18 0.0077 0.0141 




Lipid 1.09 0.0164 0.0773 2.26 0.0000 0.0005 2.06 0.0038 0.0089 






1.09 0.0193 0.0868             
myo-inositol Inositol 
Metabolism 





Amino Acid 1.09 0.0368 0.1238 1.17 0.0137 0.0192       




Nucleotide 1.08 0.0105 0.0604 1.22 0.0000 0.0003 1.12 0.0012 0.0049 
cis-4-decenoate (10:1n6) Medium Chain 
Fatty Acid 
Lipid 1.08 0.0186 0.0859 1.66 0.0005 0.0018 1.53 0.0438 0.0442 
1-methyl-4-imidazoleacetate Histidine 
Metabolism 
Amino Acid 1.08 0.0288 0.1082 1.30 0.0000 0.0002 1.20 0.0006 0.0034 











Amino Acid 1.07 0.0262 0.1027             




1.07 0.0320 0.1158 1.19 0.0002 0.0009 1.11 0.0067 0.0132 







Amino Acid 1.06 0.0126 0.0673 1.36 0.0000 0.0001 1.28 0.0000 0.0002 
N-acetylserine Glycine, Serine 
and Threonine 
Metabolism 
Amino Acid 1.06 0.0139 0.0707 1.21 0.0010 0.0029 1.14 0.0018 0.0055 











Lipid 1.06 0.0237 0.0996 1.16 0.0016 0.0040 1.09 0.0015 0.0052 
N6,N6-dimethyllysine Lysine 
Metabolism 
Amino Acid 1.05 0.0032 0.0261             
N-acetylalanine Alanine and 
Aspartate 
Metabolism 





1.05 0.0153 0.0756 1.10 0.0082 0.0129       










Lipid 1.02 0.0322 0.1159             








0.99 0.0132 0.0680 3.99 0.0000 0.0004 4.03 0.0009 0.0039 
carnitine Carnitine 
Metabolism 






Plasmalogen Lipid 0.92 0.0035 0.0280       1.15 0.0181 0.0249 
sphingomyelin (d18:1/22:2, 
d18:2/22:1, d16:1/24:2) 





Lipid 0.92 0.0162 0.0773 0.92 0.0405 0.0442       




Lipid 0.92 0.0254 0.1018             
tryptophan Tryptophan 
Metabolism 
Amino Acid 0.91 0.0027 0.0230 0.82 0.0081 0.0129       
3,5-dichloro-2,6-
dihydroxybenzoic acid 
Chemical Xenobiotics 0.90 0.0002 0.0034 0.84 0.0001 0.0005 0.93 0.0013 0.0050 




Carbohydrate 0.90 0.0010 0.0108             
1-(1-enyl-palmitoyl)-2-
palmitoyl-GPC (P-16:0/16:0) 
Plasmalogen Lipid 0.90 0.0145 0.0724             
sphingomyelin (d18:2/14:0, 
d18:1/14:1) 





Nucleotide 0.90 0.0295 0.1091             




Plasmalogen Lipid 0.89 0.0053 0.0375             
N-formylanthranilic acid Tryptophan 
Metabolism 
Amino Acid 0.89 0.0200 0.0892 0.84 0.0298 0.0346       
1-palmitoyl-GPC (16:0) Lysophospholipid Lipid 0.89 0.0252 0.1018 1.04 0.8760 0.3978       










Chemical Xenobiotics 0.88 0.0045 0.0339 0.79 0.0000 0.0001 0.90 0.0083 0.0147 










Lipid 0.87 0.0049 0.0357             




Amino Acid 0.87 0.0355 0.1206       1.36 0.0001 0.0010 
androsterone sulfate Androgenic 
Steroids 
Lipid 0.86 0.0046 0.0339 0.85 0.0082 0.0129       





Lipid 0.84 0.0001 0.0027 0.91 0.0192 0.0248       
1-(1-enyl-palmitoyl)-2-oleoyl-
GPC (P-16:0/18:1) 




Plasmalogen Lipid 0.84 0.0018 0.0166             
1-(1-enyl-palmitoyl)-GPC (P-
16:0) 
Lysoplasmalogen Lipid 0.84 0.0397 0.1291             
androstenediol (3alpha, 
17alpha) monosulfate (3) 
Androgenic 
Steroids 





Xenobiotics 0.83 0.0203 0.0892 0.49 0.0141 0.0196       
2-palmitoleoyl-GPC (16:1) Lysophospholipid Lipid 0.83 0.0447 0.1390       1.42 0.0122 0.0191 
1-cerotoyl-GPC (26:0) Lysophospholipid Lipid 0.82 0.0427 0.1351 0.70 0.0010 0.0028 0.85 0.0078 0.0141 
ceramide (d18:1/14:0, 
d16:1/16:0) 










epiandrosterone sulfate Androgenic 
Steroids 
Lipid 0.78 0.0003 0.0050 0.76 0.0033 0.0067       




Amino Acid 0.77 0.0082 0.0524             
indolepropionate Tryptophan 
Metabolism 






Lipid 0.68 0.0280 0.1071       2.57 0.0020 0.0059 
4-methylbenzenesulfonate Chemical Xenobiotics 0.67 0.0406 0.1313             
o-cresol sulfate Benzoate 
Metabolism 
Xenobiotics 0.63 0.0448 0.1390             
4-acetamidophenol Drug - Analgesics, 
Anesthetics 
Xenobiotics       260.84 0.0004 0.0017 46.73 0.0019 0.0057 
2-methoxyacetaminophen 
sulfate 
Drug - Analgesics, 
Anesthetics 
Xenobiotics       119.11 0.0003 0.0014 39.44 0.0015 0.0052 
2-methoxyacetaminophen 
glucuronide 
Drug - Analgesics, 
Anesthetics 
Xenobiotics       110.11 0.0004 0.0015 19.80 0.0015 0.0052 
3-(cystein-S-
yl)acetaminophen 
Drug - Analgesics, 
Anesthetics 
Xenobiotics       89.58 0.0003 0.0014 27.52 0.0017 0.0053 
3-(N-acetyl-L-cystein-S-yl) 
acetaminophen 
Drug - Analgesics, 
Anesthetics 
Xenobiotics       76.33 0.0003 0.0013 20.98 0.0015 0.0052 
lidocaine Drug - Analgesics, 
Anesthetics 
Xenobiotics       66.54 0.0358 0.0399 66.54 0.0364 0.0388 
3-(methylthio)acetaminophen 
sulfate 
Drug - Analgesics, 
Anesthetics 
Xenobiotics       18.41 0.0007 0.0024 10.73 0.0013 0.0049 
3-hydroxyoleate Fatty Acid, 
Monohydroxy 





Xenobiotics       6.12 0.0030 0.0064 19.51 0.0003 0.0023 
docosatrienoate (22:3n6) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 

















Xenobiotics       4.39 0.0188 0.0244 64.62 0.0173 0.0243 
3-hydroxybutyrate (BHBA) Ketone Bodies Lipid       4.28 0.0002 0.0011 4.03 0.0008 0.0038 
taurocholate Primary Bile Acid 
Metabolism 
Lipid       3.95 0.0106 0.0160       
tyramine O-sulfate Tyrosine 
Metabolism 
Amino Acid       3.46 0.0423 0.0456       
palmitoleate (16:1n7) Long Chain 
Monounsaturated 
Fatty Acid 
Lipid       3.42 0.0007 0.0023 3.33 0.0061 0.0124 
laurate (12:0) Medium Chain 
Fatty Acid 
Lipid       3.25 0.0011 0.0033 2.30 0.0122 0.0191 
hexadecadienoate (16:2n6) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 
Lipid       3.24 0.0005 0.0018 2.88 0.0073 0.0138 
10-heptadecenoate (17:1n7) Long Chain 
Monounsaturated 
Fatty Acid 
Lipid       3.19 0.0003 0.0014 3.24 0.0021 0.0060 
stearidonate (18:4n3) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 
Lipid       3.05 0.0034 0.0068 3.07 0.0067 0.0132 
myristoleate (14:1n5) Long Chain 
Monounsaturated 
Fatty Acid 
Lipid       2.91 0.0018 0.0044 2.92 0.0088 0.0150 
linolenate [alpha or gamma; 
(18:3n3 or 6)] 
Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 
Lipid       2.90 0.0009 0.0028 2.49 0.0086 0.0148 
eicosenoate (20:1) Long Chain 
Monounsaturated 
Fatty Acid 




oleate/vaccenate (18:1) Long Chain 
Monounsaturated 
Fatty Acid 
Lipid       2.79 0.0002 0.0009 2.62 0.0024 0.0066 
hexanoylglutamine Fatty Acid 
Metabolism (Acyl 
Glutamine) 
Lipid       2.77 0.0003 0.0014 3.32 0.0004 0.0028 
myristate (14:0) Long Chain 
Saturated Fatty 
Acid 
Lipid       2.69 0.0003 0.0013 2.73 0.0017 0.0053 
branched-chain, straight-
chain, or cyclopropyl 12:1 







      2.62 0.0013 0.0034       




Lipid       2.60 0.0022 0.0050 3.25 0.0061 0.0124 
linoleate (18:2n6) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 
Lipid       2.59 0.0004 0.0017 2.31 0.0073 0.0138 
10-nonadecenoate (19:1n9) Long Chain 
Monounsaturated 
Fatty Acid 
Lipid       2.56 0.0004 0.0015 2.67 0.0009 0.0039 




Lipid       2.49 0.0006 0.0019 2.67 0.0006 0.0034 
2-butenoylglycine Fatty Acid 
Metabolism (Acyl 
Glycine) 
Lipid       2.44 0.0003 0.0014 2.36 0.0004 0.0028 
erucate (22:1n9) Long Chain 
Monounsaturated 
Fatty Acid 
Lipid       2.44 0.0004 0.0016 1.68 0.0019 0.0057 
9-hydroxystearate Fatty Acid, 
Monohydroxy 




(12 or 13)-methylmyristate 
(a15:0 or i15:0) 
Fatty Acid, 
Branched 
Lipid       2.33 0.0012 0.0034 2.76 0.0004 0.0028 
5-dodecenoate (12:1n7) Medium Chain 
Fatty Acid 
Lipid       2.33 0.0013 0.0035 2.30 0.0097 0.0162 
palmitate (16:0) Long Chain 
Saturated Fatty 
Acid 
Lipid       2.32 0.0002 0.0008 2.27 0.0012 0.0049 
sucrose Disaccharides and 
Oligosaccharides 






Lipid       2.27 0.0321 0.0363       
docosatrienoate (22:3n3) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 
Lipid       2.26 0.0221 0.0274 2.87 0.0146 0.0213 
(14 or 15)-methylpalmitate 
(a17:0 or i17:0) 
Fatty Acid, 
Branched 
Lipid       2.20 0.0004 0.0015 2.27 0.0004 0.0027 
1-palmitoleoylglycerol (16:1) Monoacylglycerol Lipid       2.17 0.0085 0.0132 2.06 0.0029 0.0074 
3-methylhistidine Histidine 
Metabolism 










Nucleotide       2.14 0.0133 0.0189 1.37 0.0494 0.0476 
margarate (17:0) Long Chain 
Saturated Fatty 
Acid 
Lipid       2.11 0.0001 0.0008 2.06 0.0007 0.0036 
dihomo-linoleate (20:2n6) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 
Lipid       2.11 0.0012 0.0034 2.16 0.0032 0.0081 
N-acetyl-1-methylhistidine Histidine 
Metabolism 




3-hydroxylaurate Fatty Acid, 
Monohydroxy 
Lipid       2.09 0.0001 0.0005 2.10 0.0042 0.0097 
docosadienoate (22:2n6) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 
Lipid       2.08 0.0006 0.0022 1.97 0.0008 0.0038 




Amino Acid       2.08 0.0075 0.0122 1.98 0.0218 0.0280 
palmitoyl-linoleoyl-glycerol 
(16:0/18:2) [2]  
Diacylglycerol Lipid       2.07 0.0024 0.0052 1.59 0.0355 0.0382 





Nucleotide       2.06 0.0001 0.0005 2.12 0.0000 0.0001 





Amino Acid       2.05 0.0023 0.0051 1.98 0.0015 0.0052 
8-methoxykynurenate Tryptophan 
Metabolism 
Amino Acid       2.04 0.0036 0.0070       




Fatty Acid (n3 and 
n6) 
Lipid       2.03 0.0041 0.0078 2.19 0.0055 0.0118 




Amino Acid       2.02 0.0001 0.0007 1.85 0.0002 0.0019 
4-methylhexanoylglutamine Fatty Acid 
Metabolism (Acyl 
Glutamine) 






Lipid       1.98 0.0001 0.0005 1.75 0.0130 0.0196 
(16 or 17)-methylstearate 
(a19:0 or i19:0) 
Fatty Acid, 
Branched 
Lipid       1.98 0.0009 0.0028 1.93 0.0004 0.0028 
3-hydroxykynurenine Tryptophan 
Metabolism 
Amino Acid       1.98 0.0290 0.0339       
corticosterone Corticosteroids Lipid       1.97 0.0267 0.0316       
adrenate (22:4n6) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 
Lipid       1.95 0.0088 0.0135 1.67 0.0406 0.0418 
decadienedioic acid (C10:2-
DC)   
Fatty Acid, 
Dicarboxylate 
Lipid       1.94 0.0058 0.0099 2.28 0.0292 0.0334 
mead acid (20:3n9) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 
Lipid       1.93 0.0008 0.0026 1.89 0.0025 0.0068 
formiminoglutamate Histidine 
Metabolism 
Amino Acid       1.93 0.0011 0.0031 2.33 0.0000 0.0003 





      1.91 0.0045 0.0081       






      1.86 0.0196 0.0251       
16-hydroxypalmitate Fatty Acid, 
Monohydroxy 
Lipid       1.84 0.0003 0.0013 1.75 0.0018 0.0056 
1-methylguanidine Guanidino and 
Acetamido 
Metabolism 
Amino Acid       1.84 0.0131 0.0189 1.61 0.0429 0.0435 
1-linoleoyl-GPA (18:2) Lysophospholipid Lipid       1.82 0.0018 0.0044 1.30 0.0045 0.0100 
3-hydroxymyristate Fatty Acid, 
Monohydroxy 









Lipid       1.80 0.0203 0.0257 1.60 0.0038 0.0090 
theophylline Xanthine 
Metabolism 
Xenobiotics       1.79 0.0009 0.0027       
androstenediol (3alpha, 
17alpha) monosulfate (2) 
Androgenic 
Steroids 
Lipid       1.77 0.0089 0.0136 1.47 0.0061 0.0124 
androstenediol 
(3beta,17beta) disulfate (1) 
Androgenic 
Steroids 
Lipid       1.76 0.0012 0.0034 1.82 0.0001 0.0014 
arachidate (20:0) Long Chain 
Saturated Fatty 
Acid 
Lipid       1.75 0.0000 0.0003 1.61 0.0001 0.0010 





Lipid       1.75 0.0015 0.0039 1.90 0.0123 0.0191 











Lipid       1.74 0.0008 0.0025 1.60 0.0022 0.0062 
caprate (10:0) Medium Chain 
Fatty Acid 
Lipid       1.74 0.0055 0.0094 2.21 0.0009 0.0039 
nonadecanoate (19:0) Long Chain 
Saturated Fatty 
Acid 
Lipid       1.73 0.0001 0.0005 1.66 0.0001 0.0013 
stearate (18:0) Long Chain 
Saturated Fatty 
Acid 
Lipid       1.72 0.0001 0.0008 1.64 0.0003 0.0023 
myristoleoylcarnitine (C14:1) Fatty Acid 
Metabolism (Acyl 
Carnitine, 












Lipid       1.72 0.0034 0.0068 1.61 0.0323 0.0357 
lactose Disaccharides and 
Oligosaccharides 
Carbohydrate       1.71 0.0025 0.0054 1.53 0.0001 0.0013 
13-HODE + 9-HODE Fatty Acid, 
Monohydroxy 
Lipid       1.71 0.0308 0.0352 1.83 0.0197 0.0263 
oleoyl-arachidonoyl-glycerol 
(18:1/20:4) [1] 
Diacylglycerol Lipid       1.70 0.0011 0.0031 1.45 0.0126 0.0193 




Lipid       1.70 0.0291 0.0339       
1,3,7-trimethylurate Xanthine 
Metabolism 
Xenobiotics       1.69 0.0002 0.0011       
pentadecanoate (15:0) Long Chain 
Saturated Fatty 
Acid 
Lipid       1.69 0.0002 0.0011 1.78 0.0006 0.0035 
nisinate (24:6n3) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 










Fatty Acid (n3 and 
n6) 
Lipid       1.64 0.0013 0.0035 1.83 0.0057 0.0119 
1-oleoylglycerol (18:1) Monoacylglycerol Lipid       1.64 0.0024 0.0052       













Lipid       1.63 0.0021 0.0048 1.60 0.0341 0.0372 
undecanedioate (C11-DC) Fatty Acid, 
Dicarboxylate 
Lipid       1.63 0.0432 0.0463       





      1.62 0.0005 0.0018 1.36 0.0006 0.0034 









Nucleotide       1.62 0.0017 0.0041 1.51 0.0421 0.0428 




Fatty Acid (n3 and 
n6) 
Lipid       1.62 0.0041 0.0077 1.68 0.0070 0.0135 
1,7-dimethylurate Xanthine 
Metabolism 
Xenobiotics       1.61 0.0166 0.0220       




Fatty Acid (n3 and 
n6) 
Lipid       1.59 0.0031 0.0064 1.66 0.0084 0.0147 
dodecenedioate (C12:1-DC) Fatty Acid, 
Dicarboxylate 
Lipid       1.57 0.0016 0.0040       
2-hydroxybehenate Fatty Acid, 
Monohydroxy 
Lipid       1.56 0.0001 0.0007 1.41 0.0001 0.0014 
cyclo(phe-pro) Dipeptide Peptide       1.56 0.0034 0.0068 1.14 0.0152 0.0220 
1-methylhistidine Histidine 
Metabolism 
Amino Acid       1.56 0.0062 0.0104 1.35 0.0461 0.0460 
3-hydroxyhexanoate Fatty Acid, 
Monohydroxy 
Lipid       1.55 0.0031 0.0064 1.57 0.0318 0.0356 
cysteinylglycine Glutathione 
Metabolism 






Xenobiotics       1.55 0.0062 0.0105       
1-palmitoyl-GPA (16:0) Lysophospholipid Lipid       1.55 0.0082 0.0129 1.26 0.0042 0.0097 









Amino Acid       1.53 0.0063 0.0106 1.59 0.0009 0.0039 
pregnenetriol disulfate Pregnenolone 
Steroids 





Amino Acid       1.53 0.0488 0.0510 1.38 0.0191 0.0259 
palmitoyl ethanolamide Endocannabinoid Lipid       1.52 0.0007 0.0023 1.42 0.0020 0.0059 
caffeine Xanthine 
Metabolism 
Xenobiotics       1.52 0.0054 0.0094       




Lipid       1.52 0.0078 0.0126 1.54 0.0028 0.0073 
3-hydroxydecanoate Fatty Acid, 
Monohydroxy 





Amino Acid       1.49 0.0001 0.0006 1.36 0.0003 0.0025 
glucuronate Aminosugar 
Metabolism 









suberate (C8-DC) Fatty Acid, 
Dicarboxylate 





Lipid       1.49 0.0066 0.0110 1.70 0.0009 0.0039 
N-oleoyltaurine Endocannabinoid Lipid       1.48 0.0160 0.0215       
octadecanedioate (C18-DC) Fatty Acid, 
Dicarboxylate 
Lipid       1.47 0.0487 0.0510       
pregnenolone sulfate Pregnenolone 
Steroids 
Lipid       1.45 0.0015 0.0039 1.37 0.0235 0.0290 
1-oleoyl-GPI (18:1) Lysophospholipid Lipid       1.45 0.0016 0.0040 1.25 0.0492 0.0476 
N-acetyltheanine Food 
Component/Plant 
Xenobiotics       1.45 0.0296 0.0345 1.35 0.0480 0.0470 
7-methylxanthine Xanthine 
Metabolism 





Nucleotide       1.44 0.0065 0.0109       




Lipid       1.44 0.0240 0.0292       





Lipid       1.43 0.0007 0.0024 1.37 0.0094 0.0157 
gamma-glutamylglutamate Gamma-glutamyl 
Amino Acid 
Peptide       1.43 0.0020 0.0047 1.16 0.0153 0.0221 
arabonate/xylonate Pentose 
Metabolism 
Carbohydrate       1.42 0.0306 0.0351 1.38 0.0010 0.0042 












Fatty Acid (n3 and 
n6) 
Lipid       1.41 0.0039 0.0074 1.45 0.0183 0.0251 





Amino Acid       1.41 0.0138 0.0193 1.51 0.0042 0.0097 
N-stearoyltaurine Endocannabinoid Lipid       1.40 0.0032 0.0066       




Lipid       1.40 0.0067 0.0110 1.59 0.0054 0.0118 
N-acetyl-4-
chlorophenylalanine 
Chemical Xenobiotics       1.40 0.0095 0.0145       
hexadecanedioate (C16-DC) Fatty Acid, 
Dicarboxylate 
Lipid       1.40 0.0107 0.0160 1.31 0.0158 0.0227 
sphinganine-1-phosphate Sphingolipid 
Synthesis 
Lipid       1.39 0.0274 0.0324       
fumarate TCA Cycle Energy       1.38 0.0028 0.0059 1.27 0.0161 0.0229 
1-ribosyl-imidazoleacetate Histidine 
Metabolism 










Amino Acid       1.38 0.0131 0.0189       
N-palmitoylglycine Fatty Acid 
Metabolism (Acyl 
Glycine) 






Amino Acid       1.38 0.0159 0.0215       









Amino Acid       1.38 0.0319 0.0361 1.45 0.0235 0.0290 





Lipid       1.37 0.0014 0.0037 1.55 0.0023 0.0065 
1-carboxyethyltyrosine Tyrosine 
Metabolism 





Nucleotide       1.37 0.0454 0.0483 1.56 0.0236 0.0290 




Amino Acid       1.36 0.0001 0.0007       


























Amino Acid       1.34 0.0039 0.0074 1.25 0.0003 0.0022 
N-stearoyl-sphingosine 
(d18:1/18:0) 
Ceramides Lipid       1.33 0.0001 0.0005 1.14 0.0142 0.0210 
arabitol/xylitol Pentose 
Metabolism 
Carbohydrate       1.33 0.0003 0.0014 1.19 0.0124 0.0191 
branched-chain, straight-
chain, or cyclopropyl 10:1 







      1.33 0.0288 0.0339 2.25 0.0005 0.0033 
malonate Fatty Acid 
Synthesis 
Lipid       1.32 0.0004 0.0015 1.17 0.0108 0.0176 
arachidonate (20:4n6) Long Chain 
Polyunsaturated 
Fatty Acid (n3 and 
n6) 
Lipid       1.32 0.0132 0.0189       
1-linoleoyl-GPI (18:2) Lysophospholipid Lipid       1.32 0.0193 0.0248       
4-hydroxyphenylpyruvate Tyrosine 
Metabolism 
Amino Acid       1.32 0.0256 0.0308 1.40 0.0352 0.0380 
valylglycine Dipeptide Peptide       1.32 0.0438 0.0467 1.33 0.0123 0.0191 
N-acetylphenylalanine Phenylalanine 
Metabolism 





Carbohydrate       1.31 0.0107 0.0160       
N-acetylcarnosine Histidine 
Metabolism 
Amino Acid       1.31 0.0177 0.0233 1.24 0.0179 0.0248 
alpha-ketoglutarate TCA Cycle Energy       1.30 0.0012 0.0034 1.27 0.0002 0.0017 
heptenedioate (C7:1-DC) Fatty Acid, 
Dicarboxylate 
Lipid       1.30 0.0039 0.0074 1.48 0.0069 0.0135 
3-dehydrocholate Secondary Bile 
Acid Metabolism 
Lipid       1.30 0.0147 0.0202       








Lipid       1.29 0.0079 0.0126 1.16 0.0113 0.0182 
2-hydroxyphenylacetate Phenylalanine 
Metabolism 
Amino Acid       1.29 0.0234 0.0286 1.26 0.0007 0.0036 
N-stearoyl-sphingadienine 
(d18:2/18:0)  
Ceramides Lipid       1.28 0.0019 0.0044 1.20 0.0083 0.0147 
malate TCA Cycle Energy       1.28 0.0037 0.0070       
3-hydroxysebacate Fatty Acid, 
Monohydroxy 
Lipid       1.28 0.0068 0.0111 1.89 0.0044 0.0100 




Lipid       1.28 0.0212 0.0265 1.51 0.0013 0.0049 
3-hydroxyoctanoate Fatty Acid, 
Monohydroxy 





Carbohydrate       1.27 0.0066 0.0110       





Lipid       1.27 0.0158 0.0214 1.37 0.0092 0.0154 





      1.27 0.0177 0.0233       
kynurenate Tryptophan 
Metabolism 
Amino Acid       1.26 0.0042 0.0078 1.19 0.0306 0.0343 








10-undecenoate (11:1n1) Medium Chain 
Fatty Acid 
Lipid       1.25 0.0183 0.0239       
tetradecanedioate (C14-DC) Fatty Acid, 
Dicarboxylate 





Peptide       1.24 0.0020 0.0047 1.21 0.0013 0.0049 
3-hydroxyadipate Fatty Acid, 
Dicarboxylate 
Lipid       1.24 0.0078 0.0125       
2,6-dihydroxybenzoic acid Drug - Topical 
Agents 
Xenobiotics       1.23 0.0377 0.0415       
N-palmitoyl-sphingosine 
(d18:1/16:0) 
Ceramides Lipid       1.22 0.0027 0.0058 1.17 0.0005 0.0030 
3-hydroxydodecanedioate Fatty Acid, 
Dicarboxylate 
Lipid       1.21 0.0132 0.0189 1.44 0.0127 0.0193 
homovanillate (HVA) Tyrosine 
Metabolism 










Nucleotide       1.20 0.0411 0.0447       




Lipid       1.20 0.0462 0.0489 1.39 0.0017 0.0053 
glutarylcarnitine (C5-DC) Lysine 
Metabolism 
Amino Acid       1.20 0.0485 0.0510 1.19 0.0361 0.0386 
2-hydroxypalmitate Fatty Acid, 
Monohydroxy 




Ceramides Lipid       1.19 0.0113 0.0166 1.17 0.0019 0.0057 
N-acetylvaline Leucine, 
Isoleucine and 






tridecenedioate (C13:1-DC) Fatty Acid, 
Dicarboxylate 
Lipid       1.19 0.0350 0.0391 1.76 0.0236 0.0290 
1-stearoyl-GPG (18:0) Lysophospholipid Lipid       1.18 0.0233 0.0286       
heptanoate (7:0) Medium Chain 
Fatty Acid 



















Amino Acid       1.16 0.0010 0.0029 1.13 0.0022 0.0063 
cholesterol Sterol Lipid       1.15 0.0052 0.0091       
caproate (6:0) Medium Chain 
Fatty Acid 





Lipid       1.14 0.0163 0.0217 1.21 0.0146 0.0213 
5-oxoproline Glutathione 
Metabolism 
Amino Acid       1.13 0.0035 0.0068 1.21 0.0008 0.0039 
sphingomyelin (d17:2/16:0, 
d18:2/15:0) 












Amino Acid       1.11 0.0029 0.0061 1.09 0.0220 0.0282 
vanillylmandelate (VMA) Tyrosine 
Metabolism 
Amino Acid       1.11 0.0303 0.0351       




      1.10 0.0384 0.0420 1.06 0.0492 0.0476 
sphingomyelin (d18:2/16:0, 
d18:1/16:1) 





Lipid       1.08 0.0108 0.0160 1.04 0.0175 0.0244 
behenoyl sphingomyelin 
(d18:1/22:0) 





Lipid       1.06 0.0149 0.0204 1.02 0.0149 0.0217 
stearoyl sphingomyelin 
(d18:1/18:0) 
Sphingomyelins Lipid       1.06 0.0310 0.0354       
sphingomyelin (d18:2/18:1) Sphingomyelins Lipid       1.05 0.0008 0.0025 1.04 0.0210 0.0273 
sphingomyelin (d18:1/14:0, 
d16:1/16:0) 






Lipid       1.03 0.0142 0.0197       
deoxycarnitine Carnitine 
Metabolism 










Lipid       0.87 0.0492 0.0513 0.88 0.0259 0.0307 
asparagine Alanine and 
Aspartate 
Metabolism 
















Nucleotide       0.85 0.0143 0.0198 0.83 0.0144 0.0213 
sphingomyelin (d18:1/20:2, 
d18:2/20:1, d16:1/22:2)  
Sphingomyelins Lipid       0.84 0.0109 0.0162       





      0.84 0.0241 0.0294       




Amino Acid       0.82 0.0056 0.0095       





      0.81 0.0335 0.0378       
glycocholenate sulfate Secondary Bile 
Acid Metabolism 




Nucleotide       0.79 0.0379 0.0416 0.71 0.0009 0.0039 




Amino Acid       0.76 0.0496 0.0515       









Carbohydrate       0.74 0.0036 0.0069 0.80 0.0175 0.0244 
hydroxy-CMPF Fatty Acid, 
Dicarboxylate 




3-indoleglyoxylic acid Food 
Component/Plant 
Xenobiotics       0.72 0.0157 0.0214 0.77 0.0009 0.0039 




Lipid       0.72 0.0343 0.0385       
sphingadienine Sphingolipid 
Synthesis 
Lipid       0.70 0.0048 0.0085 0.58 0.0064 0.0129 
ergothioneine Food 
Component/Plant 
Xenobiotics       0.70 0.0111 0.0164       
N-palmitoylserine Endocannabinoid Lipid       0.69 0.0110 0.0162       
tartronate (hydroxymalonate) Food 
Component/Plant 
Xenobiotics       0.67 0.0290 0.0339 0.64 0.0320 0.0356 
N-acetylkynurenine (2) Tryptophan 
Metabolism 








      0.57 0.0012 0.0034 0.66 0.0034 0.0082 
4-allylcatechol sulfate Benzoate 
Metabolism 








      0.56 0.0033 0.0066 0.68 0.0037 0.0089 
S-1-pyrroline-5-carboxylate Glutamate 
Metabolism 
Amino Acid       0.49 0.0000 0.0003 0.52 0.0000 0.0006 
phenylacetate Phenylalanine 
Metabolism 
Amino Acid       0.47 0.0073 0.0119 0.52 0.0264 0.0310 





      0.45 0.0000 0.0003 0.40 0.0001 0.0011 
isoursodeoxycholate Secondary Bile 
Acid Metabolism 
Lipid       0.40 0.0020 0.0047 0.57 0.0046 0.0102 
4-vinylguaiacol sulfate Food 
Component/Plant 
Xenobiotics       0.40 0.0353 0.0393       
ferulic acid 4-sulfate Food 
Component/Plant 






Lipid       0.37 0.0463 0.0489 0.21 0.0469 0.0465 
ursodeoxycholate Secondary Bile 
Acid Metabolism 
Lipid       0.33 0.0009 0.0027 0.63 0.0101 0.0167 
eugenol sulfate Food 
Component/Plant 
Xenobiotics       0.32 0.0146 0.0201       
salicylate Drug - Topical 
Agents 
Xenobiotics       0.09 0.0455 0.0483 0.58 0.0232 0.0290 






            10.30 0.0009 0.0039 






            8.15 0.0067 0.0132 
saccharin Food 
Component/Plant 
Xenobiotics             5.77 0.0194 0.0260 
4-hydroxyhippurate Benzoate 
Metabolism 
Xenobiotics             4.91 0.0254 0.0304 
1,2,3-benzenetriol sulfate (2) Chemical Xenobiotics             4.54 0.0271 0.0315 






            3.84 0.0238 0.0291 
HWESASLLR Polypeptide Peptide             3.80 0.0070 0.0135 
bradykinin Polypeptide Peptide             3.68 0.0446 0.0446 
XHWESASXXR  Polypeptide Peptide             2.88 0.0475 0.0468 








            2.27 0.0473 0.0468 




Amino Acid             2.18 0.0205 0.0269 
ethyl alpha-glucopyranoside Food 
Component/Plant 








Xenobiotics             1.92 0.0072 0.0138 
acesulfame Food 
Component/Plant 
Xenobiotics             1.90 0.0300 0.0340 
phytanate Food 
Component/Plant 
Xenobiotics             1.73 0.0086 0.0148 
dihomo-linolenoylcarnitine 





Lipid             1.66 0.0015 0.0052 
hydantoin-5-propionate Histidine 
Metabolism 
Amino Acid             1.49 0.0271 0.0315 




Lipid             1.45 0.0193 0.0260 
sebacate (C10-DC) Fatty Acid, 
Dicarboxylate 
Lipid             1.45 0.0232 0.0290 
2-hydroxyarachidate Fatty Acid, 
Monohydroxy 
Lipid             1.44 0.0121 0.0191 
stachydrine Food 
Component/Plant 





Amino Acid             1.37 0.0000 0.0002 




Amino Acid             1.35 0.0437 0.0441 




Lipid             1.30 0.0221 0.0282 
phenyllactate (PLA) Phenylalanine 
Metabolism 










Amino Acid             1.28 0.0200 0.0265 
cys-gly, oxidized Glutathione 
Metabolism 
Amino Acid             1.28 0.0233 0.0290 
3,4-dihydroxybutyrate Fatty Acid, 
Dihydroxy 
Lipid             1.26 0.0000 0.0001 
cysteinylglycine disulfide Glutathione 
Metabolism 
Amino Acid             1.26 0.0111 0.0179 
N-acetylglycine Glycine, Serine 
and Threonine 
Metabolism 





Lipid             1.23 0.0263 0.0310 
gamma-glutamyltyrosine Gamma-glutamyl 
Amino Acid 





Amino Acid             1.22 0.0339 0.0371 




Amino Acid             1.19 0.0298 0.0338 





Lipid             1.19 0.0374 0.0395 
gamma-glutamyltryptophan Gamma-glutamyl 
Amino Acid 
Peptide             1.17 0.0320 0.0356 
gamma-glutamylhistidine Gamma-glutamyl 
Amino Acid 
Peptide             1.15 0.0149 0.0217 
N-acetylglutamate Glutamate 
Metabolism 








Lipid             1.13 0.0005 0.0031 
ribonate Pentose 
Metabolism 












Amino Acid             1.09 0.0129 0.0196 
tricosanoyl sphingomyelin 
(d18:1/23:0) 
Sphingomyelins Lipid             1.06 0.0294 0.0335 
sphingomyelin (d18:2/23:0, 
d18:1/23:1, d17:1/24:1) 
Sphingomyelins Lipid             1.05 0.0444 0.0446 
alanine Alanine and 
Aspartate 
Metabolism 








Nucleotide             0.81 0.0111 0.0179 
choline phosphate Phospholipid 
Metabolism 





Lipid             0.81 0.0493 0.0476 
4-hydroxy-2-oxoglutaric acid Fatty Acid, 
Dicarboxylate 














alpha-hydroxycaproate Fatty Acid, 
Monohydroxy 




Carbohydrate             0.69 0.0078 0.0141 












Nucleotide             0.66 0.0191 0.0259 
serotonin Tryptophan 
Metabolism 
Amino Acid             0.66 0.0381 0.0398 
phenylacetylglutamine Acetylated 
Peptides 
Peptide             0.64 0.0370 0.0393 
p-cresol sulfate Benzoate 
Metabolism 
Xenobiotics             0.63 0.0480 0.0470 
deoxycholic acid 12-sulfate Secondary Bile 
Acid Metabolism 
Lipid             0.59 0.0358 0.0384 
1-stearoyl-GPS (18:0) Lysophospholipid Lipid             0.58 0.0283 0.0327 
lithocholate sulfate (1) Secondary Bile 
Acid Metabolism 







APPENDIX 3A4: Table presenting metabolites for which the fold-change (FC) is significant (Welch’s two-sample t-test 
significant when p≤0.05) in the cord artery between the different mode of labour onset groups. Corresponding p- and q-values 
are shown. 





















Ranitidine Drug - Gastrointestinal Xenobiotics 959.17 0.0012 0.0951 1199.67 0.0000 0.0022       
Fibrinopeptide B Fibrinogen Cleavage Peptide Peptide 142.41 0.0013 0.0951 105.63 0.0254 0.0703       
Fibrinopeptide B (1-13)   Fibrinogen Cleavage Peptide Peptide 101.32 0.0014 0.0951 31.58 0.0314 0.0787       
Fibrinopeptide A  Fibrinogen Cleavage Peptide Peptide 76.31 0.0003 0.0731 43.27 0.0022 0.0240       
Fibrinopeptide A, phosphono-
ser(3)  
Fibrinogen Cleavage Peptide Peptide 32.93 0.0000 0.0181 26.70 0.0093 0.0394       
Fibrinopeptide A, des-ala(1)  Fibrinogen Cleavage Peptide Peptide 29.86 0.0001 0.0181 18.76 0.0198 0.0611       
Adenosine 5'-monophosphate 
(AMP) 
Purine Metabolism, Adenine 
containing 
Nucleotide 3.44 0.0214 0.2667             
2'-deoxyuridine Pyrimidine Metabolism, 
Uracil containing 
Nucleotide 1.90 0.0017 0.0951 1.96 0.0015 0.0233       
Edta Chemical Xenobiotics 1.79 0.0328 0.3059 1.98 0.0193 0.0606       
Butyrylglycine Fatty Acid Metabolism (also 
BCAA Metabolism) 
Lipid 1.75 0.0156 0.2619       0.56 0.0084 0.4340 
Sarcosine Glycine, Serine and 
Threonine Metabolism 
Amino Acid 1.66 0.0006 0.0951             
Eicosenoylcarnitine (C20:1)  Fatty Acid Metabolism (Acyl 
Carnitine, 
Monounsaturated) 
Lipid 1.66 0.0403 0.3059       0.54 0.0340 0.4506 
4-hydroxyhippurate Benzoate Metabolism Xenobiotics 1.58 0.0195 0.2619       0.56 0.0391 0.4506 
3-formylindole Food Component/Plant Xenobiotics 1.52 0.0094 0.2465             
N-acetylaspartate (NAA) Alanine and Aspartate 
Metabolism 
Amino Acid 1.32 0.0465 0.3062             
Palmitoylcarnitine (C16) Fatty Acid Metabolism (Acyl 
Carnitine, Long Chain 
Saturated) 




Lysine Lysine Metabolism Amino Acid 0.83 0.0191 0.2619             
Asparagine Alanine and Aspartate 
Metabolism 
Amino Acid 0.80 0.0338 0.3059             
1-palmitoyl-GPA (16:0) Lysophospholipid Lipid 0.78 0.0357 0.3059             
Citrate TCA Cycle Energy 0.76 0.0051 0.1773 0.41 0.0110 0.0439 0.53 0.0291 0.4506 
1-methylhistidine Histidine Metabolism Amino Acid 0.76 0.0294 0.3041             
Tryptophan Tryptophan Metabolism Amino Acid 0.75 0.0190 0.2619 0.81 0.0476 0.0978       
5-oxoproline Glutathione Metabolism Amino Acid 0.75 0.0439 0.3059 0.54 0.0000 0.0054 0.72 0.0436 0.4506 
2-hydroxyhippurate 
(salicylurate) 
Benzoate Metabolism Xenobiotics 0.73 0.0117 0.2508             
Arabitol/xylitol Pentose Metabolism Carbohydrate 0.73 0.0432 0.3059 0.67 0.0154 0.0531       
Arabonate/xylonate Pentose Metabolism Carbohydrate 0.72 0.0011 0.0951             
N1-methylinosine Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
Nucleotide 0.71 0.0377 0.3059             
Erythronate  Aminosugar Metabolism Carbohydrate 0.69 0.0019 0.0951 0.59 0.0031 0.0272       
4-hydroxy-2-oxoglutaric acid Fatty Acid, Dicarboxylate Lipid 0.69 0.0346 0.3059 0.44 0.0160 0.0531       
N-acetyltryptophan Tryptophan Metabolism Amino Acid 0.69 0.0494 0.3186             
Alanine Alanine and Aspartate 
Metabolism 
Amino Acid 0.68 0.0007 0.0951 0.53 0.0020 0.0240 0.78 0.0383 0.4506 
Beta-alanine Pyrimidine Metabolism, 
Uracil containing 
Nucleotide 0.66 0.0369 0.3059             
N-oxalyl glycine (NOG) Food Component/Plant Xenobiotics 0.66 0.0475 0.3102 0.53 0.0097 0.0401       
S-1-pyrroline-5-carboxylate Glutamate Metabolism Amino Acid 0.65 0.0162 0.2619             
N-stearoyltaurine Endocannabinoid Lipid 0.65 0.0442 0.3059 0.64 0.0233 0.0680       
3-methyl-2-oxobutyrate Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid 0.62 0.0410 0.3059             
Gamma-glutamylglutamine Gamma-glutamyl Amino 
Acid 
Peptide 0.62 0.0426 0.3059             
1-(1-enyl-palmitoyl)-2-oleoyl-
GPE (P-16:0/18:1)  
Plasmalogen Lipid 0.61 0.0103 0.2465             




3-hydroxy-2-ethylpropionate Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid 0.60 0.0414 0.3059             
Sulfate  Chemical Xenobiotics 0.60 0.0456 0.3059 0.49 0.0248 0.0694       




0.59 0.0042 0.1656 0.45 0.0136 0.0502       
N-acetyl-4-
chlorophenylalanine 
Chemical Xenobiotics 0.59 0.0153 0.2619 0.46 0.0034 0.0283       
1-(1-enyl-palmitoyl)-GPE (P-
16:0)  
Lysoplasmalogen Lipid 0.59 0.0417 0.3059 0.59 0.0439 0.0940       




0.58 0.0145 0.2619             
Glycerophosphoglycerol Glycerolipid Metabolism Lipid 0.58 0.0286 0.3041 0.41 0.0235 0.0682       
Gluconate Food Component/Plant Xenobiotics 0.58 0.0390 0.3059 0.32 0.0046 0.0329       
N-acetyltaurine Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid 0.57 0.0047 0.1756 0.42 0.0082 0.0382       
Guanidinoacetate Creatine Metabolism Amino Acid 0.57 0.0411 0.3059             
Fructose Fructose, Mannose and 
Galactose Metabolism 
Carbohydrate 0.56 0.0172 0.2619 0.35 0.0006 0.0224 0.62 0.0431 0.4506 
Aconitate [cis or trans] TCA Cycle Energy 0.56 0.0173 0.2619 0.42 0.0027 0.0256       
3-hydroxyisobutyrate Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid 0.56 0.0319 0.3059             
Dihomo-linoleate (20:2n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid 0.56 0.0396 0.3059 0.32 0.0017 0.0233 0.57 0.0295 0.4506 
Glycerol Glycerolipid Metabolism Lipid 0.54 0.0053 0.1773 0.23 0.0004 0.0224 0.43 0.0045 0.3385 
Docosahexaenoate (DHA; 
22:6n3) 
Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid 0.53 0.0418 0.3059 0.43 0.0116 0.0459       
Butyrate/isobutyrate (4:0) Short Chain Fatty Acid Lipid 0.52 0.0199 0.2619 0.47 0.0052 0.0339       
1-carboxyethylvaline Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid 0.52 0.0266 0.3028 0.27 0.0014 0.0233 0.53 0.0133 0.4422 
Androstenediol (3alpha, 
17alpha) monosulfate (2) 
Androgenic Steroids Lipid 0.52 0.0394 0.3059       1.91 0.0380 0.4506 
Dodecadienoate (12:2)  Fatty Acid, Dicarboxylate Lipid 0.51 0.0406 0.3059 0.29 0.0008 0.0228       
Phytanate Food Component/Plant Xenobiotics 0.49 0.0096 0.2465 0.39 0.0018 0.0233       




Sphinganine-1-phosphate Sphingolipid Synthesis Lipid 0.49 0.0129 0.2594 0.32 0.0017 0.0233       
Flavin adenine dinucleotide 
(FAD) 
Riboflavin Metabolism Cofactors and 
Vitamins 
0.47 0.0064 0.1953 0.34 0.0035 0.0285       




Plasmalogen Lipid 0.46 0.0111 0.2508 0.50 0.0269 0.0715       
Methylmalonate (MMA) Fatty Acid Metabolism (also 
BCAA Metabolism) 
Lipid 0.46 0.0283 0.3041             
10-nonadecenoate (19:1n9) Long Chain 
Monounsaturated Fatty Acid 
Lipid 0.46 0.0421 0.3059 0.27 0.0049 0.0329       
Tartronate 
(hydroxymalonate) 
Food Component/Plant Xenobiotics 0.45 0.0195 0.2619 0.27 0.0387 0.0867       
Nisinate (24:6n3) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid 0.45 0.0210 0.2656 0.36 0.0079 0.0382       





Lipid 0.41 0.0080 0.2326 0.33 0.0060 0.0354       
Docosapentaenoate (n3 DPA; 
22:5n3) 
Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid 0.41 0.0223 0.2729 0.27 0.0082 0.0382 0.66 0.0450 0.4506 
Malonate Fatty Acid Synthesis Lipid 0.41 0.0358 0.3059 0.31 0.0016 0.0233       
Eicosapentaenoate (EPA; 
20:5n3) 
Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid 0.40 0.0339 0.3059 0.32 0.0147 0.0518       
(12 or 13)-methylmyristate 
(a15:0 or i15:0) 
Fatty Acid, Branched Lipid 0.40 0.0460 0.3059 0.24 0.0101 0.0411       
Linoleate (18:2n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid 0.39 0.0450 0.3059 0.19 0.0012 0.0233       
Docosatrienoate (22:3n3) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid 0.38 0.0288 0.3041 0.26 0.0089 0.0394       
Hexadecadienoate (16:2n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid 0.37 0.0209 0.2656 0.12 0.0007 0.0224 0.33 0.0290 0.4506 
Myristate (14:0) Long Chain Saturated Fatty 
Acid 
Lipid 0.37 0.0329 0.3059 0.22 0.0077 0.0378 0.59 0.0449 0.4506 
(2 or 3)-decenoate (10:1n7 or 
n8) 




Isovalerate (i5:0) Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid 0.36 0.0083 0.2326 0.33 0.0089 0.0394       
1-stearoyl-2-arachidonoyl-
GPS (18:0/20:4) 
Phosphatidylserine (PS) Lipid 0.36 0.0114 0.2508 0.47 0.0280 0.0728       
Androsterone sulfate Androgenic Steroids Lipid 0.35 0.0131 0.2594 0.31 0.0069 0.0363       









Lipid 0.34 0.0140 0.2619 0.36 0.0162 0.0531       
12,13-dihome Fatty Acid, Dihydroxy Lipid 0.34 0.0191 0.2619 0.25 0.0012 0.0233       
Fructosyllysine Lysine Metabolism Amino Acid 0.34 0.0227 0.2729 0.25 0.0102 0.0414 0.74 0.0083 0.4340 




Plasmalogen Lipid 0.33 0.0019 0.0951 0.30 0.0019 0.0234       
9,10-dihome Fatty Acid, Dihydroxy Lipid 0.32 0.0257 0.2975 0.33 0.0393 0.0870       
Linolenate [alpha or gamma; 
(18:3n3 or 6)] 
Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid 0.32 0.0403 0.3059 0.13 0.0007 0.0224       




0.29 0.0332 0.3059 0.18 0.0076 0.0378       
Caprate (10:0) Medium Chain Fatty Acid Lipid 0.28 0.0193 0.2619 0.18 0.0080 0.0382       









Lipid 0.27 0.0441 0.3059             
Gamma-glutamylalanine Gamma-glutamyl Amino 
Acid 
Peptide 0.26 0.0020 0.0951 0.12 0.0029 0.0271       
Laurate (12:0) Medium Chain Fatty Acid Lipid 0.26 0.0059 0.1901 0.17 0.0017 0.0233       




0.24 0.0168 0.2619 0.21 0.0323 0.0799       
1-stearoyl-2-oleoyl-GPS 
(18:0/18:1) 









Nucleotide 0.18 0.0009 0.0951 0.05 0.0006 0.0224 0.29 0.0164 0.4422 
Caffeine Xanthine Metabolism Xenobiotics 0.18 0.0247 0.2907             
Trans-3,4-
methyleneheptanoate 
Food Component/Plant Xenobiotics 0.17 0.0156 0.2619 0.20 0.0270 0.0715       
1-stearoyl-GPS (18:0)  Lysophospholipid Lipid 0.10 0.0021 0.0951 0.07 0.0040 0.0307       
Tartarate Food Component/Plant Xenobiotics 0.09 0.0183 0.2619 0.05 0.0161 0.0531       
Metronidazole Drug - Antibiotic Xenobiotics       3583.00 0.0000 0.0003 826.8
5 
0.0016 0.1868 
Ranitidine N-oxide  Drug - Gastrointestinal Xenobiotics       11.45 0.0049 0.0329       




      9.30 0.0448 0.0943       
N-ethylglycinexylidide Drug - Analgesics, 
Anesthetics 
Xenobiotics       6.72 0.0049 0.0329       
Heptadecenamide (17:1)  Fatty Acid, Amide Lipid       5.90 0.0064 0.0354       
Valylglycine Dipeptide Peptide       3.39 0.0006 0.0224       
N6-carboxymethyllysine Advanced Glycation End-
product 
Carbohydrate       2.81 0.0011 0.0233       
Carnosine Histidine Metabolism Amino Acid       1.95 0.0263 0.0711 2.01 0.0155 0.4422 
3-ureidopropionate Pyrimidine Metabolism, 
Uracil containing 
Nucleotide       1.56 0.0428 0.0929       
Metoclopramide Drug - Gastrointestinal Xenobiotics       1.32 0.0289 0.0743 1.32 0.0289 0.4506 
Citrulline Urea cycle; Arginine and 
Proline Metabolism 
Amino Acid       1.26 0.0127 0.0489       
Gamma-glutamyltryptophan Gamma-glutamyl Amino 
Acid 
Peptide       1.18 0.0044 0.0325 1.28 0.0097 0.4422 
Palmitoyl sphingomyelin 
(d18:1/16:0) 
Sphingomyelins Lipid       0.87 0.0093 0.0394       
Proline Urea cycle; Arginine and 
Proline Metabolism 
Amino Acid       0.80 0.0139 0.0505       
N-acetylserine Glycine, Serine and 
Threonine Metabolism 
Amino Acid       0.78 0.0346 0.0822       




N-acetylvaline Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.75 0.0376 0.0859       
Creatinine Creatine Metabolism Amino Acid       0.73 0.0063 0.0354 0.82 0.0270 0.4506 
Behenoyl sphingomyelin 
(d18:1/22:0)  
Sphingomyelins Lipid       0.73 0.0208 0.0628       
Sphingomyelin (d18:1/21:0, 
d17:1/22:0, d16:1/23:0)  
Sphingomyelins Lipid       0.72 0.0348 0.0822       
1-oleoyl-GPG (18:1)  Lysophospholipid Lipid       0.71 0.0179 0.0579       
Glycerophosphoethanolamine Phospholipid Metabolism Lipid       0.71 0.0360 0.0834       
Acetylcarnitine (C2) Fatty Acid Metabolism (Acyl 
Carnitine, Short Chain) 
Lipid       0.70 0.0211 0.0633       




      0.69 0.0086 0.0390       
1-palmitoyl-GPG (16:0)  Lysophospholipid Lipid       0.69 0.0187 0.0594       
1-linoleoyl-GPG (18:2)  Lysophospholipid Lipid       0.68 0.0355 0.0831       
2-ketocaprylate Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.67 0.0346 0.0822       
Glycerophosphorylcholine 
(GPC) 
Phospholipid Metabolism Lipid       0.67 0.0456 0.0954       
Myristoylcarnitine (C14) Fatty Acid Metabolism (Acyl 
Carnitine, Long Chain 
Saturated) 
Lipid       0.66 0.0138 0.0505 0.67 0.0218 0.4506 
Decanoylcarnitine (C10) Fatty Acid Metabolism (Acyl 
Carnitine, Medium Chain) 
Lipid       0.66 0.0260 0.0710       
Alpha-tocopherol Tocopherol Metabolism Cofactors and 
Vitamins 
      0.65 0.0277 0.0728 0.63 0.0493 0.4533 
Cysteine Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.65 0.0309 0.0783       
N-palmitoyltaurine Endocannabinoid Lipid       0.63 0.0032 0.0272       
Margarate (17:0) Long Chain Saturated Fatty 
Acid 
Lipid       0.63 0.0373 0.0858       
N-palmitoylglycine Fatty Acid Metabolism (Acyl 
Glycine) 
Lipid       0.62 0.0288 0.0743       
Ethylmalonate Leucine, Isoleucine and 
Valine Metabolism 




2-hydroxydecanoate Fatty Acid, Monohydroxy Lipid       0.62 0.0443 0.0943       
1-stearoyl-2-arachidonoyl-GPI 
(18:0/20:4) 
Phosphatidylinositol (PI) Lipid       0.61 0.0063 0.0354       
Homoarginine Urea cycle; Arginine and 
Proline Metabolism 
Amino Acid       0.61 0.0314 0.0787       
Allantoin Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
Nucleotide       0.60 0.0049 0.0329       
Laurylcarnitine (C12) Fatty Acid Metabolism (Acyl 
Carnitine, Medium Chain) 
Lipid       0.59 0.0012 0.0233       
1-palmitoyl-2-oleoyl-GPI 
(16:0/18:1)  





Lipid       0.58 0.0031 0.0272       
Palmitoleoylcarnitine (C16:1)  Fatty Acid Metabolism (Acyl 
Carnitine, 
Monounsaturated) 
Lipid       0.58 0.0040 0.0307 0.55 0.0008 0.1868 
Myristoleoylcarnitine (C14:1)  Fatty Acid Metabolism (Acyl 
Carnitine, 
Monounsaturated) 
Lipid       0.58 0.0124 0.0480 0.57 0.0168 0.4422 
16-hydroxypalmitate Fatty Acid, Monohydroxy Lipid       0.58 0.0241 0.0686       
Pentadecanoate (15:0) Long Chain Saturated Fatty 
Acid 
Lipid       0.58 0.0335 0.0809       
Orotate Pyrimidine Metabolism, 
Orotate containing 
Nucleotide       0.57 0.0317 0.0788       
Glycochenodeoxycholate 3-
sulfate 
Primary Bile Acid 
Metabolism 
Lipid       0.56 0.0019 0.0234       
Benzoate Benzoate Metabolism Xenobiotics       0.56 0.0163 0.0533       
Pyruvate Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
Carbohydrate       0.56 0.0334 0.0809 0.71 0.0359 0.4506 
Mannose Fructose, Mannose and 
Galactose Metabolism 
Carbohydrate       0.54 0.0094 0.0394       
3-hydroxyhexanoate Fatty Acid, Monohydroxy Lipid       0.52 0.0214 0.0636 0.63 0.0438 0.4506 
N-oleoyltaurine Endocannabinoid Lipid       0.52 0.0251 0.0697       




Indolebutyrate Tryptophan Metabolism Amino Acid       0.52 0.0381 0.0859       
Tetradecadienedioate (C14:2-
DC)  
Fatty Acid, Dicarboxylate Lipid       0.51 0.0471 0.0977       
Glycocholenate sulfate  Secondary Bile Acid 
Metabolism 
Lipid       0.49 0.0024 0.0247 0.56 0.0432 0.4506 
Sphingosine Sphingosines Lipid       0.49 0.0161 0.0531 0.42 0.0172 0.4422 
Taurine Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.48 0.0064 0.0354 0.61 0.0471 0.4533 
(S)-3-hydroxybutyrylcarnitine Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid       0.46 0.0262 0.0711 0.58 0.0304 0.4506 
(14 or 15)-methylpalmitate 
(a17:0 or i17:0) 
Fatty Acid, Branched Lipid       0.46 0.0307 0.0781       
3-methylglutarate/2-
methylglutarate 
Fatty Acid, Dicarboxylate Lipid       0.45 0.0025 0.0250       
Palmitate (16:0) Long Chain Saturated Fatty 
Acid 
Lipid       0.45 0.0133 0.0500       
Adrenate (22:4n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.45 0.0199 0.0611       
N-acetylglutamine Glutamate Metabolism Amino Acid       0.45 0.0222 0.0652       
Glucose Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
Carbohydrate       0.44 0.0004 0.0224       
Erucate (22:1n9) Long Chain 
Monounsaturated Fatty Acid 
Lipid       0.44 0.0022 0.0240       
N-acetylneuraminate Aminosugar Metabolism Carbohydrate       0.44 0.0036 0.0287       
N-acetylglutamate Glutamate Metabolism Amino Acid       0.44 0.0062 0.0354       
1-arachidonoyl-GPA (20:4) Lysophospholipid Lipid       0.44 0.0120 0.0467       
Methionine sulfoxide Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.44 0.0215 0.0636       
Maleate Fatty Acid, Dicarboxylate Lipid       0.44 0.0410 0.0902       
Sphingosine 1-phosphate Sphingosines Lipid       0.43 0.0014 0.0233 0.61 0.0430 0.4506 
Mannitol/sorbitol Fructose, Mannose and 
Galactose Metabolism 
Carbohydrate       0.43 0.0240 0.0686       




N6-methyladenosine Purine Metabolism, Adenine 
containing 
Nucleotide       0.43 0.0463 0.0965       
Hypoxanthine Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
Nucleotide       0.42 0.0014 0.0233 0.42 0.0361 0.4506 
4-hydroxychlorothalonil Chemical Xenobiotics       0.42 0.0015 0.0233       
Lactate Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
Carbohydrate       0.42 0.0032 0.0272 0.53 0.0104 0.4422 
1-methylguanidine Guanidino and Acetamido 
Metabolism 
Amino Acid       0.42 0.0085 0.0388       
3-hydroxyoctanoate Fatty Acid, Monohydroxy Lipid       0.42 0.0098 0.0402 0.57 0.0339 0.4506 
Cis-urocanate Histidine Metabolism Amino Acid       0.42 0.0194 0.0606       
Estrone 3-sulfate Estrogenic Steroids Lipid       0.42 0.0294 0.0751 0.35 0.0132 0.4422 
Heptenedioate (C7:1-DC)  Fatty Acid, Dicarboxylate Lipid       0.42 0.0446 0.0943       
Corticosterone Corticosteroids Lipid       0.41 0.0394 0.0870 0.39 0.0377 0.4506 
3-hydroxybutyroylglycine   Fatty Acid Metabolism (Acyl 
Glycine) 
Lipid       0.41 0.0433 0.0936       
2-hydroxybutyrate/2-
hydroxyisobutyrate 
Glutathione Metabolism Amino Acid       0.40 0.0044 0.0325 0.52 0.0120 0.4422 
Mead acid (20:3n9) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.40 0.0146 0.0518       
3-hydroxydecanoylcarnitine Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid       0.40 0.0424 0.0924 0.47 0.0211 0.4506 
Fumarate TCA Cycle Energy       0.39 0.0157 0.0531 0.61 0.0416 0.4506 
Glucuronate Aminosugar Metabolism Carbohydrate       0.38 0.0052 0.0338       
Pregnanediol-3-glucuronide Progestin Steroids Lipid       0.38 0.0328 0.0804 0.57 0.0497 0.4533 
3-methylglutaconate Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.38 0.0437 0.0939       
11beta-hydroxyandrosterone 
glucuronide 
Androgenic Steroids Lipid       0.37 0.0349 0.0822       
Docosadienoate (22:2n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.36 0.0007 0.0224       




Cytosine Pyrimidine Metabolism, 
Cytidine containing 
Nucleotide       0.36 0.0279 0.0728       
5,6-dihydrouracil Pyrimidine Metabolism, 
Uracil containing 
Nucleotide       0.36 0.0445 0.0943 0.38 0.0182 0.4506 
2-isopropylmalate Food Component/Plant Xenobiotics       0.35 0.0082 0.0382       
3-bromo-5-chloro-2,6-
dihydroxybenzoic acid  
Chemical Xenobiotics       0.35 0.0475 0.0978       
17alpha-
hydroxyprogesterone 
Progestin Steroids Lipid       0.34 0.0207 0.0627 0.47 0.0144 0.4422 
Dihomo-linolenate (20:3n3 or 
n6) 
Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.34 0.0244 0.0688       
1,3-dimethylurate Xanthine Metabolism Xenobiotics       0.34 0.0490 0.1004       
Citramalate Glutamate Metabolism Amino Acid       0.33 0.0271 0.0715       
Caproate (6:0) Medium Chain Fatty Acid Lipid       0.32 0.0034 0.0283       
Undecanedioate (C11-DC) Fatty Acid, Dicarboxylate Lipid       0.32 0.0056 0.0341 0.34 0.0010 0.1868 
Androsterone glucuronide Androgenic Steroids Lipid       0.32 0.0076 0.0378       
1-carboxyethyltyrosine Tyrosine Metabolism Amino Acid       0.32 0.0159 0.0531 0.52 0.0262 0.4506 
10-undecenoate (11:1n1) Medium Chain Fatty Acid Lipid       0.31 0.0119 0.0467       
Cortisol Corticosteroids Lipid       0.31 0.0131 0.0498       
3-hydroxyoleoylcarnitine Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid       0.31 0.0182 0.0587 0.31 0.0246 0.4506 




Progestin Steroids Lipid       0.30 0.0241 0.0686 0.33 0.0221 0.4506 
14-hdohe/17-hdohe Docosanoid Lipid       0.30 0.0325 0.0801       
N-formylphenylalanine Tyrosine Metabolism Amino Acid       0.30 0.0495 0.1009       
Eicosenoate (20:1) Long Chain 
Monounsaturated Fatty Acid 
Lipid       0.29 0.0027 0.0256       
Myo-inositol Inositol Metabolism Lipid       0.28 0.0018 0.0233       
3-hydroxydecanoate Fatty Acid, Monohydroxy Lipid       0.28 0.0021 0.0240 0.43 0.0124 0.4422 





DC)   
Fatty Acid, Dicarboxylate Lipid       0.28 0.0330 0.0806       
Isocaproate (i6:0) Fatty Acid, Branched Lipid       0.27 0.0011 0.0233       
Trans-urocanate Histidine Metabolism Amino Acid       0.27 0.0017 0.0233       
Xanthine Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
Nucleotide       0.26 0.0055 0.0340 0.38 0.0066 0.3925 
Progesterone Progestin Steroids Lipid       0.26 0.0082 0.0382       
9-hydroxystearate Fatty Acid, Monohydroxy Lipid       0.26 0.0260 0.0710       
3-hydroxymyristate Fatty Acid, Monohydroxy Lipid       0.25 0.0086 0.0390       
Maltose Glycogen Metabolism Carbohydrate       0.25 0.0195 0.0608 0.37 0.0381 0.4506 
Beta-citrylglutamate Glutamate Metabolism Amino Acid       0.25 0.0202 0.0617       
1-carboxyethylisoleucine Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.24 0.0025 0.0250 0.41 0.0168 0.4422 
Cis-4-decenoate (10:1n6)  Medium Chain Fatty Acid Lipid       0.24 0.0140 0.0506       
Oleate/vaccenate (18:1) Long Chain 
Monounsaturated Fatty Acid 
Lipid       0.23 0.0061 0.0354       
Succinoyltaurine Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.23 0.0242 0.0686       
Tetradecadienoate (14:2)  Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.22 0.0073 0.0371 0.41 0.0345 0.4506 
10-heptadecenoate (17:1n7) Long Chain 
Monounsaturated Fatty Acid 
Lipid       0.22 0.0161 0.0531       
13-hode + 9-hode Fatty Acid, Monohydroxy Lipid       0.21 0.0378 0.0859       
1-carboxyethylleucine Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.19 0.0017 0.0233 0.33 0.0030 0.2907 
Cortisone 21-sulfate Corticosteroids Lipid       0.19 0.0091 0.0394 0.28 0.0048 0.3385 
Estriol Estrogenic Steroids Lipid       0.18 0.0412 0.0902       
Palmitoleate (16:1n7) Long Chain 
Monounsaturated Fatty Acid 
Lipid       0.16 0.0093 0.0394       
5-dodecenoate (12:1n7) Medium Chain Fatty Acid Lipid       0.15 0.0067 0.0362       
Testosterone sulfate Androgenic Steroids Lipid       0.15 0.0187 0.0594       





chain, or cyclopropyl 12:1 






      0.13 0.0053 0.0340       
Branched-chain, straight-
chain, or cyclopropyl 10:1 






      0.13 0.0056 0.0341       
Myristoleate (14:1n5) Long Chain 
Monounsaturated Fatty Acid 
Lipid       0.09 0.0067 0.0362 0.32 0.0411 0.4506 





      0.08 0.0340 0.0817 0.07 0.0007 0.1868 
Stearidonate (18:4n3) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.07 0.0072 0.0371       
3-(methylthio)acetaminophen 
sulfate  
Drug - Analgesics, 
Anesthetics 
Xenobiotics       0.06 0.0008 0.0224       
3-hydroxyoleate  Fatty Acid, Monohydroxy Lipid       0.06 0.0047 0.0329       





      0.03 0.0023 0.0246 0.04 0.0035 0.3005 
2-hydroxyacetaminophen 
sulfate  
Drug - Analgesics, 
Anesthetics 
Xenobiotics       0.03 0.0069 0.0363       
2-methoxyacetaminophen 
glucuronide  
Drug - Analgesics, 
Anesthetics 
Xenobiotics       0.02 0.0002 0.0195       
2-methoxyacetaminophen 
sulfate  
Drug - Analgesics, 
Anesthetics 
Xenobiotics       0.02 0.0006 0.0224       
3-(N-acetyl-L-cystein-S-yl) 
acetaminophen 
Drug - Analgesics, 
Anesthetics 
Xenobiotics       0.02 0.0054 0.0340       
4-acetaminophen sulfate Drug - Analgesics, 
Anesthetics 
Xenobiotics       0.02 0.0134 0.0500       
4-
acetamidophenylglucuronide 
Drug - Analgesics, 
Anesthetics 
Xenobiotics       0.02 0.0150 0.0524       
3-(cystein-S-
yl)acetaminophen  
Drug - Analgesics, 
Anesthetics 
Xenobiotics       0.01 0.0000 0.0054       
4-acetamidophenol Drug - Analgesics, 
Anesthetics 












Phosphatidylcholine (PC) Lipid             0.77 0.0497 0.4533 
Linolenoylcarnitine (C18:3)  Fatty Acid Metabolism (Acyl 
Carnitine, Polyunsaturated) 
Lipid             0.73 0.0288 0.4506 
Lignoceroylcarnitine (C24)  Fatty Acid Metabolism (Acyl 
Carnitine, Long Chain 
Saturated) 
Lipid             0.72 0.0003 0.1868 
3-hydroxyhexanoylcarnitine 
(1) 
Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid             0.69 0.0360 0.4506 
Vanillactate Tyrosine Metabolism Amino Acid             0.61 0.0155 0.4422 
Uridine Pyrimidine Metabolism, 
Uracil containing 
Nucleotide             0.58 0.0118 0.4422 
Cis-4-decenoylcarnitine 
(C10:1) 
Fatty Acid Metabolism (Acyl 
Carnitine, 
Monounsaturated) 
Lipid             0.58 0.0460 0.4533 
5-dodecenoylcarnitine (C12:1) Fatty Acid Metabolism (Acyl 
Carnitine, 
Monounsaturated) 
Lipid             0.57 0.0329 0.4506 




Progestin Steroids Lipid             0.48 0.0195 0.4506 
Margaroylcarnitine (C17)  Fatty Acid Metabolism (Acyl 
Carnitine, Long Chain 
Saturated) 
Lipid             0.46 0.0308 0.4506 
Undecenoylcarnitine (C11:1) Fatty Acid Metabolism (Acyl 
Carnitine, 
Monounsaturated) 
Lipid             0.44 0.0236 0.4506 
(R)-3-hydroxybutyrylcarnitine Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 




3-hydroxydodecanedioate  Fatty Acid, Dicarboxylate Lipid             0.38 0.0402 0.4506 
N,N-dimethylalanine Alanine and Aspartate 
Metabolism 
Amino Acid             0.30 0.0419 0.4506 
3-methoxycatechol sulfate (1) Benzoate Metabolism Xenobiotics             0.16 0.0328 0.4506 





            0.10 0.0053 0.3398 
Cord artery of the induction of labour group (CAIOL) and cord artery of the spontaneously labouring group (CAS) (CAIOL/CAS); cord artery of the elective 
caesarean section group (CACS) and cord artery of the spontaneous labour group (CAS) (CACS/CAS); and cord artery of the elective caesarean section group 












APPENDIX 3A5: Table presenting metabolites for which the fold-change (FC) is significant (Welch’s two-sample t-test 
significant when p≤0.05) in the cord vein between the different mode of labour onset groups. Corresponding p- and q-values 
are shown.  



















Ranitidine Drug - Gastrointestinal Xenobiotics 1013.92 0.0010 0.0927 988.83 0.0004 0.0312       
Ranitidine N-oxide  Drug - Gastrointestinal Xenobiotics 34.42 0.0291 0.2247 19.15 0.0011 0.0509       
Cis-4-decenoate (10:1n6)  Medium Chain Fatty Acid Lipid 10.10 0.0002 0.0541 4.19 0.0068 0.1430 2.41 0.0356 0.6531 
Stearidonate (18:4n3) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 9.05 0.0175 0.1917             
Estriol Estrogenic Steroids Lipid 6.45 0.0352 0.2355             
(2 or 3)-decenoate (10:1n7 or n8) Medium Chain Fatty Acid Lipid 5.47 0.0066 0.1588             
Linolenate [alpha or gamma; (18:3n3 or 6)] Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 5.30 0.0154 0.1766             




5.22 0.0275 0.2242 5.05 0.0244 0.2071       
Caprylate (8:0) Medium Chain Fatty Acid Lipid 4.52 0.0007 0.0927 2.63 0.0335 0.2182       
Isocaproate (i6:0) Fatty Acid, Branched Lipid 4.47 0.0275 0.2242             
Linoleate (18:2n6) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 4.39 0.0089 0.1588             
Branched-chain, straight-chain, or 
cyclopropyl 10:1 fatty acid (1)  
Partially Characterized Molecules Partially 
Characterized 
Molecules 
4.34 0.0472 0.2520             
Hexadecadienoate (16:2n6) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 4.31 0.0060 0.1588       2.48 0.0392 0.6800 
Progesterone Progestin Steroids Lipid 4.27 0.0105 0.1614       2.28 0.0431 0.6800 
N-acetyltheanine Food Component/Plant Xenobiotics 4.24 0.0440 0.2520 7.60 0.0415 0.2357       
Cys-gly, oxidized Glutathione Metabolism Amino Acid 4.07 0.0089 0.1588 5.66 0.0044 0.1313       
Isovalerate (i5:0) Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid 4.01 0.0079 0.1588 3.39 0.0186 0.1915       
Caproate (6:0) Medium Chain Fatty Acid Lipid 3.83 0.0008 0.0927 3.00 0.0280 0.2182       
N-formylphenylalanine Tyrosine Metabolism Amino Acid 3.82 0.0014 0.0927             
Palmitoleate (16:1n7) Long Chain Monounsaturated Fatty 
Acid 




17alpha-hydroxyprogesterone Progestin Steroids Lipid 3.50 0.0357 0.2355       2.29 0.0461 0.6800 
3-indoleglyoxylic acid Food Component/Plant Xenobiotics 3.40 0.0034 0.1411 3.35 0.0118 0.1724       
Nisinate (24:6n3) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 3.32 0.0076 0.1588 2.53 0.0200 0.1926       
N6-methyladenosine Purine Metabolism, Adenine 
containing 
Nucleotide 3.26 0.0016 0.0927             
Eicosapentaenoate (EPA; 20:5n3) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 3.24 0.0003 0.0541 3.45 0.0002 0.0244       
Oleate/vaccenate (18:1) Long Chain Monounsaturated Fatty 
Acid 
Lipid 3.22 0.0289 0.2247             
Gamma-glutamyl-2-aminobutyrate Gamma-glutamyl Amino Acid Peptide 3.07 0.0126 0.1687 3.24 0.0095 0.1488       
Tetradecadienoate (14:2)  Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 2.96 0.0380 0.2424             
Adrenate (22:4n6) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 2.93 0.0329 0.2320             
Docosapentaenoate (n3 DPA; 22:5n3) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 2.83 0.0002 0.0541 2.01 0.0307 0.2182       
Docosahexaenoate (DHA; 22:6n3) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 2.82 0.0099 0.1596 2.42 0.0326 0.2182       
Fructosyllysine Lysine Metabolism Amino Acid 2.78 0.0263 0.2242             
3-hydroxyoleoylcarnitine Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid 2.69 0.0157 0.1766       2.44 0.0148 0.6390 
Arachidonate (20:4n6) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 2.46 0.0049 0.1588             
Butyrate/isobutyrate (4:0) Short Chain Fatty Acid Lipid 2.45 0.0136 0.1688 2.34 0.0147 0.1760       
Mannitol/sorbitol Fructose, Mannose and Galactose 
Metabolism 
Carbohydrate 2.44 0.0074 0.1588 2.22 0.0228 0.2011       
Docosadienoate (22:2n6) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 2.44 0.0138 0.1688       2.01 0.0337 0.6531 
Valerate (5:0) Short Chain Fatty Acid Lipid 2.39 0.0378 0.2424             
Docosapentaenoate (n6 DPA; 22:5n6) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 2.38 0.0206 0.1999             
Hexanoylcarnitine (C6) Fatty Acid Metabolism (Acyl 
Carnitine, Medium Chain) 
Lipid 2.36 0.0181 0.1921             
Docosatrienoate (22:3n3) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 2.34 0.0134 0.1688             
Eicosenoate (20:1) Long Chain Monounsaturated Fatty 
Acid 
Lipid 2.32 0.0208 0.1999             
Taurochenodeoxycholic acid 3-sulfate Secondary Bile Acid Metabolism Lipid 2.27 0.0244 0.2134             
Dihomo-linoleate (20:2n6) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 




Dihomo-linolenate (20:3n3 or n6) Long Chain Polyunsaturated Fatty 
Acid (n3 and n6) 
Lipid 2.26 0.0137 0.1688             
1-arachidonoyl-GPA (20:4) Lysophospholipid Lipid 2.23 0.0153 0.1766             
Methionine sulfoxide Methionine, Cysteine, SAM and 
Taurine Metabolism 
Amino Acid 2.19 0.0332 0.2320 2.19 0.0329 0.2182       
Erucate (22:1n9) Long Chain Monounsaturated Fatty 
Acid 
Lipid 2.16 0.0268 0.2242             
Maleate Fatty Acid, Dicarboxylate Lipid 2.10 0.0088 0.1588             
Mannose Fructose, Mannose and Galactose 
Metabolism 
Carbohydrate 2.05 0.0062 0.1588       1.60 0.0297 0.6390 
1-linoleoyl-GPI (18:2)  Lysophospholipid Lipid 2.03 0.0410 0.2455             
Dodecenedioate (C12:1-DC)  Fatty Acid, Dicarboxylate Lipid 2.02 0.0409 0.2455             
Octanoylcarnitine (C8) Fatty Acid Metabolism (Acyl 
Carnitine, Medium Chain) 
Lipid 1.99 0.0399 0.2455             
Glycosyl-N-behenoyl-sphingadienine 
(d18:2/22:0)  
Hexosylceramides (HCER) Lipid 1.98 0.0099 0.1596             
1-arachidonoyl-GPC (20:4n6)  Lysophospholipid Lipid 1.87 0.0061 0.1588 1.96 0.0009 0.0507       
Lignoceroylcarnitine (C24)  Fatty Acid Metabolism (Acyl 
Carnitine, Long Chain Saturated) 
Lipid 1.86 0.0208 0.1999             
Palmitate (16:0) Long Chain Saturated Fatty Acid Lipid 1.85 0.0305 0.2268             
1-linoleoyl-GPC (18:2) Lysophospholipid Lipid 1.82 0.0493 0.2520 2.04 0.0072 0.1430       
Aconitate [cis or trans] TCA Cycle Energy 1.76 0.0183 0.1921             
Fructose Fructose, Mannose and Galactose 
Metabolism 
Carbohydrate 1.71 0.0223 0.2017             
2-hydroxynervonate  Fatty Acid, Monohydroxy Lipid 1.71 0.0458 0.2520             
2-hydroxybutyrate/2-hydroxyisobutyrate Glutathione Metabolism Amino Acid 1.69 0.0476 0.2520             
2-hydroxystearate Fatty Acid, Monohydroxy Lipid 1.68 0.0064 0.1588             
Glycosyl ceramide (d18:1/20:0, 
d16:1/22:0)  
Hexosylceramides (HCER) Lipid 1.66 0.0076 0.1588             
N-stearoyltaurine Endocannabinoid Lipid 1.56 0.0305 0.2268             
Glycosyl-N-stearoyl-sphingosine 
(d18:1/18:0) 
Hexosylceramides (HCER) Lipid 1.54 0.0048 0.1588             
Allantoin Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide 1.50 0.0176 0.1917 1.42 0.0328 0.2182       
Cortisone Corticosteroids Lipid 1.49 0.0416 0.2466 0.52 0.0086 0.1485 2.85 0.0004 0.1042 
1-stearoyl-GPC (18:0) Lysophospholipid Lipid 1.47 0.0469 0.2520 1.40 0.0450 0.2428       




2-aminobutyrate Glutathione Metabolism Amino Acid 1.20 0.0114 0.1678             
N2,N2-dimethylguanosine Purine Metabolism, Guanine 
containing 
Nucleotide 0.78 0.0429 0.2520             




0.78 0.0482 0.2520 0.66 0.0202 0.1926       
7-methylguanine Purine Metabolism, Guanine 
containing 
Nucleotide 0.77 0.0015 0.0927             
N1-methyladenosine Purine Metabolism, Adenine 
containing 
Nucleotide 0.77 0.0155 0.1766             
Acetylcarnitine (C2) Fatty Acid Metabolism (Acyl 
Carnitine, Short Chain) 
Lipid 0.69 0.0301 0.2268 0.56 0.0060 0.1430       
N1-methylinosine Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide 0.67 0.0273 0.2242       0.68 0.0191 0.6390 
2-hydroxyhippurate (salicylurate) Benzoate Metabolism Xenobiotics 0.56 0.0022 0.1055             
Iminodiacetate (IDA) Chemical Xenobiotics 0.56 0.0122 0.1687 0.56 0.0275 0.2182       
Hydroxy-N6,N6,N6-trimethyllysine  Lysine Metabolism Amino Acid 0.56 0.0314 0.2272 0.64 0.0483 0.2507       
1-methylguanidine Guanidino and Acetamido 
Metabolism 
Amino Acid 0.52 0.0318 0.2273 0.40 0.0304 0.2182       
Glutarate (C5-DC) Fatty Acid, Dicarboxylate Lipid 0.49 0.0473 0.2520 0.44 0.0319 0.2182       
Corticosterone Corticosteroids Lipid 0.48 0.0220 0.2017 0.19 0.0004 0.0312 2.46 0.0064 0.6373 
Deoxycarnitine Carnitine Metabolism Lipid 0.48 0.0237 0.2110 0.47 0.0212 0.1949       
Glutamate Glutamate Metabolism Amino Acid 0.44 0.0405 0.2455             
Maltose Glycogen Metabolism Carbohydrate 0.41 0.0198 0.1999 0.16 0.0017 0.0663 2.51 0.0235 0.6390 
Cortisol Corticosteroids Lipid 0.41 0.0280 0.2247 0.17 0.0000 0.0066 2.45 0.0456 0.6800 
3-hydroxyphenylacetoylglutamine Acetylated Peptides Peptide 0.40 0.0048 0.1588             
N-acetylglucosaminylasparagine Aminosugar Metabolism Carbohydrate 0.38 0.0071 0.1588 0.42 0.0123 0.1724       




0.37 0.0451 0.2520             
Cytosine Pyrimidine Metabolism, Cytidine 
containing 
Nucleotide 0.37 0.0494 0.2520 0.32 0.0383 0.2249       
Edta Chemical Xenobiotics 0.36 0.0019 0.1009 0.42 0.0133 0.1748       
2-keto-3-deoxy-gluconate Food Component/Plant Xenobiotics 0.36 0.0388 0.2445 0.39 0.0389 0.2249       
Vanillic acid glycine Food Component/Plant Xenobiotics 0.33 0.0014 0.0927             
Cysteinylglycine Glutathione Metabolism Amino Acid 0.33 0.0341 0.2327 0.35 0.0376 0.2249       
Glutamate, gamma-methyl ester Glutamate Metabolism Amino Acid 0.30 0.0291 0.2247 0.33 0.0332 0.2182       




Sphingosine Sphingosines Lipid 0.28 0.0489 0.2520 0.22 0.0340 0.2189       
Adenosine 3',5'-cyclic monophosphate 
(camp) 
Purine Metabolism, Adenine 
containing 
Nucleotide 0.22 0.0336 0.2320 0.11 0.0091 0.1488       
S-adenosylhomocysteine (SAH) Methionine, Cysteine, SAM and 
Taurine Metabolism 
Amino Acid 0.22 0.0494 0.2520             
Sarcosine Glycine, Serine and Threonine 
Metabolism 
Amino Acid 0.20 0.0126 0.1687 0.23 0.0122 0.1724       
Sphinganine Sphingolipid Synthesis Lipid 0.19 0.0218 0.2017 0.12 0.0142 0.1760       
Maltotriose Glycogen Metabolism Carbohydrate 0.16 0.0204 0.1999 0.17 0.0167 0.1839       
1-oleoyl-2-arachidonoyl-GPE (18:1/20:4)  Phosphatidylethanolamine (PE) Lipid 0.15 0.0311 0.2272 0.07 0.0195 0.1926       
Cytidine 5'-monophosphate (5'-CMP) Pyrimidine Metabolism, Cytidine 
containing 
Nucleotide 0.13 0.0087 0.1588 0.24 0.0201 0.1926       
N2,N5-diacetylornithine Urea cycle; Arginine and Proline 
Metabolism 
Amino Acid 0.12 0.0029 0.1329 0.12 0.0082 0.1485       
Cysteine-glutathione disulfide Glutathione Metabolism Amino Acid 0.11 0.0042 0.1588             
Heptadecenamide (17:1)  Fatty Acid, Amide Lipid 0.11 0.0096 0.1596             
Maltotetraose Glycogen Metabolism Carbohydrate 0.11 0.0101 0.1596 0.16 0.0193 0.1926       
1-oleoyl-2-docosahexaenoyl-GPE 
(18:1/22:6)  
Phosphatidylethanolamine (PE) Lipid 0.10 0.0404 0.2455 0.04 0.0216 0.1949       
Spermidine Polyamine Metabolism Amino Acid 0.03 0.0220 0.2017 0.08 0.0288 0.2182       
Adenosine 5'-diphosphoribose (ADP-
ribose) 




0.02 0.0120 0.1687 0.07 0.0186 0.1915       
Glutathione, oxidized (GSSG) Glutathione Metabolism Amino Acid 0.00 0.0477 0.2520             
Metronidazole Drug - Antibiotic Xenobiotics       4274.67 0.0000 0.0011 0.00 0.0000 0.0054 
N-ethylglycinexylidide Drug - Analgesics, Anesthetics Xenobiotics       6.70 0.0002 0.0244       
Gamma-glutamylcitrulline  Gamma-glutamyl Amino Acid Peptide       3.79 0.0062 0.1430       
Trimethylamine N-oxide Phospholipid Metabolism Lipid       3.04 0.0299 0.2182       
Gamma-glutamylmethionine Gamma-glutamyl Amino Acid Peptide       2.27 0.0426 0.2357       
Gamma-glutamylhistidine Gamma-glutamyl Amino Acid Peptide       2.16 0.0463 0.2437       
1-arachidonoyl-GPI (20:4)  Lysophospholipid Lipid       2.05 0.0251 0.2091       
Phenylalanylhydroxyproline  Dipeptide Peptide       2.03 0.0266 0.2179       
Gamma-glutamylglutamine Gamma-glutamyl Amino Acid Peptide       1.90 0.0235 0.2035       
Gamma-glutamyl-alpha-lysine Gamma-glutamyl Amino Acid Peptide       1.82 0.0268 0.2179       




1-linoleoyl-GPE (18:2)  Lysophospholipid Lipid       1.78 0.0422 0.2357       
1-arachidonoyl-GPE (20:4n6)  Lysophospholipid Lipid       1.71 0.0151 0.1781       
1-oleoyl-GPC (18:1) Lysophospholipid Lipid       1.66 0.0019 0.0688       
Gamma-glutamylisoleucine  Gamma-glutamyl Amino Acid Peptide       1.65 0.0066 0.1430       
Gamma-glutamylleucine Gamma-glutamyl Amino Acid Peptide       1.58 0.0067 0.1430       
Gamma-glutamyltyrosine Gamma-glutamyl Amino Acid Peptide       1.58 0.0288 0.2182       
Beta-hydroxyisovalerate Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid       1.57 0.0205 0.1931       
1-(1-enyl-palmitoyl)-GPC (P-16:0)  Lysoplasmalogen Lipid       1.55 0.0362 0.2189       
1-palmitoleoyl-GPC (16:1)  Lysophospholipid Lipid       1.54 0.0424 0.2357       
Gamma-glutamylvaline Gamma-glutamyl Amino Acid Peptide       1.44 0.0388 0.2249       
1-lignoceroyl-GPC (24:0) Lysophospholipid Lipid       1.40 0.0435 0.2368       
3-methyl-2-oxobutyrate Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid       1.39 0.0245 0.2071       
1-oleoyl-GPE (18:1) Lysophospholipid Lipid       1.36 0.0359 0.2189       
1-stearoyl-GPE (18:0) Lysophospholipid Lipid       1.34 0.0355 0.2189       
Citrulline Urea cycle; Arginine and Proline 
Metabolism 
Amino Acid       1.28 0.0459 0.2437       
Valine Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid       1.24 0.0298 0.2182       
Creatinine Creatine Metabolism Amino Acid       0.71 0.0216 0.1949       
N,N,N-trimethyl-5-aminovalerate Lysine Metabolism Amino Acid       0.70 0.0185 0.1915       
1-stearoyl-2-linoleoyl-GPI (18:0/18:2) Phosphatidylinositol (PI) Lipid       0.70 0.0352 0.2189 1.59 0.0252 0.6390 
4-hydroxychlorothalonil Chemical Xenobiotics       0.67 0.0229 0.2011       
1-palmitoyl-2-oleoyl-GPI (16:0/18:1)  Phosphatidylinositol (PI) Lipid       0.67 0.0403 0.2309       
Carboxyethyl-GABA Glutamate Metabolism Amino Acid       0.66 0.0358 0.2189       
Taurine Methionine, Cysteine, SAM and 
Taurine Metabolism 
Amino Acid       0.64 0.0433 0.2368       
N-acetyltaurine Methionine, Cysteine, SAM and 
Taurine Metabolism 
Amino Acid       0.63 0.0309 0.2182       




      0.62 0.0008 0.0507       
N,N,N-trimethyl-alanylproline betaine 
(TMAP) 
Urea cycle; Arginine and Proline 
Metabolism 
Amino Acid       0.62 0.0334 0.2182       
3-amino-2-piperidone Urea cycle; Arginine and Proline 
Metabolism 




Palmitoleoylcarnitine (C16:1)  Fatty Acid Metabolism (Acyl 
Carnitine, Monounsaturated) 
Lipid       0.57 0.0352 0.2189 1.88 0.0025 0.4356 
1-stearoyl-2-linoleoyl-GPE (18:0/18:2)  Phosphatidylethanolamine (PE) Lipid       0.55 0.0021 0.0688       
Phytanate Food Component/Plant Xenobiotics       0.50 0.0094 0.1488 2.38 0.0298 0.6390 
1-stearoyl-2-docosahexaenoyl-GPE 
(18:0/22:6)  
Phosphatidylethanolamine (PE) Lipid       0.47 0.0070 0.1430       
Succinylcarnitine (C4-DC) TCA Cycle Energy       0.47 0.0090 0.1488       
Lactate Glycolysis, Gluconeogenesis, and 
Pyruvate Metabolism 
Carbohydrate       0.45 0.0156 0.1806 1.97 0.0156 0.6390 
Inosine Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide       0.44 0.0500 0.2551 3.45 0.0421 0.6800 
Androsterone glucuronide Androgenic Steroids Lipid       0.43 0.0386 0.2249       
1-carboxyethylvaline Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid       0.42 0.0021 0.0688 2.17 0.0015 0.3332 
Glycerol Glycerolipid Metabolism Lipid       0.41 0.0107 0.1601 2.20 0.0092 0.6373 
1-carboxyethylisoleucine Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid       0.38 0.0318 0.2182       
Hypoxanthine Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide       0.37 0.0144 0.1760       
(S)-3-hydroxybutyrylcarnitine Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid       0.36 0.0066 0.1430       
1-palmitoyl-2-docosahexaenoyl-GPE 
(16:0/22:6)  
Phosphatidylethanolamine (PE) Lipid       0.35 0.0349 0.2189       
1-carboxyethyltyrosine Tyrosine Metabolism Amino Acid       0.34 0.0012 0.0515 2.21 0.0030 0.4356 
Estrone 3-sulfate Estrogenic Steroids Lipid       0.34 0.0129 0.1730 2.22 0.0240 0.6390 
1-carboxyethylleucine Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid       0.33 0.0049 0.1356 2.53 0.0081 0.6373 
1-carboxyethylphenylalanine Phenylalanine Metabolism Amino Acid       0.33 0.0159 0.1810 2.29 0.0107 0.6390 
Xanthine Purine Metabolism, 
(Hypo)Xanthine/Inosine containing 
Nucleotide       0.29 0.0178 0.1915 1.73 0.0450 0.6800 
Oleoyl-arachidonoyl-glycerol (18:1/20:4) 
[2]  
Diacylglycerol Lipid       0.28 0.0084 0.1485       
1,3-dimethylurate Xanthine Metabolism Xenobiotics       0.28 0.0097 0.1492       
Flavin adenine dinucleotide (FAD) Riboflavin Metabolism Cofactors and 
Vitamins 
      0.28 0.0322 0.2182       
2-hydroxyglutarate Fatty Acid, Dicarboxylate Lipid       0.23 0.0297 0.2182       
1,3,7-trimethylurate Xanthine Metabolism Xenobiotics       0.21 0.0328 0.2182       




1-stearoyl-2-oleoyl-GPE (18:0/18:1) Phosphatidylethanolamine (PE) Lipid       0.20 0.0473 0.2472       
1-palmitoyl-2-stearoyl-GPE (16:0/18:0)  Phosphatidylethanolamine (PE) Lipid       0.20 0.0498 0.2551       
Trans-urocanate Histidine Metabolism Amino Acid       0.16 0.0010 0.0507       
1,2-dipalmitoyl-GPE (16:0/16:0)  Phosphatidylethanolamine (PE) Lipid       0.11 0.0462 0.2437       
3-(methylthio)acetaminophen sulfate  Drug - Analgesics, Anesthetics Xenobiotics       0.07 0.0009 0.0507       
Glucuronide of C10H18O2 (7)  Partially Characterized Molecules Partially 
Characterized 
Molecules 
      0.04 0.0048 0.1356 22.28 0.0046 0.5794 
2-hydroxyacetaminophen sulfate  Drug - Analgesics, Anesthetics Xenobiotics       0.03 0.0085 0.1485       
3-(cystein-S-yl)acetaminophen  Drug - Analgesics, Anesthetics Xenobiotics       0.02 0.0000 0.0065       
2-methoxyacetaminophen glucuronide  Drug - Analgesics, Anesthetics Xenobiotics       0.02 0.0002 0.0244       
2-methoxyacetaminophen sulfate  Drug - Analgesics, Anesthetics Xenobiotics       0.02 0.0003 0.0305       
3-(N-acetyl-L-cystein-S-yl) acetaminophen Drug - Analgesics, Anesthetics Xenobiotics       0.02 0.0024 0.0762       
4-acetaminophen sulfate Drug - Analgesics, Anesthetics Xenobiotics       0.02 0.0127 0.1730       
4-acetamidophenylglucuronide Drug - Analgesics, Anesthetics Xenobiotics       0.02 0.0139 0.1760       
4-acetamidophenol Drug - Analgesics, Anesthetics Xenobiotics       0.01 0.0013 0.0546       
Glucuronide of C10H18O2 (8)  Partially Characterized Molecules Partially 
Characterized 
Molecules 
            15.58 0.0002 0.0732 
Glucuronide of C10H18O2 (1)  Partially Characterized Molecules Partially 
Characterized 
Molecules 
            10.56 0.0065 0.6373 
3-methoxycatechol sulfate (1) Benzoate Metabolism Xenobiotics             6.70 0.0191 0.6390 
N,N-dimethylalanine Alanine and Aspartate Metabolism Amino Acid             3.26 0.0228 0.6390 
5alpha-pregnan-3beta,20alpha-diol 
monosulfate (2) 
Progestin Steroids Lipid             3.09 0.0281 0.6390 
Cortolone glucuronide (1) Corticosteroids Lipid             2.56 0.0197 0.6390 
5alpha-pregnan-3beta,20beta-diol 
monosulfate (1) 
Progestin Steroids Lipid             2.29 0.0262 0.6390 
3-hydroxydecanoate Fatty Acid, Monohydroxy Lipid             2.20 0.0309 0.6428 
Undecenoylcarnitine (C11:1) Fatty Acid Metabolism (Acyl 
Carnitine, Monounsaturated) 
Lipid             2.01 0.0137 0.6390 
5,6-dihydrouracil Pyrimidine Metabolism, Uracil 
containing 
Nucleotide             1.83 0.0337 0.6531 
3-hydroxydecanoylcarnitine Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 




20a-dihydroprogesterone Progestin Steroids Lipid             1.72 0.0457 0.6800 
5-dodecenoylcarnitine (C12:1) Fatty Acid Metabolism (Acyl 
Carnitine, Monounsaturated) 
Lipid             1.70 0.0224 0.6390 
Cis-4-decenoylcarnitine (C10:1) Fatty Acid Metabolism (Acyl 
Carnitine, Monounsaturated) 
Lipid             1.63 0.0314 0.6428 
Oleoylcarnitine (C18:1) Fatty Acid Metabolism (Acyl 
Carnitine, Monounsaturated) 
Lipid             1.57 0.0233 0.6390 
Myristoleoylcarnitine (C14:1)  Fatty Acid Metabolism (Acyl 
Carnitine, Monounsaturated) 
Lipid             1.54 0.0152 0.6390 
(14 or 15)-methylpalmitate (a17:0 or i17:0) Fatty Acid, Branched Lipid             1.52 0.0479 0.6800 
Glucose Glycolysis, Gluconeogenesis, and 
Pyruvate Metabolism 
Carbohydrate             1.44 0.0348 0.6531 
Linoleoylcarnitine (C18:2)  Fatty Acid Metabolism (Acyl 
Carnitine, Polyunsaturated) 
Lipid             1.43 0.0094 0.6373 
Margarate (17:0) Long Chain Saturated Fatty Acid Lipid             1.41 0.0431 0.6800 
Myristoylcarnitine (C14) Fatty Acid Metabolism (Acyl 
Carnitine, Long Chain Saturated) 
Lipid             1.29 0.0349 0.6531 
Alanine Alanine and Aspartate Metabolism Amino Acid             1.28 0.0297 0.6390 
Cysteine Methionine, Cysteine, SAM and 
Taurine Metabolism 
Amino Acid             1.27 0.0408 0.6800 
Citrate TCA Cycle Energy             1.23 0.0193 0.6390 
Histidine Histidine Metabolism Amino Acid             0.81 0.0142 0.6390 
(N(1) + N(8))-acetylspermidine Polyamine Metabolism Amino Acid             0.77 0.0086 0.6373 
N(1)-acetylspermine Polyamine Metabolism Amino Acid             0.54 0.0221 0.6390 
3-dehydrocholate Secondary Bile Acid Metabolism Lipid             0.53 0.0262 0.6390 
Salicylate Drug - Topical Agents Xenobiotics             0.50 0.0460 0.6800 
2-butenoylglycine Fatty Acid Metabolism (Acyl 
Glycine) 
Lipid             0.49 0.0201 0.6390 
Valylglycine Dipeptide Peptide             0.49 0.0282 0.6390 
Carnosine Histidine Metabolism Amino Acid             0.41 0.0153 0.6390 
Saccharin Food Component/Plant Xenobiotics             0.13 0.0491 0.6800 
Cord vein of the induction of labour group (CVIOL) and cord vein of the spontaneously labouring group (CVS) (CVIOL/CVS); cord vein of the elective caesarean 
section group (CVCS) and cord vein of the spontaneous labour group (CVS) (CVCS/CVS); and cord vein of the elective caesarean section group (CVCS) and cord 





APPENDIX 3A6: Table presenting metabolites for which the fold-change (FC) is significant (Welch’s two-sample t-test 
significant when p≤0.05) between latent stage/early IOL/pre-operative samples between the different modes of labour onset 
and delivery. Corresponding p- and q-values are shown. 























Benzoate Metabolism Xenobiotics 7.95 0.0054 0.9742       0.08 0.0013 1.0000 
Methyl-4-hydroxybenzoate 
sulfate 
Benzoate Metabolism Xenobiotics 7.68 0.0470 0.9742       0.16 0.0393 1.0000 
Hyocholate Secondary Bile Acid 
Metabolism 
Lipid 4.42 0.0248 0.9742             
Stearoylcholine  Fatty Acid Metabolism (Acyl 
Choline) 
Lipid 3.94 0.0465 0.9742             
Arachidonoylcholine Fatty Acid Metabolism (Acyl 
Choline) 
Lipid 3.76 0.0408 0.9742             
1-arachidonoyl-GPA (20:4) Lysophospholipid Lipid 3.66 0.0377 0.9742       0.40 0.0500 1.0000 
Ribulonate/xylulonate/lyxonate  Pentose Metabolism Carbohydrate 3.37 0.0332 0.9742             
1-arachidonylglycerol (20:4) Monoacylglycerol Lipid 2.54 0.0282 0.9742             
3-ureidopropionate Pyrimidine Metabolism, Uracil 
containing 
Nucleotide 2.38 0.0324 0.9742             
2'-O-methyluridine Pyrimidine Metabolism, Uracil 
containing 
Nucleotide 1.77 0.0221 0.9742       0.61 0.0318 1.0000 
1-stearoyl-GPI (18:0) Lysophospholipid Lipid 1.69 0.0162 0.9742 1.47 0.0411 0.4355       
N-acetyl-aspartyl-glutamate 
(NAAG) 
Glutamate Metabolism Amino Acid 1.50 0.0310 0.9742             
5-methyluridine 
(ribothymidine) 
Pyrimidine Metabolism, Uracil 
containing 
Nucleotide 1.47 0.0498 0.9742       0.76 0.0373 1.0000 
N-acetylglutamate Glutamate Metabolism Amino Acid 0.73 0.0281 0.9742             
Cysteinylglycine disulfide  Glutathione Metabolism Amino Acid 0.69 0.0081 0.9742 0.77 0.0499 0.4546       
3-hydroxy-2-ethylpropionate Leucine, Isoleucine and Valine 
Metabolism 







Ceramides Lipid 0.61 0.0068 0.9742 0.63 0.0088 0.3140       
Valylglycine Dipeptide Peptide 0.52 0.0278 0.9742             
3-hydroxyisobutyrate Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid 0.46 0.0041 0.9742 0.57 0.0114 0.3140       
Nisinate (24:6n3) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid 0.44 0.0480 0.9742 0.36 0.0287 0.3865       
21-hydroxypregnenolone 
monosulfate (2) 
Pregnenolone Steroids Lipid 0.42 0.0261 0.9742             
Androsterone glucuronide Androgenic Steroids Lipid 0.42 0.0448 0.9742             
13-hode + 9-hode Fatty Acid, Monohydroxy Lipid 0.39 0.0353 0.9742             
Androstenediol (3alpha, 
17alpha) monosulfate (2) 
Androgenic Steroids Lipid 0.35 0.0025 0.9742 0.24 0.0008 0.1776       
Corticosterone Corticosteroids Lipid 0.35 0.0299 0.9742 0.19 0.0009 0.1776       
(12 or 13)-methylmyristate 
(a15:0 or i15:0) 
Fatty Acid, Branched Lipid 0.34 0.0360 0.9742 0.40 0.0164 0.3567       
21-hydroxypregnenolone 
monosulfate (1) 
Pregnenolone Steroids Lipid 0.30 0.0060 0.9742 0.45 0.0324 0.3908       
Phytanate Food Component/Plant Xenobiotics 0.30 0.0140 0.9742 0.43 0.0458 0.4499       
Glutamine conjugate of 






0.30 0.0191 0.9742 0.32 0.0314 0.3908       
Epiandrosterone sulfate Androgenic Steroids Lipid 0.30 0.0237 0.9742             
Laurate (12:0) Medium Chain Fatty Acid Lipid 0.25 0.0245 0.9742             
Leucylglycine Dipeptide Peptide 0.12 0.0219 0.9742             
Fructose Fructose, Mannose and 
Galactose Metabolism 
Carbohydrate       2.78 0.0298 0.3865       
N-palmitoylserine Endocannabinoid Lipid       2.73 0.0044 0.2967       




Dihydrosphingomyelins Lipid       1.69 0.0250 0.3865       




1-palmitoyl-GPG (16:0)  Lysophospholipid Lipid       1.52 0.0257 0.3865       
1-carboxyethylvaline Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid       1.44 0.0337 0.3939       
1-oleoyl-2-linoleoyl-GPC 
(18:1/18:2)  
Phosphatidylcholine (PC) Lipid       1.27 0.0083 0.3140       
1-stearoyl-2-docosahexaenoyl-
GPE (18:0/22:6)  
Phosphatidylethanolamine 
(PE) 
Lipid       1.23 0.0029 0.2967       
1-(1-enyl-stearoyl)-2-linoleoyl-
GPE (P-18:0/18:2)  
Plasmalogen Lipid       1.18 0.0300 0.3865       
Malonate Fatty Acid Synthesis Lipid       0.92 0.0407 0.4355       
N-acetyl-beta-alanine Pyrimidine Metabolism, Uracil 
containing 
Nucleotide       0.81 0.0332 0.3938       
1-methyl-4-imidazoleacetate Histidine Metabolism Amino Acid       0.79 0.0444 0.4462       
Ribitol Pentose Metabolism Carbohydrate       0.78 0.0069 0.3140       
Cysteine Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.78 0.0388 0.4273       
N-acetylputrescine Polyamine Metabolism Amino Acid       0.77 0.0486 0.4546 0.72 0.0411 1.0000 
2-hydroxypalmitate Fatty Acid, Monohydroxy Lipid       0.75 0.0274 0.3865       
Lactate Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
Carbohydrate       0.74 0.0472 0.4525       
4-hydroxychlorothalonil Chemical Xenobiotics       0.71 0.0237 0.3846       
Alpha-ketoglutarate TCA Cycle Energy       0.71 0.0466 0.4525       
Adenosine 3',5'-cyclic 
monophosphate (camp) 
Purine Metabolism, Adenine 
containing 
Nucleotide       0.69 0.0302 0.3865       
Cortisone Corticosteroids Lipid       0.64 0.0283 0.3865 0.67 0.0352 1.0000 
S-methylcysteine Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.61 0.0429 0.4432       
Stearate (18:0) Long Chain Saturated Fatty 
Acid 
Lipid       0.59 0.0182 0.3766       
Palmitoyl ethanolamide Endocannabinoid Lipid       0.56 0.0008 0.1776       
N-palmitoylglycine Fatty Acid Metabolism (Acyl 
Glycine) 
Lipid       0.54 0.0053 0.3106       
Arachidonate (20:4n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 




3-hydroxydecanoate Fatty Acid, Monohydroxy Lipid       0.54 0.0356 0.4040       
Nonadecanoate (19:0) Long Chain Saturated Fatty 
Acid 
Lipid       0.53 0.0058 0.3106       
3-hydroxymyristate Fatty Acid, Monohydroxy Lipid       0.52 0.0125 0.3140       
1-palmitoyl-2-arachidonoyl-GPI 
(16:0/20:4)  
Phosphatidylinositol (PI) Lipid       0.52 0.0271 0.3865 0.43 0.0205 1.0000 
Glycerol Glycerolipid Metabolism Lipid       0.51 0.0221 0.3846       
Pentadecanoate (15:0) Long Chain Saturated Fatty 
Acid 
Lipid       0.50 0.0145 0.3253       
Ceramide (d18:1/14:0, 
d16:1/16:0)  
Ceramides Lipid       0.50 0.0278 0.3865       
Cortisol Corticosteroids Lipid       0.49 0.0007 0.1776       
Dihomo-linolenate (20:3n3 or 
n6) 
Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.49 0.0295 0.3865       
16-hydroxypalmitate Fatty Acid, Monohydroxy Lipid       0.48 0.0114 0.3140       
Octadecanedioate (C18-DC) Fatty Acid, Dicarboxylate Lipid       0.48 0.0123 0.3140       
Erucate (22:1n9) Long Chain Monounsaturated 
Fatty Acid 
Lipid       0.48 0.0141 0.3240       
10-undecenoate (11:1n1) Medium Chain Fatty Acid Lipid       0.47 0.0263 0.3865       
Docosapentaenoate (n6 DPA; 
22:5n6) 
Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.46 0.0229 0.3846       
Lactose Disaccharides and 
Oligosaccharides 
Carbohydrate       0.46 0.0491 0.4546       
Linoleoyl ethanolamide Endocannabinoid Lipid       0.44 0.0239 0.3846       
9-hydroxystearate Fatty Acid, Monohydroxy Lipid       0.43 0.0028 0.2967       
Docosadienoate (22:2n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.43 0.0110 0.3140       
Palmitate (16:0) Long Chain Saturated Fatty 
Acid 
Lipid       0.41 0.0026 0.2967       
Margarate (17:0) Long Chain Saturated Fatty 
Acid 
Lipid       0.41 0.0073 0.3140       
Mead acid (20:3n9) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 




Tetradecadienoate (14:2)  Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.39 0.0235 0.3846       
Eicosenoate (20:1) Long Chain Monounsaturated 
Fatty Acid 
Lipid       0.38 0.0134 0.3240       
Tridecenedioate (C13:1-DC)  Fatty Acid, Dicarboxylate Lipid       0.38 0.0389 0.4273       
(16 or 17)-methylstearate 
(a19:0 or i19:0) 
Fatty Acid, Branched Lipid       0.38 0.0443 0.4462       
Myristate (14:0) Long Chain Saturated Fatty 
Acid 
Lipid       0.37 0.0105 0.3140       
Docosapentaenoate (n3 DPA; 
22:5n3) 
Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.37 0.0209 0.3846       
Dihomo-linoleate (20:2n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.36 0.0044 0.2967       
Oleate/vaccenate (18:1) Long Chain Monounsaturated 
Fatty Acid 
Lipid       0.36 0.0081 0.3140       
(14 or 15)-methylpalmitate 
(a17:0 or i17:0) 
Fatty Acid, Branched Lipid       0.36 0.0225 0.3846       
5-dodecenoate (12:1n7) Medium Chain Fatty Acid Lipid       0.36 0.0289 0.3865       
N-palmitoyl-sphingadienine 
(d18:2/16:0)  
Ceramides Lipid       0.35 0.0037 0.2967       
Linoleate (18:2n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.35 0.0082 0.3140       
3-hydroxybutyroylglycine   Fatty Acid Metabolism (Acyl 
Glycine) 
Lipid       0.34 0.0190 0.3785       
Linolenate [alpha or gamma; 
(18:3n3 or 6)] 
Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.34 0.0205 0.3846       
Tetradecadienedioate (C14:2-
DC)  
Fatty Acid, Dicarboxylate Lipid       0.34 0.0423 0.4425       
Adrenate (22:4n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.33 0.0115 0.3140       
3-hydroxybutyrate (BHBA) Ketone Bodies Lipid       0.32 0.0220 0.3846       
Docosatrienoate (22:3n3) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.31 0.0097 0.3140       
10-nonadecenoate (19:1n9) Long Chain Monounsaturated 
Fatty Acid 




2-butenoylglycine Fatty Acid Metabolism (Acyl 
Glycine) 
Lipid       0.25 0.0056 0.3106       
Myristoleate (14:1n5) Long Chain Monounsaturated 
Fatty Acid 
Lipid       0.25 0.0100 0.3140       
3-hydroxykynurenine Tryptophan Metabolism Amino Acid       0.25 0.0353 0.4040       
10-heptadecenoate (17:1n7) Long Chain Monounsaturated 
Fatty Acid 
Lipid       0.24 0.0137 0.3240       
Testosterone sulfate Androgenic Steroids Lipid       0.24 0.0392 0.4273       
Hexadecadienoate (16:2n6) Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.21 0.0039 0.2967       
Palmitoleate (16:1n7) Long Chain Monounsaturated 
Fatty Acid 
Lipid       0.21 0.0064 0.3140       
Trans-2-hexenoylglycine Fatty Acid Metabolism (Acyl 
Glycine) 
Lipid       0.21 0.0449 0.4462       







      0.09 0.0325 0.3908       
Phenylacetylglycine Acetylated Peptides Peptide             4.55 0.0105 1.0000 
N2,N5-diacetylornithine Urea cycle; Arginine and 
Proline Metabolism 
Amino Acid             2.43 0.0446 1.0000 
1,3-dimethylurate Xanthine Metabolism Xenobiotics             2.37 0.0265 1.0000 
Homocitrulline Urea cycle; Arginine and 
Proline Metabolism 
Amino Acid             1.48 0.0158 1.0000 
Isoleucine Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid             1.40 0.0085 1.0000 
Methylmalonate (MMA) Fatty Acid Metabolism (also 
BCAA Metabolism) 
Lipid             1.28 0.0472 1.0000 
1-palmitoyl-2-dihomo-
linolenoyl-GPC (16:0/20:3n3 or 
6)  
Phosphatidylcholine (PC) Lipid             1.20 0.0344 1.0000 




            0.70 0.0143 1.0000 
N,N,N-trimethyl-alanylproline 
betaine (TMAP) 
Urea cycle; Arginine and 
Proline Metabolism 




Butyrylcarnitine (C4) Fatty Acid Metabolism (also 
BCAA Metabolism) 
Lipid             0.63 0.0412 1.0000 
Ethylmalonate Leucine, Isoleucine and Valine 
Metabolism 
Amino Acid             0.59 0.0326 1.0000 
20a-dihydroprogesterone Progestin Steroids Lipid             0.58 0.0253 1.0000 
Early stage of induction of labour (LIOL) of the induction of labour (LIOL) and latent stage of spontaneous labour group (LS) (LIOL/LS); pre-operative sample 
of the elective caesarean section group (LCS) and latent stage of the spontaneous labour group (LS) (LCS/LS); and pre-operative sample of the elective 
















APPENDIX 3A7: Table presenting metabolites for which the fold-change (FC) is significant (Welch’s two-sample t-test 
significant when p≤0.05) in the intervillous blood between the different mode of labour onset groups. Corresponding p- and 
q-values are shown. 





















Ranitidine Drug - Gastrointestinal Xenobiotics 1547.50 0.0002 0.1451 1273.00 0.0009 0.0801       
Phenylalanylhydroxyproline  Drug - Gastrointestinal Xenobiotics 25.61 0.0049 0.7798 13.70 0.0393 0.3281       
Glutarylcarnitine (C5-DC) Glycine, Serine and Threonine 
Metabolism 
Amino Acid 0.71 0.0062 0.7798             
Ranitidine N-oxide  Glycerolipid Metabolism Lipid 0.70 0.0379 0.7798 0.64 0.0145 0.2507       
N-acetylthreonine Fatty Acid, Dihydroxy Lipid 0.70 0.0448 0.7798             
Glucuronide of C12H22O4 (1)  Histidine Metabolism Amino Acid 0.67 0.0252 0.7798 0.56 0.0052 0.1713       
Maltol sulfate Pyrimidine Metabolism, 
Orotate containing 
Nucleotide 0.67 0.0324 0.7798             
8-methoxykynurenate Pyrimidine Metabolism, 
Cytidine containing 
Nucleotide 0.67 0.0348 0.7798             
Isobutyrylglycine Pentose Metabolism Carbohydrate 0.62 0.0181 0.7798             
Arabitol/xylitol Gamma-glutamyl Amino Acid Peptide 0.62 0.0210 0.7798       0.59 0.0196 0.4939 
1-methylguanidine Aminosugar Metabolism Carbohydrate 0.62 0.0228 0.7798             
Gamma-glutamylhistidine Tryptophan Metabolism Amino Acid 0.61 0.0295 0.7798 0.50 0.0070 0.1860       
Cytosine Sterol Lipid 0.61 0.0486 0.7798             
Erythronate  Lysine Metabolism Amino Acid 0.60 0.0044 0.7798 0.55 0.0224 0.2735       




0.56 0.0339 0.7798             
Heptadecenamide (17:1)  Dipeptide Peptide 0.52 0.0041 0.7798             
1-methylhistidine Fatty Acid Synthesis Lipid 0.44 0.0230 0.7798             
Glycerophosphoglycerol Fatty Acid Metabolism (Acyl 
Glycine) 
Lipid 0.44 0.0444 0.7798             
Glycerophosphoethanolamine Guanidino and Acetamido 
Metabolism 




Kynurenate Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid 0.41 0.0172 0.7798       0.46 0.0275 0.4939 







0.39 0.0303 0.7798 0.26 0.0364 0.3281       
Orotidine Phospholipid Metabolism Lipid 0.38 0.0488 0.7798       0.31 0.0064 0.4497 
Quinolinate Fatty Acid, Amide Lipid 0.34 0.0238 0.7798             
3-methylcytidine Glycerolipid Metabolism Lipid 0.34 0.0270 0.7798             





0.33 0.0118 0.7798 0.28 0.0056 0.1713       
7-methylurate Tryptophan Metabolism Amino Acid 0.33 0.0154 0.7798 0.38 0.0198 0.2735       
Picolinoylglycine Food Component/Plant Xenobiotics 0.30 0.0122 0.7798 0.40 0.0407 0.3281       
3,4-dihydroxybutyrate Pyrimidine Metabolism, 
Cytidine containing 
Nucleotide 0.27 0.0212 0.7798 0.35 0.0465 0.3488       
7-alpha-hydroxy-3-oxo-4-
cholestenoate (7-Hoca) 
Phospholipid Metabolism Lipid 0.22 0.0293 0.7798       0.23 0.0015 0.2208 
Glycerophosphorylcholine (GPC) Xanthine Metabolism Xenobiotics 0.08 0.0414 0.7798             
Ribitol Drug - Antibiotic Xenobiotics       4018.33 0.0000 0.0000 0.00 0.0004 0.1197 
Isovalerylglycine Fatty Acid Metabolism (Acyl 
Choline) 
Lipid       22.21 0.0009 0.0801       
2-keto-3-deoxy-gluconate Fatty Acid Metabolism (Acyl 
Choline) 
Lipid       21.86 0.0029 0.1599       
Salicylate Fatty Acid Metabolism (Acyl 
Choline) 
Lipid       18.24 0.0037 0.1651       
12,13-dihome Fatty Acid Metabolism (Acyl 
Choline) 
Lipid       17.41 0.0079 0.1869       
2,3-diphosphoglycerate Fatty Acid Metabolism (Acyl 
Choline) 
Lipid       15.25 0.0150 0.2507       
Caffeic acid sulfate Fatty Acid Metabolism (Acyl 
Choline) 
Lipid       13.74 0.0004 0.0618       
N2,N5-diacetylornithine Fatty Acid Metabolism (Acyl 
Choline) 
Lipid       13.55 0.0070 0.1860       




Azelate (C9-DC) Drug - Gastrointestinal Xenobiotics       2.86 0.0022 0.1592 0.35 0.0022 0.2544 
Cortisol 21-sulfate Primary Bile Acid Metabolism Lipid       2.47 0.0201 0.2735 0.40 0.0201 0.4939 
Androsterone glucuronide Food Component/Plant Xenobiotics       2.13 0.0463 0.3488       
Maltotetraose Androgenic Steroids Lipid       1.74 0.0207 0.2735       
Nicotinamide adenine 
dinucleotide (NAD+) 
Sterol Lipid       1.53 0.0457 0.3488 0.72 0.0411 0.4939 
N-acetylcarnosine Medium Chain Fatty Acid Lipid       1.51 0.0488 0.3557 0.57 0.0155 0.4939 
Vanillic acid glycine Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
Nucleotide       1.40 0.0110 0.2206       
Suberate (C8-DC) Lysine Metabolism Amino Acid       0.76 0.0200 0.2735       
Hexadecasphingosine (d16:1)  Ceramide PEs Lipid       0.75 0.0347 0.3281       
N-acetyltaurine TCA Cycle Energy       0.74 0.0046 0.1712       
N-acetylglutamate Lysophospholipid Lipid       0.72 0.0344 0.3281       
Caffeine Fatty Acid, Dicarboxylate Lipid       0.71 0.0054 0.1713       
Erythritol Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.71 0.0105 0.2169 1.56 0.0374 0.4939 
2-hydroxyhippurate (salicylurate) Alanine and Aspartate 
Metabolism 
Amino Acid       0.71 0.0413 0.3281       
2,3-dihydroxy-5-methylthio-4-
pentenoate (DMTPA)  
Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.70 0.0122 0.2337       
1-carboxyethyltyrosine Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
Carbohydrate       0.69 0.0231 0.2735       
5-oxoproline Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid       0.68 0.0234 0.2735 1.51 0.0104 0.4842 
N-stearoyl-sphinganine 
(d18:0/18:0)  
Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.68 0.0303 0.3249       
Theophylline Sphingomyelins Lipid       0.68 0.0322 0.3249       
1-carboxyethylisoleucine Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.67 0.0030 0.1599       
7-methylguanine Chemical Xenobiotics       0.65 0.0397 0.3281       
1-palmitoyl-2-stearoyl-GPC 
(16:0/18:0) 
Fatty Acid Metabolism (Acyl 
Carnitine, Monounsaturated) 






Glutamate Metabolism Amino Acid       0.63 0.0026 0.1599       
N-acetylglucosaminylasparagine Fatty Acid, Monohydroxy Lipid       0.63 0.0049 0.1713       
1,3,7-trimethylurate Urea cycle; Arginine and 
Proline Metabolism 
Amino Acid       0.63 0.0197 0.2735       
Succinylcarnitine (C4-DC) Lysine Metabolism Amino Acid       0.61 0.0227 0.2735       
Sedoheptulose Pyrimidine Metabolism, 
Uracil containing 
Nucleotide       0.61 0.0346 0.3281       
1-stearoyl-2-oleoyl-GPS 
(18:0/18:1) 
Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.61 0.0391 0.3281       
1-linoleoyl-GPA (18:2)  Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.60 0.0216 0.2735       
Tyramine O-sulfate Fatty Acid, Dicarboxylate Lipid       0.60 0.0235 0.2735       
Homocitrulline Fatty Acid Metabolism (Acyl 
Carnitine, Hydroxy) 
Lipid       0.60 0.0406 0.3281       
N-acetyl-2-aminooctanoate  Creatine Metabolism Amino Acid       0.60 0.0425 0.3346       
Xanthosine Pyrimidine Metabolism, 
Orotate containing 
Nucleotide       0.59 0.0073 0.1860       
Gulonate  Fatty Acid, Dicarboxylate Lipid       0.59 0.0378 0.3281 1.54 0.0277 0.4939 
Sphingosine 1-phosphate Docosanoid Lipid       0.58 0.0472 0.3506       
N1-methyladenosine Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.57 0.0231 0.2735       
Lactose Lysine Metabolism Amino Acid       0.57 0.0296 0.3249       
1-arachidonoyl-GPA (20:4) Fatty Acid, Dicarboxylate Lipid       0.57 0.0411 0.3281       
Guanidinoacetate Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.57 0.0495 0.3581       
Pseudouridine Phenylalanine Metabolism Amino Acid       0.56 0.0047 0.1712       
Dihydrocaffeate sulfate (2) Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
Nucleotide       0.56 0.0190 0.2735       
3-hydroxymyristate Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
Carbohydrate       0.55 0.0007 0.0801 1.49 0.0191 0.4939 






Medium Chain Fatty Acid Lipid       0.55 0.0255 0.2887       
Cystathionine Fatty Acid Metabolism (Acyl 
Carnitine, Dicarboxylate) 
Lipid       0.55 0.0324 0.3249       
N,N-dimethylalanine Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.52 0.0384 0.3281       
5alpha-pregnan-3beta,20alpha-
diol monosulfate (1) 
Fatty Acid, Dicarboxylate Lipid       0.50 0.0073 0.1860       
1,2-dipalmitoyl-GPE (16:0/16:0)  Sphingosines Lipid       0.50 0.0154 0.2507       
Flavin adenine dinucleotide (FAD) Pregnenolone Steroids Lipid       0.50 0.0219 0.2735       
1-carboxyethylvaline Fatty Acid, Amino Lipid       0.50 0.0446 0.3442       
Orotate Glycolysis, Gluconeogenesis, 
and Pyruvate Metabolism 
Carbohydrate       0.48 0.0025 0.1599 2.18 0.0052 0.4497 
11beta-hydroxyandrosterone 
glucuronide 
Tyrosine Metabolism Amino Acid       0.48 0.0093 0.2014       
Pentose acid  Fatty Acid, Monohydroxy Lipid       0.48 0.0165 0.2590       




Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.46 0.0371 0.3281       
3-phosphoglycerate Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.43 0.0083 0.1911       
3-
hydroxyphenylacetoylglutamine 
Fatty Acid, Monohydroxy Lipid       0.43 0.0255 0.2887       
2-butenoylglycine Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.43 0.0321 0.3249 2.24 0.0387 0.4939 
Beta-citrylglutamate Fatty Acid, Dicarboxylate Lipid       0.43 0.0338 0.3281       
N1-methylinosine Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid       0.42 0.0095 0.2014       
Xanthurenate Fatty Acid, Dicarboxylate Lipid       0.42 0.0349 0.3281       
N-acetylleucine Food Component/Plant Xenobiotics       0.38 0.0311 0.3249       
Glutamine conjugate of C6H10O2 
(1)  









      0.35 0.0133 0.2478       
Propionylglycine Methionine, Cysteine, SAM 
and Taurine Metabolism 
Amino Acid       0.35 0.0315 0.3249       
1,3-dimethylurate Tyrosine Metabolism Amino Acid       0.34 0.0037 0.1651       
Creatinine Corticosteroids Lipid       0.34 0.0074 0.1860 2.44 0.0005 0.1197 
Estriol-3-glucuronide Androgenic Steroids Lipid       0.31 0.0392 0.3281       
Spermine Corticosteroids Lipid       0.31 0.0476 0.3506       
Methyl indole-3-acetate Androgenic Steroids Lipid       0.30 0.0153 0.2507       
4-acetamidobutanoate Histidine Metabolism Amino Acid       0.30 0.0307 0.3249       
Maltotriose Fatty Acid, Dicarboxylate Lipid       0.29 0.0064 0.1860       
4-hydroxyphenylacetylglutamine Pregnenolone Steroids Lipid       0.27 0.0199 0.2735       
2-hydroxysebacate Corticosteroids Lipid       0.25 0.0156 0.2507       
Glycine Fatty Acid, Dicarboxylate Lipid       0.24 0.0121 0.2337       
(S)-3-hydroxybutyrylcarnitine Pyrimidine Metabolism, 
Orotate containing 
Nucleotide       0.24 0.0403 0.3281       
Glutarate (C5-DC) Androgenic Steroids Lipid       0.21 0.0215 0.2735       
Citraconate/glutaconate Estrogenic Steroids Lipid       0.21 0.0380 0.3281       
Cysteine Histidine Metabolism Amino Acid       0.18 0.0442 0.3442       
Mannitol/sorbitol Corticosteroids Lipid       0.16 0.0032 0.1599 3.67 0.0111 0.4842 
Adenine Drug - Analgesics, Anesthetics Xenobiotics       0.06 0.0040 0.1670       
Lactate Drug - Analgesics, Anesthetics Xenobiotics       0.03 0.0093 0.2014       





      0.03 0.0283 0.3158 12.33 0.0167 0.4939 
Nicotinamide Drug - Analgesics, Anesthetics Xenobiotics       0.02 0.0008 0.0801       
Ectoine Drug - Analgesics, Anesthetics Xenobiotics       0.02 0.0077 0.1869       
14-hdohe/17-hdohe Drug - Analgesics, Anesthetics Xenobiotics       0.02 0.0141 0.2507       
1-palmitoyl-2-gamma-linolenoyl-
GPC (16:0/18:3n6)  
Drug - Analgesics, Anesthetics Xenobiotics       0.02 0.0181 0.2734       




N-acetylneuraminate Drug - Analgesics, Anesthetics Xenobiotics       0.01 0.0003 0.0618       
N-ethylglycinexylidide Drug - Analgesics, Anesthetics Xenobiotics       0.01 0.0010 0.0801       





            18.15 0.0005 0.1197 





            10.90 0.0016 0.2208 
N-acetylglutamine Benzoate Metabolism Xenobiotics             6.24 0.0305 0.4939 
Eicosanedioate (C20-DC) Phosphatidylcholine (PC) Lipid             5.18 0.0083 0.4497 
3-hydroxy-2-ethylpropionate Alanine and Aspartate 
Metabolism 
Amino Acid             3.72 0.0439 0.4939 
Acisoga Pregnenolone Steroids Lipid             2.32 0.0405 0.4939 
5alpha-androstan-3beta,17beta-
diol disulfate 
Phenylalanine Metabolism Amino Acid             1.80 0.0366 0.4939 
Pro-hydroxy-pro Dihydroceramides Lipid             1.66 0.0457 0.4939 
Alpha-ketoglutaramate Fatty Acid, Branched Lipid             1.53 0.0413 0.4939 
4-methylbenzenesulfonate Medium Chain Fatty Acid Lipid             1.51 0.0393 0.4939 
5,6-dihydrouridine Fatty Acid Metabolism (Acyl 
Carnitine, Monounsaturated) 
Lipid             1.50 0.0425 0.4939 
Indoleacetylglutamine Polyamine Metabolism Amino Acid             1.45 0.0140 0.4939 
Carnitine of C10H14O2 (5)  Tyrosine Metabolism Amino Acid             1.20 0.0084 0.4497 
Androstenediol (3alpha, 17alpha) 
monosulfate (2) 
Sphingomyelins Lipid             0.79 0.0078 0.4497 
Hydroxy-N6,N6,N6-
trimethyllysine  
Phosphatidylcholine (PC) Lipid             0.79 0.0433 0.4939 
N-acetylhistidine Phosphatidylcholine (PC) Lipid             0.77 0.0470 0.4939 
3-hydroxybutyroylglycine   Pyrimidine Metabolism, 
Uracil containing 
Nucleotide             0.69 0.0457 0.4939 
Taurine Long Chain Polyunsaturated 
Fatty Acid (n3 and n6) 
Lipid             0.64 0.0365 0.4939 
Malate Glutamate Metabolism Amino Acid             0.53 0.0267 0.4939 




Glutathione, oxidized (GSSG) Tryptophan Metabolism Amino Acid             0.38 0.0495 0.4939 
Glucuronide of piperine 
metabolite C17H21NO3 (4)  
Fatty Acid Metabolism (also 
BCAA Metabolism) 
Lipid             0.36 0.0097 0.4830 
2-O-methylascorbic acid Leucine, Isoleucine and 
Valine Metabolism 
Amino Acid             0.36 0.0355 0.4939 
1,2-dipalmitoyl-GPC (16:0/16:0) Gamma-glutamyl Amino Acid Peptide             0.34 0.0419 0.4939 
Ceramide (d18:1/14:0, 
d16:1/16:0)  
Aminosugar Metabolism Carbohydrate             0.33 0.0476 0.4939 
1-myristoyl-2-palmitoyl-GPC 
(14:0/16:0) 
Alanine and Aspartate 
Metabolism 
Amino Acid             0.30 0.0297 0.4939 
Methylmalonate (MMA) Phosphatidylcholine (PC) Lipid             0.27 0.0425 0.4939 




            0.25 0.0247 0.4939 
Laurate (12:0) Glycogen Metabolism Carbohydrate             0.24 0.0287 0.4939 
Fumarate Urea cycle; Arginine and 
Proline Metabolism 
Amino Acid             0.16 0.0072 0.4497 
N-methylhydroxyproline   Polyamine Metabolism Amino Acid             0.11 0.0032 0.3187 
Intervillous blood of the induction of labour group (IVIOL) and intervillous blood of the spontaneously labouring group (IVS) (IVIOL/IVS); intervillous blood of 
the elective caesarean section group (IVCS) and intervillous blood of the spontaneous labour group (IVS) (IVCS/IVS); and intervillous blood of the elective 










APPENDIX 4A1: Maternal pregnancy metabolites measured using NMR metabolomics among the women included in the 
analysis dataset with mean, standard deviation and number of missing/not measured values for those pregnancies included 
in the analysis sample (n=7440). The biochemical group of the metabolite and units the metabolite is measured in are also 
presented. 
Metabolite Group Units Mean Standard 
Deviation 
Missing 
Alanine Amino acids mmol/l 0.418 0.048 32 
Glutamine Amino acids mmol/l 0.460 0.046 9 
Glycine Amino acids mmol/l 0.216 0.032 19 
Histidine Amino acids mmol/l 0.061 0.010 10 
Apolipoprotein A-I Apolipoproteins g/l 1.895 0.220 5 
Apolipoprotein B Apolipoproteins g/l 1.026 0.228 5 
apolipoprotein B:apolipoprotein A-I Apolipoproteins NA 0.545 0.121 5 
Phenylalanine Aromatic amino acids mmol/l 0.080 0.011 4 
Tyrosine Aromatic amino acids mmol/l 0.037 0.006 13 
Isoleucine Branched--chain amino acids mmol/l 0.047 0.010 7 
Leucine Branched--chain amino acids mmol/l 0.069 0.010 7 
Valine Branched--chain amino acids mmol/l 0.112 0.018 14 
Esterified cholesterol Cholesterol mmol/l 4.205 0.807 31 
Free cholesterol Cholesterol mmol/l 1.592 0.334 31 
Remnant cholesterol (non-HDL, non-LDL) Cholesterol mmol/l 1.684 0.467 5 
Serum total cholesterol Cholesterol mmol/l 5.806 1.157 5 
Total cholesterol in HDL Cholesterol mmol/l 1.993 0.370 5 
Total cholesterol in HDL2 Cholesterol mmol/l 1.415 0.335 5 
Total cholesterol in HDL3 Cholesterol mmol/l 0.578 0.044 5 
Total cholesterol in LDL Cholesterol mmol/l 2.129 0.617 5 
Total cholesterol in VLDL Cholesterol mmol/l 0.811 0.276 5 




22:6 docosahexaenoic acid to total FAs Fatty acids (%) % 1.746 0.230 54 
Monounsaturated FAs to total FAs Fatty acids (%) % 27.967 2.415 54 
Omega-3 FAs to total FAs Fatty acids (%) % 3.832 0.493 54 
Omega-6 FAs to total FAs Fatty acids (%) % 31.395 2.205 54 
Polyunsaturated FAs to total FAs Fatty acids (%) % 35.227 2.386 54 
Saturated FAs to total FAs Fatty acids (%) % 36.806 1.508 54 
18:2, linoleic acid Fatty acids and saturation measures mmol/l 4.467 0.766 54 
22:6, docosahexaenoic acid Fatty acids and saturation measures mmol/l 0.274 0.043 54 
Estimated degree of unsaturation Fatty acids and saturation measures NA 1.149 0.043 54 
Monounsaturated fatty acids; 16:1, 18:1 Fatty acids and saturation measures mmol/l 4.467 0.997 54 
Omega-3 fatty acids Fatty acids and saturation measures mmol/l 0.604 0.104 54 
Omega-6 fatty acids Fatty acids and saturation measures mmol/l 4.970 0.840 54 
Polyunsaturated fatty acids Fatty acids and saturation measures mmol/l 5.574 0.917 54 
Saturated fatty acids Fatty acids and saturation measures mmol/l 5.846 1.044 54 
Total fatty acids Fatty acids and saturation measures mmol/l 15.887 2.779 54 
Albumin Fluid balance and inflammation Signal area 0.078 0.006 4 
Creatinine Fluid balance and inflammation mmol/l 0.040 0.006 9 
Glycoprotein acetyls (a1-acid glycoprotein) Fluid balance and inflammation mmol/l 1.744 0.198 4 
Phosphatidylcholine and other cholines Glycerides and phospholipids mmol/l 2.515 0.459 33 
Ratio of triglycerides to phosphoglycerides Glycerides and phospholipids NA 0.764 0.160 31 
Serum total triglycerides Glycerides and phospholipids mmol/l 1.565 0.580 5 
Sphingomyelins Glycerides and phospholipids mmol/l 0.526 0.086 33 
Total cholines Glycerides and phospholipids mmol/l 3.124 0.485 33 
Total phosphoglycerides Glycerides and phospholipids mmol/l 2.508 0.399 31 
Triglycerides in HDL Glycerides and phospholipids mmol/l 0.205 0.042 5 
Triglycerides in LDL Glycerides and phospholipids mmol/l 0.288 0.070 5 
Triglycerides in VLDL Glycerides and phospholipids mmol/l 0.906 0.460 5 
Citrate Glycolysis related metabolites mmol/l 0.110 0.017 132 
Glucose Glycolysis related metabolites mmol/l 3.257 0.489 29 




Lactate Glycolysis related metabolites mmol/l 1.642 0.493 16 
Pyruvate Glycolysis related metabolites mmol/l 0.087 0.022 20 
3-hydroxybutyrate Ketone bodies mmol/l 0.114 0.038 5 
Acetate Ketone bodies mmol/l 0.035 0.006 11 
Mean diameter for HDL particles Lipoprotein particle size nm 10.268 0.205 5 
Mean diameter for LDL particles Lipoprotein particle size nm 23.528 0.062 5 
Mean diameter for VLDL particles Lipoprotein particle size nm 36.368 1.009 5 
Cholesterol esters in large HDL Lipoprotein subclasses HDL mmol/l 0.486 0.144 0 
Cholesterol esters in medium HDL Lipoprotein subclasses HDL mmol/l 0.399 0.087 0 
Cholesterol esters in small HDL Lipoprotein subclasses HDL mmol/l 0.416 0.059 0 
Cholesterol esters in very large HDL Lipoprotein subclasses HDL mmol/l 0.245 0.074 0 
Concentration of large HDL particles Lipoprotein subclasses HDL mol/l 2.1E-06 5.56E-07 0 
Concentration of medium HDL particles Lipoprotein subclasses HDL mol/l 2.49E-06 4.49E-07 0 
Concentration of small HDL particles Lipoprotein subclasses HDL mol/l 5.31E-06 6.38E-07 0 
Concentration of very large HDL particles Lipoprotein subclasses HDL mol/l 7.46E-07 2.28E-07 0 
Free cholesterol in large HDL Lipoprotein subclasses HDL mmol/l 0.142 0.045 0 
Free cholesterol in medium HDL Lipoprotein subclasses HDL mmol/l 0.102 0.023 0 
Free cholesterol in small HDL Lipoprotein subclasses HDL mmol/l 0.115 0.017 0 
Free cholesterol in very large HDL Lipoprotein subclasses HDL mmol/l 0.087 0.030 0 
Phospholipids in large HDL Lipoprotein subclasses HDL mmol/l 0.629 0.157 0 
Phospholipids in medium HDL Lipoprotein subclasses HDL mmol/l 0.504 0.087 0 
Phospholipids in small HDL Lipoprotein subclasses HDL mmol/l 0.590 0.094 0 
Phospholipids in very large HDL Lipoprotein subclasses HDL mmol/l 0.384 0.123 0 
Total cholesterol in large HDL Lipoprotein subclasses HDL mmol/l 0.628 0.189 0 
Total cholesterol in medium HDL Lipoprotein subclasses HDL mmol/l 0.501 0.109 0 
Total cholesterol in small HDL Lipoprotein subclasses HDL mmol/l 0.531 0.067 0 
Total cholesterol in very large HDL Lipoprotein subclasses HDL mmol/l 0.333 0.104 0 
Total lipids in large HDL Lipoprotein subclasses HDL mmol/l 1.320 0.356 0 
Total lipids in medium HDL Lipoprotein subclasses HDL mmol/l 1.057 0.195 0 




Total lipids in very large HDL Lipoprotein subclasses HDL mmol/l 0.748 0.231 0 
Triglycerides in large HDL Lipoprotein subclasses HDL mmol/l 0.063 0.016 0 
Triglycerides in medium HDL Lipoprotein subclasses HDL mmol/l 0.052 0.013 0 
Triglycerides in small HDL Lipoprotein subclasses HDL mmol/l 0.058 0.016 0 
Triglycerides in very large HDL Lipoprotein subclasses HDL mmol/l 0.032 0.010 0 
Cholesterol esters in large LDL Lipoprotein subclasses LDL mmol/l 0.794 0.234 0 
Cholesterol esters in LDL Lipoprotein subclasses LDL mmol/l 0.615 0.163 0 
Cholesterol esters in medium LDL Lipoprotein subclasses LDL mmol/l 0.464 0.157 0 
Cholesterol esters in small LDL Lipoprotein subclasses LDL mmol/l 0.285 0.095 0 
Concentration of large LDL particles Lipoprotein subclasses LDL mol/l 2.33E-07 5.99E-08 0 
Concentration of LDL particles Lipoprotein subclasses LDL mol/l 1.4E-07 3.42E-08 5 
Concentration of medium LDL particles Lipoprotein subclasses LDL mol/l 0.000 0.000 0 
Concentration of small LDL particles Lipoprotein subclasses LDL mol/l 2.22E-07 5.67E-08 0 
Free cholesterol in large LDL Lipoprotein subclasses LDL mmol/l 0.308 0.076 0 
Free cholesterol in LDL Lipoprotein subclasses LDL mmol/l 0.257 0.067 0 
Free cholesterol in medium LDL Lipoprotein subclasses LDL mmol/l 0.172 0.037 0 
Free cholesterol in small LDL Lipoprotein subclasses LDL mmol/l 0.106 0.023 0 
Phospholipids in large LDL Lipoprotein subclasses LDL mmol/l 0.391 0.088 0 
Phospholipids in LDL Lipoprotein subclasses LDL mmol/l 0.369 0.090 0 
Phospholipids in medium LDL Lipoprotein subclasses LDL mmol/l 0.241 0.050 0 
Phospholipids in small LDL Lipoprotein subclasses LDL mmol/l 0.179 0.034 0 
Total cholesterol in large LDL Lipoprotein subclasses LDL mmol/l 1.101 0.310 0 
Total cholesterol in LDL Lipoprotein subclasses LDL mmol/l 0.872 0.230 0 
Total cholesterol in medium LDL Lipoprotein subclasses LDL mmol/l 0.636 0.193 0 
Total cholesterol in small LDL Lipoprotein subclasses LDL mmol/l 0.391 0.117 0 
Total lipids in large LDL Lipoprotein subclasses LDL mmol/l 1.650 0.428 0 
Total lipids in LDL Lipoprotein subclasses LDL mmol/l 1.409 0.349 5 
Total lipids in medium LDL Lipoprotein subclasses LDL mmol/l 0.957 0.258 0 
Total lipids in small LDL Lipoprotein subclasses LDL mmol/l 0.618 0.159 0 




Triglycerides in LDL Lipoprotein subclasses LDL mmol/l 0.167 0.042 0 
Triglycerides in medium LDL Lipoprotein subclasses LDL mmol/l 0.081 0.020 0 
Triglycerides in small LDL Lipoprotein subclasses LDL mmol/l 0.049 0.013 0 
Cholesterol esters in CMs & extremely large 
VLDL 
Lipoprotein subclasses VLDL mmol/l 0.003 0.002 0 
Cholesterol esters in large VLDL Lipoprotein subclasses VLDL mmol/l 0.033 0.022 0 
Cholesterol esters in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.107 0.043 0 
Cholesterol esters in small VLDL Lipoprotein subclasses VLDL mmol/l 0.161 0.054 0 
Cholesterol esters in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.007 0.006 0 
Cholesterol esters in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.191 0.053 0 
Conc. of CMs & extremely large VLDL particles Lipoprotein subclasses VLDL mol/l 1.1E-10 8.42E-11 0 
Concentration of large VLDL particles Lipoprotein subclasses VLDL mol/l 5.11E-09 3.42E-09 0 
Concentration of medium VLDL particles Lipoprotein subclasses VLDL mol/l 1.77E-08 8.93E-09 0 
Concentration of small VLDL particles Lipoprotein subclasses VLDL mol/l 3.24E-08 1.1E-08 0 
Concentration of very large VLDL particles Lipoprotein subclasses VLDL mol/l 6.97E-10 5.67E-10 0 
Concentration of very small VLDL particles Lipoprotein subclasses VLDL mol/l 4.85E-08 1.28E-08 0 
Free cholesterol in CMs & extremely large VLDL Lipoprotein subclasses VLDL mmol/l 0.002 0.002 0 
Free cholesterol in large VLDL Lipoprotein subclasses VLDL mmol/l 0.033 0.023 0 
Free cholesterol in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.074 0.039 0 
Free cholesterol in small VLDL Lipoprotein subclasses VLDL mmol/l 0.098 0.031 0 
Free cholesterol in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.006 0.005 0 
Free cholesterol in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.096 0.026 0 
Phospholipids in CMs & extremely large VLDL Lipoprotein subclasses VLDL mmol/l 0.003 0.002 0 
Phospholipids in large VLDL Lipoprotein subclasses VLDL mmol/l 0.057 0.037 0 
Phospholipids in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.122 0.058 0 
Phospholipids in small VLDL Lipoprotein subclasses VLDL mmol/l 0.148 0.044 0 
Phospholipids in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.012 0.009 0 
Phospholipids in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.186 0.052 0 
Total cholesterol in CMs & extremely large VLDL Lipoprotein subclasses VLDL mmol/l 0.005 0.004 0 




Total cholesterol in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.181 0.080 0 
Total cholesterol in small VLDL Lipoprotein subclasses VLDL mmol/l 0.258 0.082 0 
Total cholesterol in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.013 0.011 0 
Total cholesterol in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.286 0.078 0 
Total lipids in CMs & extremely large VLDL Lipoprotein subclasses VLDL mmol/l 0.024 0.018 0 
Total lipids in large VLDL Lipoprotein subclasses VLDL mmol/l 0.296 0.199 0 
Total lipids in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.598 0.298 0 
Total lipids in small VLDL Lipoprotein subclasses VLDL mmol/l 0.647 0.215 0 
Total lipids in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.068 0.055 0 
Total lipids in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.611 0.161 0 
Triglycerides in CMs & extremely large VLDL Lipoprotein subclasses VLDL mmol/l 0.016 0.012 0 
Triglycerides in large VLDL Lipoprotein subclasses VLDL mmol/l 0.173 0.117 0 
Triglycerides in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.294 0.163 0 
Triglycerides in small VLDL Lipoprotein subclasses VLDL mmol/l 0.240 0.097 0 
Triglycerides in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.043 0.035 0 
Triglycerides in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.139 0.042 0 
VLDL= very low density lipoprotein; LDL= low density lipoprotein; HDL= high density lipoprotein; CM= chylomicron; mmol/l= millimole per litre; mol/l= mole 










APPENDIX 4A2: Maternal pregnancy metabolites measured using NMR metabolomics among the women included in the 
analysis dataset comparing median, interquartile range and number of missing/not measured values between those 
pregnancies that delivered preterm (n=399), at term (n=6994) and post-term (n=58). The biochemical group of the metabolite 
and units the metabolite is measured in are also presented. 
   
Pre-term (n=392) Term (n=6994) Post-term (n=54) 
Metabolite Group Units Median IQR Missing Median IQR Missing Median IQR Missing 
Alanine Amino acids mmol/l 0.421 0.388 to 
0.454 
3 0.415 0.386 
to 
0.447 




Glutamine Amino acids mmol/l 0.459 0.434 to 
0.488 
0 0.457 0.431 
to 
0.488 




Glycine Amino acids mmol/l 0.215 0.195 to 
0.236 
4 0.213 0.194 
to 
0.235 




Histidine Amino acids mmol/l 0.061 0.055 to 
0.067 
1 0.060 0.055 
to 
0.067 




Apolipoprotein A-I Apolipoproteins g/l 1.891 1.734 to 
2.027 
0 1.885 1.748 
to 
2.027 




Apolipoprotein B Apolipoproteins g/l 1.040 0.879 to 
1.182 
0 1.002 0.864 
to 
1.155 






Apolipoproteins #N/A 0.545 0.467 to 
0.635 
0 0.531 0.461 
to 
0.615 
5 0.526 0.46 to 
0.631 
0 
Phenylalanine Aromatic amino 
acids 
mmol/l 0.080 0.074 to 
0.089 
0 0.078 0.072 
to 
0.086 







Tyrosine Aromatic amino 
acids 
mmol/l 0.038 0.035 to 
0.042 
0 0.037 0.034 
to 
0.041 







mmol/l 0.047 0.041 to 
0.055 
1 0.045 0.04 to 
0.053 







mmol/l 0.069 0.064 to 
0.077 
1 0.068 0.063 
to 
0.075 







mmol/l 0.111 0.1 to 
0.124 
2 0.110 0.1 to 
0.122 
12 0.111 0.1 to 
0.122 
0 
Esterified cholesterol Cholesterol mmol/l 4.212 3.683 to 
4.723 
2 4.151 3.648 
to 4.69 




Free cholesterol Cholesterol mmol/l 1.590 1.379 to 
1.825 
2 1.568 1.361 
to 
1.789 






Cholesterol mmol/l 1.695 1.385 to 
1.996 
0 1.633 1.353 
to 
1.947 






Cholesterol mmol/l 5.795 5.092 to 
6.578 
0 5.722 5.019 
to 6.48 




Total cholesterol in 
HDL 
Cholesterol mmol/l 1.984 1.715 to 
2.213 
0 1.976 1.745 
to 
2.217 




Total cholesterol in 
HDL2 
Cholesterol mmol/l 1.400 1.152 to 
1.608 
0 1.399 1.192 
to 
1.617 




Total cholesterol in 
HDL3 
Cholesterol mmol/l 0.577 0.55 to 
0.607 
0 0.575 0.549 
to 
0.604 







Total cholesterol in 
LDL 
Cholesterol mmol/l 2.118 1.698 to 
2.569 
0 2.076 1.708 
to 
2.482 




Total cholesterol in 
VLDL 
Cholesterol mmol/l 0.820 0.64 to 
1.001 
0 0.776 0.616 
to 0.96 




18:2 linoleic acid to 
total fas 
Fatty acids (%) % 27.885 26.08 to 
29.46 
6 28.220 26.48 
to 
30.03 





acid to total fas 
Fatty acids (%) % 1.717 1.576 to 
1.852 
6 1.724 1.593 
to 
1.878 





to total fas 
Fatty acids (%) % 28.090 26.61 to 
29.93 
6 27.880 26.29 
to 
29.49 




Omega-3 fas to total 
fas 
Fatty acids (%) % 3.771 3.489 to 
4.116 
6 3.806 3.518 
to 
4.111 




Omega-6 fas to total 
fas 
Fatty acids (%) % 31.045 29.48 to 
32.58 
6 31.435 30 to 
32.9 





to total fas 
Fatty acids (%) % 34.870 33.16 to 
36.6 
6 35.270 33.71 
to 
36.87 




Saturated fas to total 
fas 
Fatty acids (%) % 36.910 35.82 to 
37.91 
6 36.720 35.76 
to 
37.78 




18:2, linoleic acid Fatty acids and 
saturation 
measures 
mmol/l 4.427 3.95 to 
4.961 
6 4.409 3.936 
to 
4.931 






Fatty acids and 
saturation 
measures 
mmol/l 0.273 0.247 to 
0.3 
6 0.270 0.244 
to 
0.299 







Estimated degree of 
unsaturation 
Fatty acids and 
saturation 
measures 
#N/A 1.148 1.119 to 
1.173 
6 1.150 1.121 
to 
1.177 





fatty acids; 16:1, 18:1 
Fatty acids and 
saturation 
measures 
mmol/l 4.520 3.848 to 
5.221 
6 4.350 3.766 
to 
5.041 




Omega-3 fatty acids Fatty acids and 
saturation 
measures 
mmol/l 0.604 0.534 to 
0.672 
6 0.593 0.533 
to 
0.664 




Omega-6 fatty acids Fatty acids and 
saturation 
measures 
mmol/l 4.979 4.393 to 
5.541 
6 4.911 4.388 
to 
5.478 






Fatty acids and 
saturation 
measures 
mmol/l 5.586 4.934 to 
6.225 
6 5.514 4.936 
to 
6.125 




Saturated fatty acids Fatty acids and 
saturation 
measures 
mmol/l 5.966 5.224 to 
6.579 
6 5.750 5.108 
to 6.46 




Total fatty acids Fatty acids and 
saturation 
measures 
mmol/l 16.150 14.06 to 
17.83 
6 15.650 13.92 
to 
17.57 










0.079 0.077 to 
0.082 
0 0.079 0.076 
to 
0.082 




Creatinine Fluid balance 
and 
inflammation 
mmol/l 0.041 0.038 to 
0.045 
1 0.039 0.036 
to 
0.044 









mmol/l 1.755 1.633 to 
1.9 
0 1.724 1.609 
to 
1.851 





and other cholines 
Glycerides and 
phospholipids 
mmol/l 2.547 2.198 to 
2.853 
2 2.485 2.202 
to 
2.797 











#N/A 0.770 0.663 to 
0.878 
2 0.742 0.654 
to 
0.853 







mmol/l 1.576 1.218 to 
1.964 
0 1.467 1.171 
to 
1.851 
5 1.452 1.195 
to 1.98 
0 
Sphingomyelins Glycerides and 
phospholipids 
mmol/l 0.520 0.462 to 
0.591 
2 0.522 0.469 
to 0.58 
31 0.499 0.46 to 
0.584 
0 
Total cholines Glycerides and 
phospholipids 
mmol/l 3.140 2.795 to 
3.492 
2 3.097 2.791 
to 
3.417 








mmol/l 2.551 2.247 to 
2.824 
2 2.485 2.235 
to 
2.753 
29 2.448 2.2 to 
2.711 
0 
Triglycerides in HDL Glycerides and 
phospholipids 
mmol/l 0.206 0.179 to 
0.234 
0 0.200 0.177 
to 
0.229 




Triglycerides in LDL Glycerides and 
phospholipids 
mmol/l 0.290 0.244 to 
0.335 
0 0.280 0.239 
to 
0.326 




Triglycerides in VLDL Glycerides and 
phospholipids 
mmol/l 0.882 0.636 to 
1.232 
0 0.818 0.595 
to 
1.122 







mmol/l 0.108 0.099 to 
0.123 
9 0.108 0.099 
to 0.12 







mmol/l 3.245 3.014 to 
3.5 
0 3.241 3.009 
to 3.48 







mmol/l 0.056 0.047 to 
0.069 
0 0.053 0.044 
to 
0.064 










mmol/l 1.557 1.355 to 
1.855 
0 1.545 1.316 
to 1.86 






mmol/l 0.085 0.074 to 
0.102 
0 0.083 0.072 
to 
0.099 
20 0.085 0.07 to 
0.108 
0 
3-hydroxybutyrate Ketone bodies mmol/l 0.106 0.094 to 
0.128 
1 0.107 0.093 
to 
0.126 




Acetate Ketone bodies mmol/l 0.033 0.031 to 
0.038 
1 0.034 0.031 
to 
0.038 








nm 10.230 10.08 to 
10.375 
0 10.270 10.13 
to 10.4 
5 10.225 10.1 to 
10.43 
0 




nm 23.520 23.48 to 
23.56 
0 23.530 23.49 
to 
23.56 








nm 36.500 35.84 to 
37.17 
0 36.320 35.69 
to 
36.99 
5 36.320 35.64 
to 37 
0 




mmol/l 0.465 0.366 to 
0.569 
0 0.479 0.39 to 
0.576 








mmol/l 0.401 0.35 to 
0.463 
0 0.396 0.342 
to 
0.452 








mmol/l 0.419 0.388 to 
0.458 
0 0.414 0.379 
to 0.45 




Cholesterol esters in 
very large HDL 
Lipoprotein 
subclasses HDL 
mmol/l 0.234 0.182 to 
0.286 
0 0.242 0.196 
to 
0.293 


























































Concentration of very 




















mmol/l 0.135 0.105 to 
0.17 
0 0.140 0.112 
to 0.17 








mmol/l 0.102 0.089 to 
0.121 
0 0.100 0.087 
to 
0.116 








mmol/l 0.117 0.106 to 
0.129 
0 0.113 0.104 
to 
0.125 




Free cholesterol in 
very large HDL 
Lipoprotein 
subclasses HDL 
mmol/l 0.083 0.061 to 
0.104 
0 0.086 0.067 
to 
0.107 








mmol/l 0.620 0.506 to 
0.727 
0 0.622 0.526 
to 
0.725 










mmol/l 0.506 0.453 to 
0.573 
0 0.497 0.447 
to 
0.555 
0 0.485 0.44 to 
0.542 
0 




mmol/l 0.606 0.541 to 
0.667 
0 0.583 0.528 
to 
0.645 
0 0.580 0.527 
to 0.65 
0 




mmol/l 0.370 0.28 to 
0.452 
0 0.380 0.301 
to 
0.461 








mmol/l 0.600 0.469 to 
0.736 
0 0.619 0.502 
to 
0.745 








mmol/l 0.502 0.438 to 
0.582 
0 0.495 0.429 
to 
0.567 
0 0.474 0.415 
to 0.55 
0 




mmol/l 0.536 0.498 to 
0.577 
0 0.527 0.489 
to 
0.569 




Total cholesterol in 
very large HDL 
Lipoprotein 
subclasses HDL 
mmol/l 0.318 0.245 to 
0.389 
0 0.329 0.263 
to 
0.398 








mmol/l 1.278 1.037 to 
1.538 
0 1.303 1.086 
to 
1.538 








mmol/l 1.063 0.942 to 
1.209 
0 1.045 0.926 
to 
1.174 








mmol/l 1.199 1.117 to 
1.299 
0 1.165 1.085 
to 1.26 








mmol/l 0.716 0.549 to 
0.878 
0 0.738 0.591 
to 
0.893 











mmol/l 0.060 0.051 to 
0.072 
0 0.061 0.053 
to 
0.073 







mmol/l 0.053 0.046 to 
0.064 
0 0.051 0.044 
to 0.06 








mmol/l 0.059 0.049 to 
0.072 
0 0.056 0.048 
to 
0.067 
0 0.056 0.05 to 
0.071 
0 




mmol/l 0.030 0.025 to 
0.038 
0 0.031 0.025 
to 
0.038 
0 0.029 0.024 
to 0.04 
0 




mmol/l 0.791 0.635 to 
0.96 
0 0.773 0.633 
to 
0.927 
0 0.776 0.644 
to 0.92 
0 




mmol/l 0.607 0.515 to 
0.729 
0 0.600 0.503 
to 
0.708 
0 0.586 0.5 to 
0.716 
0 




mmol/l 0.464 0.363 to 
0.577 
0 0.452 0.358 
to 
0.555 








mmol/l 0.283 0.224 to 
0.354 
0 0.277 0.221 
to 
0.341 















































































mmol/l 0.303 0.256 to 
0.359 
0 0.301 0.257 
to 
0.352 








mmol/l 0.250 0.211 to 
0.302 
0 0.251 0.212 
to 
0.296 








mmol/l 0.171 0.15 to 
0.197 
0 0.169 0.147 
to 
0.193 








mmol/l 0.106 0.093 to 
0.122 
0 0.105 0.091 
to 
0.119 
0 0.105 0.091 
to 0.12 
0 




mmol/l 0.388 0.333 to 
0.452 
0 0.383 0.331 
to 
0.441 




Phospholipids in LDL Lipoprotein 
subclasses LDL 
mmol/l 0.365 0.307 to 
0.43 
0 0.361 0.309 
to 
0.421 








mmol/l 0.242 0.211 to 
0.275 
0 0.236 0.206 
to 
0.269 








mmol/l 0.180 0.158 to 
0.202 
0 0.176 0.156 
to 
0.198 











mmol/l 1.094 0.886 to 
1.322 
0 1.075 0.891 
to 
1.277 








mmol/l 0.854 0.723 to 
1.032 
0 0.851 0.714 
to 
1.003 
0 0.837 0.712 
to 1 
0 




mmol/l 0.633 0.509 to 
0.775 
0 0.620 0.505 
to 
0.748 
0 0.625 0.497 
to 0.73 
0 




mmol/l 0.386 0.315 to 
0.474 
0 0.382 0.312 
to 
0.459 








mmol/l 1.635 1.362 to 
1.943 
0 1.612 1.356 
to 
1.892 




Total lipids in LDL Lipoprotein 
subclasses LDL 
mmol/l 1.394 1.172 to 
1.646 
0 1.376 1.163 
to 
1.606 
5 1.364 1.16 to 
1.584 
0 




mmol/l 0.957 0.796 to 
1.138 
0 0.935 0.78 to 
1.104 








mmol/l 0.618 0.523 to 
0.728 
0 0.605 0.511 
to 0.71 








mmol/l 0.158 0.134 to 
0.183 
0 0.154 0.131 
to 
0.179 




Triglycerides in LDL Lipoprotein 
subclasses LDL 
mmol/l 0.168 0.141 to 
0.194 
0 0.161 0.138 
to 0.19 







mmol/l 0.081 0.069 to 
0.095 
0 0.079 0.068 
to 
0.092 










mmol/l 0.049 0.042 to 
0.058 
0 0.047 0.041 
to 
0.056 




Cholesterol esters in 




mmol/l 0.003 0.002 to 
0.005 
0 0.003 0.002 
to 
0.005 








mmol/l 0.032 0.02 to 
0.048 
0 0.029 0.019 
to 
0.044 








mmol/l 0.107 0.081 to 
0.135 
0 0.101 0.078 
to 0.13 








mmol/l 0.162 0.127 to 
0.198 
0 0.155 0.123 
to 
0.192 




Cholesterol esters in 
very large VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.006 0.004 to 
0.011 
0 0.006 0.003 
to 0.01 




Cholesterol esters in 
very small VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.188 0.155 to 
0.226 
0 0.186 0.154 
to 
0.222 




Conc. Of cms & 








































































Concentration of very 
















Concentration of very 
















Free cholesterol in 




mmol/l 0.002 0.002 to 
0.004 
0 0.002 0.001 
to 
0.003 








mmol/l 0.032 0.019 to 
0.049 
0 0.028 0.017 
to 
0.044 








mmol/l 0.074 0.053 to 
0.102 
0 0.067 0.049 
to 
0.093 








mmol/l 0.099 0.081 to 
0.119 
0 0.094 0.077 
to 
0.115 
0 0.092 0.08 to 
0.115 
0 
Free cholesterol in 
very large VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.006 0.004 to 
0.01 
0 0.005 0.003 
to 
0.009 




Free cholesterol in 
very small VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.097 0.08 to 
0.114 
0 0.093 0.078 
to 0.11 
0 0.091 0.08 to 
0.111 
0 
Phospholipids in cms 




mmol/l 0.003 0.002 to 
0.005 
0 0.003 0.002 
to 
0.005 











mmol/l 0.056 0.037 to 
0.083 
0 0.050 0.033 
to 
0.074 








mmol/l 0.120 0.091 to 
0.164 
0 0.112 0.083 
to 
0.151 








mmol/l 0.150 0.123 to 
0.181 
0 0.143 0.118 
to 
0.173 








mmol/l 0.011 0.007 to 
0.019 
0 0.010 0.006 
to 
0.017 








mmol/l 0.188 0.153 to 
0.22 
0 0.181 0.15 to 
0.216 




Total cholesterol in 




mmol/l 0.005 0.003 to 
0.008 
0 0.005 0.003 
to 
0.007 








mmol/l 0.064 0.039 to 
0.097 
0 0.057 0.036 
to 
0.088 








mmol/l 0.179 0.135 to 
0.235 
0 0.169 0.127 
to 
0.222 








mmol/l 0.265 0.209 to 
0.314 
0 0.249 0.201 
to 
0.304 




Total cholesterol in 
very large VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.012 0.007 to 
0.02 
0 0.011 0.006 
to 
0.019 
0 0.012 0.005 
to 0.02 
0 
Total cholesterol in 
very small VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.283 0.234 to 
0.34 
0 0.278 0.232 
to 
0.332 







Total lipids in cms & 
extremely large VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.023 0.014 to 
0.035 
0 0.020 0.012 
to 
0.032 
0 0.020 0.01 to 
0.033 
0 




mmol/l 0.291 0.18 to 
0.435 
0 0.258 0.162 
to 
0.386 








mmol/l 0.581 0.433 to 
0.808 
0 0.545 0.395 
to 0.74 








mmol/l 0.648 0.522 to 
0.796 
0 0.619 0.496 
to 
0.761 
0 0.604 0.51 to 
0.775 
0 




mmol/l 0.065 0.034 to 
0.105 
0 0.057 0.031 
to 
0.093 








mmol/l 0.615 0.511 to 
0.718 
0 0.593 0.498 
to 
0.703 




Triglycerides in cms & 
extremely large VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.015 0.009 to 
0.024 
0 0.013 0.008 
to 
0.021 








mmol/l 0.171 0.105 to 
0.254 
0 0.150 0.095 
to 
0.226 








mmol/l 0.284 0.198 to 
0.4 
0 0.264 0.185 
to 
0.371 








mmol/l 0.236 0.184 to 
0.31 
0 0.224 0.175 
to 
0.289 








mmol/l 0.042 0.022 to 
0.067 
0 0.035 0.019 
to 
0.059 










mmol/l 0.141 0.115 to 
0.169 
0 0.133 0.111 
to 
0.162 























APPENDIX 4A3: Results of logistical regression (adjusted) comparing maternal metabolites of those women who delivered 
preterm (<259 days or <37 completed weeks) compared with those who delivered at term (259 days to 294 days, or 37 to 42 
completed weeks), excluding those who delivered post-term (>294 days), showing odds ratio per 1 standard deviation (SD) 
increase in metabolite measured. N=399 for preterm, n=6994 for term, and n=54 excluded for post-term. The biochemical 
group of the metabolite, units, upper and lower 95% confidence interval and p-values are also presented (bold if significant at 
p<0.0029). 








Alanine Amino acids mmol/l 0.069 0.048 -0.035 0.173 1.929E-01 7347 
Glutamine Amino acids mmol/l 0.003 0.046 -0.103 0.109 9.529E-01 7370 
Glycine Amino acids mmol/l 0.059 0.032 -0.042 0.161 2.526E-01 7360 
Histidine Amino acids mmol/l 0.043 0.010 -0.061 0.146 4.178E-01 7369 
Apolipoprotein A-I Apolipoproteins g/l 0.031 0.220 -0.073 0.136 5.575E-01 7374 
Apolipoprotein B Apolipoproteins g/l 0.128 0.228 0.028 0.229 1.251E-02 7374 
Ratio of apolipoprotein B to apolipoprotein 
A-I 
Apolipoproteins #N/A 0.118 0.121 0.018 0.218 2.074E-02 7374 
Phenylalanine Aromatic amino 
acids 
mmol/l 0.151 0.011 0.044 0.257 5.638E-03 7375 
Tyrosine Aromatic amino 
acids 
mmol/l 0.069 0.006 -0.037 0.176 2.012E-01 7366 
Isoleucine Branched--chain 
amino acids 
mmol/l 0.095 0.010 -0.007 0.197 6.692E-02 7372 
Leucine Branched--chain 
amino acids 
mmol/l 0.121 0.010 0.017 0.224 2.199E-02 7372 
Valine Branched--chain 
amino acids 
mmol/l 0.036 0.018 -0.070 0.142 5.058E-01 7365 
Esterified cholesterol Cholesterol mmol/l 0.069 0.807 -0.035 0.173 1.911E-01 7348 




Remnant cholesterol (non-HDL, non-LDL -
cholesterol) 
Cholesterol mmol/l 0.114 0.467 0.013 0.215 2.707E-02 7374 
Serum total cholesterol Cholesterol mmol/l 0.073 1.157 -0.030 0.176 1.641E-01 7374 
Total cholesterol in HDL Cholesterol mmol/l -0.028 0.370 -0.133 0.078 6.090E-01 7374 
Total cholesterol in HDL2 Cholesterol mmol/l -0.039 0.335 -0.145 0.067 4.752E-01 7374 
Total cholesterol in HDL3 Cholesterol mmol/l 0.059 0.044 -0.044 0.162 2.625E-01 7374 
Total cholesterol in LDL Cholesterol mmol/l 0.065 0.617 -0.038 0.168 2.186E-01 7374 
Total cholesterol in VLDL Cholesterol mmol/l 0.137 0.276 0.039 0.236 6.197E-03 7374 
Ratio of 18:2 linoleic acid to total fatty 
acids 
Fatty acids (%) % -0.123 2.693 -0.239 -0.007 3.716E-02 7325 
Ratio of 22:6 docosahexaenoic acid to total 
fatty acids 
Fatty acids (%) % -0.102 0.230 -0.213 0.008 6.925E-02 7325 
Ratio of monounsaturated fatty acids to 
total fatty acids 
Fatty acids (%) % 0.104 2.416 -0.017 0.224 9.223E-02 7325 
Ratio of omega-3 fatty acids to total fatty 
acids 
Fatty acids (%) % -0.084 0.492 -0.195 0.028 1.421E-01 7325 
Ratio of omega-6 fatty acids to total fatty 
acids 
Fatty acids (%) % -0.114 2.207 -0.226 -0.002 4.641E-02 7325 
Ratio of polyunsaturated fatty acids to 
total fatty acids 
Fatty acids (%) % -0.122 2.387 -0.233 -0.010 3.236E-02 7325 
Ratio of saturated fatty acids to total fatty 
acids 
Fatty acids (%) % 0.047 1.508 -0.060 0.154 3.917E-01 7325 
18:2, linoleic acid Fatty acids and 
saturation 
measures 
mmol/l 0.066 0.766 -0.039 0.170 2.176E-01 7325 
22:6, docosahexaenoic acid Fatty acids and 
saturation 
measures 
mmol/l 0.061 0.043 -0.046 0.168 2.630E-01 7325 
Estimated degree of unsaturation Fatty acids and 
saturation 
measures 




Monounsaturated fatty acids; 16:1, 18:1 Fatty acids and 
saturation 
measures 
mmol/l 0.136 0.996 0.030 0.242 1.184E-02 7325 
Omega-3 fatty acids Fatty acids and 
saturation 
measures 
mmol/l 0.071 0.104 -0.035 0.178 1.890E-01 7325 
Omega-6 fatty acids Fatty acids and 
saturation 
measures 
mmol/l 0.083 0.840 -0.021 0.187 1.180E-01 7325 
Polyunsaturated fatty acids Fatty acids and 
saturation 
measures 
mmol/l 0.084 0.917 -0.020 0.188 1.143E-01 7325 
Saturated fatty acids Fatty acids and 
saturation 
measures 
mmol/l 0.133 1.044 0.029 0.237 1.228E-02 7325 
Total fatty acids Fatty acids and 
saturation 
measures 
mmol/l 0.124 2.779 0.020 0.229 1.913E-02 7325 





0.108 0.006 0.007 0.208 3.522E-02 7375 
Creatinine Fluid balance and 
inflammation 
mmol/l 0.192 0.006 0.097 0.286 6.761E-05 7370 
Glycoprotein acetyls, mainly a1-acid 
glycoprotein 
Fluid balance and 
inflammation 
mmol/l 0.202 0.198 0.105 0.298 4.301E-05 7375 
Phosphatidylcholine and other cholines Glycerides and 
phospholipids 
mmol/l 0.114 0.459 0.011 0.217 2.977E-02 7346 
Ratio of triglycerides to phosphoglycerides Glycerides and 
phospholipids 
#N/A 0.119 0.160 0.018 0.220 2.091E-02 7348 
Serum total triglycerides Glycerides and 
phospholipids 
mmol/l 0.154 0.580 0.061 0.246 1.141E-03 7374 
Sphingomyelins Glycerides and 
phospholipids 




Total cholines Glycerides and 
phospholipids 
mmol/l 0.116 0.485 0.013 0.219 2.780E-02 7346 
Total phosphoglycerides Glycerides and 
phospholipids 
mmol/l 0.129 0.398 0.026 0.233 1.422E-02 7348 
Triglycerides in HDL Glycerides and 
phospholipids 
mmol/l 0.125 0.042 0.025 0.224 1.438E-02 7374 
Triglycerides in LDL Glycerides and 
phospholipids 
mmol/l 0.129 0.070 0.028 0.231 1.256E-02 7374 
Triglycerides in VLDL Glycerides and 
phospholipids 
mmol/l 0.149 0.460 0.059 0.240 1.182E-03 7374 
Citrate Glycolysis related 
metabolites 
mmol/l 0.089 0.017 -0.022 0.200 1.177E-01 7247 
Glucose Glycolysis related 
metabolites 
mmol/l 0.009 0.490 -0.099 0.117 8.722E-01 7350 
Glycerol Glycolysis related 
metabolites 
mmol/l 0.230 0.016 0.130 0.330 6.879E-06 7361 
Lactate Glycolysis related 
metabolites 
mmol/l 0.049 0.492 -0.053 0.151 3.448E-01 7363 
Pyruvate Glycolysis related 
metabolites 
mmol/l 0.049 0.022 -0.053 0.151 3.468E-01 7359 
3-hydroxybutyrate Ketone bodies mmol/l 0.028 0.038 -0.076 0.132 6.020E-01 7374 
Acetate Ketone bodies mmol/l -0.035 0.006 -0.140 0.071 5.193E-01 7368 
Mean diameter for HDL particles Lipoprotein 
particle size 
nm -0.156 0.205 -0.263 -0.050 4.063E-03 7374 
Mean diameter for LDL particles Lipoprotein 
particle size 
nm -0.071 0.063 -0.179 0.037 1.993E-01 7374 
Mean diameter for VLDL particles Lipoprotein 
particle size 
nm 0.124 1.009 0.019 0.230 2.069E-02 7374 
Cholesterol esters in large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.086 0.144 -0.194 0.021 1.139E-01 7379 
Cholesterol esters in medium HDL Lipoprotein 
subclasses HDL 




Cholesterol esters in small HDL Lipoprotein 
subclasses HDL 
mmol/l 0.103 0.059 0.000 0.207 5.089E-02 7379 
Cholesterol esters in very large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.104 0.074 -0.212 0.003 5.669E-02 7379 
Concentration of large HDL particles Lipoprotein 
subclasses HDL 
mol/l -0.066 0.000 -0.172 0.041 2.261E-01 7379 
Concentration of medium HDL particles Lipoprotein 
subclasses HDL 
mol/l 0.109 0.000 0.006 0.212 3.833E-02 7379 
Concentration of small HDL particles Lipoprotein 
subclasses HDL 
mol/l 0.180 0.000 0.077 0.284 6.512E-04 7379 
Concentration of very large HDL particles Lipoprotein 
subclasses HDL 
mol/l -0.106 0.000 -0.214 0.001 5.243E-02 7379 
Free cholesterol in large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.086 0.045 -0.193 0.021 1.161E-01 7379 
Free cholesterol in medium HDL Lipoprotein 
subclasses HDL 
mmol/l 0.090 0.023 -0.013 0.193 8.650E-02 7379 
Free cholesterol in small HDL Lipoprotein 
subclasses HDL 
mmol/l 0.144 0.017 0.041 0.246 6.135E-03 7379 
Free cholesterol in very large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.108 0.030 -0.216 -0.001 4.865E-02 7379 
Phospholipids in large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.048 0.157 -0.154 0.058 3.727E-01 7379 
Phospholipids in medium HDL Lipoprotein 
subclasses HDL 
mmol/l 0.113 0.087 0.010 0.216 3.169E-02 7379 
Phospholipids in small HDL Lipoprotein 
subclasses HDL 
mmol/l 0.144 0.094 0.041 0.248 6.136E-03 7379 
Phospholipids in very large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.112 0.122 -0.219 -0.004 4.148E-02 7379 
Total cholesterol in large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.086 0.189 -0.193 0.021 1.143E-01 7379 
Total cholesterol in medium HDL Lipoprotein 
subclasses HDL 




Total cholesterol in small HDL Lipoprotein 
subclasses HDL 
mmol/l 0.128 0.067 0.024 0.231 1.555E-02 7379 
Total cholesterol in very large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.106 0.104 -0.213 0.002 5.334E-02 7379 
Total lipids in large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.068 0.356 -0.175 0.038 2.094E-01 7379 
Total lipids in medium HDL Lipoprotein 
subclasses HDL 
mmol/l 0.103 0.195 0.000 0.206 4.989E-02 7379 
Total lipids in small HDL Lipoprotein 
subclasses HDL 
mmol/l 0.175 0.142 0.072 0.279 8.974E-04 7379 
Total lipids in very large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.107 0.230 -0.215 0.000 5.064E-02 7379 
Triglycerides in large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.028 0.016 -0.134 0.077 5.997E-01 7379 
Triglycerides in medium HDL Lipoprotein 
subclasses HDL 
mmol/l 0.211 0.013 0.110 0.313 4.502E-05 7379 
Triglycerides in small HDL Lipoprotein 
subclasses HDL 
mmol/l 0.157 0.016 0.055 0.258 2.489E-03 7379 
Triglycerides in very large HDL Lipoprotein 
subclasses HDL 
mmol/l -0.001 0.010 -0.105 0.103 9.842E-01 7379 
Cholesterol esters in large LDL Lipoprotein 
subclasses LDL 
mmol/l 0.072 0.234 -0.031 0.175 1.703E-01 7379 
Cholesterol esters in LDL Lipoprotein 
subclasses LDL 
mmol/l 0.072 0.163 -0.031 0.175 1.703E-01 7379 
Cholesterol esters in medium LDL Lipoprotein 
subclasses LDL 
mmol/l 0.068 0.157 -0.036 0.171 1.991E-01 7379 
Cholesterol esters in small LDL Lipoprotein 
subclasses LDL 
mmol/l 0.062 0.095 -0.042 0.165 2.429E-01 7379 
Concentration of large LDL particles Lipoprotein 
subclasses LDL 
mol/l 0.079 0.000 -0.024 0.181 1.345E-01 7379 
Concentration of LDL particles Lipoprotein 
subclasses LDL 




Concentration of medium LDL particles Lipoprotein 
subclasses LDL 
mol/l 0.083 0.000 -0.019 0.186 1.114E-01 7379 
Concentration of small LDL particles Lipoprotein 
subclasses LDL 
mol/l 0.088 0.000 -0.015 0.190 9.445E-02 7379 
Free cholesterol in large LDL Lipoprotein 
subclasses LDL 
mmol/l 0.049 0.076 -0.055 0.153 3.541E-01 7379 
Free cholesterol in LDL Lipoprotein 
subclasses LDL 
mmol/l 0.048 0.067 -0.056 0.152 3.650E-01 7379 
Free cholesterol in medium LDL Lipoprotein 
subclasses LDL 
mmol/l 0.072 0.037 -0.031 0.176 1.696E-01 7379 
Free cholesterol in small LDL Lipoprotein 
subclasses LDL 
mmol/l 0.078 0.023 -0.025 0.181 1.377E-01 7379 
Phospholipids in large LDL Lipoprotein 
subclasses LDL 
mmol/l 0.074 0.088 -0.029 0.177 1.606E-01 7379 
Phospholipids in LDL Lipoprotein 
subclasses LDL 
mmol/l 0.061 0.090 -0.042 0.164 2.480E-01 7379 
Phospholipids in medium LDL Lipoprotein 
subclasses LDL 
mmol/l 0.101 0.050 -0.001 0.204 5.310E-02 7379 
Phospholipids in small LDL Lipoprotein 
subclasses LDL 
mmol/l 0.107 0.034 0.004 0.209 4.172E-02 7379 
Total cholesterol in large LDL Lipoprotein 
subclasses LDL 
mmol/l 0.067 0.310 -0.037 0.170 2.066E-01 7379 
Total cholesterol in LDL Lipoprotein 
subclasses LDL 
mmol/l 0.065 0.230 -0.038 0.169 2.156E-01 7379 
Total cholesterol in medium LDL Lipoprotein 
subclasses LDL 
mmol/l 0.069 0.193 -0.035 0.172 1.922E-01 7379 
Total cholesterol in small LDL Lipoprotein 
subclasses LDL 
mmol/l 0.065 0.117 -0.038 0.168 2.170E-01 7379 
Total lipids in large LDL Lipoprotein 
subclasses LDL 
mmol/l 0.074 0.428 -0.029 0.177 1.566E-01 7379 
Total lipids in LDL Lipoprotein 
subclasses LDL 




Total lipids in medium LDL Lipoprotein 
subclasses LDL 
mmol/l 0.081 0.258 -0.022 0.184 1.241E-01 7379 
Total lipids in small LDL Lipoprotein 
subclasses LDL 
mmol/l 0.084 0.159 -0.019 0.187 1.110E-01 7379 
Triglycerides in large LDL Lipoprotein 
subclasses LDL 
mmol/l 0.125 0.039 0.023 0.227 1.654E-02 7379 
Triglycerides in LDL Lipoprotein 
subclasses LDL 
mmol/l 0.137 0.042 0.036 0.239 7.695E-03 7379 
Triglycerides in medium LDL Lipoprotein 
subclasses LDL 
mmol/l 0.127 0.020 0.025 0.229 1.433E-02 7379 
Triglycerides in small LDL Lipoprotein 
subclasses LDL 
mmol/l 0.158 0.013 0.059 0.258 1.796E-03 7379 
Cholesterol esters in chylomicrons & 
extremely large VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.097 0.002 0.006 0.189 3.747E-02 7379 
Cholesterol esters in large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.123 0.022 0.033 0.213 7.301E-03 7379 
Cholesterol esters in medium VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.130 0.043 0.034 0.225 7.755E-03 7379 
Cholesterol esters in small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.119 0.054 0.018 0.220 2.138E-02 7379 
Cholesterol esters in very large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.108 0.006 0.020 0.196 1.609E-02 7379 
Cholesterol esters in very small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.063 0.053 -0.040 0.166 2.301E-01 7379 




mol/l 0.114 0.000 0.029 0.200 9.011E-03 7379 
Concentration of large VLDL particles Lipoprotein 
subclasses VLDL 
mol/l 0.142 0.000 0.053 0.231 1.755E-03 7379 
Concentration of medium VLDL particles Lipoprotein 
subclasses VLDL 
mol/l 0.148 0.000 0.057 0.238 1.354E-03 7379 
Concentration of small VLDL particles Lipoprotein 
subclasses VLDL 




Concentration of very large VLDL particles Lipoprotein 
subclasses VLDL 
mol/l 0.131 0.000 0.043 0.218 3.451E-03 7379 
Concentration of very small VLDL particles Lipoprotein 
subclasses VLDL 
mol/l 0.118 0.000 0.016 0.220 2.315E-02 7379 
Free cholesterol in chylomicrons & 
extremely large VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.125 0.002 0.038 0.211 4.700E-03 7379 
Free cholesterol in large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.141 0.023 0.052 0.229 1.832E-03 7379 
Free cholesterol in medium VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.151 0.039 0.061 0.242 1.055E-03 7379 
Free cholesterol in small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.176 0.031 0.079 0.274 3.787E-04 7379 
Free cholesterol in very large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.123 0.005 0.036 0.210 5.607E-03 7379 
Free cholesterol in very small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.103 0.026 0.001 0.205 4.850E-02 7379 




mmol/l 0.125 0.002 0.040 0.211 4.217E-03 7379 
Phospholipids in large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.145 0.037 0.055 0.234 1.505E-03 7379 
Phospholipids in medium VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.152 0.058 0.061 0.243 1.103E-03 7379 
Phospholipids in small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.181 0.044 0.084 0.279 2.594E-04 7379 
Phospholipids in very large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.133 0.009 0.045 0.221 2.978E-03 7379 
Phospholipids in very small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.090 0.052 -0.013 0.192 8.602E-02 7379 
Total cholesterol in chylomicrons & 
extremely large VLDL 
Lipoprotein 
subclasses VLDL 
mmol/l 0.111 0.004 0.022 0.200 1.417E-02 7379 
Total cholesterol in large VLDL Lipoprotein 
subclasses VLDL 




Total cholesterol in medium VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.142 0.080 0.050 0.235 2.602E-03 7379 
Total cholesterol in small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.146 0.082 0.046 0.246 4.374E-03 7379 
Total cholesterol in very large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.115 0.011 0.028 0.202 9.914E-03 7379 
Total cholesterol in very small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.076 0.078 -0.026 0.179 1.445E-01 7379 




mmol/l 0.115 0.018 0.029 0.201 8.891E-03 7379 
Total lipids in large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.141 0.199 0.053 0.230 1.819E-03 7379 
Total lipids in medium VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.148 0.298 0.057 0.238 1.373E-03 7379 
Total lipids in small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.167 0.215 0.071 0.264 6.952E-04 7379 
Total lipids in very large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.130 0.055 0.042 0.217 3.675E-03 7379 
Total lipids in very small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.111 0.161 0.009 0.213 3.335E-02 7379 




mmol/l 0.113 0.012 0.028 0.199 9.165E-03 7379 
Triglycerides in large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.144 0.117 0.055 0.232 1.525E-03 7379 
Triglycerides in medium VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.148 0.163 0.058 0.237 1.265E-03 7379 
Triglycerides in small VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.160 0.097 0.068 0.253 6.878E-04 7379 
Triglycerides in very large VLDL Lipoprotein 
subclasses VLDL 
mmol/l 0.133 0.035 0.045 0.220 2.924E-03 7379 
Triglycerides in very small VLDL Lipoprotein 
subclasses VLDL 




APPENDIX 4A4: Results of logistical regression (adjusted) comparing maternal metabolites of those women who delivered 
post-term (>294 days, or >42 completed weeks) compared with those who delivered at term (259 days to 294 days, or 37 to 
42 completed weeks), excluding those who delivered pre-term (<259 days, of <37 completed weeks), showing odds ratio per 
1 standard deviation (SD) increase in metabolite measured. N=54 for post-term, n=6994 for term, and n=392 excluded for pre-
term. The biochemical group of the metabolite, units, upper and lower 95% confidence interval. No p-values were significant 
at p<0.0029. 








Acetate Ketone bodies mmol/l -0.101 0.006 -0.386 0.184 4.862E-01 6350 
Alanine Amino acids mmol/l -0.194 0.048 -0.487 0.099 1.943E-01 6334 





-0.010 0.006 -0.286 0.265 9.407E-01 6356 
Apolipoprotein A-I Apolipoproteins g/l -0.142 0.220 -0.432 0.148 3.361E-01 6355 
Apolipoprotein B Apolipoproteins g/l 0.012 0.228 -0.264 0.287 9.339E-01 6355 
Ratio of apolipoprotein B to 
apolipoprotein A-I 
Apolipoproteins #N/A 0.097 0.120 -0.167 0.362 4.721E-01 6355 
3-hydroxybutyrate Ketone bodies mmol/l -0.080 0.038 -0.401 0.241 6.268E-01 6356 
Citrate Glycolysis related 
metabolites 
mmol/l -0.049 0.017 -0.356 0.257 7.520E-01 6255 
Creatinine Fluid balance and 
inflammation 
mmol/l 0.052 0.006 -0.192 0.296 6.749E-01 6353 
22:6, docosahexaenoic acid Fatty acids and saturation 
measures 
mmol/l 0.084 0.043 -0.190 0.358 5.492E-01 6317 
Ratio of 22:6 docosahexaenoic acid to 
total fatty acids 
Fatty acids (%) % 0.030 0.230 -0.246 0.306 8.319E-01 6317 




Omega-3 fatty acids Fatty acids and saturation 
measures 
mmol/l 0.011 0.104 -0.269 0.291 9.375E-01 6317 
Ratio of omega-3 fatty acids to total 
fatty acids 
Fatty acids (%) % -0.063 0.494 -0.349 0.223 6.681E-01 6317 
Omega-6 fatty acids Fatty acids and saturation 
measures 
mmol/l -0.040 0.839 -0.322 0.243 7.837E-01 6317 
Ratio of omega-6 fatty acids to total 
fatty acids 
Fatty acids (%) % -0.194 2.200 -0.492 0.104 2.011E-01 6317 
Free cholesterol Cholesterol mmol/l -0.020 0.333 -0.302 0.261 8.866E-01 6336 
Glucose Glycolysis related 
metabolites 
mmol/l 0.035 0.487 -0.293 0.363 8.327E-01 6334 
Glutamine Amino acids mmol/l -0.109 0.046 -0.398 0.181 4.614E-01 6351 
Glycerol Glycolysis related 
metabolites 
mmol/l 0.219 0.016 -0.063 0.500 1.274E-01 6341 
Glycine Amino acids mmol/l 0.104 0.032 -0.162 0.370 4.450E-01 6348 
Glycoprotein acetyls, mainly a1-acid 
glycoprotein 
Fluid balance and 
inflammation 
mmol/l 0.029 0.195 -0.258 0.316 8.410E-01 6356 
Total cholesterol in HDL2 Cholesterol mmol/l -0.145 0.333 -0.431 0.142 3.227E-01 6355 
Total cholesterol in HDL3 Cholesterol mmol/l -0.009 0.044 -0.287 0.269 9.502E-01 6355 
Total cholesterol in HDL Cholesterol mmol/l -0.132 0.368 -0.419 0.154 3.655E-01 6355 
Mean diameter for HDL particles Lipoprotein particle size nm -0.105 0.204 -0.387 0.177 4.655E-01 6355 
Triglycerides in HDL Glycerides and phospholipids mmol/l 0.025 0.042 -0.253 0.302 8.621E-01 6355 
Histidine Amino acids mmol/l 0.085 0.010 -0.186 0.355 5.393E-01 6352 
Total cholesterol in LDL Lipoprotein subclasses LDL mmol/l 0.005 0.229 -0.272 0.282 9.741E-01 6360 
Cholesterol esters in LDL Lipoprotein subclasses LDL mmol/l 0.002 0.163 -0.275 0.279 9.877E-01 6360 
Free cholesterol in LDL Lipoprotein subclasses LDL mmol/l 0.010 0.067 -0.267 0.287 9.435E-01 6360 
Total lipids in LDL Lipoprotein subclasses LDL mmol/l 0.014 0.349 -0.262 0.291 9.186E-01 6355 
Concentration of LDL particles Lipoprotein subclasses LDL mol/l 0.019 0.000 -0.257 0.295 8.938E-01 6355 
Phospholipids in LDL Lipoprotein subclasses LDL mmol/l 0.017 0.089 -0.259 0.293 9.041E-01 6360 
Triglycerides in LDL Lipoprotein subclasses LDL mmol/l 0.098 0.042 -0.170 0.366 4.722E-01 6360 




18:2, linoleic acid Fatty acids and saturation 
measures 
mmol/l -0.058 0.765 -0.345 0.228 6.904E-01 6317 
Lactate Glycolysis related 
metabolites 
mmol/l 0.151 0.493 -0.093 0.395 2.240E-01 6345 
Ratio of 18:2 linoleic acid to total fatty 
acids 
Fatty acids (%) % -0.175 2.689 -0.481 0.132 2.638E-01 6317 
Total cholesterol in LDL Cholesterol mmol/l 0.014 0.617 -0.264 0.292 9.212E-01 6355 
Mean diameter for LDL particles Lipoprotein particle size nm -0.048 0.063 -0.333 0.238 7.436E-01 6355 
Triglycerides in LDL Glycerides and phospholipids mmol/l 0.077 0.070 -0.194 0.348 5.787E-01 6355 
Leucine Branched--chain amino acids mmol/l -0.071 0.010 -0.361 0.219 6.311E-01 6354 
Total cholesterol in large HDL Lipoprotein subclasses HDL mmol/l -0.118 0.188 -0.403 0.167 4.171E-01 6360 
Cholesterol esters in large HDL Lipoprotein subclasses HDL mmol/l -0.119 0.143 -0.404 0.166 4.127E-01 6360 
Free cholesterol in large HDL Lipoprotein subclasses HDL mmol/l -0.115 0.045 -0.399 0.170 4.303E-01 6360 
Total lipids in large HDL Lipoprotein subclasses HDL mmol/l -0.117 0.354 -0.401 0.167 4.193E-01 6360 
Concentration of large HDL particles Lipoprotein subclasses HDL mol/l -0.117 0.000 -0.400 0.167 4.206E-01 6360 
Phospholipids in large HDL Lipoprotein subclasses HDL mmol/l -0.119 0.156 -0.402 0.164 4.087E-01 6360 
Triglycerides in large HDL Lipoprotein subclasses HDL mmol/l -0.041 0.016 -0.321 0.239 7.723E-01 6360 
Total cholesterol in large LDL Lipoprotein subclasses LDL mmol/l 0.014 0.309 -0.263 0.291 9.211E-01 6360 
Cholesterol esters in large LDL Lipoprotein subclasses LDL mmol/l 0.014 0.234 -0.263 0.290 9.215E-01 6360 
Free cholesterol in large LDL Lipoprotein subclasses LDL mmol/l 0.014 0.076 -0.263 0.291 9.186E-01 6360 
Total lipids in large LDL Lipoprotein subclasses LDL mmol/l 0.020 0.428 -0.256 0.296 8.865E-01 6360 
Concentration of large LDL particles Lipoprotein subclasses LDL mol/l 0.023 0.000 -0.253 0.298 8.715E-01 6360 
Phospholipids in large LDL Lipoprotein subclasses LDL mmol/l 0.011 0.088 -0.266 0.287 9.393E-01 6360 
Triglycerides in large LDL Lipoprotein subclasses LDL mmol/l 0.086 0.038 -0.184 0.355 5.330E-01 6360 
Total cholesterol in large VLDL Lipoprotein subclasses VLDL mmol/l 0.016 0.045 -0.255 0.288 9.058E-01 6360 
Cholesterol esters in large VLDL Lipoprotein subclasses VLDL mmol/l 0.017 0.022 -0.254 0.288 9.015E-01 6360 
Free cholesterol in large VLDL Lipoprotein subclasses VLDL mmol/l 0.016 0.023 -0.257 0.288 9.108E-01 6360 
Total lipids in large VLDL Lipoprotein subclasses VLDL mmol/l 0.023 0.194 -0.249 0.294 8.708E-01 6360 
Concentration of large VLDL particles Lipoprotein subclasses VLDL mol/l 0.023 0.000 -0.248 0.295 8.675E-01 6360 




Triglycerides in large VLDL Lipoprotein subclasses VLDL mmol/l 0.024 0.114 -0.247 0.296 8.612E-01 6360 
Total cholesterol in medium HDL Lipoprotein subclasses HDL mmol/l -0.155 0.108 -0.432 0.122 2.738E-01 6360 
Cholesterol esters in medium HDL Lipoprotein subclasses HDL mmol/l -0.159 0.086 -0.435 0.118 2.603E-01 6360 
Free cholesterol in medium HDL Lipoprotein subclasses HDL mmol/l -0.136 0.023 -0.417 0.144 3.404E-01 6360 
Total lipids in medium HDL Lipoprotein subclasses HDL mmol/l -0.138 0.194 -0.414 0.139 3.294E-01 6360 
Concentration of medium HDL particles Lipoprotein subclasses HDL mol/l -0.136 0.000 -0.412 0.140 3.351E-01 6360 
Phospholipids in medium HDL Lipoprotein subclasses HDL mmol/l -0.117 0.086 -0.393 0.160 4.076E-01 6360 
Triglycerides in medium HDL Lipoprotein subclasses HDL mmol/l 0.002 0.012 -0.280 0.283 9.915E-01 6360 
Total cholesterol in medium LDL Lipoprotein subclasses LDL mmol/l 0.023 0.193 -0.253 0.300 8.683E-01 6360 
Cholesterol esters in medium LDL Lipoprotein subclasses LDL mmol/l 0.023 0.157 -0.253 0.299 8.713E-01 6360 
Free cholesterol in medium LDL Lipoprotein subclasses LDL mmol/l 0.025 0.037 -0.251 0.301 8.585E-01 6360 
Total lipids in medium LDL Lipoprotein subclasses LDL mmol/l 0.027 0.258 -0.248 0.303 8.462E-01 6360 
Concentration of medium LDL particles Lipoprotein subclasses LDL mol/l 0.029 0.000 -0.246 0.304 8.367E-01 6360 
Phospholipids in medium LDL Lipoprotein subclasses LDL mmol/l 0.018 0.050 -0.257 0.294 8.956E-01 6360 
Triglycerides in medium LDL Lipoprotein subclasses LDL mmol/l 0.083 0.020 -0.188 0.354 5.479E-01 6360 
Monounsaturated fatty acids; 16:1, 
18:1 
Fatty acids and saturation 
measures 
mmol/l 0.100 0.993 -0.176 0.377 4.764E-01 6317 
Ratio of monounsaturated fatty acids to 
total fatty acids 
Fatty acids (%) % 0.209 2.410 -0.098 0.516 1.826E-01 6317 
Total cholesterol in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.020 0.078 -0.252 0.292 8.844E-01 6360 
Cholesterol esters in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.011 0.042 -0.262 0.284 9.367E-01 6360 
Free cholesterol in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.030 0.038 -0.242 0.301 8.301E-01 6360 
Total lipids in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.028 0.292 -0.244 0.299 8.419E-01 6360 
Concentration of medium VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.028 0.000 -0.243 0.299 8.394E-01 6360 
Phospholipids in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.029 0.057 -0.242 0.300 8.328E-01 6360 
Triglycerides in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.030 0.159 -0.241 0.301 8.265E-01 6360 
Phosphatidylcholine and other cholines Glycerides and phospholipids mmol/l -0.017 0.458 -0.297 0.263 9.059E-01 6334 




Polyunsaturated fatty acids Fatty acids and saturation 
measures 
mmol/l -0.035 0.916 -0.317 0.247 8.086E-01 6317 
Ratio of polyunsaturated fatty acids to 
total fatty acids 
Fatty acids (%) % -0.190 2.381 -0.484 0.104 2.061E-01 6317 
Pyruvate Glycolysis related 
metabolites 
mmol/l 0.176 0.022 -0.069 0.420 1.586E-01 6341 
Remnant cholesterol (non-HDL, non-
LDL -cholesterol) 
Cholesterol mmol/l 0.021 0.465 -0.254 0.295 8.830E-01 6355 
Serum total cholesterol Cholesterol mmol/l -0.025 1.156 -0.306 0.256 8.615E-01 6355 
Serum total triglycerides Glycerides and phospholipids mmol/l 0.043 0.568 -0.228 0.314 7.544E-01 6355 
Saturated fatty acids Fatty acids and saturation 
measures 
mmol/l 0.033 1.041 -0.245 0.311 8.170E-01 6317 
Ratio of saturated fatty acids to total 
fatty acids 
Fatty acids (%) % -0.003 1.504 -0.284 0.278 9.837E-01 6317 
Total cholesterol in small HDL Lipoprotein subclasses HDL mmol/l 0.007 0.067 -0.262 0.275 9.618E-01 6360 
Cholesterol esters in small HDL Lipoprotein subclasses HDL mmol/l 0.016 0.059 -0.255 0.287 9.101E-01 6360 
Free cholesterol in small HDL Lipoprotein subclasses HDL mmol/l -0.029 0.017 -0.304 0.245 8.337E-01 6360 
Total lipids in small HDL Lipoprotein subclasses HDL mmol/l -0.015 0.141 -0.285 0.255 9.135E-01 6360 
Concentration of small HDL particles Lipoprotein subclasses HDL mol/l -0.012 0.000 -0.283 0.258 9.291E-01 6360 
Phospholipids in small HDL Lipoprotein subclasses HDL mmol/l -0.049 0.093 -0.323 0.225 7.277E-01 6360 
Triglycerides in small HDL Lipoprotein subclasses HDL mmol/l 0.126 0.016 -0.145 0.396 3.622E-01 6360 
Total cholesterol in small LDL Lipoprotein subclasses LDL mmol/l 0.021 0.117 -0.256 0.298 8.828E-01 6360 
Cholesterol esters in small LDL Lipoprotein subclasses LDL mmol/l 0.021 0.095 -0.255 0.298 8.797E-01 6360 
Free cholesterol in small LDL Lipoprotein subclasses LDL mmol/l 0.018 0.023 -0.258 0.295 8.977E-01 6360 
Total lipids in small LDL Lipoprotein subclasses LDL mmol/l 0.021 0.159 -0.255 0.298 8.790E-01 6360 
Concentration of small LDL particles Lipoprotein subclasses LDL mol/l 0.023 0.000 -0.253 0.299 8.719E-01 6360 
Phospholipids in small LDL Lipoprotein subclasses LDL mmol/l 0.006 0.034 -0.271 0.283 9.674E-01 6360 
Triglycerides in small LDL Lipoprotein subclasses LDL mmol/l 0.062 0.013 -0.210 0.334 6.545E-01 6360 
Sphingomyelins Glycerides and phospholipids mmol/l -0.049 0.086 -0.331 0.233 7.336E-01 6334 
Total cholesterol in small VLDL Lipoprotein subclasses VLDL mmol/l 0.047 0.081 -0.224 0.319 7.331E-01 6360 




Free cholesterol in small VLDL Lipoprotein subclasses VLDL mmol/l 0.058 0.030 -0.213 0.330 6.749E-01 6360 
Total lipids in small VLDL Lipoprotein subclasses VLDL mmol/l 0.052 0.212 -0.219 0.323 7.079E-01 6360 
Concentration of small VLDL particles Lipoprotein subclasses VLDL mol/l 0.051 0.000 -0.220 0.322 7.104E-01 6360 
Phospholipids in small VLDL Lipoprotein subclasses VLDL mmol/l 0.059 0.044 -0.213 0.331 6.725E-01 6360 
Triglycerides in small VLDL Lipoprotein subclasses VLDL mmol/l 0.048 0.095 -0.222 0.319 7.267E-01 6360 
Ratio of triglycerides to 
phosphoglycerides 
Glycerides and phospholipids #N/A 0.098 0.158 -0.172 0.369 4.757E-01 6336 
Total cholines Glycerides and phospholipids mmol/l -0.025 0.483 -0.306 0.255 8.595E-01 6334 
Total fatty acids Fatty acids and saturation 
measures 
mmol/l 0.036 2.773 -0.241 0.313 7.989E-01 6317 
Total phosphoglycerides Glycerides and phospholipids mmol/l -0.022 0.397 -0.303 0.259 8.795E-01 6336 
Tyrosine Aromatic amino acids mmol/l 0.118 0.005 -0.159 0.396 4.039E-01 6349 
Estimated degree of unsaturation Fatty acids and saturation 
measures 
#N/A -0.149 0.043 -0.426 0.127 2.900E-01 6317 
Valine Branched--chain amino acids mmol/l -0.058 0.018 -0.341 0.225 6.867E-01 6349 
Total cholesterol in VLDL Cholesterol mmol/l 0.035 0.273 -0.237 0.307 8.001E-01 6355 
Mean diameter for VLDL particles Lipoprotein particle size nm 0.023 1.005 -0.259 0.305 8.715E-01 6355 
Triglycerides in VLDL Glycerides and phospholipids mmol/l 0.032 0.449 -0.240 0.303 8.181E-01 6355 
Total cholesterol in very large HDL Lipoprotein subclasses HDL mmol/l -0.060 0.104 -0.342 0.222 6.769E-01 6360 
Cholesterol esters in very large HDL Lipoprotein subclasses HDL mmol/l -0.053 0.074 -0.335 0.228 7.106E-01 6360 
Free cholesterol in very large HDL Lipoprotein subclasses HDL mmol/l -0.076 0.030 -0.359 0.208 6.003E-01 6360 
Total lipids in very large HDL Lipoprotein subclasses HDL mmol/l -0.076 0.230 -0.359 0.208 6.022E-01 6360 
Concentration of very large HDL 
particles 
Lipoprotein subclasses HDL mol/l -0.076 0.000 -0.360 0.208 6.014E-01 6360 
Phospholipids in very large HDL Lipoprotein subclasses HDL mmol/l -0.092 0.122 -0.377 0.194 5.292E-01 6360 
Triglycerides in very large HDL Lipoprotein subclasses HDL mmol/l 0.001 0.010 -0.273 0.276 9.920E-01 6360 
Total cholesterol in very large VLDL Lipoprotein subclasses VLDL mmol/l -0.005 0.011 -0.280 0.270 9.700E-01 6360 
Cholesterol esters in very large VLDL Lipoprotein subclasses VLDL mmol/l -0.001 0.006 -0.275 0.272 9.920E-01 6360 
Free cholesterol in very large VLDL Lipoprotein subclasses VLDL mmol/l -0.010 0.005 -0.286 0.267 9.446E-01 6360 




Concentration of very large VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.002 0.000 -0.272 0.277 9.860E-01 6360 
Phospholipids in very large VLDL Lipoprotein subclasses VLDL mmol/l -0.003 0.009 -0.279 0.272 9.805E-01 6360 
Triglycerides in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.005 0.034 -0.270 0.280 9.722E-01 6360 
Total cholesterol in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.060 0.078 -0.211 0.331 6.642E-01 6360 
Cholesterol esters in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.062 0.053 -0.210 0.333 6.563E-01 6360 
Free cholesterol in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.056 0.026 -0.216 0.328 6.860E-01 6360 
Total lipids in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.064 0.161 -0.207 0.334 6.444E-01 6360 
Concentration of very small VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.066 0.000 -0.204 0.336 6.311E-01 6360 
Phospholipids in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.040 0.052 -0.234 0.314 7.739E-01 6360 
Triglycerides in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.086 0.041 -0.183 0.355 5.305E-01 6360 
Total cholesterol in chylomicrons & 
extremely large VLDL 
Lipoprotein subclasses VLDL mmol/l -0.013 0.004 -0.289 0.262 9.239E-01 6360 
Cholesterol esters in chylomicrons & 
extremely large VLDL 
Lipoprotein subclasses VLDL mmol/l -0.011 0.002 -0.286 0.263 9.356E-01 6360 
Free cholesterol in chylomicrons & 
extremely large VLDL 
Lipoprotein subclasses VLDL mmol/l -0.016 0.002 -0.294 0.263 9.108E-01 6360 
Total lipids in chylomicrons & 
extremely large VLDL 
Lipoprotein subclasses VLDL mmol/l -0.031 0.018 -0.312 0.249 8.261E-01 6360 
Conc. of chylomicrons & extremely 
large VLDL particles 
Lipoprotein subclasses VLDL mol/l -0.033 0.000 -0.314 0.248 8.181E-01 6360 
Phospholipids in chylomicrons & 
extremely large VLDL 
Lipoprotein subclasses VLDL mmol/l -0.035 0.002 -0.317 0.247 8.096E-01 6360 
Triglycerides in chylomicrons & 
extremely large VLDL 






APPENDIX 4A5: Results of logistical regression (unadjusted) comparing maternal metabolites of those women who delivered 
extremely preterm (<196 days, or <28 completed weeks) compared with those who delivered at term (259 days to 294 days, 
or 37 to 42 completed weeks), excluding those who delivered very or moderate to late preterm (196 days to <259 days, or 28 
to <37 completed weeks) and post-term (>294 days, or >42 completed weeks); showing odds ratio per 1 standard deviation 
(SD) increase in metabolite measured. N=12 for extremely preterm, n=6994 for term, and n=434 excluded from analysis. The 
biochemical group of the metabolite, units, upper and lower 95% confidence interval. P-values in bold significant at p<0.0029. 








Alanine Amino acids mmol/l 0.079 0.048 -0.468 0.627 7.771E-01 6977 
Glutamine Amino acids mmol/l 0.112 0.046 -0.428 0.651 6.850E-01 6997 
Glycine Amino acids mmol/l 0.259 0.032 -0.160 0.678 2.251E-01 6991 
Histidine Amino acids mmol/l -0.071 0.010 -0.644 0.503 8.090E-01 6997 
Apolipoprotein A-I Apolipoproteins g/l 0.118 0.220 -0.422 0.658 6.687E-01 7001 
Apolipoprotein B Apolipoproteins g/l 0.473 0.228 0.031 0.915 3.614E-02 7001 
apolipoprotein B:apolipoprotein A-I Apolipoproteins #N/A 0.426 0.120 0.006 0.846 4.656E-02 7001 
Phenylalanine Aromatic amino acids mmol/l 0.536 0.011 0.118 0.954 1.203E-02 7002 
Tyrosine Aromatic amino acids mmol/l -0.202 0.006 -0.792 0.388 5.022E-01 6993 
Isoleucine Branched--chain amino acids mmol/l 0.434 0.010 0.012 0.857 4.401E-02 7000 
Leucine Branched--chain amino acids mmol/l 0.476 0.010 0.080 0.873 1.851E-02 7000 
Valine Branched--chain amino acids mmol/l 0.130 0.018 -0.407 0.666 6.355E-01 6994 
Esterified cholesterol Cholesterol mmol/l 0.194 0.806 -0.341 0.728 4.778E-01 6977 
Free cholesterol Cholesterol mmol/l 0.325 0.333 -0.185 0.836 2.112E-01 6977 
Remnant cholesterol (non-HDL, 
non-LDL) 
Cholesterol mmol/l 0.436 0.466 -0.021 0.892 6.124E-02 7001 
Serum total cholesterol Cholesterol mmol/l 0.218 1.156 -0.298 0.735 4.078E-01 7001 
Total cholesterol in HDL Cholesterol mmol/l -0.133 0.368 -0.715 0.448 6.529E-01 7001 




Total cholesterol in HDL3 Cholesterol mmol/l 0.242 0.044 -0.259 0.744 3.439E-01 7001 
Total cholesterol in LDL Cholesterol mmol/l 0.114 0.617 -0.430 0.658 6.818E-01 7001 
Total cholesterol in VLDL Cholesterol mmol/l 0.537 0.274 0.174 0.900 3.710E-03 7001 
18:2 linoleic acid to total FAs Fatty acids (%) % -0.676 2.694 -1.278 -0.074 2.775E-02 6957 
22:6 docosahexaenoic acid to total 
FAs 
Fatty acids (%) % -0.516 0.230 -1.199 0.167 1.385E-01 6957 
Monounsaturated FAs to total FAs Fatty acids (%) % 0.838 2.413 0.330 1.346 1.231E-03 6957 
Omega-3 FAs to total FAs Fatty acids (%) % -0.632 0.493 -1.290 0.027 6.000E-02 6957 
Omega-6 FAs to total FAs Fatty acids (%) % -0.671 2.204 -1.220 -0.122 1.650E-02 6957 
Polyunsaturated FAs to total FAs Fatty acids (%) % -0.716 2.384 -1.259 -0.174 9.658E-03 6957 
Saturated FAs to total FAs Fatty acids (%) % -0.326 1.505 -0.940 0.288 2.977E-01 6957 
18:2, linoleic acid Fatty acids and saturation 
measures 
mmol/l 0.132 0.766 -0.438 0.701 6.501E-01 6957 
22:6, docosahexaenoic acid Fatty acids and saturation 
measures 
mmol/l 0.170 0.043 -0.374 0.713 5.403E-01 6957 
Estimated degree of unsaturation Fatty acids and saturation 
measures 
#N/A -0.444 0.043 -1.012 0.125 1.260E-01 6957 
Monounsaturated fatty acids; 16:1, 
18:1 
Fatty acids and saturation 
measures 
mmol/l 0.648 0.994 0.193 1.104 5.299E-03 6957 
Omega-3 fatty acids Fatty acids and saturation 
measures 
mmol/l 0.081 0.104 -0.491 0.653 7.818E-01 6957 
Omega-6 fatty acids Fatty acids and saturation 
measures 
mmol/l 0.208 0.839 -0.355 0.772 4.684E-01 6957 
Polyunsaturated fatty acids Fatty acids and saturation 
measures 
mmol/l 0.201 0.916 -0.364 0.766 4.861E-01 6957 
Saturated fatty acids Fatty acids and saturation 
measures 
mmol/l 0.408 1.042 -0.123 0.938 1.322E-01 6957 
Total fatty acids Fatty acids and saturation 
measures 
mmol/l 0.480 2.774 -0.044 1.003 7.281E-02 6957 
Albumin Fluid balance and inflammation signal 
 
area 




Creatinine Fluid balance and inflammation mmol/l 0.186 0.006 -0.160 0.532 2.932E-01 6998 
Glycoprotein acetyls (a1-acid 
glycoprotein) 
Fluid balance and inflammation mmol/l 0.449 0.196 0.117 0.780 7.972E-03 7002 
Phosphatidylcholine and other 
cholines 
Glycerides and phospholipids mmol/l 0.512 0.458 0.027 0.996 3.867E-02 6975 
Ratio of triglycerides to 
phosphoglycerides 
Glycerides and phospholipids #N/A 0.536 0.159 0.160 0.912 5.177E-03 6977 
Serum total triglycerides Glycerides and phospholipids mmol/l 0.528 0.571 0.269 0.787 6.583E-05 7001 
Sphingomyelins Glycerides and phospholipids mmol/l 0.162 0.086 -0.390 0.713 5.656E-01 6975 
Total cholines Glycerides and phospholipids mmol/l 0.484 0.483 -0.015 0.982 5.742E-02 6975 
Total phosphoglycerides Glycerides and phospholipids mmol/l 0.611 0.398 0.131 1.090 1.256E-02 6977 
Triglycerides in HDL Glycerides and phospholipids mmol/l 0.638 0.042 0.289 0.988 3.450E-04 7001 
Triglycerides in LDL Glycerides and phospholipids mmol/l 0.612 0.070 0.236 0.989 1.446E-03 7001 
Triglycerides in VLDL Glycerides and phospholipids mmol/l 0.480 0.451 0.238 0.723 1.013E-04 7001 
Citrate Glycolysis related metabolites mmol/l -0.054 0.017 -0.658 0.550 8.611E-01 6882 
Glucose Glycolysis related metabolites mmol/l -0.118 0.488 -0.716 0.480 6.990E-01 6977 
Glycerol Glycolysis related metabolites mmol/l 0.612 0.016 0.207 1.017 3.087E-03 6988 
Lactate Glycolysis related metabolites mmol/l -0.147 0.492 -0.779 0.485 6.482E-01 6990 
Pyruvate Glycolysis related metabolites mmol/l -0.127 0.022 -0.735 0.482 6.835E-01 6986 
3-hydroxybutyrate Ketone bodies mmol/l 0.017 0.038 -0.533 0.566 9.520E-01 7002 
Acetate Ketone bodies mmol/l 0.115 0.006 -0.415 0.644 6.711E-01 6996 
Mean diameter for HDL particles Lipoprotein particle size nm -0.380 0.204 -0.940 0.180 1.839E-01 7001 
Mean diameter for LDL particles Lipoprotein particle size nm -0.023 0.063 -0.592 0.546 9.370E-01 7001 
Mean diameter for VLDL particles Lipoprotein particle size nm 0.574 1.006 0.061 1.088 2.846E-02 7001 
Cholesterol esters in large HDL Lipoprotein subclasses HDL mmol/l -0.299 0.143 -0.893 0.295 3.235E-01 7006 
Cholesterol esters in medium HDL Lipoprotein subclasses HDL mmol/l 0.038 0.086 -0.525 0.601 8.937E-01 7006 
Cholesterol esters in small HDL Lipoprotein subclasses HDL mmol/l 0.108 0.059 -0.451 0.666 7.047E-01 7006 
Cholesterol esters in very large HDL Lipoprotein subclasses HDL mmol/l -0.174 0.074 -0.755 0.407 5.580E-01 7006 




Concentration of medium HDL 
particles 
Lipoprotein subclasses HDL mol/l 0.298 0.000 -0.217 0.813 2.568E-01 7006 
Concentration of small HDL particles Lipoprotein subclasses HDL mol/l 0.533 0.000 0.062 1.005 2.664E-02 7006 
Concentration of very large HDL 
particles 
Lipoprotein subclasses HDL mol/l -0.232 0.000 -0.820 0.356 4.386E-01 7006 
Free cholesterol in large HDL Lipoprotein subclasses HDL mmol/l -0.305 0.045 -0.898 0.289 3.146E-01 7006 
Free cholesterol in medium HDL Lipoprotein subclasses HDL mmol/l 0.218 0.023 -0.310 0.746 4.181E-01 7006 
Free cholesterol in small HDL Lipoprotein subclasses HDL mmol/l 0.528 0.017 0.049 1.007 3.081E-02 7006 
Free cholesterol in very large HDL Lipoprotein subclasses HDL mmol/l -0.183 0.030 -0.769 0.403 5.412E-01 7006 
Phospholipids in large HDL Lipoprotein subclasses HDL mmol/l -0.174 0.156 -0.755 0.408 5.577E-01 7006 
Phospholipids in medium HDL Lipoprotein subclasses HDL mmol/l 0.347 0.086 -0.156 0.851 1.765E-01 7006 
Phospholipids in small HDL Lipoprotein subclasses HDL mmol/l 0.456 0.094 -0.058 0.969 8.201E-02 7006 
Phospholipids in very large HDL Lipoprotein subclasses HDL mmol/l -0.332 0.122 -0.925 0.262 2.732E-01 7006 
Total cholesterol in large HDL Lipoprotein subclasses HDL mmol/l -0.301 0.188 -0.895 0.293 3.212E-01 7006 
Total cholesterol in medium HDL Lipoprotein subclasses HDL mmol/l 0.078 0.108 -0.480 0.636 7.835E-01 7006 
Total cholesterol in small HDL Lipoprotein subclasses HDL mmol/l 0.235 0.067 -0.294 0.763 3.842E-01 7006 
Total cholesterol in very large HDL Lipoprotein subclasses HDL mmol/l -0.177 0.103 -0.760 0.406 5.515E-01 7006 
Total lipids in large HDL Lipoprotein subclasses HDL mmol/l -0.224 0.354 -0.811 0.364 4.553E-01 7006 
Total lipids in medium HDL Lipoprotein subclasses HDL mmol/l 0.269 0.195 -0.253 0.791 3.122E-01 7006 
Total lipids in small HDL Lipoprotein subclasses HDL mmol/l 0.504 0.141 0.029 0.979 3.753E-02 7006 
Total lipids in very large HDL Lipoprotein subclasses HDL mmol/l -0.234 0.229 -0.822 0.354 4.360E-01 7006 
Triglycerides in large HDL Lipoprotein subclasses HDL mmol/l 0.233 0.016 -0.294 0.760 3.861E-01 7006 
Triglycerides in medium HDL Lipoprotein subclasses HDL mmol/l 0.788 0.012 0.410 1.166 4.445E-05 7006 
Triglycerides in small HDL Lipoprotein subclasses HDL mmol/l 0.689 0.016 0.371 1.007 2.165E-05 7006 
Triglycerides in very large HDL Lipoprotein subclasses HDL mmol/l 0.410 0.010 -0.070 0.891 9.438E-02 7006 
Cholesterol esters in large LDL Lipoprotein subclasses LDL mmol/l 0.148 0.234 -0.389 0.685 5.896E-01 7006 
Cholesterol esters in LDL Lipoprotein subclasses LDL mmol/l 0.152 0.163 -0.383 0.688 5.775E-01 7006 
Cholesterol esters in medium LDL Lipoprotein subclasses LDL mmol/l 0.104 0.157 -0.442 0.651 7.081E-01 7006 
Cholesterol esters in small LDL Lipoprotein subclasses LDL mmol/l 0.071 0.095 -0.483 0.625 8.028E-01 7006 




Concentration of LDL particles Lipoprotein subclasses LDL mol/l 0.251 0.000 -0.257 0.760 3.324E-01 7001 
Concentration of medium LDL 
particles 
Lipoprotein subclasses LDL mol/l 0.230 0.000 -0.288 0.749 3.834E-01 7006 
Concentration of small LDL particles Lipoprotein subclasses LDL mol/l 0.248 0.000 -0.266 0.762 3.444E-01 7006 
Free cholesterol in large LDL Lipoprotein subclasses LDL mmol/l 0.043 0.076 -0.516 0.602 8.807E-01 7006 
Free cholesterol in LDL Lipoprotein subclasses LDL mmol/l 0.049 0.067 -0.508 0.607 8.620E-01 7006 
Free cholesterol in medium LDL Lipoprotein subclasses LDL mmol/l 0.166 0.037 -0.370 0.702 5.437E-01 7006 
Free cholesterol in small LDL Lipoprotein subclasses LDL mmol/l 0.198 0.023 -0.329 0.725 4.622E-01 7006 
Phospholipids in large LDL Lipoprotein subclasses LDL mmol/l 0.167 0.088 -0.367 0.701 5.395E-01 7006 
Phospholipids in LDL Lipoprotein subclasses LDL mmol/l 0.134 0.089 -0.407 0.675 6.272E-01 7006 
Phospholipids in medium LDL Lipoprotein subclasses LDL mmol/l 0.311 0.050 -0.189 0.811 2.228E-01 7006 
Phospholipids in small LDL Lipoprotein subclasses LDL mmol/l 0.334 0.034 -0.156 0.824 1.816E-01 7006 
Total cholesterol in large LDL Lipoprotein subclasses LDL mmol/l 0.123 0.310 -0.420 0.666 6.572E-01 7006 
Total cholesterol in LDL Lipoprotein subclasses LDL mmol/l 0.123 0.230 -0.419 0.665 6.565E-01 7006 
Total cholesterol in medium LDL Lipoprotein subclasses LDL mmol/l 0.116 0.193 -0.428 0.661 6.754E-01 7006 
Total cholesterol in small LDL Lipoprotein subclasses LDL mmol/l 0.096 0.117 -0.452 0.645 7.304E-01 7006 
Total lipids in large LDL Lipoprotein subclasses LDL mmol/l 0.192 0.428 -0.335 0.719 4.755E-01 7006 
Total lipids in LDL Lipoprotein subclasses LDL mmol/l 0.213 0.349 -0.306 0.732 4.210E-01 7001 
Total lipids in medium LDL Lipoprotein subclasses LDL mmol/l 0.208 0.258 -0.315 0.732 4.355E-01 7006 
Total lipids in small LDL Lipoprotein subclasses LDL mmol/l 0.221 0.159 -0.300 0.742 4.060E-01 7006 
Triglycerides in large LDL Lipoprotein subclasses LDL mmol/l 0.596 0.039 0.208 0.984 2.616E-03 7006 
Triglycerides in LDL Lipoprotein subclasses LDL mmol/l 0.631 0.042 0.260 1.001 8.504E-04 7006 
Triglycerides in medium LDL Lipoprotein subclasses LDL mmol/l 0.607 0.020 0.224 0.990 1.895E-03 7006 
Triglycerides in small LDL Lipoprotein subclasses LDL mmol/l 0.668 0.013 0.320 1.016 1.686E-04 7006 
Cholesterol esters in CMs & 
extremely large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.354 0.002 0.096 0.613 7.239E-03 7006 
Cholesterol esters in large VLDL Lipoprotein subclasses VLDL mmol/l 0.414 0.022 0.177 0.651 6.157E-04 7006 
Cholesterol esters in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.470 0.042 0.165 0.775 2.528E-03 7006 
Cholesterol esters in small VLDL Lipoprotein subclasses VLDL mmol/l 0.452 0.054 0.001 0.904 4.961E-02 7006 




Cholesterol esters in very small 
VLDL 
Lipoprotein subclasses VLDL mmol/l 0.177 0.053 -0.353 0.707 5.130E-01 7006 
Conc. of CMs & extremely large 
VLDL particles 
Lipoprotein subclasses VLDL mol/l 0.350 0.000 0.135 0.565 1.397E-03 7006 
Concentration of large VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.450 0.000 0.218 0.683 1.460E-04 7006 
Concentration of medium VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.473 0.000 0.224 0.721 1.942E-04 7006 
Concentration of small VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.589 0.000 0.285 0.893 1.461E-04 7006 
Concentration of very large VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.414 0.000 0.194 0.635 2.267E-04 7006 
Concentration of very small VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.473 0.000 0.029 0.918 3.671E-02 7006 
Free cholesterol in CMs & extremely 
large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.382 0.002 0.170 0.594 4.163E-04 7006 
Free cholesterol in large VLDL Lipoprotein subclasses VLDL mmol/l 0.440 0.023 0.213 0.667 1.418E-04 7006 
Free cholesterol in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.482 0.038 0.236 0.727 1.205E-04 7006 
Free cholesterol in small VLDL Lipoprotein subclasses VLDL mmol/l 0.638 0.030 0.314 0.961 1.107E-04 7006 
Free cholesterol in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.385 0.005 0.168 0.602 5.078E-04 7006 
Free cholesterol in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.343 0.026 -0.138 0.824 1.618E-01 7006 
Phospholipids in CMs & extremely 
large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.370 0.002 0.155 0.584 7.336E-04 7006 
Phospholipids in large VLDL Lipoprotein subclasses VLDL mmol/l 0.462 0.036 0.226 0.699 1.256E-04 7006 
Phospholipids in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.487 0.057 0.233 0.741 1.732E-04 7006 
Phospholipids in small VLDL Lipoprotein subclasses VLDL mmol/l 0.638 0.044 0.325 0.952 6.501E-05 7006 
Phospholipids in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.419 0.009 0.194 0.644 2.652E-04 7006 
Phospholipids in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.293 0.052 -0.205 0.791 2.487E-01 7006 
Total cholesterol in CMs & 
extremely large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.369 0.004 0.137 0.601 1.817E-03 7006 




Total cholesterol in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.483 0.079 0.212 0.754 4.855E-04 7006 
Total cholesterol in small VLDL Lipoprotein subclasses VLDL mmol/l 0.564 0.082 0.160 0.969 6.259E-03 7006 
Total cholesterol in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.377 0.011 0.159 0.595 6.982E-04 7006 
Total cholesterol in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.236 0.078 -0.278 0.750 3.679E-01 7006 
Total lipids in CMs & extremely 
large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.352 0.018 0.137 0.568 1.342E-03 7006 
Total lipids in large VLDL Lipoprotein subclasses VLDL mmol/l 0.449 0.195 0.217 0.681 1.501E-04 7006 
Total lipids in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.474 0.293 0.224 0.724 1.990E-04 7006 
Total lipids in small VLDL Lipoprotein subclasses VLDL mmol/l 0.599 0.213 0.285 0.914 1.882E-04 7006 
Total lipids in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.412 0.054 0.192 0.632 2.451E-04 7006 
Total lipids in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.432 0.161 -0.025 0.890 6.398E-02 7006 
Triglycerides in CMs & extremely 
large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.345 0.012 0.133 0.557 1.426E-03 7006 
Triglycerides in large VLDL Lipoprotein subclasses VLDL mmol/l 0.453 0.115 0.221 0.685 1.313E-04 7006 
Triglycerides in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.466 0.160 0.223 0.708 1.656E-04 7006 
Triglycerides in small VLDL Lipoprotein subclasses VLDL mmol/l 0.532 0.096 0.271 0.792 6.267E-05 7006 
Triglycerides in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.421 0.034 0.200 0.642 1.847E-04 7006 









APPENDIX 4A6: Results of logistical regression (unadjusted) comparing maternal metabolites of those women who delivered 
VERY preterm (196 days to <224 days, or 28 to <32 completed weeks) compared with those who delivered at term (259 days 
to 294 days, or 37 to 42 completed weeks), excluding those who delivered extremely (<196 days, or <28 completed weeks) or 
moderate to late preterm (224 days to <259 days, or 32 to <37 completed weeks) and post-term (>294 days, or >42 completed 
weeks); showing odds ratio per 1 standard deviation (SD) increase in metabolite measured. N=51 for very preterm, n=6994 for 
term, and n=395 excluded from analysis. The biochemical group of the metabolite, units, upper and lower 95% confidence 
interval. P-values in bold significant at p<0.0029. 








Alanine Amino acids mmol/l 0.057 0.048 -0.218 0.331 6.849E-01 7014 
Glutamine Amino acids mmol/l 0.031 0.046 -0.241 0.303 8.226E-01 7036 
Glycine Amino acids mmol/l 0.055 0.032 -0.212 0.322 6.866E-01 7030 
Histidine Amino acids mmol/l 0.164 0.010 -0.104 0.432 2.301E-01 7035 
Apolipoprotein A-I Apolipoproteins g/l -0.087 0.219 -0.369 0.196 5.466E-01 7040 
Apolipoprotein B Apolipoproteins g/l 0.237 0.228 -0.011 0.484 6.083E-02 7040 
apolipoprotein B:apolipoprotein A-I Apolipoproteins #N/A 0.279 0.121 0.043 0.515 2.045E-02 7040 
Phenylalanine Aromatic amino acids mmol/l 0.214 0.011 -0.038 0.466 9.569E-02 7041 
Tyrosine Aromatic amino acids mmol/l 0.087 0.006 -0.182 0.357 5.248E-01 7032 
Isoleucine Branched--chain amino acids mmol/l 0.133 0.010 -0.125 0.392 3.108E-01 7038 
Leucine Branched--chain amino acids mmol/l 0.219 0.010 -0.031 0.470 8.645E-02 7038 
Valine Branched--chain amino acids mmol/l 0.087 0.018 -0.182 0.356 5.244E-01 7032 
Esterified cholesterol Cholesterol mmol/l -0.049 0.805 -0.328 0.230 7.301E-01 7016 
Free cholesterol Cholesterol mmol/l 0.031 0.333 -0.242 0.305 8.213E-01 7016 
Remnant cholesterol (non-HDL, 
non-LDL) 
Cholesterol mmol/l 0.190 0.466 -0.064 0.444 1.431E-01 7040 
Serum total cholesterol Cholesterol mmol/l -0.033 1.156 -0.312 0.245 8.148E-01 7040 




Total cholesterol in HDL2 Cholesterol mmol/l -0.276 0.334 -0.564 0.011 5.937E-02 7040 
Total cholesterol in HDL3 Cholesterol mmol/l -0.048 0.044 -0.327 0.232 7.392E-01 7040 
Total cholesterol in LDL Cholesterol mmol/l -0.072 0.617 -0.354 0.209 6.143E-01 7040 
Total cholesterol in VLDL Cholesterol mmol/l 0.330 0.275 0.112 0.549 3.031E-03 7040 
18:2 linoleic acid to total FAs Fatty acids (%) % -0.256 2.692 -0.540 0.029 7.868E-02 6995 
22:6 docosahexaenoic acid to total 
FAs 
Fatty acids (%) % -0.245 0.230 -0.551 0.060 1.156E-01 6995 
Monounsaturated FAs to total FAs Fatty acids (%) % 0.290 2.414 0.020 0.559 3.538E-02 6995 
Omega-3 FAs to total FAs Fatty acids (%) % -0.321 0.493 -0.626 -0.016 3.926E-02 6995 
Omega-6 FAs to total FAs Fatty acids (%) % -0.304 2.203 -0.578 -0.030 2.977E-02 6995 
Polyunsaturated FAs to total FAs Fatty acids (%) % -0.337 2.384 -0.609 -0.065 1.516E-02 6995 
Saturated FAs to total FAs Fatty acids (%) % 0.068 1.507 -0.211 0.346 6.350E-01 6995 
18:2, linoleic acid Fatty acids and saturation 
measures 
mmol/l 0.035 0.766 -0.244 0.313 8.067E-01 6995 
22:6, docosahexaenoic acid Fatty acids and saturation 
measures 
mmol/l -0.019 0.043 -0.302 0.265 8.976E-01 6995 
Estimated degree of unsaturation Fatty acids and saturation 
measures 
#N/A -0.271 0.043 -0.547 0.005 5.406E-02 6995 
Monounsaturated fatty acids; 16:1, 
18:1 
Fatty acids and saturation 
measures 
mmol/l 0.264 0.995 0.009 0.519 4.278E-02 6995 
Omega-3 fatty acids Fatty acids and saturation 
measures 
mmol/l -0.080 0.104 -0.369 0.210 5.896E-01 6995 
Omega-6 fatty acids Fatty acids and saturation 
measures 
mmol/l 0.047 0.839 -0.232 0.325 7.428E-01 6995 
Polyunsaturated fatty acids Fatty acids and saturation 
measures 
mmol/l 0.034 0.916 -0.245 0.313 8.106E-01 6995 
Saturated fatty acids Fatty acids and saturation 
measures 
mmol/l 0.193 1.043 -0.074 0.460 1.562E-01 6995 
Total fatty acids Fatty acids and saturation 
measures 




Albumin Fluid balance and inflammation signal 
 
area 
0.108 0.006 -0.152 0.368 4.154E-01 7041 
Creatinine Fluid balance and inflammation mmol/l 0.212 0.006 0.039 0.386 1.647E-02 7036 
Glycoprotein acetyls (a1-acid 
glycoprotein) 
Fluid balance and inflammation mmol/l 0.372 0.197 0.196 0.548 3.318E-05 7041 
Phosphatidylcholine and other 
cholines 
Glycerides and phospholipids mmol/l 0.157 0.458 -0.108 0.422 2.450E-01 7014 
Ratio of triglycerides to 
phosphoglycerides 
Glycerides and phospholipids #N/A 0.374 0.160 0.170 0.579 3.350E-04 7016 
Serum total triglycerides Glycerides and phospholipids mmol/l 0.378 0.578 0.215 0.540 5.334E-06 7040 
Sphingomyelins Glycerides and phospholipids mmol/l -0.131 0.086 -0.412 0.149 3.595E-01 7014 
Total cholines Glycerides and phospholipids mmol/l 0.131 0.483 -0.137 0.398 3.396E-01 7014 
Total phosphoglycerides Glycerides and phospholipids mmol/l 0.224 0.398 -0.039 0.486 9.475E-02 7016 
Triglycerides in HDL Glycerides and phospholipids mmol/l 0.316 0.042 0.092 0.540 5.784E-03 7040 
Triglycerides in LDL Glycerides and phospholipids mmol/l 0.247 0.070 0.003 0.490 4.686E-02 7040 
Triglycerides in VLDL Glycerides and phospholipids mmol/l 0.368 0.458 0.218 0.518 1.569E-06 7040 
Citrate Glycolysis related metabolites mmol/l 0.135 0.017 -0.128 0.397 3.141E-01 6921 
Glucose Glycolysis related metabolites mmol/l 0.026 0.488 -0.243 0.295 8.501E-01 7016 
Glycerol Glycolysis related metabolites mmol/l 0.428 0.016 0.204 0.652 1.850E-04 7027 
Lactate Glycolysis related metabolites mmol/l 0.096 0.492 -0.158 0.350 4.591E-01 7029 
Pyruvate Glycolysis related metabolites mmol/l 0.220 0.022 -0.019 0.459 7.063E-02 7025 
3-hydroxybutyrate Ketone bodies mmol/l 0.044 0.038 -0.213 0.300 7.383E-01 7040 
Acetate Ketone bodies mmol/l 0.054 0.006 -0.216 0.324 6.952E-01 7034 
Mean diameter for HDL particles Lipoprotein particle size nm -0.517 0.204 -0.790 -0.245 1.986E-04 7040 
Mean diameter for LDL particles Lipoprotein particle size nm -0.252 0.063 -0.531 0.028 7.774E-02 7040 
Mean diameter for VLDL particles Lipoprotein particle size nm 0.416 1.008 0.157 0.674 1.604E-03 7040 
Cholesterol esters in large HDL Lipoprotein subclasses HDL mmol/l -0.409 0.143 -0.702 -0.117 6.110E-03 7045 
Cholesterol esters in medium HDL Lipoprotein subclasses HDL mmol/l 0.117 0.086 -0.153 0.387 3.973E-01 7045 
Cholesterol esters in small HDL Lipoprotein subclasses HDL mmol/l 0.038 0.059 -0.237 0.313 7.853E-01 7045 




Concentration of large HDL particles Lipoprotein subclasses HDL mol/l -0.370 0.000 -0.660 -0.080 1.246E-02 7045 
Concentration of medium HDL 
particles 
Lipoprotein subclasses HDL mol/l 0.216 0.000 -0.044 0.476 1.033E-01 7045 
Concentration of small HDL particles Lipoprotein subclasses HDL mol/l 0.320 0.000 0.065 0.576 1.404E-02 7045 
Concentration of very large HDL 
particles 
Lipoprotein subclasses HDL mol/l -0.501 0.000 -0.796 -0.205 9.126E-04 7045 
Free cholesterol in large HDL Lipoprotein subclasses HDL mmol/l -0.404 0.045 -0.696 -0.111 6.790E-03 7045 
Free cholesterol in medium HDL Lipoprotein subclasses HDL mmol/l 0.145 0.023 -0.120 0.409 2.843E-01 7045 
Free cholesterol in small HDL Lipoprotein subclasses HDL mmol/l 0.304 0.017 0.047 0.561 2.046E-02 7045 
Free cholesterol in very large HDL Lipoprotein subclasses HDL mmol/l -0.480 0.030 -0.778 -0.181 1.669E-03 7045 
Phospholipids in large HDL Lipoprotein subclasses HDL mmol/l -0.325 0.156 -0.611 -0.038 2.635E-02 7045 
Phospholipids in medium HDL Lipoprotein subclasses HDL mmol/l 0.210 0.086 -0.050 0.470 1.135E-01 7045 
Phospholipids in small HDL Lipoprotein subclasses HDL mmol/l 0.325 0.094 0.065 0.585 1.444E-02 7045 
Phospholipids in very large HDL Lipoprotein subclasses HDL mmol/l -0.502 0.122 -0.797 -0.208 8.177E-04 7045 
Total cholesterol in large HDL Lipoprotein subclasses HDL mmol/l -0.408 0.188 -0.701 -0.116 6.257E-03 7045 
Total cholesterol in medium HDL Lipoprotein subclasses HDL mmol/l 0.123 0.109 -0.146 0.392 3.697E-01 7045 
Total cholesterol in small HDL Lipoprotein subclasses HDL mmol/l 0.112 0.067 -0.158 0.383 4.160E-01 7045 
Total cholesterol in very large HDL Lipoprotein subclasses HDL mmol/l -0.497 0.104 -0.792 -0.201 9.770E-04 7045 
Total lipids in large HDL Lipoprotein subclasses HDL mmol/l -0.374 0.354 -0.664 -0.083 1.164E-02 7045 
Total lipids in medium HDL Lipoprotein subclasses HDL mmol/l 0.200 0.195 -0.061 0.461 1.336E-01 7045 
Total lipids in small HDL Lipoprotein subclasses HDL mmol/l 0.306 0.141 0.050 0.562 1.926E-02 7045 
Total lipids in very large HDL Lipoprotein subclasses HDL mmol/l -0.501 0.230 -0.797 -0.205 9.080E-04 7045 
Triglycerides in large HDL Lipoprotein subclasses HDL mmol/l -0.303 0.016 -0.596 -0.010 4.233E-02 7045 
Triglycerides in medium HDL Lipoprotein subclasses HDL mmol/l 0.507 0.012 0.293 0.721 3.328E-06 7045 
Triglycerides in small HDL Lipoprotein subclasses HDL mmol/l 0.325 0.016 0.096 0.553 5.345E-03 7045 
Triglycerides in very large HDL Lipoprotein subclasses HDL mmol/l -0.183 0.010 -0.471 0.105 2.126E-01 7045 
Cholesterol esters in large LDL Lipoprotein subclasses LDL mmol/l -0.046 0.234 -0.325 0.233 7.474E-01 7045 
Cholesterol esters in LDL Lipoprotein subclasses LDL mmol/l -0.040 0.163 -0.319 0.239 7.767E-01 7045 
Cholesterol esters in medium LDL Lipoprotein subclasses LDL mmol/l -0.067 0.157 -0.348 0.214 6.380E-01 7045 




Concentration of large LDL particles Lipoprotein subclasses LDL mol/l -0.019 0.000 -0.297 0.258 8.913E-01 7045 
Concentration of LDL particles Lipoprotein subclasses LDL mol/l -0.008 0.000 -0.285 0.268 9.524E-01 7040 
Concentration of medium LDL 
particles 
Lipoprotein subclasses LDL mol/l -0.002 0.000 -0.277 0.274 9.907E-01 7045 
Concentration of small LDL particles Lipoprotein subclasses LDL mol/l 0.015 0.000 -0.260 0.289 9.170E-01 7045 
Free cholesterol in large LDL Lipoprotein subclasses LDL mmol/l -0.148 0.076 -0.433 0.138 3.101E-01 7045 
Free cholesterol in LDL Lipoprotein subclasses LDL mmol/l -0.155 0.067 -0.441 0.132 2.902E-01 7045 
Free cholesterol in medium LDL Lipoprotein subclasses LDL mmol/l -0.042 0.037 -0.321 0.236 7.671E-01 7045 
Free cholesterol in small LDL Lipoprotein subclasses LDL mmol/l -0.016 0.023 -0.293 0.261 9.087E-01 7045 
Phospholipids in large LDL Lipoprotein subclasses LDL mmol/l -0.045 0.088 -0.324 0.234 7.539E-01 7045 
Phospholipids in LDL Lipoprotein subclasses LDL mmol/l -0.094 0.089 -0.377 0.189 5.130E-01 7045 
Phospholipids in medium LDL Lipoprotein subclasses LDL mmol/l 0.073 0.050 -0.196 0.342 5.955E-01 7045 
Phospholipids in small LDL Lipoprotein subclasses LDL mmol/l 0.091 0.034 -0.177 0.359 5.047E-01 7045 
Total cholesterol in large LDL Lipoprotein subclasses LDL mmol/l -0.071 0.310 -0.352 0.211 6.224E-01 7045 
Total cholesterol in LDL Lipoprotein subclasses LDL mmol/l -0.074 0.230 -0.355 0.208 6.086E-01 7045 
Total cholesterol in medium LDL Lipoprotein subclasses LDL mmol/l -0.063 0.193 -0.343 0.218 6.613E-01 7045 
Total cholesterol in small LDL Lipoprotein subclasses LDL mmol/l -0.078 0.117 -0.359 0.204 5.892E-01 7045 
Total lipids in large LDL Lipoprotein subclasses LDL mmol/l -0.037 0.428 -0.316 0.241 7.927E-01 7045 
Total lipids in LDL Lipoprotein subclasses LDL mmol/l -0.033 0.349 -0.312 0.246 8.157E-01 7040 
Total lipids in medium LDL Lipoprotein subclasses LDL mmol/l -0.013 0.258 -0.290 0.263 9.256E-01 7045 
Total lipids in small LDL Lipoprotein subclasses LDL mmol/l -0.002 0.159 -0.278 0.274 9.885E-01 7045 
Triglycerides in large LDL Lipoprotein subclasses LDL mmol/l 0.224 0.039 -0.024 0.472 7.729E-02 7045 
Triglycerides in LDL Lipoprotein subclasses LDL mmol/l 0.292 0.042 0.056 0.528 1.523E-02 7045 
Triglycerides in medium LDL Lipoprotein subclasses LDL mmol/l 0.221 0.020 -0.028 0.470 8.126E-02 7045 
Triglycerides in small LDL Lipoprotein subclasses LDL mmol/l 0.350 0.013 0.126 0.574 2.167E-03 7045 
Cholesterol esters in CMs & 
extremely large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.265 0.002 0.104 0.427 1.269E-03 7045 
Cholesterol esters in large VLDL Lipoprotein subclasses VLDL mmol/l 0.318 0.022 0.171 0.464 2.184E-05 7045 
Cholesterol esters in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.322 0.042 0.134 0.511 8.083E-04 7045 




Cholesterol esters in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.287 0.006 0.149 0.425 4.708E-05 7045 
Cholesterol esters in very small 
VLDL 
Lipoprotein subclasses VLDL mmol/l -0.036 0.053 -0.315 0.243 7.994E-01 7045 
Conc. of CMs & extremely large 
VLDL particles 
Lipoprotein subclasses VLDL mol/l 0.284 0.000 0.151 0.417 2.948E-05 7045 
Concentration of large VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.349 0.000 0.205 0.494 2.227E-06 7045 
Concentration of medium VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.363 0.000 0.211 0.515 2.837E-06 7045 
Concentration of small VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.411 0.000 0.227 0.595 1.198E-05 7045 
Concentration of very large VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.324 0.000 0.185 0.463 4.746E-06 7045 
Concentration of very small VLDL 
particles 
Lipoprotein subclasses VLDL mol/l 0.184 0.000 -0.071 0.439 1.570E-01 7045 
Free cholesterol in CMs & extremely 
large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.301 0.002 0.167 0.436 1.188E-05 7045 
Free cholesterol in large VLDL Lipoprotein subclasses VLDL mmol/l 0.339 0.023 0.196 0.482 3.339E-06 7045 
Free cholesterol in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.364 0.039 0.212 0.516 2.838E-06 7045 
Free cholesterol in small VLDL Lipoprotein subclasses VLDL mmol/l 0.421 0.031 0.225 0.618 2.662E-05 7045 
Free cholesterol in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.302 0.005 0.164 0.439 1.645E-05 7045 
Free cholesterol in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.081 0.026 -0.186 0.348 5.518E-01 7045 
Phospholipids in CMs & extremely 
large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.297 0.002 0.162 0.431 1.587E-05 7045 
Phospholipids in large VLDL Lipoprotein subclasses VLDL mmol/l 0.354 0.036 0.206 0.502 2.679E-06 7045 
Phospholipids in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.369 0.058 0.213 0.525 3.521E-06 7045 
Phospholipids in small VLDL Lipoprotein subclasses VLDL mmol/l 0.438 0.044 0.248 0.629 6.483E-06 7045 
Phospholipids in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.324 0.009 0.182 0.466 7.884E-06 7045 
Phospholipids in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.040 0.052 -0.232 0.311 7.746E-01 7045 
Total cholesterol in CMs & 
extremely large VLDL 




Total cholesterol in large VLDL Lipoprotein subclasses VLDL mmol/l 0.329 0.046 0.185 0.473 7.944E-06 7045 
Total cholesterol in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.349 0.080 0.183 0.516 3.945E-05 7045 
Total cholesterol in small VLDL Lipoprotein subclasses VLDL mmol/l 0.310 0.082 0.074 0.546 1.014E-02 7045 
Total cholesterol in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.293 0.011 0.156 0.431 2.855E-05 7045 
Total cholesterol in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.003 0.078 -0.272 0.278 9.831E-01 7045 
Total lipids in CMs & extremely 
large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.285 0.018 0.151 0.418 3.036E-05 7045 
Total lipids in large VLDL Lipoprotein subclasses VLDL mmol/l 0.348 0.198 0.203 0.493 2.452E-06 7045 
Total lipids in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.363 0.297 0.210 0.515 3.354E-06 7045 
Total lipids in small VLDL Lipoprotein subclasses VLDL mmol/l 0.411 0.214 0.220 0.601 2.355E-05 7045 
Total lipids in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.322 0.055 0.183 0.460 5.480E-06 7045 
Total lipids in very small VLDL Lipoprotein subclasses VLDL mmol/l 0.149 0.161 -0.110 0.408 2.591E-01 7045 
Triglycerides in CMs & extremely 
large VLDL 
Lipoprotein subclasses VLDL mmol/l 0.282 0.012 0.151 0.414 2.401E-05 7045 
Triglycerides in large VLDL Lipoprotein subclasses VLDL mmol/l 0.353 0.116 0.209 0.497 1.551E-06 7045 
Triglycerides in medium VLDL Lipoprotein subclasses VLDL mmol/l 0.365 0.162 0.217 0.513 1.332E-06 7045 
Triglycerides in small VLDL Lipoprotein subclasses VLDL mmol/l 0.396 0.097 0.237 0.555 1.082E-06 7045 
Triglycerides in very large VLDL Lipoprotein subclasses VLDL mmol/l 0.330 0.035 0.192 0.469 3.091E-06 7045 









APPENDIX 4A7: Results of logistical regression (unadjusted) comparing maternal metabolites of those women who delivered 
MODERATE TO LATE preterm (224 days to <259 days, or 32 to <37 completed weeks) compared with those who delivered at 
term (259 days to 294 days, or 37 to 42 completed weeks), excluding those who delivered extremely or very preterm (<224 
days, or <32 weeks) or post-term (>294 days, or >42 completed weeks); showing odds ratio per 1 standard deviation (SD) 
increase in metabolite measured. N=329 for moderate to late preterm, n=6994 for term, and n=117 excluded from analysis. 
The biochemical group of the metabolite, units, upper and lower 95% confidence interval. P-values in bold significant at 
p<0.0029. 








Acetate Ketone bodies mmol/l -0.045 0.006 -0.158 0.068 4.389E-01 7313 
Alanine Amino acids mmol/l 0.103 0.048 -0.004 0.210 5.831E-02 7293 





0.126 0.006 0.023 0.230 1.674E-02 7319 
Apolipoprotein A-I Apolipoproteins g/l 0.037 0.221 -0.072 0.146 5.078E-01 7318 
Apolipoprotein B Apolipoproteins g/l 0.096 0.228 -0.011 0.203 7.831E-02 7318 
apolipoprotein B:apolipoprotein A-I Apolipoproteins #N/A 0.085 0.120 -0.022 0.192 1.216E-01 7318 
3-hydroxybutyrate Ketone bodies mmol/l 0.020 0.038 -0.088 0.127 7.214E-01 7319 
Citrate Glycolysis related 
metabolites 
mmol/l 0.059 0.017 -0.050 0.169 2.891E-01 7193 
Creatinine Fluid balance and 
inflammation 
mmol/l 0.195 0.006 0.099 0.291 7.040E-05 7315 
22:6, docosahexaenoic acid Fatty acids and 
saturation measures 
mmol/l 0.085 0.043 -0.022 0.192 1.209E-01 7272 
22:6 docosahexaenoic acid to total 
FAs 
Fatty acids (%) % -0.059 0.230 -0.173 0.055 3.085E-01 7272 




Omega-3 fatty acids Fatty acids and 
saturation measures 
mmol/l 0.096 0.104 -0.011 0.204 7.851E-02 7272 
Omega-3 FAs to total FAs Fatty acids (%) % -0.036 0.492 -0.149 0.077 5.333E-01 7272 
Omega-6 fatty acids Fatty acids and 
saturation measures 
mmol/l 0.066 0.840 -0.044 0.175 2.392E-01 7272 
Omega-6 FAs to total FAs Fatty acids (%) % -0.128 2.204 -0.238 -0.018 2.310E-02 7272 
Free cholesterol Cholesterol mmol/l 0.073 0.334 -0.036 0.182 1.911E-01 7292 
Glucose Glycolysis related 
metabolites 
mmol/l 0.054 0.490 -0.051 0.160 3.142E-01 7294 
Glutamine Amino acids mmol/l -0.015 0.046 -0.126 0.096 7.890E-01 7314 
Glycerol Glycolysis related 
metabolites 
mmol/l 0.237 0.016 0.136 0.338 4.346E-06 7305 
Glycine Amino acids mmol/l 0.060 0.032 -0.048 0.167 2.780E-01 7304 
Glycoprotein acetyls (a1-acid 
glycoprotein) 
Fluid balance and 
inflammation 
mmol/l 0.162 0.196 0.062 0.263 1.577E-03 7319 
Total cholesterol in HDL2 Cholesterol mmol/l -0.014 0.335 -0.125 0.097 7.996E-01 7318 
Total cholesterol in HDL3 Cholesterol mmol/l 0.069 0.044 -0.039 0.176 2.132E-01 7318 
Total cholesterol in HDL Cholesterol mmol/l -0.005 0.369 -0.115 0.106 9.363E-01 7318 
Mean diameter for HDL particles Lipoprotein particle 
size 
nm -0.134 0.205 -0.244 -0.023 1.754E-02 7318 
Triglycerides in HDL Glycerides and 
phospholipids 
mmol/l 0.093 0.042 -0.013 0.200 8.596E-02 7318 
Histidine Amino acids mmol/l 0.041 0.010 -0.069 0.151 4.658E-01 7314 
Total cholesterol in LDL Lipoprotein subclasses 
LDL 
mmol/l 0.058 0.230 -0.051 0.167 2.952E-01 7323 
Cholesterol esters in LDL Lipoprotein subclasses 
LDL 
mmol/l 0.062 0.163 -0.047 0.171 2.626E-01 7323 
Free cholesterol in LDL Lipoprotein subclasses 
LDL 
mmol/l 0.048 0.067 -0.061 0.157 3.902E-01 7323 
Total lipids in LDL Lipoprotein subclasses 
LDL 




Concentration of LDL particles Lipoprotein subclasses 
LDL 
mol/l 0.065 0.000 -0.043 0.173 2.403E-01 7318 
Phospholipids in LDL Lipoprotein subclasses 
LDL 
mmol/l 0.056 0.089 -0.053 0.164 3.175E-01 7323 
Triglycerides in LDL Lipoprotein subclasses 
LDL 
mmol/l 0.100 0.042 -0.006 0.206 6.434E-02 7323 
Isoleucine Branched--chain 
amino acids 
mmol/l 0.112 0.010 0.008 0.217 3.561E-02 7317 
18:2, linoleic acid Fatty acids and 
saturation measures 
mmol/l 0.044 0.766 -0.066 0.154 4.344E-01 7272 
Lactate Glycolysis related 
metabolites 
mmol/l 0.049 0.493 -0.057 0.156 3.657E-01 7307 
18:2 linoleic acid to total FAs Fatty acids (%) % -0.133 2.691 -0.245 -0.021 1.963E-02 7272 
Total cholesterol in LDL Cholesterol mmol/l 0.059 0.617 -0.049 0.168 2.840E-01 7318 
Mean diameter for LDL particles Lipoprotein particle 
size 
nm -0.064 0.062 -0.175 0.048 2.643E-01 7318 
Triglycerides in LDL Glycerides and 
phospholipids 
mmol/l 0.098 0.070 -0.009 0.204 7.233E-02 7318 
Leucine Branched--chain 
amino acids 
mmol/l 0.126 0.010 0.020 0.232 1.925E-02 7317 
Total cholesterol in large HDL Lipoprotein subclasses 
HDL 
mmol/l -0.057 0.188 -0.168 0.055 3.205E-01 7323 
Cholesterol esters in large HDL Lipoprotein subclasses 
HDL 
mmol/l -0.057 0.143 -0.168 0.055 3.200E-01 7323 
Free cholesterol in large HDL Lipoprotein subclasses 
HDL 
mmol/l -0.056 0.045 -0.168 0.055 3.226E-01 7323 
Total lipids in large HDL Lipoprotein subclasses 
HDL 
mmol/l -0.041 0.355 -0.152 0.070 4.714E-01 7323 
Concentration of large HDL particles Lipoprotein subclasses 
HDL 
mol/l -0.039 0.000 -0.150 0.073 4.948E-01 7323 
Phospholipids in large HDL Lipoprotein subclasses 
HDL 




Triglycerides in large HDL Lipoprotein subclasses 
HDL 
mmol/l -0.013 0.016 -0.124 0.098 8.212E-01 7323 
Total cholesterol in large LDL Lipoprotein subclasses 
LDL 
mmol/l 0.061 0.310 -0.048 0.169 2.749E-01 7323 
Cholesterol esters in large LDL Lipoprotein subclasses 
LDL 
mmol/l 0.064 0.234 -0.044 0.173 2.458E-01 7323 
Free cholesterol in large LDL Lipoprotein subclasses 
LDL 
mmol/l 0.049 0.076 -0.060 0.158 3.804E-01 7323 
Total lipids in large LDL Lipoprotein subclasses 
LDL 
mmol/l 0.066 0.428 -0.042 0.174 2.332E-01 7323 
Concentration of large LDL particles Lipoprotein subclasses 
LDL 
mol/l 0.069 0.000 -0.040 0.177 2.137E-01 7323 
Phospholipids in large LDL Lipoprotein subclasses 
LDL 
mmol/l 0.066 0.088 -0.043 0.174 2.339E-01 7323 
Triglycerides in large LDL Lipoprotein subclasses 
LDL 
mmol/l 0.096 0.038 -0.011 0.202 7.916E-02 7323 
Total cholesterol in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.096 0.045 -0.005 0.197 6.166E-02 7323 
Cholesterol esters in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.084 0.022 -0.018 0.187 1.070E-01 7323 
Free cholesterol in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.107 0.023 0.007 0.207 3.583E-02 7323 
Total lipids in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.106 0.194 0.006 0.206 3.768E-02 7323 




mol/l 0.107 0.000 0.007 0.207 3.669E-02 7323 
Phospholipids in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.109 0.036 0.009 0.210 3.307E-02 7323 
Triglycerides in large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.109 0.114 0.009 0.209 3.261E-02 7323 
Total cholesterol in medium HDL Lipoprotein subclasses 
HDL 




Cholesterol esters in medium HDL Lipoprotein subclasses 
HDL 
mmol/l 0.076 0.086 -0.033 0.185 1.723E-01 7323 
Free cholesterol in medium HDL Lipoprotein subclasses 
HDL 
mmol/l 0.099 0.023 -0.009 0.207 7.309E-02 7323 
Total lipids in medium HDL Lipoprotein subclasses 
HDL 
mmol/l 0.108 0.195 0.000 0.216 5.008E-02 7323 




mol/l 0.112 0.000 0.004 0.220 4.126E-02 7323 
Phospholipids in medium HDL Lipoprotein subclasses 
HDL 
mmol/l 0.118 0.087 0.010 0.225 3.190E-02 7323 
Triglycerides in medium HDL Lipoprotein subclasses 
HDL 
mmol/l 0.162 0.012 0.057 0.267 2.503E-03 7323 
Total cholesterol in medium LDL Lipoprotein subclasses 
LDL 
mmol/l 0.063 0.193 -0.045 0.172 2.532E-01 7323 
Cholesterol esters in medium LDL Lipoprotein subclasses 
LDL 
mmol/l 0.063 0.157 -0.046 0.171 2.587E-01 7323 
Free cholesterol in medium LDL Lipoprotein subclasses 
LDL 
mmol/l 0.066 0.037 -0.043 0.174 2.363E-01 7323 
Total lipids in medium LDL Lipoprotein subclasses 
LDL 
mmol/l 0.071 0.258 -0.037 0.180 1.967E-01 7323 




mol/l 0.073 0.000 -0.035 0.181 1.852E-01 7323 
Phospholipids in medium LDL Lipoprotein subclasses 
LDL 
mmol/l 0.085 0.050 -0.023 0.193 1.226E-01 7323 
Triglycerides in medium LDL Lipoprotein subclasses 
LDL 
mmol/l 0.097 0.020 -0.009 0.204 7.396E-02 7323 
Monounsaturated fatty acids; 16:1, 
18:1 
Fatty acids and 
saturation measures 
mmol/l 0.115 0.993 0.007 0.222 3.623E-02 7272 
Monounsaturated FAs to total FAs Fatty acids (%) % 0.076 2.412 -0.034 0.186 1.745E-01 7272 
Total cholesterol in medium VLDL Lipoprotein subclasses 
VLDL 




Cholesterol esters in medium VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.088 0.042 -0.017 0.194 1.002E-01 7323 
Free cholesterol in medium VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.113 0.038 0.012 0.214 2.829E-02 7323 
Total lipids in medium VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.109 0.292 0.008 0.211 3.483E-02 7323 




mol/l 0.109 0.000 0.008 0.210 3.448E-02 7323 
Phospholipids in medium VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.112 0.057 0.011 0.214 2.996E-02 7323 
Triglycerides in medium VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.110 0.160 0.009 0.210 3.229E-02 7323 




mmol/l 0.092 0.459 -0.017 0.200 9.817E-02 7290 
Phenylalanine Aromatic amino acids mmol/l 0.147 0.011 0.042 0.252 6.237E-03 7319 
Polyunsaturated fatty acids Fatty acids and 
saturation measures 
mmol/l 0.071 0.917 -0.038 0.181 2.010E-01 7272 
Polyunsaturated FAs to total FAs Fatty acids (%) % -0.125 2.383 -0.235 -0.015 2.596E-02 7272 
Pyruvate Glycolysis related 
metabolites 
mmol/l 0.066 0.022 -0.041 0.172 2.259E-01 7303 
Remnant cholesterol (non-HDL, 
non-LDL) 
Cholesterol mmol/l 0.085 0.465 -0.022 0.192 1.212E-01 7318 
Serum total cholesterol Cholesterol mmol/l 0.065 1.157 -0.044 0.173 2.425E-01 7318 
Serum total triglycerides Glycerides and 
phospholipids 
mmol/l 0.113 0.570 0.011 0.215 2.962E-02 7318 
Saturated fatty acids Fatty acids and 
saturation measures 
mmol/l 0.127 1.042 0.019 0.235 2.083E-02 7272 
Saturated FAs to total FAs Fatty acids (%) % 0.076 1.505 -0.034 0.186 1.758E-01 7272 
Total cholesterol in small HDL Lipoprotein subclasses 
HDL 
mmol/l 0.137 0.067 0.028 0.245 1.329E-02 7323 
Cholesterol esters in small HDL Lipoprotein subclasses 
HDL 




Free cholesterol in small HDL Lipoprotein subclasses 
HDL 
mmol/l 0.162 0.017 0.055 0.269 3.053E-03 7323 
Total lipids in small HDL Lipoprotein subclasses 
HDL 
mmol/l 0.187 0.141 0.080 0.294 5.950E-04 7323 




mol/l 0.191 0.000 0.084 0.298 4.572E-04 7323 
Phospholipids in small HDL Lipoprotein subclasses 
HDL 
mmol/l 0.163 0.094 0.055 0.270 3.164E-03 7323 
Triglycerides in small HDL Lipoprotein subclasses 
HDL 
mmol/l 0.136 0.016 0.032 0.241 1.051E-02 7323 
Total cholesterol in small LDL Lipoprotein subclasses 
LDL 
mmol/l 0.061 0.117 -0.047 0.170 2.679E-01 7323 
Cholesterol esters in small LDL Lipoprotein subclasses 
LDL 
mmol/l 0.059 0.095 -0.050 0.168 2.877E-01 7323 
Free cholesterol in small LDL Lipoprotein subclasses 
LDL 
mmol/l 0.070 0.023 -0.038 0.179 2.040E-01 7323 
Total lipids in small LDL Lipoprotein subclasses 
LDL 
mmol/l 0.074 0.159 -0.034 0.182 1.797E-01 7323 
Concentration of small LDL particles Lipoprotein subclasses 
LDL 
mol/l 0.077 0.000 -0.031 0.185 1.644E-01 7323 
Phospholipids in small LDL Lipoprotein subclasses 
LDL 
mmol/l 0.091 0.034 -0.017 0.199 9.827E-02 7323 
Triglycerides in small LDL Lipoprotein subclasses 
LDL 
mmol/l 0.117 0.013 0.012 0.222 2.963E-02 7323 
Sphingomyelins Glycerides and 
phospholipids 
mmol/l 0.054 0.086 -0.056 0.164 3.365E-01 7290 
Total cholesterol in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.105 0.081 -0.001 0.211 5.299E-02 7323 
Cholesterol esters in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.085 0.054 -0.022 0.193 1.189E-01 7323 
Free cholesterol in small VLDL Lipoprotein subclasses 
VLDL 




Total lipids in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.120 0.212 0.016 0.224 2.395E-02 7323 




mol/l 0.120 0.000 0.016 0.224 2.391E-02 7323 
Phospholipids in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.132 0.044 0.028 0.236 1.300E-02 7323 
Triglycerides in small VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.116 0.096 0.014 0.218 2.607E-02 7323 




#N/A 0.089 0.159 -0.017 0.196 1.007E-01 7292 
Total cholines Glycerides and 
phospholipids 
mmol/l 0.095 0.484 -0.014 0.204 8.745E-02 7290 
Total fatty acids Fatty acids and 
saturation measures 
mmol/l 0.113 2.775 0.004 0.221 4.127E-02 7272 
Total phosphoglycerides Glycerides and 
phospholipids 
mmol/l 0.098 0.398 -0.011 0.207 7.694E-02 7292 
Tyrosine Aromatic amino acids mmol/l 0.068 0.006 -0.041 0.177 2.201E-01 7310 
Estimated degree of unsaturation Fatty acids and 
saturation measures 
#N/A -0.062 0.043 -0.173 0.049 2.723E-01 7272 
Valine Branched--chain 
amino acids 
mmol/l 0.052 0.018 -0.057 0.161 3.501E-01 7310 
Total cholesterol in VLDL Cholesterol mmol/l 0.097 0.273 -0.009 0.203 7.191E-02 7318 
Mean diameter for VLDL particles Lipoprotein particle 
size 
nm 0.114 1.006 0.004 0.223 4.162E-02 7318 
Triglycerides in VLDL Glycerides and 
phospholipids 
mmol/l 0.110 0.450 0.010 0.211 3.186E-02 7318 
Total cholesterol in very large HDL Lipoprotein subclasses 
HDL 
mmol/l -0.077 0.104 -0.189 0.035 1.793E-01 7323 
Cholesterol esters in very large HDL Lipoprotein subclasses 
HDL 
mmol/l -0.075 0.074 -0.187 0.036 1.863E-01 7323 
Free cholesterol in very large HDL Lipoprotein subclasses 
HDL 




Total lipids in very large HDL Lipoprotein subclasses 
HDL 
mmol/l -0.079 0.230 -0.191 0.033 1.690E-01 7323 




mol/l -0.078 0.000 -0.190 0.034 1.723E-01 7323 
Phospholipids in very large HDL Lipoprotein subclasses 
HDL 
mmol/l -0.084 0.122 -0.196 0.028 1.435E-01 7323 
Triglycerides in very large HDL Lipoprotein subclasses 
HDL 
mmol/l 0.009 0.010 -0.102 0.119 8.796E-01 7323 
Total cholesterol in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.081 0.011 -0.021 0.182 1.186E-01 7323 




mmol/l 0.071 0.006 -0.031 0.174 1.726E-01 7323 
Free cholesterol in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.091 0.005 -0.009 0.191 7.418E-02 7323 
Total lipids in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.096 0.054 -0.003 0.196 5.856E-02 7323 




mol/l 0.097 0.000 -0.002 0.197 5.598E-02 7323 
Phospholipids in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.100 0.009 0.000 0.200 4.983E-02 7323 
Triglycerides in very large VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.100 0.034 0.000 0.199 4.933E-02 7323 
Total cholesterol in very small VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.062 0.078 -0.046 0.171 2.591E-01 7323 




mmol/l 0.051 0.053 -0.058 0.159 3.624E-01 7323 
Free cholesterol in very small VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.085 0.026 -0.022 0.192 1.193E-01 7323 
Total lipids in very small VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.085 0.161 -0.023 0.192 1.222E-01 7323 








Phospholipids in very small VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.074 0.052 -0.034 0.182 1.771E-01 7323 
Triglycerides in very small VLDL Lipoprotein subclasses 
VLDL 
mmol/l 0.117 0.041 0.012 0.222 2.832E-02 7323 
Total cholesterol in CMs & 
extremely large VLDL 
Lipoprotein subclasses 
VLDL 
mmol/l 0.078 0.004 -0.025 0.180 1.366E-01 7323 
Cholesterol esters in CMs & 
extremely large VLDL 
Lipoprotein subclasses 
VLDL 
mmol/l 0.060 0.002 -0.045 0.165 2.610E-01 7323 




mmol/l 0.096 0.002 -0.003 0.196 5.674E-02 7323 




mmol/l 0.086 0.018 -0.014 0.186 9.132E-02 7323 




mol/l 0.086 0.000 -0.014 0.186 9.181E-02 7323 




mmol/l 0.099 0.002 0.000 0.198 4.965E-02 7323 
















APPENDIX 4A8: Volcano plot comparing logOR values derived from logistic 
regression outputs of post-term (red dots) and preterm (blue dots) with term for 
the 157 metabolite conditions measured (x-axis), plotted against -log10 (y-axis). 
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